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 Abstract 
Complex I (NADH:ubiquinone oxidoreductase) couples electron transfer to proton translocation across 
the inner mitochondrial membrane, to drive the synthesis of ATP. Its distinctive L-shaped structure 
comprises 45 subunits, encoded by both the mitochondrial and nuclear genomes, which are assembled 
by a complicated modular pathway. Complex I genetic defects are the most common cause of 
mitochondrial disorders and often present in early childhood, with high mortality rates. Recent high-
resolution electron cryo-microscopy structures of mammalian complex I provide a foundation for both 
interpreting biochemical and biomedical data and understanding the catalytic mechanism. 
 
First, this thesis explores how the flavin cofactor is inserted into the NADH-binding (N-) domain of 
complex I. Genetic manipulation of cultured human cells, to starve them of flavin, revealed a hierarchal 
impact on the mitochondrial flavoproteome. High riboflavin content in the growth media ameliorated 
observed phenotypes, requiring cell conditioning in low riboflavin conditions. CRISPR knockout of the 
putative mitochondrial flavin transporter SLC25A32 demonstrated the severe impact of decreased flavin 
on complexes I and II, and mass spectrometry ‘complexome’ analyses suggest that the N-domain is still 
assembled onto complex I in the absence of the flavin. 
 
Second, the model organism Yarrowia lipolytica was used to assess the importance of residues in the 
quinone-binding site of complex I. Three residues with proposed roles in binding the quinone head-
group were targeted. One variant was catalytically inactive, while two retained some activity. They 
showed decreased ability to reduce physiologically-relevant, long chain quinones, but their ability to 
reduce short-chain analogues was affected less severely. The results suggest a complicated picture in 
which interactions between the protein and both the hydrophilic quinone head-group and hydrophobic 
isoprenoid chain contribute to quinone-binding affinity and catalysis. 
 
Finally, a model for human complex I, generated from a recent high-resolution structure of mouse 
complex I, was used to investigate whether the pathogenicity of human variants could be predicted. 
Structural information on variant residues, including their secondary structure, proximity to key features 
and surface exposure, was collated and the power of each property to predict pathogenicity investigated. 
The analysis was then extended to the whole structure, to identify potential pathogenic hotspots in the 
enzyme, inform future studies of functionally important regions in complex I, and aid the diagnosis of 
clinically relevant pathogenic variants. 
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1 
Abbreviations 
Additionally, standard chemical symbols, SI units and the one and three letter abbreviations for the 20 
biologically relevant amino acids are used throughout. The letters A, C, G, T, and U represent the 
nucleotides adenosine, cytidine, guanosine, thymidine and uridine, respectively. The nomenclature of 
complex I subunits differs across species, therefore the human names for the subunits are used in this 
thesis. 
 
ΔΨ   membrane potential  
Δp   proton motive force 
143B CyWT  immortalised human osterocarcoma patient cybrid cells 
ACN   acetonitrile 
ADP   adenosine diphosphate 
APAD+   3-acetlypyridine adenine dinucleotide 
AOX   alternative oxidase 
ATP   adenosine triphosphate 
BCA   bicinchronic acid 
BLAST   basic local alignment search tool 
BN-PAGE  blue native polyacrylamide gel electrophoresis  
CHAPS  3-[(3-cholamidopropyl)-dimethylamminio]-1-propane sulphonate 
CRISPR  clustered regularly spaced short palindromic repeats 
Cryo-EM  cryogenic electron microscopy 
Cytc   cytochrome c 
DDM   n-dodecyl-β-D-maltoside 
DMSO   dimethyl sulphoxide 
dNADH  deamino reduced nicotinamide adenine dinucleotide 
DQ   decylubiquinone 
DRP1   dynamin-1-like protein  
DTT   dithioreitol 
ECAR   extracellular acidification rate 
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ECL   electrochemiluminescence  
EDTA   ethylenediaminetetraacetic acid 
EPR   electron paramagnetic resonance  
ETC   electron transfer chain 
FAD   flavin adenine dinucleotide  
FADS   flavin adenine dinucleotide synthase 
FADS1   flavin adenine dinucleotide synthase isoform 1 (mitochondrial) 
FCCP   carbonyl cyanide p-trifluoromethoxyphenylhydrazone 
FeCN   potassium hexacyanoferrate 
FeS   iron-sulphur 
FLAD1   flavin adenine dinucleotide synthase gene 
FMN   flavin mononucleotide 
gDNA   genomic DNA 
HAP1   male chronic myelogenous leukemia cell line KBM-7 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HGMD   human gene mutation database 
HPLC   high-pressure liquid chromatography 
HRP   horseradish peroxidase 
IMM   inner mitochondrial membrane  
IMS   intermembrane space 
LHON   Leber’s hereditary optic neuropathy 
MOPS   3-(N-morpholino)propanesulphonic acid 
MSH buffer  mannitol, sucrose, 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid buffer 
mtDNA  mitochondrial deoxyribonucleic acid 
MWCO  molecular weight cut-off 
NAD+   nicotinamide adenine dinucleotide 
NADH   reduced nicotinamide adenine dinucleotide 
NBT   nitroblue tetrazolium 
NCBI   US National Centre for Biotechnology Information  
vii 
3 
nDNA   nuclear deoxyribonucleic acid 
NDH2   alternative NADH dehydrogenase 
OCR   oxygen consumption rate 
OMM   outer mitochondrial membrane  
OXPHOS  oxidative phosphorylation 
PAM   protospacer motif/point accepted mutation 
PCR   polymerase chain reaction 
PDB   protein databank 
PL   proteoliposome 
PMSF   phenylmethanesulphonylfluoride 
PVDF   polyvinylidene fluoride 
Q   ubiquinone 
Q1   coenzyme quionone-1 
Q6   coenzyme quionone-6 
Q9   coenzyme quionone-9 
Q10   coenzyme quionone-10 
QH2   ubiquinol 
Q-site   ubiquinone binding site 
RFK   riboflavin kinase 
RFK KD   riboflavin kinase knockdown 
ROS   reactive oxygen species 
RNA   ribonucleic acid 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sgRNA   single guide ribonucleic acid 
shRNA   short hairpin ribonucleic acid 
SILAC   stable isotope labelling of amino acids in cell culture 
siRNA   small interfering ribonucleic acid 
SLC25A32  putative mitochondrial folate/flavin carrier 
SLCKO  putative mitochondrial folate/flavin carrier knockout 
viii 
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SOD   superoxide dismutase 
TMH   transmembrane helix 
TMRM   tetramethylrhodamine 
VDAC1  voltage dependent ion channel 1 
WT   wild type 
YPD   yeast extract peptone dextrose 
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Chapter 1 
Introduction 
1.1. Energy transduction in biological systems 
 
Biological systems must harness energy from the environment in order to drive thermodynamically 
unfavourable reactions. They achieve this through energy transducing membranes and the generation of 
ATP from ADP + Pi. The plasma membrane of prokaryotes, thylakoid membrane of chloroplasts and 
the inner membrane of mitochondria all act in this way. The fundamental components of energy 
transducing membranes are: an ion impermeable barrier containing protein complexes capable of 
pumping protons, and the movement of electrons along a chain of proteins with increasing redox 
potential to release energy, which can be harnessed to move protons across the membrane against their 
concentration gradient. In mitochondria the accumulation of protons in the intermembrane space forms 
the proton motive force (Δp), which comprises two elements: the ΔΨ due to the charge imbalance and 
ΔpH from the difference in proton concentration. Therefore, these membranes require two types of 
proton pumps – those that utilise the Gibbs free energy from electron transfer to move protons across 
the membrane to build Δp and those that couple the release of Δp to energy demanding processes, such 
as the synthesis of ATP (Nicholls & Ferguson, 2013). In mitochondrial membranes the two types are 
the electron transport chain (ETC), where a series of protein complexes couple electron transfer to the 
translocation of protons, and ATP synthase (complex V), which uses the controlled collapse of Δp to 
drive ATP synthesis.  
 
The operation of energy transducing membranes was first demonstrated by Peter Mitchell in his 
groundbreaking work on the chemiosmotic process in 1961, although it received much criticism at the 
time (Mitchell, 1961). The prevailing hypothesis was that energy was stored as a high-energy 
intermediate, despite little evidence of this species. Increased understanding of proton pumping by the 
complexes of the ETC gave further weight to the chemiosmotic theory and Mitchell received the 1978 
Noble Prize in Chemistry for his work.   
 
1.2. Mitochondria 
 
Mitochondria are the energy transforming organelles found in most eukaryotes, although they also 
perform a number of other fundamental roles. It is believed that these organelles evolved as described 
by the endosymbiotic theory, first postulated by Margulis in 1967 (Sagan, 1967). Driven by the 
evolution of the Earth, from an oxygen free to oxygen rich environment, it was hypothesised that an 
aerobe was ingested by an anaerobic prokaryote resulting in a mutually beneficial relationship. The 
engulfed cell would become a double-walled organelle, the inner lipid bilayer from the original plasma 
2 
membrane surrounded by an additional bilayer formed when ingested into a vesicle (Sagan, 1967). The 
endosymbiont theory has further been substantiated with the publication of the genome sequence of 
Rickettsia prowazekii; an ancestor of this parasite was thought to be the engulfed species (Andersson et 
al., 1998). With evolutionary time the symbiotic relationship has developed into cells with a highly 
specialised energy transducing organelle, which has retained a limited genomic DNA content and the 
ability to independently replicate (Nunnari & Suomalainen, 2012). Through transfer of genomic material 
to the nucleus the circular mtDNA of mammals now contains genes for only 13 proteins, 22 tRNAs and 
2 mitochondrial ribosomal subunits.  
 
Mitochondria have developed a highly adapted structure, with a largely permeable outer membrane 
(OMM) and an impermeable inner membrane (IMM), across which Δp is maintained. The IMM also 
forms many invaginations, known as cristae, projecting into the protein rich matrix, Figure 1.1. The first 
electron micrographs characterised the intricate structure of mitochondria, which is common to many 
different tissues, highlighting its importance to the function of the organelle (Palade, 1952). Since then 
imaging techniques have further informed knowledge of the mitochondrial structure, such that the IMM 
is considered to have two subdomains, the inner boundary membrane (IBM) and cristae membrane 
(CM). The IBM forms contact sites with the OMM, containing the import TOM and TIM machinery 
along with the ADP/ATP carrier responsible for ATP export. The tight association of the two 
membranes is also necessary for their coordinated fusion and fission (Vogel et al., 2006). In contrast the 
CM, comprising most of the IMM, forms invaginations where parts of the membrane are juxtaposed to 
one another and between the two subdomains are the narrowings of the cristae junctions, which may 
form barriers between the intermembrane space (IMS) and intracristal space.  
 
 
Figure 1.1 Electron micrograph of a mitochondrion from bat pancreas. The image shows the defining features 
of mitochondria including a double membrane. The inner membrane invaginations – cristae – are clearly visible 
extending into the mitochondrial matrix. Dark points within the matrix are mitochondrial ribosomes. Image taken 
from Porter & Bonneville, 1973. 
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Although the complex structure of individual mitochondria has long been appreciated, the importance 
of their dynamics, through fission and fusion events, was not fully understood, with the general 
paradigm of isolated mitochondria rather than an interacting network. However, live cell imaging 
showed that mitochondria exist as extended reticular networks contacting the nucleus, Golgi and 
cytoskeleton. The equilibrium between fission and fusion events is controlled by dynamin family 
proteins; mitofusins mediate OMM fusion and Opa1 IMM fusion, whereas Drp1 in the cytosol 
coordinates mitochondrial fission. Fusion enables communication and sharing of matrix contents 
between mitochondrial compartments whilst division facilitates transport, distribution and targeted 
degradation of organelles (Lackner, 2014). Mitochondria are responsive to bioenergetics changes: both 
individual mitochondria and networks shift towards more tubular-like morphologies in a high ADP 
environment, as shown in Figure 1.2, although a direct mechanistic link is still lacking. Therefore, while 
the importance of mitochondrial networks is now accepted the precise roles and processes governing 
their dynamism is still unclear.  
 
Figure 1.2 Mitochondria respond to bioenergetics changes by modification of cristae morphology. An 
electron tomogram is shown with OMM in red, IMM in yellow and cristae in green. High ADP levels stimulate 
cristae to condense to increase their internal area and form further connections with each other and the periphery 
of the organelle; the orthodox cristae structure persists in low ADP conditions. Figure adapted from Mannella, 
2006. 
 
Another process controlling the mitochondrial population of a cell is a specialised form of autophagy, 
called mitophagy. This quality control pathway is balanced with mitobiogenesis to maintain the correct 
levels of healthy mitochondria and closely linked to fission and fusion, as networks must be 
disassembled to remove damaged mitochondria. There must be recognition of impaired organelles; 
membrane potential depolarisation marks these mitochondria out for selective removal. Cytosolic 
PINK1 is known to be imported and inserted into the IMM, where it is then processed and cleaved by 
PARL. The cleaved product is targeted by a proteasome-dependent pathway, causing its removal from 
the mitochondrial membrane. However on depolarisation PINK1 is not imported or cleaved and the full-
length protein accumulates in the OMM, where it recruits Parkin. Narendra et al. demonstrated that the 
physiological role of Parkin was to promote the ubiquitination of damaged mitochondria (Narendra et 
al., 2008). The interaction with PINK1 activates the ubiquitin ligase activity of Parkin, which decorates 
protein targets on the OMM to mark them for lysosomal degradation. The exact mechanism by which 
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ubiquitinated mitochondria are recognised by autophagosomes is still unclear, but it may require adaptor 
proteins and other E3 ligases. 
 
1.3. Mitochondrial function 
 
1.3.1. Energy transduction 
 
Mitochondria play a central role in providing energy for the cell. In addition to the ETC and ATP 
synthase in the IMM, it is also the site of the citric acid cycle is in the mitochondrial matrix. Figure 1.3 
shows how glucose is oxidised to pyruvate by glycolysis in the cytosol, which requires two ATP to be 
consumed in the early enzymatic stages. However the latter steps of glycolysis yield four ATP by 
substrate level phosphorylation and two NADH, therefore there is an overall gain of two ATP and two 
NADH per glucose. Although glycolysis has a low ATP yield it can be used by organisms under low 
oxygen conditions to maintain the ATP:ADP ratio away from equilibrium, and it is a common trait of 
cancer cells to rely heavily on glycolysis for their energy demands.  
 
 
Figure 1.3 Glycolysis pathway. Steps of the glycolysis pathway and enzymes responsible for the catalysis of each 
step. Through isomerisation both products of aldolase formed from fructose-1,6-bisphosphate are converted to 
pyruvate to net yield of two ATP and two NADH for each glucose molecule. Figure adapted from Hipkiss et al., 
2013. 
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Pyruvate is a branching point for many different pathways including oxidative phosphorylation, glucose, 
lactate, fatty acid and amino acid synthesis. Enzymes that metabolise pyruvate are found in the 
mitochondrial matrix and therefore a transport-mediated process is required to move pyruvate across 
the IMM, although the pyruvate transporter was only identified relatively recently by two groups 
(Bricker et al., 2012; Herzig et al., 2012). For entry into the citric acid cycle pyruvate is converted into 
acetyl coA by the pyruvate dehydrogenase complex, additionally forming carbon dioxide and NADH. 
Figure 1.4 shows the citric acid cycle, comprising the activities of eight enzymes that sequentially 
combine acetyl coA with oxaloacetate to form citric acid and regenerate oxaloacetate. The cycle 
generates three NADH, two CO2, GTP and FADH2. The two decarboxylation steps (3: isocitrate to α-
ketoglutatarate, and 4: α-ketoglutatarate to succinyl coA) are the irreversible exergonic stages that 
ensure the progression of the cycle.   
 
 
Figure 1.4 Diagram of the citric acid cycle. The enzymes are named in blue. Reducing equivalents produced are 
shown in orange. Figure adapted from Nelson & Cox, 2008. 
 
Although the NADH generated by the citric acid cycle is available for use by complex I, NADH 
generated in the cytosol by glycolysis is not, being unable to pass across the IMM. Shuttles are utilised 
to move reducing equivalents across the mitochondrial membrane – the glycerophosphate shuttle and 
malate-aspartate shuttle. Figure 1.5A shows the glycerophosphate shuttle, which involves the 
conversion of the glycolytic intermediate dihydroxyacetone phosphate into glycerol-3-phosphate by 
glycerol-3-phosphate dehydrogenase, using NADH. The reverse reaction is carried out by another 
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glycerol-3-phosphate dehydrogenase, a flavoprotein localised to the IMM. This results in the reduction 
of FAD to FADH2, which can then reduce ubiquinone to ubiquinol for entry of electrons into the electron 
transport chain. The shuttle bypasses complex I and therefore results in fewer protons pumped and less 
ATP generated, since this process is irreversible it can be utilised under all cellular conditions.  The 
other shuttle uses oxaloacetate in the cytoplasm, which is converted into malate by malate 
dehydrogenase, coupled to NADH oxidation. Figure 1.5B shows that malate enters into mitochondria 
through an exchanger, which exports α-ketoglutatarate. Malate is then oxidised back to oxaloacetate in 
the matrix by a mitochondrial malate dehydrogenase, forming NADH that then enters the ETC at 
complex I, maximising ATP formation. Oxaloacetate is returned to the cytoplasm through a separate 
transporter, which exchanges aspartate for glutamate (α-ketoglutatarate and oxaloacetate are the α-keto 
acid equivalents of glutamate and aspartate). This is necessary to allow the net movement of electrons 
from one side of the membrane to the other. Overall both shuttles result in the transport of electrons into 
the mitochondria, without a change in metabolites. 
 
 
 
 
Figure 1.5 The mitochondrial glycerophosphate and malate-aspartate shuttles. A. The glycerophosphate 
shuttle. Dihydroxyacetone phosphate is converted to glycerol-3-phosphate by glycerol-3-phosphate 
dehydrogenase in the cytosol, consuming NADH. The reverse reaction can then be carried out by another glycerol-
3-phosphate dehydrogenase, a flavoprotein localised to the IMM (yellow). FAD is reduced to FADH2, which then 
reduces ubiquinone to ubiquinol within the IMM. Electrons can then enter the electron transport chain. B. The 
malate-aspartate shuttle. Oxaloacetate in the cytoplasm is converted into malate by malate dehydrogenase, 
requiring NADH. Malate enters the mitochondria through an exchanger (orange). Malate is oxidised back to 
oxaloacetate in the matrix by a mitochondrial malate dehydrogenase, forming NADH that may then enter the 
electron transport system at complex I, maximising ATP formation. Oxaloacetate is returned to the cytoplasm 
through a separate transporter via aspartate. Reducing equivalents can therefore be transferred across the IMM 
without net movement of metabolites. Figures adapted from Berg et al., 2002. 
 
NADH, as a source of electrons for complex I, is also formed by other mitochondrial pathways. Beta-
oxidation of fatty acids involves cyclic rounds of two-carbon removal and yields one NADH, one 
FADH2 and one acetyl coA with each round. The NADH produced is available for re-oxidation by 
complex I whereas the FADH2 is the cofactor of the flavoprotein ETF (Gregersen, 1985). The reduced 
ETF in turn reduces electron transfer flavoprotein dehydrogenase (ETFDH), which then reduces 
ubiquinone, allowing these electrons to enter the respiratory chain through the quinone pool. Another 
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key source of electrons is the oxidation of ketone bodies, where the first step is the NADH-dependent 
oxidation of β-hydroxybutyrate (Cotter et al., 2013). Additionally the end product is acetyl coA, so in 
the same way as β-oxidation of fatty acids, NADH is provided to the electron transport chain for 
complex I and acetyl coA sequestered by the citric acid cycle, all contributing towards ATP production. 
Energy production through ketone body derived reducing equivalents is utilised by some tissues under 
stress conditions, particularly the brain under low glucose; it is unable to utilise fatty acids, which do 
not pass the blood-brain barrier. The heart also derives NADH from ketone oxidation whereas the liver 
exports ketone bodies, being unable to oxidise them due to lack of succinyl-CoA: 3-ketoacid transferase 
(Orii et al., 2008). 
 
The requirement of electrons for oxidative phosphorylation and their multiple sources means that the 
ETC is intricately linked to the rest of mitochondrial metabolism and there is a reciprocal requirement 
from each to sustain turnover. Complex I cannot function without a NADH supply and if its activity is 
impaired then re-oxidation of NADH is limited for use by the citric acid cycle, fatty acid oxidation and 
ketone body oxidation. In this way complex I serves as an important connection between many 
mitochondrial pathways. 
 
Mitochondria also perform many other functions within the cell, some of which are summarised below.  
 
1.3.2. Calcium homeostasis 
 
Mitochondria are an important Ca2+ sink that can store and release the ion in response to changes in the 
cytoplasm. Ca2+ are imported across the OMM by a large voltage gated channel, VDAC, and across the 
IMM through two pathways – either using a uniporter moving the ions down their electrical gradient 
(established by ETC proton pumping) or through exchangers. The Na+/Ca2+ and the H+/Ca2+ exchangers 
are electroneutral antiporters and prevent electrochemical equilibrium. The molecular identity of the 
uniporter (MCU) was only established in 2011 (Baughman et al., 2011). Mitochondria, along with the 
endoplasmic reticulum, enable management of intracellular [Ca2+], which provides a signalling 
mechanism, allowing mitochondria to respond to the energy requirements of the cell. Three 
mitochondrial dehydrogenases, pyruvate dehydrogenase, isocitrate dehydrogenase and α-
ketoglutatarate dehydrogenase, are regulated by calcium. Increased work causes cytosolic [Ca2+] to rise 
and the matrix [Ca2+] also increases, leading to the stimulation of these mitochondrial dehydrogenases 
to increase NADH production, enhancing electron transport through the respiratory chain and ultimately 
increasing ATP production. Additionally, it has been proposed that ATP synthase can also be activated 
by calcium (Territo et al., 2000).  
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1.3.3. Iron sulphur synthesis 
 
The biogenesis of iron sulphur cofactors is also partially undertaken in mitochondria. [2Fe-2S], [3Fe-
4S] or [4Fe-4S] clusters and are required by proteins for a range of functions including electron transfer 
catalysis, and they are important sulphur donors in lipoic acid and biotin synthesis (Stehling & Lill, 
2013). Their synthesis and incorporation into apoproteins involves around 30 proteins in the 
mitochondria and cytosol. Biosynthesis starts in the matrix with the iron-sulphur assembly machinery, 
comprising more than 15 components, and the cofactor may then be retained in the mitochondria or 
exported for maturation of non-mitochondrial Fe-S proteins. Impairment of FeS protein assembly is 
associated with severe pathology including neurodegenerative, metabolic and haematological 
conditions, which often display accumulation of iron in the mitochondria (Stehling & Lill, 2013).  
 
1.3.4. Apoptosis   
 
Mitochondria also play a central role in programmed cell death, which may be in response to external 
or internal factors. This process is tightly regulated by Bcl-2 family proteins, with both anti-apoptotic 
and pro-apoptotic members (Wang & Youle, 2009). The balance of these factors controls the 
permeability of the OMM and release of caspases and cytochrome c into the cytosol. Additionally there 
is sustained IMM permeability due to the opening of the still elusive permeability transition pore (Izzo 
et al., 2016). Therefore mitochondria contain the signals necessary to bring about irreversible cell 
disassembly: and so the retention of apoptosis regulating molecules in mitochondria is essential, along 
with the fidelity of the signalling pathway that brings about their release.  
 
1.4. The electron transport chain 
 
The respiratory chain coordinates electron transfer from NADH to oxygen and couples it to proton 
translocation to maintain Δp. It is composed of four protein complexes. Complex I is the largest 
complex, it obtains electrons from oxidation of NADH in the mitochondrial matrix, and passes them to 
its other substrate, ubiquinone (Q), a hydrophobic acceptor present in the IMM. The detailed structure 
and function of complex I will be discussed separately in section 1.5.  
 
1.4.1. Complex II 
 
Complex II (succinate dehydrogenase) catalyses the oxidation of succinate to fumarate and reduces 
ubiquinone to ubiquinol by a two-electron transfer. The enzyme is both an integral part of the respiratory 
chain and participates in the citric acid cycle, but unlike complex I does not pump protons. Complex II 
is formed of four subunits, which are all nuclear-encoded and therefore is the only ETC complex without 
any mitochondrially-encoded subunits. SDHA and SDHB are the hydrophilic core components and 
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contain the redox cofactors shown in Figure 1.6. FAD is covalently bound to SDHA, and the three iron-
sulphur clusters that facilitate electron transfer to ubiquinone are coordinated by SDHB. These are a 
2Fe-2S cluster, which sits ~12 Å from the FAD, followed by a 4Fe-4S and a 3Fe-4S cluster (Sun et al., 
2005). Additionally, complex II contains a haem within the membrane domain; but its exact role is 
unclear, although it is not thought to be involved in catalysis. A mutant in Saccharomyces cerevisiae 
that lacks the haem was not catalytically comprised (Oyedotun et al., 2007). Due to the small difference 
in midpoint potential between succinate and ubiquinone (~0.03 V) there is little energy released upon 
oxidation of succinate and therefore complex II is unable to pump protons.  
 
 
Figure 1.6 Structure of succinate dehydrogenase from Sus scrofa at 2.4 Å resolution. The crystal structure of 
complex II is shown embedded in the IMM. SDHA is shown in blue ribbons, SDHB in cream, with transmembrane 
SDHC and SDHD in pink and orange. The cofactors, their midpoint potentials and distances within the structure 
are shown to the right of the structure. Figure adapted from Sun et al., 2005. 
 
The reduction of ubiquinone requires the uptake of two protons to form ubiquinol (QH2), which is 
confined to the IMM due to its hydrophobicity. QH2 acts as a carrier, shuttling electrons from complexes 
I and II to complex III. The redox state of the ubiquinone pool is also affected by the activities of other 
proteins, including the electron transfer flavoproteins (ETFs), such as ETF dehydrogenase in the β-
oxidation pathway for fatty acids.  
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1.4.2. Complex III 
 
Complex III (cytochrome bc1 complex) is the next component of the ETC: it contributes to Δp, but via 
a modified Q-cycle rather than through direct proton pumping (Crofts et al., 1983). The complex has 11 
subunits, although only three are necessary for catalysis and conserved in all systems; the others may 
aid assembly and stability. The redox cofactors are: a 2Fe-2S Rieske centre, a c-type haem and two b-
type haems. The two b-haems have differing redox potentials, which is central to the mechanism of the 
enzyme – bL with an Em,7 ~ -30mV is located adjacent to the intermembrane space, whereas bH with Em,7 
~ +100mV is proximal to the matrix (Xia et al., 2013). They connect the two binding sites for 
ubiquinone: QP is found close to the positive (intermembrane) face and QN near to the negative (matrix) 
side. 
 
 
 
Figure 1.7 Mechanism of ubiquinone oxidation by complex III. The diagram shows the net result of two proton 
motive Q-cycles by the complex III monomer. The FeS cluster is located on the Rieske protein, the c-type haem 
(c1) on the cytochrome c subunit (cytc1) and the b-type haems (bL and bH) on the cytochrome b subunit. Arrows 
show electron movement along the two pathways – high potential through the Rieske protein to the cytochrome c 
subunit and onto cytochrome c and low potential pathway along the b-type haems to the QN site to reduce 
ubiquinone. 
 
Figure 1.7 shows the mechanism of ubiquinone oxidation – first, a molecule of QH2 binds at the QP site, 
which neighbours the Rieske protein, such that one of the QH2 hydroxyls forms a hydrogen bond to a 
histidine coordinating the Fe-S centre. Oxidation of QH2 then occurs in two stages. The first electron is 
transferred to the Rieske iron-sulphur cluster and two protons are released into the intermembrane space, 
forming a free radical semiquinone (Q−) at the QP site (Trumpower, 1990). The second electron is then 
transferred to the bL haem, also near the positive side of the membrane. The semiquinone is unstable so 
the second oxidation is energetically favourable. Overall, the bifurcation reaction sends one electron to 
the high potential chain and one to the low potential chain. However the semiquinone may also reduce 
oxygen in an unwanted side reaction (Trumpower, 1990). The electron received by the Rieske protein 
11 
passes down the high potential chain to cytc1 and on to cytochrome c (top pathway in Figure 1.7). The 
low potential pathway is from the Q− to the bL haem and bH haem (lower pathway). A ΔΨ of +150 mV 
opposes the electron transfer from bL to bH, from the positive to negative side of the membrane, but the 
drop in reduction potential balances this energetically unfavourable reaction, allowing the electron to 
retain its original energy (Nicholls & Ferguson, 2013). At the second quinone-binding site QN, close to 
bH at the matrix side of the membrane, Q binds and accepts the electron from bH, forming Q−. The Q− 
is stable in the QN, such that the first and second reduction event to occur with similar energy. To 
complete the cycle another QH2 is oxidised at QP with one electron passing to cytochrome c through the 
high potential pathway and the other passing from bL to bH along the low potential pathway. The second 
electron reduces Q− to QH2 and the two protons required are taken up from the matrix, allowing QH2 to 
return to the pool. Overall one ubiquinol is reduced by two cytochrome c molecules, coupled to the 
translocation of four protons.  
 
 
 
 
Figure 1.8 Structure of cytochrome bc1 complex homodimer from Bos taurus at 3.0 Å resolution. The crystal 
structure of complex III shows its native state as a homodimer, with subunits highlighted by colour. Figure adapted 
from Iwata et al., 1998. 
 
The structure of complex III was important for confirming and increasing understanding of the 
mechanism, particularly relating to the bifurcation at the QP site. The different pathways for each 
electron have been further elucidated by the observation that the globular head of the Rieske protein – 
containing the 2Fe-2S cluster – changes its position. When the cluster is reduced the head docks onto 
cytc1 to allow transfer of the electron, after which the affinity for the cytochrome c1 subunit is decreased 
and the head returns to the QP site, where it is electrostatically stabilised. The movement occurs across 
a 20 Å range on a sub-millisecond time-scale, which matches electron transfer rates (Yu, et al., 2008). 
Additionally, as the distance limit for rapid electron transfer is 14 Å, when the Rieske head is bound to 
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cytc1 it is too far away to accept the second electron, which is directed down the low potential chain. As 
shown in Figure 1.8, complex III acts as a dimer with cooperation between the monomers: the structure 
shows there is a crossover, with the head group of the Rieske protein on one subunit interacting with QP 
and cytc1 in the other (Iwata et al., 1998).  
 
Cytochrome c then acts as an electron shuttle; it diffuses through the intermembrane space carrying a 
single electron on its c-type haem, which it transfers to complex IV in the final step of the ETC.  
 
1.4.3. Complex IV 
 
 
 
Figure 1.9 Structure of cytochrome c oxidase from Bos taurus at 1.8 Å resolution. The crystal structure of 
complex IV is shown with core subunit I in green, II purple and III in blue. The path of electron transfer is shown 
on the right of the structure. Figure adapted from Rich, 2017. 
 
Figure 1.9 shows the structure of mammalian complex IV, which comprises 13 subunits. Three are 
mitochondrially encoded (COX I, II, III). Catalysis requires four cytochrome c to sequentially donate 
four electrons to reduce oxygen to two molecules of water. Cytochrome c in the intermembrane space 
transfers an electron to the dinuclear CuA centre of subunit II, it then moves to the low spin haem a and 
onto the haem a3/CuB binuclear centre (BNC). Oxygen enters the BNC at subunit III, where it is reduced 
to two water molecules with the uptake of four protons from the matrix. Upon each electron reduction 
of oxygen one proton is moved across the membrane into the IMS and a second substrate proton is taken 
up by the oxygen. Although the protons and electrons utilised for the reduction of oxygen do not 
completely cross the membrane they do contribute to ΔΨ as they move towards the positive and negative 
sides of the membrane respectively and cross part of the dielectric distance (Belevich et al., 2007). The 
energy released upon reduction of oxygen drives the pumping of four protons into the IMS.  
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One of the least-understood aspects of complex IV biochemistry is the movement of protons, both as 
substrates to reduce oxygen and those pumped into the IMS. Two proton channels have been designated 
the K and D channels, named for particular lysine or aspartate residues. The K-channel connects the 
matrix to the catalytic tyrosine of the BNC and the D-channel leads from an aspartic aid at the matrix 
side to a region equidistant to the haems (Yoshikawa et al., 2011). Additionally a H-channel was first 
described in bovine cytochrome c oxidase and is more complex (Muramoto et al., 2010). It has been 
difficult to ascertain whether specific channels are related to the movement of substrate and translocated 
protons or whether there is some cross over, although it has been suggested that the K-channel feeds 
two substrate protons to the active site, whereas the D-channel transfers both types (Rich, 2017).  
 
1.4.4. Complex V 
 
The Δp generated by complexes I, III and IV is then harnessed to generate ATP. Mammalian ATP 
synthase (complex V) is a 580 kDa complex with 15 different subunits. It comprises a hydrophobic Fo 
domain in the membrane and a hydrophilic F1 domain that extends into the matrix, as depicted in Figure 
1.10. The F1 domain region is a hetero-hexamer of α and β subunits, which may bind ATP, ADP and Pi. 
The conformational changes at the catalytic site are controlled by the γ subunit, which rotates non-
symmetrically in the centre to bring about the three-site alternating binding site mechanism. The 
peripheral stalk anchors the F1 domain to the membrane embedded Fo domain, made up of the b subunit, 
F6, d and oligomycin-sensitivity conferring (OSCP) subunits, to prevent rotation of the α3β3 assembly. 
Recently the intact F-ATPase from Paracoccus denitrificans has been crystallised, shown in Figure 
1.11, providing additional insight into the coupling of the proton motive force to ATP synthesis 
(Morales-Rios et al., 2015). 
 
The Fo domain comprises a ring of c subunits, with the copy number depending on the species; the 
human and bovine enzymes have c-8 rings (Watt et al., 2010). Each subunit has two helices separated 
by a loop and an ionisable residue. The a subunit is thought to provide a proton entrance at the IMS side 
and an exit channel at the matrix side, through which protons access an ionisable residue of the c subunit. 
Once neutralised the residue moves the subunit away from the channel and rotates the c-ring assembly, 
the proton is then lost through the exit half channel of subunit a (Nicholls & Ferguson, 2013). One 
complete rotation of the c-ring cause the full rotation of the α3β3 assembly and generates three ATP. The 
inhibitor protein IF1 binds in a pH dependent manner and prevents ATP synthase operating in reverse. 
At lowered matrix pH it binds in response to a decreased Δp to prevent ATP hydrolysis (Gledhill et al., 
2007).  
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1.5. Complex I 
 
1.5.1. Subunits and structure  
 
Mammalian complex I (NADH:ubiquinone oxidoreductase) is the largest of the ETC enzymes, with 45 
subunits contributing to a mass of ~1 MDa. The core enzyme comprises 14 subunits, which are retained 
across all species containing complex I. They are segregated into the membrane arm, with seven 
transmembrane subunits all encoded by mtDNA (ND subunits) and seven hydrophilic subunits encoded 
in the nucleus and imported to the mitochondria giving the distinctive L-shape (Hirst, 2013). Table 1.1 
shows the subunit nomenclature for different species, demonstrating that whilst mammalian complex I 
contains 45 subunits, the yeast (Yarrowia lipolytica) enzyme shares only some of the supernumerary 
subunits found in mammals – but also has four species specific subunits. Bacterial and archaeal 
(Escherichia coli and Thermus thermophilus) complex I represent the core enzyme only.  
 
Figure 1.10 Schematic representation of E. coli ATP 
synthase. Subunits are labelled and shows the hydrophilic F1 
domain extending into the matrix. Orange subunits are static 
and green subunits rotate during ATP synthesis. The principle 
is the same for the mammalian enzyme. Figure adapted from 
Lodish et al., 2008. 
Figure 1.11 Crystal structure of ATP 
synthase from P. denitrificans at 4.0 Å 
resolution, with inhibitor protein bound. 
A. Side view of the enzyme with B. rotated 
90 ° to A. The most complete structure of 
ATP synthase showing the new features of 
the peripheral stalk and same unique fold in 
the bacterial a-subunit as in the 
mitochondrial ATP6 subunit. Helix-1 of the 
inhibitor is shown in brown. Figure adapted 
from Morales-Rios et al., 2015. 
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Domain Bos tarus Homo sapiens 
Yarrowia 
lipolytica 
Thermus 
thermophilus 
Escherichia coli 
Hydrophobic arm 
ND1 ND1 NU1M Nqo8 NuoH 
ND2 ND2 NU2M Nqo14 NuoN 
ND3 ND3 NU3M Nqo7 NuoA 
ND4 ND4 NU4M Nqo13 NuoM 
ND4L ND4L NULM Nqo11 NuoK 
ND5 ND5 NU5M Nqo12 NuoL 
ND6 ND6 NU6M Nqo10 NuoJ 
Hydrophilic arm 
24 kDa NDUFV2 NUHM Nqo2 NuoE 
49 kDa NDUFS2 NUCM Nqo4 
NuoCD 
30 kDa NDUFS3 NUGM Nqo5 
51 kDa NDUFV1 NUBM Nqo1 NuoF 
75 kDa NDUFS1 NUAM Nqo3 NuoG 
PSST NDUFS7 NUKM Nqo9 NuoB 
TYKY NDUFS8 NUIM Nqo6 NuoI 
Supernumerary 
subunits 
10 kDa NDUFV3    
13 kDa NDUFS6 NUMM   
15 kDa NDUFS5 NIPM   
18 kDa NDUFS4 NUYM   
39 kDa NDUFA9 NUEM   
42 kDa NDUFA10    
ACP NDUFAB1 
ACPM 
  
ACP NDUFAB1   
AGGG NDUFB2    
ASHI NDUFB8 NIAM   
B8 NDUFA2 NI8M   
B9 NDUFA3 NI9M   
B12 NDUFB3 NB2M   
B13 NDUFA5 NUFM   
B14 NDUFA6 NB4M   
B14.5a NDUFA7 NUZM   
B14.5b NDUFC2    
B14.7 NDUFA11 NUJM   
B15 NDUFB4 NB5M   
B16.6 NDUFA13 NB6M   
B17 NDUFB6    
B17.2 NDUFA12 N7BM   
B18 NDUFB7 NB8M   
B22 NDUFB9 NI2M   
ESSS NDUFB11 NESM   
KFYI NDUFC1    
MNLL NDUFB1    
MWFE NDUFA1 NIMM   
PGIV NDUFA8 NUPM   
PDSW NDUFB10 NIDM   
SGDH NDUFB5    
 
Species specific 
subunits 
  NEBM   
  NUNM   
  NUUM   
  NUXM   
 
Table 1.1 Subunit composition of complex I and nomenclature used across different species. The names given 
to the subunits of complex I in species commonly used for its study are shown. Only core subunits are present in 
complex I from T. thermophilus and E. coli, whereas Y. lipolytica contains 20 of the supernumerary subunits, of 
which there are 32 in total, shared by bovine, human and other mammalian complex I (Berrisford et al., 2016; 
Angerer et al., 2011). 
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The first structures of complex I were from bacterial species, so they only provided information on the 
core subunits. E. coli and T. thermophilus have both been used as model systems. The hydrophilic 
domain of T. thermophilus complex I was resolved to 3.3 Å by Sazanov and co-workers in 2006, closely 
followed by the membrane domain structure of E. coli at 3.0 Å and later a high resolution structure of 
the complete T. thermophilus enzyme at 3.3 Å in 2013, Figure 1.12 (Sazanov & Hinchliffe, 2006; 
Efremov & Sazanov, 2011; Baradaran et al., 2013). These structures elucidated the FMN active site; the 
arrangement of iron sulphur clusters and indicated a putative Q-binding site. Additionally, an unusually 
positioned 2Fe-2S cluster (2Fe[24]) was observed on the opposite side of the flavin. The membrane 
domain from E. coli also highlighted a transverse helix, running along the top of the membrane domain. 
Figure 1.12 shows the high resolution T. thermophilus complex, from which the putative Q-binding site 
was identified as a long tunnel, with a narrow entry point for the quinone. A possible structural basis for 
coupled proton pumping was also indicated. Three antiporter-like subunits - Nqo12, Nqo13, Nqo14 
(ND5, ND4 and ND2) - share homology with Mrp antiporters and pump protons, but a mechanism is 
required to couple changes at the Q-site to proton pumping by complex I. The T. thermophilus structure 
highlighted that subunit Nqo8 (ND1), which sits in the membrane domain at the base of the hydrophilic 
arm, contains a similar fold to the antiporter-like subunits, despite a low sequence similarity. It contains 
a mixture of long and short helices tilted relative to the membrane. This region can be superimposed 
onto the half-channels of the antiporter-like subunits and the second half-channel was proposed to be 
formed by Nqo10 and Nqo11 (ND6 and ND4L) (Baradaran et al., 2013). Charged residues were 
identified in Nqo8 that mirrored those found in the antiporter-like subunits, along with an additional 
network creating a ‘funnel’ to connect the charged midline residues to the Q-site, which may facilitate 
transmission of conformational changes. Therefore a fourth proton channel was elucidated from the T. 
thermophilus structure, named the E-channel for the abundance of glutamate residues, and is formed by 
Nqo8, Nqo10 and Nqo11 (ND1, ND6 and ND4L). The channel is made up of many conserved residues, 
which are crucial for complex I activity. Consequently the presence of four putatitve proton channels in 
the T. thermophilus structure supported the proposed complex I proton pumping stoichiometry of four, 
rather than three (Baradaran et al., 2013). 
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Figure 1.12 Structure of complex I from Thermus thermophilus at 3.3 Å resolution. The first complete 
structure of complex I showing all core subunits, shared with mammalian complex I (Baradaran et al., 2013: PDB 
code 4HEA). Mitochondrially encoded core subunits are coloured to match their labels and the chain of redox 
cofactors is shown next to the hydrophilic domain. The 2Fe-2S iron sulphur cluster to the right of the bound flavin 
(as shown) is isolated from the rest of the chain and not thought to be involved in electron transfer. Figure adapted 
from Hirst, 2013. 
 
 
Structures of the mammalian enzyme initially proved more elusive, with crystallography impeded by 
the large size of complex I and its membrane protein characteristics. However its size, along with its 
asymmetry, enabled single particle cryo-electron microscopy (cryo-EM) to be utilised and in 2014 Hirst 
and co-workers determined the bovine enzyme structure to 5 Å, allowing the 14 core subunits and a 
further 14 supernumerary subunits to be assigned (Vinothkumar et al., 2014). Figure 1.13 shows the 
bovine complex I structure. The conserved bovine subunits showed high similarity to the bacterial core 
components and Figure 1.13B highlights that the supernumerary subunits form a cage-like covering 
over the surface of the enzyme, possibly to stabilise the structure, whilst leaving the NADH binding site 
accessible to substrate. With further refinement more subunits were fitted to the structure and in 2016 
all 45 subunits were located and modelled in a 4.2 Å structure (Zhu et al., 2016). This structure not only 
strengthened the identity and properties of the Q-binding channel and possible proton pumping coupling 
mechanism but also demonstrated distinct conformational states of complex I, designated the deactive 
and active forms, with the elucidation of changes in the long matrix loop of ND3. 
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Figure 1.13 Structure of complex I from Bos taurus at 5.0 Å resolution. A. Assignment of supernumerary 
subunits coloured to match labels, those subunits on the reverse side of the structure are labelled with dashed 
arrows. The electron density map is shown in grey and the surface model of core subunits in wheat. The remaining 
supernumerary subunits were assigned to the refined structure in 2016 (Zhu et al., 2016). B. Location of the 
supernumerary subunits around the core enzyme. The 14 core subunits are shown as a surface representation in 
colour, enclosed by the density of the supernumerary subunits in red. These form a supportive case around the 
core protein but are missing from regions required for substrate access, such as the 51 kDa subunit for NADH 
binding.  Figure adapted from Vinothkumar et al., 2014. 
 
 
Further structures using cryo-EM have added to increasingly detailed knowledge of the structure, 
including complex I from ovine-heart mitochondria (Fiedorczuk et al., 2016). The different states of the 
enzyme have been further explored - a 4.1 Å resolution structure of the deactive bovine enzyme showed 
that in the absence of substrate the enzyme adopts a resting state, with a disordered Q-binding site, which 
requires the reintroduction of substrate for reactivation (Blaza et al., 2018). Most recently complex I 
from mouse heart mitochondria has been resolved to 3.3 Å in the active state, Figure 1.14. Comparison 
with the deactive structure revealed some conformational changes, especially in a potentially important 
-bulge in subunit ND6. Differences have also been noted from previous bacterial structures, altered 
helical geometry in ND4 may have consequences for proton translocation due to the positioning of 
charged residues (Agip et al., 2018). Along with different functional states, complex I is also found in 
supercomplexes, forming strong contacts with complex III. Respirasomes are comprised of complexes 
I, III and IV with ratios I1III2IV1-4 (Lenaz et al., 2016). High-resolution structures of supercomplexes 
have been obtained, including from porcine-heart mitochondria and cultured human cells, which have 
identified the key subunit contacts between complexes: notably NDUFB9 and NDUFA11 interact with 
UQCR1 and UQCRQ of complex III, respectively (Wu et al., 2016; Guo et al., 2017). There is much 
speculation on the function of supercomplexes, including aiding stability of complex I, allowing 
substrate channeling between complexes I and III and controlling ROS production; however, this area 
of ETC function remains contentious and still requires further biochemical assessment to determine the 
advantages of these multi-complex arrangements (Sousa et al., 2018).   
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Figure 1.14 Structure of complex I from Mus musculus at 3.3 Å resolution. An overview of the best-resolved 
structure of complex I to date, with the 14 core subunits in colour and supernumerary subunits in white. The site 
of FMN binding and position of the terminal iron sulphur cluster N2 are highlighted. The redox cofactor chain is 
shown inset above. Figure adapted from Agip et al., 2018. 
 
1.5.2. The catalytic mechanism of complex I  
 
1.5.2.1. NADH oxidation at the flavin-binding site 
 
The first step of ubiquinone reduction by complex I is the oxidation of NADH by electron transfer to 
bound FMN on NDUFV1. NADH binds with its nicotinamide ring positioned over the isoalloxazine 
moiety of FMN, as occurs in many oxidoreductases (Berrisford & Sazanov, 2009; Ferguson & Nicholls, 
2013). This configuration facilitates direct hydride transfer from C4 of the nicotinamide ring to the N5 
of FMN, avoiding the high-energy nicotinamide free radical (Berrisford & Sazanov, 2009). The redox 
potential of NAD+ is slightly higher than that of the flavin (-0.34 V and -0.38 V at pH 7.5 respectively) 
and so NADH oxidation is reversible. The FMN bound to bovine complex I has a lowered redox 
potential, as the oxidised flavin is more strongly bound than its reduced partner (Hirst, 2013). kcat for 
NADH oxidation by FMN is >15000 s-1 and kcat/KM is ~108 M-1s-1, which approaches the diffusion limit. 
The FMN site can also react with synthetic reagents, including Fe(CN)63- at very high rates, and 
transhydrogenation between NADH and an acceptor such as 3-acetylpyridine-adenine dinucleotide 
(APAD+) can also be catalysed by FMN, although on a slower timescale (Birrell et al., 2009).  
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1.5.2.2. Iron sulphur clusters and intramolecular electron transfer 
 
Seven FeS clusters form a set of stepping-stones to pass electrons from reduced FMN to bound 
ubiquinone. The isolated cluster 2Fe[24] does not participate and its role is unclear – it has only been 
observed to accept electrons in the E. coli enzyme (Uhlmann & Friedrich, 2005). Electron transfer is 
considered non-rate limiting, with the rate of transfer between the clusters determined by distance and 
redox potential. The properties of the FeS chain have predominantly been studied by electron 
paramagnetic resonance (EPR) and spectra accurately assigned to particular clusters in 2010. Hirst and 
co-workers showed that the N4 signal is derived from 4Fe[TY]1, N1b from 2Fe[75], N2 from 4Fe[PS] 
and N3 from 4Fe[51], after previous ambiguities. Consequently it was found that the iron sulphur 
clusters have alternating redox potentials – a characteristic of many enzymes with sequential cofactors 
(Roessler et al., 2010). Figure 1.15 shows this arrangement, which is expected to be more kinetically 
favourable than two adjacent clusters of similar potential (Hirst, 2013). This pattern may also reflect 
electrostatic interactions between the clusters, which are not accounted for in the experimental profiles 
(Bridges et al., 2012).  
 
 
 
Figure 1.15 Profile of redox potentials of the cofactors of complex I. Based on data from B. taurus with 
substrate potentials shown as two electron potentials. FMN1 denotes the oxidised/semi-reduced couple and FMN2 
the semi-reduced/reduced pair. Distances between iron-sulphur clusters are shown in Å as edge-to-edge distances. 
Two values for Q are ± Δp of 0.15 V. Figure adapted from Hirst, 2009. 
 
1.5.2.3. The ubiquinone binding site 
 
The ubiquinone binding site (Q-site) has been identified in all structures to date; forming a long narrow 
tunnel that extents ~ 20 Å up from the membrane interface, where the quinone head-group is proposed 
to bind, although this is not proven (Fedor et al., 2017). Both mutagenesis in E. coli and Y. lipolytica 
and densities observed in the T. thermophilus complex I structure indicate that the head-group binds 
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through hydrogen bonds to H59 and Y108 of NDUFS2 (Sinha et al., 2015; Tocilescu et al., 2010; 
Baradaran et al., 2013), placing ubiquinone within 12 Å of the final FeS cluster, N2, to facilitate electron 
transfer. Overall the tunnel is long enough to enclose most of the 50 Å isoprenoid tail of Q10, although 
many diverse inhibitors are also suggested to bind in the channel (Murai & Miyoshi, 2016). 
 
Quinone reduction proceeds in two steps, due to single electron transfer from N2. Therefore, a 
paramagnetic semiquinone intermediate is formed, which is detectable by EPR (Hirst, 2013). Two such 
intermediates have been described – a fast relaxing and slow relaxing species – that may indicate two 
quinone binding sites, although this has been excluded experimentally and is not supported by structural 
data (Ohnishi et al., 2010; Hirst & Roessler, 2016). Therefore, the exact nature of these semiquinone 
intermediates remains unclear. Interestingly the chain length of the quinone substrate has been shown 
to influence turnover of complex I, with shorter isoprenoid chains correlating with decreased kcat (Fedor 
et al., 2017). This would suggest that the rate limiting step in quinone reduction has slowed or changed 
and indicates that the rates of binding and dissociation are dictated by tail length. Higher rates with 
longer isoprenoid chains imply that the tail acts as an anchor and can be guided up the tunnel to correctly 
position the head group in the binding pocket. Q1 and Q2 with short tails may therefore lack this 
directionality due to increased conformational mobility. Additionally, the end of Q10 extends back into 
the membrane, which may encourage dissociation, whereas with an incompletely filled binding channel 
other molecules may enter and sit behind smaller quinones, impeding their exit (Fedor et al., 2017). 
There are still a number of outstanding questions regarding the quinone-binding site, particularly as 
isoprenoids 4-7 lie within a highly charged region of the channel; expected to fill with water molecules. 
This observation has been supported by molecular dynamic simulations of the T. thermophilus structure; 
although higher resolution structures are needed to further probe this unusual feature (Di Luca et al., 
2017).  
 
1.5.2.4. Proton pumping  
 
Complex I couples the reduction of ubiquinone to the pumping of protons into the IMS and so 
contributes to maintaining Δp. An important aspect of complex I function is the stoichiometry of proton 
translocation, which has been historically considered to be four, with four proton channels proposed 
(Wikström, 1984; Galkin, 2006). Three channels are found in the antiporter-like subunits ND2, ND4 
and ND5, which share homology with Na+/H+ Mrp antiporters (Efremov & Sazanov, 2011). The fourth 
channel was initially identified in the T. thermophilus structure at the interface of ND1, ND4L and ND6, 
and named the E-channel (Baradaran et al., 2013). These four channels contain broken transmembrane 
helices and conformational changes instigated by reduction of quinone at the Q-site may allow complex 
I to pump protons into the IMS. As described previously, a network of conserved charged residues 
running along the midline of the membrane domain has been proposed to connect the spatially separated 
Q-site to these proton channels, thereby transducing energy to couple proton pumping to electron 
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transfer. The stoichiometry of proton pumping was revisited by Jones et al. and used inverted membrane 
vesicles from P. denitrificans and B. taurus to confirm earlier measurements of a 4 H+/2 e- ratio rather 
than the more recently proposed 3 H+/2 e- ratio by Wikström and Hummer (Jones et al., 2017; Wikström 
& Hummer, 2012). 
 
The exact coupling mechanism is still uncertain, but two mechanisms have been proposed: one or two-
stroke. One-stroke dictates that all energy released from electron transfer from NADH is transduced in 
a single step with concomitant pumping of protons, which could be feasible due to the four proposed 
proton channels (Efremov & Sazanov 2012). The Q-site is suggested to be linked to a glutamate-
aspartate quartet in the centre of the E-channel by a hydrophilic funnel. The anionic quinol interacts 
with these negatively charged residues and drives conformational changes in the E-channel that are 
propagated to the antiporter-like subunits further along the membrane arm. This would drive changes in 
the pKa and solvent exposure of key residues, resulting in the translocation of four protons into the IMS 
or periplasm, Figure 1.16. 
 
Figure 1.16 Proposed one-stroke mechanism for redox coupled proton transfer. Overview showing that upon 
electron transfer from N2 the negative quinone initiates a series of conformational changes along the central axis 
(red arrows) comprising charged or polar residues - shown as circles in blue (lysine or histidine) and red 
(glutamate). Figure adapted from Sazanov, 2014. 
 
In the two-stroke mechanism energy transduction occurs over two steps, with the formation of a high-
energy anionic semiquinone intermediate (Q−) and then an anionic quinol (QH−) (Brandt, 2011). These 
intermediates switch between two states – an electron transfer state (E) and a substrate protonation state 
(P) linked to conformational changes that initiate proton translocation, as shown in Figure 1.17. During 
the E state the first electron from N2 reduces ubiquinone to Q−, its stabilisation provides the energy 
required to pump two protons. Then in the P state Q− is protonated to form QH and the conformation 
returns to the E state. A second electron transfer from N2 reduces the protonated semiquinone to QH− 
and its stabilisation induces the second stroke for proton pumping. Brandt hypothesises that the same 
two proton-pumping sites would be used twice, although this is not strictly necessary and the presence 
of four channels indicates different combinations could be used.  
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Figure 1.17 Proposed two-stroke mechanism for redox coupled proton transfer. Redox intermediates of 
ubiquinone drive conformational changes in the membrane arm to pump two protons. Stabilisation of the anionic 
intermediates Q- and QH- cause E (blue) to P (green) state changes. The yellow bar denotes a transmission element 
between the proton pump sites. Figure adapted from Brandt, 2011. 
 
There has been difficulty ascertaining the route of energy transduction to the proton pumping domains, 
although increasingly detailed structural data is helping to clarify this. It is thought to involve changes 
in the Q-binding cleft and propagation into the membrane domain by the chain of charged residues 
running along its midline, although this is still hypothetical (Zhu et al., 2016).  
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1.6. Mitochondrial disorders and complex I deficiency 
 
Mitochondria are central to regulating cellular bioenergetics; therefore, their dysfunction causes a 
spectrum of disorders, known collectively as mitochondrial diseases. These are a diverse range of 
disorders with clinical symptoms presenting from early childhood to late adulthood that arise from 
dysfunction in the ETC (Swalwell et al., 2011). Prevalence is around 1 in 5,000 births and diseases may 
affect a single organ (the eye in Leber’s hereditary optic neuropathy, LHON) or multiple organs (Hoefs 
et al., 2012). Mitochondrial disorders are defined as primary – caused by a mutation in a mitochondrial 
protein – or secondary – resulting from an external influence on the mitochondria (Koopman et al., 
2016). Mutations may originate from nuclear DNA or mtDNA due to the dual genomic control of the 
respiratory complexes (except complex II). nDNA mutations may inherited as autosomal dominant or 
recessive alleles, with a small number of X-linked mutations. Importantly, mitochondrial disease 
phenotypes are not only caused by mutations in respiratory chain enzymes but may also result from 
disruption of essential organellar processes, such as mtDNA maintenance, translation and mitochondrial 
homeostasis. Defective mtDNA replication caused by mutations in catalytic subunit of DNA polymerase 
γ (POLG) is responsible for a large proportion of mitochondrial disease phenotypes, which span five 
different syndromes (Stumpf et al., 2013). mtDNA mutations are maternally inherited and heteroplasmy 
occurs in mtDNA due to copy number, therefore mutations must accumulate and exceed a threshold 
level for pathogenicity (Schon et al., 1997). Therefore, the same mutation can cause different clinical 
outcomes due to load. For example, the m.8993T>G mutation in MT-ATP6 causes Leigh syndrome 
with high mutational load and neurogenic weakness with ataxia and retinitis (NARP) with lower 
heteroplasmy (Uziel et al., 1997). Interestingly the most prevalent mtDNA mutations, responsible for 
~50% of mtDNA-associated mitochondrial disorders, are found in the 22 tRNA encoding genes, despite 
these comprising only 5% of the coding sequence in mtDNA (Elson et al., 2009). Mutations may affect 
the structure of tRNAs or prevent post-transcriptional modifications that are necessary for their correct 
aminoacylation, thus tRNA mutations may severely hamper the translation of mitochondrial-encoded 
proteins (Yarham et al., 2010). 
 
Complex I deficiency is the most common respiratory chain disorder, with an estimated 20-25% caused 
by nDNA mutations and 25-30% in mtDNA, including both mutations in its subunits, assembly factors 
and those affecting POLG and tRNAs, particularly tRNALeu(UUR) (Swalwell et al., 2011). Yet, strikingly, 
nearly half of cases have an unknown genetic basis. Complex I deficiency is one of the most prevalent 
types in childhood, making up a third of cases due to its early onset, often with severe lactic acidosis 
and fatality within one year (Fassone and Rahman, 2012). Since the ground-breaking publication by 
Wallace and co-workers in 1988, which identified a point mutation in ND4 (Wallace et al., 1988), 
complex I mutations have been characterised in different subunits and more recently in assembly factors, 
although there are still many outstanding questions. This is exemplified by LHON, which is the most 
common disease caused by mtDNA mutations in complex I subunits but it is late onset, suggesting that 
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age dependent mtDNA mutation accumulation may dictate disease manifestation (Scheffler, 2015). 
Figure 1.18A illustrates data from a review of 172 patients with nDNA-encoded mutations (117 in 
nuclear-encoded subunits and 55 in assembly factors), showing the low survival rates for subunit (core 
and supernumerary) mutations compared to assembly factor mutations, which display decreased 
severity. Figure 1.18B highlights the wide range of clinical phenotypes, with more than a third of 
patients showing Leigh syndrome symptoms and 11% suffering from fatal lactic acidosis as a result of 
complex I dysfunction (Fassone & Rahman, 2012). 
 
 
 
Figure 1.18 Complex I deficiency caused by nuclear-encoded DNA mutations. A. Kaplan-Meier survival 
curves for 172 patients with mutations in different proteins related to complex I. Red shows nuclear encoded 
core subunits, green shows supernumerary nDNA encoded subunits and blue assembly factors. B. Clinical 
phenotypes of patients suffering from complex I deficiency. The pie chart shows the diverse range of symptoms 
caused by complex I subunits and assembly factor mutations in the 172 patients. Figure adapted from Fassone & 
Rahman, 2012. 
 
 
Complex I disorders are usually diagnosed by rotenone-sensitive NADH:ubiquinone oxidoreductase 
activity in muscle biopsies, however caveats remain on the reference activity used (Liolitsa et al., 2000). 
However, other methods are emerging: using oxygen consumption to assess the respiratory capacity of 
mitochondria, immunocapture and Blue Native polyacrylamide gel electrophoresis (BN-PAGE) to 
address subunit composition and structural integrity, along with in-gel activity assays (Fassone & 
Rahman, 2012). Additionally, there are some secondary complex I deficiencies, including those related 
to Parkinson’s and thyroid cancers (Schapira et al., 1990; Gasparre et al., 1997). There is no cure for 
complex I deficiency, and most treatments address the symptoms only, although some patients exhibit 
riboflavin responsiveness due to the importance of this vitamin in flavin cofactor biosynthesis - the role 
of riboflavin will be further discussed in Chapter 3 (Bersen, 1993). Targeting reactive oxygen species 
(ROS) production and mitobiogenesis are also approaches that may be viable treatment options for 
complex I disorders, but these are all in the early stages of development, with no drugs in clinical trial 
(Rahman, 2015). The genetic cause of complex I deficiencies is becoming increasingly well understood 
and documented but defining the mechanisms underpinning these defects is trailing behind. This is in 
part due to the limitations in sample amounts obtained from biopsies and that cultured patient fibroblasts 
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do not always mirror the defects observed (Ruitenbeek et al., 1996). Therefore, a reliable model system 
is crucial for investigating complex I defects. There has been development of mouse models for specific 
nDNA mutations, but these do not perfectly replicate the human disease. For example, although the 
NDUFS6 knockdown mouse, generated by gene trap (Ke et al., 2012), displays a complex I deficiency 
with isolated hypertrophic cardiomyopathy (HCM), there have been no human patients with NDUFS6 
mutations causing HCM reported (Fassone & Rahman, 2012). Human cells in culture also allow for 
genetic manipulation, however targeted mutagenesis of mtDNA remains a technical challenge and 
precludes the study of mutations in the core mtDNA-encoded subunits of complex I (Irwin et al., 2013). 
The prognosis for complex I deficiency is very poor – as shown by survival rates in Figure 1.18A - and 
due to the complexity and size of this enzyme the importance of understanding its mechanism and 
structure are fundamental to addressing the effects of mutations; with the goal to find a therapeutic 
intervention that may be used to restore mitochondrial respiratory activity to patients suffering from 
these severe disorders. 
 
1.7. Aims of the thesis 
 
The work in this thesis focuses on a number of aspects of complex I structure and function. Flavin 
handling by the cell was explored to investigate when the FMN cofactor is incorporated into complex I. 
Additionally, the quinone-binding site of complex I was studied using mutagenesis in the Y. lipolytica 
model system to affect quinone binding and catalysis. Variants in human complex I genes were also 
analysed by their location in a human model structure of the enzyme. 
 
• First, Chapter 3 aims to explore when FMN is inserted into the flavin binding subunit 
(NDUFV1) of complex I during assembly, by manipulating flavin handling in cultured human 
cells.  
• Chapter 4 aims to determine the physiological role of the mitochondrial carrier protein 
SLC25A32, due to its putative role as a flavin transporter, and by knocking out the protein 
probe the affect of disrupted flavin transport on complex I activity and structure.  
• Chapter 5 aims to investigate the role of specific residues in the quinone channel, by 
mutagenesis of the NDUFS2 subunit in Y. lipolytica and incorporation of variant complex I 
into proteoliposomes for kinetic study. 
• Finally, Chapter 6 aims to combine clinically-relevant variants with the most detailed 
information on complex I structure – using a human complex I model to identify which 
characteristics can be used to predict the likelihood that a variant will be pathogenic.
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Chapter 2 
Materials and Methods 
2.1. Materials 
 
All materials were purchased from Sigma-Aldrich or Thermo Fisher Scientific unless otherwise stated. 
 
2.2. Cell Culture 
 
143B cells (143B CyWT) are immortalised human osterocarcoma patient cybrids – haplotype H13b1b 
– prepared by Zeviani and co-workers as previously described (Corona et al., 2001; King and Attardi, 
1996). 143B CyWT cells were cultured at 37 ºC in high glucose Dulbecco’s modified eagle medium 
(DMEM, Life Technologies) + 10% foetal bovine serum (FBS, labtech.com) under 5% (v/v) CO2. 
DMEM contained 1 μM riboflavin (data from supplier) and 10% FBS contributed another 0.77 nM (Said 
et al., 1998).  
 
HAP1 cells, derived from male chronic myelogenous leukemia cell line KBM-7 (Horizon Discovery), 
were cultured at 37 ºC in Iscove's Modified Dulbecco's Medium (IMDM, Life Technologies) + 10% 
FBS under 5% v/v CO2.  IMDM contained 1 μM riboflavin (data from supplier) and 10% FBS 
contributed another 0.77 nM (Said et al., 1998).  
 
Riboflavin depletion of mammalian cells in culture  
 
Riboflavin-free DMEM (Life Technologies) was used to condition cells: the riboflavin content was 
adjusted with different proportions of riboflavin-free DMEM and standard DMEM or IMDM (for 143B 
and HAP1 respectively) in 25% steps with two passages at each stage. All media contained 10% FBS.  
 
The inhibitor lumiflavine (Santa Cruz) has been shown to inhibit riboflavin uptake by cultured cells 
(Said et al., 1998). 1 mM lumiflavine in Dulbecco's phosphate buffered saline (DPBS, Life 
Technologies) was filter sterilised and stored at -20 ºC. 1 μM, 5 μM and 10 μM concentrations were 
used by addition to DMEM + 10% FBS and incubated with 143B cells for 72 hours. 
 
To observe changes in growth rate and cellular morphology of treated 143Bs, an Incucyte HD was used 
to periodically record their physical characteristics over 7 days. Cells were seeded into 6 well plates at 
25,000 cells/well (which allowed 143B CyWT to reach confluence after one week, HAP1 cells were 
plated at 14,000 cells/well). Each well was scanned at 16 positions with images taken every 2 hours, 
resulting in an image bank for each growth condition.  
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Following conditioning, cells were maintained in low riboflavin conditions of riboflavin-free DMEM + 
10% FBS (total 0.77 nM riboflavin) for one month before further investigations were undertaken - these 
cells are hereafter referred to as ‘conditioned’. 
 
2.3. Genetic manipulation of protein expression in cultured human cells 
 
2.3.1. siRNA knockdown in 143B CyWT cells 
 
Transcripts of target proteins were transiently suppressed by 50 nM or 100 nM siRNA. 143B CyWT 
cells were plated at a density of 75,000 cells/well in 6 well plates and after 24 hours siRNA was added 
using Lipofectamine™ 2000 and OptiMEM (both Life Technologies). All siRNA were purchased from 
Eurofins Genomics and three different oligonucleotides were designed for each protein (Table 2.1), 
using the Eurofins online tool. Knockdown cells were incubated for 72 hours to maximise changes in 
protein expression.  
 
 
Table 2.1 siRNA targets for SLC25A32, RFK and FADS1. siRNA chosen for the mitochondrial isoform of 
FLAD (FADS1) only targeted sequence unique to this isoform, to leave the cytoplasmic FADS2 unaffected. 
siRNA were synthesised by Eurofins Genomics.  
 
 
 
 
 
29 
2.3.2. Stable knockdown in 143B CyWT cells using shRNA  
 
For stable expression of shRNA in human cell lines the lentiviral vector pLKO.1 was used (Figure 2.1), 
in conjunction with a second-generation lentiviral system comprising packaging and envelope plasmids 
(discussed below).  
 
 
Figure 2.1A. pLKO.1 vector map. pLKO.1 vector containing an shRNA insert (red), showing key features of the 
vector for use in shRNA expression. B. Table of key features. The pLKO.1 vector contains a number of 
engineered features chosen to improve shRNA expression within the target cell, resistance genes for bacteria and 
mammalian selection and a self-inactivating (SIN) device for safety. A deletion in the 3'LTR of the viral genome 
that is transferred into the 5'LTR after one round of reverse transcription abolishes transcription of the full-length 
virus after it has incorporated into a host cell. Figure A. from Moffat et al., 2006. 
 
 
The pLKO.1 vector was the backbone used in Sigma MISSION® shRNA and also used later for shRNA 
cloning. It contains an ampicillin resistance gene for bacterial selection and a puromycin resistance gene 
for selection within mammalian cell lines (Figure 2.1B).  
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Figure 2.2A. Template for forward and reverse oligonucleotides containing the shRNA target sequence 
chosen for the specific gene of interest. This template was used by Sigma MISSION® shRNA vectors and for 
construction of pLKO.1 shRNA vectors. For shRNA cloning the Addgene protocol was used - two 
oligonucleotides were designed as shown and annealed to produce dsDNA with overhangs for ligation into the 
restricted pLKO.1 vector (red for AgeI and dark blue for EcoRI). The template would generate a hairpin structure 
when transcribed that could be processed into siRNA within the cell to promote gene silencing. B. Schematic of 
pLKO.1 vector. The main features of the vector are highlighted. Restriction at EcoRI and AgeI sites (blue 
asterisks) decreased the vector size to 7 kb and the two resistance genes (red asterisks) allowed selection in 
bacterial and mammalian systems. The plasmid (Addgene #10878) was created by Root and co-workers (Moffat 
et al., 2006). Plasmid map is available from https://www.addgene.org/10878/. 
 
For each target gene two Sigma MISSION® shRNA pLKO.1 vectors were chosen for lentiviral 
transfection of 143B CyWT cells. The vector contained an insert made by annealing two shRNA 
containing oligonucleotides, templates shown in Figure 2.2A - the shRNA sequence was inserted as the 
sense and antisense strands between conserved short base sequences. This sequence then formed a 
hairpin on transcription due to annealing of complementary sequences and the shRNA was processed 
within the cell to form siRNA, to target its complementary mRNA sequence for expression silencing. 
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Sigma MISSION® shRNA pLKO.1 vectors 
Construct Sequence 
SLC25A32 
TRCN000043090 CCGGGCAGCAACATACCCATATCAACTCGAGTTGATATGGGTATGTTGCTGCTTTTTG 
TRCN000043088 CCGGGCCCTTCAGTTTATGGCATATCTCGAGATATGCCATAAACTGAAGGGCTTTTTG 
FADS1 
TRCN0000300338 CCGGGCACTGGTCAACCTTTCAGATCTCGAGATCTGAAAGGTTGACCAGTGCTTTTTG 
TRCN0000294377 CCGGGGCTGGGAGAAGCTATCATTGCTCGAGCAATGATAGCTTCTCCCAGCCTTTTTG 
RFK 
TRCN000037599 CCGGCCCATATTACAAGAATACGAACTCGAGTTCGTATTCTTGTAATATGGGTTTTTG 
TRCN000037602 CCGGGCATACCTTCAAAGAGGACTTCTCGAGAAGTCCTCTTTGAAGGTATGCTTTTTG 
 
Table 2.2 Sigma MISSION® shRNA pLKO.1 constructs chosen for SLC25A32, FADS1 and RFK stable 
knockdown. Two constructs for each protein target were chosen, with care taken with FADS1 to target only this 
isoform of the FLAD1 gene. Forward shRNA oligonucleotide sequences are shown and coloured to match Figure 
2.2A. 
 
 
Design of non-commercial shRNA constructs 
 
Using the online tool from the Whitehead Institute (Yuan et al., 2004) the following guidelines aided 
the design of shRNA for the genes SLC25A32 and FADS1, which could not be knocked down using 
commercial shRNA vectors (section 3.6.1.1). 
• 21 nucleotides with pattern AA(N19) or NAR(N17)YNN (N is any nucleotide, R is A or G and 
Y is C or T) chosen when possible 
• G-C content of 36-52% 
• No stretches of four or more nucleotide repeats (TTTT is a termination signal) 
 
Multiple target sequences were chosen for each gene and covered different locations (Table 2.3). All 
sequences were checked for off-target interactions using NCBI BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi; Altschul et al., 1990). 
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FADS1 
shRNA 1 
sense 5'GCTCAGTAATCTGAAGCTTGG 3' 
antisense 3'CGAGTCATTAGACTTCGAACC 5' 
shRNA 2 
sense 5'GGGAACACGTTTATTCCAGAG 3' 
antisense 3'CCCTTGTGCAAATAAGGTCTC 5' 
shRNA 3 
sense 5'GGAGTCGCTTGTCAAGGATCT 3' 
antisense 3'CCTCAGCGAACAGTTCCTAGA 5' 
   
SLC25A32 
shRNA 1 
sense 5'AAGTGAACTGCAGTTGATATT 3' 
antisense 3'GGCACTTGACGTCAACTATAA 5' 
shRNA 2 
sense 5'ATCCTAGATCCAGTTCTTGTT 3' 
antisense 3'TAGGATCTAGGTCAAGAACAA 5' 
shRNA 3 
sense 5'ACTGACACGAAGGATAGAGTT 3' 
antisense 3'TGACTGTGCTTCCTATCTCAA 5' 
 
Table 2.3 shRNA sequences chosen for FADS1 and SLC25A32 knockdown. Three shRNA sequences were 
chosen for each gene, covering different regions. The template in Figure 2.2.A was then used to design the shRNA 
hairpin oligonucleotides for insertion into the pLKO.1 vector. Primers were synthesised by Sigma. 
 
Initially, to insert the shRNA template into the multiple cloning site (MCS) the restriction digest method 
outlined by Addgene was employed (http://www.addgene.org/tools/protocols/plko/#B). The pLKO.1 
vector was restricted with EcoRI and AgeI (New England Biolabs, NEB), removing a 1.9 kb stuffer 
fragment from the MCS. Two complementary oligonucleotides were designed for each target sequence 
(as shown in Figure 2.2A), which would anneal with overhangs allowing ligation into the linearised 
vector. The oligonucleotides were annealed to form dsDNA and then ligated into pLKO.1 with T4 DNA 
ligase (NEB). After transformation into D5-α competent E. coli, colonies were assessed by mini prep 
(Qiagen). However no positive colonies could be obtained by this method, despite many repetitions, 
protocol alterations and sequencing of the pLKO.1 vector. A different approach was therefore tested. 
 
pLKO.1 was amplified with primers that also contained part of the insert and so after a PCR cycle the 
product was a linearised vector with the insert present, which could then be ligated. To achieve the same 
result as the restriction digest approach, primers were designed for the desired end construct with the 
shRNA template present between the AgeI and EcoRI sites, Figure 2.2A. 20 bases of pLKO.1 either 
side of the insert were used in the primers and, as shown in Figure 2.3A, the 58 base insert was split in 
half - the forward primer comprised the last 29 bases of the insert at the 5’ (part 2.) followed by the 20 
nucleotides downstream of the insert in pLKO.1 (part 3.). The reverse primer included the first 29 bases 
of the insert (part 1.) and the 20 bases that precede it in pLKO.1 (parts 4.). Figure 2.3A shows primer 
annealing and extension during PCR by the two primers, which were 5’ phosphorylated to allow for 
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effective ligation. Figure 2.3B shows the PCR product generated, which was then ligated to form the 
vector containing the desired shRNA sequence – example SLC25A32 shRNA 1. 
 
 
Figure 2.3 Cloning of pLKO.1 to contain shRNA inserts. A. Primer annealing and extension of the vector 
to insert the shRNA sequence into the MCS and remove the stuffer fragment. The shRNA sequence (example: 
SLC25A32 shRNA 1) was split in two with half used in the forward and reverse primers (1 and 2). This was 
attached to 20 bases upstream or downstream of the insert site to make the full primers (3 and 4, dark blue lines). 
B. PCR product of linearised pLKO.1 without the stuffer fragment between the AgeI and EcoRI restriction sites 
and containing the shRNA sequence, in two halves. Ligation by T4 DNA ligase was used to re-circularise the 
construct and produce the complete vector.  
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FADS1 
shRNA 1 
forward 
primer 
5'[Phos]GAGCCAAGCTTCAGATTACTGAGCTTTTTGAATTCTCGACCTCGAGACA 3' 
reverse 
primer 
5'[Phos]GAGCCAAGCTTCAGATTACTGAGCCCGGTGTTTCGTCCTTTCCACAAG 3' 
shRNA 2 
forward 
primer 
5'[Phos]GAGCTCTGGAATAAACGTGTTCCCTTTTTGAATTCTCGACCTCGAGACA 3' 
reverse 
primer 
5'[Phos]GAGCTCTGGAATAAACGTGTTCCCCCGGTGTTTCGTCCTTTCCACAAG 3' 
shRNA 3 
forward 
primer 
5'[Phos]GAGAGATCCTTGACAAGCGACTCCTTTTTGAATTCTCGACCTCGAGACA 3' 
reverse 
primer 
5'[Phos]GAGAGATCCTTGACAAGCGACTCCCCGGTGTTTCGTCCTTTCCACAAG 3' 
   
SLC25A32 
shRNA 1 
forward 
primer 
5'[Phos]GAGAATATCAACTGCAGTTCACGGTTTTTGAATTCTCGACCTCGAGACA 3' 
reverse 
primer 
5'[Phos]GAGAATATCAACTGCAGTTCACTTCCGGTGTTTCGTCCTTTCCACAAG 3' 
shRNA 2 
forward 
primer 
5'[Phos]GAGAACAAGAACTGGATCTAGGATTTTTTGAATTCTCGACCTCGAGACA 3' 
reverse 
primer 
5'[Phos]GAGAACAAGAACTGGATCTAGGATCCGGTGTTTCGTCCTTTCCACAAG 3' 
shRNA 3 
forward 
primer 
5'[Phos]GAGAACTCTATCCTTCGTGTCAGTTTTTTGAATTCTCGACCTCGAGACA 3' 
reverse 
primer 
5'[Phos]GAGAACTCTATCCTTCGTGTCAGTCCGGTGTTTCGTCCTTTCCACAAG 3' 
 
Table 2.4 Primers used for amplification of pLKO.1 to include the shRNA insert. To avoid the annealing step 
primers were designed to amplify the pLKO.1 vector, linearising it and adding half the shRNA template to each 
end. These ends were then ligated to form the construct containing the shRNA for transformation in D5-α E. coli. 
5’ phosphate was added to aid ligation efficiency of the blunt ended vector. Sequences are coloured to match 
previous figures. Primers were synthesised by Sigma. 
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PCR reaction 
 
A thermocycler programme was designed taking into account the different temperatures of annealing 
for the individual primer pairs and the two stages of annealing, the initial binding of just the regions 
complementary to the vector (Table 2.4 in navy) and later the full primer binding (Table 2.4 in navy 
plus green, red and cyan). These were calculated using the NEB Tm calculator for the primer pairs 
(http://tmcalculator.neb.com/#!/main). For a total volume of 50 μl the following reaction was prepared: 
2.5 μl of 10 μM forward primer, 2.5 μl of 10 μM reverse primer, 10 μl Q5® polymerase buffer, 10 μl 
Q5® enhancer, 20 ng pLKO.1 template, 1 μl 10mM dNTPs and 1μl Q5® polymerase. The PCR 
thermocycler programme used is shown in Table 2.5. 
 
Temperature (°C) Duration (min:sec) Loops 
98 00:30  
98 00:10 
 
5 loops 
Initial primer binding temperature 00:20 
72 03:30 
98 00:10 
25 loops 
Full primer binding temperature 04:00 
72 05:00  
4 Hold  
 
Table 2.5 Template thermocycler programme for PCR reaction to amplify shRNA insert containing 
pLKO.1. The programme was adapted for the individual primer pairs (initial primer binding and full primer 
binding temperatures) and the extension set at 3 min 30 sec for a 7 kb construct, 30 sec/kb. 
 
To visualise PCR products 0.8% agarose gels were prepared by dissolving 0.8% (w/v) agarose 
(BioGene) in 1X Tris-Borate-EDTA buffer (TBE) by heating. The solution (50 ml), with 2 µl of 
SYBR™ Safe (Thermo Fisher) added was then set in a mold with a sample-loading comb inserted. 5 µl 
of the amplified DNA product alongside 5 µl MassRuler Express forward DNA ladder (Thermo Fisher) 
were resolved at 100 V for 40 minutes. SYBR™ Safe that had intercalated with the DNA was imaged 
on a ChemiDoc™ imaging system (Bio-Rad) to confirm the product formed was ~ 7 kb.  
 
Ligation 
 
The ligation mixture was made up to 20 μl with 2 μl PCR product, 2 μl T4 DNA ligase buffer and 1 μl 
T4 DNA ligase and incubated at 37 °C for two hours. After heat inactivation at 65 °C for 20 minutes, 1 
μl Dpn1 (NEB) was added to digest the methylated pLKO.1 template, incubated for 15 minutes at 37 
°C and heat inactivated at 80 °C for 20 minutes.  
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Transformation and colony analysis  
 
2 μl of ligation mix were added to 50 μl competent D5-α cells and incubated on ice. A 30 second heat 
shock at 42 °C was followed by 5-minute incubation on ice and addition of 950 μl SOC medium. After 
1 hour of incubation at 220 rpm and 37 °C, E. coli were plated and incubated overnight at 37 °C on 100 
μg/ml ampicillin lysogeny broth (LB) containing agar. Resulting colonies were analysed by mini 
preparation (QIAprep spin kit) of plasmids, which were analysed by 0.8% agarose gel electrophoresis 
positive colonies sequenced to confirm successful construct formation (Genwiz).  
 
Lentiviral particle production  
 
To generate stable knockdowns the shRNA construct (commercial or synthesised as above) was 
introduced into the host cells by lentivirus using a multistep protocol from Addgene undertaken over 
several days (http://www.addgene.org/tools/protocols/plko/#E). HEK293T cells are highly transfectable 
human embryonic kidney cells that replicate vectors containing the SV40 region of replication, 
including pLKO.1 and were used to produce lentiviral particles. 
 
Firstly HEK293T cells were plated at 2.5 x106 cells per 10cm dish, in DMEM + 10% FBS. After 24 
hours the media was substituted for DMEM + 10% FBS + 25 μg/ml chloroquine – to improve 
transfection efficiency. This was done one hour before transfection to minimise exposure to chloroquine, 
due to its toxic effects on cells. Lentiviral particles were produced by transfection of HEK293T with the 
shRNA construct and two additional vectors - psPAX2, packaging vector and pMD2.G, envelope vector 
– shown in Figure 2.4. 
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Figure 2.4 Vector maps for envelope and packaging plasmids used for lentiviral production in HEK293T. 
A.  psPAX2 packaging vector (Addgene # 12260). B. pMD2.G envelope vector (Addgene #12259). Plasmids 
were created by Truno and co-workers (unpublished) and maps are available from 
https://www.addgene.org/12260/ and https://www.addgene.org/12259/, respectively. 
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psPAX2 and pMD2.G were required for the expression of lentivirus structural proteins in HEK293T 
cells. These two plasmids were amplified by transformation into D5-α cells and plated onto LB agar 
containing 100 μg/ml ampicillin. Then small volume liquid cultures were made and plasmid DNA 
purified by mini prep purification (Qiagen). 
 
The transfection mix comprised the three vectors, serum free DMEM and Fugene HD (Promega). 10.00 
μg pLKO.1 shRNA construct, 6.55 μg psPAX2 and 3.5 μg pDM2.G were used for each shRNA 
construct type and mixed with serum free DMEM to a final volume of 940 μl, then 60 μl of Fugene® 
HD transfection agent was added and the mixture incubated for 30 minutes, all under sterile conditions. 
After incubation the transfection mix was added drop-wise to the HEK293T plates with chloroquine 
containing DMEM and incubated for 8-12 hours at 37 °C, 5% CO2. The media was then changed, to 
remove chloroquine and the transfection agent, and replaced with DMEM + 10% FBS, 8 ml/plate, for 
a 48 hour incubation.  
 
The following day the host cells, 143B CyWT, were plated at 2 x106 on 10 cm plates in DMEM + 10% 
FBS and incubated for 24 hours at 37 °C, 5% CO2. One dish was plated for each construct and an 
additional control plate for puromycin selection. 
 
48 hours after transfection, media from the HEK293T cells was collected and contaminating cells 
removed by centrifuged at 4,100 xg for 5 minutes. The media contained lentiviral particles produced 
by the HEK293T cells using the transfected plasmids, which was removed and filtered through 0.45 
μm filters to obtain ~7.5 ml of particle containing media/plate. 143B cells were then prepared for 
infection, media was substituted with 8 ml DMEM + 10% FBS + 8 μg/ml polybrene, to aid lentiviral 
infection. The harvested and filtered lentiviral particle-containing DMEM was added and 143B cells 
incubated overnight at 37 °C, 5% CO2. 
 
Due to the presence of the puromycin resistance gene on pLKO.1, 143B cells containing and expressing 
the plasmid construct should be resistant to 1 μg/ml puromycin, which was added in fresh media after 
overnight incubation. The cells were then checked by Western Blot for decreased target protein 
expression after a further 4 days of incubation. Non-infected 143B cells were used as a positive 
puromycin control; after a few days of puromycin incubation these cells died. Stably knocked down 
143Bs were maintained in puromycin containing DMEM to prevent reversion.  
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2.3.3. Stable knockout using CRISPR  
 
The clustered regularly interspaced short palindromic repeats (CRISPR) technique was employed to 
produce a more severe phenotype than siRNA or stable knockdowns by shRNA.  
 
The single guide RNA (sgRNA) required for Cas9 recognition of the target gene sequence was designed 
to include a short sequence homologous to the target and requires a 2-6 nucleotide protospacer motif 
(PAM) directly downstream of the target sequence. The protocol for designing and testing the 
Cas/CRISPR system for SLC25A32 sgRNA followed the pipeline described in Figure 2.5 (guidelines 
from Clontech Guide-it™ sgRNA in vitro transcription user manual). 
 
 
 
Figure 2.5 Schematic of CRISPR sgRNA design for gene knockout. sgRNA was designed against the target 
gene using the online tool CHOPCHOP. A DNA template was purified from HAP1 cells and used to test the 
efficiency of the Cas9 mediated cleavage before the sgRNA was cloned into the pSpCas9(BB)-2A-GFP vector for 
transformation into HAP1s. Protocol from Clontech Guide-it™ sgRNA in vitro transcription user manual. 
 
The sgRNA-encoding DNA template was designed using the online tool CHOPCHOP (Montague et al., 
2014). The human gene sequence ENSG00000164933 was used in SLC25A32 analysis by 
CHOPCHOP, using the transcript identification code NM_030780. The most recent version of the 
annotated human genome (hg38/GRCh38) was used as the “in” component and Cas/CRISPR in the 
“using” input, which resulted in an output of different sgRNA sequence targets across the gene, ranked 
by predicted efficiency. A number of other parameters were provided – including GC content, self-
complementarity and predicted off-targets. A traffic light coding system aided selection and only green 
suggestions were considered. The best three sequences available in exon 1 were for sgRNA-encoding 
template design. Exon 1 was the best target as a deleterious frame-shift early on in the gene would be 
more likely to result in complete loss of protein function. Target sequences chosen were all located in 
exon 1 and received the green coding, with high-predicted efficiency and no predicted off-target effects. 
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Table 2.6 Three sgRNA chosen from CHOPCHOP results for SLC25A32.  The top three sgRNA suggested 
for exon 1 targeting. Highlighted in blue is the PAM sequence, which was omitted from subsequent steps for 
making the sgRNA template. 
 
Stage 1 – producing the sgRNA template 
  
Figure 2.6 Example of forward primer design. The 20bp sgRNA (without the downsteam PAM) was inserted 
between a T7 promoter sequence 5’ and a 3’ Scaffold template specific sequence, to produce a specific forward 
primer for each sgRNA. 
 
The forward primer (designed as shown in Figure 2.6) was produced by Sigma, diluted to 10 μM and 
used along with the Guide-it™ sgRNA in vitro transcription kit  (Clontech) to generate the sgRNA-
encoding DNA template. 5 μl Guide-it™ Scaffold template was mixed with 1 μl forward primer and 19 
μl RNAse free dH2O; with the entire 25 μl used to resuspend an aliquot of High Yield PCR EcoDry™ 
Premix (Clontech). The following thermocycler programme was then used: 
 
5 μl of the product was loaded onto 1.8% agarose gel, along with 5 μl Mass Rule Express Forward DNA 
Ladder; a single 140 bp band was expected for successful amplification.  
In vitro transcription was then carried out to generate RNA from 100 ng of the DNA template generated 
above. 7 μl transcription buffer and 3 μl T7 polymerase from the Guide-it™ in vitro transcription kit 
(Clontech) were mixed with the DNA template and made up to 20 μl before incubation at 42 °C for an 
hour.  
RNA was purified using DNAse I digestion, phenol:chloroform extraction and ethanol precipitation. 2 
μl of RNAse free DNAse I (Clontech) was added to 20 μl of the transcription mix and incubated at 37 
SLC25A32 Sequence Strand 
sgRNA 1 GGTTCTCATACCGGACGTGGCGG + 
sgRNA 2 CGGCGAAGCGGATCTTCACGAGG + 
sgRNA 3 CGGTATGAGAACCTGATAGCGGG - 
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°C for an hour, then made up to 100 μl with RNAse free dH2O. The following steps were carried out in 
a fume hood – 100 μl phenol:chloroform:isoamylalcohol (25:24:1) was added and the sample vortexed. 
Centrifugation at 13,700 xg for 2 minutes separated the solvent layers. The top aqueous layer, containing 
RNA, was retained and the organic lower layer, containing contaminating protein, was discarded. 200 
μl of chloroform was added to the upper phase, centrifuged and the aqueous phase retained. 40 μl of 3M 
sodium acetate was then added with 400 μl isopropanol, vortexed and incubated for 5 minutes at room 
temperature before centrifugation for 5 minutes at 19,500 xg. The pellet formed was carefully rinsed 
with 80% ethanol and centrifuged again. The RNA containing pellet was air-dried for 15 minutes before 
being resuspended in 20 μl RNAse free dH2O. Aliquots were then snap frozen in liquid N2 and stored at 
-80 °C until further use.  
 
Stage 2: Testing Cas90/sgRNA cleavage efficiency of target gene sequences 
 
A genomic DNA template (gDNA) was required to test sgRNA cleavage specificity, before being used 
in the chosen cell line – HAP1. gDNA PCR primers were designed around the target sequence to 
generate a ~500 bp template, which when cut would produced two fragments of different sizes, to allow 
visualisation of cleavage.  
gDNA was first prepared from HAP1 cells (1-2 x106 cells), lysed with 300 μl Cell Lysis Solution 
(Qiagen) and protein precipitated with 100 μl Protein Precipitation Buffer (Qiagen). After incubation on 
ice for 5 minutes the contaminating protein was removed by centrifugation (16,000 xg) and 300 μl 
isopropanol added to the supernatant. After thorough mixing by inversion the sample was centrifuged 
and the white DNA-containing pellet washed with 70% ethanol. After centrifugation the pellet was air-
dried and 200 μl DNA Hydration Solution (Qiagen) added, vortexed briefly and left overnight at room 
temperature to allow DNA to dissolve. DNA concentration was then measured on a NanoDrop2000 and 
frozen at -20 °C. 
Primers for amplification of a HAP1 genomic DNA template, with a 537 bp product: 
Forward primer: 5’ GACGGAGGAGATCCAGTTCG 3’ 
Reverse primer: 5’ TTCTTTAGCTGTGCAGTCGC 3’ 
 
Annealing temperatures were calculated using the NEB Tm calculator for the PCR reaction. For a total 
volume of 25 μl the following was prepared: 1.5 μl of 10 μM forward primer, 1.5 μl of 10 μM reverse 
primer, 5 μl Q5® polymerase buffer, 5 μl Q5® enhancer, 0.5 μl genomic DNA template, 0.5 μl 10mM 
dNTPs and 0.5 μl Q5® polymerase. The PCR thermocycler was set up as follows: 
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PCR products were analysed on a 1.8% agarose gel and the correct product was gel extracted, yielding 
~20 ng/μl DNA template. The cleavage reaction comprised 100 ng of the gDNA template, 20 ng of 
sgRNA, 1 μl Cas9 buffer, 1 μl 10x BSA and 1.5 μl Cas9 (Clontech) made up to 10 μl in nuclease free 
water. A positive control used 2.5 μl of the 2 kb control fragment (40 ng/μl) and 1 μl control sgRNA 
(20 ng/μl) that was run simultaneously to ensure nuclease efficacy. The test samples and control were 
incubated for 37 °C for 1 hour followed by 70 °C for 10 minutes. 5 μl were then visualised on a 1% 
TBE agarose gel to determine whether the expected banding pattern from successful cleavage was 
obtained. sgRNA-guided Cas9 cleavage of the DNA template would result in three bands – the largest 
for the uncut ~ 500 bp template and two lower bands denoting the smaller cleavage products and 
showing <100% cutting efficiency. sgRNA that did not successfully mediate cleavage would show as a 
single band of ~500 bp. 
CRISPR/Cas9 knockout in cell lines using designed sgRNA 
 
The cloning backbone used was pSpCas9(BB)-2A-GFP (PX458), shown in Figure 2.7, which contains 
GFP and Cas9 genes. PX458 was transformed into D5-α E. coli and plated onto 100 μg/ml ampicillin 
containing agar and mini-preps used to obtain high yields of PX458. The resulting DNA was checked 
by agarose gel electrophoresis (0.5 % TBE) to demonstrate one clean product band at ~9,000 bp. 
PX458 was then digested with BbsI, which cut at two locations to remove the small length of sequence 
between the U6 promoter and sgRNA scaffold (Figure 2.7B) and linearise the plasmid. 10 units of BbsI 
(10,000U/ml) and 1 μg PX458 were used along with NEBuffer 2.1. The reaction was incubated at 37 
°C for 2 hours and inactivated for 20 minutes at 65 °C. Restriction was confirmed by gel electrophoresis 
and the product purified using the QIAquick PCR Purification Kit (Qiagen), with a small volume run 
on 0.5% TBE agarose gel to ensure the correct band size and estimate concentration (using the 
MassRuler Express Forward DNA ladder).  
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Figure 2.7 pSpCas9(BB)-2A-GFP (PX458). A. Vector map for PX458. Cloning vector for sgRNA template 
transformation into HAP1 cells (Addgene #48138). The red asterisk denotes the postion of sgRNA insertion after 
double BbsI digestion (detail in B.) The plasmid was created by Zhang and co-workers (Ran et al., 2013) and the 
plasmid map is available from https://www.addgene.org/48138/. B. Restriction sites for BbsI digestion of 
PX458. BbsI removes a short sequence of DNA shown by the blue box through recognition of two six base pair 
sequences, in grey (Ran et al., 2013). The annealed sgRNA oligomers (Figure 2.8) were then ligated into the 
vector. 
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To clone the sgRNA into PX458, two single stranded oligomers of the sgRNA (and reverse complement) 
with attached overhangs were designed and obtained from Sigma, using the template shown in Figure 
2.8. The two oligomers were annealed by incubation at 95 °C for 5 minutes and then the temperature 
was ramped down to 25 °C with a decrease of 1 °C every 30 seconds, to form dsDNA with 4 bp 
overhangs at the 5’ ends. The annealed oligomers were then ligated into digested PX458 using T4 DNA 
ligase. The oligomer mix was diluted 1:200 and two different volumes were used to obtain the optimal 
ratio insert:plasmid. 100 ng of BbsI restricted PX458 was added to 2 or 4 μl of diluted oligomer duplex, 
with the addition of 2 μl T4 DNA liagse buffer, made up to 20 μl with RNAse free dH2O. The ligation 
mixtures were incubated at 37 °C for 2 hours and inactivated at 65 °C for 10 minutes.  
 
Figure 2.8 Template for sgRNA oligomers for cloning into PX458. The top oligomer comprises the sgRNA 
sequence (pink - example is SLC25A32 target sgRNA 1.) and a 5’extension of 5 bp (orange), whereas the bottom 
oligomer has a 4 bp 5’ addition (orange) ahead of the reverse complement of the sgRNA sequence (blue), with a 
single base extension on the 3’ end. These additions are required to allow ligation into the BbsI restricted PX458 
at the postiton shown in Figure 2.7B.  
 
The ligated PX458 constructs were then transformed into D5-α E. coli, plated onto 100 μg/ml ampicillin-
containing LB agar and incubated at 37 °C overnight. 5 ml LB liquid cultures were then set up from all 
plates that yielded colonies, to be used for mini-prep processing. Plasmids were purified from the 
cultures using the Qiagen mini-prep kit and the products visualised on 0.5% agarose to estimate 
molecular weight. A selection of possible positive samples were chosen for DNA sequencing using the 
U6 forward primer. Sequencing was carried out by Genewiz UK to ensure correct insertion of the 
sgRNA into the PX458 plasmid.  
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Transfection of HAP1 cells with Cas9/sgRNA construct 
 
After sequence validation of the construct the sgRNA containing PX458 plasmid was introduced into 
HAP1 cells by chemical transfection. 75,000 cells/well were plated in six-well plates ahead of 
transfection and incubated at 37°C, 5% CO2 overnight in IMDM + 20% FBS. The transfection agent 
Lipofectamine™ 3000 was used and 3 wells were prepared for each construct, with a control well. For 
each well a lipofectamine mix was made: 125 μl OptiMEM and 7.5 μl OptiMEM, along with a DNA 
mix: 125 μl OptiMEM, 6 μl P3000 reagent and 3 μg PX458 construct. These two solutions were then 
mixed and incubated for 15 minutes at room temperature. The positive control (empty PX458) was used 
to validate efficient transfection of HAP1s using Lipofectamine™ 3000. Transfection mix was then 
added drop-wise to each well of DPBS washed HAP1s and incubated for 30 minutes at 37°C, 5% CO2 
before an additional 250 μl of OptiMEM was added. The cells were then incubated with the transfection 
reagents for 5 hours at 37°C, 5% CO2 to facilitate PX458 construct uptake, then 5 ml IMDM + 20% FBS 
was added to provide growth conditions before incubation overnight. The following day the media was 
changed to remove the residual transfection reagent and 5 ml IMDM + 10% FBS added. The efficiency 
of transfection was observed by fluorescence from GFP expression on the plasmid.   
The transfected cells were then fluorescence-activated cell sorted (FACS), to segregate the small 
proportion of successfully transfected, fluorescing cells from the background of HAP1s. A negative 
control was used, HAP1 parental cells at 1x106 /ml, to prime the FACS equipment to sort the samples 
of transfected cells. Then each HAP1 line transfected with a PX458 construct was sorted and 
fluorescence data visualised by a dot-plot, showing signal scatter intensity and fluorescence intensity. 
Gating was used to select the fluorescing subpopulation, which were then seeded into pre-prepared 96 
wells plates (IMDM + 20% FBS) at a density of ~1 cell/well to allow clonal expansion. Sorted cells 
were then incubated at 37°C, 5% CO2 and checked for visible colonies. After ~7 days some colonies 
were observed, these were monitored until large enough to move into 24 wells plates, about 14 days 
after FACS. After a further 5 days these colonies were transferred to flasks (T25 or T75 as appropriate) 
with IMDM + 20% FBS. Once sufficiently expanded, and further increases in flask volume achieved, 
these colonies were banked for later testing by PCR, to validate the knockout.  
PCR screen of transfected HAP1 cells  
The commercially available SLC25A32 HAP1 knockout cell line (Horizon, HZGHC001715c10, 
SLC25A32 KO cells) was first raised in IMDM + 20% FBS, to encourage proliferation. Once 
established, along with the HAP1 parental line, these cells were conditioned in riboflavin-free DMEM 
+ 10% FBS for one month. Morphology and growth profiles were monitored using Incucyte imaging 
software, demonstrating the differences between the SLC25A32 knockout and the parental HAP1. The 
SLC25A32 KO cells were analysed to check the SLC25A32 deletion by CRISPR. This was achieved 
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by PCR amplification of the gene region (exon 2) around the knockout and sequencing rather than by 
Western Blot; as the knockout was still likely to produce protein with a frame-shift (possibly by exon-
skipping) that may be detected.  
PCR primers 
Forward primer: 5’ AACCAATTGTACAGTGTCTG 3’ 
Reverse primer: 5’ ATCATTCCACCTCATCTCTT 3’ 
 
Sequencing primer  
Forward primer: 5’ GTGATACAGAGCTAGAACTT 3’ 
 
For the CRISPR SLC25A32 knockouts I generated in HAP1 (described above) the same approach was 
used to screen the GFP positive clones, by amplifying the targeted region of exon 1 and sequencing it 
to determine whether any deletions had been achieved.  
 
PCR primers 
Forward primer: 5’ GGATAAGAGTCCTCTCGTTGG 3’ 
Reverse primer: 5’ CAGACTTCTCTACATACATGC 3’ 
 
Sequencing primer 
Forward primer: 5’ AAGAGTCCTCTCGTTGGTCC 3’ 
 
 
2.4. Mitochondrial preparation from human cell lines 
 
2.4.1. Crude mitochondrial preparation – digitonised cells  
 
Initial preparation of mitochondria from cell lines was achieved using digitonin solubilisation (Pello et 
al., 2008). ~5 x106 cultured cells were harvested and washed twice with phosphate buffered saline 
solution (PBS), all further steps were carried out at 4 °C. The pellet was resuspended in 200 μl cold PBS 
and 200 μl 8mg/mg digitonin added with incubation on ice for 10 minutes. 1 ml cold PBS was then 
added and the sample centrifuged at 10,000 xg for 10 minutes at 4 °C, the supernatant was then removed. 
Washing was repeated and the pellet resuspended in 100 μl 1.5 M aminocaproic acid, 50 mM Bis-
Tris.HCl pH 7. n-dodecyl-β-D-maltoside (DDM) was added to a final concentration of 1% for analysis 
of individual respiratory complexes. After incubation on ice for 5 minutes the sample was centrifuged 
at 18,000 xg for 30 minutes at 4 °C and the supernatant retained. It was mixed 1:10 with sample buffer 
(750 mM aminocaproic acid, 50 mM Bis-Tris.HCl pH 7, 0.5 mM EDTA and 5% Serva Blue G250). 
Samples were then aliquoted and stored at -20 °C.   
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2.4.2. Mitochondrial purification and fractionation from cultured cells 
 
Mitochondria were purified and fractionated from cell lines according to the protocol described by Hirst 
and co-workers, developed from the Holt and co-workers technique (Bridges et al., 2017; Minczuk et 
al., 2011). Cultured mammalian cells were grown in multilayer flasks until confluent (~3 days) and 
harvested after DPBS washes with 50 ml TryplE Express (Gibco) per flask. DPBS containing 10% FBS 
was then used to neutralise the detachment reagent and cells were pelleted by centrifugation at 500 xg 
for 3 minutes. Flasks were washed with DPBS to obtain all cells and used to resuspend pelleted cells 
before another centrifugation step. Pelleted cells were then washed twice with cold DPBS and the final 
pellet kept on ice. The wet cell mass was measured and, prior to cell breakage, resuspended in 3 ml 
hypotonic buffer (20 mM HEPES, pH 7.8, 5 mM KCl, 1.5 mM MgCl2 and 1mg/ml bovine serum 
albumin, BSA), plus protease inhibitor, per 1g of cells and incubated for 10 minutes on ice.  
 
Hypotonic buffer was used to swell the cells to increase breakage efficiency and cells were disrupted 
using an Isobiotec cell homogeniser. The homogeniser was chilled and kept on ice throughout breakage. 
It was first washed with hypotonic buffer and cells were then disrupted by seven passes through the 
chamber, with a gap set to be smaller than the cell diameter (12 μm for 143B and 10 μm for HAP1 cells). 
Broken cells were kept on ice and 0.7 ml of 2.5X MSH buffer (20 mM HEPES, pH 7.8, 525 mM 
mannitol, 175 mM sucrose, 5 mM EDTA), plus protease inhibitor, added per 1 ml of broken cells. The 
homogeniser was then washed with 2 ml 1X MSH and steps repeated until the cell suspension was 
homogenised, before making the volume of broken cells up to 30 ml with 1x MSH.  
To remove cell debris and nuclei, broken cells were centrifuged at 750 xg for 10 minutes at 4 °C. The 
supernatant was then re-spun if separation of the globular pellet was incomplete. The supernatant was 
then centrifuged at 10,000 xg for 10 minutes at 4 °C to pellet the mitochondria. The supernatant was re-
spun and both brown mitochondrial pellets pooled and resuspended in 1 ml 1x MSH + 50 U/ml 
benzonase, for DNA digestion. The sample was then incubated on ice for 10 minutes. To further purify 
the mitochondria and remove contaminating cellular components, particularly endoplasmic reticulum 
(ER), a sucrose gradient was used  - comprising three layers made up in SW40 Ti tubes (9/16 x 3¾”). 4 
ml of 1.5 M, 4 ml of 1.0 M and 3 ml of 0.5 M sucrose (with 10 mM HEPES, 5 mM EDTA, pH 7.8) were 
assembled and mitochondria were then layered on top, any remaining volume being filled by 1X MSH. 
The gradient was then centrifuged at 185,000 xg, 4 °C, for an hour to separate the components within 
the mitochondrial sample by density.  The mitochondria formed a brown band at the interface between 
1.5 and 1.0 M sucrose and any contaminating ER was found at the 0.5-1.0 M interface. The 
mitochondrial band was then removed and resuspended in 4 volumes of 1x MSH.   
 
If the sample was to be retained and used as mitochondria the protein concentration was measured using 
the bicinchoninic acid assay (BCA). Mitochondria were then centrifuged for 10 minutes at 10,000 xg, 4 
48 
°C, and the pellet resuspended in solubilisation buffer (1.5 M aminocaproic acid, 50 mM Bis-Tris, pH 
7) to adjust the concentration to 3-5 mg/ml. Aliquots were then snap frozen and stored at -80 °C. 
 
For mitochondrial fractionation, the mitochondrial pellet obtained after centrifugation was further 
processed immediately or stored at -80 °C. Mitochondria were resuspended in 2-3 ml sonication buffer 
(20 mM Tris, 200 mM NaCl, 10% ethylene glycol, pH 7.5). The sample was sonciated on ice using a 
microtip (amplitude of 25), in 10-second bursts, until 100 J was absorbed by the sample and it had 
clarified. The sonicated mix was then centrifuged at 444,000 xg at 4 °C (MLA 80) to separate the 
mitochondrial matrix and membranes. 
 
2.5. Protein analysis techniques 
 
2.5.1. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Cell lysate samples were separated by SDS-PAGE. Cells were lysed with 20 mM Tris.HCl (pH 7.5), 
500 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% (v/v) Triton-X-100, 10% glycerol 
and 1.5 mM MgCl2. Protease inhibitors (cOmplete™ inhibitor cocktail tablets) and benzonase 
(Millipore) were added and samples were incubated on ice for 30 minutes and then centrifuged at 10,000 
xg for 15 minutes to pellet cell debris, with the supernatant retained. Protein concentrations were 
determined by BCA and the lysate then frozen at -20 °C in 1:1 SDS loading buffer (0.125 M Tris, 20% 
(v/v) glycerol, 4% (w/v) SDS, 0.005% (v/v) bromophenol blue, pH 6.8, with 10 mM dithioreitol (DTT).  
Samples were loaded at 20-40 μg protein for SDS-PAGE, using a modified Laemmli protocol (Laemmli, 
1970). NuPAGE™ 4-12% Bis-Tris Protein Gels were run at 200 V in 1X MES-SDS running buffer 
(ForMedium) for ~40 minutes, until the dye front reached the bottom of the gel. Kaleidoscope™ 
Precision Plus (BioRad) standard protein marker was loaded alongside to allow molecular weight 
estimation. Gels were either stained with Coomassie® Brilliant Blue for 15 minutes and destained to 
remove excess dye, or taken for wet transfer onto membranes for Western Blot analysis. 
 
2.5.2. Blue Native PAGE (BN-PAGE) 
 
 
BN-PAGE was undertaken using the protocol described by Schägger and co-workers (Schägger and von 
Jagow, 1991). Mitoplasts were prepared as described in 2.4.1. Mitochondria were solubilised in either 
1.2% DDM or 8g/g digitonin and centrifuged at 10,000 xg to remove insoluble material. Samples were 
diluted in 2:1 in NativePageTM sample buffer + 0.03% Coomassie G-250 (Amnesco) before loading. 
Fractionated mitochondrial membranes were solubilised in 1.7% DDM and diluted in NativePageTM 
sample buffer in the same way. 10-well NativePAGE™ Novex® Bis-Tris (3-12%) were run at 80 V for 
1 hour at 4 °C. The outer anode buffer comprised pre-chilled 1X NativePAGE™ Running Buffer and 
the inner cathode buffer contained pre-chilled 1X NativePAGE™ Running Buffer + blue 1X 
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NativePAGE™ Cathode Buffer Additive. Another cathode buffer was also prepared with a 0.1X 
NativePAGE™ Cathode Buffer Additive. The inner buffers were exchange after 1 hour and the run 
continued at 180 V until the dye front reached the end of the gel. The gel was then removed from the 
casing and washed in dH2O to remove excess Coomassie® G-250, at either room temperature (or 4 °C 
for in-gel activity assays). If the gel was to be stained 50% methanol (v/v), 7% acetic acid (v/v) and 
0.2% Coomassie® R250 (w/v) were added for 5 minutes and destained in 20% methanol and 7% acetic 
acid overnight.  
 
2.5.3. Western Blotting 
Once protein samples had been separated by gel electrophoresis they were transferred onto an 
Immobilon®-P polyvinylidene fluoride (PVDF) membrane using a wet transfer system (300 mA, 150 
V) with transfer buffer (25 mM Tris, 190 mM glycine and 10% methanol, pH 8.3) for 60 minutes at 4 
°C. After transfer membranes were blocked in 10 ml blocking buffer containing 5% (w/v) milk in PBS 
at room temperature for ~4 hours before primary antibody incubation overnight at 4 °C. Membranes 
may be further blocked overnight with primary antibody incubation for two hours at room temperature 
the following day. Primary antibodies were used diluted in blocking buffer + 0.02% (v/v) Tween-20. 
Membrane slices were incubated in 6 ml primary antibody dilutions, after which primary antibodies 
were removed and membranes washed thrice with PBS + 0.2% Tween-20 for 20 minutes at room 
temperature. Rabbit anti-RFK was obtained from Proteintech, FADS (rabbit) from Aviva, SLC25A32 
(rabbit), NDUFV1 (rabbit) and SDHA (rabbit) from Abcam and all used at 1:1000. 
For electrochemiluminescence (ECL) detection horseradish peroxidase (HRP)-coupled secondary 
antibodies were used and diluted in blocking buffer + 0.02% (v/v) Tween-20. Goat anti-rabbit (Promega) 
and sheep anti-mouse (GE Healthcare) were used at 1:3,000 in blocking buffer and membranes 
incubated for 1 hour at room temperature. Membranes were then washed thrice with PBS + 0.2% (v/v) 
Tween-20 for 20 minutes at room temperature and a finally with PBS. ECL Prime detection kit (GE 
Healthcare) reagents were used and chemiluminescence detected using X-ray film. Once repeated and 
optimised the signal intensities could then be quantified using fluorescence coupled secondary 
antibodies (see below). Loading controls were also used (Rabbit anti-VDAC1 from Abcam and mouse 
anti-DRP1 from Abnova) to account for the total protein loaded. 
2.5.4. Quantitative Western Blotting 
Once protein samples had been separated by electrophoresis they were transferred onto an Immobilon®-
FL PVDF membrane using a wet transfer system, as describe above. After transfer membranes were 
blocked in 10 ml protein-free PBS blocking buffer (Pierce) at room temperature for ~4 hours before 
primary antibody incubation overnight at 4 °C. Primary antibodies were used at the appropriate dilution, 
ascertained from Western blot detection by ECL, and made in blocking buffer + 0.02% Tween-20. After 
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overnight incubation primary antibodies were removed and membranes washed thrice with PBS + 0.2% 
Tween-20 for 20 minutes at room temperature. 
For quantitative detection fluorophore-coupled secondary antibodies were used. These light sensitive 
antibodies (goat anti-rabbit IRDye® 680RD or goat anti-mouse IRDye® 800CW, Abcam) were diluted 
1:5,000 in blocking buffer + 0.02% (v/v) Tween-20 + 0.02% (w/v) SDS and membranes were protected 
from light and incubated for one hour. SDS was added as PVDF membranes were used rather than 
nitrocellulose membrane and extra detergent is suggested by LiCOR. Membranes were then washed 
thrice with PBS + 0.2% Tween-20 for 20 minutes at room temperature, also in the dark. After a final 
wash with PBS membranes were imaged on a LiCOR Odyssey® CLx Imager. Signal intensities were 
quantified using the software to provide a comparison between protein levels in different samples. 
Loading controls were also used (VDAC1, DRP1) to adjust the signals obtained for the total protein 
loaded and background readings made to normalise signals to the base fluorescence of the membrane. 
2.5.5. In-gel activity assays 
 
To visually assess the activity of the respiratory complexes present in cell lines (crude mitoplasts or 
purified mitochondria), solubilised samples were separated by BN-PAGE and exogenous reagents added 
to detect activity of individual complexes, as described by Dabeni-Sala and co-wokers (Zerbetto et al., 
1997). For each gel 25 ml of reagent mix was added.  
 
Complex I 
 
Complex I activity was detected using the electron acceptor nitroblue tetrazolium (NBT), that forms a 
purple, in situ precipitate when reduced. BN-PAGE gels were washed in cold dH2O to remove excess 
stain and retain activity. The reaction mixture of 0.5 mg/ml NBT and 100 μM reduced nicotinamide 
adenine dinucleotide (NADH) in 20 mM Tris pH 7.4 was added and after 30 minutes incubation at room 
temperature proteins with an active flavin cofactor - including complex I and the citric acid cycle 
oxoglutarate dehydrogenase complex (OGDH) – were highlighted by a purple band corresponding to 
their migration position. Once developed the gels were rinsed thoroughly and imaged. 
 
Complex II 
 
Complex II activity was assayed using 84 mM succinate, 2 mg/ml NBT, 10 mM sodium cyanide and 
0.2 mM phenazine methosulphate (PMS) in 20 mM Tris.HCl, pH 7.5. Succinate acts as the electron 
donor to complex II, which reduces NBT, forming a visible purple band. SDHA subunit of complex II 
contains FAD, which re-oxidises succinate to fumarate, with electrons passed on to the exogenous 
reagent NBT.  
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Complex IV 
 
The activity of complex IV was evaluated using 0.4 mg/ml 3-3 dibenzamidine (DAB) and 1 mg/ml 
cytochrome c in 50 mM phosphate, pH 7.2. Active complexes were observed as brown bands after 
incubation for ~1 hour at room temperature. 
 
2.6. Respiratory phenotype techniques 
 
2.6.1. Extracellular flux analysis of oxygen consumption rates 
Oxygen consumption rates (OCRs) were measured using a Seahorse XF96 extracellular flux analyser 
(Agilent) at 37 °C. 11,500 143B or HAP1 cells were plated per well into Seahorse Bioscience XF96 
plates and incubated for at least 12 hours at 37 °C in 5 % CO2. The medium was then exchanged for 
assay buffer, either standard DMEM (4.5 g/L glucose, 1 mM pyruvate, 32 mM NaCl, 2mM GlutaMAX, 
15mg/L phenol red and 20 mM HEPES, pH 7.4 at 37 °C) or riboflavin-free DMEM (formulation without 
riboflavin). Cells were then incubated for a further 30 minutes in a CO2 free incubator. The basal OCR 
was first established and measured for at least four cycles (5 minutes mix, 3 minutes measure) before a 
stress test was undertaken. Oligomycin to a final concentration of 1 μM was injected into each well and 
measured for at least four cycles to inhibit complex V. Then 0.5 μM carbonyl cyanide p-
trifluoromethoxyphenylhydrazone (FCCP) (0.25 μM for HAP1s) was injected with the same number of 
measurements to uncouple the mitochondria and measure maximum respiratory capacity. Lastly 
antimycin A and rotenone were both added to a final concentration of 1 μM to inhibit complex I and 
complex III to measure non-mitochondrial respiration for at least four cycles. Injection timings are 
shown in Figure 2.8, along with different components of oxygen consumption measured. After assay 
completion, to account for differences in seeding density, plates were washed with 200 μl/well PBS 
followed by cell lysis in 20 μl of 150 mM NaCl, 50 mM Tris (pH 7), 1 mM ethylenediamine tetra-acetic 
acid (EDTA), 1% Triton-X-100 per well, for 30 minutes. Protein concentrations were determined by the 
BCA assay. These values were then used to correct the OCR data (pmol/min) and extracellular 
acidification rate (ECAR, mpH/min) obtained. 
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Figure 2.8 Example extracellular flux OCR data for a stress test with adherent cells. Injection points for 
oligomycin, FCCP and rotenone & antimycin A are shown on a typical OCR trace. The different components of 
oxygen consumption are labeled, showing how the stress test can be used to assess OCR: oligomycin inhibits ATP 
synthase, FCCP uncouples the mitochondria to allow maximal respiration and rotenone & antimycin A injection 
inhibits the ETC and highlights the residual OCR attributed to non-mitochondrial respiration. 
 
 
2.6.2. Mitochondrial coupling, assessing membrane potential in live cells 
 
HAP1 cells were plated into six-well plates the day before the experiment at 250,000/well. Then they 
were harvested by trypsinisation, pelleted by centrifugation (400 xg) and resuspended in 1 ml DPBS. 
0.5 μl 50 nM tetramethylrhodamine (TMRM) and 20 μl 1 mg/ml Hoechst stain was added and samples 
incubated for 20 minutes at 37 °C, 5% (v/v) CO2 to allow uptake of the dyes. Hoechst stain was used to 
stain the cell nucleus and correct the fluorescence measured for cell number. After incubation cells were 
pelleted to remove excess dye and washed twice with 1 ml DPBS. The final sample was then 
resuspended in ~200 μl DPBS.  
 
Mitochondrial coupling was evaluated using a Chemometech NucleoCounter® NC-3000™, with 30 μl 
of cell solution loaded onto NC-Slide A2™ slides. Hoechst (excitation at 346 nm, emission at 397 nm) 
and TMRM (excitation at 488 nm, emission at 570 nm) uptake was then measured. The coupling of each 
sample was then assessed by comparison of the TMRM fluorescence to the control samples. The 
addition of 0.5 μl 2mM FCCP (10 minute incubation) uncoupled the mitochondria and by applying a 
gate to the data the proportion of uncoupled mitochondria could be assessed. This gate was then applied 
to all the data to determine the percentage of each population that was coupled and uncoupled.  
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2.7. Protein analysis by Mass Spectrometry 
 
2.7.1. Stable-isotope labelling of amino acids in cell culture (SILAC) 
 
Proteomic analysis by SILAC was undertaken as described by Walker and co-workers (Andrews et al., 
2013). 15Nitrogen labelled lysine and arginine residues were incorporated into one sample to generate a 
shift in peptide fragment peaks, to allow a direct comparison to an unlabelled sample – generating a 
ratio of heavy to light for individual proteins. To achieve this, growth media lacking lysine and arginine 
was used – SILAC DMEM (Life Technologies). Heavy labelled amino acids were added as described 
below. Riboflavin free SILAC DMEM was custom synthesised by Life Technologies. Dialysed FBS 
was used as the growth supplement as it did not contain amino acids, to prevent unlabelled Arg and Lys 
being introduced into the heavy-labelled sample. Unlabelled proline was added at a final concentration 
of 200 μg/ml to all samples to prevent transamination of 15N-Arg to 15N-Pro during passages. Heavy-
labelled amino acids were prepared in DPBS and 15N-Arg added to the growth media at 0.398 mM and 
15N-Lys at 0.798 mM, to mirror concentrations found in control growth medium. Media was filtered 
sterilised after all additions. 
 
The cell line under investigation and its appropriate control were grown in SILAC DMEM with either 
heavy labelled or unlabelled Arg and Lys, the experiment was then repeated with the opposite labelling 
for both a ‘forward’ and ‘reverse’ result. Therefore data was collected as the ratio of the heavy-labelled 
proteins within the cell line of interest compared to an unlabelled control, and vice versa. Cells were 
labelled for at least one week to ensure complete turnover of proteins and successful heavy labelling.  
 
~5x106 cells were harvested and the pellets washed twice in DPBS. To determine the protein 
concentration, cells were resuspended in a small volume of DPBS and assessed by the BCA assay. A 
1:1 mass ratio of heavy and unlabelled samples was then mixed prior to processing, and pelleted. In 
addition, a heavy-labelled only sample was processed to allow labelling efficiency to be checked.  
 
Samples were then digitonised to form a crude mitochondrial sample as described in section 2.4.1. The 
protocol related to processing of 0.8 mg protein and therefore volumes were adjusted accordingly. 
Sample buffer was not added; instead samples were reduced and alkylated ahead of SDS-PAGE and 
analysis by mass spectrometry. An equal volume of 2x gel sample buffer (1x GSB: 20% (v/v) glycerol, 
100 mM Tris pH 8, 2 mM EDTA, 2% (w/v) SDS) was added to the sample and tris-2-carboxyethyl-
phosphine hydrochloride used at 5 mM final to reduce the sample, for 30 minutes at 37 oC. 
Iodoacetamide was added to 15 mM for alkylation of samples, incubated for 30 minutes at room 
temperature in the dark. DTT was used to quench excess iodoacetamide, to a final concentration of 30 
mM. 
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Samples were then separated by SDS-PAGE and stained before bands were submitted for mass 
spectroscopy analyses. Sample lanes were divided into ~20 equal slices. 
 
2.7.1.1. Sample preparation 
 
Gel slices were further cut into four segments and rinsed twice in 100 μl HPLC-grade H2O, then 100 μl 
20 mM Tris.HCl (pH 8), both for one hour. Partial dehydration was achieved by 30-minute incubations 
in 100 μl 50% (v/v, Fluka) acetonitrile and 20 mM Tris.HCl (pH 8). Full dehydration was performed 
using 20 μl 100% (v/v) acetonitrile for 10 minutes followed by 30 minutes in a Savant Speedvac® 
vacuum concentrator at 37 °C. Gel pieces were digested with 10 μl of 12.5 μg/ml bovine trypsin in 20 
mM Tris.HCl (pH 8) and 5 mM CaCl2 with incubation overnight at 37 °C. Tryptic peptides were then 
extracted using 15 μl of 20 mM Tris.HCl (pH 7.4), 60% (v/v) acetonitrile and 4% (v/v) formic acid for 
one hour. The extracted solution was transferred to a new tube, and the gel was re-extracted for 1 hour.  
In the case of BN-PAGE gels (for complexomics, section 2.7.2.), the extracted solution was further 
vacuum dried to increase the concentration of peptides and remove excess acetonitrile, that would 
prevent peptides from adhering to the reverse-phase high-performance liquid chromatography (RP-
HPLC) column. Finally, the samples were re-suspended in 15 µl of 2% (v/v) acetonitrile and 0.1% (v/v) 
formic acid.  
 
2.7.1.2. Liquid chromatography MS/MS Orbitrap mass spectrometry 
 
The peptide mixtures were fractionated by RP-HPLC on an Acclaim PepMap nanoViper C18 column 
(75 μm internal diameter, 100 mm length) in a Proxeon Easy-nLC system using a gradient of 4.9-39.2% 
acetonitrile in 0.1% (v/v) formic acid over 84 minutes, at a flow rate of 300 nl/min. The eluate was 
transferred in line to a Q-Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific). Data 
were acquired from 400 to 16000 m/z for precursor ions and the ten most abundant precursor ions 
fragmented by higher-energy collisional dissociation in nitrogen. Analyses were performed by Dr 
Shujing Ding from the MRC MBU, University of Cambridge. 
 
2.7.1.3. SILAC protein identification and quantification  
 
Peptide mass and fragmentation data were processed with MaxQuant (version 1.5.0.12; Cox & Mann, 
2008) and the integrated Mascot search engine (Matrix Science) used to identify proteins by comparison 
to the Swiss-Prot human database. Ratios of heavy to light-labelled proteins were calculated by 
MaxQuant; each protein ratio represents the median of ratios of all assigned peptides for that protein. 
MaxQuant ISO-MS/MS peptide ratios, calculated from intensities spanning regions in the m/z retention 
time plane corresponding to isotopic patterns, were used only when fewer than three other peptide ratios 
were obtained. Quantitative data were processed using Perseus software (version 1.3.0.4; Tyanova et 
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al., 2016) and proteins identified in a contaminant database or decoy database (created by MaxQuant by 
reversing protein entries) were excluded. Proteins lacking unique peptides were also removed. For 
protein experiments in which protein labelling was in the reverse orientation the reciprocal value was 
calculated. Base 2 logarithmic values are presented on scatter plots. 
 
2.7.2. Complexomics  
 
After the completion of BN-PAGE (section 2.5.2.) each sample lane was cut into 64 1mm thick equal 
sized bands and submitted for mass spectrometry for complexome analysis according to Brandt and co-
workers (Heide et al., 2012). All analyses were performed by Dr Mike Harbour from the MRC MBU, 
University of Cambridge. 
 
Samples were digested by trypsin (section 2.7.1.1.), resolved using RP-HPLC on an Acclaim PepMap 
nanoViper C18 reverse-phase column (75 µM x 100 mm) and introduced onto a LTQ Orbitrap XL™ 
(Thermo Fisher Scientific) with a nanospray inlet interface, coupled to an in-line Proxeon EasynLC 
nano chromatograph. Buffer A (5% acetonitrile and 0.1% formic acid) and buffer B (95% acetonitrile 
and 0.1% formic acid) were used to set up a gradient up to 40% acetonitrile over 84 min with a flow 
rate of 300 nl/min. Slices were analysed in turn, with the highest molecular weight slice down to the 
lowest, without washes to maintain the same chromatographic conditions throughout. The ten highest 
scoring peptides (400-2000 m/z) were chosen for collision-based fragmentation. To improve the range 
of peptides analysed a dynamic exclusion list was generated to exclude previously analysed peptide 
fragments for a specified time.  
 
Mass spectrometry data was outputted as a .RAW file (~120 Mb for each sample). Initially files were 
processed by Proteome Discoverer software (Thermo Fisher Scientific) and the in-house Mascot server 
was used to identify the sequences of Uniprot-database-derived peptides from their fragments. 
Additionally, trypsin was specified as the digesting agent and settings adjusted to allow one missed 
cleavage site (lysine and arginine). A theoretical peptide sequence is then created. To account for noise 
within experimental samples a flexibility of 10 ppm around the calculated peptide masses was allowed 
and a window set at 0.5 Da. Four types of peptide modifications were included: oxidation of methionine, 
the acrylamide adduct of cysteine (propionamide cysteine), acetylation of protein N-termini and 
formylation of N-termini.  
 
The results from Mascot were then used by Proteome Discoverer for Peptide-Spectrum Match 
Validation - false discovery rates of 0.1 (strict) and 0.05 (relaxed) were used to derive the traffic light 
colour-coding scheme, which indicates the confidence of each Mascot identification. The remaining 
stages defined the complexomics approach, identifying and quantifying the peptide chromatographic 
peaks for relative quantification. In this way complexomics is used to quantify each peptide, of each 
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protein, within each slice – completed by Proteome Discoverer for each of the 64 slices/sample. Finally 
each of the 64 results was combined into a single MultiConsensus report. An algorithm was applied to 
convert relative peptide quantification into relative quantification of proteins: the three highest intensity 
peptides for each protein are selected, the mean value taken to generate a number representative of the 
whole protein. If less than three peptides were present the average of those present was taken. This was 
repeated for each slice to form a profile of each protein throughout the lane.  
 
Protein profiles were then further analysed using the criteria from Brandt and co-workers (Heide et al., 
2012). The Pearson uncentered correlation coefficient (PUCC) for each possible pair of protein profiles 
was used to calculate single-linkage hierarchical clustering. Profiles were scaled and normalised as a 
proportion of the highest count recorded. For data analysis of protein complexes within the samples the 
final result was used to generate a heat map, for ease of visualisation, whereby the background colour 
of each cell (representing the protein and slice number) was coloured depending upon its value. A range 
was built around 0 for white, 0.7 for yellow and 1 for red, using a visual basic for applications (VBA) 
Macro to generate a heatmap showing the relative distribution of each protein identified across the 64 
slices.  
 
2.8. Gene expression techniques 
 
2.8.1. Total cell RNA purification  
 
RNA from HAP1 lines was purified using the RNeasy kit (Qiagen), starting from a 70% confluent T75 
flask of cells. Once harvested cell number was ascertained for purification of 3-4 x106 cells/sample.  
 
Following the kit instructions 40 mM DTT was added to an aliquot of RLT buffer before use. Cells were 
disrupted with 350 μl RLT buffer and vortexed before homogenisation using Qiashredder spin columns. 
Centrifuging for 2 minutes at 8,000 xg was sufficient to process the sample; the same volume of 70% 
ethanol was then added to the lysate and mixed to remove contaminating DNA. The sample was then 
passed through a RNeasy spin column by 15-second centrifugation at 8,000 xg and flow-through 
discarded. 700 μl RW1 buffer was then added to wash the column, followed by 500 μl RPE buffer, and 
another 500 μl with a 2-minute centrifugation. To ensure the membrane was completely dry it was re-
spun for 1 minute without additions. RNA was then eluted with 30 μl RNAse free dH2O, aliquoted and 
snap frozen before being stored at -80 °C. For each HAP1 and SLC25A32 KO lines three biological 
repeats were purified, with a HAP1 and SLC25A32 KO pair purified side-by-side.  
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2.8.2. RNA quality analysis 
  
RNA quality was then assessed by the Agilent high sensitivity RNA ScreenTape system according to 
the manufacturer’s guide. High sensitivity RNA ladder and two-fold diluted RNA samples were 
prepared in high sensitivity sample buffer at 2:1 ratio. Samples were vortexed for one minute and 
centrifuged before heating to 72 °C for three minutes, incubated on ice for two minutes and centrifuged 
to collect the sample. Samples were then loaded into a 2200 TapeStation instrument and analysed for 
RNA quality, with a requirement for greater than a 7/10 quality score to proceed with transcriptomics 
analysis. 
 
2.8.3. Transcriptome profiling and analysis 
 
500 ng of each RNA sample in 25 μl was submitted to Eurofins for Favourite Transcriptome Profiling 
to provide three repeats for each cell line. RNA quality was assessed on receipt by Eurofins and the 
RNA prepared using the TruSeq stranded mRNA library preparation kit. Sequencing was then 
undertaken on an Illumina HighSeq 2500 with 100 bp pair ended reads (sequenced in both directions). 
Processing of transcriptome data was performed in house by Dr Alan Robinson from the MRC MBU, 
University of Cambridge, using DESeq2 (Love et al., 2014) to obtain parameters for fold change and 
adjusted P-value for analysis of changes in transcription profile. 
 
2.9. Preparations of complex I containing samples from Yarrowia lipolytica 
 
2.9.1. Generation of NDUFS2 mutants in Y. lipolytica 
 
The mutant strains of NDUFS2 (NUCM) in Y. lipolytica, shown in Table 2.7, were designed and 
generated by Dr Andrew Jones using the Δnucm strain produced by Brandt and co-workers (Grgic et 
al., 2004). This strain was produced from the parental GB10 strain, developed with a His-tagged 
NDUFS3 subunit and internally directed alterative NADH dehydrogenase (NDH2) to allow for 
compensation of complex I mutants (Kashani-Poor et al., 2001; Kerscher et al., 2001). Point mutations 
were made by PCR to the sequence of NUCM cloned into pUB26, to be expressed under the control of 
its native promoter. This plasmid includes ampicillin resistance for selection in bacteria and hygromycin 
for selection in Y . lipolytica. After amplification of the mutant constructs in E. coli and sequencing of 
the plasmids, the plasmids were transformed into Δnucm (ΔNDUFS2) Y. lipolytica by electroporation. 
Expression of complex I and activity was assessed by BN-PAGE of purified mitochondria compared to 
the wild type GB10 strain.  
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Residue 
number 
(Y. lipolytica) 
Codon 
sequence 
Amino acid 
Mutated 
codon 
sequence 
Resulting amino 
acid 
Human residue 
identity 
91 CAT H ATG M H55 
95 CAC H ATG M H59 
121 CGA R ATG M R85 
141 CGT R ATG M R105 
144 TAC Y TTC F Y108 
192 TCA S GTA V T156 
196 GAT D AAT N D160 
226 CAC H ATG M H190 
 
Table 2.7 NUCM Y. lipolytica mutants and equivalent residues in the mature human subunit NDUFS2. Nine 
mutants were designed in NUCM and expressed in Δnucm Y .lipolytica GB10 to assess complex I activity. 
Mutations were chosen in the putative Q-binding channel and represent a number of residues with evidence of 
ligand binding or iron sulphur cluster interactions and some with location and properties that suggest a role in 
ubiquinone binding.  
 
2.9.2. Mitochondrial membrane preparation of Y. lipolytica NDUFS2 mutants 
 
 
Y. lipolytica mutants were grown in aliquots of 25 ml 2x yeast extract peptone dextrose (YPD) medium 
(20g/L yeast extract, 40g/L peptone, 40g/L glucose, pH 5.5) containing 100 μg/ml hygromycin. Cultures 
were incubated at 30 °C, shaking at 225 rpm, for about 72 hours, until OD600 reached 10-20, then used 
to inoculate 2 litre flasks containing 500 ml 2x YPD + 50 μg/ml hygromycin to OD600 of 0.3. The flasks 
were incubated at 30 °C, shaking at 225 rpm, for about 96 hours, until OD600 reached 30. Y. lipolytica 
cells were harvested by rounds of centrifugation at 7,000 xg for 15 minutes at 4°C and washed twice 
with cold dH2O. Pellets were stored at -80 °C until membrane processing. 
 
Mitochondrial membranes were prepared as described by Varghese et al., but used a different cell 
disruptor due to smaller sample volumes (Varghese et al., 2015).  A frozen pellet was defrosted and 
resuspended in twice the volume (relative to its mass) of breaking buffer (20 mM MOPS, 400 mM 
Sorbitol, 5 mM EDTA, 2 mM benzamidine, 2% (w/v) BSA, 5 mM amino-caproic acid, pH 7.2) + 2 ml 
200mM PMSF. Cells were then disrupted in a Z-plus 2.2 KW cell homogeniser (Constant Cell 
Disruption Systems) at 35 Kpsi, for three rounds, to ensure maximum breakage. Cell debris was then 
removed by centrifugation (10,100 xg, 30 minutes, 4 °C) and the supernatant retained. Mitochondrial 
membranes were then pelleted by high speed centrifugation at 200,000 xg for 1 hour at 4 °C. Pellets 
were combined, homogenised and washed in wash buffer (20 mM MOPS, 400 mM Sorbitol, 2 mM 
benzamidine, 5 mM amino-caproic acid, pH 7.2) twice at 200,000 xg, 45 minutes, 4 °C before finally 
being resuspended in 20 mM NaH2PO4, 150 mM NaCl and snap frozen in 25 ml aliquots.  
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2.9.3. Complex I purification from Y. lipolytica mitochondrial membranes 
 
 
Complex I was isolated from Y. lipolytica as described below, based on the protocol used by Varghese 
et al. that was developed from the protocol of Brandt and co-workers (Varghese et al., 2015; Kashini-
Poor et al., 2001). Modifications include addition of 0.02% Asolectin/3-[(3-cholamidopropyl)-
dimethylamminio]-1-propane sulphonate (CHAPS) to Buffers A and B and a Superose™ 6 Increase gel 
filtration column was used. Y. lipolytica membrane aliquots were thawed (500-800 mg protein) at 4 °C 
and centrifuged at 235,000 xg for 30 minutes at 4 °C to pellet the membranes. These pellets were then 
homogenised in Buffer γ to 20 mg/ml (Table 2.8) and protease inhibitors (2x cOmplete™ protease 
inhibitor cocktail tablets) were added. The mixture was stirred with 2.9% DDM (from a 10% stock) 
added drop-wise and solubilised for 30 minutes on ice, before centrifugation at 235,000 xg for 45 
minutes at 4 °C. The supernatant was retained and solid NaCl was added to a final concentration of 400 
mM and imidazole from a neutralised 1M stock was added to 20 mM. The solubilised membranes were 
then filter sterilised and loaded onto a Nickel-Sepharose column (GE Healthcare) to bind the His-tagged 
complex I. 
 
 
 
 
 
 
 
 
 
 
Table 2.8 Buffer composition for isolation of complex I from Y. lipolytica. Purification required four buffers, 
all kept at 4 °C. Asolectin/CHAPS and DDM additions were made on the day with buffers A, B and gel filtration 
filtered before use.  
 
 
The column was then washed and bound protein eluted using an ÄKTA Prime liquid chromatography 
system (GE Healthcare). The column was washed at 2 ml/min with Buffer A (Table 2.8) until the 
conductance reading stabilised. Buffer B (Table 2.8) was then used to elute the bound His-tagged 
complex I. 3 ml fractions with the highest protein absorbance from the eluted volume were pooled (~10 
fractions) and concentrated (Millipore 50K MWCO, 50 ml) at 5,800 xg until 2x 500 μl concentrated 
aliquots were obtained. The sample was then injected onto a Superose™ 6 Increase gel filtration column 
(GE Healthcare) connected to an ÄKTA Explorer fast protein liquid chromatography system (GE 
Healthcare). 0.5 ml fractions of protein were collected by elution with gel filtration buffer (Table 2.8) 
at a rate of 0.5 ml/min. Fractions from the second peak in absorbance at 280 nm were pooled (the first 
peak represented aggregated protein). Peak fractions from multiple 500 μl injections were then 
 Buffers 
Components (mM) γ A B Gel Filtration 
Na-MOPS    20 
Na2PO4 20 20 20  
NaCl 50 400 400 150 
Imidazole  52 140  
Asolectin/CHAPS (w/v)  0.02% 0.02%  
DDM (w/v)  0.1% 0.1% 0.05% 
Glycerol (v/v)    10% 
pH at room temperature 7.45 7.20 7.20 7.45 
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concentrated together to ~250 μl. Isolated complex I was aliquoted into 10 μl samples and snap frozen 
before storage at -80 °C. 
2.9.4. Preparation of alternative oxidase (AOX) for use in proteoliposomes 
 
AOX was purified from E. coli (FN102/pTbAO strain) mitochondrial membranes at 4 °C as described 
by Hirst and co-workers (Jones et al., 2016). 20 ml of membranes were solubilised at 6 mg/ml protein 
in 25 mM Tris.HCl (pH 8.0), 200 mM MgSO4, 1.4% (w/v) n-octyl-glucopyranoside (Anagrade, 
Anatrace) and 20% (v/v) glycerol for 1 hour then centrifuged at 165,000 ×g for 30 minutes. The 
supernatant was loaded onto a ~8-mL column of Strep-Tactin® Superflow® high capacity resin (IBA 
GmbH) pre-equilibrated in strep buffer (20 mM Tris.HCl, 50 mM MgSO4, 160 mM NaCl and 20% (v/v) 
glycerol, pH 8.0 at 4 °C). AOX was eluted in strep buffer supplemented with 2.5 mM desthiobiotin 
(Sigma-Aldrich) and 0.042% DDM. Pooled AOX-containing fractions were concentrated 10-fold, then 
dialysed for six hours against 2 L of strep buffer plus 0.042% DDM. 
 
2.9.5. Preparation of proteoliposomes from Y. lipolytica complex I 
 
Proteoliposomes were generated using the protocol described by Jones et al., developed from that of 
Roberts and Hirst (Jones et al., 2016; Roberts & Hirst, 2012). Proteoliposomes were prepared in 50 mM 
KCl, 10 mM Tris.SO4 at pH 7.5 (PL buffer) at 4 °C. Stock phospholipids of 25 mg/ml (bovine heart, 
Avanti Polar Lipids) in chloroform were mixed in a glass homogeniser: phosphotidylcholine (PC), 
phosphotidylethanolamine (PE) and cardiolipin (CL) at 8:1:1 for a total of 10 mg phospholipid. Q10, 
also in chloroform, was also added at 0, 12.5, 25, 50, 75, 100 or 150 nmoles (equivalent to 0-15 mM in 
lipid). Chloroform was removed by evaporation under N2(g) and further evaporated by applying a 
vacuum. The mixture was then resuspended in ~675 μl PL buffer (depending on protein volumes added 
in later steps for a final volume of 1 ml) and extruded nine times through a 0.1 μM pore tracked edge 
membrane (Whatman). All samples were then chilled to 4 °C overnight prior to the next steps. 
 
Lipids were partially solubilised by 160 μl octyl-glucoside (OG, aqueous 10% stock), sonicated for 10 
minutes and chilled for 10 minutes on ice. All following steps were done at 4 °C. 0.2 mg AOX was 
added along with 0.2 mg of isolated Y. lipolytica complex I. After 10 minutes incubation ~100 μl of 
washed biobeads (Bio-Rad SM2 Biobeads) were added to each sample and agitated for 4 hours - ~100 
μl of fresh beads were added every hour. Biobeads were then removed using a micro bio-spin column 
(Bio-Rad) and the suspension centrifuged at 57,500 xg for 45 minutes to collect the proteoliposomes. 
The supernatant was removed and the pellet resuspended in 100 μl cold PL buffer. The final volume 
was recorded (for component quantification), aliquoted and snap frozen for storage at -80 °C. This 
protocol typically yielded ~200 μl proteoliposomes at 1.5 mg/ml total protein.  
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2.10. Kinetic measurements 
In general, a master mix containing the assay buffer, protein and electron acceptor was prepared and 
150 μl pipetted into a well of a 96-well plate. The reaction was started by the addition of 50 μl NADH 
(usually 200 μM final concentration) into each well, after a two-minute incubation at 32 °C. Kinetic 
measurements were made using a Spectramax 384 plate reader (Molecular Devices) at 32 °C and all 
data were processed using SoftMax Pro (Molecular Devices) to obtain activity rates, expressed as μmol 
reagent oxidised/min/mg protein. 
 
2.10.1. Kinetic measurements on Y. lipolytica mitochondrial membranes  
 
Assay buffer comprised 10 mM TrisHCl.SO4, 50 mM KCl, pH 7.5 at 32 °C. Concentrations given below 
represent the final concentration in the assay, taking into account the dilution of reagents when the 
master mix and NADH solutions were mixed. 
 
Complex I specific activities in mitochondrial membranes were measured with a range of electron 
acceptors and deamino NADH (dNADH) was added at 200 μM. The quinones used were 
decylubiquinone (DQ, 200 μM) and Q1 at (100 μM). For NADH:O2 assays a saturating concentration of 
cytochrome c was added (8 μM). NADH oxidation was monitored at 340-380 nm ( = 4.81 mM-1 cm-1) 
and for all assays Y. lipolytica membranes were used at 30 μg/ml. 2 μM piericidin A was added to inhibit 
quinone reduction at the Q-site.  
 
Additionally the artificial electron acceptors 3-acetylpyridine adenine dinucleotide (APAD+)  and 
potassium hexacyanoferrate (III) (FeCN) were used. APAD+ was added at 500 μM and 100 μM dNADH 
was used with the addition of 2 μM piericidin A to inhibit Q-site activity. The formation of APADH 
was followed at 400-450 nm ( = 3.16 mM-1 cm-1). For FeCN measurements FeCN was added at 1 mM, 
dNADH at 200 μM and piericidin A at 2 μM. NADH oxidation was monitored at 340-380 nm ( = 4.81 
mM-1 cm-1). 
 
2.10.2. Kinetic measurements on isolated Y. lipolytica complex I 
 
All isolated complex I assays were carried out in 20 mM Tris.HCl, pH 7.5. Concentrations given below 
represent the final concentration in the assay. 
 
NADH:DQ activity assays used complex I at 0.25 μg/ml, DQ at 200 μM and NADH at 200 μM. 0.075% 
(w/v) asolectin-CHAPS (from a 5% (w/v) stock) was also required in the complex I containing solution. 
NADH oxidation was assessed at 340-380 nm ( = 4.81 mM-1 cm-1) over several minutes. 
Production of reactive oxygen species (ROS) was assessed using the probe Amplex Red (AxR, 
Invitrogen), which reacts with hydrogen peroxide. The master mix contained 0.075% Asolectin-
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CHAPS, 10 μM AxR and 10 μg/ml complex I, with 10 U/ml horseradish peroxidase (HRP) to catalyse 
the reaction. The formation of the fluorescent product resorufin was detected by following A557 and A620 
( = 51.6 mM-1 cm-1). Superoxide dismutase (SOD) was present in the master mix at 10 U/ml, to convert 
all superoxide to hydrogen peroxide. 30 μM NADH was used to initiate the assay, after the two-minute 
incubation. Catalase insensitive (5000 U/ml) and complex I independent background rates were 
subtracted to calculate the actual rates of ROS production by complex I. This reaction was very slow 
and therefore rates were calculated in nmol resorufin produced/min/mg complex I. 
 
2.10.3. Kinetic assays on Y. lipolytica complex I containing proteoliposomes  
 
All proteoliposome assays were carried out in 50 mM KCl, 10 mM Tris.SO4, pH 7.5 at 32 °C. PLs were 
diluted 1:500 in all assays. Concentrations given below represent the final concentration in the assay. 
 
NADH:Q10 assays were carried out with PLs containing different concentrations of Q10. 200 μM NADH 
was added to initiate NADH oxidation, which was monitored at 340-380 nm ( = 4.81 mM-1 cm-1) over 
several minutes. NADH:Q1 assays used the same concentration of NADH but required PLs prepared 
without Q10. Q1 was then added from diluted ethanol stocks for concentrations of 0, 2, 5, 10, 20, 40, 60, 
80 and 100 μM (a constant ethanolic volume was used). 2 μM piericidin A was added to inhibit Q-site 
activity.  
  
To determine the IC50 for piericidin for each mutant and WT, in the presence of saturating Q10, the 
proteoliposomes with the [Q10] closest to 10 mM in the membrane (after quantification) were chosen. 
Piericidin A was diluted in ethanol for concentration of 0-2 μM and a constant volume was added to the 
assay. NADH was added to 200 μM and the activity of each mutant over the range of piericidin 
concentrations was assessed at 340-380 nm ( = 4.81 mM-1 cm-1).  
 
2.11. Analytical methods 
 
2.11.1. Quinone concentration in Q10 proteoliposomes  
 
Q10 quantification was carried out as described by Hirst and co-workers (Fedor et al., 2017). 90 µl of 
ethanol (HPLC grade, Chromasolv) was added to 10 µl of proteoliposomes solution, sonicated for 1 
minute and centrifuged at 16,300 ×g for 10 minutes. A total of 150 µl of supernatant was injected onto 
a Nucleosil 100–5C18 (Hichrom) column, and run at 30 °C at 800 µl/min on an Agilent 1100 series 
HPLC in 70% (v/v) ethanol, 30% (v/v) methanol, 0.07% (v/v) HClO4, and 50 mM NaClO4 with a 
retention time of 9 minutes. Concentrations were determined by comparison with known standards.  
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2.11.2. Complex I concentration in proteoliposomes 
Total protein contents were quantified for complex I only proteoliposomes as described by Hirst and 
co-workers (Fedor et al., 2017), using the amido black assay, which is insensitive to detergents and high 
phospholipid concentrations (Kaplan et al., 1985). 10 μl of proteoliposome sample was diluted in 2 ml 
dH2O. 0.2 ml 10% (w/v) SDS, 0.3 ml 1 M Tris/1% (w/v) SDS, pH 7.5 and 0.6 ml 104% trichloroacetic 
acid (TCA) were added sequentially with vortexing between. Samples were then incubated for at least 
3 minutes, transferred onto a 0.45 μm pore filter (Millipore, HAWP02400) and placed on a Millipore 
sampling manifold. The sample was then filtered under vacuum and washed with 2 ml 6% TCA. After 
all samples had been filtered staining was done with 200 ml 0.1% (w/v) amido black 10B dissolved in 
methanol/glacial acetic acid/deionised water (45/10/45, v/v) for 3 minutes. Three one-minute rounds of 
washing in destain solution - methanol/glacial acetic acid/deionised water (90/2/8 v/v) was used to 
remove excess stain. Filters were then washed in 200 ml dH2O, blotted dry and the blue dot excised 
before being cut into six. Stain was eluted by addition of 0.7 ml 25 mM NaOH/0.05 mM EDTA/50% 
(v/v) ethanol and incubation for one hour with vortexing. 200 μl of eluate was then read in duplicate at 
630 nm. 
The NADH:APAD+ oxidoreduction assay was used to calculate the complex I content in all samples, as 
described by Hirst and co-workers (Jones et al., 2016). A master mix containing diluted PLs and 2 μM 
piericidin A was prepared, along with another solution of 100 μM NADH and 500 μM APAD+. Solutions 
were incubated at 32 °C for two minutes and then mixed. APADH formation was followed by changes 
in A400 and A450 ( = 3.16 mM-1 cm-1).  
 
The complex I only standards were assayed with and without addition of 15 µg/ml alamethicin, which 
permeabilised the membrane to allow access to all complex I (orientated to the outside and inside of the 
PL). The percentage of complex I facing out of the PL could then be determined by comparison of the 
± alamethicin NADH:APAD+ activities. Turnover numbers (kcat) for NADH:APAD+ were calculated for 
each variant using the alamethicin-treated standard, complex I only, activity and the protein 
concentration from the Amido Black assay for these PLs (calculation described in section 5.5.1). The 
NADH:APAD+ activities for batches of PLs containing different concentrations of Q10 were measured 
in the absence of alamethicin. The kcat calculated using the standard complex I only PL, for each variant 
and WT, was then used with the corresponding NADH:APAD+ activities from the batches of PLs (with 
different [Q10]) to determine the concentration of outward facing, substrate accessible, complex I in each 
variant PL. Activities with Q10 and Q1 could then be converted into specific activities. 
 
2.11.3. Phospholipid concentration in proteoliposomes  
 
Total phospholipid contents were determined using the Ames method (Ames, 1966), applied to the 
proteoliposome system as described by Hirst and co-workers (Jones et al., 2016).
 
100 μl of each sample 
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(at several dilutions up to 0.4 mg/phospholipid ml) or standard (0 to 500 μM KH2PO4) was transferred 
into a boiling tube along with 50 μl of methanol and 30 μl of 390 mM Mg(NO3)2 in ethanol. The tubes 
were heated over a roaring blue flame in a fume-hood until no further brown fumes were formed and 
the residue in the tubes had turned white (without boiling). The tubes cooled for 5 minutes, then 0.3 ml 
of 500 mM HCl was added and the tubes were lightly stoppered with glass marbles and incubated at 99 
°C for 15 min. Once cooled, 0.7 ml of an aqueous solution of 114 mM ascorbic acid, 2.72 mM 
(NH4)6Mo7O24 and 400 mM H2SO4 was added; tubes were lightly stoppered and incubated at 37 °C for 
1 hour. 200 μl aliquots were transferred into the wells of a quartz 96-well plate, the absorbance (from 
reduced phosphomolybdate) measured at 820 nm, and the phospholipid contents of the samples 
determined by reference to the standards, accounting for the fact that each PC or PE contributes one 
orthophosphate, whereas each CL contributes two.  
65 
Chapter 3 
Investigating incorporation of the flavin mononucleotide cofactor into 
complex I 
3.1. Introduction 
 
3.1.1. Assembly of complex I 
 
The assembly pathway for complex I has long been studied; however, due to its large structure and 
number of subunits elucidation of this intricate pathway has been gradual. Additionally, the enzyme is 
under dual genomic control; requiring the coordination of subunits encoded by both the mitochondrial 
and nuclear genomes (Vartak et al., 2014). The first organism used to study the pathway was the fungus 
Neurospora crassa (containing 43 different subunits – Marques et al., 2005), and those studies suggested 
that the membrane and matrix arm subunits form as separate subassemblies before joining to make the 
mature complex. Weiss and co-workers treated N. crassa with chloramphenicol to inhibit mitochondrial 
translation and observed accumulation of nuclear encoded subunits in a smaller complex; their identities 
were determined by Western Blotting and peptide mapping - this subcomplex also showed NADH 
oxidation activity (Freidrich et al., 1989). In the same way the membrane arm was shown to assemble 
in N. crassa grown in manganese-limited conditions (which disrupts mitochondrial function); EPR 
investigations demonstrated this subcomplex contained the terminal iron-sulphur cluster N2 but lacked 
other redox cofactors (Schmidt et al., 1992). Additionally, manipulation of N. crassa, through knocking 
out the NDUFS8 homologue, identified the first chaperone-like proteins (CIA30 and CIA84), found 
associated with the membrane domain intermediate but absent from the complete enzyme (Küffner et 
al., 1998). These studies highlighted not only the modular steps in complex I assembly but also the 
involvement of other proteins, giving rise to research into related assembly factors. 
 
More recent work with mammalian mitochondria supported the modular concept and a pathway with 
the membrane and matrix arms joining together to form the mature enzyme formed the basis of more 
detailed proposals. Figure 3.1 shows the first assembly pathway, which begins with the formation of a 
400 kDa subcomplex built around NDUFS2 and NDUFS3 and membrane-bound due to ND1. Other 
subunits are added, along with assembly factors NDUFAF3 and NDUFAF4. Separately, another 
subcomplex comprising membrane arm subunits is assembled with assembly factors NDUFAF1, 
ACAD9 and ECSIT to form a 460 kDa subcomplex. These two intermediates then combine, and with 
the addition of the more distal membrane domain subunits, ND4 and ND5, an 830 kDa subassembly is 
formed. This represents the full enzyme lacking the NADH oxidising domain and therefore the last step 
involves addition of subunits NDUFA12, NDUFS1, NDUFS4, NDUFS6, NDUFV1, NDUFV2 and 
NDUFV3, facilitated by NDUFAF2. In subsequent years this pathway has been revised with the 
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increased identification of assembly factors. Using BN-PAGE Andrews et al. explored the masses of 
the different subcomplexes and revised molecular mass estimations, in addition identifying TMEM126B 
and TIMMDC1 as assembly factors of the membrane arm, through siRNA knockdown that caused 
accumulation of low molecular mass subassemblies (Andrews et al., 2013).  
 
 
 
 
Figure 3.1 First assembly pathway of human complex I. This pathway was built around knowledge gained 
without a detailed structure of the enzyme and shown without assembly factors. The molecular masses of the 
subassemblies have since been revised by Andrews et al. and more assembly factors identified. Core nuclear 
subunits are labelled in red, mitochondrial core subunits in green and supernumerary subunits in blue. Figure 
adapted from Mimaki et al., 2012. 
 
 
There have now been 18 assembly factors of complex I identified– ACAD9, ATP5SL, COA1, ECSIT, 
FOXRED1, NDUFAF1-8, NUBPL, TIMMDC1, TMEM70, TMEM126B and TMEM186. 
Understanding of their function varies as shown in Table 3.1, although patient mutations demonstrate 
disruption of complex I assembly. Some have specific enzymatic activities, such as the hydroxylase 
NDUFAF5 and methylase NDUFAF7, whereas others have been shown to associate with membrane or 
matrix intermediates (Rhein et al., 2016 & 2015). In particular NDUFAF1, ECSIT and ACAD9 co-
purify and co-migrate on BN-PAGE and have a role in ND subunit incorporation into the membrane 
arm subassemblies during mid-stage assembly (Nouws et al., 2010).  
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Assembly factor 
Homologues in 
other species 
Stage of assembly Description 
NUBPL 
(IND1) 
 
Early stage 
- matrix arm 
associated 
Knockdown decreased the incorporation of iron-sulphur clusters and levels 
of the matrix arm were reduced (Sheftel et al., 2009). 
ATP5SL  
Early stage  
– membrane arm 
associated 
 
Associated with complex I in NDUFA11 knockdown cells and in recent 
complexomics analysis of assembly (Andrews et al., 2013; Guerrero-
Castillo et al., 2017). 
Function unknown and controversial as an assembly factor. 
TMEM70  
Associated with membrane domain subcomplexes in complexomics analysis 
(Guerrero-Castillo et al., 2017). 
FOXRED1 
 
 
FAD cofactor. 
Patient mutations result in complex I deficiency (Formosa et al., 2015). 
TIMMDC1 
(C3orf1) 
 
Early stage  
– matrix arm 
associated 
Knockdown lowered cellular OCR and levels of intact complex I, with 
accumulation of subcomplexes (Andrews et al., 2013). 
NDUFAF3 
(C3orf60) 
 
Patient mutations cause complex I deficiency and protein interacts with 
NDUFAF4 (Saada et al., 2009). 
NDUFAF4 
(C6orf66) 
 Patient mutations cause complex I deficiency (Saada et al., 2008). 
NDUFAF5 
(C20orf7) 
 
Early stage  
– matrix arm 
associated 
Arginine hydroxylase acting on NDUFS7 (Rhein et al., 2016). 
NDUFAF6 
(C8orf38) 
 
Early stage  
- matrix arm 
associated 
Stable knockdown decreased complex I levels and detectable ND1 in pulse 
translation experiments (Zurita Rendón & Shoubridge, 2012). 
NDUFAF7 
(C2orf56) 
 
Early stage 
- matrix arm 
associated 
Arginine methylase acting on NDUFS2 (Rhein et al., 2015). 
NDUFAF8 
(C17orf89) 
 
Early stage  
– matrix arm 
associated 
Interacts with and stabilises NDUFAF5. Knockdown in cell lines decreased 
complex I activity and lowered levels of NDUFAF5. Proposed candidate for 
complex I deficiency in a patient (Floyd et al., 2016). 
NDUFAF1 
CIA30  
(N. crassa) 
Mid-stage  
– membrane arm 
associated 
Part of mitochondrial complex I assembly (MCIA) complex (Heide et al., 
2012). 
Knockdown by siRNA decreases complex I by ~60% (Vogel et al., 2005). 
Patient mutations cause complex I deficiency (Dunning et al., 2007). 
ACAD9  
Component of MCIA complex. 
FAD cofactor. 
Knockdown and patient mutations cause complex I deficiency but no clear 
disruption of β-oxidation of fatty acids (Nouws et al., 2010). 
ECSIT  
Component of MCIA complex. 
Knockdown severely impaired complex I assembly with membrane arm 
intermediate accumulation and reduction in NDUFAF1 (Vogel et al., 2007). 
TMEM126B  
Component of MCIA complex. 
Knockdown lowered cellular OCR and levels of intact complex I with 
accumulation of subcomplexes (Andrews et al., 2013). 
COA1 
(C7orf44) 
 
Mid-stage  
– membrane arm 
associated 
Associated with membrane domain subcomplexes in complexomics analysis 
– possibly interacts with MCIA components (Guerrero-Castillo et al., 2017). 
Complex IV assembly factor (Mick et al., 2012). 
TMEM186 
(C16orf51) 
 
Mid-stage  
– membrane arm 
associated 
Associated with membrane domain subcomplexes in complexomics analysis 
- possibly interacts with MCIA components (Guerrero-Castillo et al., 2017). 
NDUFAF2 
13.4L  
(N. crassa) 
Late stage  
– matrix arm 
associated 
Result of gene duplication of NDUFA12. 
Non-essential in assembly (Pereira et al., 2013). 
 
Table 3.1 Assembly factors of complex I. The eighteen proteins associated with complex I biogenesis are 
described. Some have defined functions whereas others are relatively newly identified and only demonstrated to 
interact with complex I subassemblies.  
The most complete work on the assembly pathway to date harnessed a different approach for studying 
complex I subassemblies; going further than analysis of mass and protein identity from electrophoresis 
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gels (Guerrero-Castillo et al., 2017). Nijtmans and co-workers used the complexomics approach, in 
which BN-PAGE is used to separate out complexes in their native form. Gel slices were then analysed 
by mass spectrometry to determine the distribution of protein complexes (Heide et al., 2012). 
Additionally, to follow complex I biogenesis the mitochondrial translation inhibitor chloramphenicol 
was used, to deplete mitochondria of assembled complex I: after removal of the inhibitor translation 
restarted, with samples taken at time points up to 24 hours for complexome profiling. The resulting 
scheme of assembly demonstrates many of the features previously identified – such as separate building 
of the membrane and matrix arms, and the involvement of assembly factors at defined stages – but also 
details further subcomplexes. Figure 3.2 shows that complex I assembles from four intermediates, the 
soluble N-domain, the connecting Q-domain, which contains the ubiquinone binding channel, and the 
membrane arm as PP and PD (proximal and distal membrane arm). The membrane arms elements were 
observed to be made up of four discreet collections of subunits: PP-a, PP-b, PD-a and PD-b and all the 
assembly factors are proposed to be released from the complex on addition of the N-domain. This data 
was used for comparison to complexomics undertaken in section 3.8 to enable assembly factor migration 
and the presence of subcomplexes to be assessed. 
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Figure 3.2 Assembly pathway of complex I determined using the complexomics approach. The most recent 
pathway for complex I assembly utilised chloramphenicol to inhibit mitochondrial translation and remove complex 
I from mitochondria. Upon removal of the inhibitor complex I biosynthesis resumed and time points up to 24 hours 
were assessed by complexomics to track the assembly of the enzyme. The identities of different intermediates are 
shown with their calculated masses. Subunits are coloured by their structural module: N-domain in orange, Q-
domain in yellow, P-P in green and P-D in blue. Assembly factors are shown in purple. All 17 assembly factors 
detailed in Table 3.1 were observed and 13 were found associated with complex I subcomplexes. Figure from 
Guerrero-Castillo et al., 2017. 
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3.1.2. Flavin insertion into the NDUFV1 subunit of complex I 
 
Figure 3.2 shows that understanding of complex I assembly is becoming increasingly detailed, 
especially with the assignment of assembly factors to particular steps. To catalyse NADH oxidation and 
quinone reduction the enzyme requires a series of cofactors: FMN and a chain of iron sulphur clusters 
for electron transport. NUBPL has been assigned as an iron sulphur cluster assembly factor: knockdown 
caused both accumulation of membrane domain subcomplexes and a decrease in the amount of iron 
associated with complex I (Sheftel et al., 2009). Despite this, no assembly factor has been found for 
incorporation of FMN into NDUFV1. An assembly factor may be required as the flavination of the 
complex II subunit SDHA requires a designated chaperone, SDHAF2, first identified in yeast (Hao et 
al., 2009). However, FAD is covalently bound to SDHA whereas in NDUFV1 FMN is non-covalently 
bound, which may dictate the insertion method (Starbird et al., 2015). NDUFV1 is assembled onto the 
growing enzyme in the very late stages, as part of the N-domain (orange in Figure 3.2). However, it is 
not known whether the full enzyme would still assemble without FMN bound to NDUFV1 and how 
overall stability would be affected, therefore this remains an aspect of assembly that has yet to be 
explored.  
 
3.1.3. Cellular flavin cofactor synthesis 
 
The cofactors FAD and FMN are derived from riboflavin, vitamin B2, which must be obtained by 
dietary uptake. Riboflavin is absorbed from the small intestine, passed into the blood stream and 
accumulated by cells; each stage requires a specialised transporter to facilitate movement across cell 
membranes (Yonezawa et al., 2008). This pathway, although crucial for providing the cofactor required 
by many proteins, is only partially defined. Cytosolic riboflavin kinase (RFK) has been characterised; 
it phosphorylates riboflavin using ATP to form FMN (Karthikeyan et al., 2003). Mitochondrial 
localisation of RFK has also been suggested, however there is currently no experimental evidence to 
substantiate this (Barile et al., 2000). FAD synthase (FADS) then converts FMN to FAD. Importantly, 
FADS was known to be present in the cytoplasm but more recently a human isoform has been located 
in mitochondria (FADS1) by Barile and co-workers; it differs from the cytoplasmic isoform (FADS2) 
by an additional, predicted, 97 amino acid mitochondrial target sequence. Additionally, FADS1 was 
shown to be imported by rat liver mitochondria and fluorescent labelling in mammalian cells also 
supported its mitochondrial localisation (Torchetti et al., 2010).  
 
The plasma membrane riboflavin transporter, SLC52, was identified after the clinical observation that 
some complex I disorders were effectively treated by dietary riboflavin supplementation and mutations 
were mapped to a transporter family (Chiong et al., 2007; Yonezawa et al., 2008). The three members 
of the SLC52 gene family: SLC52A1, A2 and A3 display differing tissue expression; it is suggested that 
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while A2 is highly expressed in the brain, A1 and A3 coordinate riboflavin uptake from the small 
intestine lumen into the blood, and also cellular uptake of the vitamin (Yonezawa et al., 2013). 
 
Many flavoproteins reside within organelles, including complex I in mitochondria, and so there must be 
transport of flavins across the IMM. FLX1 has been assigned the flavin carrier protein in yeast; it was 
discovered through complementation of respiratory deficient Saccharomyces cerevisiae strains 
(Tzagoloff et al., 1996). A human orthologue for FLX1 was found to rescue growth of a S. cerevisiae 
FLX1 mutant, which suggested that this protein, SLC25A32, was the mitochondrial FAD transporter 
(Spaan et al., 2005). However, this protein was previously characterised as a folate transporter 
(SLC25A32) since growth rescue of a glycine auxotrophic Chinese hamster ovary cell line when 
transfected with SLC25A32 increased mitochondrial folate levels (Titus et al., 2000). It may be possible 
that due to structural similarities of flavin and folate head groups, both pteridine ring-derived, substrate 
promiscuity could allow the transport of multiple substrates by a single protein (Spaan et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Schematic diagram of the proposed riboflavin pathway. Using evidence from previous research a 
putative riboflavin uptake and processing pathway was constructed: vitamin B2 is first transported into the cell 
(mint) across the plasma membrane by SLC52A1/A3 (blue), where it is converted into FMN by RFK (green) in 
the cytosol. FADS2 (yellow) converts FMN into FAD in the cytosol. The putative riboflavin transporter 
SLC25A32 (purple) carries FMN into the mitochondrial matrix (cream) across the IMM. FMN is then converted 
into FAD by FADS1 (orange) or inserted into NDUFV1 subunit of complex I (magenta). 
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Current knowledge of flavin processing within the cell is summarised in Figure 3.3. Here, to investigate 
FMN incorporation into complex I three gene candidates were chosen – RFK for its role in FMN 
production and SLC25A32 for its proposed mitochondrial flavin uptake. Additionally, since this project 
was started, riboflavin responsive mutations in SLC25A32 have been reported that further suggest its 
role in mitochondrial FAD transport (Hellebrekers et al., 2017). However due to lack of an enzyme 
producing FMN in the mitochondria it is likely that a transporter is at least required for FMN transport, 
as FADS1 is present to generate FAD in the matrix. FADS1 was also selected due to a possible indirect 
effect on complex I assembly - the assembly factors ACAD9 and FOXRED1 require FAD - therefore it 
may provide further insight into assembly of the enzyme.  
3.2. Aims  
 
The aims of work in this chapter were to investigate how FMN is incorporated into complex I, 
specifically to: 
• Identify subcomplexes and assembly factors concerned with FMN insertion into NDUFV1. 
• Understand the direct effects of depleting FMN on the activity and assembly of complex I. 
• Further characterise the upstream pathway: particularly mitochondrial riboflavin uptake and 
modification into flavin cofactors. 
• Investigate the cellular and mitochondrial effects of riboflavin depletion. 
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3.3. The importance of riboflavin in the growth medium and impact on cell line 
investigations 
 
3.3.1. Initial protein knockdown experiments with siRNA 
 
To restrict FMN incorporation into complex I three proteins of the riboflavin-processing pathway were 
targeted. RFK represents one of the best-characterised enzymes and the mitochondrial isoform of FADS 
was also selected, FADS1, because several complex I assembly factors require FAD cofactors. The 
mitochondrial transporter SLC25A32, which has a putative folate transporting function, was also chosen 
as it has been linked with flavin transport. This area of the pathway still lacks understanding; therefore 
studying the transporter may increase our functional understanding through comparison with the RFK 
and FADS1 knockdown effects.  
 
For each gene three siRNA oligonucleotides were designed for knockdowns in 143B CyWT cells 
(Chapter 2, Table 2.1). Transfection was undertaken as described (Chapter 2, section 2.3.1) and after a 
72-hour incubation with 50 nM siRNA, the level of protein expressed was determined using Western 
Blotting. Transfection resulted in some cell death, however the surviving 143Bs grew well and achieved 
sufficient cell density for OCR analysis. The effect on 143B mitochondrial respiration was then analysed 
with a stress test, using a XF96 extracellular flux analyser (Seahorse Biosciences), described in Chapter 
2, section 2.6.1. Western Blot analysis demonstrated that, for all three genes, siRNA treatments lowered 
relative expression of the target protein, notably siRNA-1 for SLC25A32, siRNA-1 and -2 for RFK and 
siRNA-1 for FADS1 at 50 nM (Figures 3.1, 3.2 and 3.3).  
 
Despite efficient siRNA knockdown of all three proteins (Figures 3.4A, 3.5A and 3.6A) none of the 
143Bs displayed a respiratory phenotype when compared to transfection agent-treated 143B controls (B 
in the respective figures). 
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Figure 3.4.A Efficiency of RFK siRNA knockdown assessed by Western Blot. 20 μg cell lysate samples from 
siRNA transfected cells and non-transfected 143Bs were blotted for RFK (17.6 kDa, antibody from Proteintech) 
to determine the level of knockdown (duplicate wells). Two controls were used, non-treated 143B lysate (WT) 
along with Lipofectamine™and Opti-MEM treated 143B lysate (control), to account for effects caused by 
transfection reagent treatment. The membrane was also blotted for VDAC1 (37 kDa, antibody from Abnova), 
demonstrating slight differences in loading. B. Seahorse extracellular flux data comparing the OCR of control 
143Bs to each knockdown. Cells were seeded at 30,000 cells/well on the morning of the assay to minimise the 
time that transfected cells were incubated in siRNA-free medium. 143B cells treated with Opti-MEM and 
Lipofectamine™ 2000 were used as the control (blue diamonds). 16 wells of each condition were assayed and the 
experiment repeated thrice (mean results for one representative assay shown, with error bars denoting standard 
error) with siRNA-1 in orange, siRNA-2 yellow, siRNA-3 red.   
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Figure 3.5A. Efficiency of SLC25A32 siRNA knockdown assessed by Western Blot. 20 μg cell lysate samples 
from transfected cells and non-transfected 143Bs were blotted for SLC25A32 (35.4 kDa, antibody from Abcam) 
to determine the level of knockdown with each siRNA. Two controls were used, non-treated 143B lysate (WT) 
along with Lipofectamine™and Opti-MEM treated 143B lysate (control), which was treated with the same 
volumes of Opti-MEM and Lipofectamine™ 2000 used to transfected the siRNAs. To ensure loading was 
consistent the membrane was also blotted for Drp1 (75 kDa, Abnova), demonstrating even loading.  B. Seahorse 
extracellular flux data comparing the OCR of control 143Bs to each knockdown. Cells were seeded at 30,000 
cells/well on the morning of the assay to reduce the time that transfected cells were incubated in siRNA-free 
medium. 143B cells treated with Opti-MEM and Lipofectamine™ 2000 were used as the control (blue). 16 wells 
of each condition were assayed and the experiment repeated thrice (mean results for one representative assay 
shown, with error bars denoting standard error) with siRNA-1 in orange, siRNA-2 yellow, siRNA-3 red.   
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Figure 3.6A. Efficiency of FADS1 siRNA knockdown assessed by Western Blot. 10 μg cell lysate samples 
from transfected cells and non-transfected 143Bs were blotted for FADS1 (65.3 kDa, antibody from Aviva 
Systems Biology) to determine the level of knockdown with each siRNA (duplicate wells). Two controls were 
used, non-treated 143B lysate (WT) along with Lipofectamine™and Opti-MEM treated 143B lysate (control), to 
account for effects caused by transfection reagent treatment VDAC1 (37 kDa) was used as a loading control, 
demonstrating even loading except for one duplicate.  B. Seahorse extracellular flux data comparing the OCR 
of control 143Bs to each knockdown. Cells were seeded at 30,000/well on the morning of the assay to reduce 
the time that transfected cells were incubated in siRNA-free medium. Control cells (blue) were assayed, with 16 
wells of each condition and the experiment was repeated thrice (mean results for one representative assay shown, 
with error bars denoting standard error). siRNA-1 in orange, siRNA-2 yellow, siRNA-3 red.  
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Two bands observed around the expected molecular weight for RFK displayed similar knockdown 
levels; these may reflect different isoforms indicated in the Ensembl database (Zerbino et al., 2018). 
Although knockdown was effective there was no meaningful change in OCR for SLC25A32 or RFK 
compared to a non-transfected lipofectamine control (Figure 3.4, 3.5B). The results suggested that cells 
maintained FMN insertion into complex I and there was catalytic activity even when the abundance of 
RFK was diminished. The same observation was made for SLC25A32. It should be noted that some 
siRNA treatments (siRNA-3, red, in Figures 3.4B and 3.5B) resulted in OCRs above the control – this 
variability, despite similar knockdown levels with the three siRNA for RFK and SLC25A32, also 
undermined the reliability of this data. Nevertheless, the control data were not consistently higher than 
the knockdowns. For FADS1 the level of knockdown varied; siRNA-3 showed little change in protein 
expression whereas siRNA-1 resulted in almost complete knockdown, Figure, 3.6A. Unfortunately all 
available antibodies targeted all isoforms and so, whilst the siRNA sequences chosen were specific to 
FADS1, blotting showed the levels of both FADS isoforms. Measurement of OCR showed decreased 
basal respiration of all knockdown cells and some correlation with the observed level of knockdown; 
siRNA-3 showed least effect whereas siRNA-1 and -2  (Figure 3.6B) resulted in basal rate decrease of 
~25% compared to the control. However, in replicate experiments, the difference between knockdown 
and control base rates was variable, with increased error and weaker correlation with protein abundance.  
 
To further investigate the possibility of an effect, a dual knockdown was tested; either siRNA-1 or the 
siRNA-2 oligonucleotides for both RFK and FADS1 were co-transfected at 100 nM, to increase the 
knockdown efficiency. The levels of knockdowns achieved are shown in Figure 3.7A and indicate that 
co-transfection decreased expression of both RFK and FADS1. However, there was still no decrease in 
OCR in the double knockdown; as noted previously some experiments even showed a higher basal OCR 
for knockdowns (siRNA-1 combination, green, in Figure 3.7B). 
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Figure 3.7A Western Blot to assess the efficiency of the dual RFK and FADS1 siRNA knockdowns at 100 
nM. 10 μg cell lysate samples from transfected cells and non-transfected 143Bs were blotted for FADS1 (65.3 
kDa) and RFK (16.4 kDa) to determine the level of knockdown with combinations of siRNA-1 for RFK and 
FADS1 or siRNA-2 for RFK and FADS1 (duplicate wells). To ensure loading was consistent the membrane was 
also blotted for VDAC1 (37 kDa), demonstrating slightly higher loading of control and WT samples. B. Seahorse 
extracellular flux data comparing the OCR of control 143Bs to each knockdown. Cells were seeded at 
30,000/ml on the morning of the assay to reduce the time that transfected cells were incubated in siRNA-free 
medium. 24 wells of each condition were assayed and the experiment was repeated thrice (mean results for one 
representative assay shown, with error bars denoting standard error) with control cells (blue), siRNA combination 
1 (green) and siRNA combination 2 (purple).  
 
 
 
Lack of respiratory phenotype for all three protein knockdowns suggested that, while protein expression 
was lowered, the amount of FMN produced was still sufficient for normal incorporation into complex 
I. Therefore, from these preliminary assays alone it was not possible to confirm the roles of these 
proteins in riboflavin handling or gain further understanding of FMN incorporation into complex I.  
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3.3.2. Targeting riboflavin uptake to decrease cytosolic riboflavin  
 
The lack of a distinct phenotype across all knockdowns suggested that the riboflavin content of the 
growth medium (DMEM) was compensating for any restriction in the processing ability of the cells. 
Standard DMEM contains 1 μM riboflavin (data from supplier) and 10% FBS contributed an additional 
0.77 nM (Said et al., 1998). Therefore a number of approaches were tested to lower the availability of 
riboflavin and limit the cellular supply for flavin cofactor synthesis.  
 
3.3.2.1. Uptake inhibition with lumiflavine  
 
Members of the plasma membrane riboflavin transporter family, SLC52, have been characterised and 
their expression investigated (Yonezawa et al., 2008; Yoshiaki et al., 2010). SLC52A1 and A3 have 
been implicated in riboflavin absorption and cellular uptake, however which transporter is expressed in 
different tissues remains ambiguous (Yonezawa et al., 2013). Thus, rather than targeting individual 
transporter types with siRNA, an inhibitor was chosen to decrease overall riboflavin uptake. Lumiflavine 
is a riboflavin analogue that competes for the substrate-binding site and has previously been used for 
direct uptake assays. In published experiments, lumiflavine was used for short-term incubation and no 
investigation was made of the downstream consequence of diminished cytosolic riboflavin. Ma and co-
workers measured radiolabelled riboflavin uptake in ARPE-19 cells, with addition of structural 
analogues and related compounds to determine the specificity of uptake (Said et al., 2005). 1 μM 
lumiflavine decreased uptake of 40 nM 3H-riboflavin by ~50%, increasing in a concentration dependent 
manner - at 10 μM uptake was lowered to ~3%. Additionally, Said et al measured the concentration 
dependent inhibition of 5 nM 3H-riboflavin uptake by HepG2 cells and calculated an inhibition constant 
(Ki) of 1.84 μM after a 3-minute incubation (Said et al., 1998). Although this work and other uptake 
studies involved low extracellular riboflavin concentrations it suggested that lumiflavine could be used 
to inhibit riboflavin uptake. Consequently 1 μM, 5 μM and 10 μM lumiflavine additions to standard 
DMEM (containing 1 μM riboflavin) were used and cells incubated for 72 hours before the OCRs were 
measured. 
 
There was no significant difference in respiratory profile for the cells incubated in lumiflavine observed 
when compared to control cells, Figure 3.8. Treatment with 20 μM lumiflavine also showed no change. 
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Figure 3.8 Seahorse extracellular flux data comparing the OCR of control 143Bs to the OCR of 143Bs 
treated with lumiflavine. Cells were seeded at 11,500/well the day before the assay and 24 wells of each condition 
were assayed, with the experiment repeated twice (mean results for one representative assay shown, with error 
bars denoting standard error). Control cell data is shown in blue, 1 μM lumiflavine-treated in light green, 5 μM 
lumiflavine-treated in bright green and 10 μM lumiflavine-treated in dark green. 
 
 
3.3.2.2. Decreasing FBS content in the growth medium to lower riboflavin availability  
 
Riboflavin deficiency has been studied in cultured cells, predominantly by Zempleni and co-workers, 
with concentrations based upon earlier work on human plasma riboflavin concentrations. 532 nM 
riboflavin was a sufficient concentration whereas 3.1 nM reflected riboflavin deficiency (Werner et al., 
2005). Notably after pre-treatment of HepG2 cells (5 weeks on 12.6 nM riboflavin) lowering riboflavin 
concentration to 3.1 nM induced cell cycle arrest, >90% decrease in flavin-dependent enzyme activity 
(measured by glutathione reductase) and <20% expression of RFK and FADS1 mRNA after 4 days 
(Werner et al., 2005). In light of this work, 143B cells were grown in riboflavin-free DMEM, 
supplemented with different volumes of standard DMEM, to control the riboflavin concentration. After 
at least 72 hours in 500 nM, 200 nM or 10 nM riboflavin-containing medium the OCR was measured 
and compared to that from 143Bs grown in 1 μM riboflavin. There was no observable morphology 
change or difference in growth rate and no significant difference in respiration rates (data not shown). 
Therefore, the concentration of riboflavin was further depleted to 4.77 nM (0.77 nM contributed by 10% 
FBS supplementation) for another 72 hours; again there was no observable change in OCR (Figure 3.9).  
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Figure 3.9 Seahorse extracellular flux data comparing the OCR of control 143Bs cells grown in riboflavin 
depleted medium. Cells were seeded at 11,500/well the day before the assay and 48 wells of each condition were 
assayed with the experiment repeated twice (mean results of one representative assay shown with error bars 
denoting standard error). Control cell data are shown in blue and data for cells incubated in 4.77 nM riboflavin in 
orange.  
 
 
Further depletion of extracellular riboflavin (4.77 nM, 3.77 nM, 2.77 nM, 1.77 nM and 0.77 nM 
riboflavin containing DMEM) for 1 week also matched the phenotype of 1 μM riboflavin-grown cells. 
Increasing the incubation time to 9 days also showed comparable OCRs to the 1 μM riboflavin-grown 
cells (data not shown). These results indicate the importance of the extended low riboflavin pre-
treatment stage adopted by Zempleni and co-workers. 
 
3.3.3. Extended depletion of riboflavin is necessary to promote a phenotype  
 
Cells were continually cultured in 0.77 nM riboflavin (riboflavin free DMEM + 10% FBS) for one 
month, to limit the cellular supply of riboflavin but maintained the cells in a relatively stress free state 
as there were no observable phenotypic changes. These cells are referred to as ‘conditioned’ cells and 
were used as the basis for preparing samples for improved investigation into changes in FMN 
incorporation into complex I. 
 
First, the use of synthetic, riboflavin free serum was tested by progressively introducing it to replace 
FBS. However, complete replacement with synthetic serum was not tolerated by 143B cells so could 
not be used to decrease riboflavin availability. 
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Second, conditioned 143Bs were treated with 50 μM lumiflavine for 3 days, but despite initial growth 
they failed to adhere when seeded in 96 well plates for OCR analysis; therefore reliable respiratory 
measurements could not be obtained. The concentration of lumiflavine was thus decreased to 35 μM but 
again the cells responded poorly. 20 μM lumiflavine treatment with a 7 day incubation resulted in good 
growth of cells with a distinct morphology, and a significant change in OCR. However, these cells were 
not viable beyond one week. 
 
3.3.3.1. Riboflavin-free DMEM with decreased FBS additions 
 
Supplementation of riboflavin-free DMEM with 10% FBS contributed only 0.77 nM riboflavin yet no 
phenotype was observed. Therefore lowering FBS addition further was used to decrease riboflavin levels 
and a series of different FBS levels were tested on conditioned cells (for at least one week). After 8 days 
those grown in 2% FBS-containing riboflavin-deficient DMEM (0.15 nM riboflavin from FBS) were 
assayed. A significant decrease in basal respiration rate was observed for 0.15 nM riboflavin-grown 
cells, by over 50%, although no change was observed regarding FCCP-induced respiration or non-
mitochondrial, rotenone insensitive respiration (data not shown).  
 
To ensure this effect was due to the low concentration of riboflavin, rather than a decrease in growth-
promoting factors present in FBS, a further control was included, 1 μM riboflavin-containing medium 
+2% FBS (light blue Figure 3.10 and 3.11). After 5 days in 0.15 nM riboflavin or 1 μM riboflavin +2% 
FBS the OCRs were measured alongside 143B cells grown in 1 μM riboflavin +10% FBS. Figure 3.11 
confirms that the lower basal OCR measured in 0.15 nM riboflavin-grown cells was due to the further 
lowering of extracellular riboflavin concentration; both controls showed a comparable respiration 
profile whereas the 0.15 nM cells displayed a ~20% decrease in basal OCR in this example. Figure 3.10 
demonstrates that a shift in metabolism occurred; 0.15 nM riboflavin-grown cells displayed increased 
basal ECAR but lowered OCR, suggestive of a glycolytic phenotype. The difference in basal OCR was 
less distinct than after 8 days of treatment, suggesting a progressive nature to the phenotype, which was 
then investigated further. 
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Figure 3.10 Seahorse extracellular flux data comparing the basal OCR and ECAR of control 143Bs to OCR 
of cells grown in riboflavin-depleted medium. After passaging for 4 days cells were seeded at 11,500/well the 
day before the assay. 40 wells of 0.15 nM riboflavin-grown cells (pink) and 1 μM riboflavin +2% FBS cells (light 
blue) were assayed along with 12 wells of 1 μM riboflavin +10% FBS treated cells (dark blue). Mean basal OCR 
is presented as positive values whereas mean ECAR on the same axis has negative values (with standard error) to 
show the relative split between oxidative phosphorylation and glycolytic pathways between the different cells. 
Data from one representative assay are shown. 
 
 
 
 
 
Figure 3.11 Seahorse extracellular flux data comparing the OCR of control 143Bs to OCR of cells grown in 
riboflavin-depleted medium. After passaging for 4 days cells were seeded at 11,500/well the day before the 
assay, 40 wells of 0.15 nM riboflavin-grown cells (pink) and 1 μM riboflavin +2% FBS (light blue) were assayed 
along with 12 wells of 1 μM riboflavin +10% FBS treated cells (dark blue). Error bars denote standard error and 
asterisks show that the basal OCR of riboflavin deficient cells was significantly different from both control cell 
samples (which were not significantly different to one another), calculated using unpaired student t-tests, P <0.05. 
Data from one representative assay are shown. 
* * * * *
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143B cells cultured in 0.15 nM riboflavin for >5 days developed a distinct morphology: they shifted 
from their usual epithelial-like morphology to more spindle-like, almost fibroblast morphology (Figure 
3.12); consistent with the change in OCR shown in Figure 3.11. This change was monitored using 
Incucyte software for 160 hours to compare the growth rate and physical characteristics with 1 μM 
riboflavin-grown cells supplemented with either 10% or 2% FBS. Figure 3.13 shows the growth curves 
of each sample, with cells grown in 1 μM riboflavin-containing DMEM +10% FBS reaching ~100% 
confluence after 100 hours (dark blue). Cells cultured in lower FBS (+2%) but 1 μM riboflavin-
containing DMEM displayed slower growth with a longer lag phase, however after ~148 hours 
confluence was achieved (light blue). In contrast, the 0.15 nM riboflavin-grown cells did not proliferate 
above ~70% confluence and growth plateaued after 100 hours (pink). The erratic nature of the final data 
points is a result of increased cell death (rounded-ended arrow in Figure 3.14K), which interfered with 
the density calculation, highlighted in the images of Figure 3.14K and L. 
 
 
 
 
 
 
Figure 3.12 143Bs grown in 0.15 nM riboflavin display a distinct morphology from cells grown in 1 μM 
riboflavin. Cells were seeded at 25,000/well with 2.5 ml of appropriate medium and incubated at 37ºC for 160 
hours. A. Incucyte software was used to record the change in growth: control 143B cells grown in standard DMEM 
showed normal epithelial-like morphology, ~100 μm in diameter. B. Conditioned 143Bs grown in 0.15 nM 
riboflavin demonstrated a change in cell shape, becoming elongated with a cell length ~300 μm.  
 
 
Figure 3.13 Growth profile of cells grown under different riboflavin concentrations. Cells were seeded at 
25,000/well with 2.5 ml of appropriate medium and incubated at 37 ºC for 160 hours. Incucyte software was used 
to record the change in growth, with images obtained every 2 hours and percentage confluence calculated with 
standard error. Two controls were used: 1 μM riboflavin +10% FBS in dark blue and 1 μM riboflavin +2% FBS 
in light blue to compare with the growth and morphology of 0.15 nM riboflavin-grown cells (pink). Data from one 
representative assay are shown. 
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Figure 3.14 shows the morphology of the two controls (1 μM riboflavin +10% FBS or 2% FBS) were 
similar, although the +2% FBS cells showed slower growth and some cell elongation (arrows) when cell 
density was low (Figure 3.11E and F). Figure 3.14I-L demonstrates the distinct morphology of cell 
grown in 0.15 nM riboflavin; cells were elongated (arrows) and a high proportion underwent cell death 
(round-ended arrow) – with a mesh-like cell network compared to the tight packing of the control cells. 
This supports the OCR data that suggested the phenotype observed was progressive; cells either adapted 
to the greatly depleted riboflavin concentrations with altered basal respiration rate, or died. Additionally, 
this experiment highlighted that reducing cellular riboflavin by depleting riboflavin in the medium had 
a widespread effect on cell growth and morphology: alterations caused by general riboflavin deficiency 
were not limited to complex I alone. 
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Figure 3.14 Time interval cell 
growth images to compare riboflavin 
depleted cells. Cells were seeded at 
25,000/well with 2.5 ml of appropriate 
medium and incubated at 37 ºC for 160 
hours. Incucyte software was used to 
image the wells in 16 segments every 2 
hours.  
Images A-D (navy blue box) show 
control cells grown in 1 μM riboflavin 
+10% FBS at 28, 76, 128 and 160 
hours.  
E-H (bright blue box) depict the 1 μM 
riboflavin +2% FBS grown controls at 
28, 76, 128 and 160 hours respectively.  
Morphology and growth of 0.15 nM 
riboflavin-treated cells are shown by 
images I-L (pink box) at 28, 76, 128 
and 160 hours. Arrows indicate 
elongated cells and a large group of 
dead cells in K are denoted by a round-
ended arrow. 
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3.4. Differences in the mitochondrial proteome observed in riboflavin-restricted cells 
 
SILAC was used to assess the changes in mitochondrial proteins between 143Bs grown in riboflavin-
free DMEM + 2% FBS (0.15 nM riboflavin) and 143Bs grown in standard DMEM + 10% FBS. The 
experiment was carried out at two time points, informed by the OCR data collected previously – 5 days 
and 13 days in riboflavin-restricted media. Due to lack of availability of riboflavin-free SILAC media 
(to allow addition of heavy labelled arginine and lysine), see Chapter 2, section 2.7.1, only a single 
labelling orientation was possible. Although this data must be interpreted with caution - due to lack of 
repeats - it was informative, showing changes in a specific group of complex I subunits and a decrease 
in many mitoflavoproteins. SILAC data for riboflavin-deficient 143Bs after 5 days demonstrated lower 
protein coverage with ratios obtained for 1850 proteins compared to 2289 in the 13-day condition 
(Appendix 7.1). Complex I subunit coverage also varied: <50% were detected in the shorter treatment 
whereas ratios for 73% were measured in the longer incubation.    
 
Figure 3.15 shows a similar spread of data points in both data sets: most proteins were unchanged in 
abundance, centring on Log2 (fold change) = 0 (one-fold/no change), tailing-off to proteins with lower 
abundance in the riboflavin-depleted condition (positive H/L ratio) or increased levels in riboflavin-
depletion (negative H/L ratio). There is some indication that the change in protein abundance was 
progressive, due to an increased number of proteins with higher or lower abundance after 13 days of 
riboflavin depletion compared to 5 days.  
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Figure 3.15 Single labelling orientation SILAC data for 143Bs grown in riboflavin-free DMEM + 2% FBS 
for 5 or 13 days. Data is displayed as Log2 H/L ratio where positive H/L ratios represent proteins with higher 
abundance in the 143B control compared to the riboflavin-deficient condition. A. SILAC data for 5-day riboflavin-
deficient incubation. B. SILAC data for 13-day riboflavin-deficient incubation. Complex I subunits are coloured 
dark blue and mitoflavoproteins shown in orange. From these two groups proteins with a greater than two-fold 
decrease in abundance in the riboflavin-deficient cells are labelled. Intensity refers to the total protein peak 
intensity (heavy and light labelled).  
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SILAC data presented in Figure 3.15 indicates growing 143B cells in 0.15 nM riboflavin-containing 
DMEM for short periods causes a change in protein abundance, with a particular subset of complex I 
subunits and mitoflavoproteins being decreased under these conditions. 20/45 complex I subunits were 
detected in the 5-day treatment and 32/45 in the 13-day treatment, and while most remained unchanged 
in abundance NDUFA7, NDUFS1, NDUFS6, NDUFV1 and NDUFV2 were the most changed subunits 
in each sample. These demonstrated above a two-fold decrease in abundance (NDUFA7 was just below 
this threshold in the 13-day treatment) and indicates that a subset of complex I subunits are detrimentally 
affected by the lack of flavin. Figure 3.16 shows the location of these subunits on the human model of 
complex I (generated as described in Chapter 6, section 6.6.) - highlighting that these proteins are 
structurally related. NDUFV1 is the flavin containing subunit and along with NDUFV2, NDUFS1 and 
NDUFS6 forms the NADH-binding (N-) domain, with four additional subunits. NDUFA7 is part of the 
Q-domain and sits just below the subunits of the N-domain. Therefore SILAC data suggest that subunits 
proximal to the bound cofactor FMN have lowered abundance when riboflavin is depleted and may 
indicate lowered stability of this region of the enzyme. However the SILAC only measures the overall 
abundance change and so the proportion incorporated into the overall enzyme cannot be determined. 
 
 
 
Figure 3.16 Structural location of subunits showing a greater than two-fold decrease in abundance after 
riboflavin deletion to 0.15 nM in 143B cells. The human model of complex I (Chapter 6, section 6.6) is shown 
in wheat with the five subunits NDUFA7 NDUFS1, NDUFS6, NDUFV1 and NDUFV2 are coloured in red – 
showing their position at the top of the hydrophilic arm surrounding the bound flavin factor FMN. Subunits that 
were not detected in either SILAC experiment are shown in grey. 
 
Additionally 13 mitochondrial flavoproteins were detected in the 5-day treatment and 16 in the 13-day 
treatment sample, but only a small proportion of these were considerably changed in abundance (seven 
in the 5-day treatment and eight in the 13-day treatment - including NDUFV1). Figure 3.16 highlights 
these proteins and comparison between the two treatment durations shows the same subset was affected. 
Notably these include the FAD-containing subunit of complex II (SDHA), which suggests further 
disruption to the respiratory chain and may contribute to the altered OCR observed in low riboflavin 
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conditions, Figure 3.11. The two mitoflavoproteins showing the greatest decrease were 
dihydrolipoamide dehydrogenase (DLD) and sulphide:quinone oxidoreductase (SQRDL), which were 
more than five-fold less abundant in cells grown in 0.15 nM riboflavin compared to riboflavin-rich 
conditions. DLD is an E3 component of dehydrogenase complexes and reduces NAD+ and SQRDL is 
involved in sulphur metabolism and reduces ubiquinone. Therefore they both influence the redox status 
of reducing equivalents within the mitochondria and so alterations in the abundance of these proteins 
may indicate wider affects on mitochondrial function. Despite these cells experiencing a high level of 
stress and not remaining viable for an extended period these data suggest that restricting riboflavin 
availability affects complex I and has wider effects on the mitochondria. This was then followed up in 
more detail with experiments undertaken on the conditioned RFK knockdown 143Bs (section 3.6.). 
 
3.5. Learning outcomes and experimental development 
 
From this work different approaches to limiting riboflavin availability had varying effects on 143B cells: 
• treatment with lumiflavine on a background of standard growth conditions had no observable 
impact. 
• decreasing riboflavin in the medium by riboflavin deficient DMEM substitution (to generate 
conditioned cells after one month) provided a basis for further treatment resulting in a 
respiratory phenotype: 
o severely lowered FBS supplementation (2%) resulted in a respiratory phenotype at 0.15 
nM riboflavin and no long term viability. 
o lumiflavine treatment of conditioned cells (with 10% FBS) increased cell stress and 
resulted in a low basal OCR, with no long term viability - showing how severe 
riboflavin deficiency impacts cells survival. 
 
These learning outcomes informed the development of future experiments using cultured mammalian 
cell lines. They showed that extracellular riboflavin was highly influential when manipulating flavin 
handling; and therefore ‘conditioned’ cells (grown in riboflavin deficient DMEM + 10% FBS for one 
month) were used in further investigations. Consequently, due to the short-lived and transient nature of 
siRNA treatment it was necessary to find an alternative technique to target protein expression for long 
periods, to allow consistent study of the effects under riboflavin-depleted conditions. Therefore a 
comparable approach was chosen: stable knockdown by shRNA.  
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3.6. Stable knockdown of flavin handling proteins in 143B cells to allow thorough 
investigation of riboflavin depletion 
 
3.6.1. Stable knockdown approach to target cellular flavin processing  
 
The stable knockdown of proteins by shRNA is a widely used tool for manipulation of animal cells. In 
contrast to siRNA-mediated knockdown, shRNA is synthesised by the host cells after delivery by a 
DNA vector, which is introduced by viral transfection. Exogenous RNA oligonucleotides, such as 
siRNA, that are introduced into the cell are degraded, which allows the target mRNA levels to recover 
and protein expression to return to normal. In contrast using shRNA allows the knockdown to be 
maintained and the DNA plasmid encoding the specific shRNA can integrate into the host genome, 
which is achieved by utilising the lentivirus system.  
 
As described in Chapter 2, section 2.3.2. the second-generation lentiviral system was chosen along with 
the pLKO.1-TRC cloning vector (referred to as pLKO.1), for shRNA insertion. This system uses 
separate plasmids for the packaging and envelope proteins (psPAX2 and pMD2.G respectively) required 
to encapsulate the shRNA-encoding vector. This replication incompetent system splits up the 
components that form an infective virus particle and so overcomes the risk of self-replication. Three 
plasmids were transfected into HEK 293T cells using the Fugene® agent. The lentviral particles 
produced were then harvested from the growth medium and used to infect the host 143B cell line with 
the shRNA-containing plasmid. 
 
3.6.1.1. shRNA knockdown of flavin-manipulating enzymes  
 
RFK and SLC25A32 were chosen for stable protein knockdowns in 143Bs, in addition to FADS1 due 
to its role in FAD synthesis from FMN. 
 
pLKO.1 vectors containing each of the shRNAs were purchased from Sigma. Sigma MISSION® 
shRNA bacterial glycerol stocks were used, with two shRNA constructs for each protein. Unfortunately, 
despite successful production of lentiviral particles by HEK293T cells and subsequent infection of 143B 
cells (described in Chapter 2, section 2.3.2.), which yielded puromycin resistant colonies and suggested 
successful introduction of the vector, screening by Western Blot only revealed successful knockdown 
of RFK. The shRNA vector TRCN0000037602 yielded puromycin resistant 143Bs displaying 
significantly decreased RFK expression (RFK KD), validated by quantitative Western Blot to show a 
reduction of approximately 90% (Figure 3.17). 
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Figure 3.17 Riboflavin kinase knockdown by shRNA shown in Western Blot analysis of cell lysates. Five 
days after infection with lentiviral particles a sample of shRNA-expressing 143Bs were harvested and cell lysate 
prepared. 20 μg protein was loaded onto a NuPAGE™ 4-12% Bis-Tris gel for separation by SDS-PAGE. Proteins 
were then transferred onto PVDF membranes and blotted for RFK (expected band at 17.6 kDa, antibody from 
Proteintech) and DRP1 (as a loading control, expected band at 75 kDa, Abnova). Vector expressing 143Bs 
(pLKO.1) demonstrated RFK expression, seen as a double band ~20 kDa, whereas the stable RFK knockdown 
from TRCN0000037602 vector expression showed no observable bands by ECL. This was repeated and then 
quantified by fluorescently coupled antibodies to obtain a knockdown efficiency measurement of 88%.  
 
 
For all future experiments a vector control was used, this was a 143B CyWT line expressing pLKO.1 
that was puromycin resistant, but did not express an shRNA.   
 
Due to the low success rate of the Sigma MISSION® shRNA plasmids a number of shRNA were 
designed, across the whole transcripts for SLC25A32 and FADS1, using the online tool from the 
Whitehead Institute (Yuan et al., 2004). Three shRNA sequences were chosen for each target, which 
were then inserted into the pLKO.1 vector - after optimisation of the cloning technique, as discussed in 
Chapter 2, section 2.3.2. However again there was no observable knockdown in the target protein, 
therefore the RFK KD was the only stable knockdown in 143Bs taken forward for characterisation. 
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3.7. Investigating the phenotype of the stable riboflavin kinase knockdown, using 
conditioned 143Bs 
 
In order to characterise the RFK knockdown, 143B cells expressing the shRNA were gradually 
introduced to riboflavin-free DMEM (containing 1 μg/ml puromycin), alongside the pLKO.1 control. 
Their morphology and growth profile were followed by image capture and cell density tracking using 
Incucyte software, which demonstrated that conditioned RFK knockdown cells did not display altered 
growth rate or cellular morphology and were viable after sustained passaging.  
 
 
 
Figure 3.18 Seahorse extracellular flux data comparing the respiratory profile of stable RFK knockdown 
in 143Bs to a vector expressing control. A. Seahorse extracellular flux data comparing the OCR of control 
pLKO.1 143Bs to the RFK stable knockdown, grown under standard conditions. Cells were seeded at 15,000 well 
the day before the assay. 46 wells of each condition were assayed and the experiment repeated thrice (mean results 
for one representative assay shown, with error bars denoting standard error). B. Corresponding ECAR data for 
143Bs grown in 1 μM riboflavin-containing DMEM. C. Seahorse extracellular flux data comparing the OCR of 
control pLKO.1 143Bs to the RFK stable knockdown, grown in riboflavin-depleted conditions. Cells were seeded 
at 15,000 well the day before the assay. 46 wells of each condition were assayed and the experiment was repeated 
thrice at different time intervals after one month conditioning, to track any respiratory phenotype changes (mean 
results from the earliest assay are shown, with error bars denoting standard error). The respiratory profile was 
representative of that obtained in all repeats. D. Corresponding ECAR data for 143Bs grown in riboflavin-depleted 
conditions. 
 
Standard DMEM (+ 10% FBS)
Riboflavin-free DMEM (+ 10% FBS)
A. B.
C. D.
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RFK knockdown cells grown under standard conditions, with abundant riboflavin, were assessed by a 
stress test to compare the OCR to the control (Figure 3.18A&B). Once conditioned, RFK knockdown 
and control cells were assessed again in the same way (Figure 3.18C&D). The respiratory profile was 
unaffected by RFK knockdown in 143Bs and even with the additional strain of riboflavin depletion the 
OCR was equivalent to the control (Figure 3.18A&C), indicating that OXPHOS capacity was retained 
and RFK knockdown had a low impact on FMN incorporation into complex I. Basal respiration was 
unaffected and addition of oligomycin and FCCP had an equivalent effect to the control; therefore spare 
respiratory capacity was also unchanged. The extracellular acidification rate also demonstrated no 
variation between the RFK knockdown and control cell lines (Figure 3.18B and D). A difference in 
basal ECAR may be an indication of a shift towards a more glycolytic phenotype, and would suggest 
impairment in OXPHOS; however this was not observed, despite additional stress introduced by 
conditioning. 
 
To further probe the impact of RFK knockdown on complex I activity, crude mitochondria were 
prepared and complex I in-gel activity assays undertaken. Figure 3.19 shows the position of monomeric 
complex I from cell lines was equivalent to that of bovine membranes; an additional higher band is often 
observed in cell line samples and may suggest the presence of two complex I populations. A band 
corresponding to complex V was also visible, demonstrating that there was slightly more protein loaded 
for the RFK KD sample compared to the control, which ameliorates the difference in active complex I 
band intensity observed. This suggested that decreased RFK expression did not affect complex I activity 
substantially. 
                       
                        
 
Figure 3.19 BN-PAGE with complex I in-gel activity stain for riboflavin depleted 143B cells. Digitonised 
cells were prepared from conditioned RFK knockdown and pLKO.1 control 143Bs and after DDM solubilisation 
~10 μg was loaded onto a NativePAGE™ 3-12% Bis-Tris gel, along with DDM solubilised bovine mitochondrial 
membranes as a standard. Complex I activity was assessed using the electron acceptor NBT. 0.5 mg/ml NBT and 
100 μM NADH in 20 mM Tris pH 7.4 were added to the gel after washing in cold dH20 to remove excess 
Coomassie stain and retain activity. After 30 minutes incubation the reagent mixture was removed and the gel 
washed in dH20. Complex I was stained purple if flavin activity was present, labelled band. 
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3.8. Complexome analysis of riboflavin kinase knockdown cells under riboflavin 
restricted conditions 
 
 
 
Figure 3.20 Mitochondrial matrix and membrane fractions from 143B CyWT and conditioned RFK KD 
143Bs. Mitochondria were purified from 143B CyWT and RFK KD cells, as described in Chapter 2, section 2.4.2. 
Matrix and membranes were then separated by sonication. Mitochondrial membranes were solubilised in 1.7% 
DDM prior to BN-PAGE. Different amounts of membranes and matrix were loaded to obtain the optimal protein 
loading for analysis by mass spectrometry. Shown above are the two lanes chosen for 143B CyWT (left panel, 
prepared by Dr Hannah Bridges) and RFK KD – containing 10 μg protein (right panel). The Serva Native ladder 
was used to estimate protein masses. Once run the gel was stained with Coomassie before submission for 
complexome analysis - both the mitochondrial membranes and matrix lanes were cut into 64 even slices, direction 
of slice numbering shown.  
 
 
Figure 3.20 displays the mitochondrial membrane and matrix fractions from control 143B CyWT and 
conditioned RFK knockdown 143Bs. The samples were prepared as described in Chapter 2, section 
2.7.2., cut into 64 1mm slices and analysed by mass spectrometry to determine the distribution of 
proteins and possible associations between them. Therefore the complexomes obtained referred to the 
matrix and mitochondrial membrane fractions separately. It was hoped that this would provide a more 
detailed understanding of any aberrations observed. 
 
The 143B CyWT samples were prepared and run previously by Dr Hannah Bridges, with cells cultured 
in standard DMEM + 10% FBS. These data were compared with the conditioned RFK knockdown 
complexomes to ascertain whether knocking down RFK and limiting flavin availability had an 
observable impact on the respiratory complexes. This could then be extended to use a specific riboflavin 
depleted/conditioned 143B control, if sufficient differences were observed. In order to compare the two 
96 
data sets protein mass calibration curves were generated, therefore results are described with relation to 
the estimated mass of the protein/complex from each gel (rather than the slice number). Calibration 
curves for the membrane data sets are shown in Figure 3.21 and proteins used given in Appendix 
7.2A&B. Data for the ETC complexes from both membrane samples is given in Appendix 7.2C&D. 
 
  
 
Figure 3.21 Protein mass calibration curves for membrane fraction complexomes. To allow comparison 
between the two complexome data sets proteins or complexes of known molecular weight were chosen and their 
position in the gel correlated to their mass. More than 20 mitochondrial proteins/complexes from each 
complexome were chosen. Despite being mitochondrial membrane fractions there is known to be some 
contamination with soluble mitochondrial elements and other cellular compartments, therefore these proteins were 
useful for mass calibration, along with mitochondrial transporters and the respiratory complexes themselves. A. 
143B CyWT. B. RFK KD. Protein masses were obtained from the UniProt database (UniProt Consortium T, 2018). 
Table of proteins used in Appendix 7.2A&B. 
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3.8.1. Mitochondrial membrane complexome analyses of conditioned RFK knockdown 
cells 
 
 
 
 
Figure 3.22 Distribution of respiratory complexes across gel slices after BN-PAGE. Solubilised mitochondrial 
membranes were separated by BN-PAGE, to maintain native complexes. Coomassie stain was used before 
submission for complexome analysis - both lanes were cut into 64 even slices. A. 143B Cybrid WT control 
membrane - positions of complex I (dark blue), II (orange) and V (green). B. Conditioned RFK knockdown 143B 
membrane complexome positions of complex I, II and V. C. 143B Cybrid WT control membrane – positions of 
complex III (cyan) and complex IV (purple). D. RFK knockdown 143B membrane complexome – positions of 
complex III and complex IV. Complexes are grouped into different panes for clarity. 
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Figure 3.22 shows the distribution of each respiratory complex across the two membrane samples. Using 
the calibration curves, complex I (calculated mass ~ 1000 kDa) was estimated to migrate at 1249 kDa 
in the control and the highest intensities for the detected subunits spanned two neighbouring slices. 
Comparatively, complex I in the RFK KD membrane sample migrated at approximately 1135 kDa and 
the subunits peaked in one gel slice. 38/45 complex I subunits were detected in 143B CyWT (lacking 
NDUFA2, NDUFB2, NDUFC1, NDUFAB1 (x2), ND4 and ND4L) and 41/45 in RFK KD (lacking 
NDUFA1, NDUFC1, ND3 and ND4L). The core mitochondrially encoded-membrane domain subunits 
are often the most difficult to detect by mass spectrometry due to their hydrophobic nature and low 
number of tryptic peptides. Additionally very small subunits, such as NDUFC1, are also less commonly 
measured. However, there was good coverage of the subunits across both data sets. A shoulder was 
present on the higher molecular weight side of the main complex I peak in each sample that may indicate 
the present of dimerised complex I. In general there were no substantial differences between the complex 
I structure and migration pattern across the two complexomes. 
 
In both complexomes all complex II subunits were detected (SDHA, B, C and D); migrating at 108 kDa 
in the control and 116 kDa in RFK knockdown (calculated mass 130 kDa). Figure 3.22A and B show 
that in both profiles the clustering of the subunits was consistent, with a clean single peak around the 
expected mass. There was no indication of misassembled complex II despite restricted flavin availability 
in the conditioned RFK knockdown. 
  
Of the 11 complex III (cytochrome b-c1 complex) subunits both membrane samples showed good 
coverage (9/11). RFK knockdown complex III migrated to the expected mass of 515 kDa (calculated 
mass of dimer 490 kDa), whereas the control complex was found at 533 kDa. Figure 3.22C and D 
demonstrate that two peaks were observed; in the 143B CyWT sample this second clustering at 795 kDa 
contained eight subunits, all with low relative intensities except subunit 6 (highest intensity peak); 
representing the III2/IV supercomplex (calculated mass 690 kDa); supported by the presence of most 
complex III subunits and some complex IV subunits (including a high intensity of subunit 7A2L). The 
RFK knockdown mirrored this dual peak profile, with the higher mass peak nearer to the expected 
III2/IV mass (estimated mass 799 kDa).  
 
The complexome profile of cytochrome c oxidase (complex IV) was generally consistent between the 
two samples, Figure 3.22C and D. A main peak of subunit intensities was observed for the complex 
(calculated mass 200 kDa) and another higher molecular weight peak coincided with the second peak 
in complex III subunits, supporting the presence of the III2/IV supercomplex. 12 subunits were detected 
in 143B CyWT and 14 subunits present in the RFK knockdown. Both samples showed a high intensity 
peak near the expected monomeric complex mass (calculated 200 kDa: 196 kDa in 143B CyWT and 
214 kDa in RFK knockdown).  
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The final complex of the electron transport chain, ATP synthase, was visible on BN-PAGE after staining 
and is often used as a marker for mitochondrial quality/purity, due to its abundance and consistent 
migration. In both samples 13 subunits were identified, 143B CyWT showed good clustering and a clean 
peak at 795 kDa (calculated mass 770 kDa), shown in Figure 3.22A. The subunit coupling factor 6 was 
found to peak in the slice above the rest of the subunits, at 859 kDa, but peaked with the complex in the 
knockdown. The RFK knockdown sample peaked at 799 kDa and also displayed a clean profile, Figure 
3.18B. In the control sample there was also a noticeable secondary peak, albeit of low subunit intensities, 
at 482 kDa that may indicate a subassembly; this was also present in the RFK knockdown (432 kDa). 
Both samples additionally contained the inhibitory protein IF1, with its peak intensity neighbouring that 
of ATP synthase. This agreement between migration patterns of both subunits and IF1 indicated that 
ATP synthase was unaffected by cellular changes resulting from RFK knockdown and riboflavin 
depletion and was supported by other experiments showing normal respiration by these cells. 
 
Overall, by comparison of the two complexomes, it was found that all respiratory complexes were 
largely unaffected by the knockdown, with small changes likely to be attributed to inherent differences 
in sample preparation or BN-PAGE analyses.  
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3.8.2. Complex I assembly factor migration patterns were unaffected in conditioned RFK 
knockdown cells 
 
 
 
 
Figure 3.23 Clustering of two groups of complex I assembly factor across gel slices after BN-PAGE. A. 143B 
CyWT control membrane complexome showing NDUFAF3 profile in green, NDUFAF4 in blue and TIMMDC1 
in pink. B. Conditioned RFK knockdown 143B membrane complexome - NDUFAF3, NDUFAF4 and 
TIMMDC1. C. 143B Cybrid WT control membrane complexome showing ACAD9 profile in red, NDUFAF1 in 
purple, COA1 in light blue and ECSIT in pink. D. Conditioned RFK knockdown 143B membrane complexome 
- TMEM126B (orange,) ACAD9 (red), NDUFAF1 (purple) and ECSIT (pink). 
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From the complexomes 10 assembly factors were detected in both 143B CyWT and RFK knockdown 
membrane samples. Two main groups were present, demonstrating assembly factors known to cooperate 
in assembling specific complex I subunits. The earliest stage assembly factors are NDUFAF3 and 
NDUFAF4, found bound to the growing Q-domain and thought to facilitate attachment to the PP-a 
subassembly (Figure 3.24, bright green) of the membrane arm, along with TIMMDC1. In Figure 3.23A, 
143B CyWT shows clustering of NDUFAF3 and NDUFAF4 as expected with a peak at 161 kDa, which 
also contains subunits NDUFA5, NDUFS2, NDUFS3, NDUFS7 and NDUFS8 at low intensities. This 
correlates well with an early subcomplex with calculated mass of 170 kDa. However TIMMDC1 does 
not comigrate with its associated assembly factors and is only found at low molecular weights, peaking 
at 36 kDa, suggesting its presence as discreet monomer (32 kDa). In contrast the RFK knockdown 
complexome shows all three assembly factors comigrating and peaking together at 363 kDa, Figure 
3.23B. Along with the presence of subunits NDUFS2, NDUFS3, NDUFS7 and NDUFS8 this indicates 
the presence of the subcomplex comprising the core Q-domain, three assembly factors and ND1 
(calculated mass of 237 kDa). TIMMDC1 was also found at low intensities at its estimated monomeric 
mass. NDUFAF3 and NDUFAF4 were also found in high intensities at a lower molecular mass of 165 
kDa and could be the earliest assembly factor bound Q-domain, with NDUFS2, NDUFS3, NDUFS7 
and NDUFS8 all present in this region. 
 
 
Figure 3.24 Complex I structure coloured by domains. The most recent assembly pathway describes the 
construction of the enzyme split into structural domains: N-domain (orange), Q-domain (yellow), peripheral 
membrane arm (PP greens) and distal membrane arm (PD blues). This is further divided into two subunit collections 
for each membrane arm region: peripheral into PP-a (bright green) and PP-b (dark green), distal into PD-a (pale blue) 
and PD-b (dark blue) due to their assembly into discreet subcomplexes. Naming reflects that of Nijtmans and co-
workers (Guerrero-Castillo et al., 2017). The human model of complex I was constructed using mouse complex I 
cryo-EM structures (Chapter 6, section 6.6).  
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Another group of assembly factors, known to cooperate in the assembly of the membrane arm PP-b 
domain (Figure 3.24, dark green), are ACAD9, ECSIT, NDUFAF1, TMEM126B, TMEM186 and 
COA1. In both complexomes ACAD9, ECSIT, NDUFAF1 were detected, along with COA1 in 143B 
CyWT and TMEM126B in the RFK knockdown. Figure 3.23C shows that in the 143B CyWT data set 
COA1, NDUFAF1, ACAD9 and ECSIT displayed a similar migration but their peak intensities differ 
across 358-533 kDa, with only NDUFAF1 and ACAD9 peaking together. COA1 is also present at high 
intensity at a lower molecular mass (65 kDa), which may be due to its role in cytochrome c oxidase 
assembly. In contrast the RFK knockdown data for these assembly factors shows much clearer 
cooperation, in Figure 3.24D, with highest intensities for all four (TMEM126B present but COA1 not 
detected) across two neighbouring slices at 363-396 kDa, which may indicate the early PP-b subcomplex. 
The remaining assembly factors detected, NDUFAF2, FOXRED1 and TMEM70, displayed different 
migration patterns, which did not correspond well to their proposed functions, therefore no valuable 
interpretation could be made from their profiles; it is possible that the strength of interactions for these 
factors is lower than those displaying a more consistent clustering pattern.  
 
Overall the assembly factors detected in the RFK knockdown membrane complexome displayed a 
consistent pattern with that proposed by Guerrero-Castillo et al., particularly the previously known 
cooperatively of NDUFAF1, ACAD9 and ECSIT and between NDUFAF3 ad NDUFAF4 at the early 
stages of assembly. Despite differences in the profiles across the two samples it can be concluded that 
conditioned RFK knockdown cells did not adversely affect complex I assembly in 143Bs, as many 
assembly factors were detected, most of which displayed migration patterns and associations matching 
those from previously published research.  
 
 
Figure 3.25 Complex I assembly factors present with mature complex I in membrane complexome samples 
slices. More complex I assembly factors were found to be present in the same slice as mature complex I in the 
RFK KD sample (red bars) compared to the 143B CyWT control (blue bars). COA1 was not detected in the RFK 
KD and TMEM126B was not detected in the 143B CyWT. 
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Interestingly assembly factors were found associated with the mature complex in RFK knockdown and 
not in the 143B CyWT. The point at which assembly factors leave the nascent enzyme has long been 
discussed and there is general agreement that on formation of the complete complex, with addition of 
the N-domain, the assembly factors all dissociate releasing the enzyme into a catalytically capable state. 
Yet in RFK KD 8/10 factors are still present, with NDUFAF2 and TMEM126B at a high relative 
intensity, Figure 3.25. It could therefore be hypothesised that the lowered availability of flavin may have 
resulted in disruption of the N-domain assembly – FMN incorporation into NDUFV1 – and as a result 
the assembly factors have not been released from the completed enzyme. Despite this, conditioned RFK 
knockdown cells have shown little differences compared to the control; section 3.7 demonstrated that 
RFK knockdown did not show altered oxygen consumption or responses to drug additions during a 
stress test and in-gel activity assay of complex I was equivalent to the control.  
 
3.8.3. Complex I assembly intermediates were present in conditioned RFK knockdown 
cells 
 
Assembly of complex I involves a series of subcomplexes, that are sequentially built together to form 
the mature, active enzyme. The assembly pathway published by the Nijtmans group describes nine 
named subcomplexes and an additional eight smaller assemblies. The possible subcomplexes found in 
the two complexomes (Tables 3.3, 3.4) were compared to this pathway and their identities inferred from 
subunit composition and estimated mass. 
 
The subassemblies were detected over a range of gel slices, making their identification less definitive 
but from each complexome a number of subassemblies were observed that contained subunits and 
assembly factors consistent with those reported in assembly pathway studies. The complex I profile 
from the 143B CyWT membrane complexome (Figure 3.26A) displayed three possible lower molecular 
weight clusters of subunits. The largest of these (Table 3.1, subcomplex 1: 650-719 kDa) could be a late 
stage assembly intermediate as the subunits found in this region span the entire complex. A small 292-
357 kDa subcomplex had three possible identities as shown in Table 3.1 (subcomplex 2); some subunits 
from each intermediate were present and the total masses were similar: Q/PP-a included assembly factors 
NDUFAF3, NDUFAF4 and TIMMDC1, with PD-a and PD-b suggested by the presence of hydrophobic 
subunits known to associate as discreet intermediates. The smallest subcomplex (subcomplex 3: 161 
kDa) most closely resembles the core Q-domain with NDUFAF3 and NDUFAF4 bound.  
 
 
 
104 
 
 
Figure 3.26 Clustering of complex I subunits at lower molecular weights indicate the present of 
subcomplexes. A. 143B Cybrid WT control membrane complexome showing the lower end of the complexome 
gel, from mature complex I. Subunits that displayed some relative intensity at lower molecular weight are shown 
in blue and possible subcomplexes highlighted. B. Conditioned RFK KD 143B membrane complexome - showing 
the lower end of the complexome gel, from mature complex I, with possible subcomplexes highlighted. 
 
  
Figure 3.26B also displays a number of smaller complex I subunit clusters, indicating the presence of 
assembly intermediates in the RFK knockdown membrane fraction. These are shown in Table 3.2 with 
subunits found in the larger peak of 664-724 kDa spanning most of the complex and include seven 
assembly factors, which may be a mix of PP-b/PD-a (680 kDa) and Q-PP (736 kDa) intermediates. 
Therefore large late stage subcomplexes were observed in both membrane fractions. Subcomplex 2 in 
the RFK knockdown was difficult to assign, with three possible identities due to the proteins present 
(Table 3.2). At its largest this collection could comprise an early PP-b subcomplex (292 kDa) of mostly 
assembly factors or Q/PP-a subcomplex (237 kDa) with NDUFAF3, NDUFAF4 and TIMMDC1 present. 
The other possibilities are less reliable, with fewer subunits present and lower total mass – PD-a (230 
kDa) or PD-b (154 kDa). As in the control, the smallest intermediate (subcomplex 3: 165 kDa) resembles 
the core Q-domain. Despite the lack of definitive assignment the presence of smaller subcomplexes 
mirrors that found in the 143 CyWT control and again strengthens the conclusion that there has been 
little impact on complex I assembly, despite reduced flavin availability.  
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143B CyWT 
 
Structure 
Estimated 
mass (kDa) 
Calculated 
mass (kDa) 
Subunits Assembly Factors 
S
u
b
co
m
p
le
x 
1
 
 
650-719 
680 
NDUFA9, A5, 
S2, S3, S7, S8, 
ND1, A3, A8, 
A13, ND6, 
ND4L, ND3, 
ND2, NDUFC1, 
C2 
NDUFAF2, NDUFAF3, 
NDUFAF4, 
TIMMDC1, 
TMEM126B, 
TMEM186, COA1, 
ACAD9, ECSIT, 
NDUFAF1 
 
736 
ND6, ND4L, 
ND3, ND2, 
NDUFC1, C2, 
A10, S5, B6, 
B5, B10, B11, 
B1, ND4, B4 
TMEM126B, 
TMEM186, COA1, 
ACAD9, ECSIT, 
NDUFAF1, TMEM70, 
FOXRED1, ATP5SL 
S
u
b
co
m
p
le
x 
2
 
 
292-357 
283 
NDUFA5, S2, 
S3, S7, S8, 
ND1, A3, A8, 
A13 
NDUFAF3, NDUFAF4, 
TIMMDC1 
 
230 
NDUFB6, B5, 
B10, B11, B1, 
ND4 
TMEM70, FOXRED1, 
ATP5SL 
 
154 
NDUFAB1, B7, 
B3, B8, ND5, 
B9, B2 
- 
S
u
b
co
m
p
le
x 
3
 
 
161 170 
NDUFA5, S2, 
S3, S7, S8 
NDUFAF3, NDUFAF4 
 
     
Table 3.1 Possible subcomplexes present in 143B CyWT membrane complexomes. Estimated mass and 
subunit composition were used to assign possible identities to each subcomplex, using the most recent detailed 
complex I assembly paper (Guerrero-Castillo et al., 2017). Table shows all subunits and assembly factors expected 
to be present in each subcomplex, those in blue and underlined were present in the slice, black denotes detected 
subunits not present in the slice and those in italics were not detected in the complexome.  
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RFK KD 
 
Structure 
Estimated 
mass (kDa) 
Calculated 
mass (kDa) 
Subunits Assembly Factors 
S
u
b
co
m
p
le
x 
I 
 
732-799 
680 
NDUFA9, 
A5, S2, S3, 
S7, S8, ND1, 
A3, A8, A13, 
ND6, ND4L, 
ND3, ND2, 
NDUFC1, C2 
NDUFAF2, NDUFAF3, 
NDUFAF4, TIMMDC1, 
TMEM126B, TMEM186, 
COA1, ACAD9, ECSIT, 
NDUFAF1 
 
736 
ND6, ND4L, 
ND3, ND2, 
NDUFC1, C2, 
A10, S5, B6, 
B5, B10, B11, 
B1, ND4, B4 
TMEM126B, TMEM186, 
COA1, ACAD9, ECSIT, 
NDUFAF1, TMEM70, 
FOXRED1, ATP5SL 
S
u
b
co
m
p
le
x 
2
 
 
302-330 
292 
ND6, ND4L, 
ND3, ND2, 
NDUFC1, C2 
TMEM126B, TMEM186, 
COA1, ACAD9, ECSIT, 
NDUFAF1 
 
283 
NDUFA5, S2, 
S3, S7, S8, 
ND1, A3, A8, 
A13 
NDUFAF3, NDUFAF4, 
TIMMDC1 
 
230 
NDUFB6, B5, 
B10, B11, B1, 
ND4 
TMEM70, FOXRED1, 
ATP5SL 
S
u
b
co
m
p
le
x 
3
 
 
165 170 
NDUFA5, S2, 
S3, S7, S8 
NDUFAF3, NDUFAF4 
 
Table 3.2 Possible subcomplexes present in the RFK KD membrane complexome. Estimated mass and subunit 
composition were used to assign possible identities to each subcomplex, using the most recent detailed complex I 
assembly paper (Guerrero-Castillo et al., 2017). Table shows all subunits and assembly factors expected to be 
present in each subcomplex, those in blue and underlined were present in the slice, black denotes detected subunits 
not present in the slice and those in italics were not detected in the complexome.  
 
 
107 
Whilst most of the subcomplexes were membrane spanning as expected in membrane fractions the 
presence of Q-domain intermediates was perhaps unexpected. The assembly pathway described by 
Guerrero-Castillo et al. was investigated using solubilised whole mitochondria and so this was not a 
factor in their data. In the complexome data above this could explained by matrix contamination or some 
association of the Q-domain intermediates with the membrane, possibly by the action of the assembly 
factors, to bring this domain nearer to its final point of assembly, on the forming complex in the inner 
mitochondrial membrane. 
 
3.9. Mitochondrial matrix complexome analyses of RFK knockdown cells 
 
The mitochondrial matrix complexomes were assessed for complex I subunits – whether subunits were 
present as free monomers or small soluble assembly intermediates (data for proteins given in Appendix 
7.2F&I). NDUFV1 is an N-domain component, which sits in the matrix, and so changes to flavin 
incorporation may affect N-domain assembly. In the 143B CyWT matrix sample four subunits were 
detected, NDUFV1, NDUFV2, NDUFS1 and NDUFA2 – all part of the N-domain – along with the 
assembly factors NDUFAF5 and NDUFAF2. In the RFK KD matrix complexome these and a further 
six subunits were present (NDUFA5, NDUFA13, NDUFS2, NDUFS3, NDUFS8 and NDUFAB1). All 
except NDUFA13 (which spans the membrane and extends into the hydrophilic domain) and 
NDUFAB1 (with two copies in different locations) are found in the hydrophilic Q-domain of complex 
I.  
 
NDUFA5, NDUFS2, NDUFS3, and NDUFS8 should assemble together as the core Q-domain; yet from 
Figure 3.27 it is clear that the profiles of these subunits demonstrated little cooperation in the RFK 
knockdown. Some subunits, particularly NDUFS2 and NDUFS3 had peaks in intensity at molecular 
weights suggesting multi-protein assemblies, whilst others suggested monomeric protein. However in 
both complexomes the profiles of NDUFV1 and NDUFV2 clustered together at lower molecular 
weights, which may indicate an association between the two subunits –supported by the assembly 
pathway from Guerrero-Castillo et al. However RFK knockdown and 143B CyWT matrix complexome 
samples were found to differ considerably in protein content – this indicated high levels of 
contamination, which is more likely in matrix compared to membrane fractions, and carry over from 
mitochondrial membranes and other cellular components during preparation. Therefore the samples 
were not consistent or homogenous and consequently not compared further. The calibration curve and 
table of proteins used to estimate the mass of proteins in the RFK knockdown matrix sample is given in 
Appendix 7.2G&H. 
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NDUFV1 and NDUFV2 associate from the early stages of assembly; therefore other proteins with a 
similar migration profile might also interact with NDUFV1 and NDUFV2. 19 proteins were found and 
investigated for known function and candidacy as flavin binding/inserting proteins. Of these proteins 14 
were non-mitochondrial and discounted, leaving five possible interactors: PDHX, GRSF1, REXO2, 
OXSM and SDHAF2. GRSF1 and REXO2 are nucleotide-binding enzymes with well-defined roles in 
mitochondrial gene expression. PDHX anchors components of the pyruvate dehydrogenase complex 
and OXSM is an acyltranferase, possibly involved in lipoic acid biosynthesis. None of these protein 
have flavin-binding motifs or chaperone characteristics and so were unlikely to be involved in the 
flavination of NDUFV1. However the complex II assembly factor SDHAF2, also known as PGL2 or 
SDH5, has been characterised as the FAD insertion factor for SDHA and the mutation G78R abolished 
interaction with, and flavin insertion into, SDHA (Hao et al., 2009). The requirement for FAD insertion 
into SDHA by a chaperone would indicate that a similar assembly factor may be required by NDUFV1. 
Additionally a shared assembly factor for two flavin-containing respiratory complexes could provide a 
sensing or regulating point through a single protein – due to the necessity for the flavin factor as the 
point of electron entry in each enzyme.  
Figure 3.27 Clustering of complex I subunits in 
the RFK KD matrix complexome do not 
indicate the presence of soluble subassemblies. 
The 10 complex I subunits detected in the RFK 
KD matrix fraction showed differing profiles. 
Subunits are coloured by structural domain, 
yellow for Q-domain, orange for N-domain and 
green for hydrophobic domain.  
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Figure 3.28 Matrix complexome profiles from RFK KD showing possible association between SDHAF2 and 
flavin containing subunits of complex I and complex II. Mitochondria were purified and matrix and membranes 
separated by sonication and after solubilisation proteins were separated by BN-PAGE, to maintain native 
complexes. A. SDHAF2 clustering with SDHA and SDHB from complex II. SDHAF2 shown in dark blue, SDHA 
in red and SDHB in orange. B. SDHAF2 clustering with NDUFV1 and NDUFV2 from complex I. SDHAF2 shown 
in dark blue, NDUFV1 in pink and NDUFV2 in light blue.  
 
Figure 3.28A and B show the profiles for SDHAF2 overlaid onto the complex I subunits NDUFV1 and 
NDUFV2 or the complex II subunits SDHA and SDHB in the RFK KD matrix sample. The highest 
relative intensity of SDHAF2 corresponded with SDHA, as expected – but it also matches the single 
shared peak of NDUFV1 and NDUFV2 migration. Although an interesting observation, the low 
resolution of proteins at low molecular weight is a limitation of BN-PAGE. Therefore, from 
complexomics alone, an interaction between SDHAF2 and NDUFV1/NDUFV2 could not be validated. 
 
Overall, complexomics provided a useful tool for assessing the structure and assembly of complex I in 
the 143B RFK knockdown. Comparison to the 143B CyWT demonstrated there were no striking 
differences in either complex I or other components of the OXPHOS chain. Lower molecular weight 
subcomplexes were detected as expected in the membrane fraction and the presence of assembly factors 
and supercomplexes were comparable to the control. Although the matrix fraction may have provided 
more detail on changes to the N-domain, the results demonstrated the high variation between matrix 
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preparations – exemplified by the migration of ribosomal proteins – which were found at smaller 
molecular weights in the knockdown but as multimers in the 143B CyWT, making comparison with the 
control unsuitable. Therefore while complexomics is a valuable technique, fractionation into matrix and 
membrane fractions may be unnecessary, as it does not necessarily enhance the data gathered.  
 
3.10. SILAC experiments demonstrated changes to the mitochondrial proteome in 
response to flavin depletion  
 
RFK knockdown coupled with flavin restriction was expected to severely affect the biosynthesis of 
flavin-containing proteins. At first it was not possible to source riboflavin-free SILAC DMEM – to 
allow heavy labelled amino acids (15N) to be added and so a riboflavin rich control was used – 143B 
CyWT grown in 1 μM riboflavin. For this reason the initial data set used conditioned RFK KD 143Bs 
(un-labelled) and 143B CyWT grown in standard DMEM (heavy-labelled). Later, once riboflavin-free 
SILAC DMEM had been custom synthesised (Chapter 2, section 2.7.1), the data set was completed by 
reversing the labelling orientation. 
 
RFK KD and 143B CyWT cells were processed simultaneously by mixing harvested cells at 1:1 protein 
ratio and then mitoplasts were prepared - along with a heavy control sample to check 15N Arg and Lys 
incorporation. Samples were then reduced and alkylated before separation by SDS-PAGE and 
subsequent analysis by mass spectrometry (Chapter 2, section 2.7). The data discussed below are the total 
output from Perseus after processing of MaxQuant SILAC peptide pair analysis of RFK KD and 143B 
CyWT mitoplasts. Forward refers to heavy-labelled control mixed with un-labelled RFK KD; the 
reverse is the opposite labelling orientation (RFK KD heavy-labelled, 143B CyWT un-labelled). The 
Perseus processing stages included removal of proteins with less than one unique peptide or with a 
peptide count less than two; the normalised protein SILAC ratios were then presented as base two 
logarithmic. Forward orientation SILAC was repeated thrice and in the reverse orientation twice to 
provide a sufficient data set to obtain averages for each orientation and demonstrate the changes in 
protein abundance between conditioned RFK KD cells and the 143B CyWT control. Figures below 
display the Log2 H/L forward ratio against the inverted Log2 H/L reverse ratio, such that positive H/L 
ratios in each orientation represent proteins with higher abundance in the 143B CyWT control (in line 
with the forward ratio) and negative values indicate increased abundance in the RFK KD. Those proteins 
with a three-fold or greater change in abundance in both labelling orientations were deemed 
considerably different between the samples (Log2 ratio ≥ 1.58) and those with a greater than two-fold 
change highly changed (Log2 ratio ≥ 1.00). 
 
Overall 2980 proteins were detected, with 25 showing a greater than three-fold decrease in the 
conditioned RFK KD cells compared to the 143B CyWT control (Appendix 7.3). Of these a high 
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proportion were found to be particularly interesting, seven were subunits of the respiratory complexes 
and four were mitochondrial flavoproteins. 
 
3.10.1. SILAC revealed changes in the abundance of complex I subunits located in the 
hydrophilic arm in RFK knockdown cells 
 
 
 
Figure 3.29 SILAC data comparing protein abundance from conditioned RFK KD 143Bs and 143B CyWT. 
Data is displayed as Log2 H/L forward ratio against the inverted Log2 H/L reverse ratio, such that positive H/L 
ratios in each orientation (top right quadrant) represent proteins with higher abundance in the 143B CyWT control 
and negative values indicate increased abundance in the RFK KD. Complex I subunits are highlighted in dark blue 
and assembly factors in purple. Complex I subunits with greater than a two-fold decrease (in both labelling 
orientations) are labelled and those with more than a three-fold decrease are underlined. Average data from three 
forward orientation (143B CyWT heavy labelled as “forward” orientation) and two reverse labelled experiments. 
 
The SILAC data demonstrated good coverage of complex I subunits, with 40/45 detected (NDUFAB1 
present as two copies, and ND2, ND4L, ND6, NDUFA1 and NDUFC1 were absent, Appendix 7.3). 29 
subunits showed little difference in abundance, with less than a two-fold difference, although most H/L 
ratios were positive, indicating some decrease in abundance in the RFK KD cells. However, as shown 
in Figure 3.29, ten subunits showed a distinct difference between the cell types, five with a greater than 
two-fold decrease in the RFK knockdown - NDUFA2, NDUFA6, NDUFV3, NDUFV1 and NDUFS1. 
Additionally NDUFS4, NDUFV2, NDUFS6, NDUFA12 and NDUFA7 showed a more pronounced 
decrease, greater than three-fold, suggesting that whilst not all complex I subunits were affected a 
specific subset displayed markedly lower levels in the conditioned RFK KD. Figure 3.30 shows that 
those with a greater than three-fold decrease (green) and greater than two-fold decrease (magenta) are 
located at the top of the hydrophilic domain – the N-domain. Eight subunits comprise this region, 
responsible for NADH oxidation using the FMN cofactor, and all were found within the ten most 
changed subunits. NDUFA6 and NDUFA7 were also less abundant; these subunits form the top of the 
Q-domain, sitting adjacent to the N-domain of complex I. Therefore the data suggest that the FMN-
NDUFS6
NDUFA7
NDUFV2
NDUFV1
NDUFS4
NDUFA6
NDUFA2
NDUFS1
NDUFV3
NDUFA12
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containing region of complex I is negatively impacted by RFK knockdown under riboflavin depleted 
growth conditions, such that there was a greater than two-fold decrease in these subunits, whereas the 
remainder of the enzyme was largely unaffected. Notably the abundance of Q-domain subunits 
NDUFA5, NDUFS2, NDUFS3, NDUFS7 and NDUFS8 are not markedly different, only the distal 
region of the hydrophilic arm was affected.  
 
 
 
Figure 3.30 Complex I subunits showing the lowest abundance in RFK knockdown 143Bs highlighted on 
the humanised mouse model structure. Those demonstrating a greater than two-fold decrease are shown in 
magenta (NDUFA2, NDUFA6, NDUFV3, NDUFV1 and NDUFS1) and greater than a three-fold decrease in green 
(NDUFS4, NDUFV2, NDUFS6, NDUFA12 and NDUFA7). Other subunits are shown in wheat, with those not 
detected shown in grey. The human model of complex I was constructed using mouse complex I cryo-EM 
structures (Chapter 6, section 6.6).  
 
 
Interestingly eleven assembly factors were detected, all of which showed little change (less than two-
fold) in abundance. FOXRED1 and ATP5SL were the most different between the cell lines, and along 
with TIMMDC1, TMEM126B, NDUFAF1, ACAD9 and ECSIT, showed deceased abundance in the 
RFK KD, although not considerably. In contrast NDUFAF2, NDUFAF3, NDUFAF4 and COA1 
displayed some increase in abundance, with COA1 showing >1.5 fold increase in the conditioned RFK 
KD. However from Figure 3.29 it can be seen that these differences are comparable to the majority of 
proteins detected – centring around Log2 = 0 - and so may not be significant.  
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3.10.2 SILAC shows decreased abundance of complex II subunits in RFK knockdown 
cells 
 
 
 
Figure 3.31 SILAC data comparing protein abundance from conditioned RFK KD 143Bs and 143B CyWT. 
Average data from three forward and two reverse labelling orientation repeats. Data is displayed as Log2 H//L 
forward ratio against the inverted Log2 H/L reverse ratio, such that positive H/L ratios in each orientation (top 
right quadrant) represent proteins with higher abundance in the 143B CyWT control and negative values indicate 
increased abundance in the RFK KD. Complex I subunits are highlighted in dark blue and assembly factors in 
purple, complex II in red, complex III in yellow, complex IV in green and complex V in light blue. Complex II 
subunits with greater than a two fold decrease (in both labelling orientations) are labelled and those with a greater 
than three-fold decease are underlined. 
 
 
The abundance of subunits from complexes II-V were also analysed to assess whether RFK KD and 
riboflavin depletion affected the overall levels of mitochondrial respiratory complexes (Appendix 7.3). 
Figure 3.31 shows eight complex III subunits (yellow), 11 complex IV subunits (green) and 16 complex 
V subunits (light blue) were detected – all demonstrating a less than two-fold change in abundance in 
both orientations.  In contrast the complex II subunit SDHD was reduced by more than 2.5 fold, with 
SDHB and the FAD containing subunit SDHA decreased by more than four-fold in conditioned RFK 
knockdown cells (red). This suggests that, whilst there was no universal decrease in the oxidative 
phosphorylation complexes, the abundance of complex II was greatly decreased, similar to the lowered 
abundance of the N-domain subunits of complex I. It could be speculated that as complex II is a smaller 
enzyme (130 kDa) than complex I (~1 MDa) the affect of low flavin would impact the stability of the 
entire protein, such that all four subunit abundances would be decreased (SDHC was not detected). In 
contrast complex I, with 45 subunits and the FMN domain at one end of the structure, may not be 
globally affected.  
 
SDHB
SDHC
SDHA
S D 
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3.10.3. SILAC highlights a hierarchal change in mitoflavoprotein abundance in RFK 
knockdown cells 
 
 
 
Figure 3.32 SILAC data comparing protein abundance from conditioned RFK KD 143Bs and 143B CyWT. 
Average data from three forward and two reverse labelling orientation repeats. Data is displayed as Log2 H/L 
forward ratio against the inverted Log2 H/L reverse ratio, such that positive H/L ratios in each orientation (top 
right quadrant) represent proteins with higher abundance in the 143B CyWT control and negative values indicate 
increased abundance in the RFK KD. All flavoproteins detected are coloured yellow, those with a greater than 
two-fold decrease (in both labelling orientations) are shown and labelled in orange and a greater than three-fold 
decrease in shown and labelled in red. Those increased by more than two-fold are highlighted and labelled in 
green. 
 
 
There are 32 flavoproteins located within mammalian mitochondria requiring either FMN or FAD as 
redox cofactors (Lienhart et al., 2013). 18 were detected in the SILAC data (Appendix 7.3) and analysis 
suggested that mitoflavoproteins reacted hieratically to flavin starvation. Although it may be 
hypothesised that all flavin-containing proteins would be detrimentally affected this was not reflected 
by the data (Figure 3.32). Instead 50% were considered unchanged and 28% demonstrated a 
considerable decrease of more than three-fold in the RFK KD.  
 
Four flavoproteins were highly decreased in conditioned RFK KD 143Bs: SQRDL (> 11-fold), DLD 
(>8-fold), SDHA (>4-fold) and electron-transfer dehydrogenase (ETFDH, >7 fold). To gain insight into 
this apparent flavoprotein hierarchy, with some proteins more detrimentally affected than others, the 
function of these proteins and possible links between them were investigated using the literature.  
 
DLD
SDHA
SQRDL
ETFDH
AIFM1
GPD2
ACADVL
NDUFV1
COQ6
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Figure 3.33 Diagram exploring the functions and pathway connections between flavoproteins detected in 
SILAC data.  Flavoproteins are coloured by the extent of change demonstrated by SILAC – for the RFK KD 
compared to the control: red for greater than three-fold decrease, orange for greater than two-fold, blue for 
unchanged and green for greater than a two-fold increase in abundance. Blue dashed arrows reflect electron 
transfer and black dashed arrows highlight linked proteins (such as complex I assembly factors).  Hexagons show 
the flavoprotein subunits of complex I and II. Other pathways are indicated in grey. The schematic was arranged 
around ubiquinone reduction as many of flavoproteins are linked to this pathway either by directly transferring 
electrons or interaction with the respiratory chain.  
 
 
Figure 3.33 classifies the 18 mitoflavoproteins by function and highlights that the beginning of the 
electron transfer chain and reduction of ubiquinol are key. Flavoproteins are coloured by the extent of 
change demonstrated by SILAC. Although not all flavoproteins were directly linked to OXPHOS (more 
distant pathways are indicated in grey), there was a striking clustering of the most decreased proteins, 
due to their roles in the reduction of ubiquinone and NAD+. Additionally NDUFV1 and GPD2 also have 
close links with this pathway and were more than two-fold decreased in the RFK KD. However a 
detrimental effect on proteins with a central role in maintaining the redox status of NADH and 
ubiquinone was unexpected – as a flavoprotein hierarchy would be expected to prioritise important 
proteins to receive their cofactor, leaving more redundant flavoproteins to cope with the biggest flavin 
reduction. Instead, as highlighted visually in Figure 3.33, most proteins demonstrating a large decrease 
in the conditioned RFK KD had a direct link to the ubiquinone pool or NADH/NAD+ ratio, with those 
least affected involved in other pathways in the mitochondria.  
 
This may be explained in part by the basal abundance of each flavoprotein, with some in large excess 
though still capable of adequate function at lower abundance, whereas others may be intolerant of small 
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changes. The apparent flavin hierarchy may also reflect the stability of these proteins and the importance 
of the flavin cofactor in their structural integrity. However it cannot be determined whether these 
differences in abundance are a direct or indirect result of decreased flavin – lowered abundance may be 
due to the inherent instability of flavoprotein lacking its cofactor, or may be a coordinated feedback 
response from the cell to lower expression of certain flavoproteins, in response to limited cofactor 
availability. To delineate this a complementary approach looking at expression levels would be required, 
such as RNA transcriptome profiling.  
 
A further curiosity was the considerable increase of one mitoflavoprotein; COQ6 is a component of the 
multi-subunit COQ complex, with a role in ubiquinone synthesis. It has an FAD cofactor and interacts 
with five other COQ proteins (COQ3-7 and 9) and was increased by more than two-fold in conditioned 
RFK KD cells, along with COQ3, 5, 7 and 9 to a lesser extent. This would suggest that, despite being a 
flavoprotein, levels of COQ6 and other members of the ubiquinone synthesis pathway, were increased 
in response to changes in the redox state of the ubiquinone pool – possibly in an attempt to increase the 
amount of ubiquinone and offset changes to its redox state. Consequently the SILAC data obtained 
demonstrated changes in protein abundance directly due to low flavin, in addition to those instigated by 
the cell in response to this stress.  
 
3.11. An intermediate condition determined that riboflavin depletion in the growth media 
was the dominant cause of the changes in protein abundance 
 
The initial SILAC analysis used a control cell line grown in standard, riboflavin-rich DMEM, due to the 
unavailability of riboflavin-free SILAC DMEM. However it later became possible to obtain the 
riboflavin-free SILAC DMEM, thus to delineate the effects of RFK knockdown from flavin depletion 
an intermediate sample was prepared – conditioned 143B CyWT cells expressing the empty pLKO.1 
vector. Two more pairs of cell lines were therefore processed for SILAC analysis:  
 
Pair 1: 143B CyWT in standard DMEM and conditioned pLKO.1 143B CyWT cells 
(two repeats in forward labelling orientation, with 143B CyWT heavy labelled – “control”, and 
two in the reverse labelling orientation).  
 
Pair 2: conditioned pLKO.1 143B CyWT cells and conditioned RFK knockdown 143B cells 
(two repeats in forward labelling orientation, with conditioned pLKO.1 143B CyWT heavy 
labelled – “control”, and one in the reverse labelling orientation) 
 
Pair 1 represented the impact of riboflavin depletion alone, whereas pair 2 showed the additional 
influence of the RFK knockdown on cells already coping with restricted flavin. The data obtained were 
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from a smaller set of repeats than SILAC from section 3.10 and the quality was therefore lower, with 
decreased protein coverage. 
 
Pair 1 - 143B CyWT/conditioned pLKO.1 cells - showed that 5.6% of proteins detected were decreased 
in abundance by more than two-fold in the conditioned pLKO.1 143Bs, demonstrated by the spread of 
data in Figure 3.34 (Appendix 7.4). Additionally Figure 3.34B shows that many mitoflavoproteins were 
decreased by more than three-fold under riboflavin starvation – including NDUFV1, SDHA, SQRDL, 
DLD and ETFDH, which were all considerably decreased in the 143B CyWT/conditioned RFK KD pair 
discussed previously (section 3.3.4.1). All proteins that showed a greater than two-fold decrease in 
section 3.10 also showed a comparable effect in this experiment – in most cases the decrease was more 
pronounced. However COQ6 did not demonstrate the same increase in abundance. The complex II 
subunit SDHA and ten complex I subunits were more than three-fold decreased, reflecting the large 
changes observed with the 143B CyWT/conditioned RFK KD pair. This would suggest that the results 
obtained from conditioned RFK KD 143Bs, with a control grown in riboflavin-rich conditions,  were 
mirrored by riboflavin depleted growth conditions (pair 1), and therefore the effect was independent of 
the RFK knockdown. Additionally the differences in protein abundance shown by the conditioned cells 
compared to those grown in riboflavin-rich conditions (pair 1) is similar to the SILAC data discussed in 
section 3.10, which showed that a shorter period of more severe riboflavin depletion also caused changes 
in complex I subunit and mitoflavoprotein abundance. Therefore whilst conditioned 143B CyWT cells 
remain viable and had no clear phenotype differences in the mitochondrial proteome did develop, 
compared to when riboflavin was abundant.   
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Figure 3.34 SILAC data for pair 1 to compare protein abundance from 143B CyWT cells grown in 
riboflavin rich and riboflavin depleted conditions. Average data from two forward and two reverse labelling 
orientation repeats. Data is displayed as Log2 H/L forward ratio against the inverted Log2 H/L reverse ratio, such 
that positive H/L ratios in each orientation (top right quadrant) represent proteins with higher abundance in the 
143B CyWT control. A. Complex I subunits are highlighted in dark blue and those with above a two-fold decrease 
in abundance (in both labelling orientations) after conditioning are labelled (underlined showed a greater than 
three-fold decrease). B. Mitoflavoproteins are highlighted in orange and those with above a two-fold decrease in 
abundance (in both labelling orientations) after conditioning are labelled (underlined showed a greater than three-
fold decrease). 
 
 
 
 
 
 
For completeness pair 2 - conditioned pLKO.1 143B/conditioned RFK KD 143B CyWT cells - was 
analysed to compare the effect of RFK knockdown on cells already coping with riboflavin depletion. 
NDUFS1
NDUFS6
NDUFA2
NDUFV1
NDUFA12
NDUFA13
NDUFA10
NDUFB4
NDUFB7
NDUFB9
NDUFC2
NDUFA11
NDUFB2
NDUFV2
NDUFA9
A.
AIFM1
SQRDL
DLD
SDHAIVD
ACADM
ETFDH
NDUFV1
GCDH
GPD2
ETFA
PPOX
B.
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Overall there was less change in protein abundance, with no proteins showing a greater than two-fold 
decrease in the RFK KD. Figure 3.35 shows that the abundance of most proteins were unchanged 
between the samples, including the 12 complex I subunits and 9 mitoflavoproteins detected (Appendix 
7.5). Although the data was of lower quality than pair 1 (1218 proteins detected in total compared to 
2090), the overall spread of data suggested little change and provided a good indication that RFK 
knockdown did not exacerbate the proteomic differences caused by conditioning the cells.  
 
 
 
Figure 3.35 SILAC data for pair 2 to compare protein abundance of conditioned pLKO.1 to conditioned 
RFK KD 143B cells. Average data from two forward and one reverse labelling orientation repeats. Data is 
displayed as Log2 H/L forward ratio against the inverted Log2 H/L reverse ratio, such that positive H/L ratios in 
each orientation (top right quadrant) represent proteins with higher abundance in the conditioned pLKO.1 control. 
Complex I subunits are highlighted in dark blue and mitoflavoproteins in orange. 
 
 
It was concluded that the results from SILAC, notably changes in certain flavoproteins – demonstrated 
a hierarchy, and decreased levels of complex I N-domain subunits were caused by the riboflavin 
depletion in the growth media and were not enhanced by the RFK knockdown. This was surprising 
given the crucial role of the enzyme in flavin metabolism at the early stages of the flavin cofactor 
pathway. However the knockdown was assessed to only be 88%, therefore a residual 10% could be 
maintaining turnover of the riboflavin required to synthesise flavin cofactors – and so there would be 
no difference from conditioned cells. 
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3.12. Discussion and conclusions  
 
3.12.1. The importance of growth conditions – riboflavin excess 
 
The work described in this chapter used the cultured human cell line 143B, widely used in mitochondrial 
studies. Manipulation of this cell line facilitated investigations into complex I assembly and flavin 
handing that would have been restricted by using other models, such as purified bovine material. Also, 
as a human system, the results obtained should more closely reflect processes occurring in vivo, in 
comparison to using genetically malleable microbial systems, such as Y. lipolytica and P. denitrificans. 
However, it must be considered that, whilst the biochemistry of cultured human cells resembles that 
within tissues, the characteristics making them suitable for prolonged culture also make them inherently 
different from those in vivo. 143Bs are derived from human osteosarcoma cells and so, as immortal 
cancer-like cells, they will have different metabolic adaptions; their response to stress and genetic 
manipulation may vary. Therefore, when interpreting results from using cultured cell lines this caveat 
must be considered. Whilst these cells are an incredibly useful tool for studying human defects, they 
cannot be directly paralleled with the processes of a whole organism. 
 
The results presented in section 3.2 demonstrate that a dominant feature affecting flavin handling by 
143Bs is the concentration of riboflavin in the growth media, which was found to be in large excess 
(standard DMEM has 1 μM riboflavin and 10% FBS contributed an additional 0.77 nM).  Thus, even 
siRNA knockdowns of known riboflavin processing enzymes had a negligible effect on cellular flavin 
availability because high extracellular riboflavin concentrations compensated for decreased uptake and 
processing by the cells. Guided by previous work from Zempleni and co-workers, a conditioning period 
was adopted with growth of 143Bs in 0.77 nM riboflavin for one month before the cells were used. This 
consideration could be beneficial for other studies, to ensure cells are closer to the threshold for 
phenotypic changes. Riboflavin supplementation has been shown to improve the clinical symptoms of 
patients with respiratory defects and other conditions, such as multiple acyl-coA dehydrogenase 
deficiency, indicating that riboflavin can ameliorate these phenotypes (Greibel et al., 1990; Cotelli et 
al., 2012). Therefore, growth of patient fibroblasts in culture may not exhibit the same level of 
impairment if riboflavin is present at high levels and so this must be accounted for.  
 
3.12.2. Complex I subunits and assembly in low flavin conditions 
 
The aims of this chapter focused on the insertion of FMN into NDUFV1 and whether manipulating the 
upstream flavin-handling pathway could provide insight into the stage at which flavin is incorporated; 
including the importance of this for complex I assembly. Complexomics was used to investigate low 
flavin conditions and determine whether assembly factors were required for flavination of NDUFV1. 
Lowered riboflavin availability did not detrimentally affect complex I assembly – as shown by the 
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complexome analyses (section 3.3.3.1). Additionally, no candidate proteins were detected in association 
with NDUFV1, however the close association of NDUFV1 and NDUFV2 was noted because they shared 
the same migration profile in the mitochondrial matrix fraction, thus they must interact from a very early 
stage. The N-domain has been shown to arise separately during assembly (Guerrero-Castillo et al., 2017) 
but the association of these two subunits could also represent a stabilising strategy; NDUFV2 may 
support NDUFV1 before FMN is inserted. Assembly factors have been identified for flavoproteins 
requiring covalent attachment of their cofactor, such as SDHAF2 for FAD insertion into SDHA. 
However the interaction of non-covalent binding flavoproteins with flavin is usually high affinity in a 
shielded binding pocket (Starbird et al., 2015). Therefore, NDUFV1 may not require an insertion factor 
and instead obtain FMN readily from the matrix. Further work with a cell line demonstrating a severe 
respiratory phenotype would more conclusively establish this hypothesis, as conditioned RFK 
knockdown 143B cells still assembled active complex I.  
 
Another consideration was highlighted by the work on the RFK knockdown. There was disparity 
between OCR measurements, complex I in-gel activity and complexomics compared to the SILAC 
proteomics data. There was no respiratory phenotype observed for either conditioned 143Bs or those 
with the RFK knockdown, suggesting that oxidative phosphorylation was not impaired by riboflavin 
depletion, and this was corroborated by the complexome data. Yet SILAC indicated a considerable 
decrease in the abundance of N-domain subunits from complex I and also a decrease in complex II 
subunits, for cells conditioning in low riboflavin. These data reflect the changes to mitochondrial 
proteins observed in section 3.4., for cells grown in 0.15 nM riboflavin that exhibited a severe 
resipiratory phenotype with reduced viability, and so it would be expected that a similar phenotype 
would be observed. The difference between SILAC and other experiments, in section 3.6 onwards, could 
indicate that a substantial pool of free complex I and II subunits exists and so despite a decrease in 
protein abundance under riboflavin restricted conditions (shown by SILAC) this was not to a level that 
impacted heavily on the assembly or the activity of the enzymes themselves, thus a phenotype did not 
manifest. However another plausible explanation involves differences in the growth conditions of these 
cells. Despite the same conditioning in all experiments, and subsequent processing to generate 
mitoplasts for analysis (for in-gel activity and SILAC), one element differed. Dialysed FBS was required 
for SILAC to prevent the introduction of unlabelled Arg and Lys into the heavy labelled cell sample, 
whereas usually all cell lines were cultured with untreated FBS. Although 10% FBS addition contains a 
low concentration of riboflavin (~0.77 nM) this will vary by batch, but importantly dialysed FBS 
contains much lower levels. Consequently the concentration of riboflavin available may be substantially 
decreased and could explain why the riboflavin depleted SILAC cells (with or without RFK knockdown, 
section 3.10) displayed highly changed levels of flavoproteins, because the concentration of riboflavin 
provided by 10% dFBS was lower than 10% untreated FBS, which pushed the cells beyond the threshold 
of tolerance, hence proteomic changes were evident. Thus under SILAC conditions these cells were 
more equivalent to the 0.15 nM riboflavin grown cells that were assayed previously, whereas in other 
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experiments the concentration of riboflavin was adequate for survival and functional OXPHOS. The 
impact of different FBS types has been found across different research areas, including receptor-ligand 
binding investigations for the pharmacological classification of ligands (Lau & Chang, 2014) and the 
sensitivity of cancer cells to bioenergetic inhibitors (Fan et al., 2010). Thus, when the precise growth 
conditions of cells must be controlled, the variation in small molecule concentrations in FBS can have 
an unintended but substantial effect.  
 
3.12.3. Flavin depletion revealed a mitoflavoprotein hierarchy 
 
From the SILAC data investigating the effects of flavin starvation on the mitochondrial proteome a 
differential change in mitoflavoprotein abundance was demonstrated. Not all flavin-containing proteins 
were affected to the same extent; some did not change in abundance whilst COQ6 was considerably 
increased. All of these proteins require a FAD cofactor, except NDUFV1 and dihydroorotate 
dehydrogenase (DHODH) that bind FMN. The hierarchy may result from a number of different factors. 
First it may indicate the strength of cofactor binding, the higher affinity proteins would monopolise the 
remaining flavin, although SILAC cannot distinguish between flavoproteins with or without their 
cofactor. Most flavoprotein cofactors are non-covalently bound but tightly associated; although it is 
estimated about 10% of flavoproteins contain covalently bound flavin and are more likely to rely on this 
association for structural stability (Heuts et al., 2009). Therefore a second factor influencing the 
mitoflavoprotein hierarchy is whether protein abundance is linked to protein stability – which in turn 
may be dictated by cofactor binding. It was shown that mutant monoamine oxidase (MAOA) that could 
not bind FAD covalently had lower stability upon purification (Nandigama & Edmonson, 2009). SDHA 
demonstrated a higher decrease in abundance compared to NDUFV1 in flavin-depleted cells, and this 
may be explained by their different flavin binding – SDHA covalently binds FAD, whereas NDUFV1 
non-covalently associates with FMN. Therefore some flavoproteins, despite being unable to obtain their 
cofactor, persist for longer before being turned over compared to those that are inherently unstable 
without flavin. SILAC data may therefore highlight two properties of mitoflavoproteins that confer 
differing abundance during flavin starvation – protein-flavin binding affinity and structural integrity.  
 
A final consideration influencing the mitoflavoprotein hierarchy is the involvement of additional 
proteins. The requirement for a flavin assembly factor adds an additional step in the flavination process, 
which in a flavin depleted environment may be detrimental. Also FAD must be synthesised from FMN, 
either in the cytoplasm or mitochondrial matrix by FADS isoforms, therefore availability of FAD will 
be limited by this enzymatic reaction – perhaps giving an advantage to FMN-containing flavoproteins. 
Although SILAC was only concerned with mitochondrial proteins it would be informative to compare 
the impact of flavin depletion on other flavoproteins, as flavin transport into organelles may affect 
cofactor availability between different compartments and subsequently affect flavoproteins. There is 
also the difference in gene or protein level effects, as SILAC provides no information on transcriptional 
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control, which would indicate a cellular feedback response to flavin starvation rather than just alterations 
to the proteins themselves. 
 
3.12.4. Robustness of the flavin handling pathway and associated proteins 
 
The surprising result was that knocking down RFK by ~90% did not further disrupt riboflavin handling, 
over conditioning alone, despite it being the only known riboflavin kinase. This suggested that the 
pathway is inherently robust and difficult to influence, which was also supported by the results presented 
in section 3.2, such that riboflavin concentrations in the growth media had to be lowered to ~0.15 nM 
to confer a phenotype on the cells, and the riboflavin uptake inhibitor lumiflavine was only effective in 
conjunction 0.77 nM riboflavin growth conditions.  
 
3.12.5. Future developments 
 
Overall, this investigation into flavin-handling by cultured cells and the impact on complex I activity 
and assembly produced a number of interesting results – including the lack of RFK knockdown 
phenotype, and that growth conditions must be addressed to decrease flavin flux within the cell. To take 
this project forward, proteins of interest would need to be knocked out. Thus the next stage would be to 
affect a genomic level knockout of RFK, along with the poorly characterised mitochondrial carrier 
SLC25A32, with a view to pushing the cell as a whole, and complex I in particular, towards a flavin 
starved state, to better study the process of flavin cofactor insertion. This should then allow a more 
detailed investigation into FMN incorporation into the crucial NDUFV1 subunit of complex I.  
 
However, data from the Mouse Genome Informatics online resource showed mice homozygous for a 
RFK knockout allele died in utero (Yazdanpanah et al., 2009). This indicates the importance of the 
enzyme, although it must be noted that inviability of an embryo with a gene knockout only demonstrates 
a crucial developmental role for the protein. It may be possible to generate a knockout in cultured cells, 
when its developmental function is no longer required. This has been shown for many proteins, 
specifically of interest is the complex I subunit NDUFA5. A mouse knockout was generated using gene 
trap by Moraes and co-workers but was embryonic lethal and survival did not exceed day E9 (Peralta et 
al., 2014). However a conditional knockout in the central nervous system was viable, but a severe 
phenotype was observed in these mice at ~11 months. Additionally, Ryan and co-workers have knocked 
out all the supernumerary subunits of complex I and showed that in HEK293T lines only NDUFAB1 
was essential for cell viability (Stroud et al., 2016). Therefore, although NDUFA5 knockout cells 
showed severely decreased complex I assembly, indicating the importance of the subunit in the 
biosynthesis and stability of the enzyme, these cells survived, unlike the knockout mice. Considering 
this the possibility of knocking out RFK in cell lines was explored. Horizon Discovery had previously 
used CRISPR to target the gene in HAP1 and other cell lines, but they were unable obtain viable clones 
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(pers.comm.). Therefore RFK may represent an essential protein in both development and cell survival, 
thus the absolute requirement for this enzyme may explain the lack of effect found on knockdown, ~90% 
decrease in protein abundance could represent the highest viable level of knockdown possible, and those 
with a higher knockdown efficiency cannot survive. Unfortunately this meant further work with RFK 
was not possible and so CRISPR knockout was pursued with SLC25A32 alone.  
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Chapter 4 
Investigating the function of SLC25A32 and the effect of its knockout on 
complex I in cell lines 
4.1. Introduction 
 
4.1.1. Mitochondrial carriers 
 
The two membranes of mitochondria exhibit differing permeability, with the OMM allowing movement 
of most small proteins and molecules due to the presence of porins and using translocases to import 
larger proteins. The IMM, in contrast, is tightly regulated and specific transporters such as the 
mitochondrial carrier family (MCF) are required for ion and metabolite movement. Figure 4.1 
demonstrates the diverse substrates transported by mitochondrial carriers and the key biochemical 
pathways of the matrix – highlighting the role of MCFs in linking cellular and mitochondrial 
metabolism. 
 
 
 
Figure 4.1 Mitochondrial carriers of the IMM. A schematic representation of the mammalian IMM respiratory 
chain complexes (grey) and mitochondrial carriers (yellow). The OMM has been omitted, orange arrows indicate 
simplified metabolic pathways, to emphasise key metabolites, with cofactors and high-energy intermediates in 
teal. Adapted from Kunji, 2004. 
 
There are over 50 MCFs with a large range of substrates, although they all share defined features that 
are essential for their function. The sequences of MCF proteins show a tripartite structure of three 
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homologous sequence repeats comprising 100 residues. Each repeat consists of two transmembrane 
helices and a short helix that extends into the mitochondrial matrix. Within these repeats there is a 
conserved signature motif of P-X-[D/E]-X-X-[R/K] on one transmembrane helix. The carriers were 
originally thought to act as homodimers, with evidence supporting this including the 1:2 stoichiometry 
of the inhibitor carboxyatractyloside (CATR) binding to the ATP/ADP carrier (Riccio et al., 1975). 
However, this dimer theory was later dispelled by a series of investigations by Kunji and co-workers 
confirming that the ADP/ATP carrier is a monomer, using purification and functional assays with work 
on the yeast protein (Bamber et al., 2007). 
 
The carriers adopt two states; one accessible to the matrix (m-state) and one open to the cytoplasm (c-
state). The signature motif contributes charged residues to form a salt bridge network that closes the 
internal cavity to the matrix side. A further conserved motif was identified ([Y/F]-[D/E]-X-X-[K/R]) on 
the second transmembrane helix in each repeat that forms a salt bridge to close the cavity to the 
cytoplasmic side during the transport cycle (Crichton et al., 2015). Fixing the carrier in different states 
using inhibitors has provided valuable insights into its binding properties and allowed mechanisms to 
be proposed.  
 
 
Figure 4.2 Topology of the yeast ADP/ATP carrier. The six transmembrane helices are shown in black, with 
red dashes separating the three sequence repeats. The position of the signature motif P-X-[D/E]-X-X-[R/K] of the 
first transmembrane helix is bordered in red. Negatively charge residues are shown in red and positively charged 
in blue. The matrix loops are numbered M1, M2 and M3, cytoplasmic loops C1, C2, C3 and C4. Adapted from 
Kunji, 2004. 
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Whilst identifying MCF members has been relatively straightforward due to their highly conserved 
motifs, determining their functions has proved challenging; to date only around a third have been 
assigned substrates by experimental evidence. The main approaches for characterisation involve 
expression in E. coli and S. cerevisiae and reconstitution into liposomes for direct measurements of 
substrate transport (Palmeiri and Pierri, 2009). More recently a Lactococcus lactis expression system 
has been used, allowing the carrier to be characterised in whole cells or membrane vesicles without 
additional purification and reconstitution steps (Kunji, 2004). Despite these approaches, the nature of 
these proteins as membrane-localised carriers has impeded successful expression and purification of 
many MCF members; they have been found to be unstable when purified in different detergents, 
hampering their functional assignment (Crichton et al., 2015). As a result many MCF proteins have been 
given a putative function based on computational prediction and observations in genetic models, 
including the rescue of mutations by expression of these carriers.  
 
4.1.2. The putative mitochondrial folate carrier, SLC25A32  
The function of SLC25A32 has divided opinion since two separate investigations into its physiological 
substrate have yielded different results. As discussed in Chapter 3, section 3.1.1. it was assigned as the 
folate transporter after rescue of glycine-auxotrophic Chinese hamster ovary-derived glyB cells by 
overexpression of the protein – the cause was later assigned to a mutation in the transporter (G192E) 
(Titus et al., 2000). However, in 2005 Spann and co-workers reported the rescue of a S. cerevisiae FLX1 
null mutant (assigned as the mitochondrial FAD transporter) with expression of human SLC25A32, and 
so this indicated an ability to transport flavin (Spaan et al., 2005). The debate has also been fuelled by 
the identification of patients with riboflavin responsive pathologies caused by mutations in SLC25A32 
that also show deficiencies in OXPHOS enzyme activities (Schiff et al., 2016; Hellebrekers et al., 2017).  
 
4.2. Aims 
 
This chapter builds on the knowledge acquired about riboflavin depletion in Chapter 3 and aims to: 
 
• Explore the function of SLC25A32 in flavin distribution using a knockout cell line. 
• Investigate the impact of severely limited flavin on complex I assembly, structure and activity. 
• Characterise the wider mitochondrial and cellular changes that occur as a result of the knockout 
using proteomic and transcriptomics approaches. 
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4.3. Preliminary study: purification of the mitochondrial transporter SLC25A32  
 
In collaboration with Dr Edmund Kunji and co-workers I attempted to characterise the transport function 
of SLC25A32. The yeast homologue FLX1 and human protein SLC25A32 had both been successfully 
cloned and overexpressed with a His-tag in S. cerevisiae by Dr Homa Majd. Due to the low yield of 
SLC25A32, the yeast homologue FLX1 was pursued instead of the human protein. FLX1 was isolated 
from mitochondria in the detergent 2-didecylpropane-1,3-bis-β-D-maltopyranoside by affinity 
chromatography and the His-tag removed; a single pure protein band was obtained, confirmed by SDS-
PAGE. Recently, a technique has been developed to probe possible substrates for MCFs using the thiol-
recative fluorophore N-[4-(7-diethylamino-4-methyl-3-courmarinyl)phenyl]maleimide (CPM) in a 
thermostability assay (Crichton et al., 2015). This is based on the rationale that, upon denaturation, 
protein unfolding exposes buried cysteine residues, which would react with CPM to increase the 
fluorescence detected, providing a melting temperature estimation for the carrier (Tm). The binding of a 
substrate would confer additional stability; therefore a shift in Tm would be expected. Thermostability 
assays with the S. cerevisiae ADP/ATP carrier showed that the high affinity inhibitor CATR caused a 
considerable shift from Tm 44.7 °C to 72.0 °C (Crichton et al., 2015). Therefore this approach was 
undertaken with FLX1, to first establish a Tm and then, by the introduction of potential substrates, 
determine any stability increase through binding. Unfortunately due to the inherent instability of the 
FLX1 during the assay, a reliable Tm could not be obtained, despite multiple attempts and protocol 
alterations; therefore this part of the project was not continued. Instead, work was focused upon cell 
lines and genetic disruption of SLC25A32.   
4.4. Gene knockout using CRISPR technology to abolish target protein expression in cell 
lines 
 
4.4.1. An introduction to CRISPR gene editing technology 
CRISPR is based on the adaptive immune response of bacteria towards invading viruses. The process 
involves excising and acquiring a small fragment of phage DNA, by inserting it into a CRISPR locus, 
within their own genome, as a protospacer, allowing bacteria to recognise foreign DNA for degradation. 
Bioinformatic analysis demonstrated that protospacers were selected using adjacent downstream motifs 
of 3-5bp (Ran et al., 2013). These protospacer adjacent motifs (PAMs) are important for two of the three 
CRISPR system types and specific to the Cas9 expressed. 
 
The nuclease Cas9 targets specific DNA sequences using a small guide RNA and promotes a double 
strand break (DSB). Two major repair mechanisms exist in bacteria to address DBSs: error prone non-
homologous end-joining (NHEJ) and high-fidelity homology-direct repair (HDR). Both pathways can 
be utilised in gene editing by CRISPR as shown in Figure 4.3. Three types of CRISPR systems have 
been identified in a range of bacteria and archaea. The best understood is Type II and the system derived 
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from Streptococcus pyogenes is the basis for most CRISPR engineering technologies (Ran et al., 2013). 
It involves Cas9 and an array of guide RNAs, which direct the nuclease towards a 20bp target at a 
specific locus. For target sequences to be recognised and CRISPR edited in S. pyogenes, the PAM 
sequence following them, at the 3’ end, must be NGG. The use of CRISPR as a genetic engineering tool 
has many benefits, as it is a highly flexible, simple system that can be manipulated to generate 
knockouts, insertions and the addition of tags to genes within mammalian and other cells, despite being 
a bacterial system in origin.  
 
 
Figure 4.3 Genome editing with CRISPR. The genomic DNA in pink is targeted by a specific guide RNA (blue) 
requiring the complementary sequence and a 3’ PAM (yellow). Cas9 (green) is directed by the guide RNA and 
makes a double stranded break. This may be repaired by either NHEJ or HDR.  NHEJ is the most active pathway 
but also more error prone – therefore likely to introduce indels into the repair site. This causes the target gene to 
be interrupted and a frame shift may also introduce a premature stop codon. For a specific change to be facilitated 
a repair template must be present, to allow a point mutation or larger insertion (such as a tag) to be included in the 
repair. However this is a much less efficient pathway and some NHEJ will also take place. Adapted from 
http://www.transomic.com/Products/CRISPR-Genome-Editing.aspx. 
 
To investigate the function of SLC25A32 a similar approach to that explored in Chapter 3 was 
employed. By disrupting the abundance of this transporter it would be possible not only to determine 
the effect on complex I and other flavin-reliant mitochondrial proteins but also demonstrate its role in 
transport of flavins across the IMM. To date, despite the work of Spaan and co-workers to address the 
similarities between yeast FLX1 and SLC25A32 (sharing 29% sequence identity and 44% similarity), 
there has been no work on the human transporter in its native system (Spann et al., 2005). Instead, it has 
been used to rescue the function of mutants in non-human model organisms. Therefore investigations 
in a human cell line would be informative and add breadth to the existing work on this protein. Knocking 
out SLC25A32 by CRISPR would generate a cell line without the functioning transporter, which could 
be characterised in detail to help understand the effects of a non-functioning transporter and attempt to 
further uncover its physiological role. This approach would overcome the inherent problems of studying 
membrane proteins by overexpression and purification and provide a stable system that could be tested 
by multiple complementary techniques to build an understanding of SLC25A32 function. Additionally, 
130 
it would immediately demonstrate whether a null mutation was lethal or if survival was still permitted 
despite a loss of function frame shift.  
 
4.4.2. SLC25A32 knockout in HAP1 cells 
 
CRISPR allows the targeted knockout of genes by the introduction of indels, but this must be achieved 
for each gene copy. Therefore the higher the copy number the more difficult it is to achieve a full 
knockout. 143Bs are known to display genomic instability and also contain more than two copies of 
most chromosomes. SLC25A32 is found on chromosomes 8. Karyotyping was undertaken by Cell 
Guidance Systems and the five 143B cells tested all displayed a range of copy numbers; three or more 
cells contained an additional copy of chromosomes 3, 4, 5, 10, 12, 13 and 16, with two extra copies of 
chromosome 8. This highlighted that 143Bs were not the most suitable choice for CRISPR knockout 
and so another cell line was chosen, the adherent human KBM-7 derived cell line HAP1. These cells 
are haploid, which therefore simplified the knockout process.  
 
A commercially available SLC25A32 knockout (referred to as SLC25A32 KO) was obtained from 
Horizon Discovery, along with the parental HAP1 line. The deletion in exon 2 was confirmed by 
sequencing, Figure 4.4, and these cells were taken forward for conditioning and investigation into the 
effects on complex I. Additionally, I used CRISPR to design guide RNAs targeting exon 1 of the 
SLC25A32 gene, to generate a number of additional knockouts in HAP1 (Chapter 2, section 2.3.3), with 
a view to validating results obtained using the commercially available SLC25A32 KO (results are 
discussed in section 4.9). All SLC25A32 knockout cells and HAP1 controls were conditioned 
(riboflavin-free DMEM + 10% FBS for one month) prior to further investigation.  
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Figure 4.4 Sequencing data alignment for SLC25A32 knockout. Sequencing confirmed an 8bp deletion 
(orange) in exon 2, although differing by one base pair compared to data provided by the supplier (Horizon). This 
brings a stop codon into frame and therefore would be expected to produce a truncated protein (<80 amino acids) 
or cause exon skipping, to produce a non-functional protein. 
 
 
 
 
 
 
Figure 4.5 HAP1 and SLC25A32 knockout cells grown under high flavin conditions in IMDM. Cells were 
seeded at 14,000/well with 4 ml of IMDM + 10% FBS and incubated at 37 ºC for 160 hours. Incucyte software 
was used to record the change in growth. A. HAP1 cells showed normal fibroblast-like morphology, <50 μm in 
diameter. B. SLC25A32 KO also showed fibroblast-like morphology, with some elongations observed.  
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Figure 4.5 demonstrates the morphology of the SLC25A32 KO and HAP1 parental cell lines grown in 
IMDM (as recommended by the supplier). On conditioning the SLC25A32 KO (SLCKO) showed a 
change in morphology and growth rate, which was progressive and correlated with lower riboflavin 
availability. Figure 4.6 shows the considerable difference in growth profiles of the two cell lines 
undergoing conditioning, in riboflavin-free DMEM; SLCKO cells grew much more slowly and after 
more than 300 hours were not confluent. This was accompanied by a change in morphology shown in 
Figure 4.7B. Cells became increasingly elongated with fewer cell-to-cell contacts. Consequently these 
initial observations indicated that riboflavin depletion resulted in changes to the SLCKO cells compared 
to the HAP1 controls. Further work then explored these differences in the context of complex I structure 
and function.  
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Figure 4.6 Growth profile of HAP1 during conditioning stages. Cells were seeded at 14,000/well with 4 ml of 
appropriate medium and incubated at 37 ºC for at least 160 hours. Incucyte software was used to record the change 
in growth, with images obtained every 4 hours and percentage confluence calculated. Error bars denote standard 
error. Cells were adapted from IMDM to riboflavin free DMEM in 25% increments after two passages. A. HAP1 
parental line – IMDM (dark blue), three increasingly lighter shades of blue for IMDM: riboflavin free DMEM 
75:25, 50:50, 25:75 and riboflavin-free DMEM (mint green). B. SLC25A32 knockout – IMDM (purple), three 
increasingly lighter shades of purple for IMDM: riboflavin free DMEM 75:25, 50:50, 25:75 and riboflavin-free 
DMEM (light pink). These cells were monitored for 400 hours to determine whether confluence would be reached, 
however the erratic nature of the later data points demonstrates the increasing levels of cell death in the riboflavin 
free DMEM knockout cell wells.  Data from one representative assay are shown. 
A.
IMDM: riboflavin-free DMEM
100:0
75:25
50:50
0:100
25:75
B.
IMDM: riboflavin-free DMEM
100:0
75:25
50:50
0:100
25:75
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Figure 4.7 Time interval cell growth images to compare conditioning of HAP1 and SLC25A32 cells. Cells 
were seeded at 14,000/well with 4 ml of appropriate medium and incubated at 37 ºC for 160 hours. Incucyte 
software was used to image the wells in 16 segments every 4 hours. A.  HAP1 conditioning – top panels (L-R) 
IMDM: riboflavin free DMEM 75:25 and 50:50, bottom panels (L-R) 25:75 and riboflavin-free DMEM. B. 
SLC25A32 knockout conditioning – top panels (L-R) IMDM: riboflavin free DMEM 75:25 and 50:50, bottom 
panels (L-R) 25:75 and riboflavin-free DMEM.  
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4.5. Characterisation of SLC25A32 knockout in riboflavin depleted HAP1s 
 
4.5.1. Respiratory phenotype 
 
To determine whether the SLC25A32 knockout differed in respiratory profile compared to the control 
under low riboflavin conditions a Seahorse X96 analyser was used to monitor the OCR and ECAR 
during a stress test (as described in Chapter 2, section 2.6.1). Figure 4.8 shows the striking and 
significant difference in oxygen consumption between the two cell lines: basal OCR of the SLC25A32 
KO was on average only 11% of the control. Also there was no observable response to the additions of 
oligomycin (after 40 minutes), FCCP (after 80 minutes) and rotenone & antimycin A (after 130 
minutes), whereas the uncoupled OCR of the control increased by 50% on addition of FCCP, compared 
to its basal rate.  This suggests that the knockout cells showed predominantly non-mitochondrial 
respiration. Interestingly no difference in ECAR was observed between the SLC25A32 KO and control 
(data not shown) suggesting that the knockout cells had not shifted towards glycolysis to meet energy 
demands.  
 
 
 
Figure 4.8 Seahorse extracellular flux data comparing the respiratory profile of conditioned SLC25A32 
knockout HAP1 cells with the parental line. The control HAP1 cell line is shown in blue and the SLC25A32 
KO in pink. Both cell lines were conditioned for one month and seeded at 11,500 per well the day before the assay. 
46 wells of each condition were assayed and the experiment repeated thrice (mean results for one representative 
assay shown, with error bars denoting standard error). OCR was corrected for seeding density using BCA protein 
quantification of wells after the assay. Significantly different basal OCR measurements between the two cell lines 
are denoted by * (P<0.0001 by unpaired T-test). 
 
 
4.5.2. Mitochondrial membrane potential of SLC25A32 knockouts  
 
The OCR data suggested that the OXPHOS system is inactive and therefore the mitochondrial 
membrane potential was investigated, as a non-functional respiratory chain is expected to result in low 
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membrane potential. The fluorescent dye TMRM is a cell permeant cation that is actively accumulated 
by mitochondria and can be used to indicate the polarisation status of a cell population (Scaduto & 
Grotyohann, 1999). Uptake was measured after 30 minutes incubation and HAP1 samples were used as 
a control to set the gating threshold, distinguishing polarised and non-polarised cells. This gate was then 
applied to all samples for comparison between the knockout and parental cell lines. Figure 4.9 shows 
that, surprisingly, the knockout cells showed an average polarised population of 88% compared to 90% 
of the parental HAP1 cells. Additionally, FCCP uncoupled both cell types to a similar extent, suggesting 
that SLC25A32 maintains a membrane potential despite the OCR data demonstrating a lack of oxidative 
phosphorylation.  
 
 
 
Figure 4.9 Proportion of cell population polarised using TMRM fluorescence. Triplicate cell samples were 
treated with TMRM for each cell line and the dye retention measured by fluorescence. 5 μM FCCP was added and 
after incubation samples were tested again for TMRM fluorescence. Data were normalised using Hoerchst DNA 
staining measurements. Gating was used to determine the polarised proportions of each population, using the 
HAP1 controls, and overlaid on each plot. Error bars denote standard deviation.  
 
 
To maintain a membrane potential without oxidative phosphorylation indicated that SLCKO cells 
employed another method, comparable to that employed by mtDNA-lacking ρ0 cells. In ρ0 cells the 
ATP:ADP transporter acts in reverse to import ATP, which is then broken down by ATP synthase also 
running backwards. ADP and Pi are then exchanged out of the mitochondria, via the phosphate carrier 
protein (SLC25A3) (Buchet & Godinot, 1998). This mechanism may provide an explanation for the 
results obtained from SLCKO cells regarding their low rotenone/antimycin insensitive oxygen 
consumption, despite presence of a membrane potential. However these results do not detail which 
components of the respiratory chain are most affected by the knockout or the impact upon complex I. 
 
4.5.3. OXPHOS chain activity 
 
To probe which of the individual complexes was most affected, in-gel activity assays were used to assess 
the activity of the flavin containing complexes I and II and also complex IV.  
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4.5.3.1. Complex I in-gel activity assay 
 
Complex I activity was assessed using the electron acceptor NBT, which on reduction produces a purple 
band of activity on BN-PAGE gels of purified mitochondria (Chapter 2, section 2.4.2). Figure 4.10 
shows in-gel complex I activities for both DDM and digitonin solubilised mitochondria from 
conditioned HAP1 and SLC25A32 KO cells. 
 
            
 
Figure 4.10 Complex I in-gel activity characterisation of the SLC25A32 knockout. Purified mitochondria 
were solubilised with 1.2% DDM or 8g/g digitonin. Complex I activity assay was carried out using 0.5 mg/ml 
NBT, 100 μM NADH in 20 mM Tris pH 7.4. 
 
 
Purple bands present in Figure 4.10 indicate protein with flavin site activity; NADH is oxidised by flavin 
and passed to the NBT electron acceptor. Therefore, other flavin active proteins were also highlighted. 
Oxoglutarate dehydrogenase complex (OGDH) contains the E3 component dihydrolipoyl 
dehydrogenase (DLD) with a FAD cofactor. This large complex is usually present ~2,500 kDa and on 
DDM solubilisation the DLD component is also observed at lower molecular weight ~ 55 kDa 
representing its monomeric state (Wittig et al., 2006). Therefore three bands were visible in the HAP1 
DDM solubilised sample, an active complex I band corresponding to the same position as found in the 
bovine mitochondrial membrane standard, along with DLD in OGDH and as a monomer. Digitonin acts 
as a milder detergent and so larger complexes remain intact; therefore DLD was only present in the large 
OGDH band. A series of high molecular weight bands with flavin activity demonstrated different 
complex I containing supercomplexes (❖). Complex I is found tightly associated with complexes II, III 
and IV in differing stoichiometries in the IMM and solubilisation with digitonin preserves these large 
assemblies. Whilst the HAP1 samples showed the active bands expected the SLCKO samples lacked all 
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flavin activity; therefore suggesting that complex I in these cells was not active and that the knockout 
had broad effects on other mitochondrial flavoproteins, as evidenced by lack of active DLD.  These 
observations were not a result of differential mitochondrial protein loading due to the similar levels of 
ATP synthase present. This band ~ 700 kDa is usually visible after BN-PAGE even without staining 
and was clearly present in all four cell samples, suggesting loading was consistent; although protein 
migration differed slightly between DDM and digitonin solubilised samples.  
 
4.5.3.2. Complex II in-gel activity 
 
Complex II in-gel activity assays revealed a distinct difference in the HAP1 control compared to the 
SLC25A32 knockout. In Figure 4.7 two loading volumes were used for each cell line - the complex II 
activity in the HAP1 samples increased proportionately, as did the intensity of the complex V band. 
However in the SLC25A32 KO samples there was no visible complex II band, even with the high 
loading volume. Therefore, from Figure 4.10 and 4.11, it was apparent that the KO cell line lacked 
functioning complex I and II, possibly due to these complexes lacking their flavin cofactor.  
 
                                          
 
Figure 4.11 Complex II in-gel activity characterisation of the SLC25A32 knockout. Purified mitochondria 
were solubilised with 1.2% DDM. Complex II activity assay was carried out using 84 mM succinate, 2mg/ml 
NBT, 10 mM sodium cyanide and 0.2 mM phenazine methosulphate (PMS) in 20 mM Tris pH 7.5. 
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4.5.2.3. Complex IV in-gel activity 
 
To complete the in-gel characterisation of SLC25A32 KO mitochondria a complex IV assay was also 
undertaken. The complex III assay, using diaminobenzidine (DAB), gave unreliable results, even for 
the bovine heart membrane control, consistent with discussion in the literature (Jung et al., 2000; Smet 
et al., 2011). In Figure 4.12 two loading volumes were used for each cell line and in both samples 
complex IV activity was apparent, increasing proportionately with sample loading. The position of the 
complex IV active band in the cell line samples was equivalent to that of the bovine mitochondrial 
membrane standard. Therefore, whilst the activities of complex I and II were compromised in the 
knockout complex IV was unaffected.  
                                
 
Figure 4.12 Complex IV in-gel activity characterisation of the SLC25A32 knockout. Purified mitochondria 
were solubilised with 1.2% DDM. Complex IV activity assay was carried out using 0.4 mg/ml 3-3 
diaminobenzidine (DAB) and 1 mg/ml cytochrome c in 50 mM phosphate, pH 7.2. 
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4.6.  The effect of SLC25A32 knockout on the mitochondrial proteome 
 
4.6.1. Changes in protein abundance were observed in SLC25A32 knockouts by Western 
Blot 
 
For an initial investigation into differences in protein abundance between the SLC25A32 KO and 
parental HAP1s, proteins were chosen that had shown decreases in previous work with the RFK 
knockdown 143B cells. Western Blot using fluorescent secondary antibodies allowed the extent of 
change to be quantified.  
 
Figure 4.13 Quantitative Western Blot for flavin containing subunits of complex I and II. 20 μg cell lysates 
from conditioned HAP1s and SLCKO were run on SDS-PAGE and probed for protein abundance. Loading was 
accounted for by the signal from VDAC1 or Drp1 antibodies and data adjusted. Protein abundance in SLC25A32 
KO is shown as a percentage of HAP1 protein levels. A representative blot for SDHA and NDUFV1 are shown. 
Error bars denote standard error and * show a significant decrease, P<0.05, by unpaired T-test. 
 
Figure 4.13 shows data for NDUFV1 and SDHA, proteins which showed large decreases in previous 
data, two-fold and four-fold respectively. In the SLC25A32 knockout these proteins also showed 
differing abundance, <20% for SDHA and <70% for NDUFV1 compared to the control. Due to their 
roles as the flavin cofactor binding subunits in complexes I and II this correlates with the activity data 
from Figures 4.6 and 4.7, demonstrating inactive complex I and II. These initial experiments indicated 
that SLCKO displayed considerable differences in key complex I and II subunits and this could extend 
to other mitoflavoproteins; therefore a more comprehensive review of these changes by SILAC was 
undertaken.  
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4.6.2. SILAC confirmed changes in protein abundance when SLC25A32 was knocked out 
in conditioned HAP1s  
 
SILAC was performed on conditioned HAP1 and SLC25A32 knockout cells to compare relative protein 
abundances. Ideally the experiment would have been repeated three times in each labelling orientation 
to provide robust data. However both cell lines displayed limited growth rates and viability in SILAC 
conditions, independent of labelling orientation, and so data could only be collected once for each 
labelling direction. This effect may be due to the necessary use of dialysed FBS (Chapter 2, section 
2.7.1). From the SILAC analysis 2805 proteins were detected in both cell lines, across both labelling 
orientations, to provide a heavy:light labelled (H/L) ratio. Figure 4.10 displays the data as Log2 H/L, 
where the SLC25A32 knockout was heavy-labelled and HAP1 un-labelled in the forward direction. 
Therefore, proteins with positive values were increased in the knockout and those with negative values 
decreased in abundance. The reverse labelling ratios were inverted to account for the opposite labelling 
- so that positive and negative values were comparable to the forward orientation. Those proteins with 
a three-fold or greater change in abundance in both labelling orientations were deemed considerably 
different between the samples (Log2 ratio ≥ 1.58) and those with a greater than two-fold change highly 
changed (Log2 ratio ≥ 1.00). 
 
 
 
Figure 4.14 SILAC data comparing protein abundance from conditioned HAP1 and SLC25A32 KO cells. 
Single repeat data from each labelling orientation are shown. Data are displayed as Log2 H/L forward ratio against 
the inverted Log2 H/L reverse ratio; such that positive H/L ratios in each orientation (top right quadrant) represent 
proteins with higher abundance in the SLC25A32 KO and negative values indicate decreased abundance in the 
knockout. Proteins with greater than two-fold increase (in both labelling orientations) are highlighted in green and 
those with a greater than two-fold decrease in the knockout are in orange. SLC25A32 protein abundance is shown 
in pink. 
 
 
SLC25A32
greater than two-fold increase in SLCKO
greater than two-fold decrease in SLCKO
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Figure 4.14 highlights that most proteins clustered around the axes intersection, showing unchanged 
abundance (Log2 = 0), whereas 38 were more than two-fold decreased in the knockout, highlighted in 
orange, and 21 were increased, shown in green (Appendix 7.6). Of the proteins with decreased 
abundance in the knockout 17 were non-mitochondrial, two were predicted mitochondrial and 19 were 
mitochondrial proteins. These included six complex III subunits, five mitoflavoproteins, one ATP 
synthase subunit and one complex II subunit. Of the non-mitochondrial proteins the plasma membrane 
riboflavin transporter SLC52A2 was more than three-fold lower than the control; however this must be 
interpreted with caution as the sample should not contain non-mitochondrial elements and so these 
proteins may not be equally represented by both samples.  
 
The SLCKO contains a deletion in exon 2 of SLC25A32, yet the protein was detected in both cell lines 
- though with a greater than two-fold decrease in the knockout. Seven unique peptides were detected by 
SILAC, with sequence coverage of 29.2%. Figure 4.15 shows the position of these peptides along the 
protein sequence; the six peptides (grey) detected in both cell lines covered the length of the protein but 
did not include sequence from exon 2 (underlined), where the 8 bp deletion is found (highlighted in red). 
The peptide missing from SLC25A32 KO cells (yellow) crosses the exon boundary from exon 1-2 and 
indicates that exon 2 was only translated in the HAP1 cells. Therefore, in the knockout, peptides could 
be detected from non-functional protein generated through alternative splicing to skip exon 2 – with 
protein generated from exons 1 and 3-7. Peptides corresponding to sequence from exon 2 were only 
detected in the HAP1 cells, as all seven exons were translated. Exon skipping induced by CRISPR 
deletions has been reported previously and allows the translation of protein despite a disrupted reading 
frame – usually resulting in a non-functional protein, although it also has the potential to encode gain of 
function or partially functional proteins (Mou et al., 2017).   
 
 
Figure 4.15 SLC25A32 peptides identified by mass spectrometry during SILAC analysis comparing protein 
abundance from conditioned HAP1 and SLC25A32 KO cells. The protein sequence for SLC25A32 is annotated 
with the seven unique peptides detected by mass spectrometry in the SILAC experiments. Those in grey were 
found in both the HAP1 and SLC25A32 cell lines – different shades are used because the final peptides (starting 
EGVG and GIAP) cover overlapping sequence (both include the sequence in light grey) but represent two unique 
peptides rather than one. The yellow peptide was only found in HAP1 cells. Exon 2 is underlined and the three 
residues disrupted by the 8 bp deletion in the knockout are highlighted in red. 
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4.6.2.1. N-domain complex I subunits were the most decreased in abundance across the 
whole enzyme in conditioned SLC25A32 knockout cells 
 
 
 
Figure 4.16 SILAC data comparing protein abundance from conditioned HAP1 and SLC25A32 KO cells. 
Single repeat data from each labelling orientation are shown. Data are displayed as Log2 H/L forward ratio against 
the inverted Log2 H/L reverse ratio; such that positive H/L ratios in each orientation (top right quadrant) represent 
proteins with higher abundance in the SLC25A32 KO and negative values indicate decreased abundance in the 
knockout. Complex I subunits are highlighted in dark blue and assembly factors in purple. 
 
Complex I subunit coverage in each orientation was over 80%, however only 28 subunits were detected 
in both directions to provide H/L ratios (Appendix 7.6). As shown in Figure 4.16, none displayed a 
greater than two-fold change in abundance, although NDUFV1, NDUFV2 and NDUFS1 were among 
the most decreased subunits, with a decrease in abundance of just below two-fold. Additionally the 11 
assembly factors detected displayed unchanged abundance when compared to the HAP1 control. It is 
interesting that despite the very low OCR of the knockout and lack of in-gel activity for complex I, there 
was no striking difference in abundance of complex I subunits. These differences are in line with the 
moderate decrease in NDUFV1 of 33%, as detected through Western Blot. However neither SILAC nor 
Western blotting give any indication of complex I structure, therefore whilst the abundance of complex 
I subunits may be largely unchanged the proportion present as the fully assembled enzyme may differ.  
 
NDUFV1
NDUFV2
NDUFS1
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4.6.2.2. Complex III subunits were highly decreased in the conditioned SLC25A32 
knockout cells 
 
  
 
Figure 4.17 SILAC data comparing protein abundance from conditioned HAP1 and SLC25A32 KO cells. 
Single repeat data from each labelling orientation are shown. Data are displayed as Log2 H/L forward ratio against 
the inverted Log2 H/L reverse ratio; such that positive H/L ratios in each orientation (top right quadrant) represent 
proteins with higher abundance in the SLC25A32 KO and negative values indicate decreased abundance in the 
knockout. Complex II subunits are shown in orange, complex III subunits in green, complex IV in gold and 
complex V subunits are highlighted in light blue. Subunits with a greater than two-fold decrease in the conditioned 
knockout (in both labelling orientations) are labelled. 
 
The abundance of subunits from the remaining respiratory chain complexes was also assessed. Figure 
4.17 highlights all subunits detected: two from complex II (orange), eight complex III subunits (green), 
eight from complex IV (gold) and 15 from complex V (cyan) (raw data in Appendix 7.6). These subunits 
were either unchanged in abundance or decreased in the knockout. Complex II subunit SDHB showed 
decreased abundance of more than two-fold and SDHA was also less abundant, decreased by at least 
1.8-fold. This difference in subunit levels correlates with the lack of complex II in-gel activity in the 
knockdown (Figure 4.11) and lowered abundance detected by Western Blot for SDHA (although this 
was more pronounced at ~ five-fold, Figure 4.13). FAD is covalently bound to SDHA, unlike non-
covalent association of FMN with NDUFV1, and this may confer some stability; therefore lack of the 
cofactor may have a larger effect on protein structure (Kim et al., 2012). 
 
In contrast complex V subunits were largely unchanged, with the exception of ATP-8 that was lowered 
by over two-fold. However as a small hydrophobic subunit this may be an artefact of mass spectrometry 
and not accurately represent protein abundance. Complex IV subunits were also mostly unchanged, 
although the zinc binding COX5B and dimerising subunit COX6B1 were less abundant. This could 
UQCRB
UQCRC2
UQCRH
CYC1
UQCRC1
UQCRQ
SDHB
ATP8
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indicate some differences in turnover of complex IV subunits in the knockout, although Figure 4.12 
demonstrates that complex IV activity was comparable to the control. 
  
The most striking change in respiratory complexes relates to complex III. Figure 4.13 demonstrates a 
shift in all eight detected subunits towards a decrease in the knockout and the abundance of six subunits 
was more than two-fold lower. Although this complex does not contain a flavin cofactor, it is 
immediately downstream of complex I and II, deriving electrons from ubiquinol to reduce cytochrome 
c. The data therefore suggest that changes to complex I and II due to flavin depletion cause changes 
further along the respiratory chain. The disparity lies in the large changes observed for complex III 
compared to the relatively unchanged protein abundances for complex IV and V subunits, as it might 
be expected that all downstream complexes would be affected. 
 
4.6.2.3. A subset of mitoflavoproteins showed decreased abundance in SLC25A32 
knockout cells 
 
 
 
Figure 4.18 SILAC data comparing protein abundance from conditioned HAP1 and SLC25A32 KO cells. 
Single repeat data from each labelling orientation are shown. Data are displayed as Log2 H/L forward ratio against 
the inverted Log2 H/L reverse ratio; such that positive H/L ratios in each orientation (top right quadrant) represent 
proteins with higher abundance in the SLC25A32 KO and negative values indicate decreased abundance in the 
knockout. Mitoflavoproteins are shown in orange and those with a greater than two-fold decrease in the 
conditioned knockout (in both labelling orientations) are labelled. 
 
 
The response of mitoflavoproteins to SLC25A32 knockout was analysed, particularly in light of a 
possible hierarchy observed from SILAC data in Chapter 3, section 3.10.3. Of the 32 human 
mitoflavoproteins 25 were detected, highlighted in orange in Figure 4.18 (raw data in Appendix 7.6). 
PRODH
IVD
TXNRD2
FDXR
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Overall there was a shift towards lowered abundance in the SLC25A32 knockout, but as noted before 
there was a range of effects, not all mitoflavoproteins are affected to the same extent. Four demonstrated 
a greater than two-fold decrease: NADPH:adrenodoxin oxidoreductase (FDXR), isovaleryl-CoA 
dehydrogenase (IVD), proline dehydrogenase 1 (PRODH) and thioredoxin reductase 2 (TXNRD2). IVD 
and PRODH are involved in amino acid metabolism, whereas TXNRD2 is a thioredoxin reductase and 
FDXR is the first electron acceptor of mitochondrial P450 systems; however all require a non-covalently 
bound FAD cofactor (Tiffany et al., 1997; Bender et al., 2005; Sibbing et al., 2011, Ziegler et al., 1999). 
Another six flavoproteins demonstrated a lower abundance in the SLCKO, including both flavoproteins 
from complex I and II. The acyl-CoA dehydrogenase ACADVL, the electron-transfer flavoprotein 
ETFDH and glutaryl-coA dehydrogenase (GCDH), which transfers electrons to ETFDH, were also 
decreased, along with the porphyrin-related oxidase PPOX. Five other mitoflavoproteins also showed 
depletion, however the extent of this change was not consistent between the labelling orientations.  
 
 
 
Figure 4.19 Schematic representation of folate metabolism and the compartmentalisation into the cytosol 
and mitochondria.  Enzymes responsible for catalysis at each step are written next to the arrows. Cytosolic 
enzymes: MTHFD1, methylenetetrahydrofolate dehydrogenase 1, SHMT1, serine hydroxymethyltransferase, 
DHFR, dihydrofolate reductase. Mitochondrial enzymes:  ALDH1L2, aldehyde dehydrogenase 1 family member 
L2, MTHFD1L, methylenetetrahydrofolate dehydrogenase 1-like, MTHFD2, methylenetetrahydrofolate 
dehydrogenase 2 – those detected in SILAC are highlighted in purple. Figure adapted from Miyo et al., 2017. 
 
Additionally, due to the prior assignment of SLC25A32 as the mitochondrial folate transporter, enzymes 
involved in folate metabolism were analysed (Appendix 7.6). Folate metabolism is compartmentalised 
into the nucleus, cytoplasm and mitochondria (Nijhout et al., 2006), Figure 4.19. Of the mitochondrial 
enzymes detected the bifunctional methylenetetrahydrofolate dehydrogenase MTHFD2 showed no 
appreciable change; serine hydroxymethyltransferase (SHMT2) and monofunctional C1-
tetrahydrofolate synthase (MTHFD1L) also showed no change, although there was discrepancy between 
the labelling orientations. Therefore, from this data, there is little indication that SLC25A32 knockout 
caused changes in mitochondrial folate-related enzyme abundance.  
 
147 
4.7. SLC25A32 knockout causes cell wide transcriptional changes 
 
Total RNA was purified from conditioned HAP1 and SLC25A32 knockout cells as biological triplicates 
and analysed by transcriptome profiling (Eurofins NGS Favourite Transcriptomics Service). The 
transcripts detected, measured as transcripts per million (TPM), were processed by Dr Alan Robinson 
using DESeq2 (Love et al., 2014) to obtain the fold change and adjusted p-value for the expression of 
each gene in the SLC25A32 KO compared to the HAP1 control. Adjusted p-values take into account 
both the level of change in expression and the variability between multi-sample testing, therefore this 
value was used to sort the data for interpretation, rather than using the fold change alone, with a cut-off 
of P <0.05 to denote significant differential expression.  
 
 
Figure 4.20 Principal component analysis (PCA) plot. The TPM for the 500 most differentially expressed genes 
were assessed for each sample using the online platform ClustVis (Metsalu and Vilo, 2015). For the six samples 
the three knockouts were more similar to one another than to the controls. The first component, PC1, accounted 
for 81.7% of the variance and overall both components represented 86.9%, demonstrating the reliability of the 
triplicates.  
 
Figure 4.20 shows a PCA plot for the data, with most variance between the sample types than between 
the triplicates. Heat mapping of differentially expressed genes in Figure 4.21B also demonstrates the 
grouping of the triplicates and the difference in expression profiles between the cell lines. 
Transcriptomics resulted in the detection of 11965 gene transcripts, of which 2054 were significantly 
differentially expressed (P <0.05) - 51% of these showed decreased expression in the knockout. 
Interestingly only 8% of these were assigned mitochondrial proteins, which represented 16% of the total 
mitochondrial protein gene transcripts detected. When compared to the proportion of non-mitochondrial 
proteins that were differentially expressed (17%) this result implied there was no difference between the 
level of expression change in mitochondrial protein genes compared to other cellular proteins. The 
transcriptome data was assessed for changes in expression of proteins of interest, particularly those 
involved in oxidative phosphorylation, riboflavin handling and folate metabolism. As expected a large 
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number of transcription factors were among the most differentially expressed genes. Regulating multiple 
pathways could be a strategy to implement large-scale changes in gene expression – 22% of the top 50 
most differentially expressed were transcription factors (raw data in Appendix 7.7). 
 
 
 
 
Figure 4.21 Transcriptional differences between HAP1 and SLC25A32 KO cell lines. A. Volcano plot of all 
detected genes. Data are plotted on as Log2 for fold change and as -Log10 for adjusted P-value. Adjusted P-value 
was used to determine significantly differentially expressed genes, P <0.05, with differentially expressed 
mitochondrial protein genes shown in orange and non-mitochondrial protein genes shown in blue. Non-
significantly expressed genes from the two groups are shown in light orange and light blue respectively. 
Mitochondrial proteins were assigned using the IMPI database (version Q3, 2017; Smith & Robinson, 2016). B.  
Heatmap showing the expression profile of each sample for all genes with adjusted P-value <0.05. Data was 
plotted using TPM for each sample using the online platform Heatmapper (Babicki et al., 2016). Green bars show 
up-regulated genes and red down-regulated genes - clustering demonstrates that the HAP1 and SLCKO triplicates 
have a distinct profile of differentially regulated genes.  
A. mitochondrial protein genesnon-mitochondrial protein genes
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4.7.1. Transcriptional changes to SLC25A32 
 
 
Figure 4.22 Volcano plot of all genes encoding mitochondrial proteins, showing SLC25A32 was one of the 
most differentially expressed of these genes. Data are plotted on as Log2 for fold change and as -Log10 for 
adjusted P-value. Adjusted P-value was used to determine significantly differentially expressed genes, P <0.05, 
with differentially expressed mitochondrial protein genes shown in orange and non-significantly expressed 
mitochondrial protein genes in light orange. SLC25A32 is highlighted in green Mitochondrial proteins were 
assigned using the IMPI database (version Q3, 2017; Smith & Robinson, 2016). 
 
As shown in Figure 4.22, SLC25A32 was detected as one of the most differentially expressed 
mitochondrial protein encoding genes; in the knockout cell line mRNA were detected at 2.25-fold lower 
levels. To investigate this further the coverage across the whole gene was assessed and analysed by 
exon, with read depth for the first three exons shown in Figure 4.23. CRISPR resulted in a frameshift 
deletion in exon 2 that introduced a premature termination codon (PTC, section 4.4.2), and due to its 
location in an early exon is known to trigger nonsense-mediated decay (Popp & Maquat, 2016). 
Therefore only low steady-state levels of abberant transcripts are likely, due to their rapid degradation, 
yet the transcriptome demonstrated coverage across the whole of SLC25A32. However read depth was 
greatly decreased, in the HAP1 control reads/base of up to 300 were detected but in the knockout values 
did not exceed 100, Figure 4.23. Interestingly there was a similar magnitude of decrease in reads (around 
three-fold) across theentire gene – exemplified by exons 1 and 3 in Figure 4.23 – and so the overall trend 
in covergae was retained. Reads across exon 1 were comparatively low in both cell lines, particularly at 
the 5’ end, with higher reads across exon 3 in both cell lines. In contrast, in HAP1 the coverage across 
exon 2 was similar to that of exon 3, whereas SLCKO showed a disproportional decrease with a 
SLC25A32 
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complete absence of coverage across the region targeted by CRISPR, Figure 4.23. Although this was 
unexpected, given that the gene should have been knocked out, there have been reports of unintended 
outcomes when using CRISPR to affect genomic level knockout. Xue and co-workers demonstrated that 
sgRNA causing a frameshift indel resulted in a moderate decrease in mRNA levels of the oncogene 
Kras and specifically fewer reads across exon 2, which contained the deletion, in adrenocarcinoma 
mouse cells. Exon-skipping was identified as responsible due to the presence of alternative splice 
variants, confirmed by reverse transcription PCR (Mou et al., 2017). This has also been demonstrated 
in HeLa cells, a single base insertion in FLOT1 resulted in mRNA corresponding to multiple splice 
variants, indicating that the insertion caused alternative splicing, therefore transcripts included different 
exons, although the correct exon-intron boundaries were used (Kapahnke et al., 2016). Consequently, 
in the same way that SLC25A32 peptides were detected by SILAC in the knockout cell line, 
transcriptomics also suggests that the CRISPR-mediated deletion did not confer a complete SLC25A32 
knockout. 
 
 
 
 
Figure 4.23 Transcript analysis for HAP1 and SLCKO across the first three exons of SLC25A32 clearly 
shows the deleted region in exon 2. Reads per base for HAP1 are shown in blue and SLCKO in pink aligned with 
the cDNA sequence. HAP1 shows good coverage with read depth up to 300, whereas SLCKO shows overall lower 
coverage across all three exons (<100) with the greatest decrease observed for exon 2. The gap in the sequence 
corresponds to the deleted region in the CRISPR knockout.  
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4.7.2. Folate metabolism and riboflavin-handling pathways  
 
The most differentially expressed gene in the knockout was ALDH1A2, an aldehyde dehydrogenase, 
which was down-regulated by over 30-fold. This hormone signalling protein catalyses the synthesis of 
retinoic acid and is key to development, but is not a flavoprotein and has no direct role in either folate 
or riboflavin metabolism. However there may be a link between retinoic acid and increased folate 
receptor expression, as investigated in cultured mouse and human cells (Bolton et al., 1999). The folate 
receptor is responsible for folate uptake by the cell and therefore changes to its expression would 
profoundly affect cellular folate metabolism. Folate receptor transcripts were detected in the 
transcriptome analysis, however no significant change was observed – therefore the significance of 
altered ALDH1A2 expression in the knockout remains unclear. However it was striking that the second 
most differentially expressed gene is directly involved in folate metabolism. The plasma membrane 
bound folate hydrolase, FOLH1, was down-regulated by over 16-fold in the knockout. Despite being 
upstream in the folate-handling pathway from SLC25A32, its lowered expression suggests that folate 
movement within the cell is altered in the knockout. However FOLH1 is also involved in alanine, 
aspartate and glutamate metabolism, which is more closely linked with mitochondria and the citric acid 
cycle - therefore this change in expression could be related to wider mitochondrial changes. The 
transcripts of nine other folate metabolising enzymes were detected – four cytosolic (DHFR, MTHFR, 
MTHFD1 and SHMT1) protein genes displayed no change in expression, along with MTHFS, 
MTHFD1L, MTHFD2 and SHMT2 that are localised to the mitochondria. However mitochondrial 
MTHFD2L showed differential expression, although the increase in expression was low (less than two-
fold). Thus on a transcriptional level there was no consistent change in levels of folate metabolising 
enzymes as a result of SLC25A32 knockout.  
  
Similarly proteins involved in riboflavin handling were assessed for transcriptional regulation. The 
plasma membrane transporter SLC52A2 and RFK were both unaffected by the knockdown, however 
the FADS gene (FLAD1), which encodes both a cytoplasmic and mitochondrial isoform was 
significantly reduced (P = 1.778 x10-10). FLAD1 was down-regulated by more than two-fold and as the 
FADS1 isoform is present downstream of mitochondrial transport this may represent some regulation 
by the cell, to decrease FAD production in response to lowered mitochondrial flavin concentration; 
although both isoforms would be affected.  
 
4.7.3. Mitoflavoproteins 
 
The transcription profiles of 28/32 known human mitoflavoproteins were detected, however only two, 
dimethylglycine dehydrogenase (DMGDH) and NDUFV1, showed a significant difference in 
expression. Unusually DMGDH expression was increased, which is counter-intuitive since this enzyme 
requires an FAD cofactor. However it is involved in amine metabolism and therefore its transcriptional 
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regulation may be dominated by changes in this pathway. Once again the transcriptome data indicates 
that any changes to the mitoflavoproteome in SLC25A32 knockout cells, as suggested by the SILAC 
data (Figure 4.18), are not due to gene regulation - protein abundance may be affected by decreased 
stability or increased turnover.  
 
4.7.4. Transcriptional changes in complex I genes 
 
  
 
Figure 4.24 Volcano plot for differentially expressed mitochondrial protein genes. Data are plotted as Log2 
for fold change and as -Log10 for adjusted P-value. Adjusted P-value was used to determine significantly 
differentially expressed genes, P <0.05, and the y-axis cut-off set at this value. Complex I subunit genes are shown 
in purple, assembly factor genes in blue and SLC25A32 in green (acting as a positive control).  
 
Transcripts for all 44 complex I subunit genes were detected but only 32% were differentially expressed; 
12 were down-regulated and two up-regulated (Figure 4.24). ND2 and ND3 showed significantly 
increased expression, whilst all other mtDNA-encoded subunits also displayed transcript increases in 
the knockout. This contrasts to the nuclear-encoded subunits, which, apart from NDUFS4 and NDUFC2, 
all demonstrated decreased expression. It is difficult to interpret this observation, especially given the 
lack of SILAC data for the ND subunits, but it may indicate some difference in regulation of the 
mitochondrial-encoded respiratory chain subunits compared to the nuclear-encoded subunits in the 
knockout; especially given the differential expression of the two mtDNA-encoded ATP synthase genes 
(Table 4.1). However the transcripts from the mtDNA-encoded complex III and IV genes were not 
detected.  
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Figure 4.25 Expression and abundance comparison for differentially expressed complex I subunit and 
assembly factor genes. 12 subunits and three assembly factors were significantly differentially expressed in the 
transcriptomics data (P <0.05) – 11 subunits (purple) and two assembly factors (blue) were detected by SILAC. 
Negative values denote decreased expression or abundance in the SLC25A32 KO compared to the HAP1 control. 
To compare the two data sets the forward and reverse values for fold change in abundance from the SILAC (section 
4.6.2.2) were averaged and plotted against fold change in expression. This demonstrated that subunits separated 
into two cohorts, those with correlating expression and abundance and those with no consensus.  
 
 
Although 12 complex I subunits displayed a significant decrease in expression none of these changes 
resulted in a large fold decrease and when compared to their structural location there was little 
correlation. Despite NDUFV1 showing significant down-regulation its neighbouring subunits 
(NDUFS1, NDUFV2, NDUFA2) did not display considerable changes. To further investigate whether 
complex I subunits were under altered transcriptional control, the transcriptome (gene expression) and 
SILAC (protein abundance) data from the differentially expressed subunits were compared. Figure 4.25 
shows that the 11 subunits detected in both experiments separated into two groups – six showed both 
lowered expression and abundance whilst five only showed decreased expression. Changes in protein 
abundance of NDUFV1, NDUFS5 and NDUFB4 (shown by a greater than 1.5-fold decrease in SILAC) 
are likely to result from down-regulation of gene expression, as transcripts detected were also decreased 
by greater than 1.5-fold in the knockout. However, in general, there was little consensus between the 
transcription profile and protein abundance of complex I subunits, which would indicate that changes 
in protein levels observed by SILAC were independent of transcriptional control. Additionally, the three 
complex I assembly factors with significant down-regulation (Figure 4.24: NDUFAF1, NDUFAF2 and 
TMEM70) also demonstrated little correlation with the SILAC data (NDUFAF2 and TMEM70 in Figure 
4.25). These assembly factors are involved in building different subcomplexes, making it difficult to 
rationalise the changes in expression observed. 
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4.7.5. Differential expression of respiratory chain genes 
 
Gene Chromosome Fold change Adjusted P-value 
NDUFS2 1 1.79 1.05 x10-7 
MT-ND3 MT 1.87 4.92 x10-4 
NDUFB10 16 1.51 9.85 x10-4 
NDUFAB1 16 1.49 2.01 x10-3 
NDUFB4 3 1.35 2.07 x10-3 
NDUFB7 19 1.38 3.70 x10-3 
NDUFB3 2 1.36 5.99 x10-3 
NDUFB11 X 1.28 7.27 x10-3 
NDUFS7 19 1.35 9.56 x10-3 
NDUFA9 12 1.29 1.52 x10-2 
NDUFS5 1 1.24 1.65 x10-2 
NDUFA6 22 1.31 2.10 x10-2 
MT-ND2 MT 1.86 2.41 x10-2 
NDUFV1 11 1.28 3.10 x10-2 
SDHC 1 1.58 4.07 x10-6 
UQCR11 19 1.39 1.26 x10-3 
UQCRC1 3 1.31 4.75 x10-3 
UQCR10 22 1.34 5.33 x10-3 
UQCRH 1 1.32 1.48 x10-2 
COX5A 15 1.54 6.93 x10-8 
COX6B1 19 1.30 5.46 x10-3 
COX5B 2 1.38 1.52 x10-2 
COX4I1 16 1.24 1.62 x10-2 
COX6A1 12 1.26 1.86 x10-2 
ATP5G1 17 1.46 1.74 x10-5 
ATP5J2 7 1.44 5.92 x10-5 
ATP5I 4 1.48 4.73 x10-4 
ATP5J 21 1.33 2.07 x10-3 
MT-ATP6 MT 1.77 4.78 x10-3 
ATP5S 14 1.39 1.02 x10-2 
MT-ATP8 MT 1.66 1.30 x10-2 
ATP5G3 2 1.34 2.65 x10-2 
ATP5H 17 1.21 4.39 x10-2 
 
Table 4.1 Differentially expressed respiratory chain subunit genes. Subunits from each of the five complexes 
that were differentially expressed between HAP1 and SLC25A32 KO lines are shown. Genes are ordered within 
each complex by adjusted P-value. Fold change is highlighted in red for down-regulation and green for up-
regulation in the SLC25A32 knockout.  
 
Although some subunit genes from each of the complexes were significantly differentially expressed, 
as shown in Table 4.1, the change in expression was below two-fold, consistent with the lack of large 
changes in protein abundance, determined by SILAC. However, the expression of two overlapping 
mtDNA-encoded subunits of complex V, ATP6 and ATP8, were significantly up-regulated, similarly to 
mtDNA-encoded ND2 and ND3 of complex I. ATP8 displayed an increase in expression but 
considerable decrease in protein abundance, although (as previously stated) it is a small hydrophobic 
protein and likely to be inconsistently detected by mass spectrometry. Comparing transcriptome and 
SILAC data (Figure 4.13) suggests that the differences in complex II subunit levels (SDHA and SDHB) 
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arose at protein level, from decreased stability or increased turnover, rather than from expression 
regulation, as there was no change in expression, although SDHC showed some down-regulation. This 
indicates that the lack of flavin has a direct effect on the SDHA protein and perhaps, due to its structural 
association, SDHB is also detrimentally affected. 
 
Importantly, complex III subunits displayed a noticeable shift towards lowered abundance in SLC25A32 
knockout cells, as shown by Figure 4.17. This is particularly interesting because the complex does not 
contain a flavin cofactor, therefore depleted flavin would not be expected to directly affect the protein. 
However, complex III subunits also demonstrated lowered transcript levels; Table 4.1 shows that 
UQCRC1, UQCR10, UQCR11 and UQCRH were differentially expressed and transcripts for all eight 
complex III subunits detected were down-regulated to some extent. Transcriptional regulation may 
therefore result in lowered complex III expression, which is also detected as decreased protein 
abundance. This could reflect a cellular response to flavin depletion and disruption of complexes I and 
II. Thus, the reason for changes in complex III abundance differs from the impact on complex II, which 
is likely to be caused by direct protein disruption due to the lack of flavin, and suggest that changes to 
complex III were instigated as a cellular feedback response, on a genomic level.  
 
4.7.6. The respiratory chain was the most down regulated pathway in the SLC25A32 
knockout cells 
 
 
Figure 4.26 Protein networks down regulated in SLC25A32 knockout cells. Differentially expressed genes 
(adjusted P-value <0.05) were assessed by protein interactions to explore changes in cellular pathways. Analysis 
was done using the online platform Network Analyst (Xia et al., 2015). The top ten most down regulated pathways 
by P-value are shown using the STRING interactome with a zero order network and the Reactome database. 
Numbers in parenthesis denote the number of genes down regulated compared to the total number in the network. 
Although it is informative to investigate changes in expression for certain gene sets, particularly those 
associated with the putative function of SLC25A32 and complex I, it is also interesting to adopt a non-
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biased approach and explore changes in protein networks as a result of SLC25A32 knockout. This was 
achieved using Network Analyst (Xia et al., 2015) to assess the differentially expressed genes and 
arrange them into an interaction network, using the STRING interactome. Figure 4.26 demonstrates the 
ten most down-regulated pathways, clearly showing the respiratory chain as the most suppressed 
pathway across the SLCKO cells. The top three networks incorporate slightly different proteins but all 
centre on the four respiratory chain complexes. Results using the Reactome protein network also 
highlights general metabolism as being down-regulated, which although non-specific does imply that 
large-scale changes have been instigated by the knockout. There has also been considerable disruption 
to the cell cycle and the endosomal pathway of the major histocompatibility complex. 
 
4.8. Complexomics demonstrated that the N-domain of complex I was still assembled in 
the mitochondria of SLC25A32 knockout cells  
 
 
Figure 4.27 Mitochondrial samples from conditioned HAP1 and SLCKO cells used for complexome 
analysis. Mitochondria were purified from cells lines, as described in Chapter 2, section 2.3.3, and solubilised in 
1.2% DDM prior to BN-PAGE. 10 μg protein was loaded and the Serva Native ladder used to indicate protein 
masses. Once run the gel was stained with Coomassie before submission for complexome analysis - both the 
sample lanes were cut into 64 even slices - direction of slice numbering shown.  
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Figure 4.28 Protein mass calibration curves for mitochondrial complexomes. Although both samples were 
run on the same gel for better comparison of complexes and their estimated masses, calibration curves were 
constructed. Proteins and protein complexes of known masses were chosen to determine molecular weight 
migration values in each gel slice. A. HAP1. B. SLCKO. Protein masses were obtained from the UniProt database 
(UniProt Consortium T, 2018). Table of proteins used in Appendix 7.8A&B. 
 
 
Complexomics was used to build on SILAC and transcriptomics data by investigating the structure of 
complex I, and other respiratory complexes, in the SLC25A32 knockout (raw data in Appendix 
7.8C&D). Figure 4.27 shows the BN-PAGE of 10 μg mitochondria samples for SLCKO and the control 
HAP1. The calibration curves in Figure 4.28 were used to determine the estimated mass of complexes 
found in each slice (table of proteins used in Appendix 7.8A&B). Slice 44 of the HAP1 complexome 
failed during mass spectrometry measurements and so was omitted from analysis; slice 64 from the 
SLCKO complexome was also unusable – so the last slice of both complexomes was removed.  
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Figure 4.29 Distribution of complex I across gel slices after BN-PAGE. A. HAP1 and B. SLCKO migration 
profiles of complex I subunits. Distinct populations of complex I subunits were observed in the HAP1 control, 
whereas in the knockout the position of mature complex I was spread over multiple slices as a broad peak. The 
four subunits of the distal N-domain are highlighted: NDUFV1 in navy, NDUFV2 in blue, NDUFS1 in purple and 
NDUFA2 in pink.   C. Position of the four subunits in the distal N-domain, coloured to match the profiles. The 
position of FMN is shown in orange. The human model of complex I was constructed using mouse complex I 
cryo-EM structures (Chapter 6, section 6.6).  
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Figure 4.29A and B show the clustering profiles of complex I subunits for HAP1 and SLCKO, 
respectively. 42/45 subunits were detected in HAP1 mitochondria (missing ND3, ND4L and NDUFB2) 
and 41/45 subunits were detected in SLC25A32 knockout mitochondria (missing ND3, ND4L, 
NDUFB2 and NDUFV3). Unlike previous analysis of complexomes from 143B cells (Chapter 3, section 
3.8.1, Figure 3.22) the complex I profile in HAP1 cells did not show a single complex I population; 
instead the HAP1 control showed a dual peak profile ~1000 kDa. This has not been observed previously, 
and although the profile may represent two populations of complex I, no differences could be found to 
account for the migration difference – the same number of subunits and low levels of assembly factors 
were present in each. The experiment was repeated and the same profile obtained for complex I in the 
HAP1 control, therefore the cause of this unusual distribution is yet to be determined. The SLC25A32 
knockout cell line, in contrast, displayed a more typical complex I profile of a single broad peak 
spanning several slices at 958-1131 kDa. Despite some uncertainty over the complex I distribution from 
the control complexome, information on the flavin containing N-domain could still be ascertained. As 
shown in Figure 4.29, the migration of the four subunits (NDUFV1, NDUFV2, NDUFS1 and NDUFA2) 
comprising the distal region of the flavin (N-) domain was analysed. These subunits are the final 
subcomplex to be assembled onto complex I during biogenesis. As previously discussed, SLCKO cells 
showed no observable complex I activity by in-gel activity (section 4.5.3.1) and compromised OXPHOS 
(section 4.5.1), which raised the question of whether the N-domain is assembled in the absence of flavin. 
Lack of complex I activity could arise from the enzyme missing the FMN containing N-domain, or 
perhaps just lacking the cofactor. The distribution of these subunits provides insight into when FMN is 
inserted into NDUFV1 and the impact of this on the stability of the enzyme. Complexome analyses 
indicate that despite lack of FMN the N-domain is correctly assembled, with NDUFV1, NDUFV2, 
NDUFS1 and NDUFA2 present in slices corresponding to complex I in the SLCKO profile, Figure 
4.29B. Compared to the HAP1 control, Figure 4.29A, there is little difference in the migration patterns 
of these subunits, they are both present at around 1000 kDa, as part of the complete enzyme, and at low 
molecular weights in their monomeric forms. Although there appears to be slightly lower relative 
intensities of these subunits associated with complex I in the knockout, and therefore more in the free 
form, overall, even in the absence of the flavin cofactor, all complex I subunits are assembled. The 
difference between complex I in HAP1 and SLCKO cells, accounting for the difference in activity, is 
therefore likely to be only the missing cofactor, rather than a stalled, incompletely assembled enzyme. 
This is new information and suggests that FMN insertion into NDUFV1 may be the final stage of 
assembly, taking place once all protein subunits are present and may correlate with the removal of 
assembly factors to release active complex I. 
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Figure 4.30 Distribution of respiratory complexes III, IV and V across gel slices after BN-PAGE. A. HAP1 
and B. SLCKO migration profiles of subunits of complexes III and IV. Complex III subunits are shown in 
cyan and complex IV subunits shown in magenta. C. HAP1 and D. SLCKO migration profiles of subunits of 
complex V. Complex V subunits are shown in green. Profiles for different complexes are shown in separate panes 
of clarity. 
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The migration profiles of subunits from complex III and IV are shown in Figure 4.30A and B; both 
complexes displayed a similar profile in HAP1 and SLCKO. The complex III dimer migrated to 526 
kDa (calculated mass 490 kDa) in HAP1 with nine subunits detected and all subunits were also found 
to migrate to 787 kDa with lower intensities, indicating a subpopulation in the complex III2/IV 
supercomplex. Complex III appeared unaffected in SLCKO mitochondria; eight subunits were detected 
with an estimated mass of 536 kDa for the dimer. The complex III profile clearly indicates the presence 
of an intact population of complex III, with one high-intensity peak, and another larger molecular mass 
peak of lower intensity. This peak, at 811 kDa in SLCKO mitochondria, represents the III2/IV 
supercomplex (calculated mass 690 kDa) and although found at a larger mass than expected it contains 
subunits from both complexes III and IV, which do not co-migrate elsewhere. Lower relative intensities 
of complex III subunits were found in the supercomplex from SLCKO, compared to the control. It is 
unclear why SLC25A32 knockout would detrimentally impact complex III association with complex 
IV, however SILAC showed complex III subunits were decreased in abundance, Figure 4.17 – and 
therefore may reflect a change in proportions of complex III assemblies due to decrease in overall 
protein levels. 12 complex IV subunits were detected in the HAP1 samples and 11 in SLCKO, with both 
showing a peak in relative subunit intensities around the expected mass of the intact complex (200 kDa) 
– 235 kDa and 215 kDa respectively – although the highest intensity of all subunits was not found in a 
single slice. Unusually the SLCKO profile also highlighted an additional low intensity peak in complex 
IV subunits at 325 kDa, this represents a slight difference compared to the control. However, the 
presence of complex IV subunits within a supercomplex with complex III, at similar relative intensities 
in both samples suggests that in general this enzyme has not been substantially affected by the knockout. 
This supports the in-gel activity shown in Figure 4.12.  
 
The distribution of ATP synthase subunits was also assessed; they showed similar migration profiles for 
HAP1 and SLCKO, with a single peak containing the same 14 subunits at 787 kDa and 811 kDa 
respectively (calculated mass 770 kDa), Figure 4.30C and D. Additionally both complexomes showed 
a smaller molecular weight peak, (526 kDa in HAP1 and 493 kDa in SLCKO) containing moderate 
relative intensities of α, β, γ and δ subunits, which are all part of the F1 domain and could indicate the 
presence of subassemblies (Walker et al., 1985). This peak contained greater relative intensities of these 
subunits in the knockout, which may indicate a higher abundance of complex V assembly intermediates 
compared to the control. However, in both cell lines mature complex V was present and all subunits 
showed highest intensity in the intact complex. 
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Figure 4.31 Distribution of complex II across gel slices after BN-PAGE. A. HAP1 and B. SLCKO migration 
profiles of subunits of complex II. Subunits are shown in different colours: SDHA in red, SDHB in orange, 
SDHC in yellow and SDHD in brown.  
 
 
In contrast, the profile of complex II differed considerably between HAP1 and SLCKO, Figure 4.31. In 
the control there was a peak in all four subunits at 123 kDa, indicating complex II (calculated mass 130 
kDa) and a smaller peak at high molecular mass (1178 kDa), which may represent complex II in a 
supercomplex. However in the knockout the four subunits did not comigrate; a peak in SDHB relative 
intensity at 120 kDa showed only moderate relative intensities of the FAD containing subunit SDHA 
and SDHC, whereas the last subunit, SDHD, was absent and only found at low molecular weights, 
indicating a monomeric form. This suggests while HAP1 contained active succinate dehydrogenase, 
along with the subunits in their free forms, the SLC25A32 knockout did not contain mature complex II. 
The highest relative intensity of SDHA in the knockout was at 57 kDa and likely to correspond to 
monomeric protein (calculated mass of 72 kDa). Therefore a complete loss of complex II and the 
presence of subunits as monomers support the lack of complex II activity observed in section 4.5.3.2. 
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4.9. CRISPR deletions in exon 1 of SLC25A32 to further validate the effect of SLC25A32 
knockout 
 
CRISPR was used to generate knockout HAP1s with deletions in exon 1 as discussed in Chapter 2, 
section 2.3.3. These were designed to provide additional confirmation of the role of SLC25A32 in 
parallel with the commercially obtained SLC25A32 KO (SLCKO). 
 
 
Figure 4.32 Sequencing data showing successful deletion in SLC25A32 exon by CRISPR. Two colonies 
treated with sgRNA-1 construct were found to contain a deletion in the correct region. Sequence alignment of 
SLC25A32 (top line) and knockout cell lines (below) show exon 1 deletions. Highlighted in orange is the deleted 
region, CRISPR KO-1 demonstrated a 26 bp deletion and CRISPR KO-2 a 7 bp deletion. Both resulted in a frame 
shift that also brought a stop codon into frame, highlighted in red. The location of the sgRNA-1 target is underlined 
in green. 
 
FACS positive colonies were cultured and screened for deletions by PCR (Chapter 2, section 2.3.3). 
Two colonies were identified from treatment with the sgRNA-1 vector, deletions are shown in Figure 
4.32. These cells were then conditioned and incucyte data collected to investigate cell proliferation and 
morphology, with respiratory profiles obtained by extracellular flux analysis.  
164 
    
 
 
 
 
Figure 4.33 Growth profiles of CRISPR knockouts during conditioning stages. Cells were seeded at 
14,000/well with 4 ml of appropriate medium and incubated at 37 ºC for at least 160 hours. Incucyte software was 
used to record the change in growth, with images obtained every 4 hours and percentage confluence calculated. 
Error bars denote standard error. Cells were adapted from IMDM to riboflavin free DMEM in 25% increments 
after two passages. CRISPR KO-1 shows IMDM grown cells in dark green, IMDM: riboflavin free DMEM 25:75 
in lighter green and riboflavin-free DMEM in bright green. CRISPR KO-2 shows IMDM grown cells in dark 
purple, IMDM: riboflavin free DMEM 25:75 in pink and riboflavin-free DMEM in lilac. The bracket at later time 
points indicates increasing cell death. Data from one representative assay are shown. 
 
 
IMDM: riboflavin-free DMEM
100:0
25:75
0:100
IMDM: riboflavin-free DMEM
100:0
25:75
0:100
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Figure 4.33 highlights that conditioning these knockouts caused a similar restriction in growth to the 
commercial SLCKO, Figure 4.6, indicating increased stress due to low riboflavin media. Figure 4.30 
shows the OCR profile for each knockout compared to the control, with considerably lower basal oxygen 
consumption. The results are not as striking as the difference between the SLCKO and control (Figure 
4.8) but there was a clear difference between the two knockouts and the parental line – CRISPR KO-1 
had a lowered basal rate, ~60%, and CRISPR KO-2, ~50%, of the control. Unlike SLCKO, these cells 
displayed a decreased OCR with oligomycin addition and recovery, along with some uncoupling in 
CRISPR KO-1, on FCCP, Figure 4.34. Therefore to establish the extend of any differences between the 
commercial and homemade CRISPR knockout cell lines, full characterisation of CRISPR KO-1 and -2 
is now required to determine whether these lines also manifest a severe OXPHOS phenotype. 
 
 
 
 
Figure 4.34 Seahorse extracellular flux data comparing the respiratory profile of CRISPR KO-1 and -2 with 
the parental HAP1 line. Cell lines were conditioned and seeded at 11,500 per well the day before the assay. 32 
wells of each condition were assayed and the experiment repeated thrice (mean results for one representative assay 
shown, with error bars denoting standard error). OCR was corrected for seeding density using BCA protein 
quantification of wells after the assay. The parental HAP1 line is shown in blue, CRISPR KO-1 in green and 
CRISPR KO-2 in purple.  
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4.10. Overexpression of SLC25A32 in knockout cells for phenotype rescue  
 
Another important validation involves the overexpression of the carrier in knockout cells, to show that 
functional SLC25A32 rescues the phenotype observed. Future work would involve transfection of 
SLCKO cells for stable expression of the SLC25A32 gene, introduced on a plasmid by lentivirus. A tag 
would be added to the C-terminus of the protein to allow expression to be checked and also purification 
of the protein if desired. For this study a small FLAG tag was chosen and inserted before the stop codon 
of the SLC25A32 sequence. Another component of the transfection plasmid is a selective marker, that 
can be used to maintain only successfully transfected cells. HAP1 cells are sensitive to the antibiotic 
puromycin at 1 μg/ml and therefore culturing in puromycin containing media would allow plasmid-
containing cells to survive, but remove any that were not transfected. Once a stable SLC25A32 knockout 
cell line overexpressing the FLAG-tagged carrier has been generated it can then be analysed to 
determine whether the phenotype has been reversed by the expression of the carrier. This project is now 
underway with cloning of the plasmid to contain the tagged gene, with a view to taking this forward for 
expression in the knockout cell lines.  
 
4.11. Discussion  
 
Work presented in this chapter demonstrates that knocking out the previously assigned folate transporter 
(SLC25A32) had a considerable impact on the respiratory capacity of the cells. Oxygen consumption 
analysis and in-gel activity assays showed that OXPHOS was decreased and no complex I or II activity 
was detected. The main aim of this work was to investigate flavin starvation and its effect on complex 
I, therefore the knockout cell line was used to pursue this aim as the phenotype suggested that 
SLC25A32 knockout prevented necessary transport of flavin into the mitochondria, starving complex I 
and II of their cofactor.  
 
SILAC data highlighted the impact on the mitoflavoproteome, SLC25A32 knockout decreased a subset 
of mitoflavoproteins and some OXPHOS complex subunits, indicating that the flux of flavin into the 
mitochondria was further restricted, on top of conditioning alone. However, as discussion in section 
3.12.2., the use of dFBS may have exacerbated the proteomic effects. Thus, although SLC25A32 cells 
displayed a strong phenotype, the difficulty of growing them under SILAC conditions may reflect this 
further decrease in cytosolic riboflavin, affecting their viability. Despite this, it was unexpected that 
there were no changes to the abundance of complex I subunits when compared to conditioned cells, 
because data from Chapter 3 suggested that very low flavin caused a decrease in N-domain subunits – 
thus it would be anticipated that SLC25A32 knockout cells, with a distinct respiratory phenotype 
attributed to severely depleted levels of mitochondrial flavin, would show a further decrease in N-
domain subunits. It is difficult to rationalise why all complex I subunits appeared unchanged; 
consequently it highlights the importance of characterising more SLC25A32 KO cell lines to determine 
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whether this effect is substantiated.  Complex II subunit levels, in contrast, were lower compared to the 
conditioned cells, possibly indicating that these proteins are more sensitive to flavin concentrations. 
Complex III subunits were also decreased, which may be indirectly caused by lack of complex I and II 
activity.  
 
Transcriptomics explored whether RNA levels were altered and showed that, overall, changes to 
mitoflavoproteins were likely to result from increased protein turnover due to lack of flavin, rather than 
from changes to transcription, which would suggest gene regulation. Only complex III showed both 
down-regulation of subunit expression and decreased protein abundance, so this could indicate a 
feedback response from the cell to lower levels of complex III.  
 
Complexomics provided further insight into how the structure of respiratory complexes was affected. 
The data suggest that complex II is not formed in the knockout, whereas complex I is assembled but 
without the FMN cofactor. Taken altogether these data strongly support the role of SLC25A32 in 
mitochondrial flavin transport and they also suggest the insertion of FMN into complex I may be the 
final stage in assembly: without it the complete enzyme is present but inactive.  
 
Further work characterising the CRISPR SLC25A32 knockouts that I generated, and also attempting to 
rescue to phenotype with over expression of the transporter are now required to validate the results 
obtained, especially in light of the slightly unusal presence of SLC25A32 peptides covering sequence 
passed the deletion and transcripts present in the SLCKO. Although CRISPR is now a widely used and 
effective technique for genomic manipulation there is increasing evidence that indels, which introduce 
PTCs and prevent expression by nonsense-mediated decay of transcripts, may have unintended genetic 
consequences. Exon-skipping to produce in-frame transcripts by removing the mutated exon have been 
identified and could therefore lead to synthesis of partial proteins, which may retain some function. 
Although not fully understood, these mutations may alter conserved regions within exons known as 
exonic splicing enhancers and silencers, which regulate alternative splicing (Kapahnke et al., 2016). 
This is an important consideration and the results with SLCKO suggest that the cell line is not a complete 
knockout. SILAC and transcriptome data support the likelihood of some protein expression, although 
the cells demonstrated a severe respiratory phenotype correlating to SLC25A32 loss-of-function. 
Therefore another cell line containing the knockout could act as a control for this outcome and an 
overexpression rescue would ensure that any additional CRISPR effects had not compounded the 
biochemical results.  
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Figure 4.35 Structures of FMN (A.), FAD (B.) and folate (C.). Both flavin species are formed from substituted 
pteridines with FAD also containing an adenosine phosphate bound to the phosphate of the flavin mononucleotide. 
Folate is composed of a pteridine ring and glutamic acid moiety connected by 4-aminobenzoicacid (PABA). 
Structures obtained from NCBI: PubChem Compound Database, 2018. 
 
From the literature the SLC25A32 carrier has two possible functions – as a folate or flavin transporter. 
As discussed in section 4.1.2. published work has shown rescue by SLC25A32 expression of glycine 
auxotrophic Chinese hamster ovary-derived glyB cells (folate related phenotype) and a yeast FLX1 null 
mutant (flavin related phenotype) (Titus et al., 2000; Spaan et al., 2005).  Two explanations exist for 
this data: either SLC25A32 is capable of transporting both flavin and folate species or the activity of 
flavoprotein enzymes in mitochondrial folate metabolism is decreased. The transcriptome data in section 
4.7. does indicate some changes in folate handling proteins, with FOLH1 the second most down-
regulated gene. However, the data more strongly support the role of SLC25A32 in flavin handling, due 
to the specific decrease in flavoproteins (particularly NDUFV1 and SDHA). Two patients with 
mutations in SLC25A32 have recently been reported, interestingly they were riboflavin-responsive and 
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supplementation let to a marked improvement in their exercise intolerance (Schiff et al., 2016; 
Hellebrekers et al., 2017). Smeets and co-workers identified a patient with an expected homozygous 
null mutation in the transporter, therefore for additional riboflavin to be beneficial it suggests that 
another, potentially low flux, pathway for mitochondrial flavin transport must exist; providing low 
levels of flavin and can be enhanced by provision of more riboflavin, for uptake and processing in the 
cytosol. However this has not been explored, but it may explain why SLC25A32 knockouts display 
severe mitochondrial effects but are still viable because some flavin enters the mitochondria through an 
independent pathway.  
Figure 4.35 shows the structures of FMN, FAD and folate for comparison. It is not known whether FAD 
and FMN are both transported into the mitochondria; the presence of FADS1 in the matrix suggests that 
at least FMN would be required, from which FAD could then be generated. Both flavins share the same 
ring structure, but FAD is much larger due to the additional adenosine moiety, so for both flavin species 
to be transported SLC25A32 would require flexibility in its binding pocket. Folate does not contain 
phosphate groups but with a pteridine ring shares some structural similarities with flavins. Additionally, 
folate and FMN have very similar topological surface areas of 209 and 202 Å2 respectively, suggesting 
that they would occupy a similar space within a binding pocket – FAD is much larger at 356 Å2 (NCBI: 
PubChem Compound Database, 2018). This work therefore supports the transport of flavins by 
SLC25A32 but the transport of folate remains ambiguous, as folate-metabolising phenotypes may be 
observed due to the importance of flavoproteins in key steps. Therefore, there still remains uncertainty 
surrounding species transported by the carrier; direct transport assays and greater structural information 
are required to finally settle the debate surrounding its function. 
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Chapter 5  
Mutagenesis at the ubiquinone binding site in Yarrowia lipolytica complex I 
5.1. Introduction  
 
5.1.1. Yarrowia lipolytica as a model organism  
 
 
Y. lipolytica is an obligate aerobic yeast that differs from fermentative yeast, such as S. cerevisiae, 
because it preferentially uses respiration and contains an electron transport chain more similar to 
mammals, including expressing complex I. In addition, its endogenous ubiquinone has a nine-isoprenoid 
tail (Q9) - most mammals use Q10, whereas S. cerevisiae contains the shorter Q6 (Kerscher et al., 2002). 
Y. lipolytica also contains complex III and IV and expresses an alternative NADH dehydrogenase 
(NDH2) and alternative oxidase (AOX) as part of its respiratory chain. Figure 5.1 shows that, in addition 
to complex I, NDH2 carries out NADH oxidation and reduces ubiquinone, but it is a single subunit 
protein and does not pump protons. Additionally, it is orientated with its active site towards the external 
face of the IMM. AOX is a terminal oxidase and transfers electrons directly from ubiquinol to water, 
without pumping protons; it bypasses complexes III and IV, therefore dissipating energy. AOX activity 
has only been detected in Y. lipolytica when complexes III and IV are non-functional, suggesting a role 
in redox homeostasis (Joseph-Horne et al., 2001). 
 
The mitochondrial and nuclear genomes of Y. lipolytica have been fully sequenced and annotated, which 
greatly increases its use as a model system (Kerscher et al., 2001; Dujon et al., 2004). Y. lipolytica has 
become an established model for complex I structural and functional studies. It has 37 complex I subunit 
homologues, with eight mammalian supernumerary subunits not found (NDUFA10, NDUFV3, 
NDUFB1, NDUFB2, NDUFB5, NDUFB6, NDUFC1 and NDUFC2) and four additional components 
(Angerer et al., 2011). A crystal structure at 3.6 Å resolution has been solved (Zickermann et al., 2015) 
and mutations in NDUFS7 and NDUFS8 that cause Leigh syndrome in humans have been explored, 
demonstrating common changes in Vmax and binding affinity of hydrophobic inhibitors (Kerscher et al., 
2002). Additional studies have been carried out on NDUFV1 mutants linked to human pathologies 
(Varghese et al., 2015), along with investigations into the importance of conserved histidines in 
NDUFS2 (Grgic et al., 2004) and the function of particular residues in the quinone-binding site 
(Tocilescu et al., 2010). Therefore Y. lipolytica has been shown to be a good genetic model for exploring 
mechanistic questions of complex I, with the advantages of being a microorganism that can be cultured 
to produce highly pure and active enzyme. 
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Figure 5.1 The respiratory chain of Y. lipolytica. In addition to complex I there is an alternative NADH 
dehydrogenase (NDH2) and oxidase (AOX). Arrows indicate the direction of electron flow.  
 
 
5.1.2. The ubiquinone binding site of complex I  
 
The proposed binding site for the ubiquinone head-group in complex I is ~20 Å above the membrane 
surface, with access through a narrow channel, Figure 5.2A. Although the channel has been structurally 
identified it has not been definitively proven as the substantial binding channel experimentally. Figure 
5.2B illustrates the cavity in the bovine structure, with the head-group binding site found between 
NDUFS2 and NDUFS7. The residues H59 and Y108 from NDUFS2 are suggested to hydrogen bond 
the quinone head-group and densities from the T. thermophilus structure show this places it within 12 
Å of the terminal iron-sulphur cluster N2, for efficient electron transfer (Baradaran et al., 2013). 
Additionally, the whole channel is long enough to accommodate the entire isoprenoid tail of the 
substrate, suggesting that this portion of the structure is important. There is a constriction in the tunnel 
near the entrance, which may influence the reactivity of different substrates and regulate access of 
inhibitors, Figure 5.2C (Zhu et al., 2016; Fedor et al., 2017).  
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Figure 5.2 The quinone binding cavity of complex I. A. Overview of the core subunits from the bovine structure 
of complex I and the relative position of the Q-site. The cavity was defined using CAVER software. B. The position 
of the substrate channel is shown in peach, positioned between NDUFS2 (49 kDa, blue) and NDUFS7 (PSST, 
green) with the entrance formed by ND1 (red). The three key head-group binding residues of NDUFS2 are 
highlighted and the direction of quinone entry denoted by the arrow. C. The bottleneck near the base of the cavity 
is shown by two red arrows, formed by structural components of the three subunits, including R71 and R77 from 
NDUFS7. Figure adapted from Zhu et al., 2016.  
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Figure 5.3 Structures of different quinones, and the structurally related inhibitor piericidin A. A. The 
structures of Q10 and Q9, the endogenous quinones in mammals and Y. lipolytica respectively. Structure of the 
quinone analogue DQ and the smaller more hydrophilic quinone Q1. B. Structure of the structurally related 
complex I inhibitor piericidin A.  
 
The kinetic properties of complex I and its variants, generated by mutagenesis, are often investigated 
using non-natural quinone substrates. Long chain quinones, such as Q9 and Q10, are insoluble in aqueous 
solution due to their hydrophobicity, therefore a hydrophilic analogue is required – decylubiquinone 
(DQ). Figure 5.3A shows that, although DQ has the same head-group structure as Q9 and Q10, its tail is 
considerably shorter and therefore it behaves more similarly to shorter chain quinones (such as Q3). The 
more hydrophilic Q1, in contrast, exhibits side reactions with complex I, oxidising NADH by a non-
proton translocating, inhibitor insensitive pathway. It has previously been shown to interact with the 
flavin site of complex I, in addition to the Q-channel (King et al., 2009). Piericidin A is structurally 
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related to ubiquinone and a potent inhibitor of complex I (nM range) that was also indicated to bind in 
the Q-site, Figure 5.3B (Darrozet et al., 1998). Therefore binding of this inhibitor provides additional 
insight into the quinone binding cavity and it is used in complex I activity assays to distinguish NADH:Q 
activity from NADH oxidation side reactions, such as at the flavin site, which is particularly important 
when Q1 is used (King et al., 2009). Molecular dynamic simulations investigating the root-mean-square 
fluctuations of different quinone species indicate that Q6 and Q8 behave similarly to Q10 and are spatially 
confined by the quinone binding channel, whereas shorter tail quinones, notably Q1 and Q2 show greater 
conformational freedom (Fedor et al., 2017). It would therefore be expected that DQ falls between these 
two classes (tail length is similar to Q3) and consequently using different tail length quinones to probe 
the activity of complex I may provide insight into how mutations affect the structure of the catalytic 
site. 
 
There is little structural information available concerning the binding of molecules within the proposed 
Q-site. However Sazanov and co-workers obtained some preliminary data by co-crystallisation of T. 
thermophilus complex I with DQ or piericidin A (Baradaran et al., 2013). Difference electron density 
was calculated prior to ligand modelling. Figure 5.4 suggests that piericidin A, along with the quinone 
analogue DQ, bind within the proposed channel and their head-groups are positioned similarly, proximal 
to His59 and Tyr108 of NDUFS2 and ~12 Å from N2. However, the resolution achieved was very low 
and therefore work is on-going to obtain a more detailed structure showing the positioning of quinone 
substrates and inhibitors within the proposed Q-site.  
 
 
Figure 5.4 Inhibitor and substrate binding in the quinone-binding site of complex I from T. thermophilus. 
A. The position of piericidin is shown by experimental electron density and ligand modelling. The three key head-
group interacting residues of NDUFS2 (green) are labelled. B. Binding of DQ is indicated by experimental electron 
density and the modelled structure. Residues are numbered for the T. thermophilus sequence such that Y87 is 
Y108, H38 is H59 and D139 is D160 in the human (and bovine) sequence. Figure adapted from Baradaran et al., 
2013.  
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5.1.3. Design of mutations in NDUFS2 
 
 
 
 
 
Figure 5.5 Alignment of NDUFS2 sequences from human, bovine and Y. lipolytica complex I. A section of 
the alignment is shown, which contains all the mutations chosen for characterisation in this chapter, highlighted 
in red. Symbols below denote conservation as analysed by Clustal Omega, where * is fully conserved, : is strongly 
conserved, . is weakly conserved and a gap demonstrates no conservation.  
 
 
The core subunit NDUFS2 is 86% conserved across mammals and 63% conserved between humans and 
Y. lipolytica, therefore making mutations in this model system a useful approach for studying the 
function of specific residues in detail. Point mutations in NDUFS2 were generated by Dr Andrew Jones 
as detailed in Chapter 2, section 2.9.1., using the ΔNDUFS2 strain produced by Brandt and co-workers 
(Grgic et al., 2004). This strain was derived from the parental GB10 strain, developed with a His-tagged 
NDUFS3 subunit and an internally directed NDH2 to compensate for deleterious complex I mutants 
(Kashani-Poor et al., 2001; Kerscher et al., 2001). The choice of residues was informed by previous 
work on the quinone binding site and observations on unusual characteristics of the channel. Figure 5.5 
shows the alignment of human, bovine and Y. lipolytica NDUFS2 sequences, with the eight residues 
selected highlighted in red. In this region, conservation between species is particularly high. Figure 5.6 
demonstrates the quinone binding cavity of complex I and the involvement of NDUFS2, NDUFS7 and 
ND1 in formation of the binding site. It also highlights that NDUFS2 is involved in forming part of the 
upper section of the binding site, interacting with the first three isoprenoid units of the quinone and the 
terminal iron-sulphur cluster N2. Therefore residues from this subunit have a key role in positioning the 
head group of quinone and also interacting with the terminal iron sulphur cluster, possibly affecting its 
redox potential. The structural positions of the mutated residues are shown in Figure 5.7, showing that 
they form two groups, those found close to the cluster N2 and those facing into the quinone-binding 
channel. All are conserved across human, bovine and Y. lipolytica sequences, apart from S192, which 
is a threonine in bovine and human complex I.  
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Figure 5.6 Modelled Q10 docked into complex I. The bovine structure of complex I (PDB code: 5LC5) showing 
the position of Q10 binding and location of the redox cofactors. Insets show the three subunits involved in the 
quinone-binding site – NDUFS2 (blue), NDUFS7 (green) and ND1 (pink) and the proximity of Q10 to the terminal 
iron-sulphur cluster N2 (orange spheres). The rotated view shows that the quinone cavity is formed at the interface 
of NDUFS2 and NDUFS7 with the tail extending down through ND1 to protrude into the lipid bilayer. Structure 
with modelled Q10 from Fedor et al., 2017. 
 
 
Figure 5.7 shows the structural location of the eight residues. Of the five residues chosen that are 
positioned near quinone in the cavity, three have a relatively well-defined role in quinone binding and 
reduction. H95 and Y144 (H59 and Y108 respectively in the mature human protein) are both proposed 
to directly interact with the quinone head-group through hydrogen bonding, protonating the quinone 
upon its reduction (Sharma et al., 2015). Y144 is ~7 Å away from the terminal cluster N2 in the T. 
thermophilus structure and so may provide a connection between the N2 coordinating region and 
substrate binding pocket (Tocilescu et al., 2010). D196 (D160 in the mature human protein) has been 
suggested to hydrogen bond to H95 (H59 in human), donating protons during quinone reduction 
(Baradaran et al., 2013). The proximity of Y144 to both the quinone head-group and N2 is clearly shown 
in Figure 5.7, along with the position of H95 and D196. The remaining three residues (R121, R141 and 
H226) are located away from quinone but near to N2 and may therefore be involved in quinone reduction 
by modulating its redox potential. 
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Figure 5.7 Positions of mutated residues and subunit NDUFS2 with Q10 docked into complex I. The figure 
was created using the structure of bovine complex (PDB code: 5LC5) with Q10 modelled. Numbering refers to Y. 
lipolytica protein and threonine in the bovine structure at position 156 was mutated to serine to denote S192 in the 
yeast protein. Q10 is shown in black and N2 in orange. Structure with modelled Q10 from Fedor et al., 2017. 
 
 
Although there has been previous work on Y. lipolytica for some of the NDUFS2 variants chosen, these 
studies predominantly used mitochondrial membranes, which as an impure system are difficult to 
characterise and modify. Additionally, for activity assays using mitochondrial membranes it is necessary 
to use the soluble quinone analogue DQ, rather than the more physiologically relevant long tail quinones 
(such as Q9 or Q10), due to their hydrophobicity. Although the reactivity of complex I in mitochondrial 
membranes with endogenous concentrations of quinone (Q9 in Y. lipolytica) could be measured, by 
addition of saturating concentrations of cytochrome c (described in section 5.3.2), the concentration of 
this quinone could not be controlled or modified, making this a suboptimal system for kinetic analysis. 
The proposed importance of particular residues in quinone binding and reduction instigated further 
investigation of their kinetic properties, which could be combined with recent high-resolution structural 
information to gain a better understanding of the channel environment.  
 
To achieve this a complex I proteoliposome system was used, which has been developed by our group. 
AOX from Trypanosoma brucei brucei was modified by removing the N-terminal mitochondrial 
targeting peptide (residues 1–24) and introducing a Twin-Strep-tag® (Fedor et al., 2017). It was then 
over-expressed in E. coli strain FN102/pTbAO. This strain is auxotrophic for 5-aminolevulinic acid as 
it lacks glutamyl-tRNA reductase (gene hemA), which is required for its production in the first step of 
E. coli haem biosynthesis. The inability to produce haem prevents formation of the cytochrome bd 
quinol oxidase and promotes AOX expression (Jones et al., 2016). AOX is incorporated into complex I 
proteoliposomes to re-oxidise NADH, and the system also allows the inclusion of specified amounts of 
Q10 into the membrane, as shown by the schematic in Figure 5.8 (Fedor et al., 2017). This enabled kinetic 
parameters to be obtained for activity of the variants with Q10. Additionally, the short tail quinone Q1 
and the inhibitor piericidin could be added to assays with proteoliposomes to explore the affect of 
mutagenesis on their binding. Thus, while previous work informed our selection of NDUFS2 residues 
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for mutation, using proteoliposomes has many advantages over mitochondrial membranes: components 
can be added and concentrations precisely defined for kinetic analysis to explore the function of 
quinone-binding site residues in greater detail. 
 
Figure 5.8 Schematic representation of complex I containing proteoliposomes. The proteoliposome system 
was developed to incorporate defined amounts of phospholipids, complex I, AOX (for quinol oxidation) and Q10, 
which could all be quantified (Chapter 2, section 2.11). PLs were made for different complex I variants and a range 
of Q10 concentrations were added. These were used for kinetic analysis to obtain a KM with Q10 and in Q10 free PLs 
the addition of exogenous Q1 allowed the comparison of complex I variant reactivity with different chain length 
quinones. Figure created by Dr Andrew Jones.  
 
5.1.4. Previous mutagenesis work of NDUFS2 in Y. lipolytica 
 
Tyrosine-144 
 
Studies in Y. lipolytica by Brandt and co-workers explored the function of Y144, replacing it with six 
different residues: F, W, I, H, S and R (Tocilescu et al., 2010). Activity in mitochondrial membranes 
showed that for all variants activity was lower than 20% of WT with DQ. However, when the activity 
with endogenous Q9 was assayed all mutants demonstrated <5% of WT activity (Y144S and R were not 
tested). Additionally, the more hydrophilic Q1 substrate was tested with Y144F/W/H and all 
demonstrated higher activities, 72%, 93% and 48% of WT, respectively. These results indicate that 
Y144 is critical for Q-binding and reduction, but very short chain quinones can compensate for the 
deleterious mutations. Interestingly, EPR measurements on purified enzyme indicated that the type of 
mutation also affected the redox potential of N2; although Y144F showed no alteration, the mutants 
Y144W/I/H/S/R all showed a spectral shift or loss of signal. This suggests that Y144 interacts with both 
the bound quinone and influences the environment of the terminal iron sulphur cluster. To build on this 
work the Y144F variant was chosen as it represents the most conservative mutation and was found to 
only have a detrimental effect on quinone reduction, leaving the N2 cluster unaffected.  
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Histidine-95 
 
This residue is also proposed to bind the quinone head-group and has also been studied by mutation to 
A, M and R (Grgić, 2004). Activities of H95 mutants in mitochondrial membranes with DQ were all 
<5% of WT, but EPR determined that N2 was unaffected by the changes. These results indicate that 
H95 has a key role in quinone reduction through binding of the substrate, but does not influence the 
properties of the terminal iron sulphur cluster. H95M was chosen for further study where mutation to 
methionine removes the positive charge but maintains a similar bulkiness of the side chain. 
 
Histidine-91 
 
In addition, three variants of H91 (H55 in human) have been studied - H91A/M/R – they also exhibited 
activities in membranes with DQ below 5% of WT but no detectable differences in the N2 signal by 
EPR (Grgić, 2004), suggesting that H91 may also have a key role in quinone binding and reduction. The 
residue is located on the same loop as H95, which extends into the quinone-binding cavity and may 
affect quinone positioning or proton transfer, Figure 5.6. H91M was chosen to reflect the histidine to 
methionine mutation of H95. 
 
Aspartate-196 and Serine-192 
 
There has been no previous mutagenesis work done on D196 in Y. lipolytica but its hydrogen bond with 
H95 is proposed to be important for proton donation, and possibly coupling of quinone reduction to 
proton pumping (Sharma et al., 2015). Therefore, D196N was chosen to hamper the ability of this 
residue to donate protons to H95. In contrast little is known about the functions of S192 (T156 in 
human), which is located on the same helix as D196, but further down the channel near the isoprenoid 
tail of the quinone. S192 is unusual in being a hydrophilic residue within a cavity evolved to bind a 
hydrophobic substrate, therefore it may be important for hydrogen bonding interactions in the head-
group binding region. Although a threonine in human and bovine complex I, serine would retain the 
same polar properties, albeit with a slightly bulkier side chain. S192V was chosen and non-polar valine 
used to replace the polar serine.  
 
Histidine-226 
 
H226 (H190 in human) is located near the terminal iron sulphur cluster N2 and proposed to 
electrostatically interact with the cluster, contributing towards its relatively high redox potential. N2 
exhibits a redox-Bohr effect brought about by coupling to H226 (Zwicker et al., 2006). Previous 
mutagenesis work on H226 - with changes to A, Q, C and M - demonstrated that complex I activity with 
DQ in mitochondrial membranes was decreased by at least 50% in all mutants, except H226M, that 
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retained 80% activity (Grgić et al., 2004). EPR of isolated complex I showed a spectral shift for H226M 
and decrease in N2 signal height. H226Q showed a considerable decrease in signal height and H226C 
and H226A demonstrated loss of signal, indicating the importance of this residue on the redox potential 
of the cluster. Further work showed that H226M abolished the pH dependence of the midpoint potential 
of N2, which at pH 7 decreased from -140 mV to -220 mV, showing it to be the redox-Bohr group 
(Zwicker et al., 2006). More recently Roessler and co-workers demonstrated that the H226M variant 
does not impair the redox reaction or proton translocation by complex I and suggested that proton-
coupled electron transfer at N2 is not required for catalysis (Le Breton et al., 2017). H226M was chosen 
to further investigate the role of this residue.  
 
Arginine-141 
 
R141 (R105 in human) is also located near N2 and has been studied in mitochondrial membranes as 
three variants: M, A and K. All demonstrated activities with DQ below 50% of WT; R141A showing 
the most severe effect with only 17% activity retained (Grgić, 2004). EPR measurements on membranes 
and purified enzyme demonstrated a marked effect on N2, with loss of signal from all mutants except 
R141K, which showed 5% of the expected signal height and shifted to lower field values. This effect on 
N2 supports the role of R141 in tuning the iron sulphur cluster for electron transfer to quinone. To 
remove the positive charge arginine was mutated to methionine.  
 
Arginine-121 
 
The other arginine proximal to N2 is R121 (R85 in human), which is highly conserved but absent in T. 
thermophilus. EPR data suggests that T. thermophilus has an N2 cluster with lower redox potential than 
NADH, and in E. coli it is also lower than other species characterised (Hinchliffe et al., 2006). 
Interestingly this residue is dimethylated in mammalian, Pichia pastoris and Paracoccus denitrificans 
complex I but not in E. coli, which provides a direct link between the presence of R121, its methylation 
status and the reduction potential of N2 (Carroll et al., 2013). Therefore R121 was chosen as a residue 
to study; in line with other arginine residues it was mutated to methionine.  
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Figure 5.9 shows an in-gel activity assay done by Dr Andrew Jones to check the expression of complex 
I by flavin site activity staining prior to the characterisation of these mutants. All variants were 
expressed, although the abundance of some variants appeared lower, notably R121M. 
 
 
 
 
Figure 5.9 BN-PAGE of mitochondrial membranes with in-gel activity staining for complex I. Complex I 
expression was assessed by Dr Andrew Jones to ensure all mutants expressed complex I with flavin activity before 
being taken forward for characterisation. Membranes (40 μg) were loaded after solubilisation with 0.6 % DDM. 
All mutants showed comparable activity to the parental strain GB10 (WT), except R121M that demonstrated 
~50%. This indicates that expression levels in the mutants were similar to WT, with the exception of R121M. 
H226M was assessed previously and also showed comparable activity to WT (data not shown).  
 
 
5.2. Aims 
 
The aims of this chapter were to: 
 
• Investigate the effects of NDUFS2 variants in Y. lipolytica on complex I activity with different 
soluble quinone substrates in mitochondrial membranes. 
• Purify His-tagged variants for isolated complex I activity assays, with the aim of incorporating 
the complex into proteoliposomes. 
• Expand the use of the AOX-containing proteoliposome system from exploring the kinetic 
properties of complex I to characterise Q-site variants using Q10 containing PLs, and with the 
addition of Q1. 
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5.3. Investigating the effect of mutations near the ubiquinone binding site in NDUFS2 on 
the expression and activity of complex I in mitochondrial membranes 
 
Mitochondrial membranes were prepared from each of the eight variants, along with WT. Kinetic assays 
were used to gain an overview of the properties of each mutant and the abundance of complex I was 
analysed by flavin site assays. Data presented in figures are grouped to show: proposed N2-related 
variants (R121M, R141M and H226M) and those possibly interacting with quinone (H91M, H95M, 
Y144F, S192V and D196N). 
 
5.3.1. Complex I abundance in NDUFS2 mutant mitochondrial membranes  
 
The abundance of each complex I variant was estimated using two assays, which both measure the 
amount of flavin present as a proxy for the amount of assembled mature protein. The artificial electron 
acceptors FeCN and APAD+ react at the flavin site with a ping-pong type mechanism, reacting with the 
fully reduced flavin in the absence of nucleotide in the binding site (Birrell et al., 2009). The main 
difference is that APAD+ follows a ping-pong reaction, the stoichiometry with NADH is 1:1, whereas 
FeCN is a one electron acceptor and so this reaction follows a ping-pong-pong mechanism due to the 
1:2 NADH:FeCN stoichiometry. It was assumed that none of the mutations at the distant quinone site 
would influence flavin site activity, therefore these reactions could be used to estimate complex I 
abundance. Measurements were done in the presence of the quinone site inhibitor piericidin A; so that 
electrons could not be passed down to quinone as a side reaction.  
 
Figure 5.10 shows the flavin site activity of each mutant compared to WT. Although APAD+ rates 
showed the largest range (green, Figure 5.10), the trend is similar to the FeCN rates (orange, Figure 
5.10). D196N consistently displayed higher activity than WT (APAD+: 192% and FeCN: 128%), 
whereas R121M showed the lowest activity of all the mutants (APAD+: 75% and FeCN: 74%), which 
is consistent with the lower observed in-gel activity of R121M shown in Figure 5.7. The data suggests 
there were some differences in either expression levels or stability of complex I in the variants, R121M 
and H91M in particular may have deleterious effects on complex I assembly or stability. However, 
overall, mutations in the Q-site region of NDUFS2 did not affect the abundance of complex I 
considerably. 
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Figure 5.10 Abundance of complex I in variant mitochondrial membranes determined using flavin site 
assays. Mitochondrial membranes were assayed with 1 mM FeCN and 200 µM NADH in the presence of 2 µM 
piericidin A, orange bars. Activity was measured by NADH oxidation (A340-380  = 4.81 mM-1 cm-1) and compared 
to WT (specific activity: 1.53 μmol/min/mg protein). Mitochondrial membranes were assayed with 500 µM 
APAD+ and 100 µM dNADH in the presence of 2 µM piericidin A, green bars. Activity was measured by the 
formation of APADH (A400-450  = 3.16 mM-1 cm-1) and compared to WT (specific activity: 0.09 μmol/min/mg 
protein). Each value is the mean of at least six measurements and error bars denote standard deviations. 
 
 
5.3.2. Complex I activity in NDUFS2 variant mitochondrial membranes differs with 
different chain length quinones 
 
Figure 5.11 shows the piericidin sensitive activity of each variant with Q1, DQ and endogenous Q9. 
dNADH was used to specifically measure the rate of oxidation by complex I, since NADH would react 
with other components in the membranes. Overall the eight variants gave substantial decreases in 
catalytic activity, regardless of the quinone, and all demonstrated less than 50% activity with Q9 
compared to WT. Results are discussed below, although variants that were taken on for further study 
are considered in more detail later in the chapter.  
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Figure 5.11 Activity of complex I in variant mitochondrial membranes with different chain length quinones. 
Mitochondrial membranes were assayed with 200 µM dNADH with different quinones. Activity was measured by 
oxidation of dNADH (A340-380  = 4.81 mM-1 cm-1). Q1 was assayed by addition of 100 µM Q1. Activities were 
compared to WT (specific activity: 0.57 μmol/min/mg protein). DQ was assayed by addition of 200 µM DQ. 
Activities were compared to WT (specific activity: 1.53 μmol/min/mg protein). Q9 was assayed by addition of 
cytochrome c to a saturating concentration of 8 µM (determined in WT membranes). Activities were compared to 
WT (specific activity: 0.71 μmol/min/mg protein). All activities are presented as piericidin A sensitive rates (final 
concentration of 2 µM). Each value is the mean of at least six measurements and error bars denote standard 
deviations. 
 
The variants R121M, R141M, H95M and H226M all demonstrated a similar level of activity with all 
three quinone substrates, compared to WT. R121 is located close to N2, mutation to methionine lowered 
activity to <5% of WT and so catalysis was almost completely abolished. Therefore in Y. lipolytica 
conservation of arginine at this position appears fundamental, distinguishing it from T. thermophilus 
complex I, where the residue is not conserved. The methylation status of R121 was not assessed by 
Carroll et al. in Y. lipolytica, but lack of arginine has been correlated with lowered redox potential of 
N2, which would decrease its ability to transfer electrons to the quinone, due to a smaller difference in 
their midpoint potentials. This variant was investigated further using the isolated protein (section 5.4). 
R141 is also close to N2 and activities of the R141M variant were low with all quinones, indicating that 
it may have a similar function to R121. H95M also showed a similar decrease with all quinone species, 
despite its suggested interaction with the quinone head-group during reduction. The activities reported 
here are in line with the measurements by Grgić using DQ in membranes, also <5% of WT; the 
additional low Q1 and Q9 activities suggest the importance of H95 in the catalytic mechanism of quinone 
reduction and this variant was chosen for further study using the purified enzyme (Grgić, 2004).  
 
 
 
Another variant that displayed equivalent rates with all three quinones, compared to WT, was H226M. 
However this mutation had a milder effect, retaining 45-50% of WT activity. This is surprising given 
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its proposed function as the Redox-Bohr group for N2 and the methionine mutation was shown to 
abolish the pH sensitivity of the N2 redox potential (Zwicker et al., 2006). Previous work therefore 
indicates that H226 is close enough to N2 to increase its electron affinity through the influence of its 
positive charge. However, the mutation to a neutral methionine does not affect complex I activity 
severely (Le Breton et al., 2017).  
 
H91M and S192V demonstrated similar trends in activity, although S192V retained higher activities 
overall. Figure 5.11 highlights that both variants had highest activity with DQ, compared to WT. The 
position of both residues within the Q-site indicates that their interaction with the bound quinone would 
be in the region of the tail, at isoprenoids 1-2, just below the head-group (Figure 5.7). H91 is located on 
the large loop of NDUFS2 and so this region may be flexible and respond to accommodate the substrate, 
whereas S192 is found on an alpha helix lining the channel. The possible interactions with isoprenoids 
near the head-group may account for the differences in activity: in this region Q9 and Q1 both share the 
first isoprenoid moiety, whereas the carbon chain tail of DQ is less bulky, more flexible and may be 
stabilised differently. The kinetic properties of S192V were explored further using the isolated protein. 
 
The remaining two variants (Y144F and D196N) showed activities that correlated with quinone chain 
length. Both demonstrated a decrease in activity with increase in chain length: >20% of WT activity 
was retained with the shortest substrate Q1 whereas <10% activity was measured with long tail Q9 
(Figure 5.11). Although these mutations are present in the upper region of the binding site, with 
structural evidence for the interaction of Y144 with the quinone head group (Baradaran et al., 2013) and 
an interaction between D196 and H95 during quinone reduction (Sharma et al., 2015), the differing 
impact of the these variants may relate to the lower predicted conformational freedom of Q9. As a result 
Q9 may be more easily perturbed by mutations, whereas a smaller quinone may have an advantage, by 
adopting alternative conformations. Therefore both Y144F and D196N demonstrated quinone chain 
length sensitivity and were investigated further by purification of the variant enzymes.  
 
Table 5.1 summarises the activity data described in this section, along with information from previous 
studies on Y. lipolytica variants. It shows good correlation between activities in membranes with DQ 
and earlier work; the reactivity with different chain length quinones provides additional insight. These 
data can be considered with the effect on N2, given by EPR measurements, to further understand how 
different variants influence complex I activity - either through direct disruption of quinone binding or 
causing changes to the environment surrounding the iron-sulphur cluster N2, affecting electron transfer 
to quinone.   
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Table 5.1 Summary of data on each of the eight Q-site variants. Previous studies on mitochondrial membranes 
- activity measurements with DQ and N2 signal monitored by EPR - have been included for comparison with data 
obtained in this section on variant mitochondrial membranes with different length quinones.  
 
 
 
 
Variant 
Previous studies Current work 
Activity in 
membranes with 
(% of WT) 
N2 signal EPR 
measurements 
Reference 
Activity in mitochondrial 
membranes (% of WT) 
DQ Q1 DQ Q9 
R121M - - - <5% <5% <5% 
R141M 40% undetectable Grgić, 2004 12% 11% <5% 
H226M 80% 
decreased intensity 
and shifted to lower 
field values, 
pH dependence 
abolished 
Grgić, 2004 
Zwicker et al., 2006 
Le Breton et al., 2017 
48% 48% 50% 
H91M <5% unchanged Grgić, 2004 <5% 15% <5% 
H95M <5% unchanged Grgić, 2004 <5% <5% <5% 
Y144F 
15% 
(72% with Q1, 
<5% with Q9) 
unchanged Tocilescu et al., 2010 29% 8% <5% 
S192V - - - 23% 56% 11% 
D196N - - - 28% 12% 11% 
187 
5.4. Purified complex I provides further insight into the properties of five NDUFS2 
mutants  
 
From the eight mutants assayed, five were chosen for further study. D196N, H95M and Y144F were 
chosen due to their suggested roles in head-group binding; R121M was chosen as representative of an 
N2 interacting residue with a severe effect; S192V was chosen as a less well-understood but potentially 
interesting residue with different effects with different quinone species.  
 
Complex I was isolated from all variants, although yields were typically lower than obtained from WT; 
the yield of R121M was only ~50%, which reflects the expression level in Figure 5.9.  Complex I from 
each mutant was then assayed with high DQ (200 μM) and activity compared with WT complex I 
(specific activity: 45 μmol/min/mg complex I). Figure 5.12 shows that all mutants had measurable 
quinone reduction rates, although H95M was only ~10% of WT, similar to its low activity in 
membranes. The other four mutants demonstrated activities of around 30% compared to WT; S192V 
did not display the highest activity as observed in membranes, Figure 5.11. However using purified 
complex I in a known reaction mixture provides more robust data than with mitochondrial membranes, 
which also contain a huge array of other components at unknown concentrations. R121M also 
demonstrated a differing activity to that measured in membranes, retaining >25%. Since this variant did 
not show an EPR signal it highlights the requirement to further characterise R121M to better understand 
changes to catalytic activity.  
 
 
 
Figure 5.12 Activity of isolated mutant complex I with 200 μM DQ. Purified complex I was assayed at 0.25 
μg/ml with 200 μM NADH and 200 μM DQ in 0.075% Asolectin-CHAPS, 20 mM Tris HCl, pH7.5. Activities 
were measured by NADH oxidation (A340-380,  = 4.81 mM-1 cm-1) and shown as a percentage of the WT (specific 
activity: 45 μmol/min/mg complex I). Each value is the mean of at least six measurements and error bars denote 
standard deviations. 
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In addition to changes in quinone reduction, the effect of mutations on production of reactive oxygen 
species (ROS) was investigated using the hydrogen peroxide probe Amplex Red (Chapter 2, section 
2.10.2). Not all ROS produced is hydrogen peroxide and therefore SOD was used to channel ROS 
formed towards the Amplex Red reaction (Kussmaul & Hirst, 2006), which is catalysed by HRP and 
forms resorufin; the fluorescence can be detected by following A557 and A620 ( = 51.6 mM-1 cm-1). This 
assay was undertaken in the absence of added quinone. Figure 5.13 shows H2O2 production for each 
mutant compared to WT. R121M showed similar activity to WT, and S192V showed slightly lowered 
production. Interestingly the three variants implicated in quinone head-group binding displayed an 
increase in ROS production; Y144F produced ~35% more H2O2. ROS is generated by complex I 
primarily at the flavin site and so this assay can be used to estimate the amount of flavin present (Pryde 
et al., 2011), but it may also provide insights into the different sites of ROS production. The quinone-
site has previously been implicated and although this has now been shown as a minor contributor 
compared to the flavin site, these variants may affect this balance. In the absence of quinone ROS is 
produced at the flavin site by electrons backing up on the iron sulphur clusters. When quinone is present 
an increase in ROS production has been observed for piericidin inhibited complex I, by preventing 
electron transfer to the ubiquinone pool (Fato et al., 2009). Changes to the quinone-binding cavity may 
also affect ROS production, by encouraging electron leak from this site. Therefore it is interesting that 
while the quinone site is a minor site of ROS generation, quinone-channel variants H95M, Y144F and 
D196N correlate with an increase in overall ROS production. 
 
  
Figure 5.13 ROS production of isolated mutant complex I. Purified complex I was assayed at 10 μg/ml with 
30 μM NADH, 10 U/ml HRP, 10 U/ml SOD and 10 μM AxR in 0.075% Asolectin-CHAPS, 20 mM Tris HCl, 
pH7.5. No protein and catalase controls were also used. Activities were measured by following A557 and A620. ( = 
51.6 mM-1 cm-1 compared with WT (specific activity: 41 nmol/min/mg protein). Each value is the mean of at least 
six measurements and error bars denote standard deviations. 
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5.5. Characterisation and kinetic properties of five Q-site variants in proteoliposomes  
 
5.5.1. The proteoliposome system  
 
 
The proteoliposome (PL) system comprises sealed lipid vesicles containing an 8:1:1 ratio of the 
phospholipids phosphotidylcholine, phosphotidylethanolamine and cardiolipin. Purified complex I was 
embedded in the membrane, adopting two orientations – the matrix arm facing the exterior or interior 
of the PL. Only complex I molecules with the matrix arm facing the outside of the PL will be accessible 
to added NADH. AOX was also introduced to the PLs during synthesis, to re-oxidase the quinone pool 
and prevent low concentrations of the quinone substrate from limiting NADH oxidation by complex I. 
This defined system allows complex I content to be measured and the hydrophobic long tail quinone 
Q10 was added at different concentrations for incorporation into the membrane; the different 
concentrations could then be assayed to obtain a KM curve (Jones et al., 2016; Fedor et al., 2017). 
Although Q9 is the endogenous quinone in Y. lipolytica, Q10 was used instead due to the higher purity of 
reagent available, and because previous work using bovine complex I in PLs also used this quinone. 
Due to the similarities in structure and the work done by Fedor et al. involving different quinones, the 
results with Q9 and Q10 were expected to be comparable. 
 
For each of the five variants, and WT, purified complex I was used to produce a series of PLs containing 
different concentrations of Q10, in addition to proteoliposomes without Q10. Standard complex I-only 
PLs were also prepared (no AOX or Q10) to provide information for the quantification of complex I 
present. Each PL type prepared was then split into aliquots to avoid freeze-thaw cycles (as described in 
Chapter 2, section 2.9.5). The partitioning of Q10 into the bilayer was determined using the total 
concentration of quinone obtained by HPLC, along with the phospholipid content of each of the PLs, 
therefore kinetic data discussed below is presented as mM of Q10 in the membrane. For Q1 and piericidin 
additions a similar calculation was done, using published octanol:H2O partition coefficients and 
measured phospholipid concentrations for each of the PLs: Q1 logP = 2.9 (Lenaz, 1998) and piericidin 
A logP = 5.02 (Höllerhage et al., 2009).  
 
The concentration of complex I present was determined via the flavin site NADH:APAD+ assay, since 
protein quantification assays would measure both complex I and AOX amounts. Standard PLs 
containing complex I only were prepared for each variant and WT. The total complex I of these standard 
PLs was quantified by the Amido Black assay (Chapter 2, section 2.11.2). The NADH:APAD+ activity 
was determined for these standards and all other PLs (Chapter 2, section 2.11.2). For standard PLs this 
was done in the presence and absence of 15 µg/ml alamethicin, which permeabilises the membrane to 
NADH and APAD+, making all complex I accessible to the substrate, regardless of insertion orientation. 
From this total activity and the Amido Black, which gave the total protein concentration, turnover 
numbers (kcat) for NADH:APAD+ were calculated for each variant. This value was then applied to the 
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PLs containing different Q10 concentrations and, along with the NADH:APAD+ activities measured for 
each, it was used to determine the outward-facing complex I present. This was done for all variants; 
Table 5.2 shows example data for complex I-only standards from WT, D196N, Y144F and H95M, 
discussed in section 5.4.2. Table 5.3 shows the quantification of the PLs containing seven different Q10 
concentrations made for these variants (the kinetic analysis of S192V and R121M, discussed in section 
5.4.1, used fewer Q10 concentrations). The concentration of complex I in each PL was then used to 
calculate specific NADH oxidation activities in µmol NADH/min/mg complex I, as displayed on graphs 
below.     
 
 
 
Table 5.2 Complex I-only standard proteoliposome data for WT, D196N, Y144F and H95M. These 
proteoliposomes were used to determine NADH:APAD+ kcat values for each complex I variant and thus to calculate 
the concentration of complex I facing out in complex I:AOX PLs used in quinone assays, Table 5.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Amido Black assay NADH:APAD+ Activity 
Complex I 
facing out (%) 
kcat  
complex I 
(s-1)  
 Total [CxI]  
(mg/ml) 
- alamethicin  
(µM/min) 
+ alamethicin 
(µM/min) 
WT 0.62 ± 0.02 5.5 ± 0.6 9.3 ± 0.7 59.1 168.2 ± 13.5 
D196N 0.79 ± 0.01 7.5 ± 0.3 11.4 ± 1.1 65.8 160.6 ± 12.4 
Y144F 0.52 ± 0.09 5.2 ± 0.9 7.5 ± 0.3 69.3 126.2 ± 14.3 
H95M 0.62 ± 0.05 3.6 ± 0.3 7.6 ± 0.6 47.4 135.9 ± 11.2 
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WT 
PL type 
(Q10) 
[Phospholipid] 
(mg/ml) 
[Q10] (µM) 
[Q10]  
(mM, membrane) 
NADH:APAD+ 
(µM/min) 
[Complex I]  
outward-facing 
 (mg/ml) 
0 nmol  8.5 ± 0.5 9.7 ± 0.5 1.1 ± 0.1 6.8 ± 0.4 0.45 ± 0.04 
12.5 nmol  14.9 ± 0.9 16.4 ± 1.0 1.1 ± 0.1 7.4 ± 0.8 0.49 ± 0.07 
25 nmol  11.5 ± 0.6 30.2 ± 1.0 2.6 ± 0.2 6.6 ± 0.3 0.43 ± 0.03 
50 nmol  11.7 ± 1.4 110.0 ± 6.0 9.4 ± 1.2 7.6 ± 0.3 0.51 ± 0.05 
75 nmol 21.0 ± 2.0 141.5 ± 26.5 6.7 ± 1.42 7.5 ± 0.5 0.49 ± 0.06 
100 nmol  14.2 ± 0.7 163.4 ± 4.5 11.5 ± 0.7 8.6 ± 0.5 0.57 ± 0.05 
150 nmol  15.9 ± 0.9 284.3 ± 16.0 17.9 ± 1.4 9.3 ± 0.4 0.61 ± 0.03 
      
D196N 
PL type 
(Q10) 
[Phospholipid] 
(mg/ml) 
[Q10] (µM) 
[Q10]  
(mM, membrane) 
NADH:APAD+ 
(µM/min) 
[Complex I]  
outward-facing 
(mg/ml) 
0 nmol  22.6 ± 0.6 2.04 ± 3.0 0.1 ± 0.1 6.0 ± 0.4 0.41 ± 0.03 
12.5 nmol  14.7 ± 0.6 15.1 ± 2.0 1.0 ± 0.1 7.4 ± 0.5 0.51 ± 0.07 
25 nmol  16.3 ± 0.6 29.3 ± 1.5 1.8 ± 0.7 8.1 ± 0.2  0.56 ± 0.07 
50 nmol  18.0 ± 0.8 74.3 ± 5.0 4.1 ± 0.3 6.4 ± 0.4 0.44 ± 0.05 
75 nmol 19.3 ± 1.2 98.6 ± 10.0 5.1 ± 0.6 5.8 ± 0.3 0.40 ± 0.04 
100 nmol  19.0 ± 0.3 152.5 ± 13.0 8.0 ± 0.7 5.7 ± 0.3 0.40 ± 0.06 
150 nmol  21.4 ± 1.5 239.4 ± 4.0 11.2 ± 0.8 4.1 ± 0.4 0.28 ± 0.03 
 
Y144F 
PL type 
(Q10) 
[Phospholipid] 
(mg/ml) 
[Q10] (µM) 
[Q10] 
 (mM, membrane) 
NADH:APAD+ 
(µM/min) 
[Complex I] 
outward-facing 
(mg/ml) 
0 nmol  19.9 ± 0.9 1.6 ± 2.0 0.08 ± 0.1 7.3 ± 0.5 0.60 ± 0.10 
12.5 nmol  29.2 ± 0.9 22.4 ± 2.5 0.75 ± 0.1 8.8 ± 0.7 0.72 ± 0.05 
25 nmol  28.5 ± 1.1 48.6 ± 2.0 1.7 ± 0.1 6.3 ± 0.3 0.51 ± 0.03 
50 nmol  12.8 ± 0.9 57.5 ± 6.0 4.5 ± 0.6 5.6 ± 0.4 0.48 ± 0.04 
75 nmol 19.0 ± 0.6 133.4 ± 0.1 7.0 ± 0.2 4.8 ± 0.4 0.39 ± 0.05 
100 nmol  30.6 ± 2.1 165.2 ± 3.5 5.4 ± 0.4 6.9 ± 0.4 0.56 ± 0.03 
150 nmol  28.6 ± 1.1 319.9 ±11.5 11.2 ± 0.6 4.8 ± 0.3 0.39 ± 0.10 
      
H95M 
PL type 
(Q10) 
[Phospholipid] 
(mg/ml) 
[Q10] (µM) 
[Q10]  
(mM, membrane) 
NADH:APAD+ 
(µM/min) 
[Complex I] 
outward-facing 
(mg/ml) 
0 nmol  13.1 ± 0.1 2.7 ± 1.5 0.2 ± 0.4 5.1 ± 0.5 0.45 ± 0.05 
12.5 nmol  19.5 ± 1.4 15.0 ± 0.5 0.8 ± 0.1 3.9 ± 0.3 0.45 ± 0.05 
25 nmol  11.8 ± 0.3 20.3 ± 0.5 2.5 ± 0.1 3.8 ± 0.2 0.34 ± 0.03  
50 nmol  24.2 ± 1.3 72.5 ± 2.0 3.0 ± 0.2 2.8 ± 0.1 0.33 ± 0.04 
75 nmol 19.3 ± 0.1 89.4 ± 3.0 4.6 ± 0.2 3.2 ± 0.2 0.24 ± 0.02 
100 nmol  20.3 ± 1.1 145.2 ± 8.5  7.1 ± 0.6 3.6 ± 0.2 0.27 ± 0.02 
150 nmol  16.9 ± 0.85 184.0 ± 3.5  10.9 ± 0.6 4.1 ± 0.3 0.32 ± 0.03 
 
Table 5.3 Quantification of components from proteoliposomes for WT, D196N, Y144F and H95M. 
Phospholipid concentration and Q10 concentration were used to determine the concentration of Q10 in mM, in the 
membrane. The activities for APAD+ reduction were used with kcat calculated in Table 5.1 to calculate the 
concentration of outward-facing complex I in each PL.  These data were then used to display activities of quinone 
reduction in µmol NADH/min/mg complex I and membrane concentrations of Q10 as mM, using the phospholipid 
densities of 1 µl/mg (Nagle & Tristram-Nagle, 2000). Phospholipid data was also used along with published 
partition coefficients to determine the concentrations of Q1 and piericidin in the membrane when added to PLs. 
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5.5.2. Kinetics analysis of the S192V and R121M variants 
 
Proteoliposomes were made for the five mutants selected with a range of Q10 concentrations (Chapter 
2, section 2.9.5). Additionally a small number of wild type PLs were prepared to compare NADH 
oxidation rates with Q10 and Q1. This initial data then informed further work and three of the mutants – 
H95M, Y144F and D196N - were taken forward for more rigorous kinetic analysis (section 5.5.3). 
Presented below are the initial data for R121M and S192V compared to the WT control, which despite 
being preliminary, gave an indication of the effect of these mutations on the Q-binding site and the 
influence of ubiquinone chain length on the rates of NADH oxidation. 
 
 
 
 
Figure 5.14 Michaelis-Menten plots for NADH oxidation by wild type, S192V and R121M mutant complex 
I proteoliposomes over a range of Q10 concentrations. Proteoliposomes incorporated complex I and AOX with 
different Q10 concentrations. Each value is the mean of at least six measurements; standard deviation was 
propagated from the underlying measurements. Wild type data is shown in blue, S192V in green and R121M in 
red.  
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Figure 5.14 shows initial data on the Michaelis-Menten characteristics of S192V and R121M, which 
despite relatively large errors demonstrate a considerable change in NADH oxidation rate with Q10 
compared to WT. Although only four Q10 concentrations of WT Y. lipolytica PLs were prepared, the 
data shows that the S192V mutant displayed a largely increased KM of 17.7 mM Q10 (WT KM of 1 mM 
Q10) and a lower Vmax of 28.8 μmol NADH/min/mg complex I (WT Vmax of 50 μmol NADH/min/mg 
complex I). This suggested that the change to valine both decreased the maximal rate of NADH 
oxidation and altered binding of the substrate. In contrast, high concentrations of Q10 were unable to 
rescue activity of R121M; suggesting this position cannot tolerate changes in property, possibly as the 
positively charged side chain is necessary to mediate electron transfer from N2 to quinone.  
 
To investigate whether the effects of the different variants were confined to long chain quinones, 
titration with Q1 was also undertaken. Proteoliposomes without Q10 were used and a range of Q1 
concentrations were added to the assay, up to 100 μM - after which partitioning into the membrane is 
not consistent and may cause destabilisation of the membrane (Fato et al., 1996). The concentration 
present in the membrane was calculated, as described in section 5.5.1. Additionally, rates were measured 
with and without the addition of 2 μM piericidin A, to account for Q1 reactivity at the flavin site.  
 
 
Figure 5.15 Michaelis-Menten plots for NADH oxidation by wild type, S192V and R121M mutant complex 
I proteoliposomes over a range of Q1 concentrations. Proteoliposomes incorporated complex I and AOX. Q1 
was added to the assay and concentration partitioned into the membrane calculated. Each value is the mean of at 
least six measurements; standard deviation was propagated from the underlying measurements. The piericidin 
insensitive rate (2 μM final concentration) was subtracted. Wild type data is shown in blue, S192V in green and 
R121M in red.  
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Figure 5.15 demonstrates the Q1 dependent NADH oxidation of WT, S192V and R121M complex I in 
proteoliposomes, kinetic parameters are given in Table 5.4. It is apparent that for WT complex I with 
Q1 there was a decrease in Vmax to 20 compared to 50 μmol NADH/min/mg complex I with Q10 – 
although a similar KM was maintained (1.5 mM). Fedor et al. have studied the effect of quinone chain 
length on complex I activity from bovine heart and demonstrated that low Vmax values were obtained 
with the short chain quinones Q1 and Q2 compared to longer chain quinones. KM values calculated 
displayed a bell shaped curve, with the highest concentration of Q4 required and the KM calculated for 
long chain quinones Q8 and Q10 was ≤1 mM (Fedor et al., 2017). This analysis suggests alteration of the 
rate-limiting step between Q1 and Q2 catalysis compared to Q4-Q10, as binding and dissociation rates 
increased with chain length. Modelling also showed that the isoprenoid tails of Q1-Q4 do not overlap the 
comparable units in Q10, demonstrating conformational mobility of these shorter chain substrates in the 
Q-site. The lack of anchoring or guide function by the tail is proposed to result in lower reactivity of 
these quinones compared to the endogenous substrate. The Q-binding channel of complex I has evolved 
to optimise the binding and catalysis of long chain quinones, Q10 in humans and bovine and Q9 in Y. 
lipolytica, although quinones of different lengths share the properties of the head group and can still be 
reduced. However, structure of the channel is not designed to orientate these smaller substrates in the 
best position for interaction with catalytic residues or facilitate rapid exchange.  
 
Comparison of kinetic parameters for the two variants with Q1 and Q10 provides insight into how these 
mutations alter the Q-site (Table 5.4). The Vmax of S192V with Q10 was nearly half that of WT (29 
compared to 50 μmol NADH/min/mg complex I), whereas with Q1 the Vmax increased to 37 μmol 
NADH/min/mg complex I and exceeded that of WT (20 μmol NADH/min/mg complex I). The location 
of S192 in the upper region of the channel, near the first few isoprenoid units following the quinone 
head-group, may affect Q10 orientation that facilitates optimal interactions with catalytic residues; 
therefore WT maximal rates could not be achieved. However, the altered catalytic effect with Q1 
suggests that maximal rate of NADH oxidation with this quinone was increased; the shorter chain 
quinone was impacted less by the mutation on the upper Q-channel structure due to the conformational 
flexibility indicated by Fedor et al. This reflects the trend observed in mitochondrial membranes (Figure 
5.11) with S192V demonstrating the lowest percentage of WT activity with long chain Q9, compared to 
Q1 and DQ. Thus, despite mutation of this residue, activity was retained with both quinones, which 
supports the function of S192 as important to the structure of the Q-channel but not catalytically 
fundamental.  
 
R121 is positioned away from the Q-binding pocket but proposed to interact with the terminal iron 
sulphur cluster. In EPR studies R121M lacks an N2 signal, therefore mutation to a neutral methionine 
was hypothesised to severely impair catalytic activity by disrupting the midpoint potential of N2. This 
was highlighted in Figure 5.14 by very low activity with all concentrations of Q10 and a similar profile 
was observed with Q1, Figure 5.15. This indicates that regardless of substrate this mutation impairs 
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catalysis and cannot be rescued (kinetic parameters indicating lack of activity are shown in Table 5.4). 
Therefore R121M is likely to have affected electron transfer to the quinone, rather than be involved in 
quinone tail binding. This is in line with observation in membranes and further strengthens the 
hypothesis that this residue directly impacts the N2 redox potential, rather than participating in the 
efficiency of downstream quinone binding.  
 
 Q10 Q1 
 Vmax KM Vmax KM 
 (μmol NADH min-1mg-1) (mM, membrane) (μmol NADH min-1mg-1) (mM, membrane) 
WT 50.1 ± 8.3 1.1 ± 1.0 19.7 ± 1.5 1.5 ± 0.6 
S192V 28.8 ± 15.6 17.7 ± 16.3 37.1 ± 13.8 52.1 ± 35.9 
R121M 3.7 ± 1.9 <0.01 0.7 ± 0.3 0.4 ± 2.0 
 
Table 5.4 Kinetic parameters for WT and NDUFS2 variants in proteoliposomes. Summary table showing 
Vmax and KM with Q10 and Q1 in the proteoliposome system for WT, S192V and R121M complex I.   
 
 
5.5.3. Kinetics analysis of the H95M, Y144F and D196N variants  
 
As described above a primary set of data was obtained from proteoliposomes from the five mutants, and 
although this data provided initial results showing changes in Q10 and Q1 reactivity, it also allowed 
preparation and quantifications to be refined, to minimise measured errors. Therefore a further set of 
proteoliposomes were made and assessed, along with a better characterisation of WT complex I. For 
this work a subset of mutations were chosen, those directly associated with quinone head-group binding 
– H95M, Y144F and D196N. 
 
Figure 5.16A shows the piericidin sensitive activity of the three mutants compared to WT at varying 
concentrations of Q10. WT demonstrated a Vmax of 53.8 ± 1.6 μmol NADH/min/mg complex I and KM 
of 3.8 ± 0.3 mM Q10, which is consistent with previously published data for the KM for bovine complex 
I proteoliposomes with Q10 of 3.9 mM (Jones et al., 2016; Fedor et al., 2017). In contrast, both D196N 
and Y144F demonstrated decreased Vmax and a slight shift in KM, whereas the H95M displayed no 
observable rate with Q10, regardless of concentration. Figure 5.16B shows the NADH oxidation data 
over a range of Q10 concentrations for D196N and Y144F, to provide clarity due to the scale of Figure 
5.16A. D196N demonstrated a Vmax of 9.1 ± 0.8 μmol NADH/min/mg complex I, which is 80% lower 
than WT and Y144F also showed a similar trend. There was a marked decrease in Vmax (6.4 ± 0.6 μmol 
NADH/min/mg complex I) and slightly increased KM of 4.3 ± 0.9 mM Q10. Therefore whilst both 
variants retained activity with Q10 the maximal rates were considerably lower. In contrast, H95M 
displayed no measurable activity and higher concentrations of Q10 did not rescue the mutant.  
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Figure 5.16 Michaelis-Menten plots for NADH oxidation by wild type, Y144F, D196N and H95M mutant 
complex I proteoliposomes over a range of Q10 concentrations. A. Activities for WT, D196N, Y144F and 
H95M mutant complex I proteoliposomes over a range of Q10 concentrations. Proteoliposomes incorporated 
complex I and AOX and different Q10 concentrations. Each value is the mean of at least six measurements; standard 
deviation was propagated from the underlying measurements. The piericidin insensitive rate (2 μM final 
concentration) was subtracted. Wild type data is shown in blue, D196N in orange, Y144F in green and H95M in 
purple. B. Zoomed in plot for activities of D196N, Y144F mutant complex I proteoliposomes over a range of Q10 
concentrations. 
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Following assessment of NADH oxidation with Q10, titrations were also done with Q1 - subtracting the 
piericidin insensitive rate. Once again each mutant showed a considerable decrease in activity, and 
H95M showed no appreciable catalytic activity, Figure 5.18. Kinetic parameters for WT were 
calculated: Vmax 28.8 ± 1.5 μmol NADH/min/mg complex I and KM 30.6 ± 4.0 mM Q1, demonstrating a 
~50% decrease in Vmax and substantially higher KM, indicating the decreased ability of Q1 to bind and its 
slower reduction by complex I compared to the longer quinone. The difference in parameters compared 
to Q10 is similar to that measured by Fedor et al. in PLs containing bovine complex I (Fedor et al., 2017). 
Vmax was lowered by two-fold for Q1 and KM increased by around eight-fold, demonstrating that although 
complex I may reduce shorter chain quinone substrates these reactions are much less efficient than with 
longer chain quinones, for which the binding site has evolved – underpinning the importance of the 
structure of this cavity for catalysis. 
 
 
 
Figure 5.17 Michaelis-Menten plots for piericidin sensitive NADH oxidation of wild type, D196N, Y144F 
and H95M mutant complex I proteoliposomes over a range of Q1 concentrations. Proteoliposomes were 
prepared from isolated complex I with AOX addition and lacking Q10. Q1 was added to the assay and 
concentration of partitioned Q1 into the membrane calculated. Each value is the mean of at least six measurements; 
standard deviation was propagated from the underlying measurements. The piericidin insensitive rate (2 μM final 
concentration) was subtracted. Wild type data is shown in blue, D196N in orange, Y144F in green and H95M in 
purple.  
 
Comparison of kinetic parameters obtained for the variants with Q10 and Q1 revealed differences in the 
effect of the variants on complex I activity. Figure 5.17 shows that D196N demonstrated a slight increase 
in maximal rate with the shorter tail quinone, but this remained lower than WT. While Q1 reacted less 
efficiently with the WT, highlighted by the lower Vmax and higher KM, the activity of the mutant was 
comparable with the two quinones (Vmax of  9.1 ± 0.8 μmol NADH/min/mg complex I with Q10 and 12.5 
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± 1.2 μmol NADH/min/mg complex I with Q1) and mirrors the difference in activity measured in the 
isolated protein with DQ, which was ~20% WT activity. This suggests that with a shorter isoprenoid 
tail Q1 achieved a slightly higher maximal rate than Q10 for D196N, consequently 43% of WT activity 
was retained compared to only 17% with Q10. These data reflect the activity measurements in 
membranes that showed some chain length sensitivity, the highest activity compared to WT was 
measured with Q1 (Figure 5.11). This may relate to the altered properties of the head-group binding 
domain after mutation and that Q1, with more conformational flexibility, may tolerate this more 
successfully. Therefore mutation to an asparagine had a dominantly Vmax effect compared to WT 
activity, which may encompass changes to the rate of catalysis, expulsion of the product or regeneration 
of the active site. It is interesting that D196N has this effect because the residue is thought to protonate 
H95 during catalysis, therefore it would be expected that H95 and D196 variants would have a similar 
impact. However, although mutation would disrupt this interaction, catalysis may still be possible 
through an alternative proton donor, which may explain why some activity is retained, whereas H95M 
is non-functional. 
 
Y144F showed similar kinetic parameters to D196N (Table 5.4) with Q10, however this variant displayed 
substantial differences with Q1. The Vmax with Q10 was only ~10% that of WT, whereas the variant 
displayed ~20% WT activity for rates with DQ measured with isolated enzyme, reflecting the trend 
demonstrated by membrane activities with different quinones (Figure 5.11); shorter chain quinones 
retained higher activity and so Y144F appears to display quinone chain sensitivity. This is perhaps 
surprising due to its equivalent function to H95, interacting with the quinone head group. However, 
despite the loss of the hydroxyl group, this mutant may retain some activity through adaptions in the Q-
binding site. Space may be opened up by the slightly shorter side chain and stabilising interactions may 
be possible via aromatic stacking with phenylalanine. Although this mutation would prevent hydrogen 
bonding and proton transfer it may be possible that, as suggested for D196N, another proton donor could 
be used, due to the slightly altered binding of the head-group, an accommodation more easily made by 
a flexibly bound short chain quinone. The most surprising aspect of this analysis was that, unusually, 
Y144F complex I displayed an almost linear trend in activity with Q1, increasing concentrations resulted 
in a higher rate, with no indication of saturation. Due to the constraints of partitioning at higher 
concentrations it was not possible to further increase Q1 addition to reach the maximal rate and so 
Michaelis-Menten kinetics could not be applied, only estimated in Table 5.5. However this behaviour 
suggests a large alteration in quinone binding and further confirms that this mutation has a large effect, 
with Q10 activity considerably decreased and Q1 appearing to subvert this change and displaying highly 
changed kinetics compared to WT. Thus the quinone chain length sensitivity of Y144F observed by 
Brandt and co-workers has been demonstrated in this work; membrane activity decreased with 
increasing quinone chain length and kinetic characteristic with Q10 and Q1 in proteoliposomes show a 
distinct change from WT. Therefore although this mutation and D196N have a similar effect on Q10 
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binding, the effect on the binding of short chain quinones is drastically altered in Y144F; whereas the 
H95M variant shows complete loss of catalytic ability.  
 
 
 
Table 5.5 Kinetic parameters for ubiquinone head-group binding mutants of NDUFS2 in proteoliposomes. 
Summary table showing Vmax and KM with Q10 and Q1 in the proteoliposome system for WT, D196N and Y144F 
complex I. H95M are not shown due to the lack of activity. Y144F showed a linear trend with Q1, therefore kinetic 
parameters are estimated given the values obtained and WT parameters.  
 
 
5.5.4. D196N and Y144F demonstrate altered piericidin sensitivity compared to wild 
type  
 
  
 
Figure 5.18 Piericidin inhibition plots of NADH oxidation for WT, D196N and Y144F mutant complex I 
proteoliposomes, at saturating [Q10]. Proteoliposomes were prepared from isolated complex I with AOX 
addition and a saturating [Q10] chosen - 17.86 mM in WT and 11.2 mM in D196N and Y144F (differences in [Q10] 
due to sample availability). Piericidin A was added to the assay and membrane concentration of partitioned 
piericidin calculated. Each value is the mean of at least six measurements; standard deviation was propagated from 
the underlying measurements. Residual activity was removed from all measurements for a range 0-100% activity. 
Wild type data is shown in blue, D196N in orange and Y144F in green.  
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 Vmax KM Vmax KM 
 (μmol NADH min-1mg-1) (mM, membrane) (μmol NADH min-1mg-1) (mM, membrane) 
WT 53.8 ± 1.6 3.8 ± 0.3 28.8 ± 1.5 30.6 ± 4.0 
Y144F 6.4 ± 0.6 4.3 ± 0.9 10<Vmax≤28.8 KM >50 
D196N 9.1 ± 0.8 4.9 ± 1.0 12.5 ± 1.2 43.7 ± 9.0 
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To further characterise the mutations introduced into the head-group binding region of the quinone-
binding site the structurally related inhibitor piericidin A was used to determine the sensitivity of D196N 
and Y144F catalysis, Figure 5.18. Piericidin is a tight binding inhibitor that mimics the enzyme-substrate 
reaction intermediate and therefore due to the effect of these variants on the Q-binding site it would be 
expected that they would bind piericidin less tightly. PLs containing a saturating [Q10] in the membrane 
were chosen and the WT enzyme demonstrated high sensitivity to piericidin with an IC50 of 0.24 mM ± 
0.05 piericidin in the membrane. The two mutants displayed considerably lower piericidin sensitivity 
and an altered Hill coefficient. D196N had an IC50 of 2.2 mM ± 0.5 piericidin in the membrane and a 
Hill coefficient of 0.8 compared to the steeper slope (1.5) of WT. Similarly Y144F was also less 
sensitive to the inhibitor, with an increased IC50 of 1.3 mM ± 0.1 piericidin in the membrane. Due to the 
differences in complex I content in the PLs the IC50 values were converted into the ratio of piericidin 
molecules per orientated complex I for each variant. This resulted in the WT ratio of 6.3 piericidin per 
complex I in the lipid, matching well with recent data for bovine complex I containing PLs (with 10 
mM Q10 in the membrane) of ~8 molecules of piericidin per complex I (Fedor et al., 2017). D196N and 
Y144F both demonstrated a large increase, shown in Table 5.6. Y144F required 15 times more piericidin 
to reach 50% inhibition and D196N was yet less sensitive, the ratio was over 25 times higher than WT. 
These data correspond well with the observed changes in quinone substrate binding and therefore 
indicate that piericidin is likely to bind in a similar way to quinone, such that mutations detrimentally 
affecting quinone reduction also decrease the sensitivity of complex I to the inhibitor.  
 
 
 
 
 
 
Table 5.6 Piericidin sensitivity of ubiquinone head-group binding mutants of NDUFS2 in proteoliposomes. 
Summary table showing the differing kinetic parameters of piericidin binding for D196N and Y144F compared to 
WT in the proteoliposome system. Piericidin:complex I in the membrane was calculated to account for differences 
in complex I content of the PLs for each variant. Errors denote standard deviations. 
 
 Piericidin sensitivity 
 IC50 Hill 
Slope 
Piericidin:complex I 
 (mM, membrane) (in the membrane) 
WT 0.24 ± 0.05 1.5 6.3 
Y144F 1.3 ± 0.40 0.6 92.9 
D196N 2.2 ± 0.50 0.8 165.9 
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5.6. Conclusions and future perspectives 
 
The work presented in this chapter was designed to build upon current knowledge of the quinone-
binding channel of complex I and provide experimental evidence for the importance of residues 
highlighted in the structures of the enzyme, along with investigating the possible roles of residues found 
on flexible loops or with unusual hydrophilic properties. Using the Y. lipolytica model system allowed 
genetic manipulation of the NDUFS2 subunit and the engineered ΔNDUFS2 strain provided an 
internally directed NDH2 to ensure that mutations compromising catalytic function could still be 
expressed, due to functional compensation by NDH2. The addition of a His-tag to NDUFS3 also allowed 
reliable purification and the proteoliposome system was harnessed to provide a defined system that 
could be used with long and short chain quinones to properly investigate complex I variants.  
 
The more extensive characterisation of five mutants immediately indicated that residues implicated in 
either quinone binding or terminal iron sulphur cluster stabilisation could both result in loss of catalytic 
activity when mutated, as exemplified by R121M and H95M, which demonstrated little measurable 
activity with Q1 or Q10 regardless of concentration. Additionally, some residues likely to interact directly 
with the quinone head group, and therefore involved in the catalytic mechanism, showed a level of 
tolerance to mutation; D196N and Y144F displayed altered kinetic parameters and lowered activity with 
Q10, however with a short chain quinone rates were increased. This apparent sensitivity to the length of 
the quinone tail provides insight into the relationship between the structure of the channel and the 
substrate. Although it may not be surprising that residues lining the channel affect the positioning of the 
quinone tail, this effect was unexpected for residues found in the head-group binding region. As their 
location precludes them from directly affecting the orientation of the substrate tail, their impact could 
be linked to the differing behaviour of the substrate in the cavity. The activity measurements with 
D196N and Y144F indicate that a shorter more flexible quinone may be able to overcome the negative 
effects of changing these residues and perhaps points to an alternative network of residues, or 
involvement of water molecules, that are utilised when the integrity of the binding site is compromised. 
High-resolution structures of complex I with bound substrate or inhibitor in the cavity are still lacking 
but these two variants may provide useful structural information when compared to WT, particularly if 
the positioning of Q1 could be resolved.  
 
Future development of this work could include functional studies in PLs using a wider range of 
quinones, which could provide further insight into the effects of these particular mutations and the 
behaviour of substrate based on chain length. Also, with the identification of specific residues an array 
of mutations could be designed, to gain a better understanding of the residue properties required for 
function and tolerance at these positions. This work could also be extended to encompass the other 
nuclear encoded Q-site structural subunit NDUFS7. The altered binding of piericidin A also highlights 
that D196N and Y144F variants could be used to probe inhibitor binding; it would be informative to test 
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the sensitivity to other known inhibitors such as rotenone. For other inhibitors that are less well 
characterised regarding their binding site, this approach could indicate whether these bind at the Q-site 
or a separate allosteric site. 
 
The advantages of using the proteoliposome system to investigate complex I function and the effects of 
specific variants also opens this approach up to testing known pathogenic mutations where there is 
limited knowledge about the mechanism of action. Of the eight mutants investigated in this chapter two 
of the residues have been linked to complex I deficiency in patients. R121 and R141 were found as R-
Q mutations in different patients displaying isolated complex I deficiency and these variants were 
heterozygous with another NDUFS2 variant (Tuppen et al., 2010). Although these patient mutations 
were further characterised, their presence as heterozygous variants meant that the impact of individual 
alleles could not assessed. Separation of the variants and assessment in the Y. lipolytica system could 
provide another level of understanding, as both alleles may not contribute equally to the phenotype. The 
remaining variant residues have not been assigned to disease phenotypes or recorded at high levels in 
the population as polymorphisms, which may indicate the importance of these amino acids due to lack 
of variation – embryonic lethal mutations would not be detected. Overall, Y. lipolytica represents a 
valuable model for investigating the function of complex I and has the flexibility to be used for further 
understanding of complex I mechanistic features by probing specific domains by mutation of nuclear-
encoded subunits, in addition to exploring the effects of clinically relevant mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
203 
Chapter 6 
Exploring the role of high resolution structures in predicting the 
pathogenicity of human complex I variants 
6.1. Introduction 
 
6.1.1. Complex I and disease-causing variants 
 
Complex I is the largest of the ETC enzymes and contains 45 subunits encoded by both the 
mitochondrial and nuclear genomes. Variation in subunit sequences is linked to mitochondrial disorders 
with a range of phenotypes and involves both the 14 core subunits and the supernumerary proteins. 
mtDNA-encoded subunits exhibit the greatest variation, both within and between species – reflecting 
the faster evolution of the mitochondrial genome (Saccone et al., 1999). Although rare, severe mutations 
cause disease whereas common genetic variants, present in >1% of the population, define haplotypes – 
the mtDNA background shared by groups of individuals. Despite being considered as benign changes 
in themselves these differences have been associated with disease, due to the potential to promote the 
clinical penetrance of other mutations in complex I genes or increase the risk of developing other 
diseases linked to complex I defects (Dimauro & Davidzon, 2005). Effects on penetrance have been 
observed in LHON patients, the disease is often caused by the m.14484T>C ND6 mutation, however 
increased penetrance is associated with the J haplotype, in contrast to low penetrance of individuals with 
the H haplotype – suggesting that genetic background has a strong influence on disease manifestation 
(Howell et al., 2003). The clinical presentation of mitochondrial diseases is also linked to the level of 
mitochondrial heteroplasmy, with different variants demonstrating different thresholds – above which 
the mutation is pathogenic. The level of heteroplasmy may also differ between tissues and therefore 
dictates the level of organ involvement in the phenotype (Stewart & Chinnery, 2015). In a similar way, 
variation in nuclear-encoded genes may result in severe homozygous or compound heterozygous 
mutations linked to mitochondrial diseases, or heterozygous variants acting as risk factors for disorders. 
Therefore, a major challenge in mitochondrial medicine is to differentiate between pathogenic mutations 
and benign polymorphisms in mitochondrial disease patients, to ensure the correct variant is attached to 
the phenotype – otherwise future use of the information in genetic counselling or research will be 
severely compromised. 
 
6.1.2. Current tools for analysis of mutations and prediction of clinical outcomes 
 
The evaluation of clinically identified novel genetic variations uses, predominantly, primary sequence 
analysis – particularly conservation and the severity of the amino acid change incurred. It also includes 
consideration of changes to the secondary structure and some structural analysis. Many in silico tools 
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have been developed to facilitate this, including PolyPhen2 (Adzhubei et al., 2010), SIFT (Ng & 
Henikoff, 2001) and MutPred2 (Pejaver et al., 2017). In a number of studies comparing different tools 
it has been noted that including structural data improves the quality of the prediction and indicates that 
consideration of a range of protein features is required (Walters-Sen et al., 2015). However, these tools 
do not always agree on the predicted outcome and therefore clinical guidelines encourage the use of 
multiple tools to interpret the outcome of a variant (de la Campa et al., 2017). Consequently, lack of 
agreement on some variants means they cannot be interpreted with confidence. More recently software 
has been developed to combine results from different tools, to improve reliability. These include the 
rare exome variant ensemble learner (REVEL) method that collated pathogenicity predictions from 18 
tools, eight conservation-based and ten functional-based, to assess the possible outcome of rare missense 
variants (Ioannidis et al., 2016). REVEL was found to outperform other combined features tools to 
distinguish rare disease from neutral variants and highlights the importance of considering a range of 
prediction methods. However it still relies on pre-existing tools, which are limited in the features of the 
residue and protein used by the prediction algorithm. Additionally, despite these tools being useful to 
prioritise genetic variants, they have not been developed for individual proteins and so the question 
remains as to whether the sensitivity and specificity of predictions could be increased by consideration 
of more detailed information on a particular protein (Pejaver et al., 2017).  
 
High confidence predictions are useful in both clinical and research settings, providing a starting point 
for genetic counselling or possible treatment and informing the investigation of biologically relevant 
regions of a protein. Thus, computational approaches can highlight residues or domains that are likely 
to be severely impacted and biochemical assays can then be used to probe them further, to enhance our 
understanding of structural and mechanistic features of the protein that cause this susceptibility.  
 
6.1.3.  Structural information on complex I may improve understanding of pathogenic 
mutations   
 
Cryo-electron microscopy has revolutionised structural knowledge of mammalian complex I, yielding 
high-resolution structures with all 45 subunits located and modelled. The first of these was bovine 
complex I, with all subunits located and modelled onto a 4.2 Å structure in 2016 (Zhu et al., 2016).  
Importantly these structures detail the residue positions within subunits and demonstrate interactions 
between domains, highlighting functionally relevant regions of the enzyme. Benign polymorphisms and 
disease-related variants have been identified in human complex I genes and, by comparison of these two 
variant types, trends may identify potential disease hotspots in the enzyme.  Although this approach has 
been used to provide a general explanation for some variants causing disease, such as those involved in 
LHON and Leigh syndrome, there has been no detailed global assessment of the high-resolution 
structures in light of the position of identified human variants (Fiedorczuk & Sazanov, 2018).  
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Therefore to increase the reliability of pathogenic outcome prediction for complex I variants a human 
model was generated from the most complete and highest resolution complex I structure. This was 
solved for active complex I from mouse heart, at 3.3 Å, with the positions of the majority of its 8,500 
residues located and 97% of residues mapped with side chains (Agip et al., 2018). Human complex I 
gene variants were collated from online databases, as discussed in section 6.3, and classified as either 
pathogenic mutations or polymorphisms into three classes for each, based on the confidence of their 
assignment. These six classes were then analysed in relation to the human complex I model to assess 
features that have predictive power for the outcome of the variant. This ranged from primary sequence 
analysis of the conservation across mammals, determined by alignment of ~20 species sequences (Table 
6.5), through to secondary structure and finally incorporating the detailed knowledge gained from the 
high-resolution structure. By considering the unique and functionally relevant features of complex I this 
analysis aimed to add depth to current prediction tools and enhance the confidence with which 
predictions about variants across the whole structure can be made. 
 
6.2 Aims 
 
The aim of this chapter was to bring structural data to bear on clinically relevant observations and 
improve our understanding of complex I variants - specifically to: 
 
• Collate and classify all variants in complex I subunit encoding genes as either pathogenic or 
polymorphic. 
• Analyse these variants on multiple levels: primary sequence, secondary structure elements and 
three-dimensional structure. 
• Draw conclusions about different features and their predictive power. 
• Construct a comprehensive table for analysis to provide a prediction for a given residue, which 
can be used in a clinical setting to improve the confidence of pathogenic mutation assignment. 
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6.3.Assigning database variants as pathogenic or polymorphic by degree of confidence 
 
A database of 271 residues with likely pathogenic variants (termed mutations) and 608 residues with 
polymorphic variants (termed polymorphisms) in human nuclear and mtDNA complex I genes was 
compiled using online resources, Table 6.1 and 6.2. Variants assigned as pathogenic (mutations) in 
nuclear-encoded complex I genes were extracted from the Human Gene Mutation Database (HGMD, 
Stenson et al., 2017 - http://www.hgmd.cf.ac.uk) and the National Centre of Biotechnology Information 
(NCBI) ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/). HGMD is a curated database that 
excludes unpublished or inadequately described variants. ClinVar includes a clinical significance 
descriptor provided by the submitter. Variants were checked to ensure they related to the canonical 
sequence and not an alternative or predicted transcript. Additionally, variants causing a premature stop 
codon were removed and only missense/non-synonymous mutations were retained. Mutations were then 
classified by the confidence level of their assignment. Class 1 mutations (highest confidence) were 
described as ‘pathogenic’ by ClinVar AND ‘complex I deficiency’ causing by HGMD. Class 2 
mutations were either denoted ‘pathogenic’ by ClinVar OR ‘complex I deficiency’ causing by HGMD. 
Class 3 mutations (lowest confidence) were rated by ClinVar as ‘likely pathogenic’ or ‘uncertain 
significance’. Those assigned as ‘benign’, ‘likely benign’, ‘protective’ or ‘haplogroup marker’ were 
discounted. For mtDNA-encoded subunits data was taken from ClinVar in the same way and also from 
MITOMAP (Lott et al., 2013 - http://www.mitomap.org). Class 1 mutations were assigned as 
‘pathogenic’ by ClinVar AND ‘confirmed’ by MITOMAP. Class 2 mutations were either rated 
‘pathogenic’ by ClinVar OR ‘confirmed’ by MITOMAP. Class 3 mutations were denoted ‘likely 
pathogenic’ or ‘uncertain significance’ by ClinVar and/or ‘reported’, ‘conflicting’, ‘unclear’ by 
MITOMAP. Where multiple pathogenic variations were identified for the same residue analyses were 
based on the highest confidence level present. Importantly, the classification does not denote disease 
severity; it refers only to the confidence of assigning the variant as the cause of a specific inherited 
mitochondrial disease such as Leigh syndrome or LHON. 
 
Polymorphisms were identified in nuclear-encoded complex I genes using the Exome Aggregation 
Consortium (ExAc, Lek et al., 2016 - http://exac.broadinstitute.org/), with exome sequencing data from 
60,706 control individuals, and in mtDNA-encoded subunits using 30,589 mtDNA sequences from 
MITOMAP. Analyses based on the residue position rather than the identity of the amino acid change 
combined variants at the same location for a total polymorphic frequency at that position. Class 1 
polymorphisms (highest confidence) vary from the canonical sequence with a frequency of >0.01 
(>1%), class 2 polymorphisms with >0.001 frequency (>0.1%) and class 3 polymorphisms (lowest 
confidence) with >0.0001 frequency (0.01%). Variants with frequencies lower than 0.0001 were 
discounted. Databases were mined by Dr Wei Wei, from the MRC MBU, University of Cambridge, 
after which I carried out the variant classifications. The features of all variant residues discussed in this 
chapter are tabulated in Appendix 7.9A-D. 
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Subunit Chain Class 1 Class 2 Class 3 
NDUFV1 F 
97, 102, 186, 
194, 403 
36, 68, 91, 127, 179, 184, 191, 
226, 232, 321, 357, 358, 366, 
412 
[7], 19, 75, 131, 133, 140, 247, 263, 297, 337, 
348 
NDUFV2 E - 177 153, 158 
NDUFS1 G 
208, 218, 229, 
385, 572, 596 
48, 143, 205, 499, 672, 684 39, 154, 181, 230, 286, 408, 432, 452, 483, 511, 
543, 553, 577, 680 
NDUFS2 D 
195, 196, 259, 
380, 393 
77, 85, 105, 115, 191, 290, 300, 
410, 413 
20, 287, 347, 376 
NDUFS3 C 109, 163 187 210 
NDUFS7 B 84 67, 107 77, 81, 167 
NDUFS8 I 
29, 43, 45, 51, 
68, 104, 125 
20, 60, 120 71, 81, 109, 127, 170 
ND1 H 
24, 52, 110, 
131, 132, 143, 
195, 289 
1, 28, 30, 31, 59, 164, 208, 214, 
215, 240, 277, 285 
2, 4, 11, 12, 25, 34, 38, 39, 56, 64, 113, 128, 
144, 147, 176, 187, 218, 230, 276, 279, 304 
ND2 N - 57, 71, 259 55, 60, 64, 122, 128, 150, 328, 331 
ND3 A 34, 45, 47 26, 60, 66 10 
ND4 M 340 109, 165, 313, 409 158, 206, 372, 387, 412, 423 
ND4L K 65 32 25, 41, 71 
ND5 L 
124, 393 1, 145, 159, 171, 236, 237, 250, 
434, 465 
9, 21, 96, 99, 100, 149, 239, 243, 253, 267, 312, 
348, 392, 398, 415, 458, 499, 505, 544, 576, 
585  
ND6 J 
36, 60, 63, 64, 
72 
26, 59, 74, 117, 132 25, 33, 58, 79, 82, 101, 112, 119, 171 
NDUFA1 A 8, 37 19 32, 43 
NDUFA2 S - 44 68 
NDUFA3 B - - - 
NDUFA5 V - - - 
NDUFA6 W - [3] - 
NDUFA7 R - - - 
NDUFA8 X - 108 - 
NDUFA9 P 286 - 26, 33, 40, 50, 279, 287, 303 
NDUFA10 O 107 64, 259 100, 173, 176, 251 
NDUFA11 Y - - 9, 77, 81, 103 
NDUFA12 Q - - - 
NDUFA13 Z [4] 56 - 
NDUFAB1 U/T - - - 
NDUFB1 F - - - 
NDUFB2 J - - - 
NDUFB3 K - 21 [6] 
NDUFB4 M - - - 
NDUFB5 H - - - 
NDUFB6 I - - - 
NDUFB7 O - - - 
NDUFB8 L - - - 
NDUFB9 N - 63, 96 60, 157 
NDUFB10 P - - - 
NDUFB11 G - 92 - 
NDUFC1 C - - - 
NDUFC2 D - - - 
NDUFS4 Q - 72, 77 [6], 42  
NDUFS5 E - 95 - 
NDUFS6 R 87 - 49, 55, 58, 60, 74 
NDUFV3 S - [22] - 
 
Table 6.1 Pathogenic variants in complex I subunit genes. Variants were classed by confidence of their 
assignment as described above, with class 1 the highest confidence class and class 3 the lowest confidence. 
Variants in brackets are residues not present in the structure.    
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Subunit Chain Class 1 Class 2 Class 3 
NDUFV1 F - - [1], [7], 11, 32, 133, 168, 175, 179, 337, 339, 366, 376, 385, 418 
NDUFV2 E 102 8 19, 76, 140 
NDUFS1 G 
- 408 6, 122, 154, 181, 280, 331, 334, 479, 483, 511, 515, 634, 646, 
689 
NDUFS2 D 319 290 80, 259, 287, 347, 379, 393, 409 
NDUFS3 C - 123 100, 210 
NDUFS7 B - - [4], [11], [15], 133, 134, 148, 167  
NDUFS8 I - - - 
ND1 H 
4, 30, 67, 81, 
164, 240, 304, 
309 
1, 10, 11, 29, 31, 39, 43, 64, 69, 73, 
87, 89, 113, 144, 147, 187, 229, 
236, 248, 263, 275, 277, 289, 307 
2, 5, 15, 17, 21, 27, 28, 52, 56, 68, 76, 77, 96, 110, 112, 116, 
128, 132, 139, 152, 153, 168, 171, 176, 196, 213, 215, 230, 239, 
241, 249, 258, 260, 265, 266, 268, 273, 276, 292, 300, 305, 310, 
313, 318 
ND2 N 
8, 119, 150, 
193, 237, 325, 
331 
13, 31, 43, 57, 64, 76, 80, 88, 89, 
100, 122, 152, 164, 202, 203, 265, 
270, 278, 284, 288, 323, 342 
11, 15, 19, 48, 49, 62, 69, 78, 79, 81, 85, 94, 98, 115, 125, 139, 
141, 145, 147, 148, 156, 159, 166, 187, 200, 209, 219, 220, 222, 
238, 239, 241, 242, 246, 266, 267, 276, 277, 281, 285, 286, 317, 
320, 328, 330, 332, 333, 343, 345, 346 
ND3 A 88, 114 9, 10, 29, 45, 49, 60, 96, 103 14, 19, 24, 34, 44, 47, 89, 90, 93, 97, 105 
ND4 M 
140, 404 47, 50, 54, 86, 89, 101, 109, 110, 
131, 138, 149, 165, 230, 299, 313, 
340, 390, 402, 423, 424, 442, 445, 
459 
6, 21, 29, 45, 46, 52, 55, 58, 70, 85, 104, 107, 121, 129, 166, 
170, 187, 193, 201, 225, 232, 291, 317, 320, 350, 365, 391, 409, 
418, 419, 420, 421, 425, 434, 435, 455 
ND4L K 47 13, 62, 94 21, 59, 71, 79, 80 
ND5 L 
8, 24, 257, 
314, 458, 475, 
482, 485, 515, 
531, 533, 544, 
555 
1, 4, 9, 13, 21, 22, 23, 52, 69, 74, 
100, 159, 182, 190, 201, 202, 205, 
261, 265, 267, 270, 283, 398, 410, 
432, 434, 439, 449, 459, 469, 471, 
478, 489, 495, 518, 530, 536, 538, 
541, 549, 556, 573, 575, 576, 592, 
598 
2, 14, 18, 27, 30, 34, 38, 39, 40, 45, 53, 59, 63, 65, 67, 70, 76, 
88, 93, 99, 109, 113, 127, 132, 141, 147, 149, 162, 169, 172, 
177, 196, 206, 209, 211, 236, 271, 273, 290, 304, 317, 323, 331, 
377, 378, 381, 400, 403, 413, 420, 423, 424, 440, 441, 442, 447, 
456, 461, 472, 473, 476, 477, 491, 492, 493, 500, 508, 509, 513, 
517, 524, 525, 546, 564, 565, 569, 571, 577, 579, 596, 602, 603 
ND6 J 
119, 166,  14, 31, 33, 41, 58, 64, 86, 97, 120, 
132, 139, 156, 159, 165, 171 
2, 4, 26, 34, 35, 36, 37, 38, 42, 45, 54, 72, 81, 85, 90, 94, 102, 
106, 112, 117, 121, 134, 135, 140, 142, 150, 155, 161, 162, 174 
NDUFA1 a - 32 - 
NDUFA2 S -  13 [10], 34, 62, 63, 93 
NDUFA3 b - 20 11, 49 
NDUFA5 V - - 2 
NDUFA6 W [8] 107 63  
NDUFA7 r 47 65 4, 7, 29, 37, 50, 57, 59 
NDUFA8 X - - 43, 54, 134 
NDUFA9 P 259 40 21, 50, 135, 187, 206, 235, 249, 279, 342 
NDUFA10 O - 30 2, 100, 137, 142, 165, 182, 251 
NDUFA11 Y - 103 19, 65, 99, 111, 128 
NDUFA12 q - - 60 
NDUFA13 Z - - 9, 24, 41, 69, 80, 87 
NDUFAB1 U/T - - - 
NDUFB1 f - 18 33, 38 
NDUFB2 j - 52 10 
NDUFB3 k - [6] 21, 60 
NDUFB4 m - - 2, 25, 66 
NDUFB5 h - - 11, 87, 137 
NDUFB6 i - - 10, 20, 25, 42, 80, 108 
NDUFB7 o - 62, [117] [1], 29, 43, 48, 55, 61, 70, 83, 92, 105, 110, 112 
NDUFB8 l - 97, 121 29, 39, 76, 88, 94, 95 
NDUFB9 n 145 - 3, 7, 36, 46, 128, 143, 157, 174, 176, 178 
NDUFB10 p - 141 34, 65, 109, 139, 164, [167] 
NDUFB11 g - - [13], [22], 55, 56 
NDUFC1 c - - 41 
NDUFC2 d 46 - 35, 59, 119 
NDUFS4 Q - - 94, 115 
NDUFS5 e - - 71, 92, 97 
NDUFS6 R - - 58, 60 
NDUFV3 s - - - 
 
Table 6.2 Polymorphic variants in complex I subunit genes. Variants were classed by confidence of their 
assignment as described above, with class 1 the highest confidence class and class 3 the lowest confidence. 
Variants in brackets are residues not present in the structure.    
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 Class 1 
polymorphisms 
Class 2 
polymorphisms 
Class 3 
polymorphisms 
Not observed as 
polymorphisms 
Class total 
Class 1 
mutations 
0 4 9 38 51 
Class 2 
mutations 
3 13 9 61 86 
Class 3 
mutations 
7 24 28 75 134 
Not 
observed as 
mutations 
31 118 362   
Class total 41 159 408   
 
Table 6.3 Distribution of variants across the six classes and overlap between the lower confidence classes. 
No overlap between the class 1 variants demonstrates the high level of confidence whereas in other classes there 
is some degree of overlap between variants, assigned as both pathogenic and polymorphic.   
 
Table 6.3 demonstrates that there was no overlap between the class 1 mutations and the class 1 
polymorphisms, confirming that these groups are the most reliably defined. Among the other categories 
a variable degree of overlap was observed and therefore class 1 variants were distinguished from the 
remaining dataset in subsequent analyses. Class 1 analyses are presented, which are cleaner but 
statistically limited by small sample sizes, alongside analyses of the larger, but less well defined, 
complete dataset. The overlap between Class 2 and 3 mutations and polymorphisms may arise from two 
effects. Clinical variants may be mis-assigned as pathogenic when a novel variant is identified in a 
patient with an appropriate biochemical defect but subsequently sequencing a larger control group 
demonstrates the presence of the same variant in healthy subjects. Additionally, the boundary between 
mutation and polymorphism is not definitive due to the impact of different biological and metabolic 
backgrounds: the same mild variant may present differently in individuals (additional factors may give 
rise to clinical symptoms, or the same variant may remain completely benign).  
 
6.4.Variant distribution across different classes of subunits  
 
Human complex I comprises 45 subunits, 38 are nuclear-encoded (nDNA) and seven are encoded by 
mtDNA. The 14 core catalytic subunits comprise the mtDNA-encoded proteins and seven nDNA 
encoded proteins, with the remaining 31 supernumerary subunits likely to have roles in stability, 
assembly and supercomplex formation. Although the core subunits only comprise 53% of the total 
residues, 90% of class 1 mutations, and 84% of all mutations, are found these subunits; as expected due 
to their essential role in complex I function. However, it was surprising to observe a high proportion of 
polymorphisms also found in the core subunits, 90% of class 1 and 79% of all polymorphisms. 
 
 
Figure 6.1 shows the distribution of variants across different types of subunits - mitochondrial-encoded, 
nuclear-encoded core and supernumerary subunits, with raw data in Table 6.4. The percentage of the 
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residues in each grouping found to be mutations or polymorphisms was compared to the expected 
segregation of variants. From this analysis it is clear that the mitochondrial-encoded subunits are 
responsible for the higher polymorphic variation among core subunits, 1.7% of residues are class 1 
polymorphisms, which is significantly higher than the 0.6% expected by chance. In contrast, nuclear-
encoded core subunits contained a significantly lower proportion than expected, 0.1% - which was 
equivalent to that of the supernumerary subunits. The distribution of mutations are more similar, 6% of 
residues in mitochondrially encoded core subunits were found as mutations, along with 4.4% of nuclear 
encoded subunits, which is higher than in supernumerary subunits, only 1.1%. Additionally, there was 
a considerable difference found in the type of variants found in the two core subunits groupings, 68% 
of all variants in the nuclear-encoded core subunits were mutations but only 23% in the mitochondrial-
encoded subunits variation and 26% in supernumerary subunits. Overall, this indicates that mtDNA-
encoded subunits are more tolerant to variation, which correlates with their lower conservation (38% in 
mammals) compared to nuclear encoded subunits (78%) and reflects the faster evolution of the 
mitochondrial genome. However it is difficult to interpret why variants in mtDNA core subunits are less 
likely to be pathogenic than nuclear encoded core subunits, although one possibility may be their 
position in the hydrophobic domain. Consequently these subunits have a higher proportion of 
transmembrane helices (TMHs) and these structures may be less subject to structural disruption than 
globular subunits, such as the nuclear-encoded core subunits.  
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Figure 6.1 The percentage of residues present as mutations and polymorphisms in different groupings of 
subunits. A. Class 1 mutations and polymorphisms. Data for core mitochondrial subunits is shown in red, 
nuclear-encoded core subunits in blue and supernumerary subunits in green. Line shows the percentage of residues 
expected in each grouping if distribution was due to ‘chance.’ B. Mutations and polymorphisms in all of classes 
1, 2 and 3. The percentage expected by ‘chance’ was calculated from the total residues in each grouping (within 
the structure) compared to the total, denoted by lines. Significance of differences between the groups and that 
expected by chance was assessed using Fischer’s Exact Test (two-tailed) and denoted * for P ≤ 0.05, ** for P ≤ 
0.01, *** for P ≤ 0.001 and **** for P ≤0.0001. Raw values are given in Table 6.4. 
 
 
Subunit 
Mutations Polymorphisms 
All residues 
Class 1  Total Class 1  Total 
mtDNA-encoded 20 126 35 434 2114 
nDNA-encoded 26 101 2 48 2311 
Supernumerary 5 44 4 126 3828 
 
 
Table 6.4 Distribution of mutations and polymorphisms across different groupings of subunits. The number 
of class 1 mutations and polymorphisms found in each type of subunit, along with the total for each variant type. 
The proportion of all residues in the structure present in each subunit type are also shown, for comparision.  
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6.5. Primary sequence analysis 
 
Residue conservation was assessed by aligning subunit sequences from twenty mammalian species, 
chosen for their diversity and availability of sequences. Table 6.5 shows the list of species and where 
necessary, predicted sequences or sequences from closely related species were used, leading to a total 
of 867 sequences included in the analyses. Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/; 
Sievers et al., 2011) was used to align the sequences from each subunit and the conservation of each 
residue classified by four categories: fully conserved (identical in all species), strongly conserved (all 
within a strong conservation group of similar residues), weakly conserved (all within a weak group of 
similar residues) and non-conserved. These levels of conservation were calculated using a point 
accepted mutations (PAM) matrix. PAM matrices are constructed by analysing substitution frequencies 
in evolutionary related proteins - to determine the probability that a given residue will be replaced by 
another particular residue, by chance, after a set evolutionary interval. PAM units reflect evolutionary 
distance, so that for the PAM250 matrix only an average of one in five residues remain unchanged. 
Using the Gonnet PAM250 matrix, Clustal Omega scored each residue position based on its mutation 
probability, with a score of 1 reflecting full conservation, 1 – 0.5 strong conservation, 0.5 – 0 weak 
conservation, and 0 not conserved. The groups of strong and weak conservation are given in Table 6.6. 
 
For analysis of the severity of amino acid change each variant was considered individually, with residue 
positions demonstrating more than one change separated and reclassified (Appendix 7.9D). The specific 
amino acid change was then assigned as severe, medium or mild. Severe represented a non-conserved 
change, medium was a change that remained within a weakly conserved residue grouping and a mild 
change remained within a strongly conserved residue grouping, according to Table 6.6. 
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Species Common name Notes 
Bos taurus  Cow   All subunit sequences fully annotated 
Gorilla gorilla 
gorilla  
Western lowland 
gorilla 
 All subunit sequences fully annotated 
Homo sapiens  Human  All subunit sequences fully annotated 
Macaca mulatta  Rhesus monkey   All subunit sequences fully annotated 
Mus musculus  Mouse   All subunit sequences fully annotated 
Pan troglodytes  Chimpanzee  All subunit sequences fully annotated 
Rattus norvegicus Rat   All subunit sequences fully annotated 
Ailuropoda 
melanoleuca  
Giant panda 
Predicted sequence used for NDUFV3, NDUFS1, NDUFS4, NDUFA12, 
NDUFA13, NDUFAB1, NDUFB2, NDUFB5 
Callithrix jacchus  
White-tufted-ear 
marmoset 
Predicted sequence used for NDUFA3, NDUFA6, NDUFA7, NDUFA10, 
NDUFA11, NDUFB5, NDUFC2, NDUFV3 
Canis familiaris Dog 
Predicted sequence used for NDUFS5, NDUFA1, NDUFA10, NDUFB1, 
NDUFB5, NDUFB8 
Cavia porcellus  Guinea pig 
Predicted sequence for NDUFV3, NDUFS7, NDUFA1, NDUFA7, 
NDUFA12, NDUFB1, NDUFB4, NDUFC2 
Equus caballus  Horse  
Predicted sequence used for NDUFA7, NDUFA11, NDUFA12, NDUFA13 
(from Equus przewalskii), NDUFB4, NDUFB6, NDUFV3 (from Equus 
asinus) 
Felis catus  Cat  
Predicted sequence used for NDUFS6, NDUFA3, NDUFA12, NDUFA13, 
NDUFB1 
No sequence for NDUFV3 
Sequences for NDUFC2, NDUFS2 incorrect (discounted) 
Ictidomys 
tricemlieantus 
Thirteen-striped 
ground squirrel 
Predicted sequence used for NDUFV3, NDUFA2, NDUFA8, NDUFA9, 
NDUFA11, NDUFA12, NDUFA13, NDUFB1, NDUFB4, NDUFB5, 
NDUFC2 
Sequence for NDUFA12 incorrect (discounted) 
Monodelphis 
domestica  
Opossum  
Predicted sequence used for NDUFS8, NDUFA12, NDUFB2, NDUFC2 
No sequence for NDUFV3 
Sequence for NDUFS8 incorrect (discounted) 
Myotis lucifugus  Little brown bat 
Predicted sequence used for NDUFV3, NDUFS1 (from Myotis brandtii) 
NDUFS4, NDUFA8, NDUFA9, NDUFA10, NDUFA11, NDUFA12, 
NDUFB2, NDUFC2 
NDUFA5 from Myotis brandtii 
No sequence for NDUFA3   
Ovis aries Sheep  
Predicted sequence for NDUFV3, NDUFS2, NDUFS6, NDUFS8 (from Ovis 
musimon), NDUFA5, NDUFA13, NDUFC1 
Pongo pygmaeus  Bornean orangutan Pongo abelii sequences used for NDUFA1, NDUFA3, NDUFB9 
Sarcophilus 
harrisii 
Tasmanian devil 
Predicted sequence used for NDUFV3, NDUFS1, NDUFS4, NDUFS6, 
NDUFA2, NDUFA8, NDUFA12, NDUFA13, NDUFB1, NDUFB5, 
NDUFB7, NDUFC1 
No sequence for NDUFS3, NDUFB6, NDUFB9 
Sequence for NDUFB7, NDUFC2 incorrect (discounted) 
Sus scrofa  Pig  
Predicted sequence used for NDUFS1, NDUFS8, NDUFA12, NDUFB7, 
NDUFB9 
No sequence for NDUFV3 
 
Table 6.5 Species used for sequence alignment by Clustal Omega to determine conservation of complex I 
subunits.  For subunits without annotated sequence in a given species predicted sequences or sequences of closely 
related species were used where available. 
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Strong conservation groups Weak conservation groups 
STA ATV 
NEQK SAG 
NHQK STNK 
NDEQ STPA 
QHRK SGND 
MILV SNDEQK 
MILF NDEQHK 
HY NEQHRK 
FYW FVLIM 
 HFY 
 
Table 6.6 Gonnet PAM250 grouping of residues for strongly and weakly conserved conservation 
assignment. These groupings were also used for the severity of amino acid change – strongly conserved were mild 
changes and weakly conserved were medium changes, with non-conserved change denoted as severe. 
 
6.5.1. Conservation 
 
Figure 6.2 demonstrates the distribution of variants across the four classes of conservation, with raw 
data shown in Table 6.7. There is a clear and significant trend in the proportion of variants that are fully 
conserved and not conserved across the classes. Class 1 mutations are in residues that are significantly 
more conserved than class 1 polymorphisms, 88% compared to 5%, whereas a significant proportion of 
class 1 polymorphisms are not conserved (71%) compared to class 1 mutations (4%).  Additionally, the 
data shows that for fully conserved residues there is segregation towards pathogenic mutations and 
against benign polymorphisms. 55% of all the residues in the structure are in fully conserved residues; 
therefore there are more than 30% more class 1 mutations and 50% fewer class 1 polymorphisms that 
are fully conserved than expected by chance. The opposite trend was observed for non-conserved 
residues; this conservation level makes up less than 25% of the total residues, but the proportion is 
considerably higher for class 1 polymorphisms and far lower for class 1 mutations. The intermediate 
classes of strongly and weakly conserved showed less pronounced trends and less difference between 
class 1 variants, therefore the predictive power of conservation levels can be simplified to considering 
whether the residue is fully conserved or not. This analysis shows that variants can be assessed for likely 
pathogenicity from their conservation level, not only is there a significant difference between the two 
highest confidence classes but a trend was also observed across all six variant classes.  
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Figure 6.2 Trends in residue conservation across the classes of mutations and polymorphisms. Conservation 
categories were determined by Clustal Omega as described in above. The proportion of variants that were fully, 
strongly, weakly or not conserved are shown in the order class 1, 2, 3 mutations and class 3, 2, 1 polymorphisms 
for trend analysis. Conservation levels across the whole structure are indicated by the lines. The percentage 
expected by ‘chance’ was calculated from the total residues in each grouping (within the structure) compared to 
the total, denoted by lines. Significance of differences observed was assessed using 2 values from the Cochran-
Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between the class 1 mutations and 
class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and **** for P ≤0.0001. Raw 
values are given in Table 6.7. 
 
 
Mutations Polymorphisms 
All 
residues 
Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Fully conserved 45 54 66 113 18 2 4505 
Strongly conserved 2 11 25 78 32 9 1414 
Weakly conserved 2 4 4 17 8 1 358 
Not conserved 2 17 39 200 101 29 1976 
 
Table 6.7 Distribution of mutations and polymorphisms across different conservation categories. The 
number of variants from each class found in conservation category. The proportion of all residues in the structure 
present in each conservation level is also shown, for comparision. 
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Figure 6.3 shows the conservation level of residues mapped onto the human complex I model (generated 
as described in section 6.6) and demonstrates the hydrophobic domain is less conserved than the 
hydrophilic arm. This correlates well with the observation that ~75% of class 1 polymorphisms are non-
conserved because, as highlighted in Figure 6.1, polymorphisms are significantly more likely in the 
mitochondrial core subunits of the membrane arm, which demonstrates low conservation of residues. 
 
 
 
 
Figure 6.3 Structure of human complex I coloured by conservation.  The conservation of all residues in the 
structure was determined by alignment of subunit sequences for 20 mammalian species (Table 6.5). Green denotes 
fully conserved residues, blue are strongly conserved, purple are weakly conserved and red are non-conserved 
residues. Both side views of the model are shown. The human model of complex I was constructed using mouse 
complex I cryo-EM structures (section 6.6). 
 
6.5.2. Severity of amino acid change 
 
Another important, clinically relevant consideration is the type of amino acid change. The severity of 
this change will have implications for the properties of the residue, directly affecting its function – 
therefore not all changes to a residue will have the same impact. For this analysis any residue positions 
with multiple changes were considered separately, so the classification of some residues was altered, 
along with the total number of residues in each variant class. Figure 6.4 shows the proportion of residues 
from each variant class in the different amino acid change categories, denoted severe for non-conserved 
changes, medium from weakly conserved changes and mild for strongly conserved changes. The data 
demonstrates that a variant changing to a very different residue is more likely to result in a pathogenic 
mutation; there is a significant trend across the six classes and significantly more class 1 mutations are 
found with a severe change compared to class 1 polymorphisms. A medium change in residue property 
did not show a clear trend and suggests that this type of change may result in either mutations or 
polymorphisms. However polymorphisms are more likely to arise from a mild change, causing little 
difference in the property of the amino acid, compared to a mutation. There was a significant increasing 
trend across the variant classes (mutations to polymorphisms), with less than 50% of class 1 mutations 
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accounted for by mild mutations whereas class 1 polymorphisms comprised a large proportion, 73%. 
Therefore the predictive power of amino acid change could be considered as binary - whether the residue 
change is severe or not.  
 
 
Figure 6.4 Trends in residue change severity across the classes of mutations and polymorphisms. Severity 
of change categories were determined by Clustal Omega as described in above. The proportion of variants with 
severe, medium and mild changes are shown in the order class 1, 2, 3 mutations and class 3, 2, 1 polymorphisms 
for trend analysis. Significance of differences observed was assessed using 2 values from the Cochran-Armitage 
test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between the class 1 mutations and class 1 
polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and **** for P ≤0.0001. Raw values 
are given in Table 6.8. 
 
 
 
Mutations Polymorphisms 
Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Severe 19 34 44 147 33 5 
Medium 12 16 27 83 36 5 
Mild 23 37 73 259 95 27 
Total 54 87 144 489 164 37 
 
Table 6.8 Distribution of mutations and polymorphisms with residue changes of different severity. Severe 
changes are non-conserved, medium changes are weakly conserved and mild changes are strongly conserved as 
determined by residue groupings from Clustal Omega, Table 6.6. 
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6.6. The high-resolution model of human complex I provides more information about 
residues in the structure 
 
Model building was carried out by Dan Grba from the MRC MBU, University of Cambridge. The 
structure of mouse complex I in the active state (RCSB protein data bank (PDB) code: 6G2J; Agip et 
al., 2018), the highest-resolution structure of mammalian complex I currently available, was used as the 
basis for the structural model of human complex I. First, sequence changes (additions, deletions and 
mutations) were performed in Coot (version 0.8.9.1-pre, Emsley et al., 2010), using the curated 
sequences of the human complex I subunits in the UniProt/Swiss-Prot database and mouse-human 
sequence alignments from LALIGN (https://www.ebi.ac.uk/Tools/psa/lalign/). The sequence identity 
between the mouse and human complexes is 81%. The humanised model was then refined against the 
cryo-EM electron density for the mouse enzyme (EMD-4345, Agip et al., 2018) by real-space 
refinement in Phenix (version 1.12-2829, Adams et al., 2010) and geometrical restraints were used for 
the iron-sulphur clusters.  Phospholipids were not included. It was then placed into the lower-resolution 
complex I portion of the human supercomplex cryo-EM density map (EMD-6775 and EMD-6773, Guo 
et al., 2017) using UCSF Chimera (version 1.11.2, Petteresen et al., 2004). Using Phenix, subunit 
positions were adjusted by rigid body fitting and then real-space refinement was performed. Minimal 
side-chain movements were observed as a result, particularly in poorly resolved regions. In a small 
number of regions the densities from the supercomplex map or a subsection of it (Guo et al., 2017) were 
better defined than the mouse density, allowing a small number of additional structures to be built using 
Coot. The final model was produced by manual adjustment and real-space refinement and validated 
using MolProbity (http://molprobity.biochem.duke.edu, Williams et al., 2018) and EMRinger 
(http://fraserlab.com/2015/02/18/EMringer/, Barad et al., 2015). The overall root-mean-square 
deviation between our model and the model presented by Guo and co-workers is very low at 0.8 Å, 
showing high general similarity, with the weakest agreement for NDUFV1 and NDUFV2 (1.2 Å, two 
subunits of relatively low resolution in the supercomplex density) and the best agreement (0.5 - 0.6 Å) 
in the heel and centre of the membrane domain. The human model generated from the structure of the 
active state of mouse complex I was used for the analyses described because it originates from a higher-
resolution analysis than the model of Guo et al. and describes an enzyme in a known functional state; 
additionally we have detailed knowledge and understanding of it. The model is summarised in Table 
6.9.  
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Subunit Chain 
Total 
residues 
Modeled 
residues 
% 
Modeled 
% 
Identity 
Number of 
residues 
cleaved from  
N-terminus 
Notes 
NDUFV1 F 444 10-444 98.0 97.3 20 FMN, 4Fe4S 
NDUFV2 E 217 1-217 100 96.3 32 2Fe2S 
NDUFS1 G 704 6-693 97.7 94.7 23 2Fe2S, 2 x 4Fe4S 
NDUFS2 D 430 1-430 100 93.7 33 Dimethyl-Arg85 
NDUFS3 C 228 8-215 91.2 91.2 36  
NDUFS7 B 175 19-175 89.7 92.0 38 4Fe4S 
NDUFS8 I 176 1-176 100 94.9 34 2 x 4Fe4S 
ND1 H 318 1-318 100 77.0 0 N-formyl 
ND2 N 347 1-347 100 57.1 0 N-formyl 
ND3 A 115 1-115 100 66.1 0 N-formyl 
ND4 M 459 1-459 100 66.9 0 N-formyl 
ND4L K 98 1-98 100 66.3 0 N-formyl 
ND5 L 603 1-603 100 63.8 0 N-formyl 
ND6 J 174 1-174 100 52.3 0 N-formyl 
NDUFV3 s 74 34-74 55.4 68.9 34  
NDUFS4 Q 133 9-133 94.0 94.0 42  
NDUFS5 e 105 1-105 100 74.3 1 2 x Cys-Cys 
NDUFS6 R 96 1-96 100 88.5 28 Zn2+ 
NDUFA1 a 70 1-70 100 82.9 0  
NDUFA2 S 98 13-95 84.7 85.7 1  
NDUFA3 b 83 1-83 100 80.7 1 N-acetyl 
NDUFA5 V 115 1-115 100 82.6 1  
NDUFA6 W 127 14-127 89.8 74.0 27  
NDUFA7 r 112 1-76, 90-122 88.4 91.1 1 N-acetyl 
NDUFA8 X 171 1-171 100 86.5 1 4 x Cys-Cys 
NDUFA9 P 342 1-342 100 79.5 35 NADPH 
NDUFA10 O 320 1-320 100 77.5 35 ADP 
NDUFA11 Y 140 1-140 100 65.0 1 Cys-Cys 
NDUFA12 q 145 1-145 100 89.0 0 N-acetyl 
NDUFA13 Z 143 5-143 97.2 83.2 1  
NDUFAB1 T 88 8-82 85.2 96.6 68 Acyl chain 
NDUFAB1 U 88 1-88 100 96.6 68 Acyl chain 
NDUFB1 f 57 1-57 100 75.4 1  
NDUFB2 j 72 1-71 98.6 87.5 33  
NDUFB3 k 97 14-92 81.4 82.5 1  
NDUFB4 m 128 1-128 100 75.0 1  
NDUFB5 h 143 1-143 100 77.6 46  
NDUFB6 i 127 1-127 100 70.1 1 N-acetyl 
NDUFB7 o 136 12-116 77.2 82.4 1 2 x Cys-Cys 
NDUFB8 l 157 1-154 98.1 84.7 29  
NDUFB9 n 178 1-178 100 86.5 1  
NDUFB10 p 171 1-165 96.5 80.7 1 2 x Cys-Cys 
NDUFB11 g 124 23-124 82.3 78.2 29  
NDUFC1 c 49 1-49 100 75.5 27  
NDUFC2 d 119 1-119 100 68.9 0  
 
Table 6.9 Summary of structure models for subunits in human complex I.  Some subunits include an N-
terminal mitochondrial targeting sequence (MTS) or initiator methionine that is cleaved; the number of residues 
removed is given and indicates the change in amino acid numbering in the mature protein. The percentage identity 
denotes the sequence similarity between the mouse and human subunit sequences.  
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6.6.1. Secondary structure   
 
The four secondary structure elements considered are: alpha helices, beta sheets, transmembrane helices 
and loops. The secondary structure elements of proteins have different properties and may be associated 
with different functions. Helices that span membranes are termed transmembrane helices. Loops 
between other elements are highly flexible and may undergo large conformational changes. 
Additionally, different secondary structure elements often associate to form a distinct fold, with 
combinations of beta sheet and alpha helices used to form the nucleotide binding Rossmann fold, and 
TIM barrels are common in the catalytic domains of enzymes (Petsko & Ringe, 2003). Secondary 
structure may be an important predictor of pathogenicity because some elements may be more tolerant 
to variation than others. The secondary structure of each residue was defined in the header of the PDB 
coordinate file, based on the secondary structure of the equivalent residue in the structure of mouse 
complex I (PBD code: 6G2J; Agip et al., 2018). 
 
Figure 6.5 shows the distribution of variants across the four secondary structure categories and 
comparison with the proportion of each in the whole structure, raw data in Table 6.10. Across complex 
I loops are the dominant category, comprising almost 50% of the structure, whereas helices and TMHs 
each account for just over 20%. Only a small population of complex I residues are found in beta sheet 
structures, just 6%. The six variant classes also show the lowest proportion of residues present in beta 
sheets and although a significant trend was calculated across the classes, with a higher proportion of 
mutations, the small size of this category implies that overall variants do not segregate into beta sheet 
elements; additionally there was no significant difference between the proportion of class 1 mutations 
and polymorphisms in this secondary structure. Helixes in complex I contain a low proportion of 
variation overall, with all classes (except class 2 mutations) showing a considerably smaller percentage 
than the expected 24%. Although a significant trend was calculated across the classes this was only due 
to the proportion found in class 2 mutations, which was similar to that expected by chance. If this value 
was removed the analysis was non-significant. Again the difference between class 1 mutations and 
polymorphisms was also non-significant, indicating that helices generally demonstrated less variation 
and there was no difference between likelihood of a pathogenic or polymorphic outcome. Although 
loops are the most prevalent secondary structure these also demonstrated lower than expected levels of 
variation and there was no significant trend across the classes. Therefore, TMHs appeared to be the only 
secondary structure showing a difference in variant distribution, with a highly significant trend across 
the classes (increasing toward polymorphisms). However, even for TMHs, there was no significant 
difference between class 1 mutations and polymorphisms, but interestingly all classes showed a higher 
proportion of residues as TMHs than expected, more than 22% - the percentage across the whole 
structure. Results for TMH elements may be convoluted by the high proportion of TMHs found in the 
core mtDNA-encoded subunits, therefore separate analysis was carried out. 
 
221 
 
 
Figure 6.5 Trends in residue secondary structure across the classes of mutations and polymorphisms. The 
proportions of different secondary structure elements across the whole structure are indicated by the lines. The 
percentage expected by ‘chance’ was calculated from the total residues in each grouping (within the structure) 
compared to the total, denoted by lines. Significance of differences observed was assessed using 2 values from 
the Cochran-Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between the class 1 
mutations and class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and **** for P 
≤0.0001. Raw values are given in Table 6.10. 
 
 
 
Table 6.10 Distribution of mutations and polymorphisms across different secondary structure elements. The 
number of variants from each class found in the four secondary structure elements. The proportion of all residues 
in the structure present in each category is also shown for comparision. 
 Mutations Polymorphisms All residues 
Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Beta sheet 6 3 14 14 3 1 457 
Helix 6 21 17 47 13 5 1968 
Loop 24 39 53 171 54 15 4003 
TMH 15 23 50 176 89 20 1825 
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Figure 6.6 (and raw data in Table 6.11) shows that the proportion of each variant class found in TMHs 
of mtDNA-encoded subunits is similar and reflects the percentage expected by chance, 63%. There was 
no significant trend across the classes or difference between class 1 mutations and polymorphisms. For 
the nuclear encoded subunits there was a trend across the classes, however there was no significant 
difference between class 1 mutations and polymorphisms. Although there are fewer mutations than 
expected compared to the proportion of residues in TMHs across the nuclear subunits, 8%, the difference 
was not significant – nor was the slight increase in polymorphisms compared to random distribution. 
Therefore Figure 6.6 show that the distribution of variants in TMHs observed in Figure 6.5 was due to 
the high proportion of TMH secondary structure in the mtDNA-encoded core subunits, 63% compared 
to 8% in nuclear-encoded subunits; when separated by genome there was no clear or significant 
correlation between variant type and TMH elements. This demonstrates that secondary structure does 
not constitute an independent predictive feature for the likelihood of pathogenic mutations or 
polymorphisms in complex I.  
 
 
Figure 6.6 Distribution of mutations and polymorphisms across TMHs in mtDNA-encoded and nuclear-
encoded subunits. The percentage expected by ‘chance’ was calculated from the total residues in each grouping 
(within the structure) compared to the total, denoted by lines. Significance of differences observed was assessed 
using 2 values from the Cochran-Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) 
between the class 1 mutations and class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 
0.001 and **** for P ≤0.0001. Raw values are given in Table 6.11.  
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Mutations Polymorphisms 
All residues 
Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
mtDNA- 
encoded 
14  
(20) 
21  
(37) 
48  
(69) 
160  
(258) 
85  
(141) 
19  
(35) 
1324  
(2114) 
nuclear 
DNA- 
encoded 
1  
(31) 
2  
(49) 
2  
(65) 
16  
(150) 
4  
(18) 
1  
(6) 
501  
(6139) 
 
Table 6.11 Distribution of all mutations and polymorphisms across TMHs in subunit groupings. Totals for 
mutations, polymorphisms and residues in mtDNA and nuclear DNA subunits are given in brackets. 
 
6.6.2. Residue environment 
 
The tertiary structure of a protein is directly linked to its function, as it requires a precise structure to be 
maintained. Residues are found either on the solvent exposed surface or within the structure, contacting 
other residues, where they may form important interactions. For multi-subunit proteins like complex I, 
the boundaries between different subunits may also be important regions that require structural integrity 
either for function or stability of the complex. To assess variant distribution across different 
environments, residues within the human model structure were grouped into three categories – surface 
exposed, buried or at subunit interfaces. The fractional surface areas of each residue in contact with the 
solvent were calculated using the get_sasa_relative command in PyMol (default probe radius of 1.4 Å). 
The values are provided as a percentage and calculated as the relative solvent accessible surface area 
(SASA) compared to the area of the fully exposed residue (with only its two neighbouring residues 
present). For a residue to be surface exposed it has more than 25% of its surface area accessible to the 
solvent. Residues with less than 25% of their surface area exposed were non-surface residues. To 
determine whether these amino acids are at interfaces or completely buried two solvent accessible values 
were compared: the surface exposed area when the subunit is within the whole enzyme and the area that 
is solvent accessible when the subunit is in isolation. From these the percentage of the surface area in 
contact with other subunits was calculated as the difference in values as the relative SASA percentage 
at a subunit interface is only exposed in the isolated subunit. Thus for non-surface residues, if the 
percentage exposed only in the isolated subunit was >25% then the residue was deemed to be at an 
interface, otherwise it was assigned as completely buried in the structure.  
 
Figure 6.7 demonstrates the distribution of variants in the six classes according to their environment, 
with raw data in Table 6.12. It is clear that variants found in buried and interface environments are more 
likely to be mutations, whereas those on the surface are more likely to be polymorphic. There is a 
significant trend in residue environment across the variant classes for buried and surface environments, 
although the difference between the highest confidence classes was only significant in the surface 
grouping, with a higher proportion of polymorphisms. Interestingly when compared to the distribution 
expected by chance, given by the distribution across the whole structure, polymorphisms have a similar 
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observed distribution, suggesting there is no selective pressure on polymorphisms due to residue 
environment – 39% of residues in the whole structure are buried, 23% at interfaces and 38% found on 
the surface – all classes of polymorphisms differ by less than 5% across all residue environments. In 
contrast, the proportion of class 1 mutations found buried or at interfaces is higher than expected and 
surface exposed mutations lower than expected, indicating a selective pressure towards variation being 
pathogenic for non-surface residues.  
 
 
Figure 6.7 Trends in residue environment across the classes of mutations and polymorphisms. The 
proportions of residues in different environments across the whole structure are indicated by the lines. The 
percentage expected by ‘chance’ was calculated from the total residues in each grouping (within the structure) 
compared to the total, denoted by lines. Significance of differences observed was assessed using 2 values from 
the Cochran-Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between the class 1 
mutations and class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and **** for P 
≤0.0001. Raw values are given in Table 6.9. 
 
 
 
  
Mutations Polymorphisms All 
residues Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Buried 32 44 67 143 58 16 3240 
Interface 18 28 32 99 41 9 1904 
Surface 1 14 35 166 60 16 3109 
 
Table 6.12 Distribution of mutations and polymorphisms across different residue environments. Buried and 
interface residue data was combined for the non-surface grouping in Figure 6.7.  
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Additionally there appears to be no difference in the segregation of variants between buried and interface 
environments. Thus these two groupings can be considered together and this feature can be used to 
predict pathogenicity by simply identifying whether the residue is surface exposed or not, Figure 6.8.  
 
 
Figure 6.8 Trends in surface and non-surface residue exposure across the classes of mutations and 
polymorphisms. The proportions of residues in the two environments across the whole structure are indicated by 
the lines. The percentage expected by ‘chance’ was calculated from the total residues in each grouping (within the 
structure) compared to the total, denoted by lines. Significance of differences observed was assessed using 2 
values from the Cochran-Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between 
the class 1 mutations and class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and 
**** for P ≤0.0001. Combining the buried and interface groupings in Table 6.6 gives the data for the non-surface 
environment. 
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6.6.3. Salt bridge formation 
 
Another aspect to be considered from structural information is the presence of salt bridges. These are 
the strongest type of non-covalent interactions and are an electrostatic interaction between two 
oppositely charged residues (Kumar & Nussiov, 2002). Therefore the types of amino acid were first 
analysed in each of the variant classes and across the whole structure. Amino acids were grouped by 
type: aromatic (Phe, Trp, Tyr), negatively charged (Asp, Glu), non-polar (Ala, Gly, Ile, Leu, Met Val), 
polar non-charged (Asn, Cys, Gln, Pro, Ser, Thr) and positively charged (Arg, His, Lys). Salt bridges 
were analysed using the ESBRI server (Constantini et al., 2008). 
 
Figure 6.9A demonstrates that, across all the variant classes, non-polar residues made up the highest 
proportion, which reflects the whole structure distribution of 39%. There was no significant trend across 
the variant classes for aromatic and non-polar residues, although there was a significant trend in polar 
non-charged residues, which increased from mutations to polymorphisms, despite the difference 
between class 1 mutations and polymorphisms being non-significant. In contrast, the distribution of 
charged residues demonstrated a clear trend; no class 1 polymorphisms were negatively charged residues 
and only one was a positively charged residue, whereas class 1 mutations showed a significantly larger 
proportion – 22% and 14% respectively. The substantial trends across the variant classes for these two 
amino acid types and between the class 1 mutations and polymorphisms indicated that, when mutated, 
charged residues were likely to be pathogenic. To rationalise this observation further the salt bridge 
forming residues were analysed, 6% of the whole structure comprises charged residues found in a salt 
bridge pair. The proportion was considerably increased to over 15% for the class 1 mutations, whereas 
there are no class 1 polymorphisms involved in salt bridges. A strong significant trend was also exhibited 
across the six classes. Therefore, there is a selection for variation in salt bridge forming residues causing 
detrimental mutations, Figure 6.9B. Therefore, salt bridges in complex I represent an important 
structural feature and their disruption is a predictive factor for the outcome of a variant; they may 
increase structural stability, or be important in bringing functionally important residues together.  
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Mutations Polymorphisms 
All 
residues 
Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Aromatic 1 11 11 20 14 4 875 
Negatively 
charged 
7 12 6 9 1 0 884 
Non-polar 18 31 67 184 75 20 3239 
Polar non-
charged 
14 16 29 132 63 16 2147 
Positively 
charged 
11 16 21 63 6 1 1108 
Salt bridge 
forming 
8 10 6 19 1 0 474 
 
Table 6.13 Distribution of mutations and polymorphisms across different amino acid types and the number 
forming salt bridges. The number of variants from each class found in the different amino acid types. The 
proportion of all residues in the structure present in each amino acid category is also shown, for comparision. 
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Figure 6.9 Trends in amino acid type across the classes of mutations and polymorphisms. The proportions of 
residues with different properties across the whole structure are indicated by the lines. The percentage expected 
by ‘chance’ was calculated from the total residues in each grouping (within the structure) compared to the total, 
denoted by lines. Significance of differences observed was assessed using 2 values from the Cochran-Armitage 
test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between the class 1 mutations and class 1 
polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and **** for P ≤0.0001. Raw values 
are given in Table 6.10. 
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6.6.4. Variant distribution across the structure of complex I 
 
Figure 6.10 displays the distribution of variants in the structure of complex I and reflects the observation 
that mutations and polymorphisms show an unequal spread across the enzyme. In addition, it is clear 
that, even within groups of subunits, there is no even distribution. Most notably the mtDNA subunits 
contain a high proportion of class 1 mutations in four of the seven subunits: ND1, ND3, ND4L and ND6 
contain 17/20 of the class 1 mutations in the core membrane subunits yet only represent one third of the 
residues in this group of subunits. Additionally, from visual inspection of Figure 6.10 there are clusters 
of mutations in two functionally important regions – the N-domain at the top of the hydrophilic arm, 
where the redox factor FMN is bound, and Q-domain near the base of the hydrophilic arm where it 
contacts the membrane arm, which contains the proposed ubiquinone-binding site. In contrast, these 
regions appear to lack polymorphisms and could indicate that variant distribution is influenced by 
proximity to certain functional domains of complex I. Therefore, to explore this further key features of 
complex I were identified and the distance from variant residues assessed. 
 
 
Figure 6.10 Distribution of mutations and polymorphisms in the complex I structure. Mutations are in red 
and polymorphisms in blue. Class 1 variants are shown by large spheres, class 2 variants by intermediate spheres 
and class 3 variants by small spheres. 
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6.6.5.  Distance from key features in complex I 
 
Due to its large structure complex I contains a number of functionally and structurally relevant elements. 
By reviewing the literature and published structures, 16 groups of features were identified (Table 6.14) 
and the distance of each feature from every residue in the structure was measured. This was achieved 
using coordinates for the key features: for those made up of residues the alpha-carbon and atoms of the 
side chain were selected, and for bound molecules coordinates for all atoms were used – details given 
in Table 6.14. Then the distance of the nearest coordinate from the alpha-carbon of each residue in the 
structure was found and attributed to the corresponding key feature, to determine the closest feature to 
each residue. For analyses the features were initially grouped as shown in Table 6.14 into functionally 
and structurally related elements. 
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Feature class Atom coordinates considered 
Redox cofactors FMN (all atoms), 2Fe2S and 4Fe4S iron sulphur clusters (all atoms) 
Q-binding site 
Ligands for ubiquinone head group - NDUFS2 His59, Tyr108 and Asp160 (C-α 
and all side chain atoms) and 49 midline coordinates for isoprenoid binding 
channel determined by CAVER  
ND3 Cys39  Cys39 (C-α and all side chain atoms) 
E-channel residues 
ND1 (Glu143, Glu192, Glu227), ND3 (Asp66, Glu68), ND4L (Glu34, Glu70) 
(C-α and all side chain atoms) 
ND6 helix π bulge Gly61-62 (C-α and all side chain atoms) 
Conserved charged residues in 
ND2, ND4 and ND5 
ND2 (Glu34, Lys105, Lys263), ND4 (Glu123, Lys206, Glu378), ND5 (Glu145, 
Lys223, Lys392) 
(C-α and all side chain atoms) 
Semi-conserved charged residues 
in ND2, ND4 and ND5 
ND2 (His186), ND4 (His220, His293, His319), ND5 (Arg176, Asp179, His328, 
His332, Lys336) 
(C-α and all side chain atoms) 
Charged residues associated with 
the transverse helix of ND5 
ND2 (His112), ND4 (His213), ND5 (His230, Asp554) 
(C-α and all side chain atoms) 
Loops that interrupt TMHs in 
ND2, ND4 and ND5 
ND2 TMH4 (Gly107-Phe111) and TMH9 (Gly252-Gly259), ND4 TMH7 
(Met207-Leu214) and TMH12 (Leu367-Thr372), ND5 TMH7 (Gly222-Pro231) 
and TMH12 (Gly382-Tyr390) 
(C-α and all side chain atoms) 
ND2, ND4 and ND5 helix π 
bulges  
ND2 (Leu131, Lys135), ND4 (Ala233, Lys237), ND5 (His248) 
(C-α and all side chain atoms) 
Acyl groups and LYR/LYK 
motifs  
NDUFA6 LYR motif (Leu34-Arg36), NDUFB9 LYK motif (Leu18-Lys20) 
(C-α and all side chain atoms) 
NDUFAB1 α/β Ser44 (C-α and all side chain atoms), panthetheine 4’-phosphate 
and acyl groups (all atoms) 
NADPH in NDUFA9 NADPH cofactor (all atoms) 
ADP in NDUFA10 ADP cofactor (all atoms) 
Zinc in NDUFS6 Bound Zn2+ 
Disulphide bonds in canonical 
CHCH-domain proteins 
NDUFA8 (Cys35&Cys65, Cys45&Cys55, Cys87&Cys99, Cys77&Cys109), 
NDUFB7 (Cys58&Cys89, Cys68&Cys79), NDUFS5 (Cys32&Cys65, 
Cys42&Cys55) 
(C-α and all side chain atoms) 
Non-canonical disulphide bonds 
NDUFA11 (Cys17&Cys74, Cys94&Cys114), NDUFB10 (Cys70&Cys77, 
Cys106&Cys118), ND5 (Cys279) & NDUFB8 (Cys115), NDUFB11 (Cys112)  
& NDUFB10 (Cys148) 
(C-α and all side chain atoms) 
 
Table 6.14 Key structural and functional features in complex I. Features were grouped as shown for distance 
measurements and coordinates used are indicated in italics in parenthesis.  
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Figure 6.11 details the positions of each feature in the structure of complex I. The redox cofactors (FMN 
and Fe-S clusters) are found in the hydrophilic arm along with three other bound molecules: a zinc ion 
in NDUFS6, ADP in NDUFA9 and NADPH in NDUFA10, which have no known function. The two 
copies of the acyl carrier protein (NDUFAB1) also include a bound acyl group and the LYR/K motifs 
of NDUFA6 and NDUFB9 interact with these subunits (Zhu et al., 2015). The position of the Q-channel 
was determined using CAVER (Chovancová et al., 2012) with a 1.4 Å probe and the oxygen of the 
hydroxyl of NDUFS2 Tyr108 used as the starting position. The 49 midline coordinates were then used 
in distance analyses. Figure 6.11A demonstrates the position of the Q-site at the hinge region of the 
matrix and membrane arm, connecting the chain of Fe-S clusters to the beginning of a network of 
charged residues running through the core membrane domain subunits, which is proposed to propagate 
conformational changes for proton translocation (Baradaran et al., 2013). Cysteine-39 of ND3 is an 
important residue, its position on a flexible loop shows altered solvent accessibility depending on the 
state of the enzyme. When complex I is in its deactive state this residue is exposed and can be trapped 
by chemical modification with fluorescent N-ethyl maleimide, allowing the proportion of complex I in 
active and deactive states to be determined (Galkin et al., 2008). There are also a number of disulphides 
present in complex I, falling into two groups, those in canonical CHCH-domain proteins and non-
canonical disulphides, including bonds between different subunits. All disulphide bonds present in the 
active mouse structure (Agip et al., 2018) were included along with three additional non-canonical 
disulphide bonds present in the human model: ND5 Cys279 & NDUFB8 Cys115, NDUFB11 Cys112 
& NDUFB10 Cys148 and NDUFA11 Cys94 & Cys114.  
 
Figure 6.11B highlights the key TMHs of the mitochondrially-encoded core subunits and the long 
transverse helix of ND5. Importantly, each of the antiporter-like subunits (ND2, 4 and 5) has a histidine 
on the loop of discontinuous TMH7 that points outside the subunit and may interact with the transverse 
helix of ND5 (ND4-His213 clamps the helix to ND4) (Agip et al., 2018). These subunits also comprise 
two TMHs that are interrupted by loops; which have been proposed to act as channels for proton 
movement, as broken alpha helices often provide ion-binding sites and conformational flexibility 
(Efremov and Sazanov, 2011). Four TMHs also demonstrate an unusual structure, distortions – π bulges 
– that have been observed in resolved structures, with those in TMH8 of ND2, 4 and 5 present in all 
structures, although the strict definition of a π bulge is not always fulfilled (Agip et al., 2018). In 
contrast, the ND6 π bulge on TMH3 was not present in the active mouse structure (used to generate the 
human model) and consequently conformational differences were observed in this region between active 
and deactive states – highlighting this π bulge as functionally important for catalysis (Zhu et al., 2016; 
Agip et al., 2018). 
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Figure 6.11 Overview of key features in complex I. A. Positions of the bound cofactors and the Q-site are 
indicated and the distribution of disulphide-bonded residues (black) in the supernumerary subunits. The E-channel 
residues of ND1, 3 and 4L are shown as pink spheres, which connect the Q-site (yellow) to the charged residues 
located along the midline of the three antiporter-like subunits (ND2, 4 and 5) shown in teal. Cys39 of ND3 is also 
highlighted; its altered solvent exposure denoted the active to deactive transition of complex I. B. Functionally 
relevant TMHs – the π bulge containing helix of ND6 (pink), the π bulge containing helix of each antiporter-like 
subunit (turquoise), the six TMHs interrupted by loops (orange) and the long transverse helix of ND5 (red).  
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These features were all chosen, although not all have assigned functional roles. Figure 6.12 provides a 
closer inspection of two functionally important regions – the network of charged residues and the Q-
site. The E-channel charged residues were grouped togther for their proposed connecting role, linking 
changes within the Q-channel on quinone reduction to the proton pumping machinery of the membrane 
domain, Figure 6.12A, in addition to forming the fourth proton channel. Charged residues of the 
sequence related antiporter subunits (ND2, ND4 and ND5) are suggested to coordinate conformational 
changes for proton pumping and are either conserved across all three subunits or partially conserved - 
so were grouped accordingly (dark blue and pale blue sticks respectively in Figure 6.12A). Figure 6.12B 
shows the position of three key residues in the head-group binding region of the Q-channel, which were 
taken along with the midline coordinates of the channel as a representation of the quinone binding 
region. Therefore, by careful consideration of structural and biochemical information, these features 
were assessed with respect to the proximity of residues in the six variant classes.  
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Figure 6.12 Detailed locations of residues in the charged network and the Q-site. A. E-channel residues are 
shown as pink sticks and residue identities coloured by subunit (ND1 in red, ND3 in cyan and ND4L in orange).   
The charged residues along the midline of the antiporter-like subunits are shown as dark blue sticks for conserved 
residues and pale blue sticks for semi-conserved residues. Residue identities are coloured by subunit (ND2 in 
green, ND4 in navy and ND5 in purple). Semi-transparent TMHs shown are the π bulge containing helix of ND6 
(pink), π bulge containing helices of ND2, 4 and 5 (teal) and the discontinuous helices of ND2, 4 and 5 (orange). 
B. The quinone channel is shown as a yellow surface mesh and the three catalytically important residues His59, 
Tyr108 and Asp160 of NDUFS2 are shown as yellow sticks. The base of the Q-channel is proximal to the first of 
the E-channel residues, Glu227 of ND1.  
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6.6.5.1. The distribution of variants differs between types of key features 
 
Figure 6.13 shows the proportions of each variant class found within 10 Å of the key features discussed, 
the raw data is given in Table 6.11. Figure 6.13A represents the features present in the core hydrophilic 
domain subunits and the adjacent mtDNA-encoded subunits (ND1, 3, 4L and 6), which do not have 
antiporter-like structures. Across these features there is selection for nearby variants to be pathogenic, 
particularly close to redox cofactors, where this is both a significant trend across the classes and 
significantly more class 1 mutations within 10 Å compared to class 1 polymorphisms. Additionally, 
compared to the distribution across the whole structure there is a higher proportion of mutations than 
expected. Despite this there were no variants within 10 Å of ND3-Cys39, which may suggest that this 
residue is intolerant to local residue changes. In contrast to the prevalence of pathogenic mutations near 
the features shown in Figure 6.13A, there was an opposite trend for the antiporter-like subunits. The 
most distinct difference was found for the loops in discontinuous TMHs, almost 20% of class 1 
polymorphisms are found <10 Å from the loops of the discontinuous TMHs. This is significantly higher 
than for class 1 mutations, only a single variant was with 10 Å and the intermediate classes mirrored 
this trend, demonstrating that variants near these loops are likely to be polymorphic. It is also interesting 
that whilst there was no trend in variant distribution near π bulges in the anti-porter-like subunits (Figure 
6.13B), there was a significant trend for proximity to the π bulge of ND6 (Figure 6.13A), with a higher 
proportion of variants being pathogenic. This feature is only observed in the deactive structure of 
complex I, thus conformational changes in this region, observed by the loss of the π bulge in the active 
enzyme, are fundamental for function and therefore more susceptible to changes in the local 
environment. The final group of features are those found in the supernumerary subunits, Figure 6.13C, 
and overall less than 5% of all variant classes were found near to these features (with no significant 
selection towards either polymorphisms or mutations).  
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Figure 6.13 Trends in distance from key features across the classes of mutations and polymorphisms. A. 
Proportion of variant classes within 10 Å of features in the core nuclear-encoded subunits and neighbouring 
mtDNA encoded subunits ND1, 3, 4L and 6. B. Proportion of variant classes within 10 Å of features in the 
antiporter-like subunits ND2, 4 and 5. C. Proportion of variant classes within 10 Å of features in the supernumerary 
subunits. The percentage of residues within 10 Å of different features across the whole structure are indicated by 
the lines. The percentage expected by ‘chance’ was calculated from the total residues in each grouping (within the 
structure) compared to the total, denoted by lines.Significance of differences observed was assessed using 2 
values from the Cochran-Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between 
the class 1 mutations and class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and 
**** for P ≤0.0001. Raw values are given in Table 6.15. 
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 Mutations Polymorphisms All 
residues  Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Redox cofactors 8 12 7 2 0 1 306 
Q-binding site 3 3 3 6 0 0 127 
ND3 Cys39 0 0 0 0 0 0 32 
E-channel 
residues 
8 4 10 12 15 0 168 
ND6 π bulge 5 3 3 3 4 0 33 
Conserved 
charged residues 
3 6 11 25 9 2 282 
Semi-conserved 
charged residues 
1 6 4 22 5 3 246 
Transverse helix 
linked charged 
residues 
0 1 0 7 5 2 103 
Intra-TMH loops 1 6 10 36 19 8 446 
π bulges 0 5 5 9 14 1 164 
NADPH 1 0 3 3 0 0 76 
ADP 0 0 1 3 1 0 55 
Acyl chains and 
LYR/K motifs 
0 1 1 4 0 0 185 
Zinc 1 0 2 2 0 0 22 
Canonical 
disulphide bonds 
0 1 0 10 1 0 211 
Non-canonical 
disulphide bonds 
0 0 1 7 2 1 183 
 
Table 6.15 Proportion of mutations and polymorphisms found within 10 Å of key features in complex I. The 
number of variants from each class found in proximal to the 16 key features in complex I. The proportion of all 
residues in the structure present within 10 Å of each key feature is also shown, for comparision. 
 
 
6.6.5.2. Grouping of complex I features by location in the structure reveals clustering of 
pathogenic variants   
 
The features in Figure 6.13A, B and C were each combined to increase the sample size, demonstrating 
clear and opposing trends between groups A and B, representing the features present in the two core 
subunits groupings, Figure 6.14 and Table 6.16. This comparison reveals that key features of complex I 
cannot be treated as a single factor in predicting pathogenic outcome - the proximity to features in the 
antiporter-like subunits indicates a significant likelihood of being polymorphic, compared to features in 
the remaining core subunits, which demonstrate selection towards a pathogenic outcome. Distance from 
supernumerary subunit features did not provide predictive information. This distinctive difference 
suggests that residue changes near features such as the redox cofactors or the quinone-binding site are 
detrimental, thus manifest and are clinically identified in disease patients. However, functionally 
important elements of the antiporter-like subunits, particularly the discontinuous helices, are more 
tolerant, with variation in local residues presenting as benign mutations. This therefore implies that 
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TMHs are inherently less affected by changes to residue identity, as shown by the increased proportion 
of polymorphic variants overall. Due to the identification of the antiporter subunits as fundamental in 
the proton pumping function of complex I the relatively low susceptibility of these regions to detrimental 
mutations is unexpected. Rather it would be anticipated that mutations would cluster around all 
functionally important regions of the protein. This result highlights the importance of specialist 
knowledge of the system. Consequently these observations further demonstrate the difference between 
the spatially distinct oxidoreductase and proton pumping functions of the enzyme.  
 
 
 
 
Figure 6.14 Distribution of variants found within 10 Å of different key feature groups. Key features were 
grouped into three sets – group A are found in the core nuclear-encoded subunits and neighbouring mtDNA-
encoded subunits ND1, 3, 4L and 6 (Figure 6.12.A). Group B are features found in the antiporter-like subunits 
ND2, 4 and 5 (Figure 6.12.B) and group C are features of the supernumerary subunits (Figure 6.12.C). The 
proportions of residues within 10 Å of different features across the whole structure are indicated by the lines. The 
percentage expected by ‘chance’ was calculated from the total residues in each grouping (within the structure) 
compared to the total, denoted by lines. Significance of differences observed was assessed using 2 values from 
the Cochran-Armitage test on the trend (arrows) and the Fischer’s Exact Test (two-tailed) between the class 1 
mutations and class 1 polymorphisms - denoted * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001 and **** for P 
≤0.0001. Raw values are given in Table 6.16. 
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 Mutations Polymorphisms All 
residues  Class 1 Class 2 Class 3 Class 3 Class 2 Class 1 
Group A 18 18 20 19 15 1 597 
Group B 2 10 17 55 27 9 640 
Group C 2 2 8 29 4 1 732 
 
Table 6.16 Distribution of mutations and polymorphisms across key feature groups of complex I. The 
number of variants from each class found in proximal to the three groups of key features in complex I. The 
proportion of all residues in the structure present within 10 Å of feature group is also shown, for comparision. 
 
 
Another interesting consideration is whether any of the residues identified in the key features have 
themselves been detected as variants in human genes. Of the 121 residues present in the 16 feature 
groups (Table 6.14), none were identified as polymorphic, and only five were pathogenic variants. These 
were the class 1 mutation ND1 Glu143 (an E-channel residue), the class 2 mutations ND3 Asp66 (an E-
channel residue) and ND5 Glu145 (a conserved charged residue in the antiporter-like subunits), along 
with the class 3 mutations ND4 Lys 206 and ND5 Lys392 (both conserved charged residues in the 
antiporter-like subunits). ND1 Glu143 is a known LHON-causing variant and therefore its important 
function in complex I would be anticipated; mutation of residues in the E-channel network may interrupt 
the transfer of conformational changes induced by quinone reduction and hamper proton pumping. ND3 
Asp66 as been implicated in Leigh syndrome and ND5 Glu145 in mitochondrial encephalopathy, lactic 
acidosis and stroke syndrome (MELAS) with differing confidence, and so again their identity as 
important charged residues is likely to explain the pathogenic outcome of variation. The remaining two 
mutations have only been reported as involved in disease: ND4 Lys206 in sporadic Creutzfelt-Jacob 
disease (sCJD) and ND5 Lys392 in Leigh syndrome, but their role in complex I function may strengthen 
their assignment. The lack of polymorphic variation in key feature residues may be informative and, 
combined with the low number pathogenic mutations identified, it suggests that in general these amino 
acids are intolerant to any variation, such that changes are embryonic lethal and incompatible with life. 
However, this interpretation must be made with caution, considering that not all possible residue 
variation has been sampled - many variants have yet to occur in nature.  
 
6.7. Rationalising class 1 variants 
 
Analysing different aspects of complex I individually demonstrated trends in distribution of 
polymorphisms and mutations, thus these criteria were then considered in combination, using class 1 
mutations and polymorphisms to make an initial assessment on whether the characteristics of the 
residues indicated the variant outcome. Although the severity of the amino acid change was shown to 
be an good indicator of the variant outcome this criteria was not considered here as it required different 
variants at the same residue to be separated: the aim of this analysis was to gain an overview on whether 
sequence and structural characteristics could be used to predict the likelihood that mutation at a specific 
residue position would be disease-causing or benign.  
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Nine criteria were chosen using the previous analyses, and for each residue it was determined whether 
the criteria indicates pathogenicity, polymorphism or has no predictive power (colour coding in Tables 
6.17 and 6.18).  
• If the variant is found in a core nuclear DNA-encoded subunit this indicates pathogenicity, but 
if found in a mtDNA-encoded subunit this suggests a polymorphism. Supernumerary subunits 
were non-predictive.  
• If a variant occurrs in a fully conserved residue it is more likely to be pathogenic, whereas 
variation in non-conserved residues has a higher propensity to be benign – the intermediate 
classes of conservation were non-indicative.  
• Secondary structure does not aid predictions. 
• If a variant is found in a surface exposed residue it is more likely to be benign, whereas changes 
in non-surface residues tend towards a pathogenic outcome.  
• If a negatively or positively charged residue is mutated it is more likely to be pathogenic.  
• Amino acids that form salt bridges are probable disease-causing variants when mutated.  
• Using the distances from key features and the three groupings shown in Figure 6.13: 
− variants <10 Å from group A features (in core nuclear and neighbouring mtDNA 
encoded core subunits ND1, ND3, ND4L and ND6) are more likely to be pathogenic. 
− variants <10 Å from group B features (in antiporter-like subunits ND2, ND4 and ND5) 
are more likely to be polymorphic.  
− the distance from features in group C (supernumerary subunits) shows no pattern.  
 
Tables 6.17 and 6.18 show the information for all class 1 mutations and polymorphisms, colour coded 
using the nine criteria (detailed data in Appendix 7.9). By comparing the number of pathogenic and 
polymorphic indicators a crude assessment was made on the outcome of variation in these residues. 
39/51 class 1 mutations were demonstrated to be pathogenic, and 22 had four or more criteria 
demonstrating a pathogenic tendency. Another eight were assessed as likely pathogenic, with more 
pathogenic indicators, but only one more than the number of criteria indicating a polymorphic outcome. 
Two were described as ambiguous, as the outcome could not be distinguished due to equal numbers of 
criteria suggesting pathogenic and benign outcomes. Two also appeared likely polymorphisms, with one 
more criteria indicating a benign outcome compared to the pathogenic indicators:  ND3 Ser34 and Ser45 
are non-conserved residues in a core mtDNA-encoded subunit, with only their location at a subunit 
interface indicating that variation may have a pathogenic outcome. Interestingly, these two variants were 
also found in polymorphic classes 3 and 2, respectively, which supports the uncertainty of these as 
pathogenic mutations – an explanation for this may be different levels of heteroplasmy and that specific 
haplogroups may confer protection or susceptibility to these mutations. This was also the case for the 
two ambiguous residues ND1 Ala52 and Ala132, which are also found as class 3 polymorphisms. 
Overall this analysis demonstrated that using the combined predictive powers of different criteria 92% 
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of class 1 mutations were correctly identified as likely disease-causing, and none displayed 
characteristics that resulted in a high confidence polymorphic outcome. 
 
The same approach was taken with class 1 polymorphisms, 18/41 were deemed polymorphic by 
comparing the criteria, another 14 were likely benign and seven appeared ambiguous with the same 
number of criteria indicating pathogenicity and neutral outcomes. The class 1 polymorphism predictions 
therefore agreed less with their annotations, with one likely pathogenic and one strongly pathogenic 
identification. NDUFV2 Val102 is found buried in a nuclear-encoded core subunit and <10 Å from an 
element in the group A features, all of which suggests this variant is pathogenic; no criteria highlighted 
it as polymorphic as it is a strongly conserved residue distant from group B key features. Therefore the 
annotation of this variant may be questioned; it is possible that it could cause disease in certain genetic 
backgrounds or with homozygous inheritance, although it was not found in any mutation class. However 
it is present in the wider population and causes no phenotype as class 1 polymorphisms have an allele 
frequency of <1%. Additionally two of the six residues assigned as ambiguous were found as class 2 
(ND2 Asn150) or class 3 mutations (ND1 Tyr30), being located in mtDNA-encoded subunits where 
different heteroplasmy levels may affect the impact of the variant.   
 
Overall, this analysis has shown that combining different types of criteria is a valuable approach to 
assessing the outcome of a variant. However this was only an initial study to compare residues with high 
confidence annotations: it requires further development to generate a useful predictive tool. This 
development will be undertaken with our collaborators, Professor Patrick Chinnery and co-workers, 
using computational techniques to build an equation that includes all criteria, weighted by the trends in 
variant distribution. Not all criteria will be treated equally (as was done above) because each criterion 
demonstrates different levels of correlation with variant type - thus variants patterns can be assessed 
accurately and complied to build an overall model biased towards criteria that have the best predictive 
power. The aim is to construct an equation to provide a probability score for pathogenicity, which could 
then be applied to every residue in complex I to map possible disease hotspot regions onto the structure. 
This would provide a specific tool for prediction of variants in complex I, and also provide insight into 
why certain variants cause disease, thus informing both clinicians and researchers, and further 
harnessing the information gained by structural studies on complex I.  
 
 
 
 
 
 
 
243 
Subunit Identity 
Subunit 
type 
Conserv. 
Secondary 
structure 
Surface 
exposure 
Amino 
acid  
type 
Salt 
bridge 
forming 
Dist. 
from 
group  
A 
features 
Dist. 
from 
group  
B 
features 
Dist. 
from 
group  
C 
features 
Outcome 
ND1 Glu24                   P 
ND1 Ala52                   A 
ND1 Ser110                   LP 
ND1 Gly131                   LP 
ND1 Ala132                   A 
ND1 Glu143                   P 
ND1 Arg195                   P 
ND1 Leu289                   P 
ND3 Ser34                   LB 
ND3 Ser45                   LB 
ND3 Ala47                   LP 
ND4 Arg340                   P 
ND4L Val65                   LP 
ND5 Phe124                   LP 
ND5 Asp393                   LP 
ND6 Gly36                   P 
ND6 Leu60                   P 
ND6 Met63                   P 
ND6 Met64                   LP 
ND6 Ala72                   LP 
NDUFA1 Gly8                   P 
NDUFA1 Arg37                   P 
NDUFA10 Gln107                   P 
NDUFA9 Arg286                   P 
NDUFS1 Leu208                   P 
NDUFS1 Arg218                   P 
NDUFS1 Asp229                   P 
NDUFS1 Arg385                   P 
NDUFS1 Thr572                   P 
NDUFS1 Asp596                   P 
NDUFS2 Arg195                   P 
NDUFS2 Pro196                   P 
NDUFS2 Met259                   P 
NDUFS2 Ser380                   P 
NDUFS2 Ala393                   P 
NDUFS3 Thr109                   P 
NDUFS3 Arg163                   P 
NDUFS6 Cys87                   P 
NDUFS7 Val84                   P 
NDUFS8 Glu29                   P 
NDUFS8 Arg43                   P 
NDUFS8 Pro45                   P 
NDUFS8 Pro51                   P 
NDUFS8 Arg68                   P 
NDUFS8 Arg104                   P 
NDUFS8 Ala125                   P 
NDUFV1 Ala97                   P 
NDUFV1 Pro102                   P 
NDUFV1 Cys186                   P 
NDUFV1 Glu194                   P 
NDUFV1 Thr403                   P 
  
Table 6.17 Residue criteria of class 1 mutations colour coded by pathogenic or polymorphic indicators. The 
51 highest confidence mutations are given along with nine criteria analysed to predict variant outcome. Red boxes 
denote pathogenic likelihood and blue suggest the variant is benign, uncoloured boxes are non-predictive criteria 
(including secondary structure as a whole). The outcome was determined by the difference in the number of 
pathogenic and benign indicators – a difference of: >+1 were assigned pathogenic (P), +1 as likely pathogenic 
(LP), no difference as ambiguous (A), -1 are likely benign (LB), <-1 are benign (B). Column heading 
abbreviations: conservation (Conserv.), distance from group A features (Dist. from group A features), distance 
from group B features (Dist. from group B features) and distance from group C features (Dist. from group C 
features). 
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Subunit Identity 
Subunit 
type 
Conserv. 
Secondary 
structure 
Surface 
exposure 
Amino 
acid  
type 
Salt 
bridge 
forming 
Dist. 
from 
group  
A 
features 
Dist. 
from 
group  
B 
features 
Dist. 
from 
group  
C 
features 
Outcome 
ND1 Ala4                   B 
ND1 Ile81                   A 
ND1 Tyr30                   A 
ND1 Thr67                   A 
ND1 Thr164                   LB 
ND1 Thr240                   LB 
ND1 Tyr304                   LB 
ND1 Ile309                   LB 
ND2 Val8                   LB 
ND2 Thr119                   B 
ND2 Asn150                   A 
ND2 Val193                   LB 
ND2 Leu237                   LB 
ND2 Ala331                   B 
ND2 Phe325                   B 
ND3 Val88                   LB 
ND3 Thr114                   B 
ND4 Pro140                   B 
ND4 Ala404                   LB 
ND4L Met47                   LB 
ND5 Thr8                   LB 
ND5 Val24                   B 
ND5 Ile257                   LB 
ND5 Met314                   LB 
ND5 Ala458                   B 
ND5 Ala475                   B 
ND5 Ile482                   LB 
ND5 Tyr485                   B 
ND5 Ser531                   B 
ND5 Thr533                   B 
ND5 Thr544                   B 
ND5 Ser515                   B 
ND5 Leu555                   B 
ND6 Asn119                   B 
ND6 Ile166                   A 
NDUFA7 Lys47                   A 
NDUFA9 Pro259                   A 
NDUFB9 Pro145                   B 
NDUFC2 Leu46                   B 
NDUFS2 Pro319                   LP 
NDUFV2 Val102                   P 
 
Table 6.18 Residue criteria of class 1 polymorphisms colour coded by pathogenic or polymorphic indicators. 
The 41 highest confidence polymorphisms are given along with nine criteria analysed to predict variant outcome. 
Red boxes denote pathogenic likelihood and blue suggest the variant is benign, uncoloured boxes are non-
predictive criteria (including secondary structure as a whole). The outcome was determined by the difference in 
the number of benign and pathogenic indicators – a difference of: >+1 were assigned benign (B), +1 as likely 
benign (LB), no difference as ambiguous (A), -1 are likely pathogenic (LP), <-1 are pathogenic (P). Column 
heading abbreviations: conservation (Conserv.), distance from group A features (Dist. from group A features), 
distance from group B features (Dist. from group B features) and distance from group C features (Dist. from group 
C features). 
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6.8. Conclusions  
 
The work in this chapter aimed to increase our ability to predict the outcome of variants in human 
complex I genes by combining recent structural information with more conventional analyses of primary 
sequence and secondary structure. Generating a human model from the best resolution mammalian 
structures available allowed spatial mapping of all variants collated from online databases. The model 
was then used to create a comprehensive table of all residues in the structure along with details of eight 
characteristics: subunit type, encoding genome, conservation, secondary structure, residue environment, 
amino acid type, participation in salt bridges and proximity to key features. From analysis of this data 
regarding the distribution of pathogenic and polymorphic variants a number of insights were made, 
exemplifying the importance of using all available information when interpreting the outcome of a 
variant and supporting the call for bespoke tools that are gene/protein specific.  
 
Firstly, conservation in complex I subunits was shown to be a strong predictive criterion, as mutations 
in conserved residues were more likely to cause disease than those in residues that have diverged in 
identity during mammalian evolution. Conservation was also closely linked to the severity of the amino 
acid change: drastic changes in residue identity were pathogenic but mild changes could be tolerated 
and were more likely to present as polymorphisms. In contrast, secondary structure alone did not help 
to identify pathogenic variants – trends seen in TMHs were linked to the mtDNA-encoded subunits, 
which were generally less well conserved and comprised a high proportion of TMHs, being found in the 
hydrophobic arm of the enzyme. Therefore although polymorphisms appeared to segregate into TMHs, 
secondary structure was not an independent predictor. This outcome may represent a distinction between 
complex I and other proteins, where secondary structure elements display greater independence; hence 
specific considerations must be made depending on the protein.  
 
Complex I is unusual as it comprises subunits encoded by two genomes. Variation is greater in the 
mtDNA-encoded subunits (26% of residues compared to 5% of nuclear-encoded subunits) and reflects 
the difference in mutation rates of the two genomes, something that will not affect other proteins and 
complexes with a single encoding genome. On top of this complex I subunits can be separated into core 
and supernumerary subunits, those that are present in the bacterial enzyme and have a defined function, 
compared to more recent evolutionary additions that appear to act as scaffolding surrounding the core 
subunits. Variants were found to distribute differently between these two groups and therefore this 
represents another characteristic of complex I to be considered that may not be applicable to other 
proteins and could be overlooked by broad prediction tools. 
 
A primary aim of this chapter was to utilise information that can only be obtained from protein structure; 
this information was scrutinised and clearly showed that criteria such as residue environment, 
participation in stabilising bonds (such as salt bridges) and proximity to functional regions increase the 
reliability of interpreting the outcome of a variant. Detrimental complex I variants clustered away from 
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the surface, perhaps as a result of its large multi-subunit structure, indicating that the most important 
interactions occur inside the complex. However, other proteins may show the inverse trend, such as 
those with chaperoning function, where surface association with partner proteins is critical. 
Additionally, as discussed above, full consideration of functionally and structural relevant features is 
required, with high-resolution structures enabling distances of all residues from these regions to be 
measured and analysed for trends. It was striking that not all of the features that are widely agreed to 
participate in the mechanism of complex I oxidoreduction and proton pumping are equally susceptible 
to mutations in nearby residues. Cofactor binding sites and the long quinone binding cavity are likely to 
be detrimentally affected by variation in the local environment - a high proportion of mutations was 
found <10 Å away but levels of polymorphisms were low. Conversely, the broken TMHs of the 
antiporter subunits demonstrated greater resilience; variation near these features tended to result in 
polymorphisms. Complex I incorporates many important sites, due to its large size, number of subunits 
and energy transferring function, and this work shows that these should be addressed separately to 
ensure specific properties, that may help identify pathogenic hotspots, are not overlooked.  
 
Overall, this work provides a step towards development of pathogenicity prediction tools that include a 
wide range of protein related criteria, and exemplifies how structural research can be harnessed to aid 
clinicians when assessing human gene variants. However, like all prediction analyses that use existing 
pathogenic and polymorphic annotations, the quality of the analysis is reliant on the databases used and 
misinterpreted entries affect the robustness of predictions. Nevertheless variant annotation is often 
updated and corrected by greater sequencing of patients and analysis of controls. New databases are 
being released that significantly increase the data available, such as the recent genome aggregation 
database (gnomAD) – a development of ExAc - comprising 123,136 exome sequences and 15,496 whole 
genome sequences for polymorphic variant analysis. Also, whilst comparison of pathogenic and 
polymorphic variants provides a strong basis for determining residue susceptibly, these variants do not 
cover the entire spectrum of changes. The most severe mutations will never be accounted for because 
these changes are embryonic lethal, thus residues that display very low variation, particularly with 
complete lack of polymorphisms, may in fact be vital and variation at these positions is never detected. 
Furthermore, not every possible variation will have occurred, further decreasing the number of 
mutations observed. The main complication in human disease is the dual inheritance of alleles; disease-
causing mutations may be recessive and require both mutated gene copies, or present as compound 
heterozygotes, whereby two different mutant alleles are present. Therfore assigning the causal variant 
is difficult, and both mutations may contribute to the phenotype. In addition mitochondrial heteroplasmy 
may vary, affecting the outcome. Therefore for the most robust analysis of disease variants biochemical 
analysis is also required. Models such as Y. lipolytica (described in Chapter 5) present malleable systems 
to study individual mutations, thereby predictions and clinical observations may be used to inform 
experiments that in turn provide greater information about the effect of the residue change on complex 
I activity and overall mitochondrial function.
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Chapter 7 
Appendices 
Appendix 7.1. SILAC data for 143B cells grown in riboflavin depleted media (5 and 13 days) and 143B CyWT cells grown in riboflavin rich media  
 
Complex I subunits 
Gene names 
Normalised Log2 
Forward Ratio H/L 
(8 days) 
Normalised Log2 
Forward Ratio H/L 
(13 days) 
Unique 
peptides  
(8 days) 
Unique 
peptides 
(13 days) 
Count  
(8 days) 
Count 
 (13 days) 
Ratio H/L 
variability [%] 
(8 days) 
Ratio H/L 
variability 
[%] 
(13 days) 
Sequence 
coverage 
[%] 
(5 days) 
Sequence 
coverage 
[%] 
(13 days) 
Molecular 
weight 
[kDa] 
NDUFS1 2.06 1.80 11 22 11 29 18.95 27.19 20.4 41.7 79.47 
NDUFV2 1.97 1.55 2 5 3 9 9.50 69.24 14.3 24.2 25.43 
NDUFV1 1.94 1.39 10 17 9 18 30.94 49.00 23.0 39.4 50.05 
NDUFS6 2.06 1.07 2 5 3 7 38.16 69.75 21.8 41.9 13.71 
NDUFA7 1.74 0.82 2 6 2 6 62.00 94.92 16.8 47.8 12.55 
NDUFA12 - 0.80 - 7 - 9 - 102.64 - 52.4 17.11 
NDUFA6 - 0.69 - 3 - 5 - 19.66 - 27.3 15.14 
NDUFB9 -0.14 0.45 6 8 9 15 9.12 42.36 48.8 42.9 20.38 
NDUFA8 - 0.44 - 3 - 3 - 47.72 - 20.9 20.11 
NDUFB8 -0.54 0.40 2 3 2 5 5.93 12.76 10.8 17.2 21.77 
NDUFA3 - 0.28 - 1 - 3 - 3.94 - 13.1 9.28 
NDUFB4 -0.23 0.26 4 5 5 9 11.20 34.97 41.9 41.1 15.21 
NDUFA10 -0.12 0.24 9 13 11 22 50.02 84.41 25.7 32.2 40.68 
NDUFA2 - 0.22 - 3 - 3 - 45.12 - 21.2 10.92 
NDUFA13 -0.04 0.21 2 8 2 10 16.54 64.34 14.6 43.1 16.70 
NDUFB7 - 0.18 - 4 - 8 - 21.90 - 26.3 16.40 
NDUFB11 0.10 0.14 2 2 4 7 3.20 16.76 22.2 22.2 17.32 
NDUFB5 0.18 0.13 3 4 3 11 5.45 29.68 13.0 23.3 20.04 
NDUFS7 -0.07 0.11 2 5 2 7 2.18 13.69 12.6 18.7 19.77 
NDUFS3 0.03 0.05 3 8 5 11 39.28 6.16 19.5 36.3 22.22 
NDUFA9 -0.69 -0.02 4 14 4 17 44.32 64.96 11.8 46.4 38.44 
MT-ND3 - -0.03 0 1 - 2 - 1.39 - 28.3 6.09 
NDUFS2 -0.04 -0.05 14 22 14 24 20.91 59.77 39.4 54.7 46.40 
NDUFB10 0.10 -0.06 4 7 6 15 7.28 51.34 21.7 51.6 19.26 
NDUFS8 - -0.10 0 1 - 4 - 42.69 - 23.3 19.21 
MT-ND5 - -0.12 1 3 - 4 - 27.01 - 8.6 53.19 
NDUFA5 - -0.12 1 3 - 3 - 4.89 - 50.0 7.84 
NDUFB3 - -0.13 1 3 - 8 - 99.08 - 29.2 7.59 
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NDUFB6 0.16 -0.24 2 5 3 8 21.03 90.98 15.6 32.8 15.49 
NDUFS5 - -0.32 1 3 - 5 - 29.53 - 32.1 12.52 
NDUFC2 -0.40 -0.33 1 5 2 6 60.40 150.65 10.1 31.9 14.19 
NDUFB1 0.04 -1.25 2 3 3 7 12.68 50.07 32.8 34.5 6.96 
 
 
Mitoflavoproteins 
Gene names 
Normalised Log2 
Forward Ratio H/L 
(8 days) 
Normalised Log2 
Forward Ratio 
H/L 
(13 days) 
Unique 
peptides (8 
days) 
Unique 
peptides 
(13 days) 
Count (8 
days) 
Count (13 
days) 
Ratio H/L 
variability [%]  
(8 days) 
Ratio H/L 
variability 
[%]  (13 
days) 
Sequence 
coverage 
[%] (5 
days) 
Sequence 
coverage 
[%] (13 
days) 
Molecular 
weight 
[kDa] 
SQRDL 2.86 4.94 13 18 11 8 21.06 23.35 34.9 53.7 44.15 
DLD 3.14 3.06 7 7 5 9 18.46 40.13 19.2 23.1 48.90 
SDHA 2.14 2.38 11 21 10 24 19.39 28.80 23.6 45.8 72.69 
AIFM1 1.56 2.11 14 21 14 28 22.36 29.93 26.4 41.6 66.90 
ACADM 1.79 1.56 3 6 3 6 43.53 61.54 10.1 22.9 42.43 
GPD2 1.11 1.52 23 35 20 43 25.80 71.56 36.9 54.5 77.25 
NDUFV1 1.94 1.39 10 17 9 18 30.94 49.00 23.0 39.4 50.05 
ACADVL 1.38 1.25 17 21 13 19 32.58 54.23 35.7 34.5 70.39 
ETFA 0.32 0.84 3 5 5 11 5.58 15.00 25.0 49.6 24.90 
FOXRED1 - 0.84 0 6 - 4 - 7.22 - 16.5 53.81 
L2HGDH 0.22 0.64 3 3 3 2 31.82 9.62 7.0 8.6 48.48 
IVD - 0.45 1 1 - 4 - 22.03 - 13.0 46.32 
GSR - 0.33 0 4 - 4 - 62.05 - 11.7 56.26 
DHODH 0.72 0.15 4 18 4 18 32.10 45.80 15.2 47.3 42.87 
ACAD9 0.26 -0.07 16 30 15 34 11.25 42.44 31.6 45.2 68.76 
CYB5R3 -0.50 -0.59 6 7 5 5 6.32 22.02 24.4 30.6 33.24 
COQ6 -0.90 -0.89 3 7 3 4 43.69 6.79 9.0 20.3 50.80 
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Appendix 7.2. Complexome data for mitochondrial membrane and matrix fractions for 143B CyWT cells and conditioned RFK KD 143B cells  
 
7.2A Table of proteins used in mass estimation of 143B CyWT membrane sample (Calibration curve Figure 3.20A) 
 
143B CyWT membrane fraction calibration proteins 
Protein Mass (kDa) Native state Total Mass (kDa) Gel slice 
Mitochondrial ribosome (39S + 28S) -  39S + 28S subunits 2900 10 
Complex I (NADH:ubiquinone oxidoreductase) 1000 monomer 1000 19.5 
Complex V (ATP synthase) 770 monomer 770 24 
Complex III (Cytochrome bc-1 complex) 245 dimer 490 28 
NADP transhydrogenase 114 dimer 228 35 
Complex  IV (cytochrome c oxidase) 200 monomer 200 38 
SLC25A13 (citrin) 74 monomer 74 39 
SLC25A12 (aralar 1) 75 monomer 75 39 
Complex II (succinate dehydrogenase) 130 monomer 130 44 
Dihydrolipoamide dehydrogenase 54 monomer 54 45 
Citrate synthase 52 dimer 104 50 
Electron transfer ubiquinone oxidoreductase 69 monomer 69 52 
Choline dehydrogenase 65 monomer 65 52 
SLC25A23 (calcium binding carrier protein) 52 monomer 52 53 
Voltage dependent ion gated channel 1 31 monomer 31 53 
Cytochrome c 12 monomer 12 55 
ADP/ATP translocase (adenine nucleotide translocase) 30 monomer 30 55 
2-oxoglutarate/malate carrier protein 34 dimer 68 57 
Sulphide:quinone oxidoreductase 49 monomer 49 57 
SLC25A3 (phosphate carrier protein) 40 monomer 40 57 
Ubiquinone biosynthesis protein COQ9 37 monomer 37 62 
Adenylate kinase 2 26 monomer 26 63 
 
7.2B Table of proteins used in mass estimation of RFK KD membrane sample (Calibration curve Figure 3.20B) 
 
RFK KD membrane fraction calibration proteins 
Protein Mass (kDa) Native state Total Mass (kDa) Gel slice 
Mitochondrial ribosome (39S + 28S)  - 39S + 28S subunits 2900 10 
Complex I (NADH:ubiquinone oxidoreductase) 1000 monomer 1000 21 
Propionyl-CoA carboxylase (α and β subunits) α -80 and β - 58 heterododecamer 820 21 
Complex V (ATP synthase) 770 monomer 770 25 
Complex III (Cytochrome bc-1 complex) 245 dimer 490 30 
NADP transhydrogenase 114 dimer 228 35 
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Glutamate dehydrogenase 61 hexamer 366 36 
Polyribonucleotide nucleotidyltransferase 1 86 trimer 258 38 
Complex  IV (cytochrome c oxidase) 200 monomer 200 40 
SLC25A13 (citrin) 74 monomer 74 41 
SLC25A12 (aralar 1) 75 monomer 75 41 
Methylmalonyl-CoA mutase 83 dimer 166 42 
Complex II (succinate dehydrogenase) 130 monomer 130 47 
Aconitate hydratase 85 monomer 85 48 
Dihydrolipoamide dehydrogenase 54 monomer 54 50 
D-beta-hydroxybutyrate dehydrogenase 38 tetramer 152 50 
Citrate synthase 52 dimer 104 55 
SLC25A23 (calcium binding carrier protein) 52 monomer 52 58 
Thymidylate synthase 36 dimer 72 59 
Electron transfer ubiquinone oxidoreductase 69 monomer 69 59 
ADP/ATP translocase (adenine nucleotide translocase) 30 monomer 30 61 
Dihydroorotate dehydrogenase 43 monomer 43 62 
Cytochrome c 12 monomer 12 63 
2-oxoglutarate/malate carrier protein 34 dimer 68 63 
L-2-hydroxyglutarate dehydrogenase 50 monomer 50 63 
SLC25A32 (folate transporter/carrier) 35 monomer 35 64 
 
7.2C Complexome data for mitochondrial membrane from 143B CyWT cells. Score threshold for 95% confidence interval is 21. 
 
Complex I subunits 
Protein Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-ND1 8.49 2 35.6 29.44 
MT-ND2 7.49 2 38.9 34.32 
MT-ND4 14.16 6 51.5 93.57 
MT-ND5 11.61 3 67.0 153.12 
MT-ND6 8.05 1 18.6 60.08 
NDUFA10 25.07 7 40.7 126.43 
NDUFA11 31.91 3 14.8 79.96 
NDUFA12 35.17 4 17.1 83.52 
NDUFA13 43.06 8 16.7 362.04 
NDUFA2 48.48 5 10.9 259.59 
NDUFA3 36.90 2 9.3 49.40 
NDUFA5 30.17 4 13.5 142.12 
NDUFA6 33.77 5 17.9 155.25 
NDUFA7 62.83 7 12.5 108.97 
NDUFA8 21.51 3 20.1 84.66 
NDUFA9 47.75 15 42.5 253.84 
NDUFB1 34.48 3 7.0 107.39 
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NDUFB10 43.60 7 20.8 251.21 
NDUFB11 28.76 2 17.3 70.61 
NDUFB3 28.57 3 11.4 73.44 
NDUFB4 36.43 4 15.2 115.55 
NDUFB5 18.52 4 21.7 93.34 
NDUFB6 42.19 4 15.5 110.99 
NDUFB7 38.69 3 16.4 243.46 
NDUFB8 20.97 3 21.8 119.90 
NDUFB9 21.23 3 21.8 98.48 
NDUFC2 31.09 4 14.2 58.46 
NDUFS1 45.12 24 79.4 877.24 
NDUFS2 33.69 12 52.5 326.21 
NDUFS3 46.59 10 30.2 282.20 
NDUFS4 34.86 4 20.1 105.79 
NDUFS5 34.91 4 12.5 173.83 
NDUFS6 37.10 5 13.7 41.67 
NDUFS7 18.31 5 23.5 318.60 
NDUFS8 23.81 5 23.7 95.31 
NDUFV1 18.75 9 50.8 182.99 
NDUFV2 37.35 8 27.4 438.09 
NDUFV3 14.81 1 11.9 16.69 
 
Complex II subunits 
Protein Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
SDHA 31.63 16 72.6 564.76 
SDHB 33.93 11 31.6 414.76 
SDHC 4.73 1 18.6 45.56 
SDHD 10.69 1 17.0 35.8 
 
Complex III subunits 
Protein Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-CYB 2.37 1 42.7 97.43 
UQCR10 38.10 2 7.3 171.50 
UQCR11 21.43 1 6.6 15.56 
UQCRB 47.75 6 13.5 249.50 
UQCRC1 32.29 12 52.6 1091.78 
UQCRC2 40.18 13 48.4 1934.88 
UQCRFS1 44.89 11 29.6 674.08 
UQCRH  28.57 1 10.7 50.74 
UQCRQ  56.10 5 9.9 64.32 
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Complex IV subunits 
Protein Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
COX4I1  44.97 7 19.6 721.04 
COX5A  32.67 5 16.8 717.80 
COX5B 41.09 6 13.7 388.99 
COX6A1 16.51 1 12.1 42.90 
COX6B1 19.77 3 10.2 116.80 
COX6C  66.67 7 8.8 379.16 
COX7A2  56.63 2 9.4 722.64 
COX7A2L 70.18 4 12.6 56.33 
COX7C 25.40 1 7.2 39.91 
COX8A 13.04 1 7.6 66.75 
MT-CO1 7.60 3 57.0 76.99 
MT-CO2 27.75 5 25.5 744.26 
 
Complex V subunits 
Protein Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
ATP5A1  51.72 25 59.7 13821.39  
ATP5B  70.70 25 56.5 15750.88  
ATP5C1  37.92 10 33.0 1034.04 
ATP5D 13.69 2 17.5 290.75 
ATP5E 31.37 2 5.8 93.60 
ATP5F1 56.25 16 28.9 1313.04  
ATP5H  75.78 12 18.5 721.14 
ATP5I  62.32 5 7.9 332.53 
ATP5J  46.30 4 12.6 334.23 
ATP5J2 25.53 2 10.9 515.13 
ATP5L 89.32 6 11.4 683.56 
ATP5O  55.40 10 23.3 1701.88 
MT-ATP6  4.42 1 24.8 222.46 
MT-ATP8  36.76 2 8.0 29.33 
ATPIF1  7.55 1 12.2 19.88 
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Complex I assembly factors 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
ACAD9  30.6 17 68.7 357.26 
COA1 13.01 2 16.7 23.77 
ECSIT 28.31 8 49.1 85.24 
NDUFAF1 32.11 7 37.7 169.02 
NDUFAF2 65.68 9 19.8 99.48 
NDUFAF3 41.85 6 20.3 93.32 
NDUFAF4 29.71 4 20.3 51.81 
TIMMDC1 29.47 7 32.2 63.85 
 
7.2D Complexome data for mitochondrial membrane from conditioned RFK KD 143B cells. Score threshold for 95% confidence interval is 21. 
 
Complex I subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-ND1  8.81 3 35.6 234.16 
MT-ND2  2.59 1 38.9 42.19 
MT-ND4  13.94 5 51.5 132.58 
MT-ND5  9.29 5 67.0 382.40 
MT-ND6  8.05 1 18.6 111.95 
NDUFA10 25.07 10 40.7 468.25 
NDUFA11 21.28 2 14.8 167.94 
NDUFA12 80.69 11 17.1 686.00 
NDUFA13 63.89 11 16.7 1091.22 
NDUFA2 48.48 5 10.9 389.63 
NDUFA3 50.00 3 9.3 154.96 
NDUFA5 36.21 5 13.5 353.47 
NDUFA6 33.77 5 17.9 347.09 
NDUFA7 61.06 9 12.5 619.23 
NDUFA8 21.51 4 20.1 282.08 
NDUFA9 57.82 21 42.5 841.02 
NDUFAB1 11.54 1 17.4 103.64 
NDUFB1 36.21 3 7.0 263.46 
NDUFB10 53.49 12 20.8 1157.36 
NDUFB11 35.29 2 17.3 96.95 
NDUFB2 8.57 1 12.1 30.73 
NDUFB3 37.76 5 11.4 98.35 
NDUFB4 49.61 6 15.2 213.48 
NDUFB5 28.04 6 21.7 363.66 
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NDUFB6 58.59 5 15.5 355.40 
NDUFB7 40.15 5 16.4 1242.45 
NDUFB8 32.26 6 21.8 83.52 
NDUFB9 49.72 8 21.8 356.49 
NDUFC2 50.42 8 14.2 60.42 
NDUFS1 50.21 32 79.4 33149.44 
NDUFS2 45.79 16 52.5 716.48 
NDUFS3 51.52 14 30.2 1142.28 
NDUFS4 29.14 6 20.1 391.13 
NDUFS5 34.91 4 12.5 138.65 
NDUFS6 38.71 4 13.7 440.87 
NDUFS7 23.47 6 23.5 639.56 
NDUFS8 27.62 5 23.7 499.44 
NDUFV1 35.78 16 50.8 496.12 
NDUFV2 40.16 10 27.4 1138.18 
NDUFV3 14.81 1 11.9 58.81 
 
Complex II subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
SDHD  11.32 2 17.0 66.12 
SDHA  45.48 22 72.6 904.21 
SDHB  40.36 13 31.6 527.71 
SDHC  14.20 1 18.6 67.75 
 
Complex III subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-CYB  5.00 2 42.7 79.79 
UQCRC1 42.71 20 52.6 2412.52 
UQCR11  21.43 1 6.6 82.33 
UQCRC2  45.25 17 48.4 1948.11 
UQCRH  28.57 1 10.7 163.22 
UQCRB 56.76 9 13.5 525.63 
UQCRQ 95.12 9 9.9 343.21 
UQCR10 39.68 3 7.3 164.86 
UQCRFS1  60.95 14 29.6 836.57 
 
Complex IV subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-CO1 7.60 3 57.0 448.88 
MT-CO2  27.75 5 25.5 1249.18 
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MT-CO3 8.81 2 29.9 40.96 
COX4I1  55.03 12 19.6 1114.07 
COX5A  38.67 7 16.8 780.93 
COX5B  51.16 8 13.7 451.38 
COX6A1  35.78 2 12.1 50.39 
COX6B1 19.77 3 10.2 97.63 
COX6C  76.00 10 8.8 659.18 
COX7A2 56.63 3 9.4 241.17 
COX7C  28.57 2 7.2 44.58 
COX8A 13.04 1 7.6 125.73 
 
Complex I assembly factors 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
ACAD9  42.67 27 68.7 899.87 
ECSIT  41.53 11 49.1 590.82 
FOXRED1  2.67 1 53.8 81.00 
NDUFAF1  42.20 11 37.7 383.67 
NDUFAF2 39.05 5 19.8 59.88 
NDUFAF3 25.00 4 20.3 257.55 
NDUFAF4  43.43 8 20.3 295.57 
TIMMDC1  44.21 10 32.2 332.44 
TMEM126B 29.57 4 25.9 57.22 
TMEM70  11.54 2 29.0 77.05 
 
7.2E Complexome data for mitochondrial matrix from 143B CyWT cells. Score threshold for 95% confidence interval is 21. 
 
Complex I subunits 
Protein Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
NDUFA2 10.10 1 10.9 10.00  
NDUFS1 9.77 3 79.4 42.56  
NDUFV1 18.53 6 50.8 18.58  
NDUFV2  24.10 4 27.4 21.50  
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7.2F Calibration curve for mass estimation of RFK KD matrix sample. 
 
 
7.2G Table of proteins used in mass estimation of RFK KD matrix sample. 
 
 
 
RFK KD matrix fraction calibration proteins 
Protein Mass (kDa) Native state Total Mass Gel slice 
Mitochondrial ribosome (39S + 28S) -  39S + 28S subunits 2900 10 
Glutamate dehydrogenase 61 hexamer 366 36 
Fumarate hydratase 55 tetramer 220 43 
Acetyl-CoA acetyltransferase 180   180 46 
Dynamin-like 120 kDa protein 112 monomer 112 49 
Citrate lyase subunit beta-like protein 37 trimer 111 49 
Acyl-CoA dehydrogenase family member 9 51 monomer 69 51 
Dihydrolipoamide dehydrogenase 54 monomer 54 51 
Electron transfer protein (α and β subunits) α - 35 and β - 28 heterodimer 63 53 
Citrate synthase 52 dimer 104 53 
Kynurenine/alpha-aminoadipate aminotransferase 47 dimer 94 57 
Medium chain specific acyl-CoA dehydrogenase 46 monomer 46 58 
39S ribosomal protein L1 36 monomer 36 61 
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7.2H Complexome data for mitochondrial matrix from conditioned RFK KD 143B cells. Score threshold for 95% confidence interval is 21. 
 
 
 
Complex I subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
NDUFA13 9.03 1 16.7 19.21 
NDUFA2 31.31 2 10.9 112.03 
NDUFA5 17.24 2 13.5 25.88 
NDUFAB1 11.54 2 17.4 74.46 
NDUFS1 36.18 19 79.4 49.14 
NDUFS2 2.59 1 52.5 27.92 
NDUFS3 16.29 3 30.2 30.06 
NDUFS8 9.05 1 23.7 19.47 
NDUFV1 23.28 8 50.8 315.38 
NDUFV2 38.96 9 27.4 585.16 
 
Complex II subunits and assembly factors 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
SDHA 43.83 19 72.6 1333.16 
SDHAF2 16.27 2 19.6 123.43 
SDHB 39.64 11 31.6 249.77 
 
 
Appendix 7.3 SILAC data for conditioned RFK KD 143B cells and riboflavin rich 143B CyWT cells 
 
 
Complex I subunits 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight 
[kDa] 
MT-ND1 1.38 0.75 3 11 138.00 11.48 3 8.8 35.66 
MT-ND3 0.77 0.52 5 4 25.74 12.62 1 13.0 13.19 
MT-ND4 -0.28 -0.02 3 4 28.81 17.86 4 10.9 51.58 
MT-ND5 0.45 0.60 4 6 21.22 6.27 4 8.0 67.03 
NDUFA10 0.49 0.84 40 45 22.44 23.12 21 47.6 40.75 
NDUFA11 1.00 1.13 4 10 17.00 8.52 5 41.8 14.85 
NDUFA12 2.68 1.59 6 24 15.78 19.89 10 82.8 17.11 
NDUFA13 0.43 0.79 17 24 34.88 8.13 7 52.8 16.70 
NDUFA2 1.60 1.74 6 11 61.20 38.33 5 42.4 10.92 
NDUFA3 0.48 0.68 7 12 14.65 4.80 3 50.0 9.28 
NDUFA5 0.02 -0.02 14 18 22.89 14.26 7 49.1 13.46 
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NDUFA6 1.65 1.31 6 9 13.68 16.22 4 33.6 15.14 
NDUFA7 2.93 1.79 6 24 31.37 18.81 9 69.0 12.55 
NDUFA8 1.35 0.86 10 20 36.24 13.33 8 47.7 20.11 
NDUFA9 0.79 0.98 28 42 20.46 21.40 21 60.2 42.51 
NDUFAB1 0.52 0.83 3 5 39.55 8.24 4 21.2 17.42 
NDUFB1 -0.06 0.37 9 10 30.13 29.01 3 34.5 6.96 
NDUFB10 0.43 0.63 56 62 14.68 14.25 17 61.6 20.78 
NDUFB11 0.23 0.44 18 20 12.22 13.07 6 45.8 17.32 
NDUFB2 0.84 0.82 2 5 18.95 15.18 2 11.5 9.39 
NDUFB3 0.64 0.74 16 19 28.39 14.79 5 32.7 11.40 
NDUFB4 0.38 0.76 11 21 53.28 22.23 8 50.4 15.21 
NDUFB5 0.38 0.63 11 17 6.50 11.37 6 35.0 15.67 
NDUFB6 0.22 0.65 12 27 20.35 13.98 7 51.6 15.49 
NDUFB7 0.98 0.72 11 17 21.26 8.11 6 48.2 16.40 
NDUFB8 1.01 0.74 18 20 32.31 9.87 6 38.7 18.48 
NDUFB9 0.23 0.62 46 29 21.08 7.42 12 69.3 21.83 
NDUFC2 0.72 0.53 15 25 29.80 14.52 9 45.4 14.19 
NDUFS1 2.18 1.54 24 72 40.72 23.60 37 63.8 79.47 
NDUFS2 0.11 0.15 43 62 19.23 16.38 24 57.0 52.55 
NDUFS3 0.05 -0.06 32 63 22.89 14.25 18 58.0 30.24 
NDUFS4 2.30 1.88 2 10 86.93 23.27 5 25.7 20.11 
NDUFS5 1.11 0.68 5 10 25.91 10.41 6 39.6 12.52 
NDUFS6 2.62 1.44 10 16 53.92 23.20 5 41.9 13.71 
NDUFS7 0.38 0.08 17 25 26.45 17.87 6 19.2 23.56 
NDUFS8 0.19 0.06 27 33 22.37 11.84 9 42.4 20.66 
NDUFV1 2.05 1.54 34 36 49.42 27.69 25 69.7 49.87 
NDUFV2 2.37 1.65 15 26 23.19 17.66 12 54.2 27.39 
NDUFV3 1.83 1.04 5 27 11.87 33.76 18 51.4 50.98 
 
Complex I assembly factors 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
ACAD9 0.09 0.21 66 73 26.48 17.56 41 50.7 68.76 
ATP5SL 0.83 1.21 2 8 13.62 11.64 6 24.1 29.27 
COA1 -0.71 -0.67 5 12 42.62 16.06 7 54.8 16.69 
ECSIT 0.17 0.27 22 37 13.01 11 15 41.8 49.15 
FOXRED1 0.83 1.25 5 12 11.89 20.87 13 34.2 53.81 
NDUFAF1 0.08 0.08 11 19 23.04 28.23 12 47.7 37.76 
NDUFAF2 -0.42 -0.89 46 43 27.75 18.58 16 72.8 19.86 
NDUFAF3 -0.32 -0.59 13 22 7.31 11.18 8 56.5 20.35 
NDUFAF4 -0.38 -0.56 20 36 16.27 8.38 13 58.3 20.27 
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TIMMDC1 0.32 0.64 14 25 10.69 15.78 13 49.8 32.18 
TMEM126B 0.52 0.58 4 9 30.73 34.57 3 51.8 18.89 
 
Complex II subunits 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
SDHA 2.45 2.08 47 75 37.37 25.79 33 69.6 72.69 
SDHB 2.54 2.00 34 47 31.98 27.86 8 68.2 31.63 
SDHD 1.33 1.83 2 8 9.72 50.54 3 15.0 12.62 
 
Complex III subunits 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
UQCC -0.46 -0.90 6 14 6.48 27.17 7 24.4 34.60 
UQCR10 0.51 -0.10 3 15 4.79 24.92 2 38.1 7.31 
UQCRB -0.32 -0.59 28 26 51.98 26.45 10 60.4 13.53 
UQCRC1 -0.12 -0.19 106 115 28.13 30.15 24 61.5 52.65 
UQCRC2 -0.12 -0.15 72 88 34.00 32.55 17 45.3 48.44 
UQCRFS1 -0.10 -0.56 44 42 32.34 23.77 15 54.0 29.67 
UQCRH 0.69 0.04 8 9 20.80 33.92 3 29.7 10.74 
UQCRQ 0.07 -0.70 8 42 35.48 26.91 5 46.3 9.91 
 
Complex IV subunits 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
COX4I1 0.46 0.66 60 86 18.62 14.71 17 56.2 19.58 
COX5A 0.49 0.59 33 50 20.66 27.42 11 64.7 16.76 
COX5B 0.30 0.76 31 25 48.75 17.81 8 45.7 13.70 
COX6B1 0.83 1.50 15 11 35.92 24.95 5 73.3 10.19 
COX6C 0.57 1.14 27 46 35.34 22.90 11 76.0 8.78 
COX7A2 0.65 1.46 3 5 10.46 13.71 2 27.7 9.40 
COX7A2L 0.26 0.01 9 25 42.38 36.60 6 49.1 12.62 
COX7C 0.49 0.80 3 2 25.56 52.53 1 16.1 6.38 
MT-CO2 0.59 1.11 33 31 30.30 19.09 7 32.2 25.57 
MT-CYB 0.52 -0.30 3 5 53.37 23.74 2 5.0 42.72 
NDUFA4 0.55 0.97 16 26 44.11 36.72 5 46.9 9.37 
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Complex V subunits 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
MT-ATP8 0.25 0.01 2 8 13.62 11.64 3 48.5 7.99 
MT-ATP6 -0.16 -0.31 2 6 11.60 5.92 1 4.4 24.82 
ATP5SL 0.83 1.21 93 81 21.25 16.38 6 24.1 29.27 
ATP5S 0.58 0.41 39 72 17.38 18.02 4 19.1 24.87 
ATP5O -0.04 -0.05 20 56 25.37 17.26 22 79.8 23.28 
ATP5L 0.11 0.05 13 13 26.89 20.36 7 55.3 11.43 
ATP5J2 0.28 0.11 13 21 20.47 14.73 3 52.1 10.92 
ATP5J 0.16 0.00 22 55 29.83 27.13 6 51.9 12.59 
ATP5I 0.23 0.00 48 88 25.99 8.77 6 66.7 7.93 
ATP5H -0.06 -0.04 73 101 21.01 16.31 21 87.0 18.49 
ATP5F1 0.08 -0.03 8 10 18.42 18.96 22 58.6 28.91 
ATP5E -0.01 0.18 9 14 17.69 15.94 3 41.2 5.78 
ATP5D -0.02 0.10 44 64 15.66 12.45 5 29.2 17.49 
ATP5C1 0.17 0.03 272 373 14.50 19.55 17 44.3 33.00 
ATP5B -0.02 0.00 2 3 17.79 10.57 21 75.8 56.56 
ATP5A1 -0.03 -0.01 179 319 38.48 19.49 48 72.5 59.75 
 
Mitoflavoproteins 
Protein 
Log2 Forward 
ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
ACAD9 0.09 0.21 66 73 26.48 17.56 41 50.7 68.76 
ACADM -0.18 1.93 11 9 38.57 35.45 12 33.5 42.43 
ACADVL 1.03 1.04 43 75 45.47 31.27 36 61.1 68.06 
AIFM1 1.86 2.39 25 49 41.67 18.69 27 52.1 66.29 
COQ6 -1.48 -1.17 9 11 21.6 28.52 7 20.3 48.59 
CYB5R3 -0.1 -0.95 18 50 40.45 16.97 17 80.9 31.63 
DHODH 0.64 0.96 31 24 17.69 16.83 18 57 42.87 
DLD 3.18 3.03 7 9 35.08 20.08 15 43.6 54.18 
ETFA 0.42 0.3 22 36 32.87 16.47 15 52.3 35.08 
ETFDH 2.22 2.81 2 10 66.91 92.62 1 32.6 68.5 
FOXRED1 0.83 1.25 5 12 11.89 20.87 13 34.2 53.81 
GPD2 1.34 1.61 59 101 30.45 24.23 51 73.6 80.85 
GSR -0.27 0.54 2 2 56.8 52.89 5 15.5 47.27 
IVD 0.39 0.95 10 8 16.25 11.62 8 18.7 46.32 
NDUFV1 2.05 1.54 34 36 49.42 27.69 25 69.7 49.87 
SDHA 2.45 2.08 47 75 37.37 25.79 33 69.6 72.69 
SQRDL 3.54 5.11 9 5 52.09 36.08 27 60 49.96 
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Proteins with greater than a three-fold decrease abundance in conditioned RFK KD cells 
Protein 
Log2 Forward 
ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique peptides 
Sequence 
coverage [%] 
Molecular weight [kDa] 
SQRDL 3.54 5.11 9 5 52.09 36.08 27 60 49.96 
DLD 3.18 3.03 7 9 35.08 20.08 15 43.6 54.18 
NDUFA7 2.93 1.79 6 24 31.37 18.81 9 69 12.55 
NDUFA12 2.68 1.59 6 24 15.78 19.89 10 82.8 17.11 
FLRT3 2.57 2.55 3 4 20.38 95.24 16 27.7 73 
SDHB 2.54 2.00 34 47 31.98 27.86 8 68.2 31.63 
MMP1 2.48 2.68 16 3 23.27 57.72 12 33.9 54.01 
AK2 2.45 2.11 5 13 45.71 17.45 12 65.5 25.61 
SDHA 2.45 2.08 47 75 37.37 25.79 33 69.6 72.69 
ENPP1 2.42 3.55 58 36 57.81 39.04 34 47.2 104.92 
NDUFV2 2.37 1.65 15 26 23.19 17.66 12 54.2 27.39 
NDUFS4 2.30 1.88 2 10 86.93 23.27 5 25.7 20.11 
FDFT1 2.25 1.75 9 13 22.57 31 15 43.4 48.12 
ETFDH 2.22 2.81 2 10 66.91 92.62 1 32.6 68.5 
GJA1 2.17 1.93 6 6 24.58 26.4 6 24.6 43.01 
APLP2 2.09 1.76 4 3 21.51 13.4 6 11.1 85.49 
TSPAN13 1.94 1.68 3 3 82.02 28.7 3 21.1 22.15 
AGPS 1.87 3.20 8 19 68.99 48.77 24 50 72.91 
AIFM1 1.86 2.39 25 49 41.67 18.69 27 52.1 66.29 
MMP14 1.86 1.71 13 6 52.27 11.23 11 18.7 65.89 
MIPEP 1.79 2.36 4 4 47.15 29.49 9 16.8 80.64 
QSOX2 1.79 1.94 3 7 23.81 24.1 11 20.3 77.53 
PC 1.63 1.68 5 3 39.18 36.38 9 11.3 129.63 
NDUFA2 1.60 1.74 6 11 61.2 38.33 5 42.4 10.92 
TNS3 1.59 1.68 4 6 19.29 25.67 9 14.1 129.06 
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Appendix 7.4 SILAC data for pair 1: conditioned pLKO.1 143B cells and riboflavin rich 143B CyWT cells. Including proteins detected in one labelling 
direction.  
 
Complex I subunits 
Protein 
Log2 Forward 
ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight [kDa] 
Score 
MT-ND1 2.08 - 2 - 7.75 - 3 8.8 35.66 59.46 
MT-ND5 - 3.14 - 4 - 187.45 5 12.6 67.03 323.31 
NDUFA10 1.62 1.69 3 7 6.48 8.71 13 38.3 40.75 143.49 
NDUFA11 1.27 2.31 2 3 14.76 93.74 5 32.6 14.85 38.70 
NDUFA12 2.64 2.52 4 8 44.32 160.62 7 57.2 17.11 61.74 
NDUFA13 2.12 2.11 16 21 7.23 12.76 13 68.8 16.70 141.77 
NDUFA2 2.73 2.90 3 7 0.85 3.12 6 56.6 10.92 81.66 
NDUFA3 -1.48 1.44 2 2 244.52 14.86 4 50.0 9.28 21.64 
NDUFA5 - 3.29 - 2 - 280.67 11 62.1 13.56 323.31 
NDUFA6 - 4.53 - 4 - 113.18 4 33.1 17.87 37.95 
NDUFA7 0.45 - 2 - 296.42 - 8 61.9 12.55 24.53 
NDUFA8 0.79 2.02 5 3 215.30 95.76 5 36.0 20.11 70.44 
NDUFA9 1.12 1.31 19 27 11.52 16.46 25 70.6 42.51 323.31 
NDUFB1 0.73 0.62 3 3 41.14 59.58 3 34.5 6.96 9.62 
NDUFB10 0.42 0.76 15 20 7.74 17.00 14 54.1 20.78 129.00 
NDUFB11 -2.76 - 2 - 342.20 - 3 28.8 17.32 47.66 
NDUFB2 1.68 1.70 2 2 5.11 2.34 2 8.6 12.06 3.56 
NDUFB3 - 1.54 - 2 - 2.33 5 32.7 11.40 26.24 
NDUFB4 1.98 1.88 9 16 30.03 11.33 6 45.0 11.40 63.92 
NDUFB5 -1.78 3.71 3 3 166.43 161.37 5 35.0 14.03 72.82 
NDUFB6 -4.15 2.20 3 3 176.41 107.71 8 60.2 15.67 40.57 
NDUFB7 1.75 1.34 7 4 6.31 32.61 4 32.1 16.40 86.56 
NDUFB8 1.82 - 7 - 12.35 - 7 41.3 18.48 40.77 
NDUFB9 1.29 1.19 8 6 23.41 142.06 7 41.9 21.83 136.50 
NDUFC2 1.06 1.13 6 8 189.37 4.74 10 51.3 14.19 34.08 
NDUFS1 2.70 2.87 24 19 22.92 21.14 26 44.3 79.47 323.31 
NDUFS2 0.70 0.72 21 28 6.88 27.83 22 65.9 52.55 323.31 
NDUFS3 0.79 0.73 23 28 18.14 14.09 19 58.3 30.24 323.31 
NDUFS5 -1.01 3.07 2 5 313.63 81.97 4 32.1 12.52 30.51 
NDUFS6 2.57 5.69 2 3 11.71 157.95 5 39.5 13.71 170.93 
NDUFS7 0.91 1.48 5 4 4.19 109.39 4 16.0 22.20 57.77 
NDUFS8 0.96 2.10 5 4 101.28 148.45 9 28.1 23.71 126.52 
NDUFV1 2.62 2.67 6 9 39.99 13.92 12 29.2 49.87 96.38 
NDUFV2 2.24 2.61 5 7 94.45 82.03 10 37.8 27.39 97.48 
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Mitoflavoproteins 
Protein 
Log2 Forward 
ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular weight 
[kDa] 
Score 
ACAD8 - 1.52 - 2 - 7.51 3 7.5 18.49 45.07 
ACAD9 -0.13 0.17 13 20 79.39 22.56 28 47.8 68.8 292.19 
ACADM 1.41 2.2 7 7 19.45 15.41 11 38 46.6 217.05 
ACADVL 0.89 1.72 15 17 11.85 18.59 30 49 68.1 323.31 
AIFM1 3.27 3.49 6 10 34.84 25.81 25 52 66.9 323.31 
COQ6 -0.79 -0.84 6 4 23.75 14.91 9 20.3 48.6 37.8 
CYB5R3 -0.49 -0.69 13 20 8.07 21.99 14 56.5 31.6 323.31 
DHODH 0.32 0.34 12 16 10.04 62.62 15 43.8 42.9 114.39 
DLD 2.69 3.66 3 5 33.61 109.13 8 23.9 49.3 143.51 
ETFA 1.63 1.82 2 3 3.27 11.97 12 60.9 30 188.97 
ETFDH 2.6 2.67 4 3 44.12 33.73 10 20.3 68.5 99.38 
FOXRED1 0.29 1.36 4 3 64.31 5.51 7 16.9 53.8 21.16 
GCDH 2.67 2.4 2 3 76.14 27.72 3 15.1 48.1 24.47 
GPD2 1.69 1.91 27 44 15.87 17.05 35 56.8 80.9 323.31 
IVD 1.51 1.91 2 6 15.39 18.58 10 33.8 46.3 105.2 
L2HGDH 0.56 0.72 6 10 9.09 59.74 13 37.1 50.3 132.98 
NDUFV1 2.62 2.67 6 9 39.99 13.92 12 29.2 49.9 96.38 
PPOX 1.52 2 2 3 9.35 71.15 7 21.2 50.8 12.72 
SDHA 2.46 2.78 28 31 8.64 3.6 21 42.9 72.7 323.31 
SQRDL 5.04 4.9 15 17 78.61 79.55 27 63.3 323.31 49.96 
TXNRD2 - -2.63 - 2 - 300.28 2 5.1 2.26 46.84 
 
Proteins with greater than a two-fold decrease in abundance in conditioned pLKO.1 cells 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular 
weight [kDa] 
Score 
SQRDL 5.04 4.90 15 17 78.61 79.55 27 63.3 49.96 323.31 
ENPP1 4.01 2.74 15 39 68.43 61.70 27 35.2 104.92 323.31 
AIFM1 3.27 3.49 6 10 34.84 25.81 25 52.0 66.90 323.31 
MMP1 2.96 2.03 12 5 7.53 20.90 10 29.6 54.01 60.12 
NDUFA2 2.73 2.90 3 7 0.85 3.12 6 56.6 10.92 81.66 
NDUFS1 2.70 2.87 24 19 22.92 21.14 26 44.3 79.47 323.31 
DLD 2.69 3.66 3 5 33.61 109.13 8 23.9 49.28 143.51 
GCDH 2.67 2.40 2 3 76.14 27.72 3 15.1 48.13 24.47 
NDUFA12 2.64 2.52 4 8 44.32 160.62 7 57.2 17.11 61.74 
NDUFV1 2.62 2.67 6 9 39.99 13.92 12 29.2 49.87 96.38 
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Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular 
weight [kDa] 
Score 
ETFDH 2.60 2.67 4 3 44.12 33.73 10 20.3 68.50 99.38 
AK2 2.59 2.77 2 5 161.33 161.05 10 60.3 25.61 89.55 
NDUFS6 2.57 5.69 2 3 11.71 157.95 5 39.5 13.71 170.93 
MMP14 2.51 1.18 9 6 16.53 91.75 9 18.6 65.89 44.67 
COL12A1 2.46 1.60 25 18 36.02 110.77 43 21.2 324.57 89.55 
SDHA 2.46 2.78 28 31 8.64 3.60 21 42.9 72.69 323.31 
FDFT1 2.43 1.56 12 9 29.13 12.85 14 40.3 48.12 228.33 
IDH2 2.28 3.18 4 8 43.43 58.62 19 38.9 50.91 233.38 
NDUFV2 2.24 2.61 5 7 94.45 82.03 10 37.8 27.39 97.48 
SLC25A1 2.20 2.04 6 13 17.76 53.71 10 38.3 34.01 96.00 
JUP 2.20 2.95 5 4 251.64 56.59 16 27.1 81.74 48.06 
NDUFA13 2.12 2.11 16 21 7.23 12.76 13 68.8 16.70 141.77 
PRDX3 2.11 2.11 9 10 33.07 3.44 11 36.1 25.84 114.55 
NT5E 2.06 1.21 7 7 32.08 8.29 13 35.9 63.37 204.55 
TST 2.03 2.49 2 6 8.47 86.71 6 34.3 33.43 142.29 
SDHB 2.01 2.82 12 13 29.79 9.53 14 40.7 31.63 78.96 
PXDN 2.01 1.02 9 7 27.06 40.16 13 12.9 165.27 67.07 
ALDH2 2.00 1.97 4 5 9.14 35.31 12 27.9 56.38 86.83 
AGPS 1.98 2.77 10 10 32.45 7.26 16 36.5 72.91 232.92 
NDUFB4 1.98 1.88 9 16 30.03 11.33 6 45.0 14.03 63.92 
SLC4A7 1.98 2.32 6 8 113.79 12.89 19 22.0 127.36 131.12 
MT-CO2 1.96 2.30 12 7 7.20 12.19 7 32.2 25.57 119.53 
CDK17 1.93 1.07 2 3 25.49 23.85 4 10.5 59.53 24.40 
P56181-2 1.88 1.94 2 3 25.07 33.41 11 36.2 50.98 302.43 
ECH1 1.87 2.04 2 3 31.33 116.40 6 34.1 35.82 82.96 
NIPSNAP1 1.87 1.89 4 7 10.47 81.95 8 28.5 33.31 118.57 
IARS2 1.85 1.88 8 10 37.65 32.16 25 30.6 113.79 153.52 
SCO2 1.83 1.11 4 5 53.59 40.20 7 33.8 29.81 124.50 
AHR 1.83 1.85 4 5 77.61 61.76 13 20.2 96.15 82.88 
SDHC 1.82 1.49 2 3 7.36 49.18 3 42.2 12.47 12.68 
MCCC2 1.82 2.03 6 13 16.64 37.07 18 42.6 61.33 127.30 
AIM1 1.78 2.58 5 7 23.97 73.80 26 24.0 188.67 132.19 
OAT 1.77 2.28 15 12 23.08 17.72 15 49.0 48.53 300.01 
COLEC12 1.75 2.66 2 3 64.97 24.70 4 6.5 81.51 11.36 
NDUFB7 1.75 1.34 7 4 6.31 32.61 4 32.1 16.40 86.56 
MCCC1 1.73 1.73 2 3 41.76 29.78 4 10.8 80.47 83.79 
PC 1.71 2.23 4 12 110.58 76.02 21 26.2 129.63 77.22 
OXCT1 1.71 1.99 4 5 18.64 11.43 8 31.0 56.16 323.31 
ME2 1.71 2.24 5 9 13.06 115.54 10 26.2 65.44 151.55 
AK3 1.70 2.11 5 5 4.45 35.08 9 43.2 25.57 120.92 
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Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular 
weight [kDa] 
Score 
ALDH7A1 1.69 2.45 2 3 39.10 38.42 9 28.6 55.37 50.20 
GPD2 1.69 1.91 27 44 15.87 17.05 35 56.8 80.85 323.31 
NDUFB2 1.68 1.70 2 2 5.11 2.34 2 8.6 12.06 3.56 
SNTB1 1.68 1.57 5 5 34.95 59.20 10 29.4 58.06 46.24 
SCD 1.67 1.54 2 5 6.03 88.29 7 27.9 41.52 74.31 
GFM1 1.66 2.12 5 6 23.06 11.35 17 26.1 83.47 111.65 
LAMC1 1.64 1.53 7 7 14.55 16.36 17 15.2 177.60 148.41 
HIP1 1.64 1.13 2 4 78.43 40.08 6 9.4 110.66 20.96 
ITGB5 1.63 1.75 6 9 48.54 85.43 11 16.4 88.05 51.08 
ETFA 1.63 1.82 2 3 3.27 11.97 12 60.9 30.03 188.97 
VPS13C 1.62 1.91 27 20 23.65 36.97 63 23.9 403.08 189.54 
NDUFA10 1.62 1.69 3 7 6.48 8.71 13 38.3 40.75 143.49 
ACO2 1.58 1.92 6 6 8.57 13.02 21 38.8 85.42 230.94 
HINT2 1.56 1.86 2 5 1.98 28.28 5 47.2 17.16 115.70 
SVIL 1.54 1.77 14 21 24.97 40.87 54 41.6 200.84 323.31 
PDP1 1.53 1.87 5 7 20.70 12.07 12 31.3 61.05 132.11 
PCYOX1 1.53 1.46 3 3 12.47 13.21 9 22.2 56.64 22.31 
PPOX 1.52 2.00 2 3 9.35 71.15 7 21.2 50.77 12.72 
IVD 1.51 1.91 2 6 15.39 18.58 10 33.8 46.32 105.20 
CLPP 1.51 1.82 2 3 3.52 127.88 9 33.6 30.18 133.64 
NADK2 1.50 1.77 3 5 42.41 135.03 8 24.4 45.97 76.94 
FASN 1.50 1.42 24 35 48.74 40.33 51 28.2 273.42 323.31 
ECHS1 1.49 1.37 13 18 3.36 5.81 15 36.6 31.39 181.93 
IDH3G 1.47 2.50 2 4 5.82 65.15 6 15.0 42.79 21.70 
ACAA2 1.46 1.79 6 7 9.62 11.53 12 45.8 41.92 270.58 
SPRYD4 1.46 1.41 3 3 82.45 29.20 8 42.5 23.13 18.18 
ETFB 1.45 1.49 11 10 23.97 1.16 16 46.3 27.84 49.09 
KRAS 1.45 1.13 19 21 40.00 20.76 2 47.6 21.66 323.31 
GLUD1 1.44 1.65 15 15 19.27 8.90 17 37.6 61.40 238.94 
PRDX5 1.44 1.58 4 2 20.14 7.32 12 54.3 17.03 172.74 
HIBCH 1.41 1.86 3 3 6.78 17.91 9 26.2 43.48 43.73 
ACADM 1.41 2.20 7 7 19.45 15.41 11 38.0 46.59 217.05 
SLC25A3 1.33 1.61 36 46 22.74 9.98 19 42.9 39.96 259.69 
CS 1.32 1.77 10 13 24.97 13.87 17 51.9 51.71 323.31 
NCKAP1 1.32 1.17 3 4 6.14 26.42 9 9.0 128.79 57.48 
GOT2 1.31 1.41 16 20 20.18 41.24 22 45.8 47.52 323.31 
AK4 1.30 1.83 6 3 14.13 19.41 7 33.2 25.27 39.70 
NDUFB9 1.29 1.19 8 6 23.41 142.06 7 41.9 21.83 136.50 
CYFIP1 1.28 1.11 9 17 38.27 80.95 11 21.2 145.18 74.85 
GBAS 1.28 1.29 4 6 26.81 37.12 5 23.8 33.74 41.83 
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Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular 
weight [kDa] 
Score 
NDUFA11 1.27 2.31 2 3 14.76 93.74 5 32.6 14.85 38.70 
ITGA1 1.26 1.85 4 8 41.15 17.18 13 13.6 130.85 42.00 
CPT2 1.26 1.52 4 10 31.28 117.33 13 27.7 73.78 111.15 
GNB4 1.26 1.10 3 4 14.92 11.57 2 11.5 37.57 3.79 
LDLR 1.25 1.48 10 12 44.22 6.33 12 22.6 75.85 110.01 
CD99L2 1.22 1.69 5 3 14.59 46.41 2 10.6 20.03 10.92 
CD109 1.19 1.44 2 13 4.72 43.47 20 21.5 161.69 98.98 
HELZ2 1.18 1.59 4 6 159.36 125.89 16 7.4 294.65 27.15 
ICAM1 1.18 2.11 2 2 15.63 24.15 5 13.5 57.83 31.37 
IDH3A 1.18 1.72 6 12 20.94 30.81 9 31.4 39.59 83.68 
SARS2 1.15 1.67 3 6 111.48 35.01 9 26.6 58.28 79.79 
KIAA0391 1.15 1.38 2 2 19.62 40.77 6 14.1 56.49 26.65 
DNAJC10 1.15 1.51 5 6 9.75 17.67 12 19.2 91.08 251.30 
ACACA 1.13 1.09 3 6 131.42 25.69 14 9.9 257.24 54.98 
NDUFA9 1.12 1.31 19 27 11.52 16.46 25 70.6 42.51 323.31 
ARHGEF40 1.12 1.19 6 9 4.79 24.00 15 12.9 164.66 96.91 
IDH3B 1.11 1.36 7 8 18.79 7.57 13 39.5 42.18 54.63 
HSD17B10 1.11 1.36 8 9 11.26 8.31 11 63.6 26.92 311.66 
PIK3C2A 1.11 1.05 8 9 18.32 30.79 30 21.0 190.68 99.79 
NDUFC2 1.06 1.13 6 8 189.37 4.74 10 51.3 14.19 34.08 
PITRM1 1.06 1.19 7 12 22.47 8.50 22 30.6 117.41 323.31 
PDPR 1.06 1.74 3 4 28.73 18.91 8 11.6 99.36 25.84 
HIBADH 1.05 1.52 3 3 46.60 7.34 10 40.5 35.33 129.53 
GLS 1.05 1.25 6 6 15.42 18.10 3 39.8 65.46 323.31 
ACOT1 1.03 1.56 4 7 26.38 31.31 2 36.8 46.28 56.57 
RTCB 1.01 1.05 13 11 6.18 7.03 22 50.1 55.21 255.26 
ACAT1 1.01 1.26 6 5 19.68 21.32 12 39.1 45.20 168.02 
ALDH1B1 1.00 1.11 7 8 39.60 55.31 14 38.5 57.21 144.32 
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Appendix 7.5 SILAC data for pair 2: conditioned RFK KD 143B cells and conditioned pLKO.1 143B cells. Including proteins detected in one labelling 
direction.  
 
Complex I subunits 
Protein 
Log2 Forward 
ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage [%] 
Molecular 
weight [kDa] 
Score 
MT-ND1 -0.15 - 2 - 119.52 - 2 6.3 35.66 43.75 
MT-ND2 -0.51 - 2 - 9.54 - 1 2.6 38.96 2.16 
MT-ND4 -0.50 - 4 - 7.48 - 4 10.2 51.58 4.42 
MT-ND5 -0.66 - 7 - 7.58 - 5 12.6 67.03 156.08 
NDUFA1 -0.95 - 2 - 11.76 - 1 18.6 8.07 2.44 
NDUFA10 -0.77 - 18 - 28.15 - 9 23.9 40.75 103.73 
NDUFA11 -1.10 - 9 - 24.20 - 6 32.6 14.85 27.85 
NDUFA12 1.18 - 4 - 109.88 - 3 29.0 17.11 28.09 
NDUFA13 -1.12 - 28 - 6.27 - 11 63.9 16.70 87.50 
NDUFA2 -0.41 - 5 - 1.55 - 3 32.3 10.92 14.82 
NDUFA3 -0.52 - 6 - 10.13 - 4 50.0 9.28 51.49 
NDUFA5 -0.57 -0.60 17 4 4.24 0.92 11 64.7 13.56 323.31 
NDUFA6 -0.41 - 10 - 24.62 - 5 39.6 17.87 19.74 
NDUFA7 -0.41 - 6 - 7.01 - 5 49.6 12.55 12.56 
NDUFA8 -1.05 - 8 - 24.46 - 5 39.0 20.11 29.61 
NDUFA9 -0.25 -0.03 30 5 8.64 4.62 17 56.2 42.51 98.16 
NDUFAB1 -0.51 - 5 - 7.21 - 3 11.5 17.42 23.97 
NDUFB1 -0.20 - 5 - 10.85 - 3 34.5 6.96 14.32 
NDUFB10 -0.31 -0.08 24 7 7.92 5.76 11 48.8 20.78 111.69 
NDUFB11 -0.16 -0.10 8 2 6.34 3.18 3 34.6 17.32 57.48 
NDUFB2 -0.87 - 2 - 8.29 - 2 8.6 12.06 3.26 
NDUFB3 -0.62 - 5 - 1.87 - 4 29.6 11.40 23.87 
NDUFB4 -0.93 - 13 - 2.79 - 6 48.1 15.21 74.57 
NDUFB5 -0.12 -0.13 17 2 2.87 0.27 8 29.6 21.75 121.64 
NDUFB6 -0.05 0.14 14 2 25.97 6.54 3 43.8 15.49 46.91 
NDUFB7 -0.89 - 5 - 57.42 - 5 32.8 16.40 57.64 
NDUFB8 -0.92 - 8 - 4.61 - 5 36.1 18.48 36.04 
NDUFB9 -0.62 - 7 - 6.06 - 6 41.9 21.83 63.43 
NDUFC1 - - - - - - 1 14.5 8.73 2.59 
NDUFC2 -0.51 -0.18 17 2 7.84 2.96 11 60.5 14.19 24.47 
NDUFS1 -0.65 -0.04 26 9 20.44 7.02 20 37.3 79.47 212.73 
NDUFS2 -0.50 -0.61 48 11 10.39 11.72 23 67.0 52.55 323.31 
NDUFS3 -0.58 -0.61 40 9 5.31 4.25 16 52.3 30.24 309.72 
NDUFS4 -0.37 - 3 - 8.53 - 3 20.0 20.11 4.37 
NDUFS5 -1.06 - 8 - 24.76 - 6 39.6 12.52 12.47 
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NDUFS6 -0.44 - 9 - 11.89 - 4 39.5 13.71 27.99 
NDUFS7 -0.64 - 14 - 8.15 - 4 16.0 22.20 75.12 
NDUFS8 -0.50 -0.62 9 3 5.39 1.77 5 23.8 23.71 130.22 
NDUFV1 -0.36 -0.20 11 3 19.60 145.76 10 24.8 49.87 24.10 
NDUFV2 -0.66 - 5 - 16.65 - 4 21.3 27.39 70.19 
 
Mitoflavoproteins 
Protein 
Log2 Forward 
ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique peptides 
Sequence 
coverage [%] 
Score 
Molecular 
weight [kDa] 
ACAD9 0.03 -0.20 49 15 16.22 4.10 32 43.3 68.76 257.83 
ACADM -0.07 - 10 - 13.64 - 9 25.9 46.59 165.95 
ACADVL -0.23 -0.27 58 14 25.42 12.91 24 44.4 68.06 305.61 
AIFM1 -0.99 - 13 - 16.71 - 12 29.6 66.29 103.32 
COQ6 -0.05 -0.71 7 2 19.13 11.11 5 14.9 48.59 30.61 
CYB5R3 0.09 0.01 35 5 8.31 9.88 17 59.4 31.63 323.31 
DHODH 0.12 -0.14 21 5 13.43 11.09 16 51.1 42.87 128.63 
ETFA -0.79 -0.36 18 3 7.59 1.11 11 53.9 30.03 180.41 
FOXRED1 -0.57 - 6 - 45.17 - 6 15.3 52.10 11.58 
GCDH -0.36 - 2 - 28.19 - 2 9.8 47.36 18.21 
GPD2 -0.25 -0.21 37 14 16.62 18.40 27 47.9 80.85 254.71 
GSR -0.23 - 7 - 7.94 - 5 17.5 47.27 17.55 
IVD -0.77 - 6 - 18.78 - 7 27.2 42.72 20.14 
L2HGDH -0.29 - 10 - 15.23 - 9 26.8 50.32 56.28 
NDUFV1 -0.36 -0.20 11 3 19.60 145.76 10 24.8 49.87 24.10 
SDHA -0.68 0.05 19 9 23.58 7.70 13 29.4 72.69 145.76 
 
Appendix 7.6 SILAC data for conditioned SLC25A32 KO cells and conditioned HAP1 cells 
 
Complex I subunits 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
MT-ND1 -0.52 0.89 2 3 5.40 29.34 3 8.8 35.66 3.98 
NDUFA10 -0.65 -0.36 12 7 7.08 9.42 10 30.7 40.75 87.86 
NDUFA11 0.29 -0.99 8 5 12.95 26.53 7 44.7 14.85 27.09 
NDUFA13 0.39 0.84 20 10 7.55 8.88 9 63.9 16.70 43.66 
NDUFA3 0.13 1.49 6 4 20.35 23.90 4 50 9.28 16.98 
NDUFA5 -0.03 0.53 8 4 13.84 26.07 8 73.3 13.46 31.86 
NDUFA6 -0.61 0.79 6 3 10.45 4.31 5 37.7 17.87 17.79 
NDUFA7 -0.30 -1.06 3 3 14.66 12.69 3 24.8 12.55 9.84 
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NDUFA8 0.37 0.70 11 10 10.11 40.03 10 64.5 20.11 67.15 
NDUFA9 0.31 0.61 35 17 8.77 21.23 21 61 42.51 147.26 
NDUFB10 0.18 -0.32 43 39 9.71 30.01 22 75.6 20.78 165.38 
NDUFB11 0.14 0.46 16 9 4.89 30.15 8 51.6 17.32 91.53 
NDUFB3 -0.18 -0.77 11 5 6.76 26.43 6 32.7 11.40 22.66 
NDUFB4 -0.60 -0.64 11 6 16.58 36.99 7 49.2 14.03 37.38 
NDUFB5 0.03 -0.46 18 12 12.38 54.30 7 29.6 21.75 84.69 
NDUFB6 0.37 0.06 20 14 17.31 13.51 10 64.1 15.49 64.92 
NDUFB7 -0.74 -0.11 10 5 17.64 21.69 6 48.2 16.40 26.94 
NDUFB9 -0.86 -0.07 13 8 5.14 32.57 11 69.3 21.83 95.96 
NDUFC2 0.44 -0.21 10 8 12.41 30.97 9 52.9 14.19 19.21 
NDUFS1 -0.76 -0.90 8 14 58.06 8.33 16 36.1 73.53 80.69 
NDUFS2 -0.12 0.74 26 17 6.68 11.82 24 71.7 52.55 263.44 
NDUFS3 -0.12 0.70 22 21 9.49 26.41 17 57.6 30.24 152.38 
NDUFS5 -0.77 -0.87 6 2 9.06 27.07 5 46.2 12.52 13.63 
NDUFS6 -0.90 -0.43 9 5 12.52 42.59 6 61.3 13.71 18.40 
NDUFS7 -0.03 0.86 7 4 12.65 21.14 6 31.5 23.56 28.85 
NDUFS8 0.04 0.71 16 5 9.08 7.42 7 44.8 23.705 42.664 
NDUFV1 -0.79 -1.15 27 8 15.00 102.65 18 58.5 49.87 109.29 
NDUFV2 -0.74 -1.03 15 9 9.50 48.44 10 43 27.39 65.96 
 
Complex I assembly factors 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight [kDa] 
Score 
ACAD9 -0.43 -0.07 38 30 15.28 12.32 27 46.4 68.76 158.80 
COA1 -0.12 -0.40 9 4 13.75 9.59 6 54.8 16.69 24.53 
ECSIT -0.36 0.03 14 10 23.53 7.15 13 43.9 49.15 173.54 
FOXRED1 -0.78 0.14 6 6 46.18 128.55 8 24.7 53.81 111.29 
NDUFAF2 0.23 0.73 21 24 8.51 18.21 16 74.6 19.86 207.05 
NDUFAF3 0.24 1.23 12 6 6.24 4.52 7 44 20.35 98.76 
NDUFAF4 0.23 1.27 19 9 9.03 18.47 14 56.6 20.27 57.02 
NDUFAF6 -0.48 0.01 5 2 11.80 42.90 7 34.5 32.85 26.96 
NDUFAF7 0.06 -0.59 3 4 30.01 41.13 5 13.8 49.24 12.84 
TIMMDC1 0.12 0.33 20 18 10.56 8.56 16 54.7 32.18 185.50 
TMEM70 0.10 1.31 12 11 5.44 6.41 6 25.8 28.97 57.09 
  
 2
7
0
 
Complex II subunits 
Protein 
Log2 Forward Ratio 
H/L (normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability 
[%] 
(forward) 
Ratio H/L 
variability 
[%] (reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
SDHA -0.87 -1.74 19 22 8.73 109.95 17 46.4 67.30 256.46 
SDHB -1.57 -2.33 3 4 39.72 39.96 6 19.6 31.63 12.28 
 
Complex III subunits 
Protein 
Log2 Forward Ratio 
H/L (normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability 
[%] 
(forward) 
Ratio H/L 
variability 
[%] (reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
CYC1 -1.03 -1.02 73 53 7.63 14.76 15 56.9 35.42 323.31 
UQCR10 -0.54 -1.87 4 3 15.60 84.12 5 57.1 7.31 25.36 
UQCRB -1.51 -1.44 24 21 6.38 38.34 14 71.2 13.53 70.41 
UQCRC1 -1.28 -1.00 47 27 8.81 14.80 21 57.1 52.65 323.31 
UQCRC2 -1.42 -1.10 28 32 10.24 11.02 18 65.3 48.44 323.31 
UQCRFS1 -0.95 -0.79 18 24 17.58 21.59 11 48.9 29.67 202.15 
UQCRH -1.00 -1.37 7 5 7.40 31.76 6 57.1 10.74 22.95 
UQCRQ -1.44 -1.09 9 5 7.42 40.93 6 48.8 9.91 27.38 
 
Complex IV subunits 
Protein 
Log2 Forward Ratio 
H/L (normalised) 
Log2 inverted reverse 
ratio H/L (normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability 
[%] 
(forward) 
Ratio H/L 
variability 
[%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
COX7A2L -1.16 -0.50 7 3 19.39 19.72 6 67.5 12.62 38.14 
COX6C -0.11 -0.28 26 12 9.93 27.56 8 52 8.78 26.72 
COX6B1 -0.88 -1.60 3 2 10.37 47.58 4 59.3 10.19 13.23 
COX5B -1.19 -0.95 11 16 13.23 29.82 9 65.1 13.70 58.64 
COX5A 0.09 -0.34 25 18 14.14 28.78 10 57.3 16.76 88.56 
COX4I1 0.26 -0.29 82 44 10.80 55.34 22 65.7 19.58 189.37 
COX17 2.55 2.86 3 4 44.81 25.05 1 25.4 6.92 16.41 
COX11 -0.14 -0.15 5 3 11.11 45.36 6 38.8 31.43 30.86 
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Complex V subunits 
Protein 
Log2 Forward Ratio 
H/L (normalised) 
Log2 inverted reverse 
ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability 
[%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
ATP5A1 -0.14 -0.02 315 295 11.10 14.87 1 71.6 59.75 323.31 
ATP5B -0.20 0.06 325 246 6.12 9.69 34 75.2 56.56 323.31 
ATP5C1 -0.16 0.03 59 42 4.56 9.16 1 46 33.00 235.78 
ATP5D -0.21 0.10 26 14 9.81 79.47 6 35.1 17.49 45.61 
ATP5E -0.13 -0.88 6 10 4.28 47.60 7 70.6 5.78 17.06 
ATP5F1 -0.29 -0.05 88 88 11.38 5.24 23 59.4 28.91 323.31 
ATP5H -0.37 0.13 50 53 5.85 36.33 24 96.3 18.49 234.20 
ATP5I -0.17 -0.09 17 13 6.28 27.87 9 71 7.93 41.64 
ATP5J -0.26 -0.46 19 11 8.74 33.41 13 66.7 12.59 143.37 
ATP5J2 -0.39 -0.38 26 23 11.41 31.23 2 53.4 10.36 7.36 
ATP5J2 -0.31 -0.68 16 15 12.81 24.64 3 56.4 10.92 97.40 
ATP5O -0.26 -0.03 77 70 5.43 22.32 26 79.8 23.28 323.31 
ATP5S -0.31 0.12 6 6 25.58 42.44 6 35.8 24.87 18.54 
MT-ATP6 -1.56 -0.67 5 4 27.40 131.82 2 6.2 24.82 10.60 
MT-ATP8 -1.26 -1.24 4 2 14.98 20.48 5 55.9 7.99 25.95 
 
Mitoflavoproteins 
Protein 
Log2 Forward Ratio 
H/L (normalised) 
Log2 inverted reverse 
ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability 
[%] (reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
ACAD8 -2.53 0.82 6 2 89.17 92.34 6 14.0 45.07 15.15 
ACAD9 -0.43 -0.07 38 30 15.28 12.32 27 46.4 68.76 158.80 
ACADM -0.37 -1.47 16 12 10.23 18.12 14 38.5 46.59 84.37 
ACADSB -0.57 -0.57 22 12 11.54 11.43 20 62.7 47.49 127.54 
ACADVL -0.95 -1.57 23 23 19.59 33.42 29 51.5 68.06 238.30 
AIFM1 1.05 -0.52 57 43 12.04 18.88 32 57.4 66.90 323.31 
COQ6 -1.25 0.58 13 7 18.71 9.31 12 43.6 48.59 51.46 
CYB5R3 -0.28 -0.27 59 49 7.23 14.48 21 81.3 31.63 323.31 
DHODH 1.16 0.36 9 9 14.70 5.64 16 47.6 42.87 69.43 
DLD -0.23 -1.01 12 6 11.52 28.15 9 29.7 49.28 95.99 
ETFA -1.62 -0.51 50 27 6.57 8.93 20 69.4 35.08 218.94 
ETFDH -0.72 -1.08 2 7 23.10 77.34 9 18.5 68.50 20.91 
FDXR -2.38 -1.30 23 12 9.88 51.71 23 61.1 53.84 153.88 
FOXRED1 -0.78 0.14 6 6 46.18 128.55 8 24.7 53.81 111.29 
GCDH -0.90 -0.66 6 4 22.01 85.87 7 27.9 48.13 89.81 
GPD2 1.14 -0.02 55 51 23.07 31.53 44 71.5 80.85 277.12 
GSR 0.03 0.24 9 5 10.35 25.13 9 26.9 51.70 30.47 
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IVD -1.42 -2.79 17 4 25.92 111.80 13 38.8 46.32 86.35 
L2HGDH -1.85 -0.42 15 6 15.99 93.72 17 44.7 50.32 77.49 
MAOA 1.86 -0.40 22 18 42.99 26.97 20 51.6 59.68 85.66 
NDUFV1 -0.79 -1.15 27 8 15.00 102.65 18 58.5 49.87 109.29 
PPOX -1.00 -1.29 3 4 14.67 131.36 8 25.6 50.77 22.70 
PRODH -1.56 -2.45 28 22 20.17 12.20 26 56.3 68.00 258.29 
SDHA -0.87 -1.74 19 22 8.73 109.95 17 46.4 67.30 256.46 
TXNRD2 -1.31 -1.14 9 2 37.31 6.77 10 37.3 53.97 99.02 
 
Folate metabolising enzymes 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted reverse 
ratio H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
MTHFD1L -0.40 0.61 31 17 53.49 11.70 28 39.7 105.79 136.15 
MTHFD2 -0.26 -0.21 31 5 8.82 43.94 13 64.9 37.90 192.14 
SHMT2 0.01 -0.36 67 34 11.30 8.18 27 71.2 53.45 323.31 
 
Proteins with greater than a two-fold decrease in abundance in SLCK25A32 KO cells 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio 
H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
Mitochondrial 
localisation? 
FAM213A -2.62 -3.44 8 2 30.46 67.42 7 36.7 24.46 27.22 Non-mitochondrial  
SLC52A2 -2.50 -1.74 7 7 35.71 39.35 3 4.5 45.78 10.19 Non-mitochondrial   
DGAT1 -2.42 -2.07 14 7 9.67 64.14 14 39.3 55.28 133.75 Non-mitochondrial   
FDXR -2.38 -1.30 23 12 9.88 51.71 23 61.1 53.84 153.88 Mitochondrial 
BDH1 -2.14 -1.21 15 19 11.11 40.37 17 57.7 38.16 96.58 Mitochondrial 
RFTN1 -1.90 -1.27 4 6 44.84 131.33 10 30.6 63.15 34.93 Non-mitochondrial   
AASS -1.79 -1.30 30 26 32.49 40.52 34 45.8 102.13 215.80 Mitochondrial 
WWOX -1.78 -1.37 5 4 27.33 138.72 12 31.2 46.68 36.34 Non-mitochondrial   
USP7 -1.71 -1.77 43 27 19.39 110.94 45 47.6 126.27 279.38 Non-mitochondrial  
EEF1D -1.66 -1.18 37 12 20.63 11.08 2 79.4 31.12 323.31 Non-mitochondrial   
BPHL -1.64 -1.24 15 6 21.93 170.15 15 56.2 31.11 68.11 Predicted mitochondrial 
IDH2 -1.58 -1.46 37 27 15.85 45.19 26 51.1 50.91 323.31 Mitochondrial 
ALDH6A1 -1.58 -1.40 24 19 76.37 15.19 20 44.6 56.23 175.28 Non-mitochondrial   
SDHB -1.57 -2.33 3 4 39.72 39.96 6 19.6 31.63 12.28 Mitochondrial 
PRODH -1.56 -2.45 28 22 20.17 12.20 26 56.3 68.00 258.29 Mitochondrial 
ATP2B4 -1.51 -2.55 21 19 13.06 48.91 20 35.3 132.59 179.93 Non-mitochondrial   
UQCRB -1.51 -1.44 24 21 6.38 38.34 14 71.2 13.53 70.41 Mitochondrial 
UQCRQ -1.44 -1.09 9 5 7.42 40.93 6 48.8 9.91 27.38 Mitochondrial 
STX1B -1.44 -2.24 2 2 59.54 20.19 5 26.4 31.79 15.72 Non-mitochondrial   
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IVD -1.42 -2.79 17 4 25.92 111.80 13 38.8 46.32 86.35 Mitochondrial 
UQCRC2 -1.42 -1.10 28 32 10.24 11.02 18 65.3 48.44 323.31 Mitochondrial 
SLC12A7 -1.42 -1.00 2 2 43.57 29.75 6 11.4 119.10 21.64 Non-mitochondrial   
MACROD1 -1.41 -1.40 6 7 6.91 32.59 13 53.2 35.51 55.19 Non-mitochondrial   
CA5B -1.36 -1.04 7 2 9.75 108.54 9 31.5 36.43 42.57 Mitochondrial 
TXNRD2 -1.31 -1.14 9 2 37.31 6.77 10 37.3 53.97 99.02 Mitochondrial 
ACAA2 -1.28 -1.02 49 36 9.00 44.65 26 80.4 41.92 323.31 Mitochondrial 
UQCRC1 -1.28 -1.00 47 27 8.81 14.80 21 57.1 52.65 323.31 Mitochondrial 
MT-ATP8 -1.26 -1.24 4 2 14.98 20.48 5 55.9 7.99 25.95 Mitochondrial 
SLC25A32 -1.25 -2.30 4 2 105.34 1.41 7 29.2 35.41 17.66 Mitochondrial 
GNAZ -1.25 -1.21 4 5 31.10 31.16 8 33.0 40.92 30.80  Non-mitochondrial  
FECH -1.17 -1.47 18 6 16.82 44.90 16 49.4 47.86 100.46 Mitochondrial 
WLS -1.15 -1.12 13 5 7.55 24.20 11 20.1 62.25 35.12 Non-mitochondrial   
CD200 -1.11 -1.09 4 4 29.72 43.35 4 21.2 30.33 32.62 Non-mitochondrial  
CYP2S1 -1.05 -1.49 10 4 17.40 37.38 12 33.7 55.82 80.00 Non-mitochondrial   
ANK2 -1.04 -1.33 5 20 39.74 50.58 19 15.1 204.75 39.28 Non-mitochondrial   
CYC1 -1.03 -1.02 73 53 7.63 14.76 15 56.9 35.42 323.31 Mitochondrial 
DHRS1 -1.03 -1.15 10 8 11.12 72.88 15 60.4 33.91 108.72 Predicted mitochondrial 
UQCRH -1.00 -1.37 7 5 7.40 31.76 6 57.1 10.74 22.95 Mitochondrial 
 
Proteins with greater than a two-fold increase in abundance in SLCK25A32 KO cells 
Protein 
Log2 Forward 
Ratio H/L 
(normalised) 
Log2 inverted 
reverse ratio 
H/L 
(normalised) 
Count 
(forward) 
Count 
(reverse) 
Ratio H/L 
variability [%] 
(forward) 
Ratio H/L 
variability [%] 
(reverse) 
Unique 
peptides 
Sequence 
coverage 
[%] 
Molecular 
weight 
[kDa] 
Score 
Mitochondrial 
localisation? 
MAGEB2 5.42 5.94 3 3 101.05 44.43 6 22.9 35.28 42.49 Non-mitochondrial   
RAB34 3.69 3.37 7 5 115.19 212.05 12 47.9 29.04 32.88 Non-mitochondrial   
SSX2 3.29 5.01 8 5 139.23 83.76 10 53.7 21.62 42.46 Non-mitochondrial   
ABCB6 2.75 3.71 5 6 130.43 120.31 13 26.4 88.60 103.33 Mitochondrial 
SLC7A3 2.61 2.14 9 6 84.63 19.75 5 11.5 67.17 121.63 Non-mitochondrial   
COX17 2.55 2.86 3 4 44.81 25.05 1 25.4 6.92 16.41 Mitochondrial 
NPR2 2.23 2.22 3 4 128.93 131.62 9 12.1 117.02 18.51 Non-mitochondrial  
SLC43A3 2.20 3.55 4 5 61.30 112.56 4 10.8 54.53 8.60 Non-mitochondrial   
ABCB1 1.90 1.00 26 6 24.98 20.85 26 27.7 134.03 207.37 Non-mitochondrial  
HMOX1 1.78 1.80 37 24 11.40 20.12 15 59.7 32.82 186.54  Non-mitochondrial  
ABCD1 1.43 1.65 3 2 35.61 9.62 3 6.4 82.94 14.88 Predicted mitochondrial 
VLDLR 1.43 1.63 19 7 16.04 9.38 22 34.0 93.38 150.93  Non-mitochondrial  
IGSF8 1.39 1.14 3 4 15.79 31.20 5 12.1 65.03 30.77  Non-mitochondrial  
PROCR 1.37 2.74 3 2 10.87 13.35 2 10.9 26.67 10.54  Non-mitochondrial  
AKAP12 1.34 1.64 96 92 11.07 31.84 70 58.6 180.99 323.31  Non-mitochondrial  
NES 1.24 2.42 71 124 23.47 35.79 57 44.5 177.44 323.31 Non-mitochondrial   
BST2 1.19 2.06 12 13 13.55 6.38 4 19.6 18.39 21.08 Non-mitochondrial   
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METTL7A 1.16 1.87 21 13 8.82 23.15 9 38.5 28.32 104.88 Non-mitochondrial   
SCD5 1.13 1.37 3 2 48.50 10.98 3 17.6 28.98 12.24 Non-mitochondrial   
VIM 1.10 1.47 109 85 20.13 19.98 32 65.9 53.65 323.31 Non-mitochondrial  
GNB4 1.02 1.20 15 12 11.08 8.44 10 67.4 37.57 236.88 Non-mitochondrial   
 
Appendix 7.7 Transcriptome data for conditioned SLC25A32 KO cells and conditioned HAP1 cells 
 
Complex I subunits 
  Transcripts per million (TPM) 
Gene baseMean 
Log2 
(FoldChange) lfcSE stat p-value 
Adjusted  
p-value Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
MT-ND1 14595.92 0.70 0.31 2.27 2.32E-02 1.02E-01 MT 948.1 728.1 460.3 830.5 2390.4 1670.2 
MT-ND2 19073.08 0.89 0.30 2.94 3.27E-03 2.41E-02 MT 1280.9 883.1 665.6 1483.0 3684.5 2457.3 
MT-ND3 7404.91 0.90 0.21 4.20 2.69E-05 4.92E-04 MT 1485.2 835.5 757.3 1852.5 2729.1 1956.1 
MT-ND4 43190.14 0.59 0.30 1.98 4.75E-02 1.68E-01 MT 2079.0 1966.3 1495.2 1606.2 4493.2 4292.1 
MT-ND4L 11848.61 0.51 0.30 1.71 8.65E-02 2.52E-01 MT 4094.0 3915.9 2974.8 3111.7 8844.9 7911.8 
MT-ND5 15985.10 0.28 0.32 0.89 3.73E-01 6.20E-01 MT 623.8 623.6 395.3 295.8 1117.4 1053.0 
MT-ND6 1792.93 0.77 0.32 2.44 1.49E-02 7.44E-02 MT 87.3 253.6 158.8 233.0 737.1 596.2 
NDUFA1 5169.87 -0.20 0.15 -1.31 1.89E-01 4.20E-01 X 488.0 560.9 693.3 489.4 574.6 496.9 
NDUFA10 3854.04 -0.20 0.11 -1.79 7.35E-02 2.27E-01 2 71.9 67.2 59.8 60.7 57.8 60.6 
NDUFA11 783.56 -0.09 0.16 -0.54 5.88E-01 7.82E-01 19 159.7 186.9 155.5 152.7 159.6 134.9 
NDUFA12 1683.81 -0.29 0.12 -2.48 1.32E-02 6.84E-02 12 92.4 128.3 119.6 116.9 102.0 83.5 
NDUFA13 290.89 -0.14 0.20 -0.69 4.88E-01 7.14E-01 19 188.8 125.6 148.1 87.0 67.4 127.3 
NDUFA2 1196.06 -0.33 0.16 -2.07 3.88E-02 1.46E-01 5 103.4 127.1 102.8 72.7 96.9 104.3 
NDUFA3 669.02 -0.35 0.14 -2.49 1.29E-02 6.70E-02 19 86.3 82.9 81.1 80.1 59.8 64.1 
NDUFA5 3622.31 -0.16 0.13 -1.23 2.18E-01 4.59E-01 7 171.6 137.0 136.7 186.6 143.0 128.6 
NDUFA6 1853.11 -0.39 0.13 -3.00 2.73E-03 2.10E-02 22 154.8 130.7 94.8 89.0 79.1 69.1 
NDUFA7 62.51 -0.11 0.28 -0.38 7.08E-01 8.55E-01 19 116.6 88.6 107.9 95.1 99.9 105.2 
NDUFA8 1808.99 -0.29 0.12 -2.43 1.52E-02 7.54E-02 9 179.1 164.8 172.5 167.5 136.7 136.2 
NDUFA9 2370.33 -0.36 0.12 -3.12 1.80E-03 1.52E-02 12 39.2 45.5 39.2 37.6 35.6 37.7 
NDUFAB1 3724.12 -0.57 0.15 -3.80 1.47E-04 2.01E-03 16 522.7 500.7 387.9 315.1 292.8 294.6 
NDUFB1 686.69 -0.23 0.18 -1.28 2.02E-01 4.37E-01 14 186.1 43.8 35.5 99.7 37.5 39.5 
NDUFB10 1681.63 -0.60 0.15 -4.01 6.19E-05 9.85E-04 16 132.4 121.0 104.4 94.8 78.6 76.1 
NDUFB11 2986.01 -0.35 0.10 -3.38 7.19E-04 7.27E-03 X 230.4 214.8 217.3 187.1 175.9 175.0 
NDUFB2 866.43 -0.13 0.13 -0.99 3.24E-01 5.74E-01 7 98.6 70.9 85.4 93.4 92.0 69.5 
NDUFB3 2635.06 -0.44 0.13 -3.45 5.66E-04 5.99E-03 2 252.8 292.9 308.4 201.1 218.8 223.1 
NDUFB4 3737.93 -0.43 0.11 -3.79 1.53E-04 2.07E-03 3 220.3 197.9 204.1 174.7 181.9 145.4 
NDUFB5 3886.16 -0.25 0.11 -2.21 2.71E-02 1.14E-01 3 122.3 164.4 129.1 117.9 117.4 115.6 
NDUFB6 2371.89 -0.19 0.16 -1.18 2.39E-01 4.85E-01 9 141.1 181.7 152.1 132.1 161.1 136.3 
NDUFB7 1092.43 -0.46 0.13 -3.61 3.10E-04 3.70E-03 19 186.4 176.6 181.0 153.8 130.9 121.2 
NDUFB8 695.14 -0.18 0.14 -1.28 1.99E-01 4.34E-01 10 203.9 164.2 234.1 179.7 151.5 130.6 
NDUFB9 4294.76 -0.30 0.15 -1.95 5.17E-02 1.78E-01 8 308.1 405.2 393.5 277.2 300.7 280.4 
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NDUFC1 2056.93 -0.30 0.12 -2.42 1.57E-02 7.70E-02 4 222.9 206.6 133.2 172.0 184.8 135.0 
NDUFC2 1158.35 0.22 0.13 1.75 8.06E-02 2.41E-01 11 82.7 68.8 71.7 84.4 84.7 85.5 
NDUFS1 7314.38 -0.04 0.14 -0.28 7.82E-01 8.96E-01 2 68.7 48.7 55.4 54.1 43.5 62.8 
NDUFS2 3763.70 -0.84 0.14 -6.02 1.77E-09 1.05E-07 1 233.8 180.1 220.4 130.2 102.7 127.9 
NDUFS3 1989.39 -0.23 0.13 -1.77 7.74E-02 2.35E-01 11 110.2 110.8 90.4 104.6 92.0 87.9 
NDUFS4 1350.04 0.13 0.18 0.71 4.79E-01 7.07E-01 5 100.0 145.7 118.3 129.4 145.2 147.2 
NDUFS5 5085.17 -0.31 0.10 -3.09 2.00E-03 1.65E-02 1 782.7 734.2 763.7 674.4 637.2 594.6 
NDUFS6 1471.07 -0.33 0.18 -1.87 6.15E-02 2.01E-01 5 137.4 85.8 100.9 81.0 79.4 54.9 
NDUFS7 1271.26 -0.44 0.13 -3.29 1.01E-03 9.56E-03 19 55.4 52.2 61.8 42.8 42.2 35.1 
NDUFS8 1542.02 -0.11 0.12 -0.99 3.23E-01 5.74E-01 11 136.8 93.2 100.1 117.6 115.0 107.5 
NDUFV1 5627.86 -0.36 0.13 -2.83 4.59E-03 3.10E-02 11 197.6 264.8 152.7 178.1 139.4 199.7 
NDUFV2 872.22 -0.04 0.15 -0.29 7.72E-01 8.91E-01 18 293.7 288.2 320.7 306.9 314.0 305.2 
NDUFV3 1224.26 -0.21 0.13 -1.62 1.05E-01 2.88E-01 21 37.8 33.5 33.9 38.3 32.5 31.4 
 
Complex II subunits 
  Transcripts per million (TPM) 
Gene 
baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted  
p-value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
SDHA 4506.50 -0.12 0.13 -0.95 3.43E-01 5.92E-01 5 150.3 124.8 144.7 151.0 113.2 135.2 
SDHB 4393.03 -0.25 0.11 -2.17 2.98E-02 1.22E-01 1 298.9 306.8 273.6 284.5 254.7 239.7 
SDHC 8704.97 -0.66 0.12 -5.31 1.11E-07 4.07E-06 1 158.0 91.1 108.2 53.6 56.6 60.3 
SDHD 3186.06 -0.12 0.12 -0.99 3.24E-01 5.74E-01 11 269.8 246.9 248.5 272.0 221.7 234.2 
 
Complex III subunits 
  Transcripts per million (TPM) 
Gene 
baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted  
p-value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
UQCRQ 2546.42 -0.16 0.13 -1.21 2.24E-01 4.67E-01 5 235.1 266.5 216.1 244.5 211.8 212.6 
UQCRH 10329.24 -0.40 0.13 -3.13 1.74E-03 1.48E-02 1 1263.1 1330.1 1313.7 941.7 1133.5 897.4 
UQCRFS1 3513.30 -0.17 0.12 -1.44 1.50E-01 3.61E-01 19 85.1 70.4 86.6 83.4 67.6 71.4 
UQCRC2 7956.88 -0.12 0.12 -0.99 3.24E-01 5.75E-01 16 231.8 244.5 221.1 238.8 311.6 273.8 
UQCRC1 4811.41 -0.39 0.11 -3.53 4.20E-04 4.75E-03 3 204.8 175.9 186.4 174.1 143.9 153.0 
UQCRB 9783.29 -0.13 0.10 -1.33 1.85E-01 4.14E-01 8 269.1 360.1 277.9 283.4 353.8 344.4 
UQCR11 1516.21 -0.47 0.12 -3.93 8.52E-05 1.26E-03 19 148.3 154.1 162.9 115.3 110.1 123.2 
UQCR10 2950.82 -0.42 0.12 -3.49 4.84E-04 5.33E-03 22 348.0 313.5 297.1 269.8 249.5 227.5 
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Complex IV subunits 
 Transcripts per million (TPM) 
Gene baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adj  
p-value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
MT-CYB 19085.01 0.21 0.23 0.93 3.55E-01 6.03E-01 MT 1301.1 1161.1 894.8 804.3 1811.4 1472.4 
MT-CO3 48790.44 0.49 0.22 2.27 2.33E-02 1.03E-01 MT 3951.6 3754.4 3426.2 3284.8 6954.6 6707.8 
MT-CO2 45726.96 0.50 0.22 2.26 2.41E-02 1.05E-01 MT 4758.7 3713.7 3374.9 3543.8 7463.8 7323.0 
MT-CO1 74446.81 0.52 0.30 1.74 8.18E-02 2.43E-01 MT 2804.1 3153.3 2582.6 2183.3 5867.1 7079.4 
COX8A 3222.50 -0.23 0.14 -1.68 9.30E-02 2.65E-01 11 671.2 551.2 586.0 607.1 523.6 442.0 
COX7C 6852.05 -0.20 0.10 -2.00 4.50E-02 1.62E-01 5 419.1 455.1 432.4 424.1 394.4 390.5 
COX7B 10523.00 -0.23 0.16 -1.42 1.55E-01 3.68E-01 X 229.5 266.4 313.7 260.7 279.9 252.3 
COX7A2L 3746.83 0.05 0.15 0.33 7.40E-01 8.74E-01 2 116.5 97.2 197.9 97.0 186.4 231.5 
COX7A2 4122.28 -0.29 0.16 -1.79 7.38E-02 2.27E-01 6 468.3 603.7 506.9 360.4 465.7 492.5 
COX6C 5872.15 -0.28 0.18 -1.54 1.23E-01 3.18E-01 8 421.8 691.4 559.5 426.2 574.9 509.1 
COX6B1 4914.69 -0.38 0.11 -3.48 5.01E-04 5.46E-03 19 595.2 544.9 536.5 497.6 416.9 434.1 
COX6A1 5094.93 -0.33 0.11 -3.04 2.35E-03 1.86E-02 12 725.1 670.8 741.5 648.4 538.4 629.1 
COX5B 2862.01 -0.46 0.15 -3.12 1.81E-03 1.52E-02 2 368.8 320.7 287.5 257.6 265.9 194.0 
COX5A 6853.96 -0.62 0.10 -6.09 1.11E-09 6.93E-08 15 506.6 468.3 458.4 327.3 309.7 300.2 
COX4I1 7072.12 -0.32 0.10 -3.10 1.95E-03 1.62E-02 16 480.4 348.4 363.0 301.6 294.1 284.5 
 
Complex V subunits 
 Transcripts per million (TPM) 
Gene baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted  
p-value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
ATP5A1 30437.53 -0.26 0.12 -2.14 3.25E-02 1.29E-01 18 1510.8 1099.1 1480.2 386.1 922.5 884.5 
ATP5B 39671.78 -0.28 0.11 -2.54 1.10E-02 6.01E-02 12 1541.3 1413.5 1521.9 1362.6 1139.6 1222.2 
ATP5C1 8610.75 -0.20 0.10 -1.97 4.87E-02 1.71E-01 10 541.5 533.0 533.4 518.1 493.4 452.2 
ATP5D 658.93 -0.42 0.21 -2.02 4.37E-02 1.59E-01 19 80.5 33.6 28.9 31.4 31.4 39.8 
ATP5E 7641.64 -0.19 0.12 -1.60 1.11E-01 2.97E-01 20 166.2 178.1 162.5 147.7 155.7 157.8 
ATP5F1 10689.84 -0.26 0.11 -2.34 1.91E-02 8.95E-02 1 536.6 488.8 420.1 411.8 219.0 430.7 
ATP5G1 2445.84 -0.55 0.11 -5.00 5.59E-07 1.74E-05 17 267.9 256.7 276.9 206.3 177.7 173.6 
ATP5G2 6291.98 -0.13 0.16 -0.85 3.95E-01 6.39E-01 12 424.6 304.8 446.3 336.6 350.6 404.9 
ATP5G3 8124.60 -0.42 0.14 -2.91 3.66E-03 2.65E-02 2 164.3 148.8 147.5 126.7 140.3 102.7 
ATP5H 3018.03 -0.28 0.10 -2.68 7.31E-03 4.39E-02 17 432.4 397.7 427.4 384.2 350.2 343.4 
ATP5I 3774.04 -0.56 0.13 -4.21 2.57E-05 4.73E-04 4 944.9 1012.9 808.5 732.5 606.3 618.0 
ATP5J 4013.39 -0.41 0.11 -3.79 1.53E-04 2.07E-03 21 529.3 507.1 535.0 426.7 400.8 358.8 
ATP5J2 5677.49 -0.53 0.11 -4.73 2.26E-06 5.92E-05 7 1268.6 1286.4 1178.8 894.7 893.2 809.0 
ATP5L 5960.49 -0.22 0.11 -1.98 4.72E-02 1.68E-01 11 238.1 242.8 228.4 209.6 212.2 218.4 
ATP5O 3654.36 -0.16 0.15 -1.08 2.80E-01 5.32E-01 21 383.5 460.3 405.4 316.5 353.9 373.6 
ATP5S 756.77 0.48 0.15 3.26 1.10E-03 1.02E-02 14 7.8 8.5 8.7 10.8 10.8 11.5 
ATP5SL 1434.19 -0.30 0.13 -2.38 1.75E-02 8.35E-02 19 52.3 52.2 43.8 58.1 40.4 43.2 
MT-ATP6 23085.29 0.82 0.23 3.52 4.24E-04 4.78E-03 MT 685.3 541.8 420.9 622.6 1323.6 1442.8 
MT-ATP8 9435.67 0.73 0.23 3.18 1.48E-03 1.30E-02 MT 6605.7 5544.1 4509.0 6287.4 12768.1 13969.6 
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Mitoflavoproteins 
 Transcripts per million (TPM) 
Gene baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted p-
value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
ACAD8 856.08 0.12 0.18 0.66 5.07E-01 7.28E-01 11 25.4 20.1 22.4 20.9 29.2 32.4 
ACAD9 1624.74 -0.02 0.14 -0.14 8.89E-01 9.47E-01 3 55.9 49.6 43.6 51.9 51.6 55.6 
ACADM 3444.27 0.11 0.14 0.76 4.46E-01 6.82E-01 1 123.3 82.5 95.5 105.8 112.1 95.5 
ACADS 384.18 -0.41 0.19 -2.14 3.24E-02 1.29E-01 12 20.3 13.5 19.6 13.3 12.9 14.5 
ACADSB 2908.66 0.22 0.18 1.26 2.07E-01 4.43E-01 10 28.2 39.3 37.0 60.0 32.5 38.1 
ACADVL 2287.98 0.29 0.19 1.58 1.14E-01 3.03E-01 17 68.0 106.5 70.2 83.2 110.0 121.4 
AIFM1 5063.42 -0.05 0.14 -0.33 7.39E-01 8.73E-01 X 160.5 134.1 194.4 171.4 161.6 160.9 
COQ6 470.35 0.17 0.16 1.08 2.81E-01 5.33E-01 14 14.8 18.4 18.0 21.6 21.2 21.8 
CYB5R3 1704.29 -0.14 0.12 -1.18 2.39E-01 4.85E-01 22 36.2 33.5 39.7 36.2 32.1 36.5 
DHODH 526.68 -0.01 0.18 -0.05 9.61E-01 9.81E-01 16 15.4 9.6 12.6 15.4 9.2 10.9 
DLD 5725.93 0.31 0.12 2.52 1.16E-02 6.25E-02 7 124.8 101.4 119.1 160.3 146.1 135.2 
DMGDH 40.39 0.89 0.31 2.86 4.29E-03 2.97E-02 5 0.6 1.7 1.7 3.9 2.8 3.6 
ETFA 9585.29 -0.14 0.11 -1.25 2.10E-01 4.48E-01 15 348.3 297.6 289.6 337.4 312.5 312.0 
ETFDH 868.33 -0.24 0.18 -1.29 1.98E-01 4.33E-01 4 27.9 16.9 26.8 23.8 22.0 17.6 
FDXR 352.22 -0.08 0.17 -0.45 6.50E-01 8.22E-01 17 14.3 13.5 13.6 13.9 13.4 13.2 
FOXRED1 1623.77 -0.05 0.12 -0.40 6.89E-01 8.45E-01 11 50.9 53.9 50.5 59.2 65.7 56.5 
GCDH 511.69 0.23 0.18 1.31 1.91E-01 4.22E-01 19 19.6 19.8 16.0 25.0 22.1 25.4 
GPD2 2921.79 0.11 0.14 0.79 4.30E-01 6.68E-01 2 35.5 29.0 41.3 48.6 42.3 35.9 
GSR 3226.33 0.13 0.17 0.73 4.62E-01 6.95E-01 8 71.5 56.2 86.7 97.7 82.5 63.1 
IVD 2008.41 0.22 0.14 1.55 1.22E-01 3.17E-01 15 53.0 61.8 41.6 70.0 72.8 65.4 
L2HGDH 1740.12 -0.31 0.12 -2.50 1.25E-02 6.58E-02 14 29.5 23.0 26.9 25.0 21.6 20.0 
MAOA 1828.29 0.13 0.12 1.08 2.80E-01 5.32E-01 X 30.1 24.1 34.4 35.8 31.4 31.1 
NDUFV1 5627.86 -0.36 0.13 -2.83 4.59E-03 3.10E-02 11 197.6 264.8 152.7 178.1 139.4 199.7 
SDHA 4506.50 -0.12 0.13 -0.95 3.43E-01 5.92E-01 5 150.3 124.8 144.7 151.0 113.2 135.2 
PPOX 608.61 -0.34 0.22 -1.57 1.16E-01 3.06E-01 1 30.8 41.9 35.4 18.3 30.6 36.5 
PRODH 7.96 -0.03 0.28 -0.10 9.22E-01 9.64E-01 22 20.3 23.0 18.2 14.9 15.9 21.3 
SQRDL 56.60 0.61 0.30 2.07 3.80E-02 1.45E-01 15 2.0 2.8 3.3 4.3 4.9 3.9 
TXNRD2 739.38 -0.17 0.14 -1.17 2.41E-01 4.87E-01 22 26.0 28.3 29.2 28.9 26.1 25.8 
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Flavin-handling proteins 
 Transcripts per million (TPM) 
Gene 
base 
Mean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted p-
value 
Chr. 
Mito. 
localisation 
(IMPI) 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
FLAD1 2173.18 -1.06 0.15 -7.06 1.65E-12 1.78E-10 1 Known 93.2 83.0 64.7 61.0 36.2 43.0 
RFK 1486.17 0.09 0.15 0.59 5.56E-01 7.61E-01 9 Non-mito. 41.7 40.1 35.6 48.4 47.5 35.1 
SLC52A2 676.41 -0.12 0.18 -0.68 4.99E-01 7.23E-01 8 Non-mito. 17.8 28.4 19.2 26.8 16.7 19.9 
 
Folate-metabolising proteins 
 Transcripts per million (TPM) 
Gene 
base 
Mean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted p-
value 
Chr. 
Mito. 
localisation 
(IMPI) 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
MTHFD1 9389.93 -0.02 0.13 -0.16 8.73E-01 9.40E-01 14 Non-mito. 181.3 162.6 189.0 206.5 205.5 159.0 
MTHFD1L 3596.58 0.01 0.15 0.08 9.34E-01 9.69E-01 6 Known 108.5 68.4 89.5 135.3 97.3 87.8 
MTHFD2 19033.36 0.23 0.17 1.35 1.78E-01 4.04E-01 2 Known 177.3 198.7 297.3 332.1 254.8 275.0 
MTHFD2L 708.60 0.45 0.15 3.10 1.95E-03 1.61E-02 4 Known 16.4 12.1 16.3 20.0 20.1 29.0 
MTHFR 449.23 -0.10 0.16 -0.64 5.22E-01 7.40E-01 1 Non-mito. 5.8 5.6 6.1 4.7 4.9 6.3 
MTHFS 301.85 0.14 0.21 0.66 5.06E-01 7.28E-01 15 Known 51.5 62.9 43.3 94.6 53.0 39.9 
DHFR 8864.72 -0.12 0.13 -0.90 3.68E-01 6.16E-01 5 Non-mito. 260.1 149.3 184.7 200.7 138.8 214.5 
SHMT1 1697.15 0.28 0.13 2.19 2.83E-02 1.17E-01 17 Non-mito. 63.4 54.4 57.6 85.9 67.8 78.1 
SHMT2 11316.49 0.39 0.16 2.53 1.15E-02 6.20E-02 12 Known 261.3 342.6 377.9 461.2 351.6 463.4 
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50 most differentially expressed genes between HAP1 and SLCKO cells 
 Transcripts per million (TPM) 
Gene baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted 
p-value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
ALDH1A2 2242.49 -5.26 0.22 -24.26 4.63E-130 5.54E-126 15 81.4 91.7 79.6 1.3 2.0 0.9 
FOLH1 650.04 -4.75 0.22 -21.30 1.16E-100 6.96E-97 11 38.0 39.3 33.0 2.2 0.7 0.8 
KLF4 1135.96 -3.70 0.21 -17.37 1.31E-67 5.24E-64 9 84.6 44.6 33.6 3.2 4.3 3.1 
DPP4 432.42 -2.83 0.18 -15.67 2.25E-55 6.72E-52 2 16.4 19.2 14.3 3.5 2.7 2.3 
ZNF544 520.01 -3.45 0.24 -14.43 3.14E-47 7.53E-44 19 10.4 18.9 10.9 1.0 2.8 2.4 
TUBB4A 4105.52 -2.13 0.15 -14.28 2.90E-46 5.78E-43 19 171.9 199.1 146.6 41.0 40.6 39.7 
PSMB8 907.56 -2.27 0.16 -13.90 6.71E-44 1.15E-40 6 84.1 101.2 86.5 16.5 19.4 16.2 
TPM2 1093.53 3.23 0.24 13.71 9.44E-43 1.41E-39 9 6.9 4.4 6.0 73.3 126.4 59.2 
ZNF788 763.83 -3.30 0.24 -13.51 1.34E-41 1.79E-38 19 27.1 34.3 23.4 2.0 2.2 0.9 
CD70 1160.09 -2.35 0.17 -13.46 2.60E-41 3.11E-38 19 195.7 221.9 170.9 34.5 30.0 42.0 
HRASLS5 480.48 3.29 0.25 13.38 7.86E-41 8.55E-38 11 1.4 0.7 2.5 20.4 23.1 27.7 
GTF2H2 200.79 -3.28 0.25 -13.37 9.43E-41 9.40E-38 5 33.1 39.7 32.4 4.6 5.7 3.7 
MEST 526.64 3.46 0.26 13.06 5.89E-39 5.42E-36 7 1.8 1.2 1.7 22.2 52.9 22.4 
ZNF329 496.44 -2.90 0.23 -12.72 4.47E-37 3.82E-34 19 8.1 9.5 5.7 1.3 2.0 2.4 
HKR1 1360.92 -1.88 0.15 -12.28 1.19E-34 9.52E-32 19 59.8 32.9 45.5 16.9 14.2 14.5 
FAM213A 677.80 -2.23 0.19 -11.68 1.58E-31 1.18E-28 10 33.5 32.3 32.5 4.8 7.6 4.9 
NLRC5 718.24 -1.80 0.16 -11.63 2.93E-31 2.06E-28 16 22.6 28.8 17.4 6.8 7.1 7.8 
TAGLN2 10615.83 -1.24 0.11 -11.61 3.58E-31 2.38E-28 1 624.9 679.0 631.8 296.6 263.9 282.0 
CLDN11 440.28 3.05 0.27 11.40 4.09E-30 2.58E-27 3 3.2 1.3 0.9 24.6 30.1 33.2 
PRLR 2528.41 -2.13 0.19 -11.25 2.45E-29 1.47E-26 5 21.5 31.0 36.1 6.0 7.5 4.5 
ZNF611 897.99 -1.66 0.16 -10.62 2.41E-26 1.37E-23 19 19.1 27.6 24.7 8.1 8.1 6.9 
MYBPC1 500.00 -2.58 0.25 -10.47 1.22E-25 6.65E-23 12 28.5 47.7 28.9 4.9 5.1 1.7 
ADGRG6 704.80 2.04 0.20 10.42 1.97E-25 1.03E-22 6 3.4 2.9 3.5 11.6 17.8 11.7 
PCDHB3 291.90 -2.26 0.22 -10.25 1.19E-24 5.94E-22 5 13.3 12.8 9.2 2.2 1.5 2.3 
KIAA1551 7765.63 -1.70 0.17 -10.10 5.50E-24 2.63E-21 12 113.5 132.9 92.0 32.9 39.3 35.6 
CD320 256.97 2.67 0.27 9.78 1.40E-22 6.44E-20 19 2.0 2.2 2.0 28.6 38.4 10.3 
SCGB3A2 341.13 -2.63 0.27 -9.63 6.08E-22 2.69E-19 5 104.8 81.7 82.7 4.0 13.7 6.6 
C3 145.10 -2.70 0.28 -9.47 2.84E-21 1.21E-18 19 5.9 6.8 6.8 0.5 1.7 1.0 
A4GALT 712.71 -1.59 0.17 -9.46 3.00E-21 1.24E-18 22 39.9 39.7 31.1 12.1 10.8 14.9 
CHST2 936.71 -2.19 0.23 -9.46 3.18E-21 1.27E-18 3 33.8 27.4 15.1 5.3 3.4 4.4 
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 Transcripts per million (TPM) 
Gene baseMean 
Log2 
(FoldChange) 
lfcSE stat p-value 
Adjusted 
p-value 
Chr. 
HAP1 
A 
HAP1 
B 
HAP1 
C 
SLCKO 
A 
SLCKO 
B 
SLCKO 
C 
GREM2 302.12 -2.37 0.25 -9.37 7.49E-21 2.89E-18 1 9.9 12.5 5.8 1.1 1.1 1.5 
ZNF701 192.81 -2.32 0.25 -9.35 8.43E-21 3.15E-18 19 8.2 12.1 7.3 1.0 1.1 1.1 
FLVCR2 637.48 -1.77 0.19 -9.32 1.14E-20 4.10E-18 14 26.6 21.6 17.1 5.5 7.1 5.5 
PIK3AP1 2778.00 -1.56 0.17 -9.32 1.17E-20 4.10E-18 10 77.7 65.2 53.3 25.3 16.7 22.4 
TCEAL9 2139.46 2.82 0.30 9.32 1.20E-20 4.10E-18 X 14.2 5.4 18.0 266.3 316.8 322.4 
GLIPR2 781.01 -1.88 0.20 -9.29 1.56E-20 5.18E-18 9 37.6 64.6 46.1 11.4 12.3 11.5 
KCNK1 880.05 -2.17 0.24 -9.16 5.13E-20 1.66E-17 1 44.7 62.4 47.1 13.8 5.3 7.5 
ASPHD1 285.08 1.80 0.20 9.08 1.06E-19 3.34E-17 16 5.1 5.1 6.9 24.4 24.3 18.6 
FEZ2 2963.56 -1.03 0.11 -9.02 1.92E-19 5.90E-17 2 69.1 66.2 63.9 41.3 32.0 37.9 
MOCOS 619.98 1.68 0.19 8.88 6.68E-19 2.00E-16 18 2.9 3.0 4.5 11.6 15.3 9.7 
PPP1R3B 807.50 -2.00 0.23 -8.84 9.47E-19 2.76E-16 8 20.2 19.3 12.9 3.0 2.8 4.9 
MLF1 519.35 -2.42 0.27 -8.83 1.05E-18 2.98E-16 3 17.8 31.8 21.0 2.0 5.0 3.0 
COL5A2 1110.47 2.70 0.31 8.72 2.70E-18 7.51E-16 2 0.8 0.6 1.6 24.3 17.9 15.6 
HLA-B 5700.95 -1.19 0.14 -8.57 1.02E-17 2.77E-15 6 395.5 450.9 407.6 134.9 202.2 186.6 
TTYH1 871.01 -2.24 0.26 -8.53 1.48E-17 3.95E-15 19 55.5 65.3 66.6 4.1 16.6 8.8 
CA8 191.64 -2.18 0.26 -8.51 1.67E-17 4.35E-15 8 8.3 10.2 5.4 1.4 1.5 1.5 
TNFSF9 353.33 -1.93 0.23 -8.41 4.27E-17 1.09E-14 19 20.4 34.5 20.3 5.5 5.6 5.1 
PLA2G4A 1999.12 -1.15 0.14 -8.33 8.28E-17 2.06E-14 1 68.6 75.5 73.0 31.5 36.4 29.8 
KLF3 2116.76 -1.00 0.12 -8.31 9.45E-17 2.31E-14 4 41.4 42.5 38.4 21.5 20.7 20.6 
FOXE1 207.35 -1.97 0.24 -8.26 1.46E-16 3.50E-14 9 6.2 9.7 7.2 1.5 1.3 1.8 
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Appendix 7.8 Complexome data for conditioned SLC25A32 KO cells and conditioned HAP1 cells  
 
7.8A Table of proteins used in mass estimation of HAP1 mitochondrial sample. 
 
Protein Mass (kDa) Native state Total Mass (kDa) Gel slice 
Mitochondrial ribosome (39S + 28S)  - 39S + 28S subunits 2900 11 
Complex V (ATP synthase) 770 monomer 770 25 
Complex III (Cytochrome bc-1 complex) 245 dimer 490 30 
Trifunctional enzyme α - 80, β - 51 hetero-octamer 485 31 
Isocitrate (NAD) dehydrogenase α - 40, β - 42, γ - 43 (2:1:1, heterotetramer = 165) hetero-octamer 330 32 
NADP transhydrogenase 114 dimer 228 36 
Complex  IV (cytochrome c oxidase) 200 monomer 200 40 
Complex II (succinate dehydrogenase) 130 monomer 130 48 
Mitochondrial intermediate peptidase 80 monomer 80 50 
Arginase-2 38 monomer 114 51 
SLC25A13 (citrin) 74 monomer 74 53 
SLC25A12 (aralar 1) 75 monomer 75 53 
Electron transfer protein α - 35, β - 28 heterodimer 63 54 
Citrate synthase 52 dimer 104 55 
Acylpyruvase 24 dimer 48 55 
NADH-cytochrome b5 reductase 3 34 monomer 34 59 
Proline dehydrogenase 68 monomer 68 59 
Electron transfer ubiquinone oxidoreductase 69 monomer 69 60 
NADPH:adrenodoxin oxidoreductase 54 monomer 54 62 
2-oxoglutarate/malate carrier protein 34 dimer 68 62 
 
7.8B Table of proteins used in mass estimation of SLC25A32 knockout mitochondrial sample. 
 
Protein Mass (kDa) Native state Total Mass (kDa) Gel slice 
Mitochondrial ribosome (39S + 28S)  - 39S + 28S subunits 2900 10 
Propionyl-CoA carboxylase α -80 and β - 58 heterododecamer 820 20 
Complex V (ATP synthase) 770 monomer 770 23 
Complex III (Cytochrome bc-1 complex) 245 dimer 490 28 
Isocitrate (NAD) dehydrogenase α - 40, β - 42, γ - 43 (2:1:1, heterotetramer = 165) hetero-octamer 330 31 
NADP transhydrogenase 114 dimer 228 34 
Complex  IV (cytochrome c oxidase) 200 monomer 200 39 
SLC25A13 (citrin) 74 monomer 74 40 
SLC25A12 (aralar 1) 75 monomer 75 40 
Arginase-2 38 monomer 114 49 
Mitochondrial intermediate peptidase 80 monomer 80 50 
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Citrate synthase 52 dimer 104 51 
Dimethyladenosine transferase 2 45 monomer 45 52 
Sulphite oxidase 60 dimer 120 58 
Folylpolyglutamate synthase 64 monomer 64 59 
ADP/ATP translocase (adenine nucleotide translocase) 30 monomer 30 59 
Electron transfer ubiquinone oxidoreductase 69 monomer 69 59 
NADH-cytochrome b5 reductase 3 34 monomer 34 59 
NADPH:adrenodoxin oxidoreductase 54 monomer 54 59 
Acylpyruvase 24 dimer 48 62 
2-oxoglutarate/malate carrier protein 34 dimer 68 63 
Adenylate kinase 2 26 monomer 26 63 
 
7.8C Complexome data for mitochondria from conditioned HAP1 cells. Score threshold for 95% confidence interval is 21. 
 
Complex I subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-ND1 11.95 3 35.6 92.81  
MT-ND2  7.49 1 38.9 84.82  
MT-ND4  10.02 4 51.5 45.56  
MT-ND5 7.96 4 67.0 242.82  
MT-ND6  8.05 1 18.6 119.95  
NDUFA1  18.57 1 8.1 39.34  
NDUFA10  36.62 12 40.7 345.74  
NDUFA11  31.91 3 14.8 269.83  
NDUFA12  61.38 8 17.1 438.88  
NDUFA13  67.36 10 16.7 890.89  
NDUFA2 50.51 6 10.9 288.83  
NDUFA3 50.00 3 9.3 118.39  
NDUFA5 43.97 5 13.5 414.57  
NDUFA6 53.25 6 17.9 406.45  
NDUFA7 55.75 8 12.5 723.27  
NDUFA8  21.51 4 20.1 230.93  
NDUFA9 67.37 16 42.5 757.27  
NDUFAB1 17.95 2 17.4 158.57  
NDUFB1 34.48 3 7.0 172.09  
NDUFB10 62.21 11 20.8 405.27  
NDUFB11  42.48 4 17.3 153.42  
NDUFB3  41.84 4 11.4 220.67  
NDUFB4 44.19 4 15.2 419.82  
NDUFB5  31.22 5 21.7 391.27  
NDUFB6  36.72 4 15.5 205.12  
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NDUFB7  24.09 2 16.4 541.78  
NDUFB8 38.17 4 21.8 339.74  
NDUFB9 55.31 5 21.8 409.76  
NDUFC1  27.63 1 8.7 30.52  
NDUFC2  37.82 6 14.2 106.69  
NDUFS2  45.14 13 52.5 716.81  
NDUFS3  48.11 12 30.2 824.76  
NDUFS4 39.43 5 20.1 395.91  
NDUFS5  25.47 4 12.5 189.94  
NDUFS6  29.03 3 13.7 133.76  
NDUFS7 23.00 5 23.5 631.25  
NDUFS8 35.71 6 23.7 413.99  
NDUFV1 36.85 12 50.8 613.79  
NDUFV2 49.00 12 27.4 830.41  
NDUFV3  22.22 1 11.9 47.19  
  
Complex II subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
SDHA  44.73 19 72.6 252.26  
SDHB 52.50 13 31.6 17.99  
SDHC  8.88 1 18.6 49.43  
SDHD 21.38 2 17.0 45.12  
  
Complex III subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-CYB  2.37 1 42.7 62.90  
UQCR10  38.10 2 7.3 377.71  
UQCRB  58.56 7 13.5 897.52  
UQCRC1  40.42 15 52.6 2042.28  
UQCRC2  46.58 13 48.4 2184.56  
UQCRFS1  45.99 11 29.6 1097.92  
UQCRH  12.09 1 10.7 23.96  
UQCRQ  36.59 4 9.9 151.76  
  
Complex IV subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
COX4I1  55.03 9 19.6 1274.03  
COX5A  38.67 6 16.8 796.31  
COX5B  46.51 6 13.7 615.10  
 2
8
4
 
COX6A1  16.51 1 12.1 69.35  
COX6B1  31.40 3 10.2 116.25  
COX6C 52.00 7 8.8 559.30  
COX7A2  37.35 2 9.4 294.16  
COX7C  25.40 1 7.2 37.80  
COX8A  27.54 1 7.6 111.91  
MT-CO1  7.60 3 57.0 169.95  
MT-CO2  27.75 5 25.5 736.43  
MT-CO3  3.45 1 29.9 31.97  
  
Complex V subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
ATP5A1 66.18 36 59.7 17329.07  
ATP5B  77.69 30 56.5 15579.59  
ATP5F1 54.69 15 28.9 3126.85  
ATP5O  59.62 12 23.3 2427.68  
ATP5H  72.67 10 18.5 1830.72  
ATP5C1  34.90 12 33.0 1402.16  
ATP5L  47.57 5 11.4 1289.88  
ATP5J  53.70 7 12.6 989.00  
ATP5I  66.67 6 7.9 954.78  
ATP5J2 39.36 3 10.9 805.97  
ATP5D  23.81 3 17.5 548.77  
ATP5E  31.37 2 5.8 181.37  
MT-ATP6  6.19 2 24.8 166.48  
MT-ATP8 36.76 2 8.0 106.41  
  
7.8D Complexome data for mitochondria from conditioned SLC25A32 knockout cells. Score threshold for 95% confidence interval is 21. 
 
Complex I subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-ND1  11.95 3 35.6 111.11  
MT-ND2  2.59 1 38.9 79.27  
MT-ND4  8.93 3 51.5 187.37  
MT-ND5  7.96 4 67.0 423.21  
MT-ND6  8.05 1 18.6 124.03  
NDUFA1  18.57 1 8.1 51.08  
NDUFA10 31.83 13 40.7 433.47  
NDUFA11 31.91 3 14.8 243.74  
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NDUFA12  46.90 6 17.1 312.57  
NDUFA13 67.36 10 16.7 1018.67  
NDUFA2  42.42 4 10.9 199.82  
NDUFA3  50.00 3 9.3 80.45  
NDUFA5  43.97 5 13.5 361.40  
NDUFA6  44.16 7 17.9 311.90  
NDUFA7 55.75 8 12.5 194.57  
NDUFA8  21.51 4 20.1 248.06  
NDUFA9  61.01 19 42.5 1007.59  
NDUFAB1 16.67 2 17.4 91.03  
NDUFB1 34.48 3 7.0 135.93  
NDUFB10  62.21 12 20.8 521.55  
NDUFB11  34.64 4 17.3 206.71  
NDUFB3  28.57 3 11.4 307.42  
NDUFB4  37.21 4 15.2 315.70  
NDUFB5  31.22 7 21.7 280.74  
NDUFB6 36.72 4 15.5 387.85  
NDUFB7 31.39 3 16.4 618.25  
NDUFB8  36.02 4 21.8 299.38  
NDUFB9 29.05 4 21.8 447.14  
NDUFC1  27.63 2 8.7 24.78  
NDUFC2 37.82 8 14.2 147.63  
NDUFS1  49.79 27 79.4 1362.51  
NDUFS2  40.82 15 52.5 687.42  
NDUFS3  50.38 12 30.2 1103.22  
NDUFS4  31.43 5 20.1 202.27  
NDUFS5  25.47 3 12.5 135.58  
NDUFS6  19.35 3 13.7 46.45  
NDUFS7 18.31 5 23.5 661.13  
NDUFS8  28.10 5 23.7 478.53  
NDUFV1 29.53 12 50.8 405.43  
NDUFV2  37.35 9 27.4 308.04  
 
Complex II subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
SDHA 35.99 18 72.6 150.42  
SDHB 26.79 6 31.6 202.55  
SDHC 14.20 2 18.6 66.11  
SDHD 10.69 2 17.0 68.54  
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Complex III subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
CYC1 32.00 7 35.4 859.95  
MT-CYB  2.37 1 42.7 83.21  
UQCR10  38.10 2 7.3 291.46  
UQCRB  47.75 7 13.5 1050.50  
UQCRC1  35.00 14 52.6 1808.48  
UQCRC2  35.10 11 48.4 2444.43  
UQCRFS1  41.97 9 29.6 977.41  
UQCRQ  18.29 2 9.9 158.75  
 
Complex IV subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-CO1  7.60 3 57.0 173.41  
MT-CO2  27.75 5 25.5 816.86  
COX4I1  46.75 11 19.6 944.28  
COX5A  38.67 6 16.8 755.66  
COX5B 41.09 6 13.7 742.77  
COX6A1  16.51 1 12.1 147.50  
COX6B1  22.09 2 10.2 26.05  
COX6C  44.00 7 8.8 300.47  
COX7A2 27.71 2 9.4 434.35  
COX7C 14.29 1 7.2 44.16  
COX8A  13.04 1 7.6 118.16  
 
Complex V subunits 
Protein  Coverage [%] Unique Peptides Molecular weight [kDa] Score (/21) 
MT-ATP8  36.76 2 8.0 68.71  
MT-ATP6  6.19 2 24.8 195.22  
ATP5A1  60.58 32 59.7 8799.92  
ATP5F1 52.34 15 28.9 2423.69  
ATP5B  70.32 24 56.5 10386.55  
ATP5H 69.57 12 18.5 1435.37  
ATP5D  18.45 2 17.5 418.45  
ATP5I  62.32 5 7.9 1000.34  
ATP5EP2  47.06 2 5.8 170.40  
ATP5J2  39.36 3 10.9 827.35  
ATP5L  47.57 5 11.4 1491.45  
ATP5C1  27.85 9 33.0 1768.72  
ATP5O 71.83 12 23.3 2390.34  
ATP5J  46.30 4 12.6 739.63  
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Appendix 7.9. Variant data for human complex I subunit genes  
 
Appendix 7.9A Subunit classification  
 
Subunit Encoding genome Subunit type Subunit Encoding genome Subunit type 
ND1 
Mitochondrial 
Core 
NDUFV3 
Nuclear Supernumerary 
ND2 NDUFS4 
ND3 NDUFS5 
ND4 NDUFS6 
ND4L NDUFA1 
ND5 NDUFA2 
ND6 NDUFA3 
NDUFV1 
Nuclear 
NDUFA5 
NDUFV2 NDUFA6 
NDUFS1 NDUFA7 
NDUFS2 NDUFA8 
NDUFS3 NDUFA9 
NDUFS7 NDUFA10 
NDUFS8 NDUFA11 
   NDUFA12 
   NDUFA13 
   NDUFAB1-α/β 
   NDUFB1 
   NDUFB2 
   NDUFB3 
   NDUFB4 
   NDUFB5 
   NDUFB6 
   NDUFB7 
   NDUFB8 
   NDUFB9 
   NDUFB10 
   NDUFB11 
   NDUFC1 
   NDUFC2 
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Appendix 7.9B Complete data for human complex I subunit gene variants. Residue number refers to the mature protein (distances from key residues in Appendix 7.9C).  
 
Residue 
number 
Identity Subunit Conservation Amino acid type Salt bridge 
Mutation 
class 
Residue 
change 
Polymorphism 
class 
Residue change 
Secondary 
structure 
Residue 
environ. 
289 LEU ND1 Fully Non-polar no 1 L-M 2 L-M, L-Q TMH Buried 
45 SER ND3 Not Polar non-charged no 1 S-P 2 S-A, S-Y, S-F Loop Interface 
340 ARG ND4 Fully Positively charged no 1 R-H, R-S 2 R-H Loop Buried 
64 MET ND6 Strongly Non-polar no 1 M-I, M-V 2 M-I, M-V TMH Interface 
52 ALA ND1 Fully Non-polar no 1 A-T 3 A-T Helix Surface 
110 SER ND1 Weakly Polar non-charged no 1 S-N 3 S-N TMH Interface 
132 ALA ND1 Strongly Non-polar no 1 A-T 3 A-T TMH Buried 
34 SER ND3 Not Polar non-charged no 1 S-P 3 
S-A, S-Y, S-T, 
S-C, S-F 
Loop Interface 
47 ALA ND3 Fully Non-polar no 1 A-T 3 A-T Loop Interface 
36 GLY ND6 Fully Non-polar no 1 G-S 3 G-S TMH Buried 
72 ALA ND6 Fully Non-polar no 1 A-V 3 A-P, A-V TMH Interface 
259 MET NDUFS2 Fully Non-polar no 1 M-T 3 M-T Loop Buried 
393 ALA NDUFS2 Fully Non-polar no 1 A-S 3 A-S Loop Buried 
24 GLU ND1 Fully Negatively charged yes 1 E-K   TMH Buried 
131 GLY ND1 Fully Non-polar no 1 G-S   TMH Buried 
143 GLU ND1 Fully Negatively charged no 1 E-K, E-Q   TMH Buried 
195 ARG ND1 Fully Positively charged no 1 R-Q   Loop Buried 
65 VAL ND4L Fully Non-polar no 1 V-A   TMH Interface 
124 PHE ND5 Fully Aromatic no 1 F-L   TMH Buried 
393 ASP ND5 Fully Negatively charged no 1 D-N, D-G   TMH Buried 
60 LEU ND6 Fully Non-polar no 1 L-S   TMH Interface 
63 MET ND6 Fully Non-polar no 1 M-V   TMH Buried 
8 GLY NDUFA1 Fully Non-polar no 1 G-R   TMH Interface 
37 ARG NDUFA1 Fully Positively charged yes 1 R-S   Loop Interface 
107 GLN NDUFA10 Fully Polar non-charged no 1 Q-R   Helix Buried 
286 ARG NDUFA9 Fully Positively charged yes 1 R-P   Helix Buried 
208 LEU NDUFS1 Fully Non-polar no 1 L-V   Beta sheet Buried 
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Residue 
number 
Identity Subunit Conservation Amino acid type Salt bridge 
Mutation 
class 
Residue 
change 
Polymorphism 
class 
Residue change 
Secondary 
structure 
Residue 
environ. 
218 ARG NDUFS1 Fully Positively charged no 1 R-W   Loop Interface 
229 ASP NDUFS1 Fully Negatively charged no 1 D-G   Loop Buried 
385 ARG NDUFS1 Fully Positively charged yes 1 R-C   Loop Buried 
572 THR NDUFS1 Fully Polar non-charged no 1 T-A   Beta sheet Buried 
596 ASP NDUFS1 Fully Negatively charged yes 1 D-N   Helix Buried 
195 ARG NDUFS2 Fully Positively charged no 1 R-Q   Loop Buried 
196 PRO NDUFS2 Fully Polar non-charged no 1 P-Q   Loop Buried 
380 SER NDUFS2 Fully Polar non-charged no 1 S-P   Beta sheet Buried 
109 THR NDUFS3 Fully Polar non-charged no 1 T-I   Beta sheet Buried 
163 ARG NDUFS3 Fully Positively charged yes 1 R-W   Loop Buried 
87 CYS NDUFS6 Fully Polar non-charged no 1 C-Y   Loop Buried 
84 VAL NDUFS7 Fully Non-polar no 1 V-M   Beta sheet Buried 
29 GLU NDUFS8 Fully Negatively charged yes 1 E-Q   Loop Interface 
43 ARG NDUFS8 Fully Positively charged no 1 R-W   Loop Interface 
45 PRO NDUFS8 Fully Polar non-charged no 1 P-L   Loop Interface 
51 PRO NDUFS8 Fully Polar non-charged no 1 P-L   Loop Interface 
68 ARG NDUFS8 Fully Positively charged no 1 R-H   Beta sheet Buried 
104 ARG NDUFS8 Fully Positively charged no 1 R-H   Loop Interface 
125 ALA NDUFS8 Fully Non-polar no 1 A-D   Helix Interface 
97 ALA NDUFV1 Weakly Non-polar no 1 A-T   Loop Buried 
102 PRO NDUFV1 Fully Polar non-charged no 1 P-L   Loop Interface 
186 CYS NDUFV1 Fully Polar non-charged no 1 C-G   Loop Buried 
403 THR NDUFV1 Fully Polar non-charged no 1 T-M   Loop Buried 
30 TYR ND1 Strongly Aromatic no 2 Y-H, Y-C 1 Y-H, Y-C, Y-S TMH Interface 
164 THR ND1 Not Polar non-charged no 2 T-A 1 T-A, T-S Helix Buried 
240 THR ND1 Not Polar non-charged no 2 T-M 1 T-A, T-S, T-M TMH Buried 
1 MET ND1 Fully Non-polar no 2 M-K 2 
M-T, M-L,  
M-K 
Loop Surface 
31 MET ND1 Not Non-polar no 2 
M-V, M-I, 
M-T 
2 M-T, M-V, M-I TMH Interface 
277 TYR ND1 Fully Aromatic no 2 Y-C 2 Y-C, Y-H Loop Interface 
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Residue 
number 
Identity Subunit Conservation Amino acid type Salt bridge 
Mutation 
class 
Residue 
change 
Polymorphism 
class 
Residue change 
Secondary 
structure 
Residue 
environ. 
57 ILE ND2 Not Non-polar no 2 I-M 2 I-M, I-V, I-T TMH Interface 
60 ILE ND3 Fully Non-polar no 2 I-T 2 I-M, I-T TMH Interface 
109 THR ND4 Strongly Polar non-charged no 2 T-A 2 T-A TMH Buried 
165 ILE ND4 Not Non-polar no 2 I-T 2 I-T, I-V TMH Interface 
313 VAL ND4 Not Non-polar no 2 V-I 2 V-I TMH Buried 
1 MET ND5 Not Non-polar no 2 M-T 2 M-T, M-V Loop Surface 
159 TYR ND5 Weakly Aromatic no 2 Y-H 2 Y-H Loop Interface 
434 GLN ND5 Not Polar non-charged no 2 Q-R 2 Q-R Loop Interface 
132 SER ND6 Not Polar non-charged no 2 S-A 2 
S-A, S-L,  
S-W, S-P, S-T 
Loop Surface 
290 ARG NDUFS2 Strongly Positively charged yes 2 R-Q 2 R-Q, R-G Loop Surface 
28 LEU ND1 Fully Non-polar no 2 L-M 3 L-M TMH Buried 
215 TYR ND1 Fully Aromatic no 2 Y-H 3 Y-H, Y-N Loop Buried 
409 TYR ND4 Strongly Aromatic no 2 Y-H 3 Y-H TMH Buried 
236 ALA ND5 Fully Non-polar no 2 A-T 3 A-T, A-V TMH Buried 
26 ILE ND6 Strongly Non-polar no 2 I-M, I-T 3 I-V TMH Interface 
117 ASN ND6 Weakly Polar non-charged no 2 N-D 3 N-D, N-S Loop Buried 
21 TRP NDUFB3 Fully Aromatic no 2 L-P 3 W-R Loop Buried 
179 ARG NDUFV1 Fully Positively charged no 2 R-C 3 R-C, R-H Beta sheet Interface 
366 ARG NDUFV1 Not Positively charged no 2 R-C, R-H 3 R-C, R-H Loop Interface 
59 GLU ND1 Fully Negatively charged yes 2 E-K   Loop Interface 
208 VAL ND1 Fully Non-polar no 2 V-L   Loop Interface 
214 GLU ND1 Fully Negatively charged no 2 E-K   Loop Interface 
285 LEU ND1 Fully Non-polar no 2 L-P   TMH Buried 
71 LEU ND2 Strongly Non-polar no 2 L-M   TMH Buried 
259 GLY ND2 Fully Non-polar no 2 G-S   Loop Buried 
26 GLN ND3 Fully Polar non-charged no 2 Q-K   Loop Surface 
66 ASP ND3 Fully Negatively charged no 2 D-N   TMH Interface 
32 CYS ND4L Fully Polar non-charged no 2 C-R   TMH Buried 
145 GLU ND5 Fully Negatively charged yes 2 E-G   TMH Interface 
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171 ALA ND5 Fully Non-polar no 2 A-V   TMH Buried 
237 MET ND5 Fully Non-polar no 2 M-L   Loop Buried 
250 SER ND5 Fully Polar non-charged no 2 S-C   TMH Buried 
465 GLY ND5 Fully Non-polar no 2 G-E   TMH Buried 
59 TYR ND6 Fully Aromatic no 2 Y-C   TMH Interface 
74 ALA ND6 Fully Non-polar no 2 A-V   Loop Surface 
19 PRO NDUFA1 Fully Polar non-charged no 2 P-S   TMH Interface 
64 GLY NDUFA10 Fully Non-polar no 2 G-E   Loop Interface 
259 LEU NDUFA10 Strongly Non-polar no 2 L-P   Helix Buried 
56 ARG NDUFA13 Fully Positively charged no 2 R-H   TMH Interface 
44 LYS NDUFA2 Not Positively charged no 2 K-T   Helix Surface 
108 GLU NDUFA8 Weakly Negatively charged no 2 E-K   Helix Surface 
92 GLU NDUFB11 Fully Negatively charged yes 2 E-K   Helix Buried 
63 LEU NDUFB9 Fully Non-polar no 2 Y-C   Helix Buried 
96 TYR NDUFB9 Fully Aromatic no 2 V-D   Loop Interface 
48 VAL NDUFS1 Strongly Non-polar no 2 G-E   Loop Interface 
143 GLY NDUFS1 Fully Non-polar no 2 V-A   Loop Surface 
205 VAL NDUFS1 Fully Non-polar no 2 V-A   Loop Buried 
499 GLN NDUFS1 Fully Polar non-charged no 2 Y-C   Helix Buried 
672 TYR NDUFS1 Fully Aromatic no 2 M-V   Loop Buried 
684 MET NDUFS1 Fully Non-polar no 2 Y-C   Helix Buried 
77 ASP NDUFS2 Fully Negatively charged no 2 D-V   Beta sheet Buried 
85 ARG NDUFS2 Fully Positively charged no 2 R-Q   Loop Interface 
105 ARG NDUFS2 Fully Positively charged no 2 R-Q   Helix Interface 
115 GLU NDUFS2 Fully Negatively charged no 2 E-K   Helix Buried 
191 ALA NDUFS2 Fully Non-polar no 2 A-V   Loop Buried 
300 ARG NDUFS2 Fully Positively charged yes 2 R-Q   Helix Buried 
410 MET NDUFS2 Fully Non-polar no 2 M-K   Loop Interface 
413 ASP NDUFS2 Fully Negatively charged yes 2 D-N   Helix Buried 
187 PRO NDUFS3 Fully Polar non-charged no 2 P-L   Beta sheet Surface 
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72 TRP NDUFS4 Fully Aromatic no 2 W-R   Loop Interface 
77 ASP NDUFS4 Fully Negatively charged yes 2 D-H   Loop Buried 
95 PRO NDUFS5 Not Polar non-charged no 2 P-S   Loop Surface 
67 ARG NDUFS7 Fully Positively charged no 2 R-C   Loop Interface 
107 ARG NDUFS7 Not Positively charged no 2 R-H   Loop Buried 
20 ARG NDUFS8 Not Positively charged yes 2 R-W   Helix Surface 
60 ARG NDUFS8 Fully Positively charged no 2 R-C   Loop Interface 
120 GLY NDUFS8 Fully Non-polar no 2 G-S   Loop Buried 
36 SER NDUFV1 Strongly Polar non-charged no 2 S-P   Helix Buried 
68 ARG NDUFV1 Fully Positively charged no 2 R-G   Loop Buried 
91 LYS NDUFV1 Not Positively charged no 2 K-E   Loop Buried 
127 ARG NDUFV1 Strongly Positively charged no 2 R-W   Helix Surface 
184 TYR NDUFV1 Fully Aromatic no 2 Y-C   Loop Buried 
191 ALA NDUFV1 Fully Non-polar no 2 A-V   Helix Buried 
226 GLU NDUFV1 Fully Negatively charged yes 2 E-K   Helix Buried 
232 PRO NDUFV1 Fully Polar non-charged no 2 P-L   Helix Buried 
321 ALA NDUFV1 Weakly Non-polar no 2 A-V   Loop Buried 
357 GLU NDUFV1 Not Negatively charged no 2 E-K   Helix Buried 
358 SER NDUFV1 Not Polar non-charged no 2 S-R   Loop Buried 
412 ALA NDUFV1 Fully Non-polar no 2 A-P   Helix Buried 
177 LYS NDUFV2 Strongly Positively charged yes 2 K-R   Helix Surface 
4 ALA ND1 Not Non-polar no 3 A-T 1 A-T, A-V TMH Surface 
304 TYR ND1 Not Aromatic no 3 Y-H 1 Y-H TMH Buried 
150 ASN ND2 Strongly Polar non-charged no 3 N-D 1 N-D, N-S Loop Buried 
331 ALA ND2 Not Non-polar no 3 A-T, A-S 1 
A-T, A-S, A-G, 
A-V 
TMH Interface 
458 ALA ND5 Not Non-polar no 3 A-T 1 A-T TMH Buried 
544 THR ND5 Not Polar non-charged no 3 T-M 1 T-A, T-M Helix Surface 
119 ASN ND6 Not Polar non-charged no 3 N-D 1 N-D, N-S Loop Surface 
11 VAL ND1 Strongly Non-polar no 3 V-A 2 
V-A, V-M, V-L, 
V-E 
TMH Surface 
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39 VAL ND1 Strongly Non-polar no 3 V-I 2 V-G, V-I Loop Surface 
64 ALA ND1 Not Non-polar no 3 A-S, A-V 2 A-S, A-T, A-V Loop Surface 
113 VAL ND1 Fully Non-polar no 3 V-A 2 V-A, V-G TMH Buried 
144 VAL ND1 Strongly Non-polar no 3 V-I 2 V-I TMH Interface 
147 ALA ND1 Strongly Non-polar no 3 A-L 2 A-L, A-T TMH Interface 
187 ILE ND1 Not Non-polar no 3 I-T 2 I-S, I-T, I-V TMH Buried 
64 ALA ND2 Strongly Non-polar no 3 A-T 2 A-S, A-T TMH Buried 
122 THR ND2 Not Polar non-charged no 3 T-A 2 T-A, T-I Loop Buried 
10 ASN ND3 Weakly Polar non-charged no 3 N-D 2 N-D TMH Interface 
423 ILE ND4 Not Non-polar no 3 I-V, I-T 2 I-V, I-T Loop Buried 
9 THR ND5 Not Polar non-charged no 3 T-A 2 T-A, T-I TMH Buried 
21 THR ND5 Not Polar non-charged no 3 T-A 2 T-A, T-I TMH Buried 
100 ILE ND5 Fully Non-polar no 3 I-V 2 I-T, I-V TMH Buried 
267 ALA ND5 Not Non-polar no 3 A-T 2 A-T Loop Buried 
398 THR ND5 Strongly Polar non-charged no 3 T-A 2 T-A, T-S TMH Buried 
576 ILE ND5 Not Non-polar no 3 I-T 2 I-T, I-V Helix Surface 
33 ILE ND6 Weakly Non-polar no 3 I-V 2 I-L, I-V, I-F TMH Interface 
58 ILE ND6 Strongly Non-polar no 3 I-T 2 I-T, I-V TMH Interface 
171 ALA ND6 Not Non-polar no 3 A-T 2 A-T, A-V TMH Interface 
32 GLY NDUFA1 Not Non-polar no 3 G-R 2 G-R Loop Surface 
103 ARG NDUFA11 Not Positively charged no 3 R-L 2 R-H, R-L TMH Surface 
40 ARG NDUFA9 Strongly Positively charged no 3 R-H, R-L 2 R-H, R-L, R-C Helix Interface 
408 LEU NDUFS1 Strongly Non-polar no 3 L-V 2 L-V Beta sheet Buried 
2 PRO ND1 Not Polar non-charged no 3 P-L 3 P-L, P-S TMH Surface 
56 PHE ND1 Fully Aromatic no 3 F-L 3 F-L, F-S Helix Surface 
128 ALA ND1 Strongly Non-polar no 3 A-T 3 A-P, A-T TMH Buried 
176 LEU ND1 Strongly Non-polar no 3 L-M 3 L-M Loop Surface 
230 ASN ND1 Fully Polar non-charged no 3 N-S 3 
N-D, N-H, N-T, 
N-S 
TMH Buried 
276 ALA ND1 Strongly Non-polar no 3 A-T 3 A-T Loop Interface 
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328 THR ND2 Not Polar non-charged no 3 T-M 3 T-A, T-P, T-M TMH Interface 
71 ALA ND4L Not Non-polar no 3 A-T 3 A-T TMH Buried 
99 SER ND5 Fully Polar non-charged no 3 S-T 3 S-A TMH Buried 
149 ILE ND5 Fully Non-polar no 3 I-S 3 I-T, I-V TMH Interface 
112 VAL ND6 Not Non-polar no 3 V-M 3 V-M Loop Surface 
100 LEU NDUFA10 Fully Non-polar no 3 L-S 3 L-S Helix Buried 
251 GLN NDUFA10 Fully Polar non-charged no 3 Q-E 3 Q-E Loop Surface 
50 ARG NDUFA9 Fully Positively charged no 3 R-W 3 R-W Loop Surface 
279 ILE NDUFA9 Not Non-polar no 3 I-M 3 I-M Loop Buried 
157 ARG NDUFB9 Fully Positively charged yes 3 R-G 3 R-G Loop Surface 
154 ILE NDUFS1 Fully Non-polar no 3 I-M 3 I-M, I-V Loop Buried 
181 MET NDUFS1 Fully Non-polar no 3 M-I 3 M-I, M-T Loop Buried 
483 VAL NDUFS1 Weakly Non-polar no 3 V-I 3 V-G, V-I Loop Surface 
511 VAL NDUFS1 Fully Non-polar no 3 V-M 3 V-M Loop Buried 
287 VAL NDUFS2 Strongly Non-polar no 3 V-A 3 V-A Loop Interface 
347 HIS NDUFS2 Fully Positively charged no 3 H-D 3 H-D Helix Buried 
210 ARG NDUFS3 Fully Positively charged no 3 R-C 3 R-C Loop Interface 
58 ALA NDUFS6 Strongly Non-polar no 3 A-V 3 A-V Beta sheet Surface 
60 ASP NDUFS6 Fully Negatively charged no 3 D-N 3 D-N Beta sheet Surface 
167 ARG NDUFS7 Not Positively charged no 3 R-G 3 R-G, R-W, R-Q Loop Surface 
133 ALA NDUFV1 Not Non-polar no 3 A-T 3 A-T Beta sheet Buried 
337 MET NDUFV1 Fully Non-polar no 3 M-L 3 M-L, M-T Beta sheet Buried 
12 PRO ND1 Not Polar non-charged no 3 P-S   TMH Interface 
25 ARG ND1 Fully Positively charged yes 3 R-Q   TMH Buried 
34 ARG ND1 Fully Positively charged yes 3 R-H   Loop Interface 
38 ASN ND1 Fully Polar non-charged no 3 N-D   Loop Interface 
218 GLY ND1 Fully Non-polar no 3 G-D   TMH Buried 
279 ARG ND1 Fully Positively charged no 3 R-Q   Loop Interface 
55 ALA ND2 Strongly Non-polar no 3 A-G   TMH Buried 
60 PHE ND2 Fully Aromatic no 3 F-S   TMH Interface 
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128 LEU ND2 Strongly Non-polar no 3 L-Q   TMH Buried 
158 LEU ND4 Strongly Non-polar no 3 L-P   TMH Interface 
206 LYS ND4 Fully Positively charged no 3 K-Q   TMH Buried 
372 THR ND4 Not Polar non-charged no 3 T-N   Loop Buried 
387 SER ND4 Strongly Polar non-charged no 3 S-F   TMH Interface 
412 THR ND4 Not Polar non-charged no 3 T-I   TMH Interface 
25 HIS ND4L Fully Positively charged no 3 H-R   Loop Buried 
41 PHE ND4L Fully Aromatic no 3 F-C   TMH Interface 
96 VAL ND5 Not Non-polar no 3 V-I   TMH Buried 
239 GLY ND5 Fully Non-polar no 3 G-S   Loop Buried 
243 VAL ND5 Fully Non-polar no 3 V-I   TMH Buried 
253 VAL ND5 Fully Non-polar no 3 V-A   TMH Buried 
312 LEU ND5 Fully Non-polar no 3 L-P   TMH Buried 
348 HIS ND5 Fully Positively charged no 3 N-S   TMH Buried 
392 LYS ND5 Fully Positively charged no 3 K-M   TMH Buried 
415 ALA ND5 Strongly Non-polar no 3 A-G   TMH Buried 
499 LEU ND5 Not Non-polar no 3 L-M   TMH Surface 
505 ASN ND5 Not Polar non-charged no 3 N-H   TMH Surface 
585 LYS ND5 Fully Positively charged no 3 K-N   TMH Surface 
25 PRO ND6 Fully Polar non-charged no 3 P-L   TMH Interface 
79 PRO ND6 Fully Polar non-charged no 3 P-S   Loop Interface 
82 TRP ND6 Fully Aromatic no 3 W-R   Loop Surface 
101 GLY ND6 Not Non-polar no 3 G-V   TMH Buried 
43 TYR NDUFA1 Not Aromatic no 3 Y-H   Helix Interface 
173 ASP NDUFA10 Fully Negatively charged no 3 D-N   Beta sheet Surface 
176 VAL NDUFA10 Fully Non-polar no 3 V-I   Helix Buried 
9 TRP NDUFA11 Not Aromatic no 3 W-C   Loop Surface 
77 ALA NDUFA11 Not Non-polar no 3 A-T   TMH Buried 
81 GLU NDUFA11 Not Negatively charged no 3 E-G   Loop Surface 
68 TYR NDUFA2 Not Aromatic no 3 Y-C   Loop Buried 
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26 ALA NDUFA9 Fully Non-polar no 3 A-V   Loop Buried 
33 TYR NDUFA9 Fully Aromatic no 3 Y-C   Helix Buried 
287 MET NDUFA9 Strongly Non-polar no 3 M-T   Helix Buried 
303 LEU NDUFA9 Strongly Non-polar no 3 L-F   Loop Buried 
60 THR NDUFB9 Fully Polar non-charged no 3 T-S   Helix Interface 
39 ARG NDUFS1 Fully Positively charged no 3 R-Q   Loop Buried 
230 VAL NDUFS1 Fully Non-polar no 3 V-G   Loop Buried 
286 ASN NDUFS1 Fully Polar non-charged no 3 N-S   Loop Surface 
432 ILE NDUFS1 Strongly Non-polar no 3 I-V   Helix Buried 
452 VAL NDUFS1 Strongly Non-polar no 3 V-F   Beta sheet Buried 
543 ILE NDUFS1 Fully Non-polar no 3 I-F   Beta sheet Buried 
553 GLY NDUFS1 Fully Non-polar no 3 G-E   Helix Buried 
577 GLU NDUFS1 Fully Negatively charged no 3 E-D   Loop Buried 
680 ALA NDUFS1 Fully Non-polar no 3 A-T   Helix Buried 
20 TYR NDUFS2 Fully Aromatic no 3 Y-C   Loop Interface 
376 VAL NDUFS2 Fully Non-polar no 3 V-M   Beta sheet Buried 
42 ARG NDUFS4 Fully Positively charged no 3 R-H   Loop Surface 
49 VAL NDUFS6 Fully Non-polar no 3 V-M   Loop Surface 
55 ARG NDUFS6 Fully Positively charged yes 3 R-W   Loop Surface 
74 ASN NDUFS6 Fully Polar non-charged no 3 N-I   Beta sheet Interface 
77 ARG NDUFS7 Strongly Positively charged no 3 R-C   Loop Interface 
81 VAL NDUFS7 Not Non-polar no 3 V-I   Beta sheet Buried 
71 PRO NDUFS8 Fully Polar non-charged no 3 P-S   Loop Surface 
81 LYS NDUFS8 Fully Positively charged no 3 K-E   Loop Interface 
109 TYR NDUFS8 Fully Aromatic no 3 Y-F   Beta sheet Buried 
127 PRO NDUFS8 Fully Polar non-charged no 3 P-T   Loop Interface 
170 GLN NDUFS8 Fully Polar non-charged no 3 Q-L   Helix Surface 
19 ASP NDUFV1 Fully Negatively charged yes 3 D-G   Loop Buried 
75 THR NDUFV1 Fully Polar non-charged no 3 T-A   Helix Buried 
131 ALA NDUFV1 Not Non-polar no 3 A-T   Loop Buried 
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140 GLY NDUFV1 Weakly Non-polar no 3 G-E   Loop Buried 
247 ARG NDUFV1 Fully Positively charged no 3 R-K   Loop Surface 
263 ASN NDUFV1 Fully Polar non-charged no 3 N-S   Loop Surface 
297 VAL NDUFV1 Fully Non-polar no 3 V-A   Beta sheet Buried 
348 ALA NDUFV1 Not Non-polar no 3 A-T   Helix Buried 
153 MET NDUFV2 Fully Non-polar no 3 M-V   Beta sheet Buried 
158 ASP NDUFV2 Fully Negatively charged yes 3 D-G   Loop Interface 
67 THR ND1 Strongly Polar non-charged no   1 T-A, T-I Loop Buried 
81 ILE ND1 Strongly Non-polar no   1 I-L, I-V, I-T TMH Buried 
309 ILE ND1 Not Non-polar no   1 I-T, I-V TMH Interface 
8 VAL ND2 Not Non-polar no   1 V-G, V-I TMH Interface 
119 THR ND2 Not Polar non-charged no   1 T-A TMH Buried 
193 VAL ND2 Not Non-polar no   1 V-I TMH Buried 
237 LEU ND2 Not Non-polar no   1 L-M Loop Interface 
325 PHE ND2 Not Aromatic no   1 F-L TMH Surface 
88 VAL ND3 Not Non-polar no   1 V-A, V-I TMH Interface 
114 THR ND3 Not Polar non-charged no   1 T-A, T-S, T-I Loop Surface 
140 PRO ND4 Not Polar non-charged no   1 P-S, P-T Loop Surface 
404 ALA ND4 Weakly Non-polar no   1 A-T, A-V TMH Buried 
47 MET ND4L Not Non-polar no   1 M-I, M-T TMH Interface 
8 THR ND5 Not Polar non-charged no   1 T-A TMH Buried 
24 VAL ND5 Not Non-polar no   1 V-I Loop Surface 
257 ILE ND5 Strongly Non-polar no   1 I-V TMH Buried 
314 MET ND5 Strongly Non-polar no   1 M-V TMH Buried 
475 ALA ND5 Not Non-polar no   1 A-T Loop Surface 
482 ILE ND5 Not Non-polar no   1 
I-L, I-V,  
I-T, I-M 
Loop Buried 
485 TYR ND5 Not Aromatic no   1 Y-C, Y-H Loop Surface 
515 SER ND5 Not Polar non-charged no   1 
S-F, S-T,  
S-P, S-Y 
Loop Surface 
531 SER ND5 Not Polar non-charged no   1 
S-C, S-N,  
S-T, S-I 
Helix Buried 
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533 THR ND5 Not Polar non-charged no   1 T-A, T-M Helix Surface 
555 LEU ND5 Not Non-polar no   1 L-Q Helix Interface 
166 ILE ND6 Strongly Non-polar no   1 I-M, I-V TMH Interface 
47 LYS NDUFA7 Strongly Positively charged no   1 K-Q Loop Surface 
259 PRO NDUFA9 Fully Polar non-charged no   1 P-L Loop Surface 
145 PRO NDUFB9 Not Polar non-charged no   1 P-S Loop Surface 
46 LEU NDUFC2 Not Non-polar no   1 L-V TMH Surface 
319 PRO NDUFS2 Fully Polar non-charged no   1 P-A, P-L Loop Surface 
102 VAL NDUFV2 Strongly Non-polar no   1 V-A Beta sheet Buried 
10 ILE ND1 Not Non-polar no   2 I-T, I-V, I-N TMH Buried 
29 GLY ND1 Fully Non-polar no   2 G-A, G-S, G-D TMH Buried 
43 TYR ND1 Not Aromatic no   2 Y-C, Y-H Loop Surface 
69 THR ND1 Not Polar non-charged no   2 T-A, T-S TMH Surface 
73 THR ND1 Not Polar non-charged no   2 T-A, T-S TMH Surface 
87 THR ND1 Not Polar non-charged no   2 T-A TMH Buried 
89 LEU ND1 Strongly Non-polar no   2 L-F Loop Buried 
229 THR ND1 Not Polar non-charged no   2 T-A, T-M TMH Buried 
236 THR ND1 Not Polar non-charged no   2 T-A, T-S, T-I TMH Buried 
248 ASP ND1 Not Negatively charged no   2 D-N Loop Surface 
263 THR ND1 Strongly Polar non-charged no   2 T-A, T-I TMH Buried 
275 THR ND1 Strongly Polar non-charged no   2 T-A Loop Interface 
307 MET ND1 Fully Non-polar no   2 M-T, M-V TMH Buried 
13 ILE ND2 Strongly Non-polar no   2 I-V TMH Buried 
31 VAL ND2 Not Non-polar no   2 V-A, V-M, V-G TMH Interface 
43 VAL ND2 Strongly Non-polar no   2 V-I TMH Buried 
76 PHE ND2 Not Aromatic no   2 F-L, F-S TMH Buried 
80 LEU ND2 Not Non-polar no   2 L-F, L-I Loop Surface 
88 ASN ND2 Not Polar non-charged no   2 N-S Loop Interface 
89 THR ND2 Not Polar non-charged no   2 T-A, T-N Loop Buried 
100 MET ND2 Not Non-polar no   2 M-I, M-V, M-T TMH Buried 
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152 SER ND2 Not Polar non-charged no   2 S-G, S-N, S-T TMH Interface 
164 ALA ND2 Not Non-polar no   2 A-T, A-V TMH Buried 
202 ILE ND2 Strongly Non-polar no   2 I-T, I-V TMH Buried 
203 LEU ND2 Strongly Non-polar no   2 L-F TMH Buried 
265 ALA ND2 Not Non-polar no   2 A-T, A-V TMH Buried 
270 PHE ND2 Strongly Aromatic no   2 F-L TMH Buried 
278 ILE ND2 Not Non-polar no   2 I-L, I-V, I-T TMH Buried 
284 THR ND2 Not Polar non-charged no   2 T-A, T-S, T-I TMH Surface 
288 LEU ND2 Strongly Non-polar no   2 L-I TMH Buried 
323 THR ND2 Not Polar non-charged no   2 T-A, T-P, T-I Loop Surface 
342 PHE ND2 Not Aromatic no   2 F-C, F-L TMH Interface 
9 ILE ND3 Not Non-polar no   2 I-T, I-V TMH Interface 
29 GLY ND3 Not Non-polar no   2 G-S Loop Surface 
49 VAL ND3 Strongly Non-polar no   2 V-I Loop Surface 
96 ILE ND3 Not Non-polar no   2 
I-V, I-L,  
I-T, I-M 
TMH Surface 
103 ALA ND3 Strongly Non-polar no   2 A-T, A-V TMH Surface 
47 ASN ND4 Not Polar non-charged no   2 N-S Loop Buried 
50 PHE ND4 Not Aromatic no   2 F-L, F-S Beta sheet Buried 
54 PRO ND4 Not Polar non-charged no   2 P-L Loop Surface 
86 SER ND4 Not Polar non-charged no   2 S-G, S-N Loop Surface 
89 LEU ND4 Not Non-polar no   2 L-P TMH Surface 
101 SER ND4 Not Polar non-charged no   2 S-C, S-F TMH Surface 
110 PHE ND4 Fully Aromatic no   2 F-L, F-S TMH Buried 
131 ALA ND4 Not Non-polar no   2 A-T, A-V TMH Buried 
138 ASN ND4 Not Polar non-charged no   2 N-S Loop Surface 
149 PHE ND4 Fully Aromatic no   2 F-L TMH Buried 
230 VAL ND4 Strongly Non-polar no   2 V-L, V-M TMH Buried 
299 THR ND4 Not Polar non-charged no   2 T-A, T-M TMH Buried 
390 ASN ND4 Weakly Polar non-charged no   2 N-S Loop Surface 
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402 VAL ND4 Strongly Non-polar no   2 V-I, V-L TMH Buried 
424 ASN ND4 Not Polar non-charged no   2 N-S, N-K Loop Interface 
442 SER ND4 Not Polar non-charged no   2 S-A, S-F TMH Buried 
445 LEU ND4 Strongly Non-polar no   2 L-F, L-I TMH Surface 
459 SER ND4 Not Polar non-charged no   2 
S-F, S-T,  
S-P, S-Y 
Loop Interface 
13 THR ND4L Not Polar non-charged no   2 T-A, T-P TMH Surface 
62 ALA ND4L Not Non-polar no   2 A-P, A-T, A-V TMH Interface 
94 ASN ND4L Fully Polar non-charged no   2 N-S Loop Surface 
4 HIS ND5 Not Positively charged no   2 H-Y TMH Buried 
13 THR ND5 Not Polar non-charged no   2 T-A TMH Surface 
22 THR ND5 Not Polar non-charged no   2 T-A, T-I TMH Surface 
23 LEU ND5 Not Non-polar no   2 L-F TMH Surface 
52 THR ND5 Not Polar non-charged no   2 T-C, T-M Loop Buried 
69 ALA ND5 Not Non-polar no   2 A-T, A-V Loop Interface 
74 THR ND5 Not Polar non-charged no   2 T-A, T-I Loop Buried 
182 PHE ND5 Strongly Aromatic no   2 F-L TMH Buried 
190 ILE ND5 Not Non-polar no   2 
I-M, I-V,  
I-S 
TMH Interface 
201 MET ND5 Strongly Non-polar no   2 M-V Loop Buried 
202 ALA ND5 Not Non-polar no   2 A-T, A-V Loop Interface 
205 ASN ND5 Not Polar non-charged no   2 N-S, N-T Loop Buried 
261 ILE ND5 Strongly Non-polar no   2 I-V TMH Buried 
265 PRO ND5 Not Polar non-charged no   2 P-H, P-S Loop Surface 
270 SER ND5 Weakly Polar non-charged no   2 
S-C, S-N,  
S-T 
Loop Surface 
283 ILE ND5 Strongly Non-polar no   2 
I-T, I-V,  
I-M 
TMH Buried 
410 SER ND5 Not Polar non-charged no   2 
S-A, S-P,  
S-F 
TMH Surface 
432 THR ND5 Not Polar non-charged no   2 T-A Loop Buried 
439 THR ND5 Not Polar non-charged no   2 T-A, T-P Loop Interface 
449 THR ND5 Not Polar non-charged no   2 T-A TMH Surface 
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459 ALA ND5 Not Non-polar no   2 A-T, A-V TMH Surface 
469 THR ND5 Strongly Polar non-charged no   2 T-A, T-I TMH Surface 
471 ASN ND5 Not Polar non-charged no   2 N-S, N-T TMH Surface 
478 PHE ND5 Not Aromatic no   2 F-I, F-L Loop Surface 
489 THR ND5 Not Polar non-charged no   2 T-A, T-M TMH Surface 
495 PHE ND5 Not Aromatic no   2 F-L, F-S TMH Surface 
518 CYS ND5 Not Polar non-charged no   2 C-R, C-Y, C-S Helix Surface 
530 PRO ND5 Not Polar non-charged no   2 P-S Helix Surface 
536 THR ND5 Not Polar non-charged no   2 T-A, T-M Helix Buried 
538 PRO ND5 Not Polar non-charged no   2 P-S Helix Surface 
541 GLY ND5 Not Non-polar no   2 G-A Helix Surface 
549 PRO ND5 Not Polar non-charged no   2 P-S Helix Interface 
556 THR ND5 Not Polar non-charged no   2 T-A, T-I Helix Interface 
573 THR ND5 Not Polar non-charged no   2 T-A Helix Interface 
575 ILE ND5 Not Non-polar no   2 
I-M, I-V,  
I-T 
Helix Surface 
592 PHE ND5 Strongly Aromatic no   2 F-L TMH Surface 
598 THR ND5 Not Polar non-charged no   2 T-A, T-I TMH Interface 
14 MET ND6 Not Non-polar no   2 M-L, M-V TMH Surface 
31 VAL ND6 Not Non-polar no   2 V-A TMH Buried 
41 VAL ND6 Not Non-polar no   2 V-A, V-I TMH Surface 
86 VAL ND6 Not Non-polar no   2 V-A Loop Surface 
97 ALA ND6 Not Non-polar no   2 A-P, A-V, A-S TMH Surface 
120 SER ND6 Not Polar non-charged no   2 S-G, S-M, S-N Loop Buried 
139 PRO ND6 Not Polar non-charged no   2 P-L, P-S Helix Interface 
156 THR ND6 Not Polar non-charged no   2 T-A, T-I TMH Interface 
159 THR ND6 Not Polar non-charged no   2 T-A, T-M, T-P TMH Interface 
165 TYR ND6 Not Aromatic no   2 Y-H, Y-C, Y-S TMH Interface 
30 ASN NDUFA10 Fully Polar non-charged no   2 N-S Beta sheet Buried 
13 LEU NDUFA2 Not Non-polar no   2 L-V Loop Surface 
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20 VAL NDUFA3 Weakly Non-polar no   2 V-L TMH Surface 
107 HIS NDUFA6 Fully Positively charged no   2 H-Y, H-Q Loop Surface 
65 PRO NDUFA7 Fully Polar non-charged no   2 P-A Loop Interface 
18 MET NDUFB1 Not Non-polar no   2 M-L TMH Surface 
141 ALA NDUFB10 Weakly Non-polar no   2 A-V, A-T Loop Interface 
52 PRO NDUFB2 Not Polar non-charged no   2 P-L Loop Surface 
62 LEU NDUFB7 Fully Non-polar no   2 L-V Helix Buried 
96 SER NDUFB8 Weakly Polar non-charged no   2 S-T Loop Interface 
120 VAL NDUFB8 Not Non-polar no   2 V-M TMH Surface 
8 VAL NDUFV2 Fully Non-polar no   2 V-M Loop Interface 
5 ASN ND1 Fully Polar non-charged no   3 N-D TMH Interface 
15 ILE ND1 Not Non-polar no   3 I-T, I-V, I-M TMH Surface 
17 MET ND1 Strongly Non-polar no   3 M-V, M-I TMH Buried 
21 MET ND1 Not Non-polar no   3 M-T, M-V TMH Buried 
27 ILE ND1 Strongly Non-polar no   3 
I-F, I-V,  
I-T, I-M 
TMH Buried 
68 ILE ND1 Not Non-polar no   3 I-M, I-V, I-T TMH Surface 
76 THR ND1 Not Polar non-charged no   3 T-I TMH Interface 
77 LEU ND1 Strongly Non-polar no   3 L-M TMH Surface 
96 VAL ND1 Strongly Non-polar no   3 V-A, V-I Loop Interface 
112 ALA ND1 Not Non-polar no   3 A-T TMH Surface 
116 ILE ND1 Fully Non-polar no   3 I-N, I-V TMH Buried 
139 THR ND1 Fully Polar non-charged no   3 T-A TMH Buried 
152 SER ND1 Fully Polar non-charged no   3 S-A TMH Buried 
153 THR ND1 Not Polar non-charged no   3 T-A, T-M TMH Buried 
168 THR ND1 Fully Polar non-charged no   3 T-A Helix Interface 
171 HIS ND1 Not Positively charged no   3 H-Y Loop Surface 
196 THR ND1 Strongly Polar non-charged no   3 T-A Loop Buried 
213 ILE ND1 Not Non-polar no   3 I-M, I-V, I-T Loop Interface 
239 THR ND1 Not Polar non-charged no   3 T-A, T-S TMH Buried 
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241 ILE ND1 Strongly Non-polar no   3 I-M TMH Buried 
249 ALA ND1 Not Non-polar no   3 A-V Loop Surface 
258 TYR ND1 Not Aromatic no   3 Y-C TMH Surface 
260 VAL ND1 Not Non-polar no   3 V-I TMH Interface 
265 LEU ND1 Not Non-polar no   3 L-F TMH Surface 
266 LEU ND1 Strongly Non-polar no   3 L-M TMH Buried 
268 SER ND1 Not Polar non-charged no   3 S-F TMH Surface 
273 ILE ND1 Strongly Non-polar no   3 I-V TMH Buried 
292 ASN ND1 Weakly Polar non-charged no   3 N-D, N-S TMH Surface 
300 LEU ND1 Not Non-polar no   3 L-S TMH Buried 
305 VAL ND1 Strongly Non-polar no   3 V-I TMH Interface 
310 THR ND1 Not Polar non-charged no   3 T-A, T-S Loop Interface 
313 SER ND1 Strongly Polar non-charged no   3 S-G Loop Interface 
318 THR ND1 Not Polar non-charged no   3 T-A, T-I Loop Surface 
11 SER ND2 Not Polar non-charged no   3 S-F, S-T, S-P TMH Surface 
15 ALA ND2 Not Non-polar no   3 A-T TMH Buried 
19 ILE ND2 Strongly Non-polar no   3 I-T TMH Buried 
48 MET ND2 Not Non-polar no   3 M-T Loop Surface 
49 ASN ND2 Not Polar non-charged no   3 N-S Loop Buried 
62 THR ND2 Not Polar non-charged no   3 T-M TMH Buried 
69 ILE ND2 Strongly Non-polar no   3 I-V TMH Buried 
78 ASN ND2 Not Polar non-charged no   3 N-S TMH Interface 
79 MET ND2 Not Non-polar no   3 M-L, M-V, M-T TMH Interface 
81 SER ND2 Not Polar non-charged no   3 S-F, S-T Loop Interface 
85 THR ND2 Not Polar non-charged no   3 T-A Loop Interface 
94 SER ND2 Not Polar non-charged no   3 S-P TMH Buried 
98 ILE ND2 Not Non-polar no   3 I-M TMH Buried 
115 VAL ND2 Strongly Non-polar no   3 V-A, V-I, V-L TMH Buried 
125 THR ND2 Not Polar non-charged no   3 T-M, T-S TMH Surface 
139 ILE ND2 Not Non-polar no   3 I-L TMH Buried 
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141 ILE ND2 Strongly Non-polar no   3 I-V TMH Buried 
145 ILE ND2 Not Non-polar no   3 I-L, I-M TMH Buried 
147 PRO ND2 Not Polar non-charged no   3 P-S Loop Surface 
148 SER ND2 Not Polar non-charged no   3 S-A Loop Surface 
156 THR ND2 Not Polar non-charged no   3 T-I, T-S TMH Surface 
159 ILE ND2 Not Non-polar no   3 I-V TMH Buried 
166 SER ND2 Weakly Polar non-charged no   3 S-G, S-N TMH Buried 
187 MET ND2 Strongly Non-polar no   3 M-T, M-V TMH Buried 
200 MET ND2 Not Non-polar no   3 M-I, M-T, M-V TMH Buried 
209 ILE ND2 Not Non-polar no   3 I-T, I-V TMH Buried 
219 LEU ND2 Strongly Non-polar no   3 L-I, L-V TMH Buried 
220 ASN ND2 Not Polar non-charged no   3 N-D, N-Y, N-S TMH Surface 
222 ASN ND2 Not Polar non-charged no   3 N-S Loop Buried 
238 THR ND2 Not Polar non-charged no   3 T-A Loop Interface 
239 TRP ND2 Not Aromatic no   3 W-C Loop Surface 
241 THR ND2 Not Polar non-charged no   3 T-M TMH Buried 
242 PRO ND2 Not Polar non-charged no   3 P-L TMH Surface 
246 SER ND2 Not Polar non-charged no   3 
S-A, S-P,  
S-C, S-F 
TMH Buried 
266 ILE ND2 Fully Non-polar no   3 I-V TMH Buried 
267 ILE ND2 Strongly Non-polar no   3 I-V TMH Interface 
276 LEU ND2 Not Non-polar no   3 L-F, L-I Loop Surface 
277 ILE ND2 Not Non-polar no   3 I-V TMH Surface 
281 ILE ND2 Not Non-polar no   3 I-M, I-V TMH Surface 
285 ILE ND2 Not Non-polar no   3 I-L TMH Buried 
286 THR ND2 Strongly Polar non-charged no   3 T-S TMH Buried 
317 PHE ND2 Not Aromatic no   3 F-L, F-V Loop Interface 
320 THR ND2 Not Polar non-charged no   3 T-A Loop Surface 
330 ILE ND2 Not Non-polar no   3 I-V TMH Buried 
332 LEU ND2 Not Non-polar no   3 L-F TMH Surface 
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333 THR ND2 Strongly Polar non-charged no   3 T-A TMH Buried 
343 MET ND2 Not Non-polar no   3 M-V TMH Surface 
345 MET ND2 Not Non-polar no   3 M-I, M-T, M-V TMH Interface 
346 ILE ND2 Not Non-polar no   3 I-M, I-V TMH Surface 
14 ALA ND3 Strongly Non-polar no   3 A-S, A-T TMH Interface 
19 ILE ND3 Not Non-polar no   3 I-T TMH Surface 
24 LEU ND3 Fully Non-polar no   3 L-M Loop Surface 
44 MET ND3 Not Non-polar no   3 M-V Loop Interface 
89 MET ND3 Not Non-polar no   3 M-T, M-V TMH Surface 
90 SER ND3 Not Polar non-charged no   3 S-L, S-P, S-T TMH Interface 
93 LEU ND3 Not Non-polar no   3 L-S TMH Surface 
97 ILE ND3 Strongly Non-polar no   3 I-T TMH Interface 
105 GLU ND3 Fully Negatively charged no   3 E-D, E-K TMH Buried 
6 VAL ND4 Not Non-polar no   3 V-A TMH Interface 
21 HIS ND4 Not Positively charged no   3 H-Q Loop Surface 
29 THR ND4 Not Polar non-charged no   3 T-I TMH Interface 
45 ILE ND4 Not Non-polar no   3 I-F Loop Interface 
46 ASN ND4 Not Polar non-charged no   3 N-D Loop Interface 
52 CYS ND4 Not Polar non-charged no   3 C-Y Beta sheet Surface 
55 THR ND4 Not Polar non-charged no   3 T-A, T-I Loop Surface 
58 SER ND4 Not Polar non-charged no   3 S-P Beta sheet Buried 
70 THR ND4 Not Polar non-charged no   3 T-A TMH Buried 
85 SER ND4 Not Polar non-charged no   3 S-F, S-Y Loop Surface 
104 ILE ND4 Not Non-polar no   3 I-V TMH Buried 
107 ILE ND4 Fully Non-polar no   3 I-V TMH Buried 
121 PHE ND4 Strongly Aromatic no   3 F-L TMH Buried 
129 THR ND4 Fully Polar non-charged no   3 T-S TMH Buried 
166 TYR ND4 Not Aromatic no   3 Y-H TMH Interface 
170 THR ND4 Not Polar non-charged no   3 T-I TMH Surface 
187 SER ND4 Not Polar non-charged no   3 S-A, S-P, S-T Loop Surface 
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193 ASN ND4 Not Polar non-charged no   3 N-S TMH Buried 
201 MET ND4 Not Non-polar no   3 M-T TMH Surface 
225 ILE ND4 Fully Non-polar no   3 I-V Loop Buried 
232 ALA ND4 Fully Non-polar no   3 A-T TMH Buried 
291 ILE ND4 Strongly Non-polar no   3 I-V TMH Buried 
317 ILE ND4 Strongly Non-polar no   3 I-V TMH Buried 
320 GLY ND4 Fully Non-polar no   3 G-E TMH Buried 
350 THR ND4 Not Polar non-charged no   3 T-A Loop Interface 
365 ALA ND4 Strongly Non-polar no   3 A-T TMH Buried 
391 ILE ND4 Not Non-polar no   3 I-T, I-V Loop Surface 
418 SER ND4 Not Polar non-charged no   3 S-A, S-P, S-L Loop Interface 
419 LEU ND4 Not Non-polar no   3 L-F, L-P Loop Buried 
420 THR ND4 Not Polar non-charged no   3 T-A Loop Buried 
421 HIS ND4 Not Positively charged no   3 H-Y, H-P Loop Surface 
425 ASN ND4 Not Polar non-charged no   3 N-S Loop Interface 
434 ASN ND4 Not Polar non-charged no   3 N-H TMH Buried 
435 THR ND4 Not Polar non-charged no   3 T-I TMH Interface 
455 THR ND4 Not Polar non-charged no   3 T-I Loop Interface 
21 VAL ND4L Not Non-polar no   3 V-L, V-M Loop Surface 
59 VAL ND4L Not Non-polar no   3 V-M, V-G TMH Interface 
79 VAL ND4L Not Non-polar no   3 V-I TMH Interface 
80 SER ND4L Not Polar non-charged no   3 S-A TMH Interface 
2 THR ND5 Not Polar non-charged no   3 T-A, T-I TMH Surface 
14 SER ND5 Not Polar non-charged no   3 S-A TMH Buried 
18 PRO ND5 Fully Polar non-charged no   3 P-L TMH Buried 
27 ASN ND5 Not Polar non-charged no   3 N-S Loop Surface 
30 ASN ND5 Not Polar non-charged no   3 N-S Loop Surface 
34 HIS ND5 Not Positively charged no   3 H-R, H-Y TMH Surface 
38 SER ND5 Not Polar non-charged no   3 S-T TMH Surface 
39 ILE ND5 Not Non-polar no   3 I-V TMH Buried 
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40 VAL ND5 Not Non-polar no   3 V-I TMH Buried 
45 ILE ND5 Not Non-polar no   3 I-V TMH Surface 
53 MET ND5 Not Non-polar no   3 M-V Loop Surface 
59 GLN ND5 Not Polar non-charged no   3 Q-L Loop Interface 
63 ILE ND5 Weakly Non-polar no   3 I-V Beta sheet Buried 
65 ASN ND5 Weakly Polar non-charged no   3 N-S Beta sheet Surface 
67 HIS ND5 Not Positively charged no   3 H-Y Loop Surface 
70 THR ND5 Not Polar non-charged no   3 T-A, T-M Loop Interface 
76 LEU ND5 Strongly Non-polar no   3 L-F, L-V, L-H Loop Buried 
88 MET ND5 Not Non-polar no   3 M-T TMH Buried 
93 ALA ND5 Fully Non-polar no   3 A-S, A-T TMH Buried 
109 ASN ND5 Not Polar non-charged no   3 
N-D, N-K, N-Y, 
N-S 
Loop Surface 
113 ASN ND5 Not Polar non-charged no   3 N-S Loop Surface 
127 THR ND5 Strongly Polar non-charged no   3 T-A, T-I TMH Buried 
132 VAL ND5 Not Non-polar no   3 V-F, V-I TMH Buried 
141 PHE ND5 Strongly Aromatic no   3 F-L, F-C TMH Buried 
147 VAL ND5 Strongly Non-polar no   3 V-M TMH Buried 
162 ALA ND5 Strongly Non-polar no   3 A-T TMH Interface 
169 ILE ND5 Strongly Non-polar no   3 I-T, I-V TMH Interface 
172 ILE ND5 Strongly Non-polar no   3 I-V TMH Buried 
177 ILE ND5 Strongly Non-polar no   3 I-M, I-V TMH Surface 
196 TRP ND5 Fully Aromatic no   3 W-G, W-L Loop Buried 
206 ALA ND5 Not Non-polar no   3 A-T Loop Surface 
209 SER ND5 Not Polar non-charged no   3 S-G Loop Buried 
211 THR ND5 Not Polar non-charged no   3 T-A, T-P Loop Surface 
271 PRO ND5 Not Polar non-charged no   3 P-L, P-S TMH Surface 
273 ILE ND5 Not Non-polar no   3 I-T, I-V TMH Buried 
290 VAL ND5 Strongly Non-polar no   3 V-I TMH Surface 
304 PHE ND5 Fully Aromatic no   3 F-L TMH Buried 
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317 ILE ND5 Strongly Non-polar no   3 I-V TMH Buried 
323 HIS ND5 Strongly Positively charged no   3 H-Y TMH Buried 
331 THR ND5 Not Polar non-charged no   3 T-A TMH Buried 
377 SER ND5 Weakly Polar non-charged no   3 S-N, S-T TMH Buried 
378 LEU ND5 Strongly Non-polar no   3 L-P, L-Q TMH Interface 
381 ALA ND5 Not Non-polar no   3 A-P, A-V, A-T TMH Surface 
400 ASN ND5 Weakly Polar non-charged no   3 N-S Loop Interface 
403 TYR ND5 Not Aromatic no   3 Y-D, Y-N, Y-H Loop Surface 
413 LEU ND5 Fully Non-polar no   3 L-I TMH Surface 
420 SER ND5 Strongly Polar non-charged no   3 S-G TMH Buried 
423 SER ND5 Fully Polar non-charged no   3 S-R, S-T TMH Buried 
424 THR ND5 Not Polar non-charged no   3 T-A TMH Buried 
440 LEU ND5 Not Non-polar no   3 L-F Loop Surface 
441 THR ND5 Not Polar non-charged no   3 T-I Loop Interface 
442 ASN ND5 Not Polar non-charged no   3 N-D, N-S Loop Surface 
447 ASN ND5 Not Polar non-charged no   3 N-D, N-S Loop Surface 
456 ARG ND5 Fully Positively charged no   3 R-G TMH Surface 
461 SER ND5 Fully Polar non-charged no   3 S-T, S-G TMH Buried 
472 ILE ND5 Strongly Non-polar no   3 I-M Loop Buried 
473 SER ND5 Not Polar non-charged no   3 
S-F, S-P,  
S-T 
Loop Surface 
476 SER ND5 Not Polar non-charged no   3 
S-A, S-T,  
S-F 
Loop Interface 
477 PRO ND5 Not Polar non-charged no   3 P-H, P-S, P-L Loop Interface 
491 LEU ND5 Strongly Non-polar no   3 L-F TMH Buried 
492 ALA ND5 Not Non-polar no   3 A-T TMH Surface 
493 VAL ND5 Not Non-polar no   3 V-I TMH Surface 
500 THR ND5 Not Polar non-charged no   3 T-A, T-S, T-M TMH Surface 
508 THR ND5 Not Polar non-charged no   3 T-A TMH Surface 
509 ASN ND5 Not Polar non-charged no   3 N-S Loop Surface 
513 MET ND5 Not Non-polar no   3 M-T Loop Surface 
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517 LEU ND5 Not Non-polar no   3 L-M, L-V Loop Surface 
524 ASN ND5 Weakly Polar non-charged no   3 N-S Helix Interface 
525 MET ND5 Not Non-polar no   3 M-L Loop Surface 
546 GLN ND5 Not Polar non-charged no   3 Q-L Helix Interface 
564 LYS ND5 Fully Positively charged no   3 K-M Helix Surface 
565 THR ND5 Not Polar non-charged no   3 T-A, T-M Helix Surface 
569 HIS ND5 Not Positively charged no   3 H-Y Helix Surface 
571 ILE ND5 Not Non-polar no   3 I-T, I-V Helix Interface 
577 THR ND5 Not Polar non-charged no   3 T-A, T-I Helix Surface 
579 THR ND5 Weakly Polar non-charged no   3 T-A Loop Interface 
596 ILE ND5 Not Non-polar no   3 I-L, I-V TMH Surface 
602 ILE ND5 Not Non-polar no   3 I-M, I-S Loop Surface 
603 THR ND5 Not Polar non-charged no   3 T-M Loop Surface 
2 MET ND6 Not Non-polar no   3 M-I, M-T Loop Surface 
4 ALA ND6 Not Non-polar no   3 A-T, A-V TMH Surface 
34 VAL ND6 Not Non-polar no   3 V-A, V-I TMH Surface 
35 SER ND6 Strongly Polar non-charged no   3 S-C TMH Buried 
37 VAL ND6 Not Non-polar no   3 V-A TMH Surface 
38 VAL ND6 Not Non-polar no   3 V-I, V-L TMH Buried 
42 ILE ND6 Strongly Non-polar no   3 I-V TMH Buried 
45 ASN ND6 Not Polar non-charged no   3 N-S TMH Interface 
54 MET ND6 Strongly Non-polar no   3 M-I, M-V TMH Interface 
81 ALA ND6 Not Non-polar no   3 A-T Loop Buried 
85 GLY ND6 Not Non-polar no   3 G-E Loop Surface 
90 VAL ND6 Not Non-polar no   3 V-A TMH Surface 
94 VAL ND6 Not Non-polar no   3 V-A, V-M TMH Surface 
102 LEU ND6 Not Non-polar no   3 L-F TMH Surface 
106 VAL ND6 Not Non-polar no   3 V-A TMH Surface 
121 VAL ND6 Not Non-polar no   3 V-A, V-M Loop Buried 
134 LEU ND6 Not Non-polar no   3 L-F, L-M Loop Interface 
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135 ILE ND6 Weakly Non-polar no   3 I-V Loop Interface 
140 ILE ND6 Not Non-polar no   3 I-V Helix Interface 
142 ALA ND6 Not Non-polar no   3 A-V Helix Interface 
150 ARG ND6 Not Positively charged no   3 R-C, R-P TMH Surface 
155 VAL ND6 Strongly Non-polar no   3 V-A, V-I TMH Interface 
161 PHE ND6 Strongly Aromatic no   3 F-L TMH Interface 
162 VAL ND6 Not Non-polar no   3 V-A TMH Interface 
174 ASN ND6 Not Polar non-charged no   3 N-S, N-H Loop Surface 
2 ARG NDUFA10 Not Positively charged no   3 R-C Loop Surface 
137 ALA NDUFA10 Fully Non-polar no   3 A-V Helix Buried 
142 GLY NDUFA10 Not Non-polar no   3 G-R Loop Surface 
165 PRO NDUFA10 Fully Polar non-charged no   3 P-L Loop Buried 
182 ARG NDUFA10 Strongly Positively charged no   3 R-W, R-Q Helix Buried 
19 ARG NDUFA11 Fully Positively charged no   3 R-H TMH Surface 
65 VAL NDUFA11 Not Non-polar no   3 V-F TMH Buried 
99 THR NDUFA11 Not Polar non-charged no   3 T-I, T-S TMH Buried 
111 ALA NDUFA11 Weakly Non-polar no   3 A-T, A-V TMH Surface 
128 ARG NDUFA11 Strongly Positively charged no   3 R-W, R-Q TMH Surface 
60 ARG NDUFA12 Fully Positively charged yes   3 R-Q, R-G Loop Buried 
9 MET NDUFA13 Fully Non-polar no   3 M-T, M-I Loop Surface 
24 LEU NDUFA13 Fully Non-polar no   3 L-W, L-F Loop Surface 
41 THR NDUFA13 Strongly Polar non-charged no   3 T-N, T-I TMH Surface 
69 ALA NDUFA13 Fully Non-polar no   3 A-T, A-V, A-S TMH Interface 
80 ARG NDUFA13 Fully Positively charged yes   3 R-Q TMH Interface 
87 ARG NDUFA13 Fully Positively charged no   3 R-W TMH Interface 
34 ASP NDUFA2 Not Negatively charged no   3 D-N, D-E Helix Surface 
62 PRO NDUFA2 Not Polar non-charged no   3 P-L Loop Buried 
63 LYS NDUFA2 Strongly Positively charged no   3 K-R Beta sheet Buried 
93 VAL NDUFA2 Fully Non-polar no   3 V-I Helix Buried 
11 ALA NDUFA3 Weakly Non-polar no   3 A-G Helix Buried 
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49 PRO NDUFA3 Fully Polar non-charged no   3 P-T, P-R Loop Interface 
2 GLY NDUFA5 Weakly Non-polar no   3 G-C Loop Surface 
63 ARG NDUFA6 Fully Positively charged yes   3 R-Q Helix Surface 
4 THR NDUFA7 Fully Polar non-charged no   3 T-P, T-A Loop Surface 
7 ILE NDUFA7 Strongly Non-polar no   3 I-V, I-S Helix Buried 
29 GLU NDUFA7 Fully Negatively charged no   3 E-K Loop Surface 
37 PRO NDUFA7 Not Polar non-charged no   3 P-S Loop Surface 
50 ASN NDUFA7 Not Polar non-charged no   3 N-S Loop Surface 
57 ASP NDUFA7 Fully Negatively charged no   3 D-G Loop Buried 
59 ARG NDUFA7 Fully Positively charged no   3 R-C Loop Interface 
43 MET NDUFA8 Fully Non-polar no   3 M-V, M-I Helix Interface 
54 ARG NDUFA8 Strongly Positively charged yes   3 R-W, R-Q Loop Surface 
134 ARG NDUFA8 Fully Positively charged yes   3 R-Q Loop Surface 
21 ALA NDUFA9 Fully Non-polar no   3 A-V Beta sheet Buried 
135 LEU NDUFA9 Fully Non-polar no   3 L-M Loop Buried 
187 ARG NDUFA9 Not Positively charged no   3 R-Q, R-W Loop Surface 
206 TYR NDUFA9 Fully Aromatic no   3 Y-C, Y-H Loop Buried 
235 ARG NDUFA9 Strongly Positively charged yes   3 R-Q, R-W Loop Buried 
249 ALA NDUFA9 Strongly Non-polar no   3 A-D, A-T Loop Buried 
342 ILE NDUFA9 Not Non-polar no   3 I-M, I-T Loop Surface 
33 ARG NDUFB1 Strongly Positively charged no   3 R-W, R-Q, R-L TMH Surface 
38 ARG NDUFB1 Not Positively charged no   3 R-W, R-Q, R-P Loop Buried 
34 VAL NDUFB10 Strongly Non-polar no   3 V-L Helix Interface 
65 PRO NDUFB10 Fully Polar non-charged no   3 P-R Loop Surface 
109 ARG NDUFB10 Fully Positively charged no   3 R-M, R-S Helix Interface 
139 LEU NDUFB10 Fully Non-polar no   3 L-M, L-P Loop Buried 
164 LYS NDUFB10 Strongly Positively charged no   3 K-E Loop Surface 
55 VAL NDUFB11 Strongly Non-polar no   3 V-I TMH Surface 
56 TRP NDUFB11 Fully Aromatic no   3 W-C TMH Surface 
10 ARG NDUFB2 Fully Positively charged no   3 R-W, R-Q Loop Interface 
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60 VAL NDUFB3 Not Non-polar no   3 V-A Loop Interface 
2 PHE NDUFB4 Not Aromatic no   3 F-L Loop Surface 
25 SER NDUFB4 Fully Polar non-charged no   3 S-F Loop Surface 
66 ARG NDUFB4 Not Positively charged no   3 R-C, R-H, R-L Helix Interface 
11 ILE NDUFB5 Strongly Non-polar no   3 I-F, I-M Loop Surface 
87 TYR NDUFB5 Fully Aromatic no   3 Y-H Helix Interface 
137 PRO NDUFB5 Not Polar non-charged no   3 P-L Loop Surface 
10 ARG NDUFB6 Fully Positively charged no   3 R-Q Loop Interface 
20 ARG NDUFB6 Not Positively charged no   3 R-Q Loop Surface 
25 GLN NDUFB6 Fully Polar non-charged no   3 Q-E Loop Interface 
42 MET NDUFB6 Not Non-polar no   3 M-V Loop Surface 
80 ILE NDUFB6 Strongly Non-polar no   3 I-T TMH Surface 
108 THR NDUFB6 Not Polar non-charged no   3 T-A, T-I Loop Surface 
29 GLY NDUFB7 Fully Non-polar no   3 G-C Loop Surface 
43 GLN NDUFB7 Fully Polar non-charged no   3 Q-R Loop Surface 
48 ALA NDUFB7 Fully Non-polar no   3 A-T, A-V Loop Interface 
55 ARG NDUFB7 Fully Positively charged no   3 R-Q Loop Interface 
61 HIS NDUFB7 Strongly Positively charged no   3 H-D Helix Interface 
70 ARG NDUFB7 Fully Positively charged yes   3 R-C Helix Interface 
83 ARG NDUFB7 Strongly Positively charged yes   3 R-W Helix Surface 
92 ARG NDUFB7 Not Positively charged no   3 R-H Helix Surface 
105 ARG NDUFB7 Fully Positively charged no   3 R-G, R-Q Helix Surface 
110 ARG NDUFB7 Strongly Positively charged yes   3 R-Q Helix Interface 
112 LYS NDUFB7 Strongly Positively charged no   3 K-Q Helix Surface 
28 MET NDUFB8 Strongly Non-polar no   3 M-I Loop Buried 
38 ASP NDUFB8 Fully Negatively charged no   3 D-N Loop Surface 
75 PRO NDUFB8 Not Polar non-charged no   3 P-L Loop Buried 
87 ARG NDUFB8 Not Positively charged no   3 R-C, R-H Loop Interface 
93 THR NDUFB8 Not Polar non-charged no   3 T-A Loop Surface 
94 PRO NDUFB8 Not Polar non-charged no   3 P-R Loop Interface 
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3 LEU NDUFB9 Not Non-polar no   3 L-W Loop Surface 
7 PRO NDUFB9 Not Polar non-charged no   3 P-L, P-H Loop Surface 
36 TYR NDUFB9 Fully Aromatic no   3 Y-H Helix Buried 
46 ARG NDUFB9 Fully Positively charged no   3 R-L Helix Surface 
128 ARG NDUFB9 Strongly Positively charged no   3 R-Q Helix Buried 
143 THR NDUFB9 Fully Polar non-charged no   3 T-M Loop Surface 
174 ARG NDUFB9 Fully Positively charged no   3 R-W, R-Q Loop Interface 
176 ARG NDUFB9 Fully Positively charged no   3 R-Q Loop Surface 
178 MET NDUFB9 Not Non-polar no   3 M-T Loop Buried 
41 GLU NDUFC1 Fully Negatively charged yes   3 E-Q TMH Buried 
35 PHE NDUFC2 Strongly Aromatic no   3 F-L TMH Surface 
59 ARG NDUFC2 Fully Positively charged no   3 R-C, R-H TMH Buried 
119 ARG NDUFC2 Strongly Positively charged yes   3 R-H, R-C Loop Interface 
6 SER NDUFS1 Fully Polar non-charged no   3 S-G Loop Surface 
122 MET NDUFS1 Fully Non-polar no   3 M-L Helix Interface 
280 THR NDUFS1 Not Polar non-charged no   3 T-S Loop Buried 
331 LEU NDUFS1 Strongly Non-polar no   3 L-H Helix Buried 
334 LEU NDUFS1 Fully Non-polar no   3 L-F Helix Buried 
479 MET NDUFS1 Not Non-polar no   3 M-R Helix Surface 
515 ARG NDUFS1 Not Positively charged yes   3 R-G Helix Surface 
634 ASP NDUFS1 Fully Negatively charged yes   3 D-N Loop Surface 
646 ASN NDUFS1 Weakly Polar non-charged no   3 N-S, N-D Helix Buried 
689 LYS NDUFS1 Fully Positively charged no   3 K-R, K-T Helix Surface 
80 ILE NDUFS2 Fully Non-polar no   3 I-V Loop Interface 
379 VAL NDUFS2 Fully Non-polar no   3 V-L Beta sheet Buried 
409 HIS NDUFS2 Fully Positively charged yes   3 H-Y Loop Surface 
100 ARG NDUFS3 Fully Positively charged yes   3 R-C Loop Interface 
94 SER NDUFS4 Not Polar non-charged no   3 S-A Helix Surface 
115 SER NDUFS4 Fully Polar non-charged no   3 S-T Loop Surface 
71 THR NDUFS5 Weakly Polar non-charged no   3 T-M Helix Interface 
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92 THR NDUFS5 Fully Polar non-charged no   3 T-A Loop Surface 
97 HIS NDUFS5 Fully Positively charged yes   3 H-Q, H-P, H-Y Loop Interface 
133 ASP NDUFS7 Fully Negatively charged yes   3 D-N, D-E Loop Interface 
134 ARG NDUFS7 Fully Positively charged yes   3 R-H, R-L Loop Interface 
148 THR NDUFS7 Fully Polar non-charged no   3 T-M Loop Interface 
11 SER NDUFV1 Strongly Polar non-charged no   3 S-P Loop Surface 
32 ARG NDUFV1 Fully Positively charged no   3 R-S Loop Surface 
168 GLY NDUFV1 Not Non-polar no   3 G-D Loop Surface 
175 VAL NDUFV1 Fully Non-polar no   3 V-M Beta sheet Buried 
339 ARG NDUFV1 Not Positively charged no   3 R-C, R-H Loop Surface 
376 MET NDUFV1 Fully Non-polar no   3 M-I, M-T Helix Buried 
385 ARG NDUFV1 Strongly Positively charged no   3 R-L, R-Q, R-W Loop Surface 
418 LEU NDUFV1 Fully Non-polar no   3 L-M Helix Buried 
19 THR NDUFV2 Not Polar non-charged no   3 T-N, T-I Loop Surface 
76 PRO NDUFV2 Fully Polar non-charged no   3 P-T, P-R Loop Surface 
140 ILE NDUFV2 Fully Non-polar no   3 I-T, I-M Beta sheet Surface 
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Appendix 7.9C Distances of variants from nearest key feature in each grouping (A, B & C). Residue number refers to the mature protein. 
 
 
 
Residue 
number 
Identity Subunit 
Mutation 
class 
Polymorphism 
class 
Group A features:  
Core nuclear & 
ND1, 3, 4L & 6 subunits  
Distance 
(Å) 
Group B features: 
ND2, 4 & 5 subunits 
Distance 
(Å) 
Group C features: 
Supernumerary subunits  
Distance 
(Å) 
289 LEU ND1 1 2 ND1 Glu143 9.44 ND2 Glu34 29.78 NDUFA8 Cys87&Cys99 47.00 
45 SER ND3 1 2 ND3-Cys39 13.28 ND2 Glu34 41.43 NDUFAB1 (α)-acyl chain 18.83 
340 ARG ND4 1 2 ND4L Glu70 69.34 ND4 His220 11.95 NDUFA11 Cys94&Cys114 41.76 
64 MET ND6 1 2 ND6 pi-bulge (Gly61-62) 4.97 ND2 Glu34 20.80 NDUFS5 Cys32&Cys65 40.25 
52 ALA ND1 1 3 Q-site 4.40 ND2 Glu34 51.87 NDUFA9 NADPH 27.86 
110 SER ND1 1 3 ND1 Glu143 3.30 ND2 Glu34 25.37 NDUFS5 Cys32&Cys65 38.98 
132 ALA ND1 1 3 ND1 Glu227 11.54 ND2 Glu34 31.91 NDUFAB1 (α)-acyl chain 36.34 
34 SER ND3 1 3 ND3-Cys39 13.76 ND2 Glu34 47.59 NDUFA9 NADPH 22.99 
47 ALA ND3 1 3 ND3-Cys39 14.09 ND2 Glu34 37.03 NDUFAB1 (α)-acyl chain 23.97 
36 GLY ND6 1 3 ND4L Glu34 10.50 ND2 Glu34 19.99 NDUFS5 Cys32&Cys65 29.86 
72 ALA ND6 1 3 ND4L Glu34 15.31 ND2 Glu34 26.46 NDUFAB1 (α)-acyl chain 33.84 
259 MET NDUFS2 1 3 NDUFS2 H59 16.05 ND2 Glu34 59.36 NDUFAB1 (α)-acyl chain 41.04 
393 ALA NDUFS2 1 3 Q-site 12.70 ND2 Glu34 66.99 NDUFAB1 (α)-acyl chain 33.29 
24 GLU ND1 1  Q-site 7.98 ND2 Glu34 50.87 NDUFA9 NADPH 41.83 
131 GLY ND1 1  ND1 Glu227 11.63 ND2 Glu34 34.94 NDUFAB1 (α)-acyl chain 35.28 
143 GLU ND1 1  ND1 Glu143 0.00 ND2 Glu34 25.13 NDUFS5 Cys32&Cys65 41.32 
195 ARG ND1 1  ND1 Glu227 6.78 ND2 Glu34 41.27 NDUFA9 NADPH 43.77 
65 VAL ND4L 1  ND3 Glu68 8.41 ND2 Glu34 7.99 NDUFS5 Cys32&Cys65 28.60 
124 PHE ND5 1  ND4L Glu70 96.76 ND5 Lys223 10.07 ND5 Cys279&NDUFB8 Cys115 31.97 
393 ASP ND5 1  ND4L Glu70 119.39 ND5 Lys392 3.78 ND5 Cys279&NDUFB8 Cys115 19.22 
60 LEU ND6 1  ND6 pi-bulge (Gly61-62) 3.76 ND2 Glu34 19.62 NDUFS5 Cys32&Cys65 34.53 
63 MET ND6 1  ND6 pi-bulge (Gly61-62) 3.78 ND2 Glu34 18.25 NDUFS5 Cys32&Cys65 37.29 
8 GLY NDUFA1 1  Q-site 13.60 ND2 Glu34 56.24 NDUFA8 Cys87&Cys99 40.43 
37 ARG NDUFA1 1  ND1 Glu192 30.76 ND2 Glu34 44.18 NDUFA8 Cys87&Cys99 13.59 
107 GLN NDUFA10 1  ND4L Glu70 46.90 ND2 Leu131 pi bulge 36.61 NDUFA10 ADP 13.21 
286 ARG NDUFA9 1  ND3-Cys39 43.71 ND2 TMH4 Gly107-Phe111 65.50 NDUFA9 NADPH 9.34 
208 LEU NDUFS1 1  Fe-S cluster 6.15 ND2 Glu34 114.83 NDUFS6 Zinc 21.26 
218 ARG NDUFS1 1  Fe-S cluster 10.89 ND2 Glu34 99.45 NDUFS6 Zinc 22.76 
229 ASP NDUFS1 1  Fe-S cluster 25.80 ND2 Glu34 109.91 NDUFS6 Zinc 42.69 
385 ARG NDUFS1 1  Fe-S cluster 23.56 ND2 Glu34 126.83 NDUFS6 Zinc 44.46 
572 THR NDUFS1 1  Fe-S cluster 35.59 ND2 TMH4 Gly107-Phe111 104.15 NDUFAB1 (α)-acyl chain 39.56 
596 ASP NDUFS1 1  Fe-S cluster 40.10 ND2 TMH4 Gly107-Phe111 100.58 NDUFAB1 (α)-acyl chain 39.58 
195 ARG NDUFS2 1  Fe-S cluster 15.28 ND2 Glu34 84.17 NDUFS6 Zinc 33.40 
196 PRO NDUFS2 1  Fe-S cluster 17.84 ND2 Glu34 85.86 NDUFS6 Zinc 34.58 
380 SER NDUFS2 1  Fe-S cluster 24.19 ND2 Glu34 86.19 NDUFAB1 (α)-acyl chain 38.72 
109 THR NDUFS3 1  Q-site 32.69 ND2 Leu131 pi bulge 78.68 NDUFA6 LYR (34-36) 30.86 
163 ARG NDUFS3 1  Fe-S cluster 24.42 ND2 Glu34 76.77 NDUFAB1 (α)-acyl chain 21.39 
87 CYS NDUFS6 1  Fe-S cluster 11.70 ND2 Glu34 107.75 NDUFS6 Zinc 3.82 
 3
1
6
 
Residue 
number 
Identity Subunit 
Mutation 
class 
Polymorphism 
class 
Group A features:  
Core nuclear & 
ND1, 3, 4L & 6 subunits  
Distance 
(Å) 
Group B features: 
ND2, 4 & 5 subunits 
Distance 
(Å) 
Group C features: 
Supernumerary subunits  
Distance 
(Å) 
84 VAL NDUFS7 1  Fe-S cluster 9.80 ND2 Glu34 62.65 NDUFA9 NADPH 28.58 
29 GLU NDUFS8 1  NDUFS2 D160 22.34 ND2 Glu34 50.06 NDUFA8 Cys87&Cys99 50.03 
43 ARG NDUFS8 1  Q-site 22.28 ND2 Glu34 65.11 NDUFA8 Cys87&Cys99 52.11 
45 PRO NDUFS8 1  Q-site 18.89 ND2 Glu34 65.23 NDUFA9 NADPH 48.29 
51 PRO NDUFS8 1  Fe-S cluster 23.74 ND2 Glu34 73.96 NDUFA9 NADPH 36.84 
68 ARG NDUFS8 1  Fe-S cluster 9.11 ND2 Glu34 95.16 NDUFS6 Zinc 15.97 
104 ARG NDUFS8 1  Fe-S cluster 10.51 ND2 Glu34 105.38 NDUFS6 Zinc 13.01 
125 ALA NDUFS8 1  Fe-S cluster 6.14 ND2 Glu34 92.41 NDUFS6 Zinc 19.82 
97 ALA NDUFV1 1  FMN 6.03 ND2 Glu34 148.68 NDUFS6 Zinc 50.70 
102 PRO NDUFV1 1  Fe-S cluster 4.98 ND2 Glu34 143.08 NDUFS6 Zinc 44.12 
186 CYS NDUFV1 1  FMN 6.60 ND2 Glu34 139.85 NDUFS6 Zinc 42.00 
194 GLU NDUFV1 1  Fe-S cluster 11.96 ND2 Glu34 138.64 NDUFS6 Zinc 43.17 
403 THR NDUFV1 1  Fe-S cluster 4.64 ND2 Glu34 125.44 NDUFS6 Zinc 36.23 
30 TYR ND1 2 1 Q-site 14.55 ND2 Glu34 59.27 NDUFA9 NADPH 47.00 
164 THR ND1 2 1 ND1 Glu192 21.53 ND2 Glu34 37.63 NDUFA8 Cys87&Cys99 18.49 
240 THR ND1 2 1 ND1 Glu192 14.93 ND2 Glu34 40.19 NDUFA8 Cys87&Cys99 24.70 
1 MET ND1 2 2 Q-site 27.60 ND2 Glu34 48.74 NDUFA8 Cys87&Cys99 28.00 
31 MET ND1 2 2 Q-site 13.90 ND2 Glu34 57.03 NDUFA9 NADPH 48.76 
277 TYR ND1 2 2 NDUFS2 D160 12.27 ND2 Glu34 46.74 NDUFA8 Cys87&Cys99 51.03 
57 ILE ND2 2 2 ND4L Glu70 12.56 ND2 Lys105 14.14 NDUFA6 LYR (34-36) 42.25 
60 ILE ND3 2 2 ND3 Asp66 8.68 ND2 Glu34 17.03 NDUFS5 Cys32&Cys65 41.75 
109 THR ND4 2 2 ND4L Glu70 55.19 ND4 Glu123 9.52 NDUFB10 Cys70&Cys77 29.55 
165 ILE ND4 2 2 ND4L Glu70 44.55 ND2 Lys263 12.44 NDUFB10 Cys70&Cys77 27.47 
313 VAL ND4 2 2 ND4L Glu70 69.26 ND4 Lys237 8.09 
NDUFB11 Cys112&NDUFB10 
Cys148 
25.28 
1 MET ND5 2 2 ND4L Glu70 111.68 ND5 His328 27.99 NDUFB10 Cys106&Cys118 18.79 
159 TYR ND5 2 2 ND4L Glu70 91.18 ND5 His248 14.50 NDUFB9 LYK (18-20) 29.58 
434 GLN ND5 2 2 ND4L Glu70 123.55 
ND5 TMH12 Gly382-
Tyr390 
24.84 NDUFB9 LYK (18-20) 22.05 
132 SER ND6 2 2 ND3 Glu68 33.76 ND2 Glu34 37.07 NDUFS5 Cys32&Cys65 17.50 
290 ARG NDUFS2 2 2 NDUFS2 D160 22.15 ND2 Glu34 54.72 NDUFA6 LYR (34-36) 48.73 
28 LEU ND1 2 3 Q-site 9.40 ND2 Glu34 54.07 NDUFA9 NADPH 44.49 
215 TYR ND1 2 3 ND1 Glu227 11.79 ND2 Glu34 42.97 NDUFA9 NADPH 28.18 
409 TYR ND4 2 3 ND4L Glu70 79.22 
ND4 TMH12 Leu367-
Thr372 
10.31 ND5 Cys279&NDUFB8 Cys115 35.81 
236 ALA ND5 2 3 ND4L Glu70 97.21 ND5 His248 4.69 ND5 Cys279&NDUFB8 Cys115 25.07 
26 ILE ND6 2 3 ND4L Glu34 11.07 ND2 Glu34 24.80 NDUFAB1 (α)-acyl chain 36.94 
117 ASN ND6 2 3 ND4L Glu34 32.56 ND2 Glu34 35.77 NDUFS5 Cys32&Cys65 19.50 
21 TRP NDUFB3 2 3 ND4L Glu70 133.90 
ND5 TMH12 Gly382-
Tyr390 
39.46 NDUFB9 LYK (18-20) 24.14 
179 ARG NDUFV1 2 3 FMN 14.36 ND2 Glu34 149.61 NDUFS6 Zinc 48.60 
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366 ARG NDUFV1 2 3 Fe-S cluster 5.61 ND2 Glu34 124.37 NDUFS6 Zinc 26.89 
59 GLU ND1 2  Q-site 15.42 ND2 Glu34 51.65 NDUFA9 NADPH 18.14 
208 VAL ND1 2  ND3-Cys39 7.33 ND2 Glu34 43.81 NDUFAB1 (α)-acyl chain 33.44 
214 GLU ND1 2  ND3-Cys39 11.75 ND2 Glu34 42.93 NDUFA9 NADPH 28.50 
285 LEU ND1 2  ND1 Glu192 12.09 ND2 Glu34 34.43 NDUFAB1 (α)-acyl chain 47.67 
71 LEU ND2 2  ND4L Glu70 10.11 ND2 Glu34 7.61 NDUFS5 Cys32&Cys65 22.31 
259 GLY ND2 2  ND4L Glu70 34.76 ND2 TMH9 Gly252-Gly259 0.00 NDUFA11 Cys94&Cys114 37.23 
26 GLN ND3 2  Q-site 20.98 ND2 Glu34 57.06 NDUFA9 NADPH 12.25 
66 ASP ND3 2  ND3 Asp66 0.00 ND2 Glu34 16.99 NDUFS5 Cys32&Cys65 35.34 
32 CYS ND4L 2  ND4L Glu34 5.53 ND2 Glu34 14.54 NDUFS5 Cys32&Cys65 34.41 
145 GLU ND5 2  ND4L Glu70 89.17 ND5 Glu145 0.00 ND5 Cys279&NDUFB8 Cys115 27.23 
171 ALA ND5 2  ND4L Glu70 91.00 ND5 His248 7.28 ND5 Cys279&NDUFB8 Cys115 23.85 
237 MET ND5 2  ND4L Glu70 100.27 ND5 His248 6.19 ND5 Cys279&NDUFB8 Cys115 26.88 
250 SER ND5 2  ND4L Glu70 105.54 ND5 His332 5.71 ND5 Cys279&NDUFB8 Cys115 23.87 
465 GLY ND5 2  ND4L Glu70 119.28 
ND5 TMH12 Gly382-
Tyr390 
3.92 NDUFB7 Cys68&Cys79 18.83 
59 TYR ND6 2  ND6 pi-bulge (Gly61-62) 4.90 ND2 Glu34 16.01 NDUFS5 Cys32&Cys65 31.84 
74 ALA ND6 2  ND4L Glu34 16.16 ND2 Glu34 26.47 NDUFAB1 (α)-acyl chain 31.56 
19 PRO NDUFA1 2  Q-site 18.54 ND2 Glu34 47.59 NDUFA8 Cys87&Cys99 26.20 
64 GLY NDUFA10 2  ND4L Glu70 54.27 ND2 TMH9 Gly252-Gly259 36.50 NDUFA10 ADP 21.48 
259 LEU NDUFA10 2  ND4L Glu70 32.27 ND2 Leu131 pi bulge 27.22 NDUFA10 ADP 26.56 
56 ARG NDUFA13 2  ND3 Glu68 30.99 ND2 Glu34 42.80 NDUFA8 Cys87&Cys99 15.33 
44 LYS NDUFA2 2  Fe-S cluster 58.15 ND2 His112 123.85 NDUFAB1 (α)-acyl chain 58.86 
108 GLU NDUFA8 2  ND1 Glu192 52.70 ND2 Glu34 64.28 NDUFA8 Cys77&Cys109 3.80 
92 GLU NDUFB11 2  ND4L Glu70 88.26 
ND4 TMH12 Leu367-
Thr372 
31.73 
NDUFB11 Cys112&NDUFB10 
Cys148 
19.22 
63 LEU NDUFB9 2  ND4L Glu70 107.43 ND5 TMH7 Gly222-Pro288 37.46 NDUFAB1 (β)-acyl chain 5.28 
96 TYR NDUFB9 2  ND4L Glu70 95.21 ND5 His248 22.65 NDUFB9 LYK (18-20) 28.67 
48 VAL NDUFS1 2  Fe-S cluster 8.10 ND2 Glu34 123.68 NDUFS6 Zinc 39.22 
143 GLY NDUFS1 2  Fe-S cluster 14.43 ND2 Glu34 120.58 NDUFS6 Zinc 24.41 
205 VAL NDUFS1 2  Fe-S cluster 4.07 ND2 Glu34 111.67 NDUFS6 Zinc 22.04 
499 GLN NDUFS1 2  Fe-S cluster 37.85 ND2 TMH4 Gly107-Phe111 115.30 NDUFAB1 (α)-acyl chain 51.45 
672 TYR NDUFS1 2  Fe-S cluster 25.78 ND2 Glu34 120.72 NDUFS6 Zinc 39.03 
684 MET NDUFS1 2  Fe-S cluster 23.80 ND2 Glu34 116.89 NDUFS6 Zinc 33.81 
77 ASP NDUFS2 2  ND3-Cys39 14.15 ND2 Glu34 49.84 NDUFAB1 (α)-acyl chain 22.54 
85 ARG NDUFS2 2  NDUFS2 Y108 9.37 ND2 Glu34 68.69 NDUFAB1 (α)-acyl chain 25.92 
105 ARG NDUFS2 2  NDUFS2 Y108 5.62 ND2 Glu34 70.91 NDUFAB1 (α)-acyl chain 35.58 
115 GLU NDUFS2 2  NDUFS2 Y108 12.76 ND2 Glu34 77.67 NDUFS6 Zinc 39.06 
191 ALA NDUFS2 2  Fe-S cluster 10.58 ND2 Glu34 77.44 NDUFS6 Zinc 34.79 
300 ARG NDUFS2 2  NDUFS2 H59 16.31 ND2 Glu34 61.57 NDUFAB1 (α)-acyl chain 48.26 
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410 MET NDUFS2 2  NDUFS2 D160 14.09 ND2 Glu34 39.72 NDUFAB1 (α)-acyl chain 35.71 
413 ASP NDUFS2 2  NDUFS2 D160 10.37 ND2 Glu34 43.80 NDUFAB1 (α)-acyl chain 37.82 
187 PRO NDUFS3 2  Fe-S cluster 24.02 ND2 Glu34 74.42 NDUFAB1 (α)-acyl chain 18.57 
72 TRP NDUFS4 2  Fe-S cluster 16.47 ND2 Glu34 87.51 NDUFS6 Zinc 33.45 
77 ASP NDUFS4 2  Fe-S cluster 25.77 ND2 Glu34 82.61 NDUFAB1 (α)-acyl chain 23.44 
95 PRO NDUFS5 2  ND4L Glu34 51.54 ND2 Glu34 55.11 NDUFA8 Cys45&Cys55 29.91 
67 ARG NDUFS7 2  Q-site 13.20 ND2 Glu34 62.05 NDUFA9 NADPH 35.78 
107 ARG NDUFS7 2  Q-site 16.68 ND2 Glu34 58.60 NDUFA9 NADPH 18.11 
20 ARG NDUFS8 2  ND1 Glu192 28.74 ND2 Glu34 48.62 NDUFA8 Cys87&Cys99 53.19 
60 ARG NDUFS8 2  Fe-S cluster 13.53 ND2 Glu34 85.32 NDUFS6 Zinc 27.42 
120 GLY NDUFS8 2  Fe-S cluster 3.81 ND2 Glu34 84.17 NDUFS6 Zinc 26.26 
36 SER NDUFV1 2  FMN 24.18 ND2 Glu34 169.01 NDUFS6 Zinc 70.94 
68 ARG NDUFV1 2  FMN 3.70 ND2 Glu34 146.18 NDUFS6 Zinc 54.97 
91 LYS NDUFV1 2  FMN 16.92 ND2 Glu34 148.30 NDUFS6 Zinc 59.29 
127 ARG NDUFV1 2  FMN 16.51 ND2 Glu34 155.57 NDUFS6 Zinc 66.14 
184 TYR NDUFV1 2  FMN 5.48 ND2 Glu34 139.57 NDUFS6 Zinc 39.78 
191 ALA NDUFV1 2  FMN 8.30 ND2 Glu34 137.31 NDUFS6 Zinc 42.02 
226 GLU NDUFV1 2  FMN 7.24 ND2 Glu34 151.35 NDUFS6 Zinc 57.63 
232 PRO NDUFV1 2  FMN 15.21 ND2 Glu34 159.85 NDUFS6 Zinc 67.89 
321 ALA NDUFV1 2  FMN 17.92 ND2 Glu34 141.01 NDUFS6 Zinc 57.69 
357 GLU NDUFV1 2  Fe-S cluster 7.92 ND2 Glu34 134.23 NDUFS6 Zinc 32.84 
358 SER NDUFV1 2  Fe-S cluster 4.37 ND2 Glu34 131.67 NDUFS6 Zinc 32.53 
412 ALA NDUFV1 2  Fe-S cluster 10.93 ND2 Glu34 127.62 NDUFS6 Zinc 36.25 
177 LYS NDUFV2 2  Fe-S cluster 24.84 ND2 Glu34 160.54 NDUFS6 Zinc 51.37 
4 ALA ND1 3 1 Q-site 22.57 ND2 Glu34 49.33 NDUFA8 Cys87&Cys99 28.40 
304 TYR ND1 3 1 ND3 Glu68 16.56 ND2 Glu34 31.99 NDUFA8 Cys87&Cys99 33.11 
150 ASN ND2 3 1 ND4L Glu70 25.97 ND2 TMH4 Gly107-Phe111 14.20 NDUFS5 Cys42&Cys55 23.64 
331 ALA ND2 3 1 ND4L Glu70 39.18 ND2 TMH9 Gly252-Gly259 7.50 NDUFB10 Cys70&Cys77 46.11 
458 ALA ND5 3 1 ND4L Glu70 119.87 
ND5 TMH12 Gly382-
Tyr390 
9.18 NDUFB7 Cys68&Cys79 27.84 
544 THR ND5 3 1 ND4L Glu70 73.97 ND5 Asp554 pi bulge 11.18 NDUFA11 Cys94&Cys114 28.58 
119 ASN ND6 3 1 ND4L Glu34 35.24 ND2 Glu34 39.23 NDUFS5 Cys32&Cys65 22.01 
11 VAL ND1 3 2 Q-site 11.63 ND2 Glu34 48.05 NDUFA8 Cys87&Cys99 34.57 
39 VAL ND1 3 2 Q-site 16.08 ND2 Glu34 64.86 NDUFA9 NADPH 34.68 
64 ALA ND1 3 2 ND3-Cys39 17.40 ND2 Glu34 43.73 NDUFA9 NADPH 24.62 
113 VAL ND1 3 2 ND1 Glu143 6.45 ND2 Glu34 27.93 NDUFS5 Cys32&Cys65 43.39 
144 VAL ND1 3 2 ND1 Glu143 3.80 ND2 Glu34 23.51 NDUFS5 Cys32&Cys65 40.50 
147 ALA ND1 3 2 ND1 Glu143 6.07 ND2 Glu34 25.01 NDUFA8 Cys87&Cys99 36.99 
187 ILE ND1 3 2 ND1 Glu192 8.79 ND2 Glu34 36.69 NDUFA8 Cys87&Cys99 40.94 
64 ALA ND2 3 2 ND4L Glu70 4.74 ND2 Glu34 6.39 NDUFS5 Cys32&Cys65 33.21 
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122 THR ND2 3 2 ND4L Glu70 21.41 ND2 Leu131 pi bulge 11.09 NDUFA10 ADP 35.82 
10 ASN ND3 3 2 ND1 Glu227 16.59 ND2 Glu34 39.26 NDUFA9 NADPH 38.63 
423 ILE ND4 3 2 ND4L Glu70 80.22 ND4 Ala223 pi bulge 24.72 NDUFB9 LYK (18-20) 36.26 
9 THR ND5 3 2 ND4L Glu70 104.03 
ND4 TMH12 Leu367-
Thr372 
19.14 NDUFB10 Cys106&Cys118 23.76 
21 THR ND5 3 2 ND4L Glu70 98.62 
ND4 TMH12 Leu367-
Thr372 
20.13 NDUFB10 Cys106&Cys118 41.82 
100 ILE ND5 3 2 ND4L Glu70 108.53 ND5 Lys336 12.70 ND5 Cys279&NDUFB8 Cys115 34.64 
267 ALA ND5 3 2 ND4L Glu70 100.78 ND5 TMH7 Gly222-Pro258 17.43 ND5 Cys279&NDUFB8 Cys115 15.93 
398 THR ND5 3 2 ND4L Glu70 118.28 
ND5 TMH12 Gly382-
Tyr390 
9.96 ND5 Cys279&NDUFB8 Cys115 17.46 
576 ILE ND5 3 2 ND4L Glu70 33.21 ND2 His112 10.93 NDUFA11 Cys94&Cys114 22.86 
33 ILE ND6 3 2 ND4L Glu34 9.78 ND2 Glu34 21.97 NDUFS5 Cys32&Cys65 34.81 
58 ILE ND6 3 2 ND6 pi-bulge (Gly61-62) 4.93 ND2 Glu34 16.18 NDUFS5 Cys32&Cys65 31.61 
171 ALA ND6 3 2 ND4L Glu70 14.83 ND2 Glu34 20.12 NDUFA10 ADP 42.98 
32 GLY NDUFA1 3 2 Q-site 38.15 ND2 Glu34 54.76 NDUFA8 Cys87&Cys99 13.43 
103 ARG NDUFA11 3 2 ND4L Glu70 50.28 ND2 His112 29.59 NDUFA11 Cys94&Cys114 14.12 
40 ARG NDUFA9 3 2 Fe-S cluster 27.78 ND2 Glu34 74.28 NDUFA9 NADPH 17.27 
408 LEU NDUFS1 3 2 Fe-S cluster 32.88 ND2 TMH4 Gly107-Phe111 136.61 NDUFS6 Zinc 55.40 
2 PRO ND1 3 3 Q-site 25.33 ND2 Glu34 45.79 NDUFA8 Cys87&Cys99 27.17 
56 PHE ND1 3 3 Q-site 9.72 ND2 Glu34 50.90 NDUFA9 NADPH 23.11 
128 ALA ND1 3 3 ND3-Cys39 11.28 ND2 Glu34 36.90 NDUFAB1 (α)-acyl chain 31.52 
176 LEU ND1 3 3 ND1 Glu192 22.24 ND2 Glu34 43.61 NDUFA8 Cys87&Cys99 28.96 
230 ASN ND1 3 3 ND1 Glu227 5.41 ND2 Glu34 37.50 NDUFA8 Cys87&Cys99 37.80 
276 ALA ND1 3 3 Q-site 12.68 ND2 Glu34 49.92 NDUFA8 Cys87&Cys99 50.52 
328 THR ND2 3 3 ND4L Glu70 36.70 ND2 TMH9 Gly252-Gly259 11.53 NDUFA10 ADP 46.02 
71 ALA ND4L 3 3 ND4L Glu70 3.79 ND2 Glu34 9.89 NDUFS5 Cys32&Cys65 35.68 
99 SER ND5 3 3 ND4L Glu70 111.75 ND5 Lys336 12.69 NDUFB7 Cys68&Cys79 32.95 
149 ILE ND5 3 3 ND4L Glu70 89.06 ND5 Glu145 6.11 ND5 Cys279&NDUFB8 Cys115 30.12 
112 VAL ND6 3 3 ND4L Glu34 33.15 ND2 TMH4 Gly107-Phe111 28.98 NDUFS5 Cys32&Cys65 18.59 
100 LEU NDUFA10 3 3 ND4L Glu70 51.24 ND2 Leu131 pi bulge 38.28 NDUFA10 ADP 6.64 
251 GLN NDUFA10 3 3 ND3 Glu68 30.62 ND2 Leu131 pi bulge 33.50 NDUFA10 ADP 31.23 
50 ARG NDUFA9 3 3 Q-site 33.71 ND2 Glu34 74.53 NDUFA9 NADPH 5.81 
279 ILE NDUFA9 3 3 Q-site 36.45 ND2 TMH4 Gly107-Phe111 59.08 NDUFA9 NADPH 15.06 
157 ARG NDUFB9 3 3 ND4L Glu70 102.56 ND4 Ala223 pi bulge 54.90 NDUFAB1 (β)-acyl chain 31.94 
154 ILE NDUFS1 3 3 Fe-S cluster 4.69 ND2 Glu34 117.52 NDUFS6 Zinc 22.67 
181 MET NDUFS1 3 3 Fe-S cluster 10.05 ND2 Glu34 126.93 NDUFS6 Zinc 25.62 
483 VAL NDUFS1 3 3 Fe-S cluster 43.34 ND2 His112 133.15 NDUFAB1 (α)-acyl chain 66.41 
511 VAL NDUFS1 3 3 Fe-S cluster 48.75 ND2 TMH4 Gly107-Phe111 121.34 NDUFAB1 (α)-acyl chain 60.09 
287 VAL NDUFS2 3 3 NDUFS2 H59 23.71 ND2 Glu34 63.18 NDUFAB1 (α)-acyl chain 51.08 
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347 HIS NDUFS2 3 3 Fe-S cluster 10.24 ND2 Glu34 99.43 NDUFS6 Zinc 22.25 
210 ARG NDUFS3 3 3 Fe-S cluster 21.75 ND2 Glu34 98.98 NDUFS6 Zinc 44.15 
58 ALA NDUFS6 3 3 Fe-S cluster 16.49 ND2 Glu34 114.68 NDUFS6 Zinc 7.85 
60 ASP NDUFS6 3 3 Fe-S cluster 14.69 ND2 Glu34 108.34 NDUFS6 Zinc 5.15 
167 ARG NDUFS7 3 3 Q-site 24.00 ND2 Glu34 68.70 NDUFA9 NADPH 12.53 
133 ALA NDUFV1 3 3 FMN 17.71 ND2 Glu34 154.23 NDUFS6 Zinc 60.73 
337 MET NDUFV1 3 3 Fe-S cluster 12.43 ND2 Glu34 142.09 NDUFS6 Zinc 47.31 
12 PRO ND1 3  Q-site 12.41 ND2 Glu34 48.79 NDUFA8 Cys87&Cys99 32.58 
25 ARG ND1 3  Q-site 7.57 ND2 Glu34 53.83 NDUFA9 NADPH 40.15 
34 ARG ND1 3  Q-site 14.52 ND2 Glu34 62.00 NDUFA9 NADPH 44.39 
38 ASN ND1 3  Q-site 15.48 ND2 Glu34 63.30 NDUFA9 NADPH 37.82 
218 GLY ND1 3  Q-site 10.58 ND2 Glu34 46.45 NDUFA9 NADPH 25.17 
279 ARG ND1 3  NDUFS2 D160 9.72 ND2 Glu34 41.89 NDUFAB1 (α)-acyl chain 45.73 
55 ALA ND2 3  ND4L Glu70 16.32 ND2 Leu131 pi bulge 13.07 NDUFA10 ADP 41.34 
60 PHE ND2 3  ND4L Glu70 8.41 ND2 Lys105 9.21 NDUFS5 Cys32&Cys65 38.86 
128 LEU ND2 3  ND4L Glu70 21.87 ND2 Leu131 pi bulge 5.09 NDUFA10 ADP 41.42 
158 LEU ND4 3  ND4L Glu70 43.19 ND4 Glu123 6.25 NDUFA11 Cys94&Cys114 25.09 
206 LYS ND4 3  ND4L Glu70 55.39 ND4 Lys206 0.00 NDUFA11 Cys94&Cys114 28.06 
372 THR ND4 3  ND4L Glu70 81.05 
ND4 TMH12 Leu367-
Thr372 
0.00 NDUFB10 Cys106&Cys118 32.25 
387 SER ND4 3  ND4L Glu70 78.21 ND4 Glu378 14.24 
NDUFB11 Cys112&NDUFB10 
Cys148 
22.15 
412 THR ND4 3  ND4L Glu70 82.83 
ND4 TMH12 Leu367-
Thr372 
12.42 NDUFB9 LYK (18-20) 34.05 
25 HIS ND4L 3  ND4L Glu34 14.16 ND2 TMH4 Gly107-Phe111 19.56 NDUFA6 LYR (34-36) 36.91 
41 PHE ND4L 3  ND4L Glu34 10.51 ND2 Glu34 12.41 NDUFS5 Cys32&Cys65 21.81 
96 VAL ND5 3  ND4L Glu70 109.85 ND5 Lys336 10.51 NDUFB7 Cys68&Cys79 30.15 
239 GLY ND5 3  ND4L Glu70 98.96 ND5 His248 7.57 NDUFB9 LYK (18-20) 28.89 
243 VAL ND5 3  ND4L Glu70 101.56 ND5 His248 6.09 ND5 Cys279&NDUFB8 Cys115 30.69 
253 VAL ND5 3  ND4L Glu70 100.10 ND5 TMH7 Gly222-Pro242 4.62 ND5 Cys279&NDUFB8 Cys115 19.22 
312 LEU ND5 3  ND4L Glu70 108.91 ND5 His328 6.17 ND5 Cys279&NDUFB8 Cys115 11.14 
348 HIS ND5 3  ND4L Glu70 110.87 ND5 His248 18.70 NDUFB9 LYK (18-20) 24.81 
392 LYS ND5 3  ND4L Glu70 117.19 ND5 Lys392 0.00 ND5 Cys279&NDUFB8 Cys115 19.17 
415 ALA ND5 3  ND4L Glu70 113.63 ND5 Lys392 8.20 ND5 Cys279&NDUFB8 Cys115 14.50 
499 LEU ND5 3  ND4L Glu70 125.67 
ND5 TMH12 Gly382-
Tyr390 
14.66 ND5 Cys279&NDUFB8 Cys115 28.37 
505 ASN ND5 3  ND4L Glu70 120.74 
ND5 TMH12 Gly382-
Tyr390 
21.49 NDUFAB1 (β)-acyl chain 18.17 
585 LYS ND5 3  ND4L Glu34 19.34 ND2 TMH4 Gly107-Phe111 12.58 NDUFA11 Cys94&Cys114 38.52 
25 PRO ND6 3  ND4L Glu34 10.09 ND2 Glu34 22.70 NDUFAB1 (α)-acyl chain 37.33 
79 PRO ND6 3  ND4L Glu34 19.05 ND2 TMH4 Gly107-Phe111 30.39 NDUFAB1 (α)-acyl chain 28.90 
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82 TRP ND6 3  ND4L Glu34 20.01 ND2 TMH4 Gly107-Phe111 29.73 NDUFAB1 (α)-acyl chain 34.90 
101 GLY ND6 3  ND4L Glu34 25.56 ND2 TMH4 Gly107-Phe111 25.79 NDUFS5 Cys32&Cys65 29.99 
43 TYR NDUFA1 3  ND3 Glu68 33.17 ND2 Glu34 38.51 NDUFA8 Cys87&Cys99 20.64 
173 ASP NDUFA10 3  NDUFS2 H59 52.46 ND2 Leu131 pi bulge 56.39 NDUFA10 ADP 13.67 
176 VAL NDUFA10 3  NDUFS2 H59 60.40 ND2 Leu131 pi bulge 58.73 NDUFA10 ADP 13.95 
9 TRP NDUFA11 3  ND4L Glu70 47.28 ND2 TMH4 Gly107-Phe111 28.47 NDUFA11 Cys17-Cy74 12.17 
77 ALA NDUFA11 3  ND4L Glu70 58.84 ND4 TMH7 Met207-Leu214 31.94 NDUFA11 Cys17-Cy74 5.23 
81 GLU NDUFA11 3  ND4L Glu70 63.62 ND4 TMH7 Met207-Leu214 33.69 NDUFA11 Cys17-Cy74 10.48 
68 TYR NDUFA2 3  Fe-S cluster 61.42 ND2 His112 107.55 NDUFAB1 (α)-acyl chain 45.81 
26 ALA NDUFA9 3  ND3-Cys39 31.70 ND2 Glu34 72.16 NDUFA9 NADPH 5.47 
33 TYR NDUFA9 3  ND3-Cys39 28.38 ND2 TMH4 Gly107-Phe111 68.88 NDUFA9 NADPH 8.10 
287 MET NDUFA9 3  ND3-Cys39 42.83 ND2 TMH4 Gly107-Phe111 62.64 NDUFA9 NADPH 10.39 
303 LEU NDUFA9 3  ND3-Cys39 44.53 ND2 TMH4 Gly107-Phe111 78.40 NDUFA9 NADPH 17.77 
60 THR NDUFB9 3  ND4L Glu70 106.36 ND5 TMH7 Gly222-Pro288 41.00 NDUFAB1 (β)-acyl chain 7.62 
39 ARG NDUFS1 3  Fe-S cluster 3.72 ND2 Glu34 113.46 NDUFS6 Zinc 32.84 
230 VAL NDUFS1 3  Fe-S cluster 28.23 ND2 TMH4 Gly107-Phe111 110.75 NDUFS6 Zinc 44.06 
286 ASN NDUFS1 3  Fe-S cluster 49.51 ND2 TMH4 Gly107-Phe111 104.99 NDUFA9 NADPH 37.38 
432 ILE NDUFS1 3  Fe-S cluster 44.92 ND2 His112 143.29 NDUFS6 Zinc 68.45 
452 VAL NDUFS1 3  Fe-S cluster 34.95 ND2 His112 129.63 NDUFS6 Zinc 58.10 
543 ILE NDUFS1 3  Fe-S cluster 51.66 ND2 TMH4 Gly107-Phe111 110.68 NDUFA9 NADPH 48.03 
553 GLY NDUFS1 3  Fe-S cluster 43.60 ND2 TMH4 Gly107-Phe111 112.85 NDUFA9 NADPH 50.23 
577 GLU NDUFS1 3  Fe-S cluster 32.27 ND2 His112 117.01 NDUFAB1 (α)-acyl chain 51.57 
680 ALA NDUFS1 3  Fe-S cluster 30.93 ND2 Glu34 113.18 NDUFS6 Zinc 38.46 
20 TYR NDUFS2 3  ND4L Glu70 39.62 ND2 His112 18.85 NDUFA11 Cys94&Cys114 27.98 
376 VAL NDUFS2 3  NDUFS2 Y108 17.11 ND2 Glu34 76.01 NDUFAB1 (α)-acyl chain 37.56 
42 ARG NDUFS4 3  Fe-S cluster 18.01 ND2 Glu34 104.58 NDUFS6 Zinc 35.96 
49 VAL NDUFS6 3  Fe-S cluster 23.83 ND2 Glu34 118.27 NDUFS6 Zinc 11.87 
55 ARG NDUFS6 3  Fe-S cluster 21.62 ND2 Glu34 124.51 NDUFS6 Zinc 15.25 
74 ASN NDUFS6 3  Fe-S cluster 16.26 ND2 Glu34 120.76 NDUFS6 Zinc 12.63 
77 ARG NDUFS7 3  ND3-Cys39 11.19 ND2 Glu34 48.95 NDUFA9 NADPH 25.02 
81 VAL NDUFS7 3  Q-site 14.31 ND2 Glu34 59.09 NDUFA9 NADPH 23.48 
71 PRO NDUFS8 3  Fe-S cluster 15.18 ND2 Glu34 102.71 NDUFS6 Zinc 12.47 
81 LYS NDUFS8 3  Fe-S cluster 4.81 ND2 Glu34 95.31 NDUFS6 Zinc 19.95 
109 TYR NDUFS8 3  Fe-S cluster 8.76 ND2 Glu34 91.70 NDUFS6 Zinc 22.93 
127 PRO NDUFS8 3  Fe-S cluster 5.82 ND2 Glu34 98.04 NDUFS6 Zinc 13.76 
170 GLN NDUFS8 3  Fe-S cluster 18.02 ND2 Glu34 95.55 NDUFS6 Zinc 20.11 
19 ASP NDUFV1 3  FMN 21.99 ND2 Glu34 162.88 NDUFS6 Zinc 71.24 
75 THR NDUFV1 3  FMN 6.01 ND2 Glu34 146.28 NDUFS6 Zinc 59.43 
131 ALA NDUFV1 3  FMN 16.48 ND2 Glu34 151.99 NDUFS6 Zinc 62.11 
140 GLY NDUFV1 3  FMN 12.36 ND2 Glu34 148.02 NDUFS6 Zinc 45.30 
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247 ARG NDUFV1 3  FMN 18.21 ND2 Glu34 149.15 NDUFS6 Zinc 65.90 
263 ASN NDUFV1 3  Fe-S cluster 17.14 ND2 Glu34 154.36 NDUFS6 Zinc 57.69 
297 VAL NDUFV1 3  Fe-S cluster 14.78 ND2 Glu34 140.75 NDUFS6 Zinc 48.57 
348 ALA NDUFV1 3  Fe-S cluster 13.37 ND2 Glu34 131.13 NDUFS6 Zinc 33.24 
153 MET NDUFV2 3  Fe-S cluster 5.01 ND2 Glu34 150.27 NDUFS6 Zinc 46.19 
158 ASP NDUFV2 3  Fe-S cluster 14.90 ND2 Glu34 154.70 NDUFS6 Zinc 48.81 
67 THR ND1  1 ND1 Glu227 20.84 ND2 Glu34 36.53 NDUFAB1 (α)-acyl chain 30.71 
81 ILE ND1  1 ND1 Glu227 11.26 ND2 Glu34 32.67 NDUFA8 Cys87&Cys99 38.80 
309 ILE ND1  1 ND3 Glu68 21.02 ND2 Glu34 34.38 NDUFA8 Cys87&Cys99 30.88 
8 VAL ND2  1 ND3 Glu68 15.88 ND2 Glu34 15.63 NDUFS5 Cys32&Cys65 42.70 
119 THR ND2  1 ND4L Glu70 20.63 ND2 Leu131 pi bulge 6.76 NDUFA10 ADP 39.68 
193 VAL ND2  1 ND4L Glu70 28.34 ND2 TMH4 Gly107-Phe111 10.63 NDUFS5 Cys42&Cys55 29.49 
237 LEU ND2  1 ND4L Glu70 44.62 ND2 TMH9 Gly252-Gly259 20.42 NDUFA10 ADP 29.38 
325 PHE ND2  1 ND4L Glu70 33.67 ND2 TMH9 Gly252-Gly259 15.55 NDUFA10 ADP 42.73 
88 VAL ND3  1 ND3 Glu68 14.18 ND2 Glu34 26.91 NDUFS5 Cys32&Cys65 33.39 
114 THR ND3  1 ND3 Asp66 21.37 ND2 Glu34 28.72 NDUFA6 LYR (34-36) 42.15 
140 PRO ND4  1 ND4L Glu70 55.01 ND4 Ala223 pi bulge 11.72 NDUFA11 Cys94&Cys114 36.53 
404 ALA ND4  1 ND4L Glu70 79.98 
ND4 TMH12 Leu367-
Thr372 
4.17 ND5 Cys279&NDUFB8 Cys115 30.44 
47 MET ND4L  1 ND4L Glu34 20.33 ND2 Glu34 19.29 NDUFS5 Cys32&Cys65 11.90 
8 THR ND5  1 ND4L Glu70 107.32 
ND4 TMH12 Leu367-
Thr372 
22.07 NDUFB10 Cys106&Cys118 23.66 
24 VAL ND5  1 ND4L Glu70 96.39 
ND4 TMH12 Leu367-
Thr372 
23.29 NDUFB10 Cys106&Cys118 46.35 
257 ILE ND5  1 ND4L Glu70 101.38 ND5 TMH7 Gly222-Pro246 5.59 ND5 Cys279&NDUFB8 Cys115 15.09 
314 MET ND5  1 ND4L Glu70 104.67 ND5 TMH7 Gly222-Pro258 5.92 ND5 Cys279&NDUFB8 Cys115 9.25 
475 ALA ND5  1 ND4L Glu70 116.65 
ND5 TMH12 Gly382-
Tyr390 
13.80 NDUFB7 Cys58-89 14.41 
482 ILE ND5  1 ND4L Glu70 126.16 
ND5 TMH12 Gly382-
Tyr390 
12.56 NDUFB7 Cys58-89 16.77 
485 TYR ND5  1 ND4L Glu70 127.33 
ND5 TMH12 Gly382-
Tyr390 
12.86 ND5 Cys279&NDUFB8 Cys115 23.04 
515 SER ND5  1 ND4L Glu70 116.07 ND5 His230 24.88 NDUFAB1 (β)-acyl chain 12.12 
531 SER ND5  1 ND4L Glu70 93.56 ND5 TMH7 Gly222-Pro289 9.65 NDUFAB1 (β)-acyl chain 22.40 
533 THR ND5  1 ND4L Glu70 90.02 ND5 TMH7 Gly222-Pro289 7.67 ND5 Cys279&NDUFB8 Cys115 21.07 
555 LEU ND5  1 ND4L Glu70 59.50 ND5 Asp554 pi bulge 3.80 NDUFA11 Cys94&Cys114 22.57 
166 ILE ND6  1 ND4L Glu70 10.73 ND2 Glu34 13.36 NDUFS5 Cys32&Cys65 42.42 
47 LYS NDUFA7  1 Fe-S cluster 24.36 ND2 Glu34 107.83 NDUFS6 Zinc 30.26 
259 PRO NDUFA9  1 ND3-Cys39 51.07 ND2 TMH4 Gly107-Phe111 58.83 NDUFA9 NADPH 23.50 
145 PRO NDUFB9  1 ND4L Glu70 87.77 ND5 Asp554 pi bulge 46.64 NDUFAB1 (β)-acyl chain 33.51 
46 LEU NDUFC2  1 ND4L Glu70 45.34 ND2 TMH9 Gly252-Gly259 17.40 NDUFA10 ADP 37.87 
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319 PRO NDUFS2  1 NDUFS2 Y108 30.93 ND2 Glu34 91.15 NDUFS6 Zinc 40.20 
102 VAL NDUFV2  1 Fe-S cluster 7.97 ND2 Glu34 146.25 NDUFS6 Zinc 40.47 
10 ILE ND1  2 Q-site 13.63 ND2 Glu34 44.61 NDUFA8 Cys87&Cys99 32.88 
29 GLY ND1  2 Q-site 11.15 ND2 Glu34 57.66 NDUFA9 NADPH 43.66 
43 TYR ND1  2 Q-site 16.17 ND2 Glu34 62.98 NDUFA9 NADPH 39.79 
69 THR ND1  2 ND1 Glu227 19.68 ND2 Glu34 35.61 NDUFA9 NADPH 32.36 
73 THR ND1  2 ND1 Glu227 15.45 ND2 Glu34 35.08 NDUFA9 NADPH 34.22 
87 THR ND1  2 ND1 Glu192 15.86 ND2 Glu34 36.85 NDUFA8 Cys87&Cys99 28.71 
89 LEU ND1  2 ND1 Glu192 14.78 ND2 Glu34 38.05 NDUFA8 Cys87&Cys99 25.50 
229 THR ND1  2 ND1 Glu227 5.86 ND2 Glu34 40.53 NDUFA8 Cys87&Cys99 37.50 
236 THR ND1  2 ND1 Glu192 11.40 ND2 Glu34 40.60 NDUFA8 Cys87&Cys99 29.33 
248 ASP ND1  2 ND1 Glu192 30.07 ND2 Glu34 51.86 NDUFA8 Cys87&Cys99 11.85 
263 THR ND1  2 ND1 Glu192 15.16 ND2 Glu34 45.87 NDUFA8 Cys87&Cys99 30.54 
275 THR ND1  2 Q-site 10.44 ND2 Glu34 50.03 NDUFA9 NADPH 48.29 
307 MET ND1  2 ND3 Glu68 20.10 ND2 Glu34 35.20 NDUFA8 Cys87&Cys99 32.89 
13 ILE ND2  2 ND4L Glu70 14.10 ND2 Glu34 10.00 NDUFS5 Cys32&Cys65 38.04 
31 VAL ND2  2 ND4L Glu70 8.66 ND2 Glu34 4.88 NDUFS5 Cys32&Cys65 26.60 
43 VAL ND2  2 ND4L Glu70 15.72 ND2 Leu131 pi bulge 13.25 NDUFA10 ADP 41.45 
76 PHE ND2  2 ND4L Glu70 18.50 ND2 Glu34 16.12 NDUFS5 Cys32&Cys65 16.03 
80 LEU ND2  2 ND4L Glu70 23.70 ND2 Glu34 21.18 NDUFS5 Cys32&Cys65 11.55 
88 ASN ND2  2 ND4L Glu70 24.52 ND2 Lys105 19.01 NDUFS5 Cys42&Cys55 14.70 
89 THR ND2  2 ND4L Glu70 25.12 ND2 Lys105 20.45 NDUFS5 Cys42&Cys55 12.99 
100 MET ND2  2 ND4L Glu70 16.00 ND2 TMH4 Gly107-Phe111 5.37 NDUFS5 Cys32&Cys65 30.13 
152 SER ND2  2 ND4L Glu70 28.63 ND2 TMH4 Gly107-Phe111 11.93 NDUFS5 Cys42&Cys55 28.53 
164 ALA ND2  2 ND4L Glu70 27.14 ND2 His112 4.76 NDUFA11 Cys94&Cys114 25.87 
202 ILE ND2  2 ND4L Glu70 26.46 ND2 Lys135 11.01 NDUFS5 Cys42&Cys55 31.31 
203 LEU ND2  2 ND4L Glu70 29.42 ND2 Lys263 10.19 NDUFS5 Cys42&Cys55 34.21 
265 ALA ND2  2 ND4L Glu70 36.45 ND2 Lys263 6.01 NDUFB10 Cys70&Cys77 33.53 
270 PHE ND2  2 ND4L Glu70 35.95 ND2 Lys263 10.98 NDUFA11 Cys94&Cys114 31.39 
278 ILE ND2  2 ND4L Glu70 35.54 ND2 Lys263 13.04 NDUFA11 Cys94&Cys114 23.70 
284 THR ND2  2 ND4L Glu70 38.44 ND2 Lys263 10.75 NDUFA11 Cys94&Cys114 20.92 
288 LEU ND2  2 ND4L Glu70 36.61 ND2 TMH9 Gly252-Gly259 9.80 NDUFA11 Cys94&Cys114 23.62 
323 THR ND2  2 ND4L Glu70 33.67 ND2 Leu131 pi bulge 18.82 NDUFA10 ADP 38.84 
342 PHE ND2  2 ND4L Glu70 39.16 ND2 TMH9 Gly252-Gly259 12.06 NDUFB10 Cys70&Cys77 34.30 
9 ILE ND3  2 Q-site 19.16 ND2 Glu34 41.22 NDUFA8 Cys87&Cys99 37.62 
29 GLY ND3  2 ND3-Cys39 19.72 ND2 Glu34 54.22 NDUFA9 NADPH 14.52 
49 VAL ND3  2 ND3-Cys39 18.54 ND2 Glu34 33.50 NDUFAB1 (α)-acyl chain 25.57 
96 ILE ND3  2 ND3 Glu68 6.97 ND2 Glu34 22.73 NDUFS5 Cys32&Cys65 39.75 
103 ALA ND3  2 ND3 Glu68 11.93 ND2 Glu34 24.73 NDUFS5 Cys32&Cys65 47.49 
47 ASN ND4  2 ND4L Glu70 69.72 ND4 Lys237 20.73 NDUFB11 Cys112&NDUFB10 Cys148 16.34 
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50 PHE ND4  2 ND4L Glu70 66.68 ND4 Lys237 23.18 NDUFB10 Cys70&Cys77 15.76 
54 PRO ND4  2 ND4L Glu70 57.45 ND2 TMH9 Gly252-Gly259 21.17 NDUFB10 Cys70&Cys77 18.77 
86 SER ND4  2 ND4L Glu70 65.33 ND4 Ala223 pi bulge 18.42 NDUFA10 ADP 37.87 
89 LEU ND4  2 ND4L Glu70 59.43 ND4 Ala223 pi bulge 20.84 NDUFA10 ADP 38.11 
101 SER ND4  2 ND4L Glu70 53.84 ND2 TMH9 Gly252-Gly259 10.42 NDUFB10 Cys70&Cys77 40.82 
110 PHE ND4  2 ND4L Glu70 58.85 ND4 Lys237 11.13 NDUFB10 Cys70&Cys77 28.07 
131 ALA ND4  2 ND4L Glu70 50.12 ND4 Ala223 pi bulge 10.50 NDUFA11 Cys94&Cys114 38.81 
138 ASN ND4  2 ND4L Glu70 58.86 ND4 Ala223 pi bulge 7.37 NDUFA11 Cys94&Cys114 40.73 
149 PHE ND4  2 ND4L Glu70 50.24 ND4 Lys206 7.65 NDUFA11 Cys94&Cys114 27.77 
230 VAL ND4  2 ND4L Glu70 61.28 ND4 His220 7.24 NDUFA11 Cys94&Cys114 40.39 
299 THR ND4  2 ND4L Glu70 67.26 ND4 TMH7 Met207-Leu214 7.93 
NDUFB11 Cys112&NDUFB10 
Cys148 
25.99 
390 ASN ND4  2 ND4L Glu70 79.13 ND4 Glu378 16.48 ND5 Cys279&NDUFB8 Cys115 27.22 
402 VAL ND4  2 ND4L Glu70 77.36 ND5 Arg176 7.24 ND5 Cys279&NDUFB8 Cys115 29.93 
424 ASN ND4  2 ND4L Glu70 80.92 ND4 Ala223 pi bulge 25.66 NDUFB9 LYK (18-20) 38.65 
442 SER ND4  2 ND4L Glu70 79.33 
ND4 TMH12 Leu367-
Thr372 
10.39 NDUFB10 Cys106&Cys118 40.66 
445 LEU ND4  2 ND4L Glu70 81.14 
ND4 TMH12 Leu367-
Thr372 
6.42 NDUFB10 Cys106&Cys118 35.62 
459 SER ND4  2 ND4L Glu70 76.59 ND4 Glu378 17.16 
NDUFB11 Cys112&NDUFB10 
Cys148 
16.18 
13 THR ND4L  2 ND4L Glu34 13.15 ND2 TMH4 Gly107-Phe111 14.55 NDUFS5 Cys32&Cys65 27.90 
62 ALA ND4L  2 ND3 Glu68 11.14 ND2 Glu34 8.73 NDUFS5 Cys32&Cys65 23.70 
94 ASN ND4L  2 ND4L Glu70 24.26 ND2 His112 16.39 NDUFA6 LYR (34-36) 34.25 
4 HIS ND5  2 ND4L Glu70 111.18 ND5 His328 25.63 NDUFB10 Cys106&Cys118 21.65 
13 THR ND5  2 ND4L Glu70 101.42 
ND4 TMH12 Leu367-
Thr372 
16.65 NDUFB10 Cys106&Cys118 28.77 
22 THR ND5  2 ND4L Glu70 95.91 
ND4 TMH12 Leu367-
Thr372 
19.26 NDUFB10 Cys106&Cys118 43.55 
23 LEU ND5  2 ND4L Glu70 94.19 
ND4 TMH12 Leu367-
Thr372 
19.51 NDUFB10 Cys106&Cys118 43.48 
52 THR ND5  2 ND4L Glu70 114.54 ND5 His328 17.59 NDUFB7 Cys68&Cys79 15.97 
69 ALA ND5  2 ND4L Glu70 82.80 
ND4 TMH12 Leu367-
Thr372 
11.78 NDUFB10 Cys106&Cys118 23.52 
74 THR ND5  2 ND4L Glu70 85.31 
ND4 TMH12 Leu367-
Thr372 
16.32 NDUFB10 Cys106&Cys118 17.21 
182 PHE ND5  2 ND4L Glu70 88.63 ND5 Asp179 4.50 ND5 Cys279&NDUFB8 Cys115 20.47 
190 ILE ND5  2 ND4L Glu70 85.68 ND4 Glu378 15.06 NDUFB10 Cys106&Cys118 18.33 
201 MET ND5  2 ND4L Glu70 94.48 ND5 Asp179 19.75 NDUFB10 Cys106&Cys118 11.09 
202 ALA ND5  2 ND4L Glu70 98.18 ND5 Asp179 21.33 NDUFB10 Cys106&Cys118 10.07 
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205 ASN ND5  2 ND4L Glu70 94.77 ND5 Asp179 21.70 NDUFB10 Cys106&Cys118 12.72 
261 ILE ND5  2 ND4L Glu70 103.19 ND5 His328 10.72 ND5 Cys279&NDUFB8 Cys115 18.09 
265 PRO ND5  2 ND4L Glu70 102.72 ND5 His328 16.07 ND5 Cys279&NDUFB8 Cys115 17.57 
270 SER ND5  2 ND4L Glu70 100.81 ND5 TMH7 Gly222-Pro258 19.34 ND5 Cys279&NDUFB8 Cys115 14.86 
283 ILE ND5  2 ND4L Glu70 104.21 ND5 TMH7 Gly222-Pro265 4.40 ND5 Cys279&NDUFB8 Cys115 6.13 
410 SER ND5  2 ND4L Glu70 114.74 ND5 Lys392 12.77 ND5 Cys279&NDUFB8 Cys115 10.91 
432 THR ND5  2 ND4L Glu70 124.24 
ND5 TMH12 Gly382-
Tyr390 
20.87 NDUFAB1 (β)-acyl chain 22.17 
439 THR ND5  2 ND4L Glu70 121.56 ND5 Lys336 33.58 NDUFB9 LYK (18-20) 18.56 
449 THR ND5  2 ND4L Glu70 116.00 ND5 Lys336 19.36 NDUFB9 LYK (18-20) 38.31 
459 ALA ND5  2 ND4L Glu70 121.84 
ND5 TMH12 Gly382-
Tyr390 
9.46 NDUFB7 Cys68&Cys79 24.84 
469 THR ND5  2 ND4L Glu70 120.30 
ND5 TMH12 Gly382-
Tyr390 
6.05 NDUFB7 Cys68&Cys79 13.51 
471 ASN ND5  2 ND4L Glu70 121.21 
ND5 TMH12 Gly382-
Tyr390 
11.19 NDUFB7 Cys68&Cys79 10.56 
478 PHE ND5  2 ND4L Glu70 121.28 
ND5 TMH12 Gly382-
Tyr390 
10.11 NDUFB7 Cys58-89 11.69 
489 THR ND5  2 ND4L Glu70 124.84 
ND5 TMH12 Gly382-
Tyr390 
7.32 ND5 Cys279&NDUFB8 Cys115 21.91 
495 PHE ND5  2 ND4L Glu70 125.55 
ND5 TMH12 Gly382-
Tyr390 
8.78 ND5 Cys279&NDUFB8 Cys115 25.76 
518 CYS ND5  2 ND4L Glu70 108.82 ND5 His230 18.02 NDUFAB1 (β)-acyl chain 17.74 
530 PRO ND5  2 ND4L Glu70 94.52 ND5 TMH7 Gly222-Pro288 5.92 ND5 Cys279&NDUFB8 Cys115 21.56 
536 THR ND5  2 ND4L Glu70 85.43 ND5 TMH7 Gly222-Pro289 13.51 ND5 Cys279&NDUFB8 Cys115 26.29 
538 PRO ND5  2 ND4L Glu70 83.04 ND5 TMH7 Gly222-Pro289 13.18 ND5 Cys279&NDUFB8 Cys115 27.98 
541 GLY ND5  2 ND4L Glu70 78.47 ND4 TMH7 Met207-Leu214 14.75 ND5 Cys279&NDUFB8 Cys115 29.23 
549 PRO ND5  2 ND4L Glu70 67.28 ND4 TMH7 Met207-Leu214 4.62 NDUFA11 Cys94&Cys114 23.85 
556 THR ND5  2 ND4L Glu70 58.45 ND5 Asp554 pi bulge 5.89 NDUFA11 Cys94&Cys114 19.83 
573 THR ND5  2 ND4L Glu70 36.53 ND2 His112 13.34 NDUFA11 Cys94&Cys114 18.99 
575 ILE ND5  2 ND4L Glu70 34.83 ND2 His112 12.61 NDUFA11 Cys94&Cys114 23.95 
592 PHE ND5  2 ND4L Glu34 21.60 ND2 TMH4 Gly107-Phe111 8.39 NDUFA11 Cys94&Cys114 32.91 
598 THR ND5  2 ND4L Glu70 24.66 ND2 TMH4 Gly107-Phe111 10.76 NDUFA11 Cys17-Cy74 30.66 
14 MET ND6  2 ND4L Glu34 16.24 ND2 Glu34 25.38 NDUFS5 Cys32&Cys65 32.17 
31 VAL ND6  2 ND4L Glu34 11.31 ND2 Glu34 23.39 NDUFS5 Cys32&Cys65 36.58 
41 VAL ND6  2 ND6 pi-bulge (Gly61-62) 17.48 ND2 Glu34 25.36 NDUFS5 Cys32&Cys65 25.99 
86 VAL ND6  2 ND4L Glu34 24.00 ND2 TMH4 Gly107-Phe111 26.65 NDUFAB1 (α)-acyl chain 35.93 
97 ALA ND6  2 ND4L Glu34 23.24 ND2 TMH4 Gly107-Phe111 24.96 NDUFS5 Cys32&Cys65 34.49 
120 SER ND6  2 ND4L Glu34 33.24 ND2 Glu34 36.53 NDUFS5 Cys32&Cys65 18.55 
139 PRO ND6  2 ND3 Glu68 16.65 ND2 Glu34 22.96 NDUFS5 Cys32&Cys65 21.04 
156 THR ND6  2 ND3 Glu68 8.00 ND2 Glu34 10.36 NDUFS5 Cys32&Cys65 29.64 
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159 THR ND6  2 ND3 Glu68 8.61 ND2 Glu34 9.20 NDUFS5 Cys32&Cys65 33.64 
165 TYR ND6  2 ND3 Glu68 12.09 ND2 Glu34 15.48 NDUFS5 Cys32&Cys65 43.17 
30 ASN NDUFA10  2 NDUFS2 H59 58.47 ND2 Leu131 pi bulge 51.77 NDUFA10 ADP 6.62 
13 LEU NDUFA2  2 Fe-S cluster 67.52 ND2 His112 109.83 NDUFAB1 (α)-acyl chain 50.00 
20 VAL NDUFA3  2 ND3 Glu68 20.89 ND2 Glu34 37.39 NDUFA8 Cys87&Cys99 46.22 
107 HIS NDUFA6  2 ND3-Cys39 25.20 ND2 TMH4 Gly107-Phe111 66.74 NDUFAB1 (α)-acyl chain 11.13 
65 PRO NDUFA7  2 Fe-S cluster 33.96 ND2 Glu34 93.94 NDUFAB1 (α)-acyl chain 50.29 
18 MET NDUFB1  2 ND4L Glu70 65.55 ND2 TMH9 Gly252-Gly259 26.35 NDUFB10 Cys70&Cys77 40.91 
141 ALA NDUFB10  2 ND4L Glu70 69.80 ND4 TMH7 Met207-Leu214 16.58 
NDUFB11 Cys112&NDUFB10 
Cys148 
12.54 
52 PRO NDUFB2  2 ND4L Glu70 133.75 
ND5 TMH12 Gly382-
Tyr390 
14.29 NDUFB7 Cys58-89 13.68 
62 LEU NDUFB7  2 ND4L Glu70 126.05 
ND5 TMH12 Gly382-
Tyr390 
19.68 NDUFB7 Cys58-89 5.89 
96 SER NDUFB8  2 ND4L Glu70 97.54 ND5 His230 19.33 NDUFAB1 (β)-acyl chain 17.48 
120 VAL NDUFB8  2 ND4L Glu70 110.70 ND5 TMH7 Gly222-Pro264 20.20 ND5 Cys279&NDUFB8 Cys115 9.25 
123 VAL NDUFS3  2 NDUFS2 H59 30.37 ND2 Leu131 pi bulge 63.57 NDUFA6 LYR (34-36) 29.01 
8 VAL NDUFV2  2 Fe-S cluster 16.31 ND2 Glu34 130.26 NDUFS6 Zinc 24.07 
5 ASN ND1  3 Q-site 21.97 ND2 Glu34 46.65 NDUFA8 Cys87&Cys99 26.48 
15 ILE ND1  3 Q-site 7.68 ND2 Glu34 50.35 NDUFA8 Cys87&Cys99 37.54 
17 MET ND1  3 Q-site 6.54 ND2 Glu34 46.90 NDUFA8 Cys87&Cys99 39.17 
21 MET ND1  3 Q-site 6.47 ND2 Glu34 49.78 NDUFA9 NADPH 37.75 
27 ILE ND1  3 Q-site 12.04 ND2 Glu34 54.79 NDUFA9 NADPH 45.62 
68 ILE ND1  3 ND1 Glu227 20.09 ND2 Glu34 38.16 NDUFA9 NADPH 29.64 
76 THR ND1  3 ND1 Glu227 12.49 ND2 Glu34 36.89 NDUFA9 NADPH 35.01 
77 LEU ND1  3 ND1 Glu227 12.43 ND2 Glu34 33.23 NDUFA9 NADPH 38.48 
96 VAL ND1  3 ND1 Glu192 20.77 ND2 Glu34 37.42 NDUFA8 Cys87&Cys99 23.94 
112 ALA ND1  3 ND1 Glu143 7.41 ND2 Glu34 29.31 NDUFS5 Cys32&Cys65 42.07 
116 ILE ND1  3 ND1 Glu227 8.75 ND2 Glu34 31.59 NDUFAB1 (α)-acyl chain 39.96 
139 THR ND1  3 ND1 Glu143 4.65 ND2 Glu34 26.99 NDUFS5 Cys32&Cys65 45.08 
152 SER ND1  3 ND1 Glu143 14.21 ND2 Glu34 29.41 NDUFA8 Cys87&Cys99 32.32 
153 THR ND1  3 ND1 Glu143 15.28 ND2 Glu34 32.45 NDUFA8 Cys87&Cys99 29.53 
168 THR ND1  3 ND1 Glu192 23.42 ND2 Glu34 40.85 NDUFA8 Cys87&Cys99 18.33 
171 HIS ND1  3 ND1 Glu192 27.84 ND2 Glu34 48.04 NDUFA8 Cys87&Cys99 17.94 
196 THR ND1  3 ND1 Glu192 8.59 ND2 Glu34 41.09 NDUFA8 Cys87&Cys99 46.31 
213 ILE ND1  3 ND3-Cys39 10.05 ND2 Glu34 42.92 NDUFA9 NADPH 30.90 
239 THR ND1  3 ND1 Glu192 14.27 ND2 Glu34 42.09 NDUFA8 Cys87&Cys99 27.27 
241 ILE ND1  3 ND1 Glu192 14.16 ND2 Glu34 37.76 NDUFA8 Cys87&Cys99 26.06 
249 ALA ND1  3 ND1 Glu192 29.57 ND2 Glu34 50.32 NDUFA8 Cys87&Cys99 10.69 
258 TYR ND1  3 ND1 Glu192 22.85 ND2 Glu34 50.95 NDUFA8 Cys87&Cys99 23.86 
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260 VAL ND1  3 ND1 Glu192 19.26 ND2 Glu34 48.91 NDUFA8 Cys87&Cys99 27.39 
265 LEU ND1  3 ND1 Glu192 17.78 ND2 Glu34 49.21 NDUFA8 Cys87&Cys99 33.99 
266 LEU ND1  3 ND1 Glu192 14.20 ND2 Glu34 45.61 NDUFA8 Cys87&Cys99 34.52 
268 SER ND1  3 Q-site 15.40 ND2 Glu34 48.96 NDUFA8 Cys87&Cys99 38.65 
273 ILE ND1  3 Q-site 13.67 ND2 Glu34 46.67 NDUFA8 Cys87&Cys99 44.62 
292 ASN ND1  3 ND1 Glu143 14.63 ND2 Glu34 32.54 NDUFA8 Cys87&Cys99 48.07 
300 LEU ND1  3 ND3 Glu68 14.91 ND2 Glu34 31.17 NDUFA8 Cys87&Cys99 37.59 
305 VAL ND1  3 ND3 Glu68 14.84 ND2 Glu34 29.50 NDUFA8 Cys87&Cys99 33.75 
310 THR ND1  3 ND3 Glu68 22.85 ND2 Glu34 36.94 NDUFA8 Cys87&Cys99 32.73 
313 SER ND1  3 ND3 Glu68 24.96 ND2 Glu34 38.29 NDUFA8 Cys87&Cys99 25.05 
318 THR ND1  3 ND3 Glu68 26.79 ND2 Glu34 36.46 NDUFA8 Cys87&Cys99 17.89 
11 SER ND2  3 ND4L Glu70 18.10 ND2 Glu34 14.22 NDUFS5 Cys32&Cys65 40.47 
15 ALA ND2  3 ND4L Glu70 15.57 ND2 Glu34 10.82 NDUFS5 Cys32&Cys65 34.61 
19 ILE ND2  3 ND4L Glu70 14.90 ND2 Glu34 10.20 NDUFS5 Cys32&Cys65 28.81 
48 MET ND2  3 ND4L Glu70 19.79 ND2 Leu131 pi bulge 20.31 NDUFA10 ADP 34.93 
49 ASN ND2  3 ND4L Glu70 22.07 ND2 Leu131 pi bulge 19.81 NDUFA10 ADP 32.89 
62 THR ND2  3 ND4L Glu70 10.12 ND2 Lys105 7.40 NDUFS5 Cys32&Cys65 36.96 
69 ILE ND2  3 ND4L Glu70 10.42 ND2 Lys105 9.04 NDUFS5 Cys32&Cys65 26.27 
78 ASN ND2  3 ND4L Glu70 20.16 ND2 Glu34 17.34 NDUFS5 Cys32&Cys65 12.01 
79 MET ND2  3 ND4L Glu70 21.16 ND2 Glu34 18.84 NDUFS5 Cys32&Cys65 11.74 
81 SER ND2  3 ND4L Glu70 25.52 ND2 Glu34 22.73 NDUFS5 Cys32&Cys65 10.32 
85 THR ND2  3 ND4L Glu70 21.32 ND2 Glu34 18.41 NDUFS5 Cys32&Cys65 15.83 
94 SER ND2  3 ND4L Glu70 19.10 ND2 Lys105 14.79 NDUFS5 Cys32&Cys65 20.80 
98 ILE ND2  3 ND4L Glu70 15.26 ND2 Lys105 8.97 NDUFS5 Cys32&Cys65 25.33 
115 VAL ND2  3 ND4L Glu70 18.57 ND2 His112 5.60 NDUFA11 Cys94&Cys114 37.31 
125 THR ND2  3 ND4L Glu70 23.37 ND2 Leu131 pi bulge 9.85 NDUFA10 ADP 37.32 
139 ILE ND2  3 ND4L Glu70 17.82 ND2 Lys135 6.00 NDUFS5 Cys42&Cys55 29.45 
141 ILE ND2  3 ND4L Glu70 16.62 ND2 Lys135 10.04 NDUFS5 Cys42&Cys55 25.50 
145 ILE ND2  3 ND4L Glu70 21.54 ND2 Lys105 14.59 NDUFS5 Cys42&Cys55 20.09 
147 PRO ND2  3 ND4L Glu70 26.70 ND2 TMH4 Gly107-Phe111 17.03 NDUFS5 Cys42&Cys55 18.71 
148 SER ND2  3 ND4L Glu70 26.19 ND2 TMH4 Gly107-Phe111 17.76 NDUFS5 Cys42&Cys55 17.62 
156 THR ND2  3 ND4L Glu70 27.41 ND2 TMH4 Gly107-Phe111 6.88 NDUFA11 Cys94&Cys114 26.21 
159 ILE ND2  3 ND4L Glu70 28.55 ND2 TMH4 Gly107-Phe111 7.21 NDUFA11 Cys94&Cys114 24.91 
166 SER ND2  3 ND4L Glu70 30.69 ND2 His112 9.48 NDUFA11 Cys94&Cys114 25.62 
187 MET ND2  3 ND4L Glu70 22.75 ND2 His186 3.78 NDUFA11 Cys94&Cys114 34.24 
200 MET ND2  3 ND4L Glu70 29.75 ND2 Lys263 9.82 NDUFS5 Cys42&Cys55 30.66 
209 ILE ND2  3 ND4L Glu70 25.37 ND2 Leu131 pi bulge 7.45 NDUFS5 Cys42&Cys55 41.02 
219 LEU ND2  3 ND4L Glu70 31.89 ND2 Leu131 pi bulge 12.33 NDUFA10 ADP 33.21 
220 ASN ND2  3 ND4L Glu70 31.73 ND2 Leu131 pi bulge 14.04 NDUFA10 ADP 32.38 
222 ASN ND2  3 ND4L Glu70 36.11 ND2 Leu131 pi bulge 17.69 NDUFA10 ADP 28.08 
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238 THR ND2  3 ND4L Glu70 47.09 ND2 TMH9 Gly252-Gly259 19.32 NDUFA10 ADP 31.12 
239 TRP ND2  3 ND4L Glu70 46.03 ND2 TMH9 Gly252-Gly259 16.48 NDUFA10 ADP 34.51 
241 THR ND2  3 ND4L Glu70 43.66 ND2 TMH9 Gly252-Gly259 13.68 NDUFA10 ADP 35.18 
242 PRO ND2  3 ND4L Glu70 43.48 ND2 TMH9 Gly252-Gly259 10.12 NDUFA10 ADP 39.00 
246 SER ND2  3 ND4L Glu70 39.11 ND2 TMH9 Gly252-Gly259 5.26 NDUFA11 Cys94&Cys114 40.42 
266 ILE ND2  3 ND4L Glu70 33.78 ND2 Lys263 5.40 NDUFA11 Cys94&Cys114 33.60 
267 ILE ND2  3 ND4L Glu70 36.84 ND2 Lys263 6.58 NDUFA11 Cys94&Cys114 31.01 
276 LEU ND2  3 ND4L Glu70 40.25 ND2 Lys263 14.47 NDUFA11 Cys94&Cys114 25.39 
277 ILE ND2  3 ND4L Glu70 39.20 ND2 Lys263 15.25 NDUFA11 Cys94&Cys114 22.12 
281 ILE ND2  3 ND4L Glu70 36.48 ND2 Lys263 12.55 NDUFA11 Cys94&Cys114 20.71 
285 ILE ND2  3 ND4L Glu70 35.39 ND2 Lys263 10.16 NDUFA11 Cys94&Cys114 21.45 
286 THR ND2  3 ND4L Glu70 34.48 ND2 Lys263 6.85 NDUFA11 Cys94&Cys114 24.98 
317 PHE ND2  3 ND4L Glu70 45.47 ND2 Leu131 pi bulge 29.29 NDUFA10 ADP 23.46 
320 THR ND2  3 ND4L Glu70 38.85 ND2 Leu131 pi bulge 23.48 NDUFA10 ADP 29.95 
330 ILE ND2  3 ND4L Glu70 36.90 ND2 TMH9 Gly252-Gly259 8.03 NDUFA10 ADP 43.93 
332 LEU ND2  3 ND4L Glu70 36.49 ND2 TMH9 Gly252-Gly259 5.50 NDUFB10 Cys70&Cys77 44.54 
333 THR ND2  3 ND4L Glu70 36.18 ND2 TMH9 Gly252-Gly259 3.32 NDUFA11 Cys94&Cys114 44.25 
343 MET ND2  3 ND4L Glu70 36.26 ND2 TMH9 Gly252-Gly259 8.86 NDUFB10 Cys70&Cys77 36.79 
345 MET ND2  3 ND4L Glu70 35.21 ND2 TMH9 Gly252-Gly259 14.81 NDUFS5 Cys42&Cys55 32.26 
346 ILE ND2  3 ND4L Glu70 31.98 ND2 TMH9 Gly252-Gly259 14.86 NDUFS5 Cys42&Cys55 31.49 
14 ALA ND3  3 Q-site 14.72 ND2 Glu34 41.28 NDUFA9 NADPH 32.76 
19 ILE ND3  3 Q-site 18.93 ND2 Glu34 45.37 NDUFA9 NADPH 25.95 
24 LEU ND3  3 Q-site 18.06 ND2 Glu34 54.28 NDUFA9 NADPH 17.52 
44 MET ND3  3 ND3-Cys39 10.72 ND2 Glu34 44.75 NDUFAB1 (α)-acyl chain 17.46 
89 MET ND3  3 ND3 Glu68 13.07 ND2 Glu34 25.17 NDUFS5 Cys32&Cys65 33.75 
90 SER ND3  3 ND3 Glu68 10.42 ND2 Glu34 21.57 NDUFS5 Cys32&Cys65 31.31 
93 LEU ND3  3 ND3 Glu68 7.59 ND2 Glu34 21.25 NDUFS5 Cys32&Cys65 35.44 
97 ILE ND3  3 ND3 Glu68 4.68 ND2 Glu34 19.17 NDUFS5 Cys32&Cys65 38.43 
105 GLU ND3  3 ND3 Glu68 13.03 ND2 Glu34 23.28 NDUFS5 Cys32&Cys65 48.28 
6 VAL ND4  3 ND4L Glu70 59.27 ND2 TMH9 Gly252-Gly259 17.73 NDUFB10 Cys70&Cys77 35.02 
21 HIS ND4  3 ND4L Glu70 68.40 ND4 Ala223 pi bulge 25.71 NDUFA10 ADP 45.01 
29 THR ND4  3 ND4L Glu70 70.25 ND4 Lys237 23.75 NDUFB10 Cys70&Cys77 47.33 
45 ILE ND4  3 ND4L Glu70 74.41 ND4 Lys237 23.58 NDUFB10 Cys70&Cys77 20.74 
46 ASN ND4  3 ND4L Glu70 73.00 ND4 Lys237 21.80 
NDUFB11 Cys112&NDUFB10 
Cys148 
17.84 
52 CYS ND4  3 ND4L Glu70 63.89 ND4 Lys237 23.87 NDUFB10 Cys70&Cys77 19.40 
55 THR ND4  3 ND4L Glu70 55.45 ND2 TMH9 Gly252-Gly259 17.56 NDUFB10 Cys70&Cys77 22.12 
58 SER ND4  3 ND4L Glu70 63.86 ND4 Lys237 16.69 NDUFB10 Cys70&Cys77 22.75 
70 THR ND4  3 ND4L Glu70 65.49 ND4 Lys237 13.13 NDUFB10 Cys70&Cys77 37.73 
85 SER ND4  3 ND4L Glu70 66.13 ND4 Ala223 pi bulge 17.53 NDUFA10 ADP 41.40 
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104 ILE ND4  3 ND4L Glu70 56.00 ND2 TMH9 Gly252-Gly259 11.53 NDUFB10 Cys70&Cys77 36.19 
107 ILE ND4  3 ND4L Glu70 58.39 ND4 Glu123 13.05 NDUFB10 Cys70&Cys77 31.91 
121 PHE ND4  3 ND4L Glu70 49.93 ND4 Glu123 5.35 NDUFB10 Cys70&Cys77 32.30 
129 THR ND4  3 ND4L Glu70 52.34 ND4 Lys206 8.71 NDUFA11 Cys94&Cys114 36.65 
166 TYR ND4  3 ND4L Glu70 45.79 ND2 Lys263 15.27 NDUFB10 Cys70&Cys77 26.90 
170 THR ND4  3 ND4L Glu70 49.11 ND2 Lys263 20.24 NDUFB10 Cys70&Cys77 21.86 
187 SER ND4  3 ND4L Glu70 58.05 ND4 TMH7 Met207-Leu214 23.66 
NDUFB11 Cys112&NDUFB10 
Cys148 
20.03 
193 ASN ND4  3 ND4L Glu70 54.21 ND4 TMH7 Met207-Leu214 15.94 NDUFA11 Cys94&Cys114 21.18 
201 MET ND4  3 ND4L Glu70 52.92 ND4 TMH7 Met207-Leu214 5.97 NDUFA11 Cys94&Cys114 22.36 
225 ILE ND4  3 ND4L Glu70 63.28 ND4 Ala223 pi bulge 5.63 NDUFA11 Cys94&Cys114 43.44 
232 ALA ND4  3 ND4L Glu70 62.86 ND4 His220 3.58 NDUFA11 Cys94&Cys114 36.91 
291 ILE ND4  3 ND4L Glu70 64.86 ND4 TMH7 Met207-Leu214 4.49 NDUFA11 Cys94&Cys114 30.05 
317 ILE ND4  3 ND4L Glu70 69.63 ND4 His319 5.52 
NDUFB11 Cys112&NDUFB10 
Cys148 
31.34 
320 GLY ND4  3 ND4L Glu70 67.88 ND4 His319 3.78 
NDUFB11 Cys112&NDUFB10 
Cys148 
35.96 
350 THR ND4  3 ND4L Glu70 88.82 
ND4 TMH12 Leu367-
Thr372 
22.00 NDUFB9 LYK (18-20) 34.11 
365 ALA ND4  3 ND4L Glu70 78.32 
ND4 TMH12 Leu367-
Thr372 
5.21 ND5 Cys279&NDUFB8 Cys115 37.97 
391 ILE ND4  3 ND4L Glu70 78.20 ND4 Glu378 16.53 ND5 Cys279&NDUFB8 Cys115 26.24 
418 SER ND4  3 ND4L Glu70 87.66 
ND4 TMH12 Leu367-
Thr372 
22.90 NDUFB9 LYK (18-20) 26.32 
419 LEU ND4  3 ND4L Glu70 86.48 
ND4 TMH12 Leu367-
Thr372 
23.71 NDUFB9 LYK (18-20) 28.91 
420 THR ND4  3 ND4L Glu70 83.56 
ND4 TMH12 Leu367-
Thr372 
25.13 NDUFB9 LYK (18-20) 30.79 
421 HIS ND4  3 ND4L Glu70 84.86 
ND4 TMH12 Leu367-
Thr372 
27.86 NDUFB9 LYK (18-20) 31.67 
425 ASN ND4  3 ND4L Glu70 78.29 ND4 Ala223 pi bulge 22.28 NDUFB9 LYK (18-20) 41.01 
434 ASN ND4  3 ND4L Glu70 78.54 
ND4 TMH12 Leu367-
Thr372 
19.70 NDUFB9 LYK (18-20) 50.46 
435 THR ND4  3 ND4L Glu70 77.56 
ND4 TMH12 Leu367-
Thr372 
18.93 
NDUFB11 Cys112&NDUFB10 
Cys148 
50.73 
455 THR ND4  3 ND4L Glu70 74.16 ND4 Glu378 13.94 
NDUFB11 Cys112&NDUFB10 
Cys148 
22.87 
21 VAL ND4L  3 ND4L Glu34 15.93 ND2 TMH4 Gly107-Phe111 13.34 NDUFS5 Cys32&Cys65 40.52 
59 VAL ND4L  3 ND4L Glu70 14.99 ND2 Glu34 11.93 NDUFS5 Cys32&Cys65 18.51 
79 VAL ND4L  3 ND4L Glu34 13.91 ND2 Glu34 20.97 NDUFA6 LYR (34-36) 38.94 
80 SER ND4L  3 ND4L Glu70 15.49 ND2 Glu34 21.16 NDUFA6 LYR (34-36) 38.34 
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2 THR ND5  3 ND4L Glu70 109.80 
ND4 TMH12 Leu367-
Thr372 
27.79 NDUFB10 Cys106&Cys118 20.27 
14 SER ND5  3 ND4L Glu70 104.05 
ND4 TMH12 Leu367-
Thr372 
19.62 NDUFB10 Cys106&Cys118 31.87 
18 PRO ND5  3 ND4L Glu70 100.97 
ND4 TMH12 Leu367-
Thr372 
19.09 NDUFB10 Cys106&Cys118 39.01 
27 ASN ND5  3 ND4L Glu70 99.99 
ND4 TMH12 Leu367-
Thr372 
26.05 NDUFB9 LYK (18-20) 46.48 
30 ASN ND5  3 ND4L Glu70 105.77 ND5 His248 29.05 NDUFB9 LYK (18-20) 47.73 
34 HIS ND5  3 ND4L Glu70 109.31 ND5 His248 22.83 NDUFB7 Cys68&Cys79 41.26 
38 SER ND5  3 ND4L Glu70 110.72 ND5 Lys336 23.57 NDUFB7 Cys68&Cys79 36.73 
39 ILE ND5  3 ND4L Glu70 108.05 ND5 His248 22.93 NDUFB7 Cys68&Cys79 36.23 
40 VAL ND5  3 ND4L Glu70 108.04 ND5 His248 19.64 NDUFB7 Cys68&Cys79 33.96 
45 ILE ND5  3 ND4L Glu70 114.73 ND5 His332 21.10 NDUFB7 Cys68&Cys79 26.85 
53 MET ND5  3 ND4L Glu70 117.91 ND5 His328 18.95 NDUFB7 Cys68&Cys79 14.45 
59 GLN ND5  3 ND4L Glu70 110.95 ND5 His328 22.95 NDUFB10 Cys106&Cys118 14.83 
63 ILE ND5  3 ND4L Glu70 100.12 
ND4 TMH12 Leu367-
Thr372 
18.91 NDUFB10 Cys106&Cys118 14.76 
65 ASN ND5  3 ND4L Glu70 95.78 
ND4 TMH12 Leu367-
Thr372 
15.90 NDUFB10 Cys106&Cys118 18.33 
67 HIS ND5  3 ND4L Glu70 88.89 
ND4 TMH12 Leu367-
Thr372 
12.50 NDUFB10 Cys106&Cys118 20.58 
70 THR ND5  3 ND4L Glu70 82.90 
ND4 TMH12 Leu367-
Thr372 
15.38 NDUFB10 Cys106&Cys118 21.58 
76 LEU ND5  3 ND4L Glu70 86.94 
ND4 TMH12 Leu367-
Thr372 
11.70 NDUFB10 Cys106&Cys118 19.39 
88 MET ND5  3 ND4L Glu70 110.82 ND5 His328 12.50 NDUFB7 Cys68&Cys79 21.43 
93 ALA ND5  3 ND4L Glu70 107.38 ND5 His332 10.59 NDUFB7 Cys68&Cys79 28.62 
109 ASN ND5  3 ND4L Glu70 107.80 ND5 His248 20.39 NDUFB9 LYK (18-20) 32.56 
113 ASN ND5  3 ND4L Glu70 98.54 ND5 His248 19.92 NDUFB9 LYK (18-20) 35.12 
127 THR ND5  3 ND4L Glu70 95.48 ND5 Glu145 8.54 NDUFB10 Cys106&Cys118 29.79 
132 VAL ND5  3 ND4L Glu70 100.26 ND5 Lys223 10.27 NDUFB10 Cys106&Cys118 23.37 
141 PHE ND5  3 ND4L Glu70 89.06 
ND4 TMH12 Leu367-
Thr372 
4.43 NDUFB10 Cys106&Cys118 25.31 
147 VAL ND5  3 ND4L Glu70 93.54 ND5 Lys223 4.99 ND5 Cys279&NDUFB8 Cys115 27.42 
162 ALA ND5  3 ND4L Glu70 90.26 ND5 His248 16.13 NDUFB9 LYK (18-20) 25.28 
169 ILE ND5  3 ND4L Glu70 86.97 ND5 Arg176 9.51 ND5 Cys279&NDUFB8 Cys115 28.39 
172 ILE ND5  3 ND4L Glu70 87.83 ND5 Arg176 5.39 ND5 Cys279&NDUFB8 Cys115 25.38 
177 ILE ND5  3 ND4L Glu70 86.50 ND5 Arg176 3.79 ND5 Cys279&NDUFB8 Cys115 20.17 
196 TRP ND5  3 ND4L Glu70 89.41 
ND4 TMH12 Leu367-
Thr372 
12.94 NDUFB10 Cys106&Cys118 16.07 
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206 ALA ND5  3 ND4L Glu70 97.89 ND5 Asp179 22.77 NDUFB10 Cys106&Cys118 13.57 
209 SER ND5  3 ND4L Glu70 93.36 ND5 Asp179 18.31 ND5 Cys279&NDUFB8 Cys115 19.81 
211 THR ND5  3 ND4L Glu70 89.69 ND5 Asp179 14.21 ND5 Cys279&NDUFB8 Cys115 18.02 
271 PRO ND5  3 ND4L Glu70 103.33 ND5 TMH7 Gly222-Pro264 17.74 ND5 Cys279&NDUFB8 Cys115 11.89 
273 ILE ND5  3 ND4L Glu70 99.56 ND5 TMH7 Gly222-Pro258 13.53 ND5 Cys279&NDUFB8 Cys115 9.62 
290 VAL ND5  3 ND4L Glu70 108.30 ND5 His230 10.67 ND5 Cys279&NDUFB8 Cys115 16.34 
304 PHE ND5  3 ND4L Glu70 105.76 ND5 Lys336 8.28 ND5 Cys279&NDUFB8 Cys115 18.44 
317 ILE ND5  3 ND4L Glu70 106.10 ND5 His328 8.49 ND5 Cys279&NDUFB8 Cys115 11.65 
323 HIS ND5  3 ND4L Glu70 110.82 ND5 His328 8.44 ND5 Cys279&NDUFB8 Cys115 20.01 
331 THR ND5  3 ND4L Glu70 114.30 ND5 His332 3.78 NDUFB7 Cys68&Cys79 22.49 
377 SER ND5  3 ND4L Glu70 118.45 
ND5 TMH12 Gly382-
Tyr390 
6.96 ND5 Cys279&NDUFB8 Cys115 26.73 
378 LEU ND5  3 ND4L Glu70 121.49 
ND5 TMH12 Gly382-
Tyr390 
4.24 ND5 Cys279&NDUFB8 Cys115 27.42 
381 ALA ND5  3 ND4L Glu70 119.78 
ND5 TMH12 Gly382-
Tyr390 
3.77 ND5 Cys279&NDUFB8 Cys115 23.27 
400 ASN ND5  3 ND4L Glu70 117.57 
ND5 TMH12 Gly382-
Tyr390 
14.95 ND5 Cys279&NDUFB8 Cys115 16.05 
403 TYR ND5  3 ND4L Glu70 112.13 ND5 TMH7 Gly222-Pro264 20.13 ND5 Cys279&NDUFB8 Cys115 12.39 
413 LEU ND5  3 ND4L Glu70 115.92 ND5 Lys392 8.26 ND5 Cys279&NDUFB8 Cys115 13.53 
420 SER ND5  3 ND4L Glu70 118.30 
ND5 TMH12 Gly382-
Tyr390 
8.28 ND5 Cys279&NDUFB8 Cys115 21.86 
423 SER ND5  3 ND4L Glu70 116.57 ND5 Lys336 10.85 ND5 Cys279&NDUFB8 Cys115 24.31 
424 THR ND5  3 ND4L Glu70 119.78 
ND5 TMH12 Gly382-
Tyr390 
11.99 NDUFAB1 (β)-acyl chain 26.27 
440 LEU ND5  3 ND4L Glu70 118.65 ND5 Lys336 32.38 NDUFB9 LYK (18-20) 18.59 
441 THR ND5  3 ND4L Glu70 118.95 ND5 Lys336 29.01 NDUFB9 LYK (18-20) 20.44 
442 ASN ND5  3 ND4L Glu70 119.08 ND5 Lys336 27.51 NDUFB9 LYK (18-20) 23.80 
447 ASN ND5  3 ND4L Glu70 119.48 ND5 Lys336 22.28 NDUFB9 LYK (18-20) 36.35 
456 ARG ND5  3 ND4L Glu70 119.09 
ND5 TMH12 Gly382-
Tyr390 
13.61 NDUFB7 Cys68&Cys79 28.10 
461 SER ND5  3 ND4L Glu70 118.81 
ND5 TMH12 Gly382-
Tyr390 
5.08 NDUFB7 Cys68&Cys79 24.71 
472 ILE ND5  3 ND4L Glu70 118.10 
ND5 TMH12 Gly382-
Tyr390 
11.48 NDUFB7 Cys68&Cys79 12.88 
473 SER ND5  3 ND4L Glu70 118.40 
ND5 TMH12 Gly382-
Tyr390 
12.82 NDUFB7 Cys68&Cys79 11.81 
476 SER ND5  3 ND4L Glu70 116.04 
ND5 TMH12 Gly382-
Tyr390 
13.72 NDUFB7 Cys58-89 14.40 
477 PRO ND5  3 ND4L Glu70 119.57 
ND5 TMH12 Gly382-
Tyr390 
11.56 NDUFB7 Cys58-89 12.51 
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491 LEU ND5  3 ND4L Glu70 124.58 
ND5 TMH12 Gly382-
Tyr390 
3.64 ND5 Cys279&NDUFB8 Cys115 23.18 
492 ALA ND5  3 ND4L Glu70 126.16 
ND5 TMH12 Gly382-
Tyr390 
7.39 ND5 Cys279&NDUFB8 Cys115 24.37 
493 VAL ND5  3 ND4L Glu70 122.69 
ND5 TMH12 Gly382-
Tyr390 
7.83 ND5 Cys279&NDUFB8 Cys115 21.26 
500 THR ND5  3 ND4L Glu70 122.96 
ND5 TMH12 Gly382-
Tyr390 
16.56 NDUFAB1 (β)-acyl chain 25.47 
508 THR ND5  3 ND4L Glu70 124.95 
ND5 TMH12 Gly382-
Tyr390 
25.71 NDUFAB1 (β)-acyl chain 18.51 
509 ASN ND5  3 ND4L Glu70 122.35 
ND5 TMH12 Gly382-
Tyr390 
27.38 NDUFAB1 (β)-acyl chain 14.76 
513 MET ND5  3 ND4L Glu70 119.60 ND5 His230 29.38 NDUFAB1 (β)-acyl chain 9.96 
517 LEU ND5  3 ND4L Glu70 111.43 ND5 His230 20.98 NDUFAB1 (β)-acyl chain 15.03 
524 ASN ND5  3 ND4L Glu70 105.79 ND5 His230 12.68 NDUFAB1 (β)-acyl chain 15.82 
525 MET ND5  3 ND4L Glu70 103.54 ND5 His230 9.81 NDUFAB1 (β)-acyl chain 18.66 
546 GLN ND5  3 ND4L Glu70 71.22 ND5 Asp554 pi bulge 7.93 NDUFA11 Cys94&Cys114 28.93 
564 LYS ND5  3 ND4L Glu70 48.60 ND4 TMH7 Met207-Leu214 8.81 NDUFA11 Cys94&Cys114 17.50 
565 THR ND5  3 ND4L Glu70 47.70 ND4 TMH7 Met207-Leu214 11.30 NDUFA11 Cys94&Cys114 14.06 
569 HIS ND5  3 ND4L Glu70 42.32 ND4 TMH7 Met207-Leu214 16.05 NDUFA11 Cys94&Cys114 15.29 
571 ILE ND5  3 ND4L Glu70 39.41 ND2 His112 16.47 NDUFA11 Cys94&Cys114 20.52 
577 THR ND5  3 ND4L Glu70 29.90 ND2 His112 7.22 NDUFA11 Cys94&Cys114 24.74 
579 THR ND5  3 ND4L Glu70 30.70 ND2 His112 10.97 NDUFA11 Cys94&Cys114 28.93 
596 ILE ND5  3 ND4L Glu34 25.52 ND2 TMH4 Gly107-Phe111 11.47 NDUFA11 Cys17-Cy74 29.73 
602 ILE ND5  3 ND4L Glu70 29.90 ND2 TMH4 Gly107-Phe111 16.80 NDUFS5 Cys42&Cys55 26.76 
603 THR ND5  3 ND4L Glu70 33.20 ND2 TMH4 Gly107-Phe111 18.91 NDUFA11 Cys17-Cy74 26.34 
2 MET ND6  3 ND4L Glu34 31.91 ND2 Glu34 37.92 NDUFS5 Cys32&Cys65 26.40 
4 ALA ND6  3 ND4L Glu34 26.15 ND2 Glu34 32.66 NDUFS5 Cys32&Cys65 25.76 
34 VAL ND6  3 ND4L Glu34 13.03 ND2 Glu34 24.31 NDUFS5 Cys32&Cys65 34.24 
35 SER ND6  3 ND4L Glu34 11.71 ND2 Glu34 21.78 NDUFS5 Cys32&Cys65 31.01 
37 VAL ND6  3 ND6 pi-bulge (Gly61-62) 12.81 ND2 Glu34 23.45 NDUFS5 Cys32&Cys65 30.54 
38 VAL ND6  3 ND4L Glu34 15.27 ND2 Glu34 23.83 NDUFS5 Cys32&Cys65 28.50 
42 ILE ND6  3 ND4L Glu34 18.12 ND2 Glu34 23.93 NDUFS5 Cys32&Cys65 22.72 
45 ASN ND6  3 ND6 pi-bulge (Gly61-62) 22.38 ND2 Glu34 27.49 NDUFS5 Cys32&Cys65 21.38 
54 MET ND6  3 ND3 Asp66 10.28 ND2 Glu34 17.95 NDUFS5 Cys32&Cys65 27.00 
81 ALA ND6  3 ND4L Glu34 17.96 ND2 TMH4 Gly107-Phe111 28.59 NDUFAB1 (α)-acyl chain 33.24 
85 GLY ND6  3 ND4L Glu34 22.55 ND2 TMH4 Gly107-Phe111 28.16 NDUFAB1 (α)-acyl chain 33.81 
90 VAL ND6  3 ND4L Glu34 22.09 ND2 TMH4 Gly107-Phe111 23.67 NDUFAB1 (α)-acyl chain 42.49 
94 VAL ND6  3 ND4L Glu34 20.87 ND2 TMH4 Gly107-Phe111 21.74 NDUFS5 Cys32&Cys65 36.85 
102 LEU ND6  3 ND4L Glu34 23.93 ND2 TMH4 Gly107-Phe111 25.02 NDUFS5 Cys32&Cys65 26.33 
106 VAL ND6  3 ND4L Glu34 28.78 ND2 TMH4 Gly107-Phe111 28.68 NDUFS5 Cys32&Cys65 23.75 
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121 VAL ND6  3 ND4L Glu34 29.75 ND2 Glu34 33.67 NDUFS5 Cys32&Cys65 19.12 
134 LEU ND6  3 ND3 Glu68 28.89 ND2 Glu34 34.45 NDUFS5 Cys32&Cys65 19.84 
135 ILE ND6  3 ND3 Glu68 25.56 ND2 Glu34 31.01 NDUFS5 Cys32&Cys65 18.59 
140 ILE ND6  3 ND3 Glu68 18.35 ND2 Glu34 24.22 NDUFS5 Cys32&Cys65 19.60 
142 ALA ND6  3 ND3 Glu68 13.75 ND2 Glu34 19.02 NDUFS5 Cys32&Cys65 20.94 
150 ARG ND6  3 ND3 Glu68 13.24 ND2 Glu34 18.39 NDUFS5 Cys32&Cys65 26.10 
155 VAL ND6  3 ND3 Glu68 10.32 ND2 Glu34 11.31 NDUFS5 Cys32&Cys65 29.74 
161 PHE ND6  3 ND3 Glu68 6.52 ND2 Glu34 14.08 NDUFS5 Cys32&Cys65 38.16 
162 VAL ND6  3 ND3 Glu68 9.95 ND2 Glu34 12.04 NDUFS5 Cys32&Cys65 38.74 
174 ASN ND6  3 ND4L Glu70 22.87 ND2 Glu34 25.79 NDUFA10 ADP 34.81 
2 ARG NDUFA10  3 ND4L Glu70 37.15 ND2 Leu131 pi bulge 27.01 NDUFA10 ADP 34.68 
137 ALA NDUFA10  3 ND4L Glu70 56.79 ND2 Leu131 pi bulge 47.40 NDUFA10 ADP 9.82 
142 GLY NDUFA10  3 ND4L Glu70 61.51 ND4 Ala223 pi bulge 48.56 NDUFA10 ADP 15.88 
165 PRO NDUFA10  3 ND4L Glu70 40.18 ND2 Leu131 pi bulge 36.86 NDUFA10 ADP 18.91 
182 ARG NDUFA10  3 NDUFS2 H59 66.36 ND2 Leu131 pi bulge 61.10 NDUFA10 ADP 9.15 
19 ARG NDUFA11  3 ND4L Glu34 49.75 ND2 TMH4 Gly107-Phe111 31.76 NDUFA11 Cys17-Cy74 6.33 
65 VAL NDUFA11  3 ND4L Glu70 46.97 ND2 TMH4 Gly107-Phe111 26.36 NDUFA11 Cys94&Cys114 10.30 
99 THR NDUFA11  3 ND4L Glu70 50.78 ND4 TMH7 Met207-Leu214 28.01 NDUFA11 Cys94&Cys114 9.21 
111 ALA NDUFA11  3 ND4L Glu70 52.58 ND4 TMH7 Met207-Leu214 18.43 NDUFA11 Cys94&Cys114 4.42 
128 ARG NDUFA11  3 ND4L Glu70 46.60 ND2 TMH4 Gly107-Phe111 26.49 NDUFA11 Cys17-Cy74 16.52 
60 ARG NDUFA12  3 Fe-S cluster 29.51 ND2 Glu34 80.62 NDUFS6 Zinc 41.63 
9 MET NDUFA13  3 Fe-S cluster 31.26 ND2 Glu34 91.45 NDUFS6 Zinc 38.45 
24 LEU NDUFA13  3 NDUFS2 D160 25.85 ND2 Glu34 61.70 NDUFA8 Cys87&Cys99 58.87 
41 THR NDUFA13  3 ND1 Glu192 27.29 ND2 Glu34 46.90 NDUFA8 Cys87&Cys99 32.59 
69 ALA NDUFA13  3 ND3 Glu68 41.75 ND2 Glu34 47.82 NDUFA8 Cys35&Cys65 9.34 
80 ARG NDUFA13  3 ND3 Glu68 48.36 ND2 Glu34 49.22 NDUFA8 Cys45&Cys55 10.74 
87 ARG NDUFA13  3 ND4L Glu34 49.83 ND2 Glu34 50.06 NDUFA8 Cys45&Cys55 16.63 
34 ASP NDUFA2  3 Fe-S cluster 55.83 ND2 His112 120.22 NDUFAB1 (α)-acyl chain 53.79 
62 PRO NDUFA2  3 Fe-S cluster 54.20 ND2 His112 106.10 NDUFAB1 (α)-acyl chain 39.77 
63 LYS NDUFA2  3 Fe-S cluster 55.50 ND2 His112 105.64 NDUFAB1 (α)-acyl chain 39.81 
93 VAL NDUFA2  3 Fe-S cluster 65.73 ND2 His112 111.73 NDUFAB1 (α)-acyl chain 49.04 
11 ALA NDUFA3  3 ND3 Glu68 26.34 ND2 Glu34 41.04 NDUFA10 ADP 54.82 
49 PRO NDUFA3  3 ND3 Glu68 31.98 ND2 Glu34 38.90 NDUFA8 Cys35&Cys65 20.14 
2 GLY NDUFA5  3 NDUFS2 D160 46.83 ND2 Glu34 67.79 NDUFA10 ADP 39.85 
63 ARG NDUFA6  3 ND3-Cys39 32.63 ND2 His112 60.36 NDUFA6 LYR (34-36) 4.85 
4 THR NDUFA7  3 Q-site 31.83 ND2 Glu34 71.68 NDUFA8 Cys87&Cys99 49.35 
7 ILE NDUFA7  3 Q-site 28.58 ND2 Glu34 66.00 NDUFA8 Cys87&Cys99 46.60 
29 GLU NDUFA7  3 NDUFS2 Y108 31.92 ND2 Glu34 81.78 NDUFS6 Zinc 45.83 
37 PRO NDUFA7  3 Fe-S cluster 25.81 ND2 Glu34 96.57 NDUFS6 Zinc 26.93 
50 ASN NDUFA7  3 Fe-S cluster 23.64 ND2 Glu34 110.97 NDUFS6 Zinc 34.07 
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57 ASP NDUFA7  3 Fe-S cluster 22.29 ND2 Glu34 99.87 NDUFS6 Zinc 36.37 
59 ARG NDUFA7  3 Fe-S cluster 23.16 ND2 Glu34 95.58 NDUFS6 Zinc 37.64 
43 MET NDUFA8  3 ND3 Glu68 44.13 ND2 Glu34 46.55 NDUFA8 Cys45&Cys55 5.21 
54 ARG NDUFA8  3 ND3 Glu68 50.81 ND2 Glu34 49.75 NDUFA8 Cys45&Cys55 3.82 
134 ARG NDUFA8  3 ND3 Glu68 54.98 ND2 Glu34 55.02 NDUFA8 Cys45&Cys55 8.42 
21 ALA NDUFA9  3 Fe-S cluster 35.76 ND2 Glu34 82.47 NDUFA9 NADPH 14.46 
135 LEU NDUFA9  3 ND3-Cys39 44.95 ND2 TMH4 Gly107-Phe111 71.76 NDUFA9 NADPH 7.64 
187 ARG NDUFA9  3 ND3-Cys39 31.50 ND2 TMH4 Gly107-Phe111 46.42 NDUFA9 NADPH 21.68 
206 TYR NDUFA9  3 ND3-Cys39 32.83 ND2 TMH4 Gly107-Phe111 64.00 NDUFA9 NADPH 9.18 
235 ARG NDUFA9  3 ND3-Cys39 43.50 ND2 TMH4 Gly107-Phe111 62.45 NDUFA9 NADPH 16.59 
249 ALA NDUFA9  3 ND3-Cys39 28.05 ND2 TMH4 Gly107-Phe111 45.73 NDUFA9 NADPH 19.59 
342 ILE NDUFA9  3 ND3-Cys39 51.05 ND2 TMH4 Gly107-Phe111 64.97 NDUFA9 NADPH 23.16 
33 ARG NDUFB1  3 ND4L Glu70 61.37 ND2 TMH9 Gly252-Gly259 28.06 NDUFB10 Cys70&Cys77 22.05 
38 ARG NDUFB1  3 ND4L Glu70 71.26 ND2 TMH9 Gly252-Gly259 37.92 NDUFB10 Cys70&Cys77 16.15 
34 VAL NDUFB10  3 ND4L Glu70 113.60 
ND4 TMH12 Leu367-
Thr372 
31.69 NDUFB10 Cys106&Cys118 30.79 
65 PRO NDUFB10  3 ND4L Glu70 76.85 ND4 TMH7 Met207-Leu214 38.61 NDUFB10 Cys70&Cys77 7.04 
109 ARG NDUFB10  3 ND4L Glu70 106.01 
ND4 TMH12 Leu367-
Thr372 
28.41 NDUFB10 Cys106&Cys118 5.41 
139 LEU NDUFB10  3 ND4L Glu70 72.99 ND4 TMH7 Met207-Leu214 22.93 
NDUFB11 Cys112&NDUFB10 
Cys148 
7.31 
164 LYS NDUFB10  3 ND4L Glu70 89.26 ND4 Glu378 48.81 
NDUFB11 Cys112&NDUFB10 
Cys148 
24.83 
55 VAL NDUFB11  3 ND4L Glu70 80.10 ND4 Ala223 pi bulge 29.83 NDUFA10 ADP 55.64 
56 TRP NDUFB11  3 ND4L Glu70 78.03 ND4 Ala223 pi bulge 29.59 NDUFA10 ADP 55.94 
10 ARG NDUFB2  3 ND4L Glu70 124.68 ND5 Lys336 33.54 NDUFB9 LYK (18-20) 28.15 
60 VAL NDUFB3  3 ND4L Glu70 130.29 
ND5 TMH12 Gly382-
Tyr390 
21.34 NDUFAB1 (β)-acyl chain 27.29 
2 PHE NDUFB4  3 ND4L Glu70 107.07 ND5 His230 31.61 NDUFAB1 (β)-acyl chain 12.74 
25 SER NDUFB4  3 ND4L Glu70 96.39 ND5 Asp554 pi bulge 47.02 NDUFAB1 (β)-acyl chain 19.37 
66 ARG NDUFB4  3 ND4L Glu70 68.86 ND5 Asp554 pi bulge 19.54 NDUFB9 LYK (18-20) 39.62 
11 ILE NDUFB5  3 ND4L Glu70 96.01 ND5 His248 30.40 NDUFB9 LYK (18-20) 33.87 
87 TYR NDUFB5  3 ND4L Glu70 70.59 ND4 Lys237 29.80 NDUFB10 Cys70&Cys77 13.26 
137 PRO NDUFB5  3 ND3 Glu68 34.44 ND2 Glu34 35.17 NDUFS5 Cys32&Cys65 16.27 
10 ARG NDUFB6  3 ND4L Glu70 103.18 ND5 His248 46.61 NDUFB9 LYK (18-20) 23.62 
20 ARG NDUFB6  3 ND4L Glu70 105.96 ND5 His248 44.27 NDUFB9 LYK (18-20) 30.03 
25 GLN NDUFB6  3 ND4L Glu70 108.19 ND5 His248 39.22 NDUFB9 LYK (18-20) 35.09 
42 MET NDUFB6  3 ND4L Glu70 114.43 
ND4 TMH12 Leu367-
Thr372 
43.36 NDUFB7 Cys68&Cys79 58.21 
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80 ILE NDUFB6  3 ND4L Glu70 104.02 ND4 TMH12 Leu367-Thr372 23.77 NDUFB10 Cys106&Cys118 30.11 
108 THR NDUFB6  3 ND4L Glu70 125.75 
ND5 TMH12 Gly382-
Tyr390 
34.18 NDUFB7 Cys68&Cys79 15.91 
29 GLY NDUFB7  3 ND4L Glu70 129.92 
ND5 TMH12 Gly382-
Tyr390 
40.31 NDUFB7 Cys58-89 25.53 
43 GLN NDUFB7  3 ND4L Glu70 118.85 
ND5 TMH12 Gly382-
Tyr390 
32.52 NDUFB7 Cys58-89 14.69 
48 ALA NDUFB7  3 ND4L Glu70 113.48 ND5 His328 25.17 NDUFB10 Cys106&Cys118 12.43 
55 ARG NDUFB7  3 ND4L Glu70 118.13 
ND5 TMH12 Gly382-
Tyr390 
23.39 NDUFB7 Cys58-89 9.72 
61 HIS NDUFB7  3 ND4L Glu70 129.78 
ND5 TMH12 Gly382-
Tyr390 
21.40 NDUFB7 Cys58-89 5.43 
70 ARG NDUFB7  3 ND4L Glu70 123.92 
ND5 TMH12 Gly382-
Tyr390 
20.00 NDUFB7 Cys68&Cys79 5.40 
83 ARG NDUFB7  3 ND4L Glu70 128.25 
ND5 TMH12 Gly382-
Tyr390 
13.30 NDUFB7 Cys68&Cys79 7.11 
92 ARG NDUFB7  3 ND4L Glu70 131.33 
ND5 TMH12 Gly382-
Tyr390 
18.24 NDUFB7 Cys58-89 5.15 
105 ARG NDUFB7  3 ND4L Glu70 127.87 
ND5 TMH12 Gly382-
Tyr390 
31.49 NDUFB7 Cys58-89 25.55 
110 ARG NDUFB7  3 ND4L Glu70 133.02 
ND5 TMH12 Gly382-
Tyr390 
39.51 NDUFB7 Cys58-89 32.04 
112 LYS NDUFB7  3 ND4L Glu70 130.11 
ND5 TMH12 Gly382-
Tyr390 
42.18 ND5 Cys279&NDUFB8 Cys115 34.28 
28 MET NDUFB8  3 ND4L Glu70 77.85 ND5 Asp554 pi bulge 29.02 NDUFB9 LYK (18-20) 31.15 
38 ASP NDUFB8  3 ND4L Glu70 67.21 ND5 Asp554 pi bulge 18.29 NDUFA11 Cys94&Cys114 27.75 
75 PRO NDUFB8  3 ND4L Glu70 76.90 ND5 Asp554 pi bulge 23.75 NDUFB9 LYK (18-20) 30.87 
87 ARG NDUFB8  3 ND4L Glu70 84.28 ND5 TMH7 Gly222-Pro289 15.43 NDUFB9 LYK (18-20) 28.78 
93 THR NDUFB8  3 ND4L Glu70 96.95 ND5 TMH7 Gly222-Pro288 16.87 NDUFAB1 (β)-acyl chain 15.05 
94 PRO NDUFB8  3 ND4L Glu70 100.15 ND5 TMH7 Gly222-Pro288 19.19 NDUFAB1 (β)-acyl chain 12.16 
3 LEU NDUFB9  3 ND4L Glu70 101.46 ND5 TMH7 Gly222-Pro288 47.49 NDUFAB1 (β)-acyl chain 13.21 
7 PRO NDUFB9  3 ND4L Glu70 94.61 ND5 TMH7 Gly222-Pro288 39.76 NDUFB9 LYK (18-20) 17.56 
36 TYR NDUFB9  3 ND4L Glu70 119.85 ND5 TMH7 Gly222-Pro288 32.50 NDUFAB1 (β)-acyl chain 9.99 
46 ARG NDUFB9  3 ND4L Glu70 118.88 ND5 TMH7 Gly222-Pro288 40.35 NDUFAB1 (β)-acyl chain 5.36 
128 ARG NDUFB9  3 ND4L Glu70 93.57 ND4 Ala223 pi bulge 42.34 NDUFB9 LYK (18-20) 36.93 
143 THR NDUFB9  3 ND4L Glu70 92.65 ND4 Ala223 pi bulge 49.50 NDUFAB1 (β)-acyl chain 31.65 
174 ARG NDUFB9  3 ND4L Glu70 99.94 ND5 His248 30.38 NDUFB9 LYK (18-20) 24.04 
176 ARG NDUFB9  3 ND4L Glu70 103.08 ND5 His248 26.93 NDUFB9 LYK (18-20) 22.36 
178 MET NDUFB9  3 ND4L Glu70 100.49 ND5 His248 25.87 NDUFB9 LYK (18-20) 27.96 
41 GLU NDUFC1  3 ND4L Glu70 53.26 ND2 TMH9 Gly252-Gly259 35.42 NDUFB10 Cys70&Cys77 40.95 
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35 PHE NDUFC2  3 ND4L Glu70 47.72 ND2 TMH9 Gly252-Gly259 14.20 NDUFB10 Cys70&Cys77 41.47 
59 ARG NDUFC2  3 ND4L Glu70 46.71 ND2 TMH9 Gly252-Gly259 22.92 NDUFA10 ADP 45.98 
119 ARG NDUFC2  3 ND4L Glu70 74.11 ND4 Glu378 20.01 
NDUFB11 Cys112&NDUFB10 
Cys148 
14.40 
6 SER NDUFS1  3 Fe-S cluster 27.71 ND2 Leu131 pi bulge 124.07 NDUFS6 Zinc 62.54 
122 MET NDUFS1  3 Fe-S cluster 13.50 ND2 Glu34 103.41 NDUFS6 Zinc 30.73 
280 THR NDUFS1  3 Fe-S cluster 34.13 ND2 TMH4 Gly107-Phe111 99.77 NDUFA9 NADPH 37.67 
331 LEU NDUFS1  3 Fe-S cluster 48.37 ND2 TMH4 Gly107-Phe111 104.67 NDUFAB1 (α)-acyl chain 43.15 
334 LEU NDUFS1  3 Fe-S cluster 52.97 ND2 TMH4 Gly107-Phe111 102.81 NDUFAB1 (α)-acyl chain 42.07 
479 MET NDUFS1  3 Fe-S cluster 49.47 ND2 His112 138.27 NDUFAB1 (α)-acyl chain 71.38 
515 ARG NDUFS1  3 Fe-S cluster 53.71 ND2 TMH4 Gly107-Phe111 123.90 NDUFAB1 (α)-acyl chain 63.85 
634 ASP NDUFS1  3 Fe-S cluster 31.97 ND2 His112 108.88 NDUFAB1 (α)-acyl chain 43.59 
646 ASN NDUFS1  3 Fe-S cluster 49.47 ND2 His112 130.88 NDUFAB1 (α)-acyl chain 64.46 
689 LYS NDUFS1  3 Fe-S cluster 25.35 ND2 Glu34 123.28 NDUFS6 Zinc 33.45 
80 ILE NDUFS2  3 Q-site 10.35 ND2 Glu34 58.14 NDUFAB1 (α)-acyl chain 22.70 
379 VAL NDUFS2  3 Fe-S cluster 24.00 ND2 Glu34 82.71 NDUFAB1 (α)-acyl chain 36.57 
409 HIS NDUFS2  3 NDUFS2 D160 15.77 ND2 Glu34 41.42 NDUFAB1 (α)-acyl chain 35.96 
100 ARG NDUFS3  3 NDUFS2 Y108 32.82 ND2 Glu34 74.09 NDUFA6 LYR (34-36) 48.74 
94 SER NDUFS4  3 Fe-S cluster 39.93 ND2 His112 87.82 NDUFAB1 (α)-acyl chain 24.68 
115 SER NDUFS4  3 Fe-S cluster 15.94 ND2 Glu34 123.13 NDUFS6 Zinc 48.66 
71 THR NDUFS5  3 ND4L Glu34 36.77 ND2 Glu34 36.32 NDUFS5 Cys32&Cys65 9.70 
92 THR NDUFS5  3 ND4L Glu34 52.69 ND2 Glu34 56.26 NDUFS5 Cys32&Cys65 32.70 
97 HIS NDUFS5  3 ND4L Glu34 47.24 ND2 Glu34 50.28 NDUFA8 Cys45&Cys55 26.75 
133 ASP NDUFS7  3 Fe-S cluster 14.93 ND2 Glu34 69.12 NDUFA9 NADPH 23.23 
134 ARG NDUFS7  3 Fe-S cluster 16.73 ND2 Glu34 68.65 NDUFA9 NADPH 23.09 
148 THR NDUFS7  3 Fe-S cluster 10.20 ND2 Glu34 72.00 NDUFA9 NADPH 38.42 
11 SER NDUFV1  3 FMN 26.76 ND2 Glu34 154.51 NDUFS6 Zinc 69.07 
32 ARG NDUFV1  3 FMN 23.45 ND2 Glu34 167.69 NDUFS6 Zinc 67.16 
168 GLY NDUFV1  3 FMN 27.80 ND2 Glu34 169.25 NDUFS6 Zinc 75.73 
175 VAL NDUFV1  3 FMN 18.13 ND2 Glu34 157.00 NDUFS6 Zinc 60.14 
339 ARG NDUFV1  3 Fe-S cluster 18.30 ND2 Glu34 140.65 NDUFS6 Zinc 48.26 
376 MET NDUFV1  3 Fe-S cluster 17.96 ND2 Glu34 125.58 NDUFS6 Zinc 29.41 
385 ARG NDUFV1  3 Fe-S cluster 27.88 ND2 Glu34 117.39 NDUFS6 Zinc 30.44 
418 LEU NDUFV1  3 Fe-S cluster 19.54 ND2 Glu34 129.65 NDUFS6 Zinc 40.50 
19 THR NDUFV2  3 Fe-S cluster 31.54 ND2 Glu34 146.18 NDUFS6 Zinc 40.59 
76 PRO NDUFV2  3 Fe-S cluster 19.12 ND2 Glu34 137.45 NDUFS6 Zinc 40.03 
140 ILE NDUFV2  3 Fe-S cluster 12.99 ND2 Glu34 142.83 NDUFS6 Zinc 35.60 
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Appendix 7.9D Type of residue change for complex I subunit gene variants (with variant class reclassification). Residue number refers to the mature protein. 
 
Residue 
number 
Identity Subunit 
Mutation 
class 
Residue 
change 
Mutation change 
type 
Polymorphism class Residue change Polymorphism change type 
340 ARG ND4 1 R-H Mild 2 R-H Mild 
64 MET ND6 1 M-I Mild 2 M-V Mild 
52 ALA ND1 1 A-T Mild 3 A-T Mild 
110 SER ND1 1 S-N Medium 3 S-N Medium 
132 ALA ND1 1 A-T Mild 3 A-T Mild 
289 LEU ND1 1 L-M Mild 3 L-Q Severe 
34 SER ND3 1 S-P Medium 3 S-F Severe 
45 SER ND3 1 S-P Medium 3 S-Y Severe 
47 ALA ND3 1 A-T Mild 3 A-T Mild 
36 GLY ND6 1 G-S Medium 3 G-S Medium 
72 ALA ND6 1 A-V Medium 3 A-P Medium 
259 MET NDUFS2 1 M-T Severe 3 M-T Severe 
393 ALA NDUFS2 1 A-S Mild 3 A-S Mild 
30 TYR ND1 2 Y-H Mild 1 Y-H Mild 
1 MET ND1 2 M-K Severe 2 M-T Severe 
31 MET ND1 2 M-V Mild 2 M-V Mild 
164 THR ND1 2 T-A Mild 2 T-A Mild 
240 THR ND1 2 T-M Severe 2 T-A Mild 
57 ILE ND2 2 I-M Mild 2 I-M Mild 
60 ILE ND3 2 I-T Severe 2 I-T Severe 
109 THR ND4 2 T-A Mild 2 T-A Mild 
165 ILE ND4 2 I-T Severe 2 I-T Severe 
313 VAL ND4 2 V-I Mild 2 V-I Mild 
1 MET ND5 2 M-T Severe 2 M-T Severe 
159 TYR ND5 2 Y-H Mild 2 Y-H Mild 
434 GLN ND5 2 Q-R Mild 2 Q-R Mild 
132 SER ND6 2 S-A Mild 2 S-P Medium 
290 ARG NDUFS2 2 R-Q Mild 2 R-Q Mild 
28 LEU ND1 2 L-M Mild 3 L-M Mild 
277 TYR ND1 2 Y-C Severe 3 Y-H Mild 
409 TYR ND4 2 Y-H Mild 3 Y-H Mild 
26 ILE ND6 2 I-M Mild 3 I-V Mild 
117 ASN ND6 2 N-D Mild 3 N-D Mild 
21 TRP NDUFB3 2 L-P Severe 3 W-R Severe 
179 ARG NDUFV1 2 R-C Severe 3 R-C Severe 
366 ARG NDUFV1 2 R-C Severe 3 R-C Severe 
4 ALA ND1 3 A-T Mild 1 A-T Mild 
304 TYR ND1 3 Y-H Mild 1 Y-H Mild 
150 ASN ND2 3 N-D Mild 1 N-D Mild 
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number 
Identity Subunit 
Mutation 
class 
Residue 
change 
Mutation change 
type 
Polymorphism class Residue change Polymorphism change type 
331 ALA ND2 3 A-T Mild 1 A-T Mild 
458 ALA ND5 3 A-T Mild 1 A-T Mild 
544 THR ND5 3 T-M Severe 1 T-A Mild 
119 ASN ND6 3 N-D Mild 1 N-S Medium 
11 VAL ND1 3 V-A Medium 2 V-A Medium 
31 MET ND1 3 M-I Mild 2 M-T Severe 
39 VAL ND1 3 V-I Mild 2 V-I Mild 
64 ALA ND1 3 A-S Mild 2 A-S Mild 
64 ALA ND1 3 A-V Medium 2 A-V Medium 
113 VAL ND1 3 V-A Medium 2 V-A Medium 
144 VAL ND1 3 V-I Mild 2 V-I Mild 
147 ALA ND1 3 A-L Severe 2 A-T Mild 
64 ALA ND2 3 A-T Mild 2 A-T Mild 
122 THR ND2 3 T-A Mild 2 T-A Mild 
10 ASN ND3 3 N-D Mild 2 N-D Mild 
423 ILE ND4 3 I-V Mild 2 I-V Mild 
9 THR ND5 3 T-A Mild 2 T-A Mild 
21 THR ND5 3 T-A Mild 2 T-A Mild 
100 ILE ND5 3 I-V Mild 2 I-V Mild 
267 ALA ND5 3 A-T Mild 2 A-T Mild 
398 THR ND5 3 T-A Mild 2 T-A Mild 
33 ILE ND6 3 I-V Mild 2 I-V Mild 
58 ILE ND6 3 I-T Severe 2 I-V Mild 
32 GLY NDUFA1 3 G-R Severe 2 G-R Severe 
103 ARG NDUFA11 3 R-L Severe 2 R-L Severe 
408 LEU NDUFS1 3 L-V Mild 2 L-V Mild 
2 PRO ND1 3 P-L Severe 3 P-L Severe 
30 TYR ND1 3 Y-C Severe 3 Y-C Severe 
31 MET ND1 3 M-T Severe 3 M-I Mild 
128 ALA ND1 3 A-T Mild 3 A-P Medium 
176 LEU ND1 3 L-M Mild 3 L-M Mild 
187 ILE ND1 3 I-T Severe 3 I-V Mild 
230 ASN ND1 3 N-S Medium 3 N-S Medium 
276 ALA ND1 3 A-T Mild 3 A-T Mild 
328 THR ND2 3 T-M Severe 3 T-M Severe 
331 ALA ND2 3 A-S Mild 3 A-V Medium 
71 ALA ND4L 3 A-T Mild 3 A-T Mild 
99 SER ND5 3 S-T Mild 3 S-A Mild 
149 ILE ND5 3 I-S Severe 3 I-V Mild 
576 ILE ND5 3 I-T Severe 3 I-T Severe 
33 ILE ND6 3 I-V Mild 3 I-L Mild 
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change 
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type 
Polymorphism class Residue change Polymorphism change type 
112 VAL ND6 3 V-M Mild 3 V-M Mild 
171 ALA ND6 3 A-T Mild 3 A-V Medium 
100 LEU NDUFA10 3 L-S Severe 3 L-S Severe 
251 GLN NDUFA10 3 Q-E Mild 3 Q-E Mild 
40 ARG NDUFA9 3 R-L Severe 3 R-L Severe 
40 ARG NDUFA9 3 R-H Mild 3 R-H Mild 
50 ARG NDUFA9 3 R-W Severe 3 R-W Severe 
279 ILE NDUFA9 3 I-M Mild 3 I-M Mild 
157 ARG NDUFB9 3 R-G Severe 3 R-G Severe 
154 ILE NDUFS1 3 I-M Mild 3 I-V Mild 
181 MET NDUFS1 3 M-I Mild 3 M-T Severe 
483 VAL NDUFS1 3 V-I Mild 3 V-I Mild 
511 VAL NDUFS1 3 V-M Mild 3 V-M Mild 
287 VAL NDUFS2 3 V-A Medium 3 V-A Medium 
347 HIS NDUFS2 3 H-D Medium 3 H-D Medium 
210 ARG NDUFS3 3 R-C Severe 3 R-C Severe 
58 ALA NDUFS6 3 A-V Medium 3 A-V Medium 
60 ASP NDUFS6 3 D-N Medium 3 D-N Mild 
133 ALA NDUFV1 3 A-T Mild 3 A-T Mild 
337 MET NDUFV1 3 M-L Mild 3 M-L Mild 
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24 GLU ND1 1 E-K Mild  196 PRO NDUFS2 1 P-Q Severe 
131 GLY ND1 1 G-S Medium  380 SER NDUFS2 1 S-P Medium 
143 GLU ND1 1 E-K Mild  109 THR NDUFS3 1 T-I Severe 
195 ARG ND1 1 R-Q Mild  163 ARG NDUFS3 1 R-W Severe 
340 ARG ND4 1 R-S Severe  87 CYS NDUFS6 1 C-Y Severe 
65 VAL ND4L 1 V-A Medium  84 VAL NDUFS7 1 V-M Mild 
124 PHE ND5 1 F-L Mild  29 GLU NDUFS8 1 E-Q Mild 
393 ASP ND5 1 D-G Medium  43 ARG NDUFS8 1 R-W Severe 
393 ASP ND5 1 D-N Medium  45 PRO NDUFS8 1 P-L Severe 
60 LEU ND6 1 L-S Severe  51 PRO NDUFS8 1 P-L Severe 
63 MET ND6 1 M-V Mild  68 ARG NDUFS8 1 R-H Mild 
64 MET ND6 1 M-V Mild  104 ARG NDUFS8 1 R-H Mild 
8 GLY NDUFA1 1 G-R Severe  125 ALA NDUFS8 1 A-D Severe 
37 ARG NDUFA1 1 R-S Severe  97 ALA NDUFV1 1 A-T Mild 
107 GLN NDUFA10 1 Q-R Mild  102 PRO NDUFV1 1 P-L Severe 
286 ARG NDUFA9 1 R-P Severe  186 CYS NDUFV1 1 C-G Severe 
208 LEU NDUFS1 1 L-V Mild  194 GLU NDUFV1 1 E-K Mild 
218 ARG NDUFS1 1 R-W Severe  403 THR NDUFV1 1 T-M Severe 
229 ASP NDUFS1 1 D-G Medium        
385 ARG NDUFS1 1 R-C Severe        
572 THR NDUFS1 1 T-A Mild        
596 ASP NDUFS1 1 D-N Medium        
195 ARG NDUFS2 1 R-Q Mild        
 
 
 
 
 
 
 
 
 3
4
1
 
Residue 
number 
Identity Subunit 
Mutation 
class 
Residue change 
Mutation change 
type 
 Residue 
number 
Identity Subunit 
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Residue change 
Mutation change 
type 
59 GLU ND1 2 E-K Mild  684 MET NDUFS1 2 Y-C Severe 
208 VAL ND1 2 V-L Mild  77 ASP NDUFS2 2 D-V Severe 
214 GLU ND1 2 E-K Mild  85 ARG NDUFS2 2 R-Q Mild 
215 TYR ND1 2 Y-H Mild  105 ARG NDUFS2 2 R-Q Mild 
285 LEU ND1 2 L-P Severe  115 GLU NDUFS2 2 E-K Mild 
71 LEU ND2 2 L-M Mild  191 ALA NDUFS2 2 A-V Medium 
259 GLY ND2 2 G-S Medium  300 ARG NDUFS2 2 R-Q Mild 
26 GLN ND3 2 Q-K Mild  410 MET NDUFS2 2 M-K Severe 
66 ASP ND3 2 D-N Medium  413 ASP NDUFS2 2 D-N Medium 
32 CYS ND4L 2 C-R Severe  187 PRO NDUFS3 2 P-L Severe 
145 GLU ND5 2 E-G Severe  72 TRP NDUFS4 2 W-R Severe 
171 ALA ND5 2 A-V Medium  77 ASP NDUFS4 2 D-H Medium 
236 ALA ND5 2 A-T Mild  95 PRO NDUFS5 2 P-S Medium 
237 MET ND5 2 M-L Mild  67 ARG NDUFS7 2 R-C Severe 
250 SER ND5 2 S-C Severe  107 ARG NDUFS7 2 R-H Mild 
465 GLY ND5 2 G-E Severe  20 ARG NDUFS8 2 R-W Severe 
59 TYR ND6 2 Y-C Severe  60 ARG NDUFS8 2 R-C Severe 
74 ALA ND6 2 A-V Medium  120 GLY NDUFS8 2 G-S Medium 
19 PRO NDUFA1 2 P-S Medium  36 SER NDUFV1 2 S-P Medium 
64 GLY NDUFA10 2 G-E Severe  68 ARG NDUFV1 2 R-G Severe 
259 LEU NDUFA10 2 L-P Severe  91 LYS NDUFV1 2 K-E Mild 
56 ARG NDUFA13 2 R-H Mild  127 ARG NDUFV1 2 R-W Severe 
44 LYS NDUFA2 2 K-T Medium  184 TYR NDUFV1 2 Y-C Severe 
108 GLU NDUFA8 2 E-K Mild  191 ALA NDUFV1 2 A-V Medium 
92 GLU NDUFB11 2 E-K Mild  226 GLU NDUFV1 2 E-K Mild 
63 LEU NDUFB9 2 Y-C Severe  232 PRO NDUFV1 2 P-L Severe 
96 TYR NDUFB9 2 V-D Severe  321 ALA NDUFV1 2 A-V Medium 
48 VAL NDUFS1 2 G-E Severe  357 GLU NDUFV1 2 E-K Mild 
143 GLY NDUFS1 2 V-A Medium  358 SER NDUFV1 2 S-R Severe 
205 VAL NDUFS1 2 Q-K Mild  412 ALA NDUFV1 2 A-P Medium 
499 GLN NDUFS1 2 Y-C Severe  177 LYS NDUFV2 2 K-R Mild 
672 TYR NDUFS1 2 M-V Mild        
 
 
 
 
 
 
 
 3
4
2
 
Residue 
number 
Identity Subunit 
Mutation 
class 
Residue 
change 
Mutation 
change type  
Residue 
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12 PRO ND1 3 P-S Medium  9 TRP NDUFA11 3 W-C Severe 
25 ARG ND1 3 R-Q Mild  77 ALA NDUFA11 3 A-T Mild 
34 ARG ND1 3 R-H Mild  81 GLU NDUFA11 3 E-G Severe 
38 ASN ND1 3 N-D Mild  68 TYR NDUFA2 3 Y-C Severe 
56 PHE ND1 3 F-L Mild  26 ALA NDUFA9 3 A-V Medium 
143 GLU ND1 3 E-Q Mild  33 TYR NDUFA9 3 Y-C Severe 
218 GLY ND1 3 G-D Medium  287 MET NDUFA9 3 M-T Severe 
279 ARG ND1 3 R-Q Mild  303 LEU NDUFA9 3 L-F Mild 
55 ALA ND2 3 A-G Medium  60 THR NDUFB9 3 T-S Mild 
60 PHE ND2 3 F-S Severe  39 ARG NDUFS1 3 R-Q Mild 
128 LEU ND2 3 L-Q Severe  230 VAL NDUFS1 3 V-G Severe 
158 LEU ND4 3 L-P Severe  286 ASN NDUFS1 3 N-S Medium 
206 LYS ND4 3 K-Q Mild  432 ILE NDUFS1 3 I-V Mild 
372 THR ND4 3 T-N Medium  452 VAL NDUFS1 3 V-F Medium 
387 SER ND4 3 S-F Severe  543 ILE NDUFS1 3 I-F Mild 
412 THR ND4 3 T-I Severe  553 GLY NDUFS1 3 G-E Severe 
423 ILE ND4 3 I-T Severe  577 GLU NDUFS1 3 E-D Mild 
25 HIS ND4L 3 H-R Mild  680 ALA NDUFS1 3 A-T Mild 
41 PHE ND4L 3 F-C Severe  20 TYR NDUFS2 3 Y-C Severe 
96 VAL ND5 3 V-I Mild  376 VAL NDUFS2 3 V-M Mild 
239 GLY ND5 3 G-S Medium  42 ARG NDUFS4 3 R-H Mild 
243 VAL ND5 3 V-I Mild  49 VAL NDUFS6 3 V-M Mild 
253 VAL ND5 3 V-A Medium  55 ARG NDUFS6 3 R-W Severe 
312 LEU ND5 3 L-P Severe  74 ASN NDUFS6 3 N-I Severe 
348 HIS ND5 3 N-S Medium  77 ARG NDUFS7 3 R-C Severe 
392 LYS ND5 3 K-M Severe  81 VAL NDUFS7 3 V-I Mild 
415 ALA ND5 3 A-G Medium  167 ARG NDUFS7 3 R-G Severe 
499 LEU ND5 3 L-M Mild  71 PRO NDUFS8 3 P-S Medium 
505 ASN ND5 3 N-H Mild  81 LYS NDUFS8 3 K-E Mild 
585 LYS ND5 3 K-N Mild  109 TYR NDUFS8 3 Y-F Mild 
25 PRO ND6 3 P-L Severe  127 PRO NDUFS8 3 P-T Medium 
26 ILE ND6 3 I-T Severe  170 GLN NDUFS8 3 Q-L Severe 
79 PRO ND6 3 P-S Medium  19 ASP NDUFV1 3 D-G Medium 
82 TRP ND6 3 W-R Severe  75 THR NDUFV1 3 T-A Mild 
101 GLY ND6 3 G-V Severe  131 ALA NDUFV1 3 A-T Mild 
43 TYR NDUFA1 3 Y-H Mild  140 GLY NDUFV1 3 G-E Severe 
173 ASP NDUFA10 3 D-N Medium  247 ARG NDUFV1 3 R-K Mild 
176 VAL NDUFA10 3 V-I Mild  263 ASN NDUFV1 3 N-S Medium 
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297 VAL NDUFV1 3 V-A Medium  67 THR ND1 1 T-A Mild 
348 ALA NDUFV1 3 A-T Mild  81 ILE ND1 1 I-V Mild 
153 MET NDUFV2 3 M-V Mild  309 ILE ND1 1 I-T Severe 
158 ASP NDUFV2 3 D-G Medium  8 VAL ND2 1 V-I Mild 
       119 THR ND2 1 T-A Mild 
       193 VAL ND2 1 V-I Mild 
       237 LEU ND2 1 L-M Mild 
       325 PHE ND2 1 F-L Mild 
       88 VAL ND3 1 V-A Medium 
       114 THR ND3 1 T-A Mild 
       140 PRO ND4 1 P-S Medium 
       404 ALA ND4 1 A-T Mild 
       47 MET ND4L 1 M-T Severe 
       8 THR ND5 1 T-A Mild 
       24 VAL ND5 1 V-I Mild 
       257 ILE ND5 1 I-V Mild 
       314 MET ND5 1 M-V Mild 
       475 ALA ND5 1 A-T Mild 
       482 ILE ND5 1 I-V Mild 
       485 TYR ND5 1 Y-H Mild 
       531 SER ND5 1 S-T Mild 
       533 THR ND5 1 T-M Severe 
       555 LEU ND5 1 L-Q Severe 
       166 ILE ND6 1 I-V Mild 
       47 LYS NDUFA7 1 K-Q Mild 
       259 PRO NDUFA9 1 P-L Severe 
       145 PRO NDUFB9 1 P-S Medium 
       46 LEU NDUFC2 1 L-V Mild 
       102 VAL NDUFV2 1 V-A Medium 
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11 VAL ND1 2 V-M Mild  49 VAL ND3 2 V-I Mild 
29 GLY ND1 2 G-S Medium  88 VAL ND3 2 V-I Mild 
43 TYR ND1 2 Y-C Severe  96 ILE ND3 2 I-T Severe 
64 ALA ND1 2 A-T Mild  103 ALA ND3 2 A-T Mild 
69 THR ND1 2 T-A Mild  47 ASN ND4 2 N-S Medium 
87 THR ND1 2 T-A Mild  50 PHE ND4 2 F-L Mild 
89 LEU ND1 2 L-F Mild  54 PRO ND4 2 P-L Severe 
164 THR ND1 2 T-S Mild  86 SER ND4 2 S-N Medium 
187 ILE ND1 2 I-T Severe  89 LEU ND4 2 L-P Severe 
229 THR ND1 2 T-M Severe  101 SER ND4 2 S-F Severe 
240 THR ND1 2 T-M Severe  110 PHE ND4 2 F-L Mild 
248 ASP ND1 2 D-N Mild  131 ALA ND4 2 A-T Mild 
263 THR ND1 2 T-A Mild  131 ALA ND4 2 A-V Medium 
275 THR ND1 2 T-A Mild  138 ASN ND4 2 N-S Medium 
277 TYR ND1 2 Y-C Severe  149 PHE ND4 2 F-L Mild 
307 MET ND1 2 M-V Mild  230 VAL ND4 2 V-M Mild 
13 ILE ND2 2 I-V Mild  299 THR ND4 2 T-A Mild 
31 VAL ND2 2 V-A Medium  390 ASN ND4 2 N-S Medium 
43 VAL ND2 2 V-I Mild  402 VAL ND4 2 V-I Mild 
57 ILE ND2 2 I-T Severe  424 ASN ND4 2 N-S Medium 
88 ASN ND2 2 N-S Medium  442 SER ND4 2 S-F Severe 
100 MET ND2 2 M-V Mild  442 SER ND4 2 S-A Mild 
152 SER ND2 2 S-N Medium  445 LEU ND4 2 L-F Mild 
164 ALA ND2 2 A-T Mild  459 SER ND4 2 S-Y Severe 
164 ALA ND2 2 A-V Medium  13 THR ND4L 2 T-A Mild 
202 ILE ND2 2 I-T Severe  94 ASN ND4L 2 N-S Medium 
203 LEU ND2 2 L-F Mild  4 HIS ND5 2 H-Y Mild 
265 ALA ND2 2 A-T Mild  9 THR ND5 2 T-I Severe 
265 ALA ND2 2 A-V Medium  13 THR ND5 2 T-A Mild 
270 PHE ND2 2 F-L Mild  23 LEU ND5 2 L-F Mild 
278 ILE ND2 2 I-T Severe  69 ALA ND5 2 A-V Medium 
278 ILE ND2 2 I-V Mild  74 THR ND5 2 T-I Severe 
284 THR ND2 2 T-S Mild  182 PHE ND5 2 F-L Mild 
288 LEU ND2 2 L-I Mild  201 MET ND5 2 M-V Mild 
342 PHE ND2 2 F-L Mild  202 ALA ND5 2 A-T Mild 
9 ILE ND3 2 I-T Severe  205 ASN ND5 2 N-S Medium 
29 GLY ND3 2 G-S Medium  205 ASN ND5 2 N-T Medium 
45 SER ND3 2 S-F Severe  261 ILE ND5 2 I-V Mild 
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265 PRO ND5 2 P-S Medium  30 ASN NDUFA10 2 N-S Medium 
270 SER ND5 2 S-N Medium  13 LEU NDUFA2 2 L-V Mild 
283 ILE ND5 2 I-V Mild  20 VAL NDUFA3 2 V-L Mild 
410 SER ND5 2 S-F Severe  107 HIS NDUFA6 2 H-Y Mild 
432 THR ND5 2 T-A Mild  65 PRO NDUFA7 2 P-A Medium 
439 THR ND5 2 T-A Mild  18 MET NDUFB1 2 M-L Mild 
449 THR ND5 2 T-A Mild  141 ALA NDUFB10 2 A-T Mild 
459 ALA ND5 2 A-T Mild  52 PRO NDUFB2 2 P-L Severe 
469 THR ND5 2 T-A Mild  62 LEU NDUFB7 2 L-V Mild 
471 ASN ND5 2 N-S Medium  96 SER NDUFB8 2 S-T Mild 
478 PHE ND5 2 F-L Mild  120 VAL NDUFB8 2 V-M Mild 
495 PHE ND5 2 F-L Mild  123 VAL NDUFS3 2 V-L Mild 
515 SER ND5 2 S-Y Severe  8 VAL NDUFV2 2 V-M Mild 
515 SER ND5 2 S-P Medium  
       
518 CYS ND5 2 C-Y Severe  
       
530 PRO ND5 2 P-S Medium  
       
531 SER ND5 2 S-N Medium  
       
533 THR ND5 2 T-A Mild  
       
536 THR ND5 2 T-A Mild  
       
538 PRO ND5 2 P-S Medium  
       
541 GLY ND5 2 G-A Medium  
       
544 THR ND5 2 T-M Severe  
       
549 PRO ND5 2 P-S Medium  
       
556 THR ND5 2 T-A Mild  
       
573 THR ND5 2 T-A Mild  
       
575 ILE ND5 2 I-V Mild  
       
592 PHE ND5 2 F-L Mild  
       
598 THR ND5 2 T-I Severe  
       
598 THR ND5 2 T-A Mild  
       
14 MET ND6 2 M-V Mild  
       
31 VAL ND6 2 V-A Medium  
       
86 VAL ND6 2 V-A Medium  
       
97 ALA ND6 2 A-V Medium  
       
119 ASN ND6 2 N-D Mild  
       
120 SER ND6 2 S-N Medium         
159 THR ND6 2 T-M Severe         
165 TYR ND6 2 Y-C Severe        
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2 PRO ND1 3 P-S Medium  266 LEU ND1 3 L-M Mild 
5 ASN ND1 3 N-D Mild  268 SER ND1 3 S-F Severe 
10 ILE ND1 3 I-T Severe  273 ILE ND1 3 I-V Mild 
10 ILE ND1 3 I-V Mild  292 ASN ND1 3 N-D Mild 
15 ILE ND1 3 I-T Severe  292 ASN ND1 3 N-S Medium 
15 ILE ND1 3 I-V Mild  300 LEU ND1 3 L-S Severe 
17 MET ND1 3 M-V Mild  305 VAL ND1 3 V-I Mild 
21 MET ND1 3 M-T Severe  307 MET ND1 3 M-T Severe 
27 ILE ND1 3 I-V Mild  309 ILE ND1 3 I-V Mild 
29 GLY ND1 3 G-A Medium  310 THR ND1 3 T-S Mild 
68 ILE ND1 3 I-T Severe  313 SER ND1 3 S-G Medium 
68 ILE ND1 3 I-M Mild  318 THR ND1 3 T-I Severe 
73 THR ND1 3 T-A Mild  11 SER ND2 3 S-P Medium 
73 THR ND1 3 T-S Mild  15 ALA ND2 3 A-T Mild 
76 THR ND1 3 T-I Severe  19 ILE ND2 3 I-T Severe 
77 LEU ND1 3 L-M Mild  31 VAL ND2 3 V-M Mild 
81 ILE ND1 3 I-T Severe  48 MET ND2 3 M-T Severe 
96 VAL ND1 3 V-A Medium  49 ASN ND2 3 N-S Medium 
112 ALA ND1 3 A-T Mild  62 THR ND2 3 T-M Severe 
116 ILE ND1 3 I-V Mild  69 ILE ND2 3 I-V Mild 
139 THR ND1 3 T-A Mild  76 PHE ND2 3 F-S Severe 
147 ALA ND1 3 A-L Severe  76 PHE ND2 3 F-L Mild 
152 SER ND1 3 S-A Mild  78 ASN ND2 3 N-S Medium 
153 THR ND1 3 T-M Severe  79 MET ND2 3 M-T Severe 
168 THR ND1 3 T-A Mild  80 LEU ND2 3 L-F Mild 
171 HIS ND1 3 H-Y Mild  81 SER ND2 3 S-F Severe 
196 THR ND1 3 T-A Mild  85 THR ND2 3 T-A Mild 
213 ILE ND1 3 I-V Mild  89 THR ND2 3 T-A Mild 
236 THR ND1 3 T-I Severe  89 THR ND2 3 T-N Medium 
236 THR ND1 3 T-A Mild  94 SER ND2 3 S-P Medium 
239 THR ND1 3 T-A Mild  98 ILE ND2 3 I-M Mild 
241 ILE ND1 3 I-M Mild  100 MET ND2 3 M-T Severe 
249 ALA ND1 3 A-V Medium  115 VAL ND2 3 V-I Mild 
258 TYR ND1 3 Y-C Severe  125 THR ND2 3 T-M Severe 
260 VAL ND1 3 V-I Mild  139 ILE ND2 3 I-L Mild 
263 THR ND1 3 T-I Severe  141 ILE ND2 3 I-V Mild 
265 LEU ND1 3 L-F Mild  145 ILE ND2 3 I-L Mild 
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145 ILE ND2 3 I-M Mild  19 ILE ND3 3 I-T Severe 
147 PRO ND2 3 P-S Medium  24 LEU ND3 3 L-M Mild 
148 SER ND2 3 S-A Mild  44 MET ND3 3 M-V Mild 
152 SER ND2 3 S-T Mild  89 MET ND3 3 M-T Severe 
152 SER ND2 3 S-G Medium  90 SER ND3 3 S-L Severe 
156 THR ND2 3 T-I Severe  90 SER ND3 3 S-T Mild 
159 ILE ND2 3 I-V Mild  90 SER ND3 3 S-P Medium 
166 SER ND2 3 S-G Medium  93 LEU ND3 3 L-S Severe 
187 MET ND2 3 M-T Severe  97 ILE ND3 3 I-T Severe 
187 MET ND2 3 M-V Mild  103 ALA ND3 3 A-V Medium 
200 MET ND2 3 M-I Mild  114 THR ND3 3 T-S Mild 
200 MET ND2 3 M-V Mild  6 VAL ND4 3 V-A Medium 
209 ILE ND2 3 I-T Severe  21 HIS ND4 3 H-Q Mild 
220 ASN ND2 3 N-D Mild  29 THR ND4 3 T-I Severe 
220 ASN ND2 3 N-S Medium  45 ILE ND4 3 I-F Mild 
222 ASN ND2 3 N-S Medium  46 ASN ND4 3 N-D Mild 
238 THR ND2 3 T-A Mild  50 PHE ND4 3 F-S Severe 
239 TRP ND2 3 W-C Severe  52 CYS ND4 3 C-Y Severe 
241 THR ND2 3 T-M Severe  58 SER ND4 3 S-P Medium 
242 PRO ND2 3 P-L Severe  70 THR ND4 3 T-A Mild 
246 SER ND2 3 S-F Severe  85 SER ND4 3 S-F Severe 
246 SER ND2 3 S-P Medium  86 SER ND4 3 S-G Medium 
266 ILE ND2 3 I-V Mild  104 ILE ND4 3 I-V Mild 
267 ILE ND2 3 I-V Mild  107 ILE ND4 3 I-V Mild 
276 LEU ND2 3 L-F Mild  121 PHE ND4 3 F-L Mild 
277 ILE ND2 3 I-V Mild  129 THR ND4 3 T-S Mild 
284 THR ND2 3 T-A Mild  165 ILE ND4 3 I-V Mild 
285 ILE ND2 3 I-L Mild  166 TYR ND4 3 Y-H Mild 
286 THR ND2 3 T-S Mild  170 THR ND4 3 T-I Severe 
317 PHE ND2 3 F-L Mild  187 SER ND4 3 S-P Medium 
320 THR ND2 3 T-A Mild  193 ASN ND4 3 N-S Medium 
323 THR ND2 3 T-I Severe  201 MET ND4 3 M-T Severe 
323 THR ND2 3 T-A Mild  225 ILE ND4 3 I-V Mild 
330 ILE ND2 3 I-V Mild  232 ALA ND4 3 A-T Mild 
332 LEU ND2 3 L-F Mild  291 ILE ND4 3 I-V Mild 
333 THR ND2 3 T-A Mild  317 ILE ND4 3 I-V Mild 
343 MET ND2 3 M-V Mild  320 GLY ND4 3 G-E Severe 
346 ILE ND2 3 I-V Mild  350 THR ND4 3 T-A Mild 
14 ALA ND3 3 A-S Mild  365 ALA ND4 3 A-T Mild 
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391 ILE ND4 3 I-V Mild  53 MET ND5 3 M-V Mild 
402 VAL ND4 3 V-L Mild  59 GLN ND5 3 Q-L Severe 
418 SER ND4 3 S-L Severe  63 ILE ND5 3 I-V Mild 
418 SER ND4 3 S-P Medium  65 ASN ND5 3 N-S Medium 
419 LEU ND4 3 L-F Mild  67 HIS ND5 3 H-Y Mild 
420 THR ND4 3 T-A Mild  70 THR ND5 3 T-M Severe 
421 HIS ND4 3 H-Y Mild  76 LEU ND5 3 L-F Mild 
424 ASN ND4 3 N-K Mild  76 LEU ND5 3 L-V Mild 
425 ASN ND4 3 N-S Medium  88 MET ND5 3 M-T Severe 
434 ASN ND4 3 N-H Mild  93 ALA ND5 3 A-T Mild 
435 THR ND4 3 T-I Severe  109 ASN ND5 3 N-S Medium 
445 LEU ND4 3 L-I Mild  109 ASN ND5 3 N-Y Medium 
455 THR ND4 3 T-I Severe  113 ASN ND5 3 N-S Medium 
459 SER ND4 3 S-F Severe  127 THR ND5 3 T-A Mild 
459 SER ND4 3 S-P Medium  132 VAL ND5 3 V-I Mild 
21 VAL ND4L 3 V-L Mild  141 PHE ND5 3 F-L Mild 
21 VAL ND4L 3 V-M Mild  147 VAL ND5 3 V-M Mild 
47 MET ND4L 3 M-I Mild  162 ALA ND5 3 A-T Mild 
62 ALA ND4L 3 A-T Mild  169 ILE ND5 3 I-T Severe 
62 ALA ND4L 3 A-V Medium  172 ILE ND5 3 I-V Mild 
79 VAL ND4L 3 V-I Mild  190 ILE ND5 3 I-M Mild 
80 SER ND4L 3 S-A Mild  190 ILE ND5 3 I-V Mild 
1 MET ND5 3 M-V Mild  196 TRP ND5 3 W-L Severe 
2 THR ND5 3 T-I Severe  206 ALA ND5 3 A-T Mild 
2 THR ND5 3 T-A Mild  209 SER ND5 3 S-G Medium 
14 SER ND5 3 S-A Mild  211 THR ND5 3 T-A Mild 
18 PRO ND5 3 P-L Severe  270 SER ND5 3 S-C Severe 
21 THR ND5 3 T-I Severe  271 PRO ND5 3 P-S Medium 
22 THR ND5 3 T-I Severe  273 ILE ND5 3 I-V Mild 
22 THR ND5 3 T-A Mild  283 ILE ND5 3 I-T Severe 
27 ASN ND5 3 N-S Medium  290 VAL ND5 3 V-I Mild 
30 ASN ND5 3 N-S Medium  304 PHE ND5 3 F-L Mild 
34 HIS ND5 3 H-Y Mild  317 ILE ND5 3 I-V Mild 
38 SER ND5 3 S-T Mild  323 HIS ND5 3 H-Y Mild 
39 ILE ND5 3 I-V Mild  331 THR ND5 3 T-A Mild 
40 VAL ND5 3 V-I Mild  377 SER ND5 3 S-T Mild 
45 ILE ND5 3 I-V Mild  378 LEU ND5 3 L-Q Severe 
52 THR ND5 3 T-C Severe  381 ALA ND5 3 A-T Mild 
52 THR ND5 3 T-M Severe  400 ASN ND5 3 N-S Medium 
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403 TYR ND5 3 Y-D Severe  569 HIS ND5 3 H-Y Mild 
413 LEU ND5 3 L-I Mild  571 ILE ND5 3 I-V Mild 
420 SER ND5 3 S-G Medium  575 ILE ND5 3 I-T Severe 
423 SER ND5 3 S-R Severe  575 ILE ND5 3 I-M Mild 
424 THR ND5 3 T-A Mild  576 ILE ND5 3 I-V Mild 
440 LEU ND5 3 L-F Mild  577 THR ND5 3 T-A Mild 
441 THR ND5 3 T-I Severe  579 THR ND5 3 T-A Mild 
442 ASN ND5 3 N-S Medium  596 ILE ND5 3 I-L Mild 
447 ASN ND5 3 N-D Mild  596 ILE ND5 3 I-V Mild 
456 ARG ND5 3 R-G Severe  602 ILE ND5 3 I-M Mild 
469 THR ND5 3 T-I Severe  603 THR ND5 3 T-M Severe 
472 ILE ND5 3 I-M Mild  2 MET ND6 3 M-T Severe 
473 SER ND5 3 S-F Severe  4 ALA ND6 3 A-T Mild 
473 SER ND5 3 S-P Medium  34 VAL ND6 3 V-I Mild 
476 SER ND5 3 S-A Mild  35 SER ND6 3 S-C Severe 
478 PHE ND5 3 F-I Mild  37 VAL ND6 3 V-A Medium 
482 ILE ND5 3 I-T Severe  38 VAL ND6 3 V-I Mild 
482 ILE ND5 3 I-M Mild  41 VAL ND6 3 V-I Mild 
485 TYR ND5 3 Y-C Severe  41 VAL ND6 3 V-A Medium 
489 THR ND5 3 T-M Severe  42 ILE ND6 3 I-V Mild 
489 THR ND5 3 T-A Mild  45 ASN ND6 3 N-S Medium 
491 LEU ND5 3 L-F Mild  54 MET ND6 3 M-V Mild 
492 ALA ND5 3 A-T Mild  58 ILE ND6 3 I-T Severe 
493 VAL ND5 3 V-I Mild  81 ALA ND6 3 A-T Mild 
495 PHE ND5 3 F-S Severe  85 GLY ND6 3 G-E Severe 
500 THR ND5 3 T-A Mild  90 VAL ND6 3 V-A Medium 
508 THR ND5 3 T-A Mild  94 VAL ND6 3 V-A Medium 
509 ASN ND5 3 N-S Medium  97 ALA ND6 3 A-P Medium 
513 MET ND5 3 M-T Severe  102 LEU ND6 3 L-F Mild 
515 SER ND5 3 S-T Mild  106 VAL ND6 3 V-A Medium 
524 ASN ND5 3 N-S Medium  120 SER ND6 3 S-M Severe 
525 MET ND5 3 M-L Mild  111 ALA NDUFA11 3 A-T Mild 
531 SER ND5 3 S-I Severe  128 ARG NDUFA11 3 R-W Severe 
536 THR ND5 3 T-M Severe  134 LEU ND6 3 L-F Mild 
546 GLN ND5 3 Q-L Severe  135 ILE ND6 3 I-V Mild 
556 THR ND5 3 T-I Severe  139 PRO ND6 3 P-L Severe 
564 LYS ND5 3 K-M Severe  139 PRO ND6 3 P-S Medium 
565 THR ND5 3 T-A Mild  140 ILE ND6 3 I-V Mild 
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142 ALA ND6 3 A-V Medium  43 MET NDUFA8 3 M-V Mild 
150 ARG ND6 3 R-C Severe  54 ARG NDUFA8 3 R-Q Mild 
150 ARG ND6 3 R-P Severe  134 ARG NDUFA8 3 R-Q Mild 
155 VAL ND6 3 V-I Mild  21 ALA NDUFA9 3 A-V Medium 
156 THR ND6 3 T-I Severe  135 LEU NDUFA9 3 L-M Mild 
156 THR ND6 3 T-A Mild  187 ARG NDUFA9 3 R-Q Mild 
159 THR ND6 3 T-A Mild  206 TYR NDUFA9 3 Y-C Severe 
159 THR ND6 3 T-P Medium  235 ARG NDUFA9 3 R-Q Mild 
161 PHE ND6 3 F-L Mild  249 ALA NDUFA9 3 A-T Mild 
162 VAL ND6 3 V-A Medium  342 ILE NDUFA9 3 I-M Mild 
174 ASN ND6 3 N-S Medium  33 ARG NDUFB1 3 R-Q Mild 
2 ARG NDUFA10 3 R-C Severe  38 ARG NDUFB1 3 R-W Severe 
137 ALA NDUFA10 3 A-V Medium  34 VAL NDUFB10 3 V-L Mild 
142 GLY NDUFA10 3 G-R Severe  65 PRO NDUFB10 3 P-R Severe 
165 PRO NDUFA10 3 P-L Severe  109 ARG NDUFB10 3 R-M Severe 
19 ARG NDUFA11 3 R-H Mild  164 LYS NDUFB10 3 K-E Mild 
65 VAL NDUFA11 3 V-F Medium  55 VAL NDUFB11 3 V-I Mild 
99 THR NDUFA11 3 T-I Severe  56 TRP NDUFB11 3 W-C Severe 
60 ARG NDUFA12 3 R-Q Mild  60 VAL NDUFB3 3 V-A Medium 
24 LEU NDUFA13 3 L-W Severe  2 PHE NDUFB4 3 F-L Mild 
41 THR NDUFA13 3 T-I Severe  25 SER NDUFB4 3 S-F Severe 
41 THR NDUFA13 3 T-N Medium  11 ILE NDUFB5 3 I-F Mild 
80 ARG NDUFA13 3 R-Q Mild  87 TYR NDUFB5 3 Y-H Mild 
87 ARG NDUFA13 3 R-W Severe  137 PRO NDUFB5 3 P-L Severe 
34 ASP NDUFA2 3 D-N Mild  10 ARG NDUFB6 3 R-Q Mild 
62 PRO NDUFA2 3 P-L Severe  20 ARG NDUFB6 3 R-Q Mild 
63 LYS NDUFA2 3 K-R Medium  25 GLN NDUFB6 3 Q-E Mild 
93 VAL NDUFA2 3 V-I Mild  42 MET NDUFB6 3 M-V Mild 
11 ALA NDUFA3 3 A-G Medium  80 ILE NDUFB6 3 I-T Severe 
49 PRO NDUFA3 3 P-T Medium  108 THR NDUFB6 3 T-I Severe 
2 GLY NDUFA5 3 G-C Severe  29 GLY NDUFB7 3 G-C Severe 
63 ARG NDUFA6 3 R-Q Mild  43 GLN NDUFB7 3 Q-R Mild 
4 THR NDUFA7 3 T-P Medium  48 ALA NDUFB7 3 A-T Mild 
7 ILE NDUFA7 3 I-S Severe  55 ARG NDUFB7 3 R-Q Mild 
29 GLU NDUFA7 3 E-K Mild  61 HIS NDUFB7 3 H-D Medium 
37 PRO NDUFA7 3 P-S Medium  70 ARG NDUFB7 3 R-C Severe 
50 ASN NDUFA7 3 N-S Medium  83 ARG NDUFB7 3 R-W Severe 
57 ASP NDUFA7 3 D-G Medium  92 ARG NDUFB7 3 R-H Mild 
59 ARG NDUFA7 3 R-C Severe  105 ARG NDUFB7 3 R-G Severe 
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110 ARG NDUFB7 3 R-Q Mild  133 ASP NDUFS7 3 D-N Mild 
112 LYS NDUFB7 3 K-Q Mild  134 ARG NDUFS7 3 R-H Mild 
28 MET NDUFB8 3 M-I Mild  148 THR NDUFS7 3 T-M Severe 
38 ASP NDUFB8 3 D-N Mild  11 SER NDUFV1 3 S-P Medium 
75 PRO NDUFB8 3 P-L Severe  32 ARG NDUFV1 3 R-S Severe 
93 THR NDUFB8 3 T-A Mild  168 GLY NDUFV1 3 G-D Medium 
94 PRO NDUFB8 3 P-R Severe  175 VAL NDUFV1 3 V-M Mild 
3 LEU NDUFB9 3 L-W Severe  339 ARG NDUFV1 3 R-C Severe 
7 PRO NDUFB9 3 P-L Severe  418 LEU NDUFV1 3 L-M Mild 
36 TYR NDUFB9 3 Y-H Mild  76 PRO NDUFV2 3 P-T Medium 
46 ARG NDUFB9 3 R-L Severe  140 ILE NDUFV2 3 I-T Severe 
128 ARG NDUFB9 3 R-Q Mild        
143 THR NDUFB9 3 T-M Severe        
174 ARG NDUFB9 3 R-Q Mild        
176 ARG NDUFB9 3 R-Q Mild        
178 MET NDUFB9 3 M-T Severe        
41 GLU NDUFC1 3 E-Q Mild        
35 PHE NDUFC2 3 F-L Mild        
59 ARG NDUFC2 3 R-H Mild        
119 ARG NDUFC2 3 R-H Mild        
6 SER NDUFS1 3 S-G Medium        
122 MET NDUFS1 3 M-L Mild        
280 THR NDUFS1 3 T-S Mild        
331 LEU NDUFS1 3 L-H Severe        
334 LEU NDUFS1 3 L-F Mild        
479 MET NDUFS1 3 M-R Severe        
515 ARG NDUFS1 3 R-G Severe        
634 ASP NDUFS1 3 D-N Mild        
646 ASN NDUFS1 3 N-S Medium        
689 LYS NDUFS1 3 K-R Medium        
80 ILE NDUFS2 3 I-V Mild        
379 VAL NDUFS2 3 V-L Mild        
409 HIS NDUFS2 3 H-Y Mild        
100 ARG NDUFS3 3 R-C Severe        
94 SER NDUFS4 3 S-A Mild        
115 SER NDUFS4 3 S-T Mild        
71 THR NDUFS5 3 T-M Severe        
92 THR NDUFS5 3 T-A Mild        
97 HIS NDUFS5 3 H-Q Mild        
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